,id,ticker,title,category,content,date,provider,url,article_id
14771,236286,ISRG,USPTO allows challenge to key Intuitive Surgical patent,news,"The USPTO s Patent Trial and Appeal Board  PTAB  has agreed to review the validity of Intuitive Surgical s  ISRG  1 4   U S  Patent No  8 801 601 covering its surgical navigation guidance system 
Johnson   Johnson  JNJ  0 5   unit Auris Health filed a petition in June seeking to have the patent invalidated saying that it covers well known ideas 
Intuitive counters that the patent covers ways to limit the risk of perforation or tissue damage from an endoscope  It sued Auris in August 2018 for infringement 
The PTAB declined Auris  petition to review a second patent ",2019-12-16,Seeking Alpha,https://invst.ly/p4bbv,2042262
111517,333032,ISRG,4 Charts That Show Why You Should Buy Intuitive Surgical Stock,news,"Intuitive Surgical  NASDAQ ISRG  delivered a solid performance in 2019  with shares rising more than 23   But that wasn t as good as the S P 500 index  which gave investors a total return of over 31   If you think that Intuitive Surgical is likely to lag behind the market over the long run  though  think again 
The robotic surgical systems pioneer presented on Tuesday at the annual J P  Morgan Healthcare Conference in San Francisco  CEO Gary Guthart made a compelling case for his company s business prospects  In particular  there were four charts that Guthart discussed that show why Intuitive Surgical is a stock you can buy right now and hold for the long run  

1  Procedure trends
Probably the single most important metric for Intuitive Surgical is the growth in procedures performing using its flagship da Vinci robotic surgical system  The more procedures that are performed  the more customers will need replacement instruments and accessories    which translates to higher revenue for Intuitive  The following chart presented at the J P  Morgan conference shows just how strong the procedure growth tailwinds are for Intuitive Surgical 

There are a couple of things that especially stand out with this chart  First  the overall growth in worldwide procedure volume over the last six years has been impressive  Second  Intuitive Surgical continues to enjoy really strong growth in general surgery procedures 
However  you might look at the company s guidance of 13  to 16  growth in 2020 and wonder if da Vinci might be losing its sizzle to some extent  Keep in mind  though  that Intuitive has a history of sandbagging on its guidance  For example  in January 2019 the company projected that full year procedure growth in 2019 would be between 13  and 17   As the above chart shows  Intuitive beat the top end of that range  Don t be surprised if the company again delivers stronger growth than its guidance in 2020 
2  System placements and install base growth
Another important metric for Intuitive Surgical is how many da Vinci systems are installed  Some customers purchase the systems outright while others lease their da Vinci systems  Either way  Intuitive not only makes a lot of money over the near term  but it can also look forward to more future revenue as these customers perform surgical procedures using the da Vinci system  Below is a two in one chart from the company s J P  Morgan presentation that underscores how much progress Intuitive continues to make in expanding its install base 

Note the right chart above shows that Intuitive Surgical s installed base grew by more than 12  last year  That should directly translate to solid procedure growth  as seen in the chart in the first point 
It s a little hard to tell from the small section of purple in the left chart above  but Intuitive is really picking up momentum in Asia  That s great news for the company  which historically has seen higher growth in the U S  market 
3  Recurring revenue
Some companies experience wild swings in revenue from quarter to quarter and year to year because they re highly dependent on new sales  Intuitive Surgical doesn t have to worry too much about such volatility  The chart below shows the reason why 

Intuitive makes 72  of its revenue from recurring sources  That s a phenomenal level of recurring revenue  And it s only going to grow as the company s install base increases  driving procedure growth  which in turn drives sales of replacement instruments and accessories 
But Guthart also discussed another important factor fueling Intuitive Surgical s recurring revenue growth  operating leases  Customers are increasingly opting to lease robotic systems rather than make up front purchases  Intuitive s operating lease revenue more than doubled in 2019 from the previous year to  107 million  Operating leases now account for 34  of total system placements  and the number is likely to head higher in 2020 and beyond 
4  What rivals have to do just to catch up
Several other companies have made news over the last year with key developments in their own robotic surgical systems efforts  Medtronic unveiled its new surgical robot system that will compete head to head against da Vinci  Johnson   Johnson is stepping up its game  acquiring Auris Health  which was founded by Intuitive Surgical founder Fred Moll  and buying Alphabet s stake in Verb Surgical 
Should investors be worried about new competition for Intuitive Surgical  The following chart shown by Guthart at the J P  Morgan conference gives a pretty good reason why the answer should be  no  

The point of this chart is that there s a lot that has to be done to build out an ecosystem to survive and thrive in the robotic surgical systems market  Developing new systems and instruments isn t enough  There are regulatory hurdles to clear  customer training programs to develop  clinical support to establish  and a whole lot more  It s a long  multiphase process 
Medtronic and J J could be successful in the robotic surgical systems market  However  both big companies are well behind Intuitive Surgical  It seems quite possible that the introduction of new robotic surgical systems could even improve Intuitive s prospects as the technology gains wider adoption 
Why buy Intuitive Surgical 
How do these four charts show why Intuitive Surgical is a great stock to buy  They demonstrate that the company has a strong underlying business with excellent growth prospects and an impressive and increasing level of recurring revenue  They also underscore the substantial first mover advantage that Intuitive has over new competitors entering the scene 
Some healthcare stocks require investors to hope for regulatory approvals and strong commercial launches to achieve success  Intuitive Surgical doesn t  Its growth is practically guaranteed  And that s why the company s charts from the major healthcare conference this week highlight why this stock is a great pick for investors to buy and hold ",2020-01-15,The Motley Fool,https://invst.ly/piaxo,2059863
111521,333036,ISRG,3 Charts That Show Intuitive Surgical Is Transforming Before Our Eyes,news,"Sometimes  change happens so slowly it s easy to miss  That s what s happening with Intuitive Surgical  NASDAQ ISRG   The health focused robotics company pre released fourth quarter results this month that continued to impress  This early release has become commonplace  as it allows executives to speak freely at the J P  Morgan Health Conference taking place this week 
But if we look beyond the headline numbers  we see the nascent stages of a healthcare subscription company forming  That s a huge shift investors need to be aware of  Here are three charts that demonstrate this move 

Lowering barriers to entry
Buying a daVinci robotic surgical system is a big investment for hospitals  as each machine costs over  1 5 million    prohibitively expensive for some  
But lately  Intuitive has offered up operating leases to lower these barriers  For much lower up front costs  hospitals can effectively lease the daVinci machines for a recurring rate    and upgrade when newer versions come out  
The number of systems using this alternative financing has boomed over the past two years 

As you can see  one third of all the systems placed over the past year have been operating via leases  This creates a long term trade off that s good news for everyone 

Hospitals and doctors can afford to buy a daVinci and test it out 
Patients benefit from improved outcomes and quicker recovery 
Intuitive Surgical collects as much or more revenue from systems and  more importantly  has a recurring source of revenue instead of one off purchases 

I wouldn t be surprised to see this trend continue  as it works in everyone s best interest to transition to this leasing model 
Gathering and distributing data
Intuitive is taking all of the data it has collected over 25 years and creating a platform for surgeons  In essence  it s offering up the type of data and science that s more reminiscent of a software company 

Think about it  Over 90  of Intuitive s machines are connected to the cloud  All of the data provided by those connected machines form the basis for better training on the company s simulators 
Not only does this help train surgeons  but it also provides an advantage that Intuitive s coming competitors won t be able to match for years 
Tinkering leads to new procedures
Finally  we get to the most important long term metric for investors to watch  procedure growth  Intuitive Surgical s stock currently trades for about 50 times earnings  That s a high price tag    which means high expectations are baked in  
Intuitive matches those expectations by helping more patients via minimally invasive procedures  

As you can see  general surgery is booming  But it isn t the only growth driver  While the core gynecology market is mature  international urology procedures are also adding a lot of operations to the slate 
For the upcoming year  management said it expects to continue seeing robust growth in hernia  bariatric  and colorectal procedures  all of which fall under the broader general surgery label 
There are powerful forces leading me to believe this trend of upward procedure growth will continue  More doctors are using daVinci thanks to operating leases  As they continue tinkering on the platform with new procedures  that data is collected and distributed to other doctors  Over time  that leads to using the machine for more procedures  improving operating outcomes 
Investor takeaway
None of this is to say you should run out and put all of your money behind Intuitive Surgical  Instead  it deserves a spot on your own watch list for due diligence  The growth of operations is nothing new  But the drivers of that growth    essentially  a transition to a subscription based model    can t be ignored  It s the type of development that could keep the company relevant for decades to come ",2020-01-16,The Motley Fool,https://invst.ly/pis2x,2060861
111523,333038,ISRG,Intuitive Surgical Earnings  Revenue Beat in Q4,news,"Investing com   Intuitive Surgical  NASDAQ ISRG  announced fourth quarter earnings  that beat analysts  expectations on Thursday and revenue that topped forecasts 
The company reported earnings per share of  3 48 on revenue of  1 28B  Analysts polled by Investing com anticipated EPS of  3 37 on revenue of  1 23B  That was in comparison with EPS of  2 96 on revenue of  1 05B in the same period a year before  Intuitive Surgical had reported EPS of  3 43 on revenue of  1 13B in the previous quarter 
Analysts are forecasting EPS of  3 02 and revenue of  1 13B in the next quarter 
Intuitive Surgical share s are up 3 91  for the year to date   still down 0 38  from its 52 week high of  616 56 set on January 10 
Intuitive Surgical follows other major Healthcare sector earnings this monthOn Wednesday  J J announced fourth quarter EPS of  1 88 on revenue of  20 75B  was in comparison with a forecasts for EPS of  1 87 on revenue of  20 78B 
Abbott Labs earnings matched analysts  expectations on Wednesday  with fourth quarter EPS of  0 95 on revenue of  8 31B  Investing com analysts anticipated EPS of  0 95 on revenue of  8 26B
Stay up to date on all of the upcoming earnings reports by visiting Investing com s earnings calendar",2020-01-23,Investing.com,https://www.investing.com/news/stock-market-news/intuitive-surgical-earnings-revenue-beat-in-q4-2066505,2066505
111525,333040,ISRG,Intuitive Surgical EPS beats by  0 10  beats on revenue,news,"Intuitive Surgical  NASDAQ ISRG   Q4 Non GAAP EPS of  3 48 beats by  0 10  GAAP EPS of  2 99 beats by  0 19 
Revenue of  1 28B   21 9  Y Y  beats by  10M 
Shares  0 2  
Press Release",2020-01-23,Seeking Alpha,https://invst.ly/pm2dt,2066510
111527,333042,ISRG,Intuitive Surgical Grows Profits by 22  in the Fourth Quarter,news,"Following up on preliminary fourth quarter results released earlier this month  Intuitive Surgical  NASDAQ ISRG  reported its official results after the closing bell on Thursday  Revenue for the period increased 22  to  1 28 billion  exactly what the company had calculated with its preliminary number 
The full report also includes expenses and net income  which weren t in the initial report since it takes businesses longer to add up all their expenses for the quarter  Income from operations was up 19 8  in the quarter  but grew slower than revenue because research and development expenses  which were up 30  year over year  ate into operating profits 
A lower tax rate and an increase in interest and other income helped the healthcare company grow its bottom line faster than its operating income  Net income for the quarter increased 22  to  358 million  Intuitive Surgical brought in  2 99 per share  also up 22  year over year 

The company sold 336 da Vinci Surgical Systems in Q4  a 16  year over year increase  The number of procedures performed using the machines increased by 19   driven by growth in general surgery procedures in the U S  and urologic procedures worldwide 
The rise in procedures boosted sales of instruments and accessories by 24  year over year in the quarter  Intuitive Surgical generates more than half of its total revenue from sales of instruments and accessories 
The company added  415 million to its coffers to end the quarter with  5 8 billion in cash  cash equivalents  and investments ",2020-01-23,The Motley Fool,https://invst.ly/pm3te,2066634
111529,333044,ISRG,Intuitive Surgical  ISRG  Q4 Earnings Top  Margins Expand,opinion,"Intuitive Surgical  Inc    NASDAQ ISRG   reported adjusted earnings per share  EPS  of  3 48 in the fourth quarter of 2019  beating the Zacks Consensus Estimate of  3 26  Adjusted EPS improved 17 6  year over year  The Zacks Rank  1  Strong Buy  company recorded revenues of  1 28 billion  which improved 22 1  from the prior year quarter  The figure also outpaced the Zacks Consensus Estimate of  1 23 billion  2019 Results at a Glance Intuitive Surgical s 2019 revenues totaled  4 48 billion  beating the Zacks Consensus Estimate of  4 44 billion  The figure improved 20 3  from 2018  Adjusted EPS was  12 76  surpassing the consensus mark of  12 57 and rising 16 1  year over year  The company s Instruments   Accessories sales were  2 41 billion  53 8  of net revenues   Systems revenues were  1 35 billion  30   and Services revenues grossed  724 2 million  16 2    Segment Details Instruments   Accessories Revenues at the segment came in at  671 2 million  reflecting a year over year increase of 24 5  on 19  growth in da Vinci procedure volumes  Systems In the reported quarter  System revenues increased 22 2  year over year to  416 2 million  Notably  the company shipped 336 da Vinci Surgical Systems in the quarter  Services Services revenues came in at  190 3 million  up 14 2  from the year ago quarter Intuitive Surgical  Inc  Price  Consensus and EPS Surprise
 

   International Sales Up Outside the United States  revenues totaled  422 million  up 37  on a year over year basis  The improvement can be attributed to higher instruments and accessory revenues  driven by procedure growth and favorable customer buying patterns  Outside the United States  Intuitive Surgical placed 140 systems in the fourth quarter compared with 115 in the fourth quarter of 2018  Of these  54 were in Europe  26 in Japan and 39 in China  Margins Adjusted gross profit in the reported quarter was  922 6 million  up 22 8  year over year  As a percentage of revenues  gross margin in the quarter was 72 2   up 40 basis points  bps   Adjusted operating income totaled  505 6 million  up 22 8  year over year  As a percentage of revenues  operating margin in the quarter was 39 6   up 20 bps Outlook For 2020  the company expects full year procedure growth within 13  to 16   driven by U S  general surgery and procedures outside the United States  Wrapping Up Intuitive Surgical ended the fourth quarter on a solid note  The flagship da Vinci procedures recorded solid growth in the quarter  which drove the core Instrument   Accessories arm  In fact  management continues to expect strong procedure growth in 2020  The company looks to accelerate business in China  which saw a solid fourth quarter as well  Overall international sales surged in the quarter  Expansion in gross and operating margins is an added positive  On the flip side  the da Vinci system is in the early stages of adoption in some of the markets outside the United States which is likely to impede placements  Intense competition in the global MedTech space is concerning as well  Other Key Picks Other top ranked stocks in the broader medical space are Cerner Corporation   NASDAQ CERN    DexCom   NASDAQ DXCM   and HealthEquity   NASDAQ HQY    each carrying a Zacks Rank  2  Buy   You can see   The Zacks Consensus Estimate for Cerner s fourth quarter revenues is pegged at  1 43 billion  suggesting a year over year increase of 5   The same for EPS stands at 74 cents  indicating a year over year upside of 17 5   The Zacks Consensus Estimate for DexCom s fourth quarter revenues is pinned at  457 million  calling for a year over year increase of 35 2   The same for EPS stands at 72 cents  hinting at year over year growth of 33 3   The Zacks Consensus Estimate for HealthEquity s fiscal fourth quarter revenues is pegged at  193 6 million  calling for a year over year increase of 155 5   The same for EPS stands at 19 cents  Zacks Top 10 Stocks for 2020 In addition to the stocks discussed above  would you like to know about our 10 finest buy and hold tickers for the entirety of 2020  Last year s 2019 Zacks Top 10 Stocks portfolio returned gains as high as  102 7   Now a brand new portfolio has been handpicked from over 4 000 companies covered by the Zacks Rank  Don t miss your chance to get in on these long term buys ",2020-01-24,Zacks Investment Research,https://www.investing.com/analysis/intuitive-surgical-isrg-q4-earnings-top-margins-expand-200501319,200501319
111530,333045,ISRG,Here s Why You Should Invest In Intuitive Surgical Stock Now,opinion,Intuitive Surgical  Inc    NASDAQ ISRG   is well poised for growth on improving adoption of da Vinci Surgical System  strong international presence and solid recurring revenue base Shares of Intuitive Surgical have gained 18 7  compared with the  s growth of 15  in a year s time  Meanwhile  the S P 500 Index has rallied 23 8  in the same timeframe The company  with a market capitalization of  68 09 billion  designs  manufactures and markets the da Vinci surgical system and related instruments and accessories  Notably  the da Vinci surgical system is an advanced robot assisted surgical system  It anticipates earnings to improve 11 8  over the next five years  Moreover  it has beat estimates in the trailing four quarters by 8 3   on average Let s take a closer look at the factors that substantiate the company s Zacks Rank  1  Strong Buy  What s Favoring the Stock Intuitive Surgical s robot based da Vinci surgical system enables minimally invasive surgery  which reduces risks associated with open surgery  The company continues to gain from this system  which in turn bolsters overall performance In third quarter 2019  da Vinci procedures improved 20  globally compared with the prior year quarter  The upside was driven by healthy growth in U S  General Surgery  In the third quarter  Intuitive Surgical placed 275 da Vinci surgical systems  with the installed base growing 12  year over year  In fact  it now anticipates 2019 procedure growth to be 17 18  compared with the previously anticipated rise of 16 17  Intuitive Surgical is gradually gaining prominence in markets outside the United States  In third quarter 2019  international revenues rose 36  year over year  owing to solid show by the Instruments   Accessories segment Notably  the segment grew on solid procedure growth and customer buying patterns  Intuitive Surgical placed 80 systems in third quarter 2019 compared with 90 units in third quarter 2018  Of these  36 were in Europe  27 in Japan and 10 in China Intuitive Surgical s business model ensures that it continues to generate revenues from initial capital sales of da Vinci Surgical Systems  and subsequent sales of instruments  accessories and services  In the last reported quarter  total recurring revenues were  817 million  up 24  year over year and accounting for a whopping 72  of total revenues Recurring revenues  as portion of total revenues  continue to grow at a much higher rate compared with system sales  This ensures a steady stream of income  even in testing times  Moreover  Intuitive Surgical operates in a niche MedTech market  with no direct competition  which is a major positive Which Way Are Estimates Headed For 2020  the Zacks Consensus Estimate for revenues is pegged at  5 billion  indicating an improvement of 11 7  from the year ago quarter  The same for earnings stands at  13 83 per share  suggesting growth of 8 4  from the year ago reported figure Other Stocks to ConsiderOther top ranked stocks in the broader medical space are Cerner Corporation   NASDAQ CERN    HealthEquity   NASDAQ HQY   and Veeva Systems   NYSE VEEV    each carrying a Zacks Rank  2  Buy   You can see  Cerner s long term earnings growth rate is estimated at 13 6  HealthEquity s long term earnings growth rate is pegged at 25  Veeva s long term earnings growth rate is estimated at 21 9  Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through 2019  while the S P 500 gained an impressive  53 6   five of our strategies returned  65 8    97 1    118 0    175 7  and even  186 7  This outperformance has not just been a recent phenomenon  From 2000   2019  while the S P averaged  6 0  per year  our top strategies averaged up to  54 7  per year ,2020-01-27,Zacks Investment Research,https://www.investing.com/analysis/heres-why-you-should-invest-in-intuitive-surgical-stock-now-200501703,200501703
111531,333046,ISRG,Intuitive Surgical Inc  ISRG  Q4 2019 Earnings Call Transcript,news,"Intuitive Surgical Inc  NASDAQ ISRG Q4 2019 Earnings CallJan 23  2020  4 30 p m  ETContents 

Prepared Remarks
Questions and Answers
Call Participants

Prepared Remarks 
OperatorLadies and gentlemen  thank you for standing by and welcome to Intuitive Surgical s Fourth Quarter 2019 Earnings Release  At this time  all lines are in a listen only mode  Later  we will have a question and answer session   Operator Instructions   As a reminder  today s conference is being recorded  I d now like to turn the conference over to Senior Director of Finance Investor Relations  Calvin Darling  Please go ahead Calvin Darling    Senior Director of Finance Investor RelationsThank you  good afternoon and welcome to Intuitive s fourth quarter earnings call  With me today we have Gary Guthart  our CEO and Marshall Mohr  our Chief Financial Officer  Before we begin  I would like to inform you that comments mentioned on today s call may be deemed to contain forward looking statements  Actual results may differ materially from those expressed or implied as a result of certain risks and uncertainties  These risks and uncertainties are described in detail in the company s Securities and Exchange Commission filings  including our most recent Form 10 K filed on February 4th  2019 and 10 Q filed on October 18th  2019  Our SEC filings can be found through our website or at the SEC s website  Investors are cautioned not to place undue reliance on such forward looking statements  Please note that this conference call will be available for audio replay on our website at intuitive com on the latest events section under our Investor Relations page  In addition  today s press release and supplementary financial data tables have been posted to our website Today s format will consist of providing you with highlights of our fourth quarter results as described in our press release announced earlier today  followed by a question and answer session  Gary will present the quarter s business and operational highlights  Marshall will provide a review of our fourth quarter financial results  Then I will discuss procedures and clinical highlights and provide our financial outlook for 2020  And finally  we will host a question and answer session  With that  I will turn it over to Gary Gary S  Guthart    Chief Executive Officer  Member of the Board of DirectorsThank you for joining us today  At Intuitive  we measure our efforts by their ability to positively impact the quadruple aim  better outcomes  better patient experience  better care team experience  and lower total cost to treat per patient episode  This fourth quarter of 2019 was another strong one for Intuitive in pursuit of these aims capping a good year for the company  Our performances reflected in healthy total growth in customer use of our systems  new capital installations  sustained quality service of our customers  clinical publications  and the launch of new products and services For the quarter  global procedure growth was approximately 19   Growth was led by general surgery in the United States with positive contributions to the global growth rate from Japan  China  Germany and Korea  Globally  customer utilization of systems increased again in the quarter  indicating greater productivity per installed system  Leasing and alternative placement models have also helped our customers gain access to additional procedure capacity with lower capital outlays  In the United States  year over year procedure growth for the quarter was 18   General surgery accounted for the largest increase accompanied by stable growth in urology and gynecology  Within general surgery  hernia repair  cholecystectomy  bariatric and colorectal surgery showed strength  Outside the United States  several markets are early in their transition from growth in urology to other surgical categories including gynecology  thoracic surgery  and general surgery with growth varying by country  Calvin will take you through global procedure dynamics in more detail later in the call With regard to our installed base  placement of new systems in the quarter was solid  We placed 336 systems in the quarter with growth in total placements rising 16  from Q4 of 2018  Net of trade ins and retirements  our da Vinci installed base grew to approximately 5 582  The mix of system placements this quarter continues to favor our flagship Xi system and trade ins were healthy  The proportion of systems placed under operating leases was 38  this quarter compared with 33  last quarter  As a reminder  total placements in that percentage of systems placed under lease were usage based  Arrangements can vary substantially quarter to quarter  Over the past several years  we ve been working to enable greater access to our products and services  For example  we believe  leasing in usage based models benefit our customers by lowering barriers for them to provide high quality computer aided interventions  We anticipate continuing to expand access and lower cost for our customers as our business progresses into different procedures and geographies Turning to expenses  we believe we are still in the early days of computer aided surgery and acute interventions  As a result  we are investing in building our capability in several important ways including deepening internationally  launching our new platforms  strengthening our computational capabilities  and executing projects that support future scale and provide leverage opportunities as we grow  Our spending for the quarter and for the year was within the upper end of the spend guidance we shared with you in 2019  It is supported by solid procedure growth  capital placements  and product cost reductions  Financial highlights of our fourth quarter results are as follows  Procedures grew approximately 19  over the fourth quarter last year  We placed 336 da Vinci surgical systems  up from 290 in the fourth quarter of 2018  Our installed base grew 12  from a year ago  Revenue for the quarter was approximately  1 3 billion  up 22   Pro forma gross profit margin was 72 2  compared to 71 8  in the fourth quarter last year  Instrument and accessory revenue increased to  671 million  up 24   Total recurring revenue in the quarter was  896 million growing 24  over Q4 of 2018 and representing 70  of total revenue  We generated a pro forma operating profit of  506 million in the quarter  up 23  from the fourth quarter of last year and pro forma net income was  417 million  up 18   Highlights for the full year 2019 are as follows  procedures grew approximately 18  over 2018  We placed 1 119 systems in the year growing the installed base 12  over 2018  Revenue for the year was approximately  4 5 billion growing 20  over 2018 and pro forma net income was approximately  1 5 billion  up 17  over 2018 Turning to progress in our innovation pipeline  I ll start first with systems  We are in our Phase 1 launch of da Vinci SP and we are working to expand its clinical clearances and build SP products at scale  In the quarter  we installed six systems to bring our installed base of SP to 44  Customer response and early clinical results using SP remain encouraging with over 50  Phonetic  peer reviewed clinical articles on SP to date  With regard to additional indications for SP  we ve been in discussion with FDA regarding data requirements for a colorectal indication  We expect this to require an IDE trial that includes follow up analysis  This implies  we do not expect the third indication for SP in the U S  in 2020  While I would like a faster launch of SP  the combination of additional indications for SP and our readiness for deployment at larger scale will pace the speed of our SP commercial expansion In flexible diagnostics  our Ion platform is focused on the need for accurate and timely biopsies to support definitive early diagnosis of suspicious lesions  As of the end of the quarter  there are approximately 16 systems in the field  some commercial and some clinical trial sites with several hundred procedures performed  To date  the roll out is meeting our expectations and user feedback during this initial launch period has been strong  We expect several publications reviewing the performance of Ion to be presented during 2020  Turning to instruments and accessories  our team has been making great progress in building out our instrument portfolio with high quality products  Our experience has shown that procedure adoption occurs when the holistic needs of the care team are met when the right system and imaging products come together with the right instruments and accessories  Our team initiated our first phase launch in the quarter for our SynchroSeal sealing and transection device along with our first integrated energy controller called the E 100  SynchroSeal provides surgeons with wristed precise and fast sealing and transection ability often used in general surgery  Early feedback on its performance has been outstanding  SynchroSeal joins our portfolio of advanced instruments stapling instruments and advanced energy instruments that customers are now adopting in their da Vinci cases Turning to imaging and analytics  we are working on imaging  computing  and real time cloud technologies that allowed for capabilities from big data analytics to telementoring to augmented reality   Technical Issues  alone  Intuitive Surgical simulators have been used for over 17 000 hours by more than 5 800 surgeons  Our IRIS augmented reality system entered clinical use in the fourth quarter of 2019 and we re pleased with our first customer responses  Over the past several years  our analytical capability has increased and we now routinely engage our customers to help assess the performance of their robotic assisted surgery programs relative to other surgical modalities  Armed with local comparative analysis of robotic assisted surgery within their institutions  hospitals with active programs have been building access to da Vinci systems and growing their programs  We expect continued investment and progress in these areas in 2020 As we move into 2020  let s step back and review the da Vinci surgery universe  In the past several years  general surgeons have increased their adoption of our offerings underpinned by improvements in the quadruple aim in procedures they perform from hernia repair  cholecystectomy  and colorectal surgery to bariatric surgery  These surgical procedures span a broad range of complexity and economics  At the same time  Intuitive continues to deepen our capability in key countries to support the adoption of robotic assisted surgery and their healthcare environments  We are flexing our company to better serve these customers with the launch of new systems  new instruments  and updates to our software along with changes to our sales and support models and pricing structures  Given the large global opportunity to pursue the quadruple aim  I believe the next few years for the company will be dynamic  We will guide the company to meet our customers  clinical and economic needs across this wide range of procedures and geographies  Doing so will involve continued investment in innovation in both technology and business models and we see a path to do both Moving into 2020  we are focused on the following  first  supporting adoption of da Vinci and general surgery including hernia repair  colorectal procedures  and bariatrics  second  launching our SP  Ion  imaging  instruments and analytics platforms  third  extending our depth in OUS markets particularly Asia and EU with growth beyond urology  and finally supporting additional clinical and economic validation in our focus procedures and countries  Lastly  we are pleased to publish today our inaugural sustainability report  which you can find on our website outlining our multi year efforts in these areas  I ll now turn the call over to Marshall  who will review financial highlights Marshall L  Mohr    Executive Vice President and Chief Financial OfficerGood afternoon  I would describe the highlights of our performance on a non GAAP or pro forma basis  I will also summarize our GAAP performance later in my prepared remarks  A reconciliation between our pro forma and GAAP results is posted on our website  Revenue in procedures are consistent with our preliminary press release of January 9th  Key business metrics for the fourth quarter were as follows  Fourth quarter 2019 procedures increased approximately 19  compared with the fourth quarter of 2018 and increased approximately 11  compared with last quarter  Procedure growth continues to be driven by general surgery in the U S  and urology worldwide Calvin will review details of procedure growth later in this call  Fourth quarter system placements of 336 systems increased 16  compared with 290 systems last year and increased 22  compared with 275 systems last quarter  We expanded our installed base of da Vinci systems by 12  to approximately 5 582 systems  This growth rate compares with 12  in the last quarter and 13  last year  Utilization of clinical systems in the field measured by procedures per system grew approximately 6   which is the same as the 6  growth last quarter and last year  Our revenue overview is as follows  Fourth quarter 2019 revenue was  1 3 billion  an increase of 22  compared with  1 billion for the fourth quarter of 2018 and an increase of 13  compared with  1 1 billion last quarter Instrument and accessory revenue of  671 million increased 24  compared with last year  which is higher than procedure growth  primarily reflecting customer buying patterns and increased usage of our advanced instruments  Instrument and accessory revenue realized per procedure was approximately  1 980  an increase of 5  compared with the fourth quarter 2018 and was consistent with last quarter  Instrument and accessory revenue per procedure has grown in the low single digits over the past couple of years reflecting increased usage of our advanced instruments  partially offset by higher growth in benign procedures where revenue per procedure is lower than the overall average  While adoption of benign procedures has been a major contributor to the overall INA revenue  to the extent benign procedures grow faster than complex procedures  INA per procedure may decline  In addition  over time as we achieve greater penetration of our advanced instruments in da Vinci procedures  the growth rate for advanced instruments will slow and align with the growth rate of underlying procedures in which advanced instruments are used Systems revenue for the fourth quarter of 2019 was  416 million  an increase of 22  compared with the fourth quarter of 2018 and an increase of 23  compared with last quarter  Relative to the fourth quarter of 2018  systems revenue reflected higher system placements  higher ASPs  and higher lease related revenue  We completed 126 operating lease transactions representing 38  of total placements compared with 84 or 29  of total placements in the fourth quarter of 2018 and 92 or 33  of total placements last quarter  As of December 31st  we have 658 operating leases outstanding and realized approximately  34 million of revenue related to these arrangements in the quarter compared with  16 million last year and  27 million last quarter Operating leases create a future source of recurring revenue and reduce the volatility of system revenue while the increased number of operating leases placed in the quarter dampens short term revenue growth for the quarter in which they are placed  Operating leases include usage based financings that we provided to certain hospitals with advanced robotics experience  We believe that our lease financing alternatives align with customer objectives and have enabled faster market adoption  Relative to systems purchased over the lease period  we earn a small premium reflecting the time value of money and in the case of usage based arrangements  the risk that those systems may not achieve anticipated usage levels  The proportion of operating lease in usage based arrangements will likely increase long term and will vary quarter to quarter  We recognized  34 million of lease buyout revenue in the fourth quarter compared with  20 million last quarter and  17 million last year  Lease buyout revenue has varied significantly from quarter to quarter and will likely continue to do so  138 or 41  of current quarter system placements involved trade ins reflecting customer desire to access or standardize on our fourth generation technology contributing to an Xi installed base growth of 39  year over year  This is an increase compared with 81 or 28  of system placements in the fourth quarter of 2018 and 116 or 42  last quarter Trading activity can fluctuate and could be difficult to predict  However  given prior product trade in cycles  we expect the proportion of the installed base traded in  in future quarters to decrease over time  81  of the systems placed in the quarter were da Vinci Xi s and 16  were da Vinci X systems compared with 79  da Vinci Xi s and 17  da Vinci X s last quarter  Six of the systems placed in the fourth quarter were SP systems  Our roll out of SP surgical system will continue to be measured putting systems in hand of experienced da Vinci users while we optimize training pathways in our supply chain  We placed seven Ion systems in the quarter  Ion system placements are excluded from our overall systems count and will be reported separately  Procedures and other information associated with Ion are excluded from our prepared remarks and will be reported separately when they become more substantive  Globally  our average selling price  which excludes the impact of operating lease revenue and lease buyouts was approximately  1 61 million compared with  1 46 million last year and  1 57 million last quarter  Our fourth quarter ASPs reflect a favorable geographic mix as we sold 39 systems into China and 26 into Japan where ASPs are higher given the higher cost of doing business in those geographies  Excluding geographic mix  ASPs for the quarter declined slightly relative to the third quarter reflecting pricing arrangements associated with a higher mix of multi system contracts  System ASPs will fluctuate with geographic and system mix and may decline relative to the average total 2019 ASP reflecting increased multi system arrangements Outside of the US  results were as follows  OUS procedures grew approximately 22  compared with the fourth quarter 2018 and increased 9  compared with last quarter  Fourth quarter revenue outside of the US of  422 million increased 37  compared with the fourth quarter of 2018 and increased 27  compared with last quarter  The increase compared with the prior year reflects increased instruments and accessories revenue of  47 million or 39  growth and increased systems revenue of  58 million or 42  growth  The increase in instrument and accessory revenue was primarily driven by procedure growth and stocking orders associated with China system sales  The increase in systems revenue is primarily the result of increased placements and increased ASPs reflecting favorable geographic and product mix  Outside of the US  we placed 140 systems in the fourth quarter compared compared with 115 in the fourth quarter of 2018 and 90 systems last quarter  Current quarter system placements included 54 into Europe  26 into Japan  and 39 into China compared with 55 into Europe  31 into Japan  and two into China in the fourth quarter of 2018  71  of the systems placed in the quarter were da Vinci Xi s and 24  were da Vinci X systems compared with 55  da Vinci Xi s and 30  da Vinci X s last year  32 of the system placements in the current quarter were operating leases compared with 15 last year and 21 last quarter  The 39 systems into China included customers who had begun their tender processes and we believe expedited their purchase cycles to avoid a tariff increase that was expected on December 15th  The proposed tariff was suspended on December 13th  We would expect remaining purchases under the quota to be completed  consistent with historical timelines and therefore we expect placements to be lower in the first quarter and skew more toward the end of 2020 and into 2021 While overall European system placements were relatively flat in the quarter and for 2019  shipments by country fluctuate significantly  Placements into the four largest European markets increased 29  in the fourth quarter and 19  for the year for the year  Overall placements outside of the US will continue to vary as some of the OUS markets are in early stages of adoption  Some markets are highly seasonal reflecting budget cycles or vacation patterns and sales into some markets are constrained by government limitations Moving on to gross margin and operating expenses  Pro forma gross margin for the fourth quarter of 2019 was 72 2  compared with 71 8  for the fourth quarter 2018 and 72  last quarter  The increase compared with the fourth quarter of 2018 and last quarter primarily reflects higher system ASPs and part of cost reductions  Future margins will fluctuate based on the mix of our newer products  mix of systems and instrument and accessory revenue  system ASPs and our ability to further reduce product costs and improve manufacturing efficiency  Pro forma operating expenses increased 23  compared with the fourth quarter 2018 and increased 19  compared with last quarter  Spending is consistent with our plan and includes an order of magnitude of increase costs associated with the expansion of our OUS markets  spending on our imaging and analytics capabilities  and investment in our infrastructure in order to scale the business  We believe we have a unique opportunity to expand the benefits of computer aided surgery and acute interventions around the world and have been and will continue to invest in the business accordingly  Our pro forma tax rate for the quarter was 21 1  compared with our expectations of 19  to 20  reflecting geographic mix  Our actual tax rate will fluctuate with changes in the geographic mix of income  changes in taxation made by local authorities  and with the impact of one time items  Our fourth quarter 2019 pro forma net income was  417 million or  3 48 per share compared with  353 million or  2 96 per share for the fourth quarter 2018 and  409 million or  3 43 per share for last quarter I will now summarize our GAAP results  GAAP net income was  358 million or  2 99 per share for the fourth quarter of 2019 compared with GAAP net income of  293 million or  2 45 per share for the fourth quarter 2018 and GAAP net income of  397 million or  3 33 per share for last quarter  The adjustments between pro forma and GAAP net income are outlined and quantified on our website and include excess tax benefits associated with employee stock awards  employee stock based compensation and IP charges  amortization of intangibles and acquisition related items  and legal settlements  We ended the quarter with cash and investments of  5 8 billion compared with  5 4 billion at September 30  2019  The cash generated from operations was partially offset by investments in working capital and infrastructure during the quarter  Capital expenditures for the quarter and the year are higher than historical averages as we invest in our infrastructure  We expect investments in our infrastructure to continue into 2020  In the quarter  we grew inventory by approximately  16 million to  596 million  representing approximately 142 days of inventory  which is slightly lower than at the end of the third quarter  We did not repurchase any shares in the quarter and have approximately  1 7 billion remaining under the Board buyback authorization In summary  I want to highlight certain business dynamics that may impact your models  First  as I noted  we will grow operating expenses appropriately as we see the substantial opportunity to expand the benefits of computer aided surgery and acute interventions  Calvin will provide you with operating expense growth guidance  In addition  as we align with our customer needs  we believe the percentage of leasing and alternative financing arrangements will increase over time  We also believe the number of trade in transactions will level off in the short term and then decline over time  System ASPs will fluctuate with geographic and system mix and may decline relative to the average total 2019 ASP reflecting increased multi system arrangements  While adoption of benign procedures has been a major contributor to overall INA revenue  to the extent benign procedures grow faster than complex procedures  INA per procedure may decline  Lastly  it is likely we will see elongated negotiation timelines and possibly price pressures as competition gets closer to launching their products  We will continue to manage the business for the long term as we believe that the fundamentals of the business are strong  And with that  I d like to turn it over to Calvin who ll go over procedure performance and our outlook for 2020 Calvin Darling    Senior Director of Finance Investor RelationsThank you  Marshall  Our overall fourth quarter procedure growth was approximately 19  compared to 19  during the fourth quarter of 2018 and nearly 20  last quarter  Our Q4 procedure growth was driven by 18  growth in U S  procedures and 22  growth in OUS markets  Overall procedure growth for the full year 2019 was approximately 18   equal to 18  in 2018 comprised of 17  growth in the U S  and 21  growth in OUS markets  In the U S  Q4 procedure growth was consistent with recent trends and was largely driven by continued strength in general surgery with substantive contributions from gynecologic and urologic procedures  In U S  general surgery fourth quarter growth in leading procedures  hernia repair and colorectal  remained solid at rates consistent with last quarter  Cholecystectomy growth continued to accelerate in the fourth quarter and now represents a significant driver of incremental procedures  While da Vinci cholecystectomy adoption has been robust given the high level of lab penetration  it is difficult for us to predict the extent and pace of future adoption chole  Phonetic  adoption  Bariatric procedures also showed continued solid growth in Q4 and will become an increasing area of field focus for us in 2020  For the full year 2019  approximately 421 000 U S  general surgery procedures were performed  up 29  from 2018  representing approximately 48  of overall U S  da Vinci procedures  Q4 U S  gynecology procedure growth was largely consistent with the first three quarters of 2019  For the full year 2019  approximately 282 000 U S  gynecologic surgery procedures were performed  up 6  from 2018  representing approximately 32  of overall U S  procedures  In U S  urology  fourth quarter dVP growth rates continued to exceed our expectations although  Phonetic  growth did moderate from Q3  For the full year 2019 approximately 138 000 U S  urologic procedures were performed  up just under 10  from 2018 representing approximately 16  of overall U S  da Vinci procedures  As a highly penetrated procedure category  we believe that our U S  prostatectomy volumes should track to the broader prostate surgery market and will likely grow more modestly in 2020  Fourth quarter OUS procedure volume grew approximately 22  compared with 24  for the fourth quarter of 2018 and 23  last quarter  Fourth quarter 2019 OUS procedure growth was driven by continued growth in urology procedures and earlier stage growth in general  gynecologic  and thoracic surgery In China  as in Q3  procedure growth accelerated modestly as new systems installed under the latest system quota began to provide capacity for incremental growth  In Q4  the China procedure growth rate slightly exceeded the overall OUS metric  As Marshall mentioned  39 systems were shipped into China in Q4  Note that 35 of these 39 systems went to new hospitals  Teams in these hospitals will need to move through training pathways and establish da Vinci procedure processes before these new systems contribute meaningfully to procedure growth in China In Japan  procedure growth was again strong at just over 40   reflecting growth in procedures granted reimbursement status in April 2018 and continued later stage growth in urology procedures  Our emphasis in Japan remains on surgeon and team training and building proctoring networks  Overall  European procedure growth was largely consistent with prior periods with variation by country  German results were particularly strong while results in the U K  lagged Now turning to the clinical side of our business  Each quarter on these calls we highlight certain recently published studies that we deem to be notable  However  to gain a more complete understanding of the body of evidence  we encourage all stakeholders to thoroughly review the extensive detail of scientific studies that have been published over the years  A recent article by doctors Wexner and Emile et all in the Journal of Techniques in Coloproctology provided results from a systemic review and meta analysis of intracorporeal versus extracorporeal anastomosis in minimally invasive right colectomy  This study analyzed data from 25 studies and 4 450 patients  Intracorporeal anastomosis was associated with significantly shorter length extraction site incisions  earlier bowel recovery  fewer complications  and lower rates of conversion  anastomotic leaks  surgical site infections  and incisional hernia as compared to extracorporeal anastomosis  This study highlighted the many clinical outcome advantages associated with intracorporeal anastomosis  da Vinci systems  instruments  and smart stapling technology enabling performing anastomosis of the bowel inside the body and it is our hope that more patients can benefit from intracorporeal anastomosis with continued adoption of our technology  Intuitive s investment in a prospective  multi center intracorporeal versus extracorporeal anastomosis study comparing robotic versus laparoscopic approaches called the ANCOR study is timely and the enrollment for this study is expected to be completed this year with results expected in 2021  The details of the ANCOR study are available online at clinicaltrials gov I will now turn to our financial outlook for 2020  Starting with procedures  as described in our announcement earlier this month  total 2019 da Vinci procedures grew approximately 18  to roughly 1 229 000 procedures performed worldwide  As communicated previously  during 2020  we anticipate full year procedure growth within a range of 13  to 16   We expect 2020 procedure growth to continue to be driven by U S  general surgery and procedures outside the United States where we are at earlier stages of adoption  We expect similar seasonal timing of procedures in 2019 as we have experienced in previous years with Q1 being the seasonally weakest quarter as patient deductibles are reset  Q1 and full year 2020 will benefit from one extra working day attributable to leap year With respect to revenue  as we have mentioned previously  capital sales are ultimately driven by procedure demand  catalyzing hospitals to establish or expand robotic system capacity  Capital sales can vary substantially from period to period based upon many factors including U S  healthcare policy  hospital capital spending cycles  reimbursement and government quotas  product cycles  economic cycles  and competitive factors  Within this framework  we d expect 2020 capital placements seasonality to generally follow historical patterns by quarter  During the fourth quarter of 2019  126 of the 336 systems shipped or 38  were under operating leases  We expect the proportion of systems placed via operating leases will vary from quarter to quarter and could trend up in the future  During Q3 and Q4  42   indecipherable  41  respectively of systems placements were upgrades to our Gen 4 platform  As we mentioned last quarter  we expect the proportion of trade in transactions to generally trend downwards in 2020 Turning to gross profit  Our full year 2019 pro forma gross profit margin was 71 7   In 2020  we expect our pro forma gross profit margin to be within a range of between 70  and 71  of net revenue  The slightly lower gross profit margin anticipated in 2020 reflects higher sales of newer products and infrastructure investments  Our actual gross profit margin will vary quarter to quarter depending largely on product  regional  and trade in mix  and the impact of new product introductions Turning to operating expenses  in 2019  our pro forma operating expenses grew 27   In 2020  we expect pro forma operating expenses to grow between 15  and 20   We expect our non cash stock compensation expense to range between  400 million and  440 million in 2020 compared to  336 million in 2019  We expect other income  which is comprised mostly of interest income  to total between  100 million and  115 million in 2020  With regard to income tax  in 2019  our pro forma income tax rate was 19 5   As we look forward  we estimate our 2020 pro forma tax rate to be between 20  and 21  of pre tax income with the increase primarily reflecting the anticipated geographic mix of pre tax income  That concludes our prepared comments  we will now open the call to your questions Questions and Answers Operator Operator Instructions  Our first question will come from the line of David Lewis with Morgan Stanley  Please go ahead David Lewis    Morgan Stanley    AnalystGreat  good afternoon  Just two questions from me  Gary  I wanted to start with you first on chole  it s probably your largest procedure set in terms of volume  two sequential quarters of acceleration within chole obviously still very low penetration  Historically  that was tied to sort of training  Physicians would use chole as a way of training in broader general surgery procedures  but just talk about the last two quarters of acceleration in this procedure  Do you think that s simply training  a leading indicator of general surgery or do you think something is going on distinct from that within broader chole and a quick follow up Gary S  Guthart    Chief Executive Officer  Member of the Board of DirectorsOkay  on the first one  just I m going to put a post it note on the assumption of its size relative to everything else  I ll let Calvin come back and put it in context size wise in terms of current run rate  but the underlying question of what are we seeing in cholecystectomy  we think there is a segment there where we re bringing differentiated clinical value  could be underlying clinical ailments like obesity  comorbidities  state of disease of the gall bladder  So while it s a large category as a whole  generally well served by minimally invasive surgery today  there are segments in it that are difficult and for which we think current product sets do really well  There is also a set of training or people deepening their experience as they go through it  So there is a mix of those two  We think there is a durable component segmenting out how big that is over time  We re still working through where we think those endpoints are  We have seen it both grow in the last few quarters and appear to be sticky not to have be a transient  Calvin  in terms of kind of setting in context relative to other procedures Calvin Darling    Senior Director of Finance Investor RelationsNo  I mean the size of the market  you can tell from our commentary  it s gotten to the point where general surgery is a meaningful enough category and a more and more significant contributor to growth within the general surgery category that s growing overall  Again  as we mentioned in the commentary  it s hard for us to gauge given the high lab penetration there to what extent and what pace it may ultimately adopt David Lewis    Morgan Stanley    AnalystOkay and Gary  second question for me is just on the capital environment  your fourth quarter U S  net placement growth was a little lower and Europe in 2019 was a little lower on a net placement basis  Maybe just comment on underlying demand for systems in the U S  and the European markets and also curious if has in any respect as competitors introducing new systems or talking about their new systems more publicly  has that in any way impacted demand or change the conversation you re having with large IDNs in the U S  or European customers  Thanks so much Gary S  Guthart    Chief Executive Officer  Member of the Board of DirectorsOn the outline of the first question  you just sort of think about what the installed base growth was  So if you think about capital demand underneath there is what s happening to installed base  so opening additional capacity in various places or trade ins of older generation systems  I ll let Marshall speak to the quantitative nature of your question with regard to the U S  and in Europe  but I d say there is  it s something    there is some trade in dynamics that I think the team has been discussing with you the last couple of quarters  In general  I think we re feeling like it s reasonably stable On the second piece of what will competitive advertising and conversation do  From time to time  we see it delay deals  We definitely see increasing conversations as they get closer to market with what they want to do or other companies are starting to get some clearances in other regions  In general  our teams have handled that pretty well  but I think the noise level will increase  I think that customers are interested in listening to other pitches  I think we re pretty well positioned to have a conversation about that  but I do see delay from time to time  It kind of comes in waves and then it will settle as the world figures out kind of what they re offering  but Marshall maybe a little bit on    a little more quantitative answer than that Marshall L  Mohr    Executive Vice President and Chief Financial OfficerYes  first  the capital environment has been approximately the same  There hasn t been much in terms of change in motives and so forth over the last several quarters  The number of systems that we placed in the U S  which is disclosed in the website is what is healthy in our view  In fact  the other way we measure how healthy we re    how well we re doing is the utilization of systems and utilization of systems growth as I said was 6   which is consistent with where it s been and in Europe we saw as I said  maybe flattish number of systems placed both in the quarter as well as compared to the previous year in total and just be aware of averages and it s going to be lumpy  when you re in earlier stages of adoption in less mature markets  you re going to see a lumpiness to placements of capital  When we look at the four largest markets  we saw nice growth  which again as Calvin commented  procedure growth in Germany was strong and we saw a nice placements in Germany for example  That help David Lewis    Morgan Stanley    AnalystGreat  thank you so much OperatorOur next question will come from the line of Tycho Peterson with J P  Morgan  Please go ahead Tycho Peterson    J P  Morgan    AnalystHey  thanks  I ll start with SP  just curious following your discussions with FDA  any color you can provide on just when the trial is going to start  a size  and what s expected for follow up analysis and then outside the U S   you re obviously generating data on SP and thoracic and OSA in Korea  Can you just talk about some of the data generations outside the U S  as well Gary S  Guthart    Chief Executive Officer  Member of the Board of DirectorsSure  on the first one  I think we re settling in on what the trial will look like and I m not ready yet to answer that  but I think we re getting close  So in future quarters we should be able to answer that question  With regard to what we re seeing elsewhere  we re starting to see in terms of Korea where we have more regulatory room and in clinical indications  We ll start seeing a whole series of publications coming out talking about where there is opportunity  It s I think going to be quite interesting and shows real potential for us  it s the thing that drives our underlying commitment and excitement  I don t have them off the tip of my fingers  I do know that in future quarters we will start describing to you what the substance of some of these publications are as they start to release Tycho Peterson    J P  Morgan    AnalystAnd then  just sticking with the pipeline for a minute  Can you just comment on IRIS  Where we are in the roll out  It s obviously early days and then also if you could just comment separately on the Scholly endoscope acquisition and have you worked the supply chain headwinds there Gary S  Guthart    Chief Executive Officer  Member of the Board of DirectorsGreat  I will do so  IRIS  first couple of accounts up and running  We expect more this quarter  It s really testing the whole order to delivery pipeline  I think of that as a digital pipeline that has to go through  Feedback is really encouraging  So this early part  it s one of these things that s easier to describe  but to do well is hard  Making sure all your cloud connections are right  making sure you have all your security protocols done  getting the turnaround times right  getting all your machine learning algorithms right  Feedback has been really good about its ability to help surgeons visualize pre case  which is fantastic  used in other kinds of ways in terms of patient consultation and then access during the case  So the kind of the core idea I think is being vetted nicely  We have said before  we don t think it s a significant revenue driver in 2020  I think I would encourage people to think about this as baseline core technology  the kinds of things that as you develop systems like this in the future that customers will come to expect a little bit like our Firefly product  it is additive in the way that it s    the system itself becomes greater than the sum of its parts  So IRIS I think looks quite strong On the Scholly acquisition  the team is doing a really nice job  We were right to bring it in  We were right to bring in when we did  That is doing a couple of things for us  It s giving us a little more alignment around next gen products which is exciting for us  it s helping us double down on some investments in terms of capacity and efficiency that goes with that capacity and it will in the medium term start releasing some profitability and financing with regard to the way we produce our endoscopes that can be turned around and reinvested in the business  So  so far so good  It is real work  They are a very good team  I think we knew what we were bringing in and acquiring  I m really pleased with the leadership of the group and our team members that have joined us in Germany and in Boston or in Massachusetts  It s not to say there isn t work to be done  but so far so good Tycho Peterson    J P  Morgan    AnalystOkay and then one just last clarification for Marshall  you called out of China pull forward dynamic around the tariff  Can you just in the context of the 39 systems  are you able to quantify how much of that was tied to the tariff Marshall L  Mohr    Executive Vice President and Chief Financial OfficerWell  not    I can t quantify specifically  I would just tell you that there were a number of systems that the customers decided to expedite the process and we were the beneficiary of that obviously Tycho Peterson    J P  Morgan    AnalystOkay  thank you OperatorOur next question will come from the line of Bob Hopkins with Bank of America  Please go ahead Robert Hopkins    Bank of America    AnalystGreat  thank you  Just a first  congratulations on the Ion  Technical Issue  from the case  you highlighted some tailwind potential headwinds  but called out that revenue per case could decline  Phonetic  next year Gary S  Guthart    Chief Executive Officer  Member of the Board of DirectorsHey Bob  we heard  Speech Overlap  you got kind of broken up on the call  so could you reask the question Robert Hopkins    Bank of America    AnalystSorry about that  just on instrument  Technical Issue  just want to make sure I hear the messaging because there s some positives  Technical Issue   So I just want to make sure the messaging on the INA line for the next 12 months Gary S  Guthart    Chief Executive Officer  Member of the Board of DirectorsYeah  so what I said Bob was we ve really seen good contribution to INA revenue overall from benign procedures  but as we ve described before the increase in the INA per procedure is really a reflection of additional advanced instrument revenue and then per procedure offset by benign procedure growth  So all I m calling out is if we re successful in growing benign procedures much faster than complex procedures  then you will see then that it will win the tug of war and therefore your INA per procedure might decline  On the advanced instruments  we ve enjoyed further penetration into procedures in which advanced instruments are used and as that has occurred  then our revenue associated with procedures  our revenue per procedure has grown disproportionately to the number of procedures  Over time as you penetrate that  then you will revert to your advanced technology growth  We ll be consistent with the number of additional procedures you add versus adding also incremental procedures that were previously not including it  So all we re saying is that there is the potential that the growth rate will decline  We still expect growth  just a lower rate Robert Hopkins    Bank of America    AnalystOkay  thank you  And then quick question on U S  capital  Over the last couple of years  the growth in procedures per average system has been remarkably consistent at about 5  especially in the U S  Is there a reason in your view why that number might change meaningfully in 2020 or is that trend line expected to continue Gary S  Guthart    Chief Executive Officer  Member of the Board of DirectorsNo  I think directionally  continued growth in procedures per system is something we would expect  It s something that we re actively working with customers sharing analytics and data to help them to make their practices programs as efficient as they can be  So I think the trend I don t know if it going to continue exactly at the same rates  but increasing utilization is something we would expect Robert Hopkins    Bank of America    AnalystThank you OperatorOur next question will come from the line of Larry Biegelsen with Wells Fargo  Please go ahead Lawrence Biegelsen    Wells Fargo Securities    AnalystGood afternoon and thanks for taking the question  Hopefully you guys can hear me OK  Just one on the Ion and then one on the P L  How should we think about the ramp of Ion in 2020  Is it still going to be a controlled launch or we just expect a steady increase in placements and I have one follow up Gary S  Guthart    Chief Executive Officer  Member of the Board of DirectorsAs we ve said in our prepared remarks  Ion is in the early stages of a measured launch and so you should expect that it will grow slowly over time Calvin Darling    Senior Director of Finance Investor RelationsSlowly through 2020 and then more rapidly thereafter Lawrence Biegelsen    Wells Fargo Securities    AnalystI got it and gross margins came in better in 2019 versus your original guidance  What are the puts and takes on the gross margin in 2020 and separately Gary  R D as a percent of sales has been increasing steadily  it s almost 10  of sales in 2019  Where do you see that going over time  Thanks for taking the questions guys Gary S  Guthart    Chief Executive Officer  Member of the Board of DirectorsOkay  sure  So for gross margins  the gives and takes are  as I outlined in my prepared remarks  pricing on systems  reductions in cost  manufacturing efficiency and mix  mix of both customers and types of product and I think that what we re messaging for next year is that the gross margins will decline slightly reflecting primarily product mix and a shift    the effect of new product and investments in the infrastructure Lawrence Biegelsen    Wells Fargo Securities    AnalystAnd R D  Marshall as a percent of sales  I m just curious if you expect that to continue to increase  Sorry  Gary Gary S  Guthart    Chief Executive Officer  Member of the Board of DirectorsYeah  I know I can jump in and take that one  I think about    we haven t  Phonetic  grown R D as a percentage of sales pretty consistently over the last three years and our messaging to you has been  we re going to bring a couple of new platforms to market in parallel with some of our multiport efforts SP and Ion being those two that we think that next gen imaging and non optical imaging is important  non white light imaging is important and we ve been investing in that domain  We have been investing for scale  We ve talked about the fact that I think there is a virtuous cycle here  which is as utilization goes up and volumes go up  it allows us to start taking advantage of automation opportunities and changing the way we manufacture  That has taken the company to be a little more capital intensive than in years past  but some of the things you were just talking about the linkage to your prior question on gross margin are enabled by these capital investments on multi year timelines that allow us to get production scale advantages and that allows us to share some of that cost savings with our customer and be able to be into lower complexity procedures at good economics and good economics for the company as well as the customer  So we ve been doing that as well  And then lastly  it s been building in digital infrastructure  So those are the major buckets that have been taking the R D spend side  I think we are not thinking that that number will leap going forward  but we also think we re still in the early innings of a baseball game here that have real opportunity long term for the growth of the market and we think that we can position ourselves really well by making sure that those four buckets are adequately stacked  Marshall anything Lawrence Biegelsen    Wells Fargo Securities    AnalystThanks for taking the question OperatorOur next question will come from the line of Rick Wise with Stifel  Please go ahead Frederick Wise    Stifel Nicolaus    AnalystHi  good afternoon  Gary  everybody  You talked    Marshall mentioned it    I think Calvin mentioned it that system trade ins may slow  may trend down  I just want to make sure that I m understanding the reasons why  Is it the lack of a major new next gen system launch and so you ve seen the trade ins  quote the easy trade ins and maybe just as part of that  Gary  just reflecting back on R D and innovation  obviously  you re launching a lot of new products and innovation  but should we be thinking that you don t need to launch next gen big iron  Phonetic  or how do we think about that  those two aspects of trade ins and the pipeline Calvin Darling    Senior Director of Finance Investor RelationsSo trade ins  we ve been in the middle of a fairly strong cycle of trade ins and you ve seen it go up quarter over quarter  last two quarters kind of flattening out and what we commented on it at the third quarter  Rick  was that the total population of SI s that are out there that can be traded in obviously is decreasing as customers trade in their systems and so the population is decreasing and when we look back at historical patterns for previous generation products  we think that we re at the peak of how much of that remaining base will be traded in  in any particular quarter and so the two of those things lead us to the conclusion that you will see a decrease in the number of trade ins as we go forward Gary S  Guthart    Chief Executive Officer  Member of the Board of DirectorsThe second half of the question I might quibble with  the description is big iron  so I m not going to own that  but I will talk to innovation in multiport  We re not done innovating in multiport  We re often asked  are you  but I see SP  I see Ion as  is that it and the answer is categorically no  We think there s room for additional innovation beyond our Gen 4 multiport products and we re working on those things Frederick Wise    Stifel Nicolaus    AnalystAnd just two other quick ones  I d be curious to hear more about sales force productivity  you highlighted  Gary the improved productivity in the third quarter  it seems like that s has to be part of the equation I m guessing in the fourth quarter  how do we think about that factor as a driver in 2020  I ll just ask my second one  Your competitors or potential robotic competitors are talking about digital surgery and we ve talked about this before but I just wonder if you have competitors marketing something called digital surgery  how do we imagine Intuitive answering that kind of a functional or marketing push  Thank you so much Gary S  Guthart    Chief Executive Officer  Member of the Board of DirectorsOkay  on the first question of sales force productivity  we saw a move in the right direction in the fourth quarter  some of the underlying dynamics in terms of rapid procedure growth or a healthy procedure growth driving the need for new territories still exists  So I credit our sales leadership team is doing a really nice job both managing growth and helping the organization become more productive while thinking through territory opportunities as well as efficiency opportunities  That s a long way of saying we made a step in the right direction  I think they have opportunity to keep moving in the right direction in terms of productivity  So far so good With regard to some of the commentary around digital surgery  The short answer is  welcome to the party  I think that we ve been working these issues for more than a decade  As I said before  my initial response is it s a valuable thing to be working on and that s why we ve been doing it  We ve been the Internet of Things in surgical robots for a decade  cloud enabled for a decade  We are quite deep  As you go out and talk a little more than the tag line  you talk about what tag lines are  what s the substance  So dig down a little bit and the substance comes down to I think four opportunities  One opportunity is in the use of big data for analytic power and that says that  as you look across large sets of customers doing various things  can you help establish benchmarks that people can improve upon and we have done that  It s been something we ve been working on  So I think we re becoming quite skilled and will become more so  That s one category  Another category is the use of computing power in real time to aid the surgeon or interventionalists during a case to get a better outcome and absolutely interesting There are many  many companies in the world that are thinking about that and making progress and we are one of them  Ion is fundamentally powered by computing to help you make good decisions  IRIS is fundamentally a real time computing capability in addition to Big Data  So that s one  The next bucket is around education and the reduction of variation team to team  We know that care team variation in any acute intervention  be it surgery robotic surgery  laparoscopy  Phonetic  is highly variable and the use of computing and analytics to help that process is clear and I talk to a little bit about how much we have in simulation  200 000 simulated tasks done by surgeons this last year  17 000 hours of simulation capability  These are things that we can help turn into better learning environments and reduction in care team variation  And the last bucket is efficiency improvement  the use of computing technologies and networking to help hospitals become more productive and to help our company become more productive and we re leveraging those opportunities on both to help our customers and otherwise  So I look forward to the conversation  I think it will win  The winner won t be the tag line  I think the winner will be those who deliver real value that s validated against those four categories Frederick Wise    Stifel Nicolaus    AnalystThank you so much Gary S  Guthart    Chief Executive Officer  Member of the Board of DirectorsWe ll take one more question  operator OperatorOkay  The final question    one moment here  That final question will come from the line of Richard Newitter with SVB  Please go ahead Richard Newitter    SVB Leerink    AnalystHi  thanks for taking the questions  Just two quick ones  The first    I ll ask them both just right upfront  The first one  the comments on chole    second is the training procedure and kind of what you re seeing there as a spillover to again comfortable with the general surgery  are you seeing that same dynamic increase in the usage or the utilization within hernia as kind of like a training ground for other types of general surgeries or is hernia kind of also equally as sticky and then the second question just Marshall  on the INA per case  if the benign growth does accelerate relative to the advanced type cases  what s the impact to gross margin there  Thank you Gary S  Guthart    Chief Executive Officer  Member of the Board of DirectorsI ll take the first one  I ll let Marshall take the second one  One thing I would    just to be clear on general surgery  is general surgery is a quite a diverse set of procedures with quite a diverse set of practice patterns among general surgeon practitioners or practices  I d  first of all  I think they choose procedures to do not simply to be trained but because they think  they and the patient can be benefited by that procedure  So I don t think they run off and train for the sake of training  I think they decide that there is some value here  They will sequence their way into a practice and that would make sense  both by patient selection and by the type of procedure they do  You had asked does the same kind of effect of  well  let s start with the right patient population for cholecystectomy also apply to something like hernia  The answer to that is yes  Some surgeons will elect to go into a hernia set first then if they find value in the product find value in the process  they may elect to move from there to a different procedure  Interestingly  we found that there is not a one size fits all way that a practice adopts  They may choose a different entry point depending on their interests and experiences  Second question  Marshall Marshall L  Mohr    Executive Vice President and Chief Financial OfficerINA per case  if benign procedures were to grow faster than more complex procedures  it s a very slight improvement in gross margin and the advanced instruments have just a slightly lower gross margin than our other instruments Gary S  Guthart    Chief Executive Officer  Member of the Board of DirectorsOkay  that was our last question  In closing  we believe there is a substantial and durable opportunity to fundamentally improve surgery and acute interventions  Our teams continue to work closely with hospitals  physicians  and care teams in pursuit of what our customers have termed the quadruple aim  better more predictable patient outcomes  better patient experiences  better experiences for care teams  and ultimately a lower total cost of care per patient episode  We believe value creation in surgery and acute care is foundationally human  It flows from respect for and understanding of patients and care teams  their needs and the environment in which they operate  Thank you for your support on this extraordinary journey  We look forward to talking with you again in three months Operator Operator Closing Remarks Duration  64 minutesCall participants Calvin Darling    Senior Director of Finance Investor RelationsGary S  Guthart    Chief Executive Officer  Member of the Board of DirectorsMarshall L  Mohr    Executive Vice President and Chief Financial OfficerDavid Lewis    Morgan Stanley    AnalystTycho Peterson    J P  Morgan    AnalystRobert Hopkins    Bank of America    AnalystLawrence Biegelsen    Wells Fargo Securities    AnalystFrederick Wise    Stifel Nicolaus    AnalystRichard Newitter    SVB Leerink    Analyst
More ISRG analysis
All earnings call transcripts",2020-01-23,The Motley Fool,https://invst.ly/pm58k,2066706
111532,333047,ISRG,Quest Diagnostics To Buy Select Assets Of Memorial Hermann ,opinion,Quest Diagnostics   NYSE DGX   recently signed a multi pronged  long term definitive deal to acquire select assets of Memorial Hermann Health System  one of the largest not for profit health systems in Southeast Texas  However  the financial terms of the deal have been kept under wraps According to Quest Diagnostics  this is a step forward in its commitment toward offering high quality  cost efficient diagnostic services in Texas  especially in the Houston metropolitan area Per the terms of the deal  the assets that will be acquired comprise all operations of Memorial Hermann Diagnostic Laboratories   MHDL    the outreach laboratory segment of Memorial Hermann  Nearly 30 MHDL patient service centers and 60 in office laboratory service sites will be acquired by the company  This implies that these services will shift to the Quest Diagnostics full service laboratory in Houston We note that Memorial Hermann Health comprises a network of 17 hospitals and more than 300 care delivery sites in the Greater Houston region More About the DealAfter completion of the deal  Quest Diagnostics will be offering professional laboratory management services for all of Memorial Hermann s 21 hospital laboratories  which specialize in offering onsite rapid response testing  Apart from this  Quest Diagnostics will become the sole preferred provider of laboratory services for the Memorial Hermann Health Plan  Physicians and patients will be benefiting from access to Quest Diagnostics  market leading test menu and broad health plan coverage as well as an expanded community of nearly 80 patient services centers throughout Houston Subject to customary regulatory approvals  the transaction is expected to be completed within the second quarter of 2020 Recent DevelopmentIn December 2019  Quest Diagnostics acquired select assets of the clinical laboratory services business segment of Boston Clinical Laboratories   BCL    a Waltham based regional provider of laboratory services  BCL s patients and providers now have access to Quest Diagnostics  expanded range of diagnostic services  a broader network of patient service centers as well as an array of unique tools  such as the company s Quanum portfolio of healthcare information technologies and data analytics Price PerformanceIn the past year  the company s shares have outperformed the   The stock has rallied 28  against the industry s 15  decline Zacks Rank and Stocks Worth a LookQuest Diagnostics currently has a Zacks Rank  4  Sell  A few better ranked stocks from the broader medical space are West Pharmaceutical Services   NYSE WST    Hill Rom Holdings  Inc   NYSE HRC   and Intuitive Surgical   NASDAQ ISRG    each currently carrying a Zacks Rank  2  Buy  West Pharmaceutical Services has a projected long term earnings growth rate of 14   You can see Hill Rom s long term earnings growth rate is estimated at 11 7  Intuitive Surgical has a long term earnings growth rate of 11 8  5 Stocks Set to Double Each was hand picked by a Zacks expert as the  1 favorite stock to gain  100  or more in 2020  Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth Most of the stocks in this report are flying under Wall Street radar  which provides a great opportunity to get in on the ground floor ,2020-01-28,Zacks Investment Research,https://www.investing.com/analysis/quest-diagnostics-to-buy-select-assets-of-memorial-hermann-200502079,200502079
111533,333048,ISRG,Here s Why You Should Add HealthEquity  HQY  To Portfolio Now,opinion,HealthEquity  Inc    NASDAQ HQY   is likely to gain from solid prospects in Health Savings Account   HSA   business Shares of this company have rallied 11  against the  s 11 1  decline in a year s time  Meanwhile  the S P 500 index has risen 23 8  over the same time frame This  5 billion health care account management company currently has a Zacks Rank  2  Buy   HealthEquity s earnings are expected to grow 25  in the next five years  Also  the company has a trailing four quarter positive earnings surprise of 46 4   on average The stock also has a  of A  Our research shows that stocks with a Momentum Score of A or B  when combined with a Zacks Rank  1  Strong Buy  or 2  are better picks than most Let s take a closer look at the factors working in favor of the company right now Strength in HSA   GuidanceHealthEquity is an Internal Revenue Service approved non bank custodian of HSA  which is a medical savings account available to taxpayers in the United States As of Oct 31  2019  the total number of HSAs for which HealthEquity served as a non bank custodian was 5 million HealthEquity clinched the top position in the HSA industry through its first mover advantage  focus on innovation and differentiated capabilities The company s market share  measured by custodial assets  has literally tripled from 4  in December 2010 to 13  in December 2018  per the 2018  HSA Research Report  Currently  HealthEquity is the third largest HSA custodian in terms of market share HealthEquity  Inc  Price and Consensus   Devenir further suggests that the HSA market will reach a worth of  88 billion in HSA assets held over by 30 million accounts by 2021 end Driven by the solid aspects  the company recently raised its fiscal 2020 revenue expectations Notably  HealthEquity now expects revenues between  520 million and  526 million  much higher than the earlier projected range of  341  347 million Adjusted net income is projected between  101 million and  105 million  much above the earlier stated range of  76  80 million Adjusted earnings per share  EPS  for fiscal 2020 are expected within  1 46  1 52  compared to  1 10  1 16 issued earlier Estimates ScenarioFor fiscal 2020  the Zacks Consensus Estimate for revenues is pegged at  524 1 million  suggesting a year over year upside of 82 5   For adjusted EPS  the same stands at  1 50 per share  indicating growth of 26 1  from the year ago reported figure Other Stocks to ConsiderOther top ranked stocks in the broader medical space are Cerner Corporation   NASDAQ CERN    Intuitive Surgical   NASDAQ ISRG   and DexCom   NASDAQ DXCM    each carrying a Zacks Rank  2  You can see  Cerner s long term earnings growth rate is estimated at 13 6  Intuitive Surgical s long term earnings growth rate is projected at 11 8  DexCom s fourth quarter earnings growth rate is estimated at 31 5  5 Stocks Set to DoubleEach was hand picked by a Zacks expert as the  1 favorite stock to gain  100  or more in 2020  Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth Most of the stocks in this report are flying under Wall Street radar  which provides a great opportunity to get in on the ground floor ,2020-01-28,Zacks Investment Research,https://www.investing.com/analysis/heres-why-you-should-add-healthequity-hqy-to-portfolio-now-200502077,200502077
111534,333049,ISRG,Intuitive Surgical down 4  after Q4 report,news,"Sell side analysts weigh in after Intuitive Surgical  ISRG  4 1   reported Q4 and 2019 results after the close yesterday 
Evercore ISI s Vijay Kumar  Neutral   Gross margin guide for this year  will  fluctuate  according to CFO Marshall Mohr  70   71  versus 72 2  last quarter  implicitly assuming geographical skew towards U S  Price target cut to  595 from  600 
SVB Leerink s Richard Newitter  Outperform  670   Guidance  probably conservative  leaving room for share appreciation 
Cantor Fitzgerald s Craig Bijou  Overweight  690   Continued investment in imaging and analytics capability could slow EPS growth  but fundamentals remain strong 
SA Authors and Sell Side ratings both Bullish ",2020-01-24,Seeking Alpha,https://invst.ly/pmfu3,2067218
111536,333051,ISRG,Why Intuitive Surgical Is a Buy After Reporting Q4 2019 Earnings,news,"Connected healthcare company Intuitive Surgical  NASDAQ ISRG  put the final wrap on 2019  reporting a strong finish to the year for the company s daVinci lineup of robotic surgery machines and related services  It s been an epic run over the last decade  and the still nascent robotic assisted surgery industry has plenty of open space ahead of it 
However  Intuitive s guidance to kick off 2020 left some investors looking for more  and the stock has pulled back over 7  from all time highs as of this writing  A breather was perhaps in the cards after the 23  increase the stock notched last year  but short termism looks to be setting up another buying opportunity for long term shareholders   

A strong finish to a strong year
Intuitive s results accelerated in the final quarter of the year  with revenue and adjusted earnings growing 22  and 18   respectively  Business was boosted by both a growth in worldwide procedures  which grew 16  year over year  driven by higher general surgery and urology   new daVinci machines placed in service  up 12   with the total installed systems totaling 5 582 at year end   and instrument and accessory sales  which increased 24     
It all added up to a great year for Intuitive  albeit one in which earnings grew slower than revenue as the company invested in new research to expand the types of procedures its robots can handle 

Pp   percentage point  Data source  Intuitive Surgical   
As for the point regarding new machines  daVinci SP  which stands for single port  designed for deep tissue access  and Ion  for lung biopsies  are early on in the sales cycle  Six SPs were installed in Q4  bringing the installed base up to 44  and the first three Ion systems placed in Q3 grew to an installed base of 16 by the end of Q4  New uses for both machines continue to be developed  as well as new instruments for the flagship daVinci X and Xi platforms  For example  the E 100 generator and SyncroSeal systems designed to help surgeons cut and seal tissue got FDA approval and began to be sold in the last quarter  and the new IRIS augmented reality system for imaging and analytics also began clinical use 
Don t sweat the early 2020 outlook
All of the new developments at Intuitive are well and good  but in spite of the upbeat news  guidance for the new year fell short of hopes  Total procedures using one of Intuitive s robots grew 18  to 1 23 million worldwide last year  but procedure growth was forecast to slow to a 13  to 16  rate in 2020  As the primary generator of revenue sources  a slowdown in procedure growth would imply sales will follow suit after the 22  surge that marked the end of 2019   
It isn t the only way daVinci can make money  though  as new instruments to support new kinds of surgeries and training and support services should also provide a boost  After the post report pullback  Intuitive s stock trades for 44 5 times adjusted earnings    the cheapest it s been in a few years  Based on average analysts  expected profits in 2020  the stock trades for an earnings multiple of 36 8  implying the general view that profits will keep expanding at a double digit pace   
That is nonetheless a hefty premium for this healthcare stock  but such is the case for high quality companies taking the lead in advancing technology  Besides  this is still a high growth enterprise worth holding for the long haul  especially as healthcare starts to feel the effects of the cloud  connectivity  and big data forces that have been at work in other industries in the past decade  Put another way  investors might be expressing a little displeasure with the immediate term outlook  but there is plenty to like with Intuitive Surgical  The recent pullback looks like an opportunity to start or add to positions in the robotic surgery leader ",2020-01-29,The Motley Fool,https://invst.ly/pog9a,2070645
111540,333055,ISRG,Intuitive Surgical Shows No Signs of Slowing Down,news,"Intuitive Surgical  NASDAQ ISRG  is the company behind the da Vinci surgical system  one of the leading robotic assisted surgery devices on the market  The da Vinci system was first approved by the U S  Food and Drug Administration  FDA  back in 2000  and the innovative piece of tech has helped Intuitive Surgical perform incredibly well over the years  
The company s shares are up by 236 4  over the past five years alone  whereas the S P 500 is up by only 61 4  over the same period  Despite being about two decades old  though  Intuitive Surgical s signature da Vinci system continues to make headway  and the company s impressive run on the market is likely not over  at least if its latest earnings report is any indication 

Impressive fourth quarter results
Intuitive Surgical s fourth quarter financial results were impressive across the board  The company shipped 336 da Vinci systems during the quarter  compared to 290 during the fourth quarter of 2018  Intuitive Surgical now has 5 582 da Vinci systems installed  which represents a 12  year over year increase 
Furthermore  the number of procedures performed with da Vinci systems increased by 19  year over year  while Intuitive Surgical s revenue of  1 28 billion and its net income under generally accepted accounting principles  GAAP  of  358 million both grew by about 22   Digging a little deeper  it is worth noting that the company s top line now relies primarily on its recurring revenue  
Intuitive Surgical derives recurring revenue from several sources  First  there is the sale of instruments and accessories for its da Vinci system  and as the number of procedures performed with Intuitive Surgical s signature robotic surgery device grows  so will the company s sale of instruments and accessories  During the fourth quarter  the company s sales of instruments and accessories were  671 million  representing a 24  year over year increase  And according to the company s CFO  Marshall L  Mohr   The increase in instrument and accessory revenue was primarily driven by procedure growth and stocking orders associated with China system sales   
Once a healthcare provider installs one of its da Vinci systems  Intuitive Surgical provides various services    including maintenance and repair services    to that provider  The company also generates revenue from leasing its da Vinci system  These pricey devices cost anywhere between  500 000 and  2 5 million depending on several factors  the model  configuration  etc    a sum that is beyond the means of some healthcare providers 
Intuitive Surgical started offering  operating lease arrangements  back in 2013 to allow some of its customers the flexibility to acquire the da Vinci system without paying the entire lump sum up front  During the fourth quarter  the company shipped 126 systems under operating lease arrangements  compared to 84 during the prior year quarter  
Intuitive Surgical s recurring revenue accounted for about 67 4  of its total revenue during the third quarter  This is important since it means the company doesn t rely exclusively    or even significantly    on the sale of its da Vinci systems  and Intuitive Surgical can easily weather the storm if sales of da Vinci systems decline  
Worth the premium
Intuitive Surgical is currently trading at 49 37 times past and 37 times future earnings  Also  the company s price to earnings growth  PEG  ratio is 3 89  These valuation metrics aren t particularly attractive  but if there s any company that is worth the premium  Intuitive Surgical most definitely is 
The company is the leader in robotic assisted surgery devices  and despite some 20 years of growth under its belt  Intuitive Surgical continues to make headway  What s more  the company s top line is relying more and more on recurring revenue  and as the number of procedures performed with its da Vinci system continues to rise  so will that recurring revenue  
Of course  there are no certainties in life  but given the strength of its model  Intuitive Surgical looks like a screaming buy  Investors looking for top growth stocks need not look any further ",2020-01-29,The Motley Fool,https://invst.ly/poi8h,2070804
111543,333058,ISRG,Intuitive  ISRG  At A 52 Week High  What s Driving The Stock ,opinion,On Nov 29  shares of Intuitive Surgical   NASDAQ ISRG   scaled a new 52 week high of  594 17  closing the session slightly lower at  592 90  In fact  the stock has rallied nearly 11 9  since its third quarter earnings announcement on Oct 17 Solid growth in the flagship da Vinci procedures  surge in international sales and impressive full year guidance prompted the rally Let s take a closer look at the growth propellers Robust Q3 Earnings The company exited the third quarter on a promising note  with better than expected earnings and revenue numbers International revenues improved 36  year over year during the quarter  Per management  this upside was driven by higher uptake of instruments and accessories  robust procedure growth and impressive customer buying patterns Adjusted gross profit in the quarter improved 23 4  year over year Gross margin in the quarter was 72   highlighting an expansion of 50 basis points  bps  The raised outlook for 2019 procedure growth buoys optimism among investors  indicating the continuation of this bullish momentum through the year Other Growth Driving FactorsIn November 2019  Intuitive Surgical attained FDA approval for two of the company s da Vinci surgical systems  With the recent nods  Intuitive Surgical is likely to witness further momentum in its da Vinci surgical system  The clearance for these two innovative technologies is expected to enhance procedures that required sealing Moreover  investors are looking to a strong integration synergy from the company s recent acquisition of the robotic endoscope unit of Sch lly Fiberoptic s business  This acquisition has integrated Sch lly s robotic endoscope manufacturing business and two Sch lly sites into Intuitive Surgical s operations Moreover  the company s da Vinci procedures registered a 20  global uptick in the third quarter of 2019  The upside was driven by healthy growth in U S  General Surgery  In the reported quarter  Intuitive Surgical placed 275 da Vinci surgical systems  with the installed base growing 12  year over year Meanwhile  Intuitive Surgical had a great run on the bourses in the past year  Over the past year  the stock has rallied 8   higher than the broader  s growth of 5 4   The company currently has a market cap of  68 52 billion  An earnings growth rate of 12 2  for the next five years instills optimism Zacks Rank   Other Stocks Worth a LookIntuitive Surgical currently carries a Zacks Rank  2  Buy  A few other top rankedstocks from the broader medical space are Haemonetics Corporation   NYSE HAE    NuVasive  Inc   NASDAQ NUVA   and ResMed   NYSE RMD    While ResMed sports a Zacks Rank  1  Strong Buy   the other two carry a Zacks Rank  2  You can see Haemonetics has a projected long term earnings growth rate of 13 5  NuVasive has an expected long term earnings growth rate of 10 9  ResMed has a long term earnings growth rate of 12 9  Free  Zacks  Single Best Stock Set to DoubleToday you are invited to download our latest Special Report that reveals 5 stocks with the most potential to gain  100  or more in 2020  From those 5  Zacks Director of Research  Sheraz Mian hand picks one to have the most explosive upside of all This pioneering tech ticker had soared to all time highs and then subsided to a price that is irresistible  Now a pending acquisition could super charge the company s drive past competitors in the development of true Artificial Intelligence  The earlier you get in to this stock  the greater your potential gain ,2019-12-02,Zacks Investment Research,https://www.investing.com/analysis/intuitive-isrg-at-a-52week-high-whats-driving-the-stock-200489210,200489210
111544,333059,ISRG,Which Healthcare Mutual Fund To Buy  FSMEX Or PRHSX ,opinion,Often  the healthcare sector is relied on for safeguarding investments  This is because demand for healthcare services does not vary much with market conditions and investments in the sector provide sufficient protection to the capital invested Many pharmaceutical companies also offer regular dividends  Companies that pay out consistent dividends are financially stable and generate consistent cash flows irrespective of market conditions  Mutual funds are perfect choices for investors looking to enter this sector since they possess the advantages of wide diversification and analytical insight The U S  healthcare sector has performed decently so far this year  The Health Care Select Sector SPDR Fund  XLV  has gained 16 7  year to date despite fears related to a slowdown in the global economy as well as trade tensions So far this year  mega scale healthcare mergers  corporate restructuring as well as FDA approvals have buoyed gains for the space  As a matter of fact  America s healthcare sector is being anticipated to experience a major revolution in the days to come  With an uptick in over the counter drug sales coupled with major breakthroughs in the treatment of rare conditions  the healthcare space is deemed to gain big Under such circumstances  investing in healthcare mutual funds seems prudent  However  choosing the right mutual funds for your portfolio can become cumbersome  Let us  therefore  discuss which of these two funds are better for you Fidelity Select Medical Technology and Devices Portfolio This fund aims for capital growth  It invests the majority of its assets in companies that are engaged in activities such as research  manufacturing  supply and sale of medical equipment and related technologies etc  The non diversified fund invests in common stocks and in U S  and non U S  issuers  This Sector Health product has a history of positive total returns for over 10 years  Specifically  the fund s returns are 11 7  over the 3 year and 7 5  of the 5 year period  To see how this fund performed compared in its category  and other  1 and  2 Ranked Mutual Funds     The Fidelity Select Medical Technology and Devices Portfolio fund  as of the last filing  allocates its assets in top two major groups   Large Growth and Intermediate Bond  Further  as of the last filing  Boston Scientific Corp  NYSE BSX   Becton Dickinson  NYSE BDX    Company and Thermo Fisher Scientific  NYSE TMO  were the top holdings for FSMEX This Zacks Mutual Fund Rank  1  Strong Buy  was incepted in April 1998 and is managed by   FSMEX carries an expense ratio of 0 73  and requires a minimal initial investment of  0 T  Rowe Price Health Sciences Fund The fund seeks appreciation of capital in the long term  It invests a minimum of 80  of its assets in common stocks of companies which are involved in research  development  production and distribution of products and services which are related to healthcare  medicine or life sciences  The fund mostly invests in mid  and large capitalization companies This Sector Health product has a history of positive total returns for over 10 years  Specifically  the fund s returns over the 3 and 5 year benchmarks are14 2  and 12 9   respectively  To see how this fund performed compared in its category  and other  1 and  2 Ranked Mutual Funds     T  Rowe Price Health Sciences Fund  as of the last filing  allocates its assets in the top two major groups   Small Growth and Intermediate Bond  Further  as of the last filing  Unitedhealth Group Inc and Intuitive Surgical Inc  NASDAQ ISRG  were the top holdings for PRHSX This Zacks Rank  1  Strong Buy  was incepted in December 1995 and is managed by   PRHSX carries an expense ratio of 0 77  and requires a minimal initial investment of  2 500 To ConcludeWhile both FSMEX and PRHSX are recommended buys  upon having a closer look  we find that the former is a clear winner  PRHSX is much more expensive compared to FSMEX  it has a minimum initial investment  2 500 compared to FSMEX s  0   Further  its administrative and other operating expenses are also higher compared to FSMEX  So  one should clearly bet on FSMEX for higher returns on low investments Want key mutual fund info delivered straight to your inbox Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing mutual funds  each week ,2019-12-12,Zacks Investment Research,https://www.investing.com/analysis/which-healthcare-mutual-fund-to-buy-fsmex-or-prhsx-200492435,200492435
111546,333061,ISRG,Minimally Invasive Surgery Gains Ground  3 Stocks In Focus,opinion,With innovation rapidly changing the face of healthcare space  minimally invasive surgery  MIS  is becoming a crucial part of general surgery  In fact  it is being preferred over the traditional open surgery and laparoscopic techniques  Apart from lowering treatment costs  these surgical procedures have received widespread clinical acceptance owing to their advantages over open surgeries  like lesser incisions and post operative complications  and faster recovery  thereby making MIS highly desirable Per a report by   the global MIS systems market is projected to reach  58 2 billion  witnessing a CAGR of 8  from 2019 2024  Increasing demand for MIS procedures  rising surgical need particularly among the growing geriatric population  and the prevalence of arthritis  cancer and cardiovascular diseases are driving the market Interestingly  North America is the leading contributor to the global minimally invasive surgical systems market  Notably  in 2017  in terms of revenues  North America contributed around  9 31 billion and is expected to see a CAGR of 12 9  from 2018 2025 Needless to say  investors can take a look at the space as MIS presents alluring prospects for the MedTech players Technological Advancement in MISInnovation in healthcare is a dynamic and continuous process  Here we will discuss about how three key technologies will help to revolutionize MIS Robot Assisted SurgeryThe potential for this type of surgery was recognized nearly two decades back  According to   in the near future  robots will be able to do the mechanical setup for the surgery by correctly positioning the right tools in the patient s body  Moreover  usage of robotic surgery devices remotely from anywhere in the world will become possible  thereby making high quality surgeries accessible to millions of people Notably  Intuitive Surgical received FDA approval for the da Vinci Surgical System in 2000  Since then  the company has amassed an installed base of over 2 900 systems in the United States and over 4 500  globally Per a new report by   the global surgical robots market is estimated to reach  19 41 billion by 2026 at a CAGR of 14 1  Predictive Modeling and AI Using Big DataIn the age of informatics  it is now possible to collect  analyze and share data enabling surgeons to make better and informed decisions in real time One of the biggest areas for data capture and analysis in hospitals is surgical workflows  A smooth workflow lowers the chance of complications  reduces the time spent under anesthesia and minimizes staff fatigue to make for a more vigilant and capable workforce Enhanced Real Time ImagingWhen it comes to real time imaging in MIS  fluoroscopy deserves a mention  Fluoroscopy is a medical imaging technology that is widely used to create real time movies of internal body structures through X ray radiation In United States alone  over 5 million fluoroscopic procedures are performed every year  With improvement in MIS technology  this number is only growing  These minimally invasive interventions offer a better  safer and cheaper solution when compared to open surgery Stocks With Strong MIS ProspectsHere are three MedTech stocks that have been exhibiting significant potential in the MIS space Intuitive Surgical  Inc    NASDAQ ISRG    Intuitive Surgical s robot based da Vinci surgical system is powered by robotic technology  This has provided the company with valuable knowledge about the use of medical mechatronics  robotics and AI for healthcare  which in turn has strengthened its position in the space  In 2017  the company got the FDA approval for its new budget friendly da Vinci X robotic surgical system  The company is known for continuously introducing technologies for surgical systems For 2019  this Zacks Rank  2  Buy  company s Zacks Consensus Estimate for revenues is pegged at  4 40 billion  indicating an improvement of 18 1  from the year ago period  You can see  Over the past year  Intuitive Surgical s shares have gained 18 1   outperforming the  s growth of 13 2  Stryker Corporation   NYSE SYK    In 2017  Stryker captured the second position in the robotic assisted surgery system market  The company s strong position can be attributed to the sustained robust sales of its Mako robotic arm  Notably  Mako system is the first and only robotic technology that can be used for total knee  hip and partial knee replacement procedures For 2019  Stryker s Zacks Consensus Estimate for revenues is pegged at  14 85 billion  suggesting growth of 9 2  from the year ago period  The company carries a Zacks Rank  3  Hold  Over the past year  Stryker s shares have gained 20   outperforming the  s rally of 9  Medtronic plc   NYSE MDT    In September this year  Medtronic unveiled a robot assisted surgical platform that will be upgradable  modular and able to support laparoscopic applications  The company claims this system to be more cost effective compared to systems already present in the market  This initiative has strengthened its already strong and extensive surgical instruments portfolio For fiscal 2020  the Zacks Rank  2 company s Zacks Consensus Estimate for revenues is pegged at  31 52 billion  indicating an improvement of 3 2  from the year ago period Over the past year  Medtronic s shares have gained 19 9   outperforming the  s growth of 9  Breakout Biotech Stocks with Triple Digit Profit Potential The biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119 and  164 in as little as 1 month  The stocks in this report could perform even better ,2019-12-13,Zacks Investment Research,https://www.investing.com/analysis/minimally-invasive-surgery-gains-ground-3-stocks-in-focus-200492411,200492411
111548,333063,ISRG,Here s Why You Should Hold On To Intuitive Surgical For Now,opinion,Intuitive Surgical  Inc    NASDAQ ISRG   is well poised for growth on improving adoption of da Vinci Surgical System  strong international presence and solid recurring revenue base  However  contraction in margins remains a concern Shares of Intuitive Surgical have gained 23 5  compared with the  s growth of 22 2  in a year s time  Meanwhile  the S P 500 Index has rallied 28  in the same timeframe The company  with a market capitalization of  68 billion  designs  manufactures and markets the da Vinci surgical system and related instruments and accessories  Notably  the da Vinci surgical system is an advanced robot assisted surgical system  It anticipates earnings to improve 11 8  over the next five years  Moreover  it has beat estimates in the trailing four quarters by 6 4   on average Let s take a closer look at the factors that substantiate the company s Zacks Rank  3  Hold  What s Deterring the Stock Intuitive Surgical has been witnessing contraction in margins for time quite some time now  In fact  in the third quarter of 2019  the company s operating margin in the quarter was 41   down 140 bps Management expects margins to fluctuate based on a mix of new products and systems  Further  the company is incurring additional costs for expansion in markets outside the United States  which in turn is adding to woes What s Favoring the Stock Intuitive Surgical s robot based da Vinci surgical system enables minimally invasive surgery  which reduces risks associated with open surgery  The company continues to gain from this system  which in turn boosts overall performance In the third quarter of 2019  da Vinci procedures grew 20  globally compared with the prior year quarter  The upside was driven by healthy growth in U S  General Surgery  In the third quarter  Intuitive Surgical placed 275 da Vinci surgical systems  with the installed base growing 12  year over year  In fact  it now anticipates 2019 procedure growth to be 17 18  compared with the previously anticipated rise of 16 17  Intuitive Surgical is gradually gaining prominence in markets outside the United States  In third quarter 2019  international revenues rose 36  year over year  owing to solid show by the Instruments   Accessories segment Notably  the segment grew on solid procedure growth and customer buying patterns  Intuitive Surgical placed 80 systems in third quarter 2019 compared with 90 units in third quarter 2018  Of these  36 were in Europe  27 in Japan and 10 in China Intuitive Surgical s business model ensures that it continues to generate revenues from initial capital sales of da Vinci Surgical Systems  and subsequent sales of instruments  accessories and services  In the last reported quarter  total recurring revenues were  817 million  up 24  year over year and accounting for a whopping 72  of total revenues Recurring revenues  as a proportion of total revenues  continue to grow at a much higher rate compared with system sales  This ensures a steady stream of income  even in testing times  Moreover  Intuitive Surgical operates in a niche MedTech market  with no direct competition  which is a major positive Which Way Are Estimates Headed For 2019  the Zacks Consensus Estimate for revenues is pegged at  4 40 billion  indicating an improvement of 18 1  from the year ago quarter  The same for earnings stands at  12 53 per share  suggesting growth of 14  from the year ago reported figure Stocks to ConsiderSome better ranked stocks from the broader medical space are Cardinal Health  Inc    NYSE CAH    West Pharmaceutical Services  Inc    NYSE WST   and DexCom  Inc    NASDAQ DXCM    each currently carrying a Zacks Rank  2  Buy   You can see  Cardinal Health has an expected long term earnings growth rate of 6 2  West Pharmaceutical has an estimated long term earnings growth rate of 14  DexCom has a projected earnings growth rate of 260  for the next quarter Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through Q3 2019  while the S P 500 gained  39 6   five of our strategies returned  51 8    57 5    96 9    119 0   and even  158 9  This outperformance has not just been a recent phenomenon  From 2000   Q3 2019  while the S P averaged  5 6  per year  our top strategies averaged up to  54 1  per year ,2019-12-31,Zacks Investment Research,https://www.investing.com/analysis/heres-why-you-should-hold-on-to-intuitive-surgical-for-now-200495619,200495619
111551,333066,ISRG,Intuitive Surgical Earnings  Revenue Miss in Q1,news,"Investing com   Intuitive Surgical  NASDAQ ISRG  reported first quarter earnings  that missed analysts  expectations on Thursday and revenue that fell short of forecasts 
The firm reported earnings per share of  2 61 on revenue of  973 7M  Analysts polled by Investing com forecast EPS of  2 71 on revenue of  977 44M  That compared to EPS of  2 44 on revenue of  847 5M in the same period a year earlier  The company had reported EPS of  2 96 on revenue of  1 05B in the previous quarter 
Intuitive Surgical shares lost 4 76  to trade at  502 93 in after hours trade following the report 
Intuitive Surgical follows other major Healthcare sector earnings this month
 On Tuesday  J J reported first quarter EPS of  2 1 on revenue of  20 02B  compared to forecasts of EPS of  2 04 on revenue of  19 62B 
Abbott Labs earnings Beat analysts  expectations on Wednesday  with first quarter EPS of  0 63 on revenue of  7 37B  Investing com analysts expected EPS of  0 61 on revenue of  7 47B
Stay up to date on all of the upcoming earnings reports by visiting Investing com s earnings calendar",2019-04-18,Investing.com,https://www.investing.com/news/stock-market-news/intuitive-surgical-earnings-revenue-miss-in-q1-1840334,1840334
111552,333067,ISRG,Intuitive Surgical Earnings  Revenue Beat in Q2,news,"Investing com   Intuitive Surgical  NASDAQ ISRG  reported second quarter earnings  that beat analysts  expectations on Thursday and revenue that topped forecasts 
The firm reported earnings per share of  3 25 on revenue of  1 09B  Analysts polled by Investing com anticipated EPS of  2 87 on revenue of  1 03B  That compared to EPS of  2 76 on revenue of  909 3M  NYSE MMM  in the same period a year earlier  The company had reported EPS of  2 61 on revenue of  973 7M in the previous quarter 
Intuitive Surgical shares gained 1 54  to trade at  544 88 in after hours trade following the report 
Intuitive Surgical follows other major Healthcare sector earnings this month
 On Tuesday  J J reported second quarter EPS of  2 58 on revenue of  20 56B  compared to forecasts of EPS of  2 44 on revenue of  20 29B 
Novartis ADR earnings beat analysts  expectations on Thursday  with second quarter EPS of  1 34 on revenue of  11 76B  Investing com analysts expected EPS of  1 21 on revenue of  11 51B
Stay up to date on all of the upcoming earnings reports by visiting Investing com s earnings calendar",2019-07-18,Investing.com,https://www.investing.com/news/stock-market-news/intuitive-surgical-earnings-revenue-beat-in-q2-1927965,1927965
111553,333068,ISRG,Intuitive Surgical Earnings  Revenue Beat in Q3,news,"Investing com   Intuitive Surgical  NASDAQ ISRG  reported third quarter earnings  that beat analysts  expectations on Thursday and revenue that topped forecasts 
The firm reported earnings per share of  3 43 on revenue of  1 13B  Analysts polled by Investing com expected EPS of  2 99 on revenue of  1 06B  That compared to EPS of  2 83 on revenue of  920 9M in the same period a year earlier  The company had reported EPS of  3 25 on revenue of  1 1B in the previous quarter 
Intuitive Surgical shares gained 3 65  to trade at  549 00 in after hours trade following the report 
Intuitive Surgical follows other major Healthcare sector earnings this monthOn Tuesday  J J reported third quarter EPS of  2 12 on revenue of  20 73B  compared to forecasts of EPS of  2 on revenue of  20 1B 
Abbott Labs earnings matched analysts  expectations on Wednesday  with third quarter EPS of  0 84 on revenue of  8 08B  Investing com analysts expected EPS of  0 84 on revenue of  8 11B
Stay up to date on all of the upcoming earnings reports by visiting Investing com s earnings calendar",2019-10-17,Investing.com,https://www.investing.com/news/stock-market-news/intuitive-surgical-earnings-revenue-beat-in-q3-1998545,1998545
111557,333072,ISRG,GNC Holdings  GNC  Q3 Loss Meets Estimates  Revenues Miss,opinion,"GNC Holdings  Inc    NYSE GNC   reported third quarter 2019 adjusted loss per share of 2 cents  down from adjusted earnings per share of 2 cents from the year ago quarter  The bottom line was in line with the Zacks Consensus Estimate Reported loss per share for the quarter was 9 cents  narrower than loss of 10 cents reported a year ago RevenuesRevenues for the third quarter were  499 1 million  down 13 9  year over year  The top line missed the Zacks Consensus Estimate by 1 8  GNC Holdings  Inc  Price  Consensus and EPS Surprise
 

   Segmental Details
GNC Holdings operates under three segments   U S    Canada  including company owned stores in the United States  Puerto Rico and Canada  franchise stores in the United States  and e commerce   International  inclusive of franchise locations in approximately 50 countries  The Health Store and China operations   and Manufacturing Wholesale  comprising manufactured products sold to other segments  third party contract manufacturing and sales to wholesale partners  In the reported quarter  GNC Holdings  revenues from the U S    Canada segment fell 6 7  year over year to  444 7 million  Notably  e commerce sales accounted for 8 6  of U S  and Canada revenues  declining from 7 2  in the prior year quarter Company owned net store closures negatively impacted revenues by  14 8 million  Further  a decline of 2 8  in same store sales led to a fall of  9 7 million in the segment s revenues  Moreover  in domestic franchise locations  same store sales declined 0 8  from the year ago period Revenues in the International segment dipped 28 1  to  36 9 million for the quarter under review  The downside can be primarily attributed to lower sales in Hong Kong  and other temporary challenges faced in Saudi Arabia and South Korea  Also  revenues from China fell  5 1 million in the third quarter due to the transfer of the China business to the newly formed joint venture  with Harbin Pharmaceutical Group Co   Ltd  or Hayao   effective February 13  2019 The Manufacturing   Wholesale segment s revenues registered 66 7  year over year plunge to  17 4 million  excluding intersegment sales  This mainly resulted from the transfer of the Nutra manufacturing business to the newly formed manufacturing joint venture with International Vitamin Corporation  effective Mar 1  2019 MarginsGross profit declined 11 9  year over year to  162 6 million  However  gross margin expanded 75 bps to 32 6  in the third quarter Selling  general and administrative expenses declined 9 4  to  135 8 million  Despite that  adjusted operating profit fell 22 9  to  26 8 million  Adjusted operating margin contracted 62 bps to 5 4  Financial PositionGNC Holdings exited the third quarter with cash and cash equivalents of  121 9 million compared with  95 9 million at the end of the second quarter  Long term debt was  705 7 million in the quarter under review  down from  854 7 million at the end of the previous quarter Year to date net cash flow from operating activities totaled  97 6 million compared with  55 7 million recorded in the year ago period Further  the company generated year to date free cash flow of  86 7 million compared with  42 3 million in the prior year quarter Our TakeGNC Holdings exited the third quarter of 2019 on a disappointing note  as revenues lagged the Zacks Consensus Estimate  The company once again registered adjusted loss per share  which was in line with the consensus mark All three operating segments reported year over year sales declines  Despite the negatives  we are optimistic about the company s recent contract with Walmart  NYSE WMT  to use the latter s online marketplace  The newly formed partnership with BFG Brasil Comercial de Vitaminas LTDA to expand customer base in Latin America and GNC Holdings  partnership with ProShip Inc  a Wisconsin based shipping software company  to offer ship from store service at more than 400 locations also buoy optimism We are encouraged about the company s gross margin expansion in the quarter despite the contraction of the operating margin Zacks Rank   Stocks to ConsiderGNC Holdings currently carries a Zacks Rank  3  Hold  A few better ranked stocks in the broader medical space are ResMed  Inc   NYSE RMD    Intuitive Surgical  Inc   NASDAQ ISRG   and Thermo Fisher Scientific Inc   NYSE TMO    All three stocks currently carry a Zacks Rank  2  Buy  ResMed reported first quarter fiscal 2020 adjusted EPS of 93 cents  surpassing the Zacks Consensus Estimate by 6 9   Its revenues of  681 1 million outpaced the consensus mark by 3 7  Intuitive Surgical s third quarter 2019 adjusted EPS of  3 43 surpassed the Zacks Consensus Estimate by 15 9   Its revenues totaled  1 13 billion  which surpassed the consensus estimate of  1 06 billion  You can see Thermo Fisher delivered third quarter 2019 adjusted EPS of  2 94  beating the Zacks Consensus Estimate by 2 1   Its revenues of  6 27 billion beat the Zacks Consensus Estimate by 1 3  5 Stocks Set to DoubleEach was hand picked by a Zacks expert as the  1 favorite stock to gain  100  or more in 2020  Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth Most of the stocks in this report are flying under Wall Street radar  which provides a great opportunity to get in on the ground floor ",2019-10-24,Zacks Investment Research,https://www.investing.com/analysis/gnc-holdings-gnc-q3-loss-meets-estimates-revenues-miss-200478586,200478586
111558,333073,ISRG,NextGen  NXGN  Q2 Earnings Beat  Revenues Miss Estimates,opinion,"NextGen Healthcare  Inc    NASDAQ NXGN   reported second quarter fiscal 2020 adjusted earnings per share  EPS  of 24 cents  flat with the year ago quarter s figure  The metric edged past the Zacks Consensus Estimate by a penny Revenues of this Zacks Rank  3  Hold  company totaled  134 3 million  up 3  year over year  However  the figure missed the Zacks Consensus Estimate by a nominal 0 1  Bookings UpdateBookings for the quarter came in at  36 6 million  up 1 4  from the year ago quarter s figure NEXTGEN HEALTHCARE  INC Price  Consensus and EPS Surprise
    Segment DetailsThe company reported second quarter fiscal 2020 revenues under the following segments Total Recurring revenues grossed  120 6 million  up 3 7  from the year ago quarter s figure Meanwhile  total Software  hardware and other non recurring revenues came in at  13 7 million  down 2 4  on a year over year basis  Per management  this reflects headwinds in the managed services and software areas MarginIn the quarter under review  gross profit totaled  68 5 million  down 1   from the prior year quarter s tally  Gross margin was 51   down 210 basis points  bps  Adjusted operating income in the fiscal second quarter was  75 4 million  down 3  from the year ago quarter s figure  Adjusted operating margin  as a percentage of revenues  was 56 2   down 340 bps Fiscal 2020 View RetainedFor fiscal 2020  NextGen continues to expect revenues between  536 million and  550 million  The Zacks Consensus Estimate for revenues is pegged at  541 8 million  which is within the guided range Full year EPS are expected between 82 cents and 90 cents  The Zacks Consensus Estimate for EPS is pegged at 85 cents  which is within the projected range Summing UpNextGen exited the fiscal second quarter on a mixed note  The company gained from its Recurring segment in the quarter under review  Bookings surged in the quarter on significant deal size growth  Impressive rates of client addition have worked well for NextGen  Management has retained its fiscal 2020 outlook  Meanwhile  NectGen s Software  hardware and other non recurring revenues were soft in the quarter  Significant contraction in gross margin and operating margins raises concern  Additionally  NextGen faces stiff rivalry in the MedTech space Earnings of Other MedTech Majors at a GlanceSome better ranked stocks which posted solid results this earnings season are Intuitive Surgical  Inc    NASDAQ ISRG    Thermo Fisher Scientific Inc    NYSE TMO   and ResMed Inc    NYSE RMD    each carrying a Zacks Rank of 2   Buy   You can see  Intuitive Surgical delivered third quarter 2019 adjusted EPS of  3 43  beating the Zacks Consensus Estimate by 15 9   Revenues of  1 13 billion surpassed the Zacks Consensus Estimate by 6 6  Thermo Fisher delivered third quarter 2019 adjusted EPS of  2 94  which surpassed the Zacks Consensus Estimate by 2 1   Revenues of  6 27 billion outpaced the Zacks Consensus Estimate by 1 3  ResMed reported third quarter 2019 adjusted EPS of 93 cents  which beat the Zacks Consensus Estimate of 87 cents by 6 9   Revenues were  681 1 million  surpassing the Zacks Consensus Estimate by 3 6  5 Stocks Set to DoubleEach was hand picked by a Zacks expert as the  1 favorite stock to gain  100  or more in 2020  Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth Most of the stocks in this report are flying under Wall Street radar  which provides a great opportunity to get in on the ground floor ",2019-10-24,Zacks Investment Research,https://www.investing.com/analysis/nextgen-nxgn-q2-earnings-beat-revenues-miss-estimates-200478542,200478542
111559,333074,ISRG,Cerner  CERN  Earnings Beat Estimates In Q3  Improve Y Y,opinion,Cerner Corporation   NASDAQ CERN   reported third quarter 2019 adjusted earnings of 66 cents per share  which beat the Zacks Consensus Estimate of 65 cents by 1 5   The bottom line also improved from the prior year quarter figure by 4 8   The company reported revenues of  1 43 billion  which increased 6 7  year over year but missed the Zacks Consensus Estimate Revenues by Geography Per management  U S  revenues grossed  1 27 billion  up 6  from the prior year quarter Non U S  revenues increased 8  to  164 million from the year ago quarter Cerner Corporation Price  Consensus and EPS Surprise    Bookings In the reported quarter  the company s bookings totaled  1 65 billion  up 4  from the year ago quarter Segmental PerformanceLicensed software revenues improved 10 5  to  154 5 million  driven by strong growth in SaaS offerings  Technology resale revenues were  70 2 million  up 16 2  on a year over year basis  Revenues from Subscriptions grossed  91 9 million  up 16 2  year over year  Professional services  revenues totaled  507 5 million  up 11 1  from the prior year quarter number  on the back of solid growth in implementation services  Revenues at the Managed services unit summed  302 4 million  up 0 1  from the prior year quarter  Support and maintenance revenues were  277 3 million  down 0 2  year over year  Reimbursed travel revenues amounted to  25 6 million  reflecting a year over year increase of 5 9   Margins In the quarter under review  gross profit summed  1 16 billion  up 4 3  year over year  Gross margin was 80 9   down 190 bps on a year over year basis  General and administrative expenses increased 48 2  to  152 3 million  Further  software development expenses rose 8 8  to  187 5 million  Adjusted operating margin contracted 110 bps to 18 1  during the reported quarter Guidance For the fourth quarter of 2019  Cerner expects revenues between  1 41 billion and  1 46 billion  The Zacks Consensus Estimate for revenues stands at  1 47 billion  higher than management s guided range  Adjusted earnings per share are expected between 73 cents and 75 cents  The Zacks Consensus Estimate stands at 75 cents  lies within the company s guided range New business bookings for the fourth quarter of 2019 is estimated to range between  1 45 billion and  1 65 billion  Wrapping Up Cerner exited the third quarter on a mixed note  The company continues to witness strong contributions from key areas like Population Health  Revenue Cycle and IT Works  Further  gains in Licensed software  Technology resale  Professional and Managed Services units buoy optimism  International revenues also moved up in the quarter  Bookings witnessed a noticeable improvement in the quarter under review  The company benefited from electronic health record  EHR   electronic patient record  EPR  or electronic medical record  EMR  platforms that provide patient care in acute inpatient and outpatient settings  Meanwhile  Support   Maintenance revenues witnessed a year over year decline in the quarter under review  Contraction in operating margins remains a concern  Furthermore  competition in the global MedTech space is a woe Zacks RankCurrently  Cerner carries a Zacks Rank  3  Hold  Earnings of Other MedTech Majors at a GlanceSome better ranked stocks which posted solid results this earning season are Intuitive Surgical  Inc    NASDAQ ISRG    Thermo Fisher Scientific Inc    NYSE TMO   and ResMed Inc    NYSE RMD    each carrying a Zacks Rank of 2   Buy  Intuitive Surgical delivered third quarter 2019 adjusted earnings per share of  3 43  beating the Zacks Consensus Estimate by 15 9   Revenues of  1 13 billion surpassed the Zacks Consensus Estimate by 6 6   You can see  Thermo Fisher delivered third quarter 2019 adjusted earnings of  2 94 per share  which surpassed the Zacks Consensus Estimate by 2 1   Revenues of  6 27 billion outpaced the Zacks Consensus Estimate by 1 3  ResMed reported third quarter 2019 adjusted earnings per share of 93 cents  which beat the Zacks Consensus Estimate of 87 cents by 6 9   Revenues were  681 1 million  surpassing the Zacks Consensus Estimate by 3 6  5 Stocks Set to Double Each was hand picked by a Zacks expert as the  1 favorite stock to gain  100  or more in 2020  Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth Most of the stocks in this report are flying under Wall Street radar  which provides a great opportunity to get in on the ground floor ,2019-10-24,Zacks Investment Research,https://www.investing.com/analysis/cerner-cern-earnings-beat-estimates-in-q3-improve-yy-200478421,200478421
111560,333075,ISRG,Top 5 Things to Know in the Market on Thursday,news,"Investing com   Here are the top five things you need to know in financial markets on Thursday  October 18 
1  Fed to push ahead with rate hikes  jobless claims  Philly Fed on tap
Markets will continue to digest the minutes from the latest meeting of the Federal Reserve while looking ahead to data on the U S  labor market and a regional manufacturing survey to be released later on Thursday 
The Fed minutes showed that policymakers had some doubts about the future path of the economy but were united on the need to hike rates in September and anticipated continuing with plans to gradually increase interest rates with one more this year and perhaps an additional three in 2019 
In economic indicators to be released Thursday  the weekly jobless claims numbers come in at 8 30 AM ET  12 30 GMT  
Economists expect that claims for first time unemployment benefits dipped slightly to 211 000 from 214 000 the week before 
Labor numbers have been consistently good  with this week s latest JOLTs report showing job openings at a record level 
At the same time the Philadelphia Fed s manufacturing index is issued  Manufacturing activity is forecast to have dipped in October to a measure of 19 7 
2  Travelers set to release earnings as reporting season revs on
Earnings season remained in focus for investors as around 10  of S P firms have rolled out numbers for the third quarter 
As of Wednesday s close  54 S P companies have published results with 81  beating profit estimates with growth of 26 1  and 68  topping consensus on sales with growth of 7 9   according to The Earnings Scout 
Dow component Dow component Travelers  NYSE TRV  will be the main focus for Thursday s session  while Blackstone  NYSE BX   Bank of NY Mellon  NYSE BK   Philip Morris  NYSE PM   PPG Industries  NYSE PPG  and  Nucor   NYSE NUE  will also report before the opening bell 
After the close  results are expected from  American Express   NYSE AXP   PayPal  NASDAQ PYPL   E Trade  NASDAQ ETFC   Intuitive Surgical  NASDAQ ISRG   and Skechers  NYSE SKX  
3  U S  futures point to lower open amid WTO warnings  higher bond yields
U S  futures pointed to a lower open on Thursday as the World Trade Organization warned of the economic risks of trade wars  bringing back into focus the reigning dispute between the U S  and China  while heightened expectations for future rate hikes on the back of the Fed minutes pushed U S  bond yields higher 
 Without action to ease tensions and recommit to cooperation in trade  we could see serious harm done to the multilateral trading system   WTO director general Roberto Azevedo said   The long term economic consequences of this could be severe  
At 5 50 AM ET  9 50GMT   the blue chip Dow futures fell 60 points  or 0 23   S P 500 futures lost 7 points  or 0 26   while the Nasdaq 100 futures traded down 22 points  or 0 30  
Earlier  Chinese stocks lead losses in Asia with the Shanghai Composite ending nearly 3  lower 
Elsewhere  European shares showed mixed trade as traders kept eyes on developments over Brexit negotitations 
4  Oil continues lower as inventory build weighs
Oil continued to trade lower on Thursday  adding to losses of nearly 3  in the prior session  as a surprise rise in U S  stockpiles weighed on prices  while geopolitical tensions  the upcoming deadline for U S  sanctions on Iran and continuing concern over production have all been factors involved in recent market volatility 
U S  crude stocks rose 6 5 million barrels last week  the U S  Energy Information Administration said on Wednesday  the fourth straight weekly build and almost triple what analysts had forecast 
U S  crude oil futures fell 0 96  to  69 08 by 6 02 AM ET  10 02 GMT   while Brent oil traded down 1 04  to  79 22 
5  Chinese yuan hits January 2017 low
The Chinese yuan moved slightly higher against the dollar on Thursday  after hitting its lowest level since January 2017 overnight  despite the fact that the U S  Treasury avoided labeling the world s second largest economy as a currency manipulator 
In its semiannual forex policy report  the Treasury Department declined to label China or any other trading partner of the U S  as currency manipulators  but it noted that Chinese currency practices were a source of  particular concern  
The Treasury also added that Beijing and some other countries including Germany  Japan and India have been put on a watch list 
U S  Treasury Secretary Steven Mnuchin had said over the weekend that currency issues would be a necessary component of any trade discussions between the U S  and China ",2018-10-18,Investing.com,https://www.investing.com/news/economy-news/top-5-things-to-know-in-the-market-on-thursday-1649235,1649235
111561,333076,ISRG,Omnicell  OMCL  Beats On Q3 Earnings  Raises  19 EPS View ,opinion,Omnicell  Inc  s   NASDAQ OMCL   third quarter 2019 adjusted earnings per share  EPS  of 76 cents outpaced the Zacks Consensus Estimate by 5 6  Also  adjusted EPS increased 20 6  from the year ago figure and surpassed the company s guided range of 67 72 cents as well Revenues in DetailRevenues in the third quarter increased 11 9  year over year to  228 8 million  However  the top line missed the Zacks Consensus Estimate of  232 5 million Quarterly DetailsOn a segmental basis  Product revenues improved 12 6  year over year to  168 5 million in the reported quarter Moreover  Service and other revenues climbed 10 4  year over year to  60 3 million Operational UpdateIn the quarter under review  Omnicell s adjusted gross profit rose 12 4  to  115 5 million  Further  adjusted gross margin expanded 20 basis points  bps  to 50 5  Omnicell  Inc  Price  Consensus and EPS Surprise   However  adjusted operating expenses were  77 6 million in the third quarter  up 7  year over year  Meanwhile  adjusted operating profit totaled  37 9 million  reflecting a 25 1  jump from the prior year quarter  Adjusted operating margin in the third quarter too grew 180 bps to 16 6  Financial UpdateOmnicell exited the third quarter with cash and cash equivalents of  137 2 million compared with  87 5 million at the end of the second quarter GuidanceFor the fourth quarter of 2019  Omnicell expects adjusted revenues between  240 million and  246 million  The Zacks Consensus Estimate for the metric stands at  244 3 million  within the guided range On an adjusted basis  product revenues are forecast between  181 million and  186 million while service revenues are projected within  59  60 million Fourth quarter adjusted EPS is envisioned in the band of 75 80 cents  The Zacks Consensus Estimate for the same is pegged at 81 cents  above the upper end of the predicted range For 2019  adjusted revenues are now anticipated within  889  895 million  narrowed from the earlier band of  886  900 million  The Zacks Consensus Estimate for the same is pegged at  896 7 million  ahead of the guided range Product revenues for the full year are tightened to  653  658 million  earlier guidance was  653  663 million  while service revenues are tapered between  236 million and  237 million  past estimate   233  237 million  Adjusted EPS is forecast between  2 79 and  2 84 for 2019  raised from the earlier range of  2 65  2 82  The Zacks Consensus Estimate for the metric stands at  2 79  in line with the lower end of the guided range Our TakeOmnicell delivered better than expected third quarter 2019 adjusted earnings  Although revenues lagged the mark  the top line registered strong year over year growth  The company continued to see solid segmental contributions  Expansion of gross and operating margins in the reported quarter is encouraging as well  The company issued an upbeat guidance for the fourth quarter and lifted its 2019 EPS view Currently  the company is working on product innovation through R D  Moving ahead  Omnicell is expected to gain traction from product launches  strategic partnerships and digital transformation However  a tough competitive landscape acts as a dampener Zacks Rank Omnicell currently carries a Zacks Rank  3  Hold   A few better ranked stocks in the broader medical space are ResMed  Inc    NYSE RMD    Intutive Surgical  Inc    NASDAQ ISRG   and Thermo Fisher Scientific Inc    NYSE TMO    all three carrying a Zacks Rank  2  Buy  ResMed reported first quarter fiscal 2020 adjusted EPS of 93 cents  ahead of the Zacks Consensus Estimate by 6 9   Revenues of  681 1 million too topped the consensus mark by 3 6  Intutive Surgical  third quarter 2019 adjusted EPS of  3 43 exceeded the Zacks Consensus Estimate by 21 2   Moreover  revenues of  1 13 billion surpassed the consensus estimate of  1 06 billion  You can see  Thermo Fisher delivered third quarter 2019 adjusted EPS of  2 94  beating the Zacks Consensus Estimate by 2 1   Revenues of  6 27 billion also beat the Zacks Consensus Estimate by 1 3  5 Stocks Set to DoubleEach was hand picked by a Zacks expert as the  1 favorite stock to gain  100  or more in 2020  Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth Most of the stocks in this report are flying under Wall Street radar  which provides a great opportunity to get in on the ground floor ,2019-10-24,Zacks Investment Research,https://www.investing.com/analysis/omnicell-omcl-beats-on-q3-earnings-raises-19-eps-view-200478472,200478472
111562,333077,ISRG,Intuitive Surgical Earnings miss  Revenue beats In Q3,news,"Investing com   Intuitive Surgical  NASDAQ ISRG  reported third quarter earnings  that missed analyst s expectations on Thursday and revenue that topped forecasts 
The firm reported earnings per share of  2 45 on revenue of  920 9M  Analysts polled by Investing com expected EPS of  2 66 on revenue of  916 63M  That compared to EPS of  2 77 on revenue of  806 1M in the same period a year earlier The company had reported EPS of  2 76 on revenue of  909 3M  NYSE MMM  in the previous quarter 
Intuitive Surgical shares gained 2 05  to trade at  533 00 in after hours trade following the report 
For the year  Intuitive Surgical shares are up 41 97   outperforming the S P 500 which is up 3 17  year to date 
Intuitive Surgical follows other major Healthcare sector earnings this month
 On Tuesday  J J  NYSE JNJ  reported third quarter EPS of  2 05 on revenue of  20 35B  compared to forecasts of EPS of  2 03 on revenue of  20 04B 
Novartis ADR earnings beat analyst s expectations on Thursday  with third quarter EPS of  1 32 on revenue of  12 78B  Investing com analysts expected EPS of  1 31 on revenue of  12 98B
Stay up to date on all of the upcoming earnings reports by visiting Investing com s earnings calendar",2018-10-18,Investing.com,https://www.investing.com/news/stock-market-news/intuitive-surgical-earnings-miss-revenue-beats-in-q3-1650655,1650655
111563,333078,ISRG,Moving Average Crossover Alert  Intuitive Surgical,opinion,Intuitive Surgical  Inc    NASDAQ ISRG   is looking like an interesting pick from a technical perspective  as the company is seeing favorable trends on the moving average crossover front  Recently  the 50 Day Moving Average for ISRG broke out above the 200 Day Simple Moving Average  suggesting a short term bullish trend This has already started to take place  as the stock has moved higher by 3 7  in the past four weeks  Plus  the company currently has a Zacks Rank  2  Buy  suggesting that now could definitely be the time for this breakout candidate More bullishness may especially be the case when investors consider what has been happening for ISRG on the earnings estimate revision front lately  No estimate has gone lower in the past two months  compared to 8 higher  while the consensus estimate has also moved higher too So  given this move in estimates  and the positive technical factors  investors may want to watch this breakout candidate closely for more gains in the near future  You can see  Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-11-07,Zacks Investment Research,https://www.investing.com/analysis/moving-average-crossover-alert-intuitive-surgical-200483819,200483819
111564,333079,ISRG,Intuitive Surgical sees 17  increase in Q4 revenue  shares up 2  premarket,news,Intuitive Surgical  NASDAQ ISRG  is up 2  premarket on light volume following its announcement of preliminary Q4 and full year results  Highlights Q4  revenues were up 17  to  1 047B  Da Vinci procedures up 19   shipments up 34  to 290 2018  revenues were  3 724B   19    Da Vinci procedures up 18   surpassing 1M year for the first time  Shipments up 35  to 926  JPM19Now read ,2019-01-09,Seeking Alpha,https://www.investing.com/news/stock-market-news/intuitive-surgical-sees-17-increase-in-q4-revenue-shares-up-2-premarket-1742333,1742333
111567,333082,ISRG,Intuitive Surgical Earnings miss  Revenue beats In Q4,news,"Investing com   Intuitive Surgical  NASDAQ ISRG  reported fourth quarter earnings  that missed analysts  expectations on Thursday and revenue that topped forecasts 
The firm reported earnings per share of  2 96 on revenue of  1 05B  Analysts polled by Investing com expected EPS of  3 07 on revenue of  1 04B  That compared to EPS of  2 54 on revenue of  892 4M in the same period a year earlier  The company had reported EPS of  2 83 on revenue of  920 9M in the previous quarter 

Intuitive Surgical follows other major Healthcare sector earnings this month
 On Tuesday  J J reported fourth quarter EPS of  1 97 on revenue of  20 39B  compared to forecasts of EPS of  1 95 on revenue of  20 2B 
Abbott Labs earnings matched analyst s expectations on Wednesday  with fourth quarter EPS of  0 81 on revenue of  7 77B  Investing com analysts expected EPS of  0 81 on revenue of  7 81B
Stay up to date on all of the upcoming earnings reports by visiting Investing com s earnings calendar",2019-01-24,Investing.com,https://www.investing.com/news/stock-market-news/intuitive-surgical-earnings-miss-revenue-beats-in-q4-1757075,1757075
111569,333084,ISRG,Johnson   Johnson to buy surgical robotics firm Auris for  3 4 billion,news,"By Manas Mishra  Reuters    Johnson   Johnson  NYSE JNJ  said on Wednesday it would buy Auris Health Inc for  3 4 billion in cash  gaining access to the privately held company s surgical robotic scope used in respiratory procedures and the detection of lung cancer   The deal marks J J s expansion into the healthcare robotics market that is expected to reach nearly  12 billion by 2023  and pushed down shares of  Intuitive Surgical Inc   NASDAQ ISRG    the current leader in minimally invasive robotic surgery  J J has sold some divisions such as diabetes care  as it tries to focus on and improve sales at better performing businesses like cancer treatments   We are encouraged to see J J moving more aggressively in the robotics field  which has been a gap for its medical device business    Wells Fargo   NYSE WFC  analyst Larry Biegelsen said   Sales in J J s medical device unit have been recovering since turnaround efforts began in 2016  and the company now expects that unit to achieve above market growth in 2020  Auris was founded by surgical robotics pioneer Frederic Moll  who also co founded Intuitive Surgical  Moll will join J J after its acquisition closes  the company said  but did not disclose what role he would play  J J s shares were up marginally at  134 24 in midday trade  while Intuitive Surgical fell as much as 2 5 percent to  526 36 as analysts said Auris could become a formidable competitor given J J s commercial scale   Auris s flagship product is a robot used by surgeons via a controller to direct a scope through a patient s body with cameras   The device  called Monarch  was approved by U S  regulators last year for diagnostic and therapeutic bronchoscopic procedures  where an instrument is inserted into the nose or mouth  Auris initially focused on lung cancer  the leading cause of cancer death worldwide  J J said the acquisition would complement its purchase last year of Orthotaxy  a privately held developer of software enabled robotic technology for surgery  J J s Ethicon unit  which will absorb Auris  has a partnership with Alphabet  NASDAQ GOOGL  Inc s Verily Life Sciences  under which the companies formed a surgery focused company called Verb Surgical Inc in 2015   Investors have been yearning for an acquisition for JNJ s MedTech and while this entity may not have been top of mind  it complements JNJ s Ethicon franchise and its respiratory health focus   BMO Capital Markets analyst Joanne Wuensch said  
J J s agreement also includes additional payments to Auris of  2 35 billion  based upon Auris hitting certain milestones  which J J did not specify ",2019-02-13,Reuters,https://www.investing.com/news/technology-news/johnson--johnson-to-buy-surgical-robotics-firm-auris-in-34-billion-deal-1778297,1778297
111576,333091,ISRG,Stocks   ETF To Invest In Healthcare Robotics And Innovation,opinion," 1 00    Health Care Technology Mass Expansion  How Robotics Is Changing The Industry 10 20    What Growth Factors Should Investors Be Watching  14 05    Robo Global Healthcare Technology and Innovation ETF  HTEC 26 25    Big Takeaways From Fast Changing Healthcare Industry In this episode of ETF Spotlight  I speak with Travis Briggs  CEO of ROBO Global  creators of the index for the first ever robotics ETF listed in the US  the Global Robotics and Automation Index ETF   TASE ROBO    which has about  1 3 billion in assets 
They recently launched the ROBO Global Healthcare Technology and Innovation ETF  which provides exposure to global companies leading the healthcare technology revolution 
We have seen a lot of innovation in the healthcare industry  Advanced technologies like AI and robotics are transforming the space with disruption in diagnosis  regenerative medicine  robotic surgery  genomic analysis  DNA sequencing and smart monitoring devices 
A lot of private capital is flowing into these areas as investors want to get exposure to companies powering this technological revolution  And we are probably in the early stages of this revolution since healthcare is one of the least digitized among all sectors  according to a  report 
The world is short of surgeons  according to   143 million people are denied operations each year and 5 billion lack access to safe  affordable surgical services  While we re still quite far from totally robotic surgeries  artificial intelligence and machine learning are helping surgeons perform complex procedures with more precision 
Intuitive Surgical   NASDAQ ISRG    whose da Vinci surgical system enables minimally invasive surgery  is one of the holdings in HTEC 
We talk about key growth areas like gene editing  regenerative medicine and virtual care and why investors should not ignore this space   We also discuss some of the companies that are doing very innovative work in these areas 
Genomic Health   NASDAQ GHDX   develops genomic based clinical tests for cancer diagnosis that allows physicians to offer individualized treatment options 
Tabula Rasa   NASDAQ TRHC   enables optimization of medication regimens to improve patient outcomes  reduce hospitalizations and lower healthcare costs 
DexCom   NASDAQ DXCM   developed the continuous glucose monitoring systems for ambulatory use by people with diabetes 
Teladoc Health   NYSE TDOC   is a leader in virtual care 
Please tune into the podcast to learn more about the ETF and these companies  Make sure to be on the lookout for the next edition of ETF Spotlight  If you have any comments or questions  please email  
Want key ETF info delivered straight to your inbox 
Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ",2019-09-23,Zacks Investment Research,https://www.investing.com/analysis/stocks--etf-to-invest-in-healthcare-robotics-and-innovation-200467258,200467258
111578,333093,ISRG,Here s Why You Should Retain Intuitive Surgical For Now,opinion,Intuitive Surgical  Inc    NASDAQ ISRG   is well poised for growth on improving adoption of da Vinci Surgical System  strong international presence and solid recurring revenue base  However  contraction in margins remains a concern The company currently carries a Zacks Rank  3  Hold  Price PerformanceShares of Intuitive Surgical have gained 10 3  compared with the  s growth of 10 5  on a year to date basis  Meanwhile  the S P 500 Index has rallied 17 1  in the same timeframe What s Deterring the Stock Intuitive Surgical has been witnessing contraction in margins for time quite some time now Management expects margins to fluctuate based on a mix of new products and systems  Further  the company is incurring additional costs for expansion in markets outside the United States  which in turn is adding to woes What s Favoring the Stock Intuitive Surgical s robot based da Vinci surgical system enables minimally invasive surgery  which reduces risks associated with open surgery  The company continues to gain from this system  which in turn boosts overall performance In the second quarter of 2019  da Vinci procedure improved 17  globally from the second quarter of last year  This was driven by healthy growth in U S  General Surgery  In the last reported quarter  Intuitive Surgical placed 273 da Vinci surgical systems  with the installed base growing 13  year over year to approximately 5 270  In fact  it now forecasts 2019 procedure growth to be 16 17  compared with the previously anticipated rise of 15 17  Intuitive Surgical is gradually gaining prominence in markets outside the United States  In the second quarter of 2019  international revenues rose 19  year over year  owing to solid show by the Instruments   Accessories segment Notably  the segment grew on solid procedure growth and customer buying patterns  Intuitive Surgical placed 80 systems in the second quarter of 2019 compared with 82 units in the second quarter of 2018  Of these  30 were in Europe  24 in Japan and eight in China Intuitive Surgical s business model ensures that it continues to generate revenues from initial capital sales of da Vinci Surgical Systems  and subsequent sales of instruments  accessories and services  In the second quarter  total recurring revenues were  780 million  up 21  year over year and accounting for a whopping 71  of total revenues Recurring revenues  as a proportion of total revenues  continue to grow at a much higher rate as compared with system sales  This ensures a regular stream of income  even in testing times  Moreover  Intuitive Surgical operates in a niche MedTech market  with no direct competition  which is a major positive Which Way Are Estimates Headed For 2019  the Zacks Consensus Estimate for revenues is pegged at  4 33 billion  indicating an improvement of 16 3  from the year ago quarter  The same for earnings stands at  10 12 per share  suggesting growth of 6 6  from the year ago reported figure Key PicksSome better ranked stocks from the broader medical space are Nissan Chemical Corporation   OTC NNCHY    Straumann Holding AG  and McKesson Corporation   NYSE MCK    each currently carrying a Zacks Rank  2  Buy   You can see   Nissan Chemical has a long term earnings growth rate of 10  Straumann Holding has a long term earnings growth rate of 18  McKesson has a long term earnings growth rate of 6 9  Free  Zacks  Single Best Stock Set to Double Today you are invited to download our just released Special Report that reveals 5 stocks with the most potential to gain  100  or more in 2020  From those 5  Zacks Director of Research  Sheraz Mian hand picks one to have the most explosive upside of all This pioneering tech ticker had soared to all time highs and then subsided to a price that is irresistible  Now a pending acquisition could super charge the company s drive past competitors in the development of true Artificial Intelligence  The earlier you get in to this stock  the greater your potential gain ,2019-10-15,Zacks Investment Research,https://www.investing.com/analysis/heres-why-you-should-retain-intuitive-surgical-for-now-200474129,200474129
111580,333095,ISRG,Medical Products Industry Outlook  Prospects Seem Promising,opinion,The Zacks  industry comprises companies that provide medical products and cutting edge technologies for diagnosis  observation  consultation  treatment and other healthcare services  Emphasis on research and development is the primary area of focus for companies in the space The industry participants cater to vital therapeutic areas like cardiovascular devices  nephrology and urology devices  ophthalmic devices  neurological devices  dermatological devices  respiratory devices  skin care devices  dental devices  orthopedic devices and gastrointestinal devices Notably  some of the key players in this industry are Medtronic  NYSE MDT  plc  MDT   Abbott Laboratories  NYSE ABT   ABT   Baxter International Inc  NYSE BAX    BAX   Boston Scientific Corporation  NYSE BSX   BSX   Zimmer Biomet Holdings  Inc   ZBH   Perrigo Company plc  PRGO  and ResMed Inc   RMD  Let us take a look at the three major themes in the industry AI  Medical Mechatronics   Robotics  The rising utilization of minimally invasive robot assisted surgeries  self automated home based care  use of IT for quick and improved patient care  and shift of the payment system to a value based model indicate the growing significance of AI in the Medical Products space  Mechatronics   a high end technology incorporating electronics  ML and mechanical engineering   also characterizes the industry now  Intuitive Surgical  NASDAQ ISRG   ISRG  deserves a special mention with respect to AI  robotics and medical mechatronics  The company designs  manufactures and markets the da Vinci surgical system   an advanced robot assisted surgical platform  This Mechatronic based platform enables minimally invasive surgery that helps reduce trauma associated with open surgery  Rampant M As  In recent times  there has been a pickup in M A activities in this space  In fact  apart from lessening pricing pressure and competition  dominant Medical Products players are increasingly relying on this strategy to expand customer base and gain leverage  Recently  Stryker Corporation  NYSE SYK   SYK  inked a deal to acquire of Mobius Imaging  LLC  and is an instance of this strategy that deserves special mention  The buyout is expected to add value and expertise to Stryker s imaging and robotics profile and boost its already robust product portfolio  Moreover  the transaction is expected to enable the acquirer s Spine division to offer more complete procedural solutions  which includes sales  service and support  Emerging Markets Hold Promise  Given the rising medical awareness and economic prosperity  emerging economies have been witnessing solid demand for medical products  An aging population  relaxed regulations  cheap skilled labor  increasing wealth and government focus on healthcare infrastructure make these markets a happy hunting ground for global medical device players  Zacks Industry Rank Indicates Bright ProspectsThe Zacks  Products industry falls within the broader Zacks Medical sector  It carries a Zacks Industry Rank  105  which places it in the top 41  of more than 250 Zacks industries The group s   which is basically the average of the Zacks Rank of all the member stocks  indicates bright near term prospects  Our research shows that the top 50  of the Zacks ranked industries outperforms the bottom 50  by a factor of more than 2 to 1 Before we present a few medical products stocks that you may want to consider for your portfolio  let s take a look at the industry s recent stock market performance and valuation picture Industry s Stock Market PerformanceThe industry has outperformed its sector in the past year  However  it fell short of the Zacks S P 500 composite over the same time frame The industry has increased 3 8  over this period compared with the S P 500 s growth of 7 5   However  the broader sector has declined 9 5  One Year Price PerformanceIndustry s Current ValuationOn the basis of the forward 12 month price to earnings  P E  ratio  which is commonly used for valuing medical stocks  the industry is currently trading at 24 34X compared with the sector s 19 14X and the S P 500 s 17 15X Over the past five years  the industry has traded as high as 25 44X and as low as 17 03X  with the median being at 19 46X as the charts show below Price to Earnings Forward Twelve Months  F12M  Price to Earnings Forward Twelve Months  F12M Bottom LineFollowing the bipartisan two year suspension of a 2 3  excise tax on Medical Products and Medical Device manufacturers at the beginning of 2018  the industry witnessed massive investments  The reintroduction of the controversial 2 3  medical device tax  repeal by the Senate in April 2019 has instilled optimism in the sector Meanwhile  per a CISION report  the United States remains the largest Medical Products market in the world with a market size of approximately  156 billion  The industry has been raking in more than  180 billion a year due to rising research and development activities  and growing exposure to AI Here  we present three stocks that either have a Zacks Rank  1  Strong Buy  or 2  Buy   which investors can take a look at  These stocks are well positioned to grow in the days ahead  You can see  BioLife Solutions  Inc   BLFS BioLife Solutions  Inc   develops  manufactures  and markets grade cell and tissue hypothermic storage and cryopreservation freeze media products for cells  tissues  and organs in the United States  The company has pioneered the next generation of preservation solutions designed to maintain the viability and health of cellular matter and tissues during freezing  transportation and storage  The stock carries a Zacks Rank of 2 For this Bothell  WA based company  the Zacks Consensus Estimate for 2019 revenues indicates a year over year improvement of 43 4   It has an average positive earnings surprise of 31 3  in the trailing four quarters Price and Consensus  BLFSSurmodics  Inc   SRDX Surmodics  Inc   SRDX  provides medical devices and in vitro diagnostic technologies to the healthcare industry in the United States and internationally  The company operates through two segments   Medical Device and In Vitro Diagnostics  The stock sports a Zacks Rank of 1 For this Eden Prairie  MN based company  the Zacks Consensus Estimate for 2019 earnings indicates year over year improvement of 40 8   It has an average positive earnings surprise of a whopping 700  in the trailing four quarters Price and Consensus  SRDXAphria Inc   APHA Aphria Inc  produces and sells medical cannabis in Canada and internationally  The company offers sativa  indica and hybrid medical marijuana products  and cannabis oils For this Leamington  Canada based company  the Zacks Consensus Estimate for 2019 revenues indicates a year over year improvement of 160 4  Price and Consensus  APHA 7 Best Stocks for the Next 30 Days Just released  Experts distill 7 elite stocks from the current list of 220 Zacks Rank  1 Strong Buys  They deem these tickers  Most Likely for Early Price Pops  Since 1988  the full list has beaten the market more than 2X over with an average gain of  24 50  per year  So be sure to give these hand picked 7 your immediate attention ,2019-10-21,Zacks Investment Research,https://www.investing.com/analysis/medical-products-industry-outlook-prospects-seem-promising-200476269,200476269
111582,333097,ISRG,Illumina  ILMN  Beats Q3 Earnings Estimates  Raises View,opinion,"Illumina  Inc  s   NASDAQ ILMN   third quarter 2019 adjusted earnings per share  EPS  of  1 93 surpassed the Zacks Consensus Estimate by 37 9   Moreover  the bottom line improved 26 9  from the year ago quarter s figure Including one time items  the company reported EPS of  1 58  up 18 8  year over year RevenuesIn the quarter under review  Illumina s revenues rose 6 3  year over year to  907 million  The top line also surpassed the Zacks Consensus Estimate by 4   The year over year growth can be attributed to the company s collaborations to develop distributable clinical IVDs for Illumina sequencers Illumina  Inc  Price  Consensus and EPS Surprise
 

    Segment DetailsSequencing consumable revenues were  525 million in the reported quarter  up 11  year over year  Sequencing systems revenues were  142 million  slightly up from the year ago quarter s figures During the third quarter  HiSeq consumables declined due to customers  transition to NovaSeq  Nevertheless  the overall high throughput consumables portfolio witnessed sequential and year over year growth  NextSeq shipments witnessed sequential and year over year growth on placement of record number of NextSeq Dx Systems in the quarter MarginsAdjusted gross margin  excluding amortization of acquired intangible assets  was 72 4  in the reported quarter  up 126 basis points  bps  year over year Research and development expenses declined 5  year over year to  151 million and selling  general   administrative expenses fell 4 1  to  189 million  Operating margin came in at 34 9   reflecting a surge of 553 bps year over year Financial UpdateIllumina exited the third quarter of 2019 with cash and cash equivalents plus short term investments of  3 17 billion  almost flat on a sequential basis  Year to date net cash provided by operating activities was  608 million compared with  842 million from the year ago quarter s level 2019 GuidanceIllumina has updated its 2019 view  The company continues to expect revenue growth to be around 6   unchanged from the earlier projection   The Zacks Consensus Estimate for 2019 revenues is pegged at  3 53 billion Adjusting for certain net specified items with respect to the full year  EPS is estimated in the range of  6 40  6 45 compared with the earlier projection of  6  6 10  The consensus mark for earnings is pegged at  6 04  which lies below the projected range  This outlook excludes any impact from the pending acquisition of Pacific Biosciences that is expected to be concluded by Dec 31  2019 Our TakeIllumina exited the third quarter of 2019 on an impressive note  with earnings and revenues beating the respective Zacks Consensus Estimates  It is encouraging to note that top line growth was witnessed across the company s high and low throughput categories  Raised 2019 EPS guidance indicates that this bullish trend will continue through the rest of the year Illumina continues to showcase robust performance across a broad range of sequencing applications  The recently formed partnerships with QIAGEN and Adaptive Biotechnologies regarding IVD test kits buoy optimism  Collaboration with Broad Institute to develop open source genomic secondary analysis tools is expected to provide a major boost On the flip side  a year over year decline in selling  general and administrative costs as well as research and development costs are concerns Zacks Rank   Key PicksIllumina currently carries a Zacks Rank  3  Hold  Some better ranked stocks in the broader medical space are ResMed  Inc    NYSE RMD    Intuitive Surgical  Inc    NASDAQ ISRG   and Thermo Fisher Scientific Inc    NYSE TMO    All the three stocks carry a Zacks Rank  2  Buy   You can see ResMed reported first quarter fiscal 2020 adjusted EPS of 93 cents  which beat the Zacks Consensus Estimate by 6 9   Revenues of  681 1 million outpaced the consensus mark by 3 7  Intuitive Surgical s third quarter 2019 adjusted EPS of  3 43 exceeded the Zacks Consensus Estimate by 15 9   Revenues totaled  1 13 billion  which surpassed the consensus mark of  1 06 billion Thermo Fisher delivered third quarter 2019 adjusted EPS of  2 94  which topped the Zacks Consensus Estimate by 2 1   Revenues of  6 27 billion beat the consensus mark by 1 3  5 Stocks Set to DoubleEach was hand picked by a Zacks expert as the  1 favorite stock to gain  100  or more in 2020  Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth Most of the stocks in this report are flying under Wall Street radar  which provides a great opportunity to get in on the ground floor ",2019-10-24,Zacks Investment Research,https://www.investing.com/analysis/illumina-ilmn-beats-q3-earnings-estimates-raises-view-200478380,200478380
111583,333098,ISRG,U S  stocks mixed at close of trade  Dow Jones Industrial Average down 0 16 ,news,"Investing com   U S  stocks were mixed after the close on Wednesday  as gains in the Oil   Gas  Basic Materials and Industrials sectors led shares higher while losses in the Consumer Goods  Utilities and Telecoms sectors led shares lower 
At the close in NYSE  the Dow Jones Industrial Average lost 0 16   while the S P 500 index climbed 0 08   and the NASDAQ Composite index climbed 0 19  
The best performers of the session on the Dow Jones Industrial Average were  Home Depot  Inc  NYSE HD   which rose 2 82  or 4 94 points to trade at 179 85 at the close  Meanwhile   Chevron  Corporation  NYSE CVX  added 1 94  or 2 36 points to end at 123 82 and  Caterpillar  Inc  NYSE CAT  was up 1 72  or 2 64 points to 155 95 in late trade 
The worst performers of the session were International Business Machines  NYSE IBM   which fell 7 53  or 12 12 points to trade at 148 79 at the close  Johnson   Johnson  NYSE JNJ  declined 2 16  or 2 82 points to end at 127 72 and  Nike  Inc  NYSE NKE  was down 1 94  or 1 31 points to 66 20 
The top performers on the S P 500 were  Intuitive Surgical Inc   NASDAQ ISRG  which rose 8 17  to 471 03  CSX Corporation  NASDAQ CSX  which was up 7 85  to settle at 61 01 and  Devon Energy  Corporation  NYSE DVN  which gained 7 15  to close at 36 10 
The worst performers were International Business Machines  NYSE IBM  which was down 7 53  to 148 79 in late trade  Applied Materials Inc  NASDAQ AMAT  which lost 5 41  to settle at 54 73 and  Juniper Networks Inc   NYSE JNPR  which was down 4 05  to 24 38 at the close 
The top performers on the NASDAQ Composite were  vTv Therapeutics Inc   NASDAQ VTVT  which rose 84 87  to 2 20   Izea Inc   NASDAQ IZEA  which was up 44 09  to settle at 3 1700 and SAExploration Holdings Inc  NASDAQ SAEX  which gained 27 21  to close at 1 730 
The worst performers were Onconova Therapeutics Inc  NASDAQ ONTX  which was down 24 05  to 0 6000 in late trade  Innovate Biopharmaceuticals Inc  NASDAQ INNT  which lost 16 81  to settle at 25 00 and Monaker Group Inc  NASDAQ MKGI  which was down 10 98  to 3 0000 at the close 
Rising stocks outnumbered declining ones on the New York Stock Exchange by 1710 to 1335 and 136 ended unchanged  on the Nasdaq Stock Exchange  1250 rose and 1249 declined  while 173 ended unchanged 
Shares in Intuitive Surgical Inc  NASDAQ ISRG  rose to 52 week highs  up 8 17  or 35 58 to 471 03  Shares in CSX Corporation  NASDAQ CSX  rose to all time highs  gaining 7 85  or 4 44 to 61 01  Shares in Onconova Therapeutics Inc  NASDAQ ONTX  fell to all time lows  falling 24 05  or 0 1900 to 0 6000  Shares in Monaker Group Inc  NASDAQ MKGI  fell to 52 week lows  down 10 98  or 0 3700 to 3 0000  
The CBOE Volatility Index  which measures the implied volatility of S P 500 options  was up 2 56  to 15 64 
Gold Futures for June delivery was up 0 21  or 2 80 to  1352 30 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in May rose 3 44  or 2 29 to hit  68 81 a barrel  while the June Brent oil contract rose 3 12  or 2 23 to trade at  73 81 a barrel 
EUR USD was up 0 07  to 1 2379  while USD JPY rose 0 20  to 107 22 
The US Dollar Index Futures was up 0 12  at 89 33 ",2018-04-18,Investing.com,https://www.investing.com/news/stock-market-news/us-stocks-mixed-at-close-of-trade-dow-jones-industrial-average-down-016-1402024,1402024
111584,333099,ISRG,Healthcare investors weigh bets as election risks loom,news,By Lewis Krauskopf NEW YORK  Reuters    If 2016 is any guide  pharmaceutical  biotech and other healthcare stocks could be in for a rough summer and fall heading into another round of U S  elections   But investors may be able to hedge such risks while remaining in the sector if they are willing to pay a premium for medical product companies outside the pharmaceutical supply chain  As with the 2016 presidential election  prescription drug costs could become a hot topic as mid term U S  Congressional elections near  inflaming investor concerns that prices for medicines may not be sustainable in the face of government and market pressures  Just on Wednesday  U S  President Donald Trump said major drug companies would announce price cuts in two weeks  underscoring how the issue remains in the political spotlight  Shares of pharmaceutical  biotechnology and other companies in the supply chain will be in the cross hairs of investor unease over a tougher environment for drug pricing  But given their already sluggish performance  many of those stocks trade at relatively discounted levels and are enticing to investors who believe risks from Washington rhetoric or from the election results already are accounted for in share prices  Shares of other medical product companies  like makers of heart devices  knee replacements or tools for drug research  present healthcare options shielded from pricing attacks  But those stocks generally trade at steeper valuations  based on price to earnings ratios   There are opportunities within healthcare that really don t have much concerns they are going to go after pricing   said David Heupel  a healthcare analyst with Thrivent Financial  But  Heupel added   there certainly is a price to pay   ELECTIONS EQUAL VOLATILITY So far in 2018  the S P 500 healthcare sector  SPXHC  is down about 0 2 percent against a 1 4 percent increase for the broader S P 500  SPX    The health sector lagged severely in 2016 over concerns of a victory by Democratic presidential candidate Hillary Clinton  who made high drug prices an issue in her campaign against Trump  That year  the healthcare sector dropped nearly 10 percent from Aug  1 until the Nov  8 election  versus only a modest overall market drop   Elections bring volatility  especially within healthcare   Heupel said   I don t think this will be any different   Healthcare stocks briefly rallied last month after Trump unveiled an administration plan to lower drug costs for consumers that avoided aggressive measures  But some analysts say the plan could cause volatility as details become clear  Overall this year  shares of pharmaceutical  and large biotechs  have slumped 6 percent and 5 percent  respectively  Those companies  along with pharmacy benefit managers  drug wholesalers and others in the supply chain  comprise over half of the sector  By contrast  healthcare equipment shares overall  are up 10 percent in 2018  with the life science tools and services index  up 7 percent  although a couple of company stocks have lagged  Shares of other companies in the sector  such as health insurer Humana  N HUM  and lab testing company Quest Diagnostics  N DGX   have also climbed this year   In the healthcare space  it really depends on where you re allocated in terms of success   said King Lip  chief investment strategist at Baker Avenue Asset Management  The San Francisco firm s holdings include animal health company Zoetis  N ZTS  and surgical robot maker Intuitive Surgical  O ISRG   Analysts also point to lackluster outlooks for much of large pharma and biotech  with company specific setbacks afflicting  Celgene Corp   O CELG  and others  versus strong financial results and outlooks by healthcare equipment companies  GOOD FUNDAMENTALS  A lot of the medtech stocks  it s not just that Washington isn t targeting them   said Teresa McRoberts  healthcare portfolio manager at Fred Alger Management   Fundamentally  a lot of them do have interesting new products   she said  adding they are beating earnings expectations and raising forecasts  But buying healthcare stocks away from the prescription pricing glare comes at a cost  The healthcare equipment index  for example  trades at 21 2 times earnings estimate for the next 12 months  according to Thomson Reuters Datastream  16 percent above its five year average  Conversely  pharmaceutical companies trade at 13 7 times forward earnings estimates  14 percent below their five year average  with biotech companies at 12 6 times  a nearly 20 percent discount  Matthew Miskin  market strategist at John Hancock Investments  said he worries about risks facing biotech and pharmaceutical stocks heading into the election  but  you are getting compensated for that risk    The market has already priced a lot of that in and these companies are still turning out really good earnings growth and the demographic backdrop isn t going away   Miskin said  referring to the expanding aging and middle class population globally  Some investors shrug off the political risks  Nathan Thooft  co head of global asset allocation at Manulife Asset Management  expects healthcare to outperform the broader market over the next year  citing potential deal making activity and reasonable valuations without much sensitivity to interest rates   The headline risks come and go  They are always going to come and go   Thooft said   But ultimately people will look at this and say these stocks do deserve some attention  ,2018-06-01,Reuters,https://www.investing.com/news/stock-market-news/healthcare-investors-weigh-bets-as-election-risks-loom-1477328,1477328
111586,333101,ISRG,Cooper Companies  COO  Q3 Earnings Beat  Revenues Rise Y Y,opinion,"The Cooper Companies  Inc    NYSE COO   reported third quarter fiscal 2019 adjusted earnings per share  EPS  of  3 23  which surpassed the Zacks Consensus Estimate of  3 16  The bottom line increased 7 7  on a year over year basis Revenues of this Zacks Rank  2  Buy  company came in at  679 4 million  missing the Zacks Consensus Estimate of  686 9 million  However  on a year over year basis  the top line improved 2 9  Q3 Segment DetailsCooperVision  CVI This segment s revenues totaled  509 1 million  up 6  on a pro forma basis and 4  on a reported basis Per management  the segment saw a noticeable uptick in the Single use sphere lenses  29  of CVI   reflecting pro forma growth of 9   driven by accelerating growth in both Clariti and MyDay  Single use sphere lenses revenues totaled  146 3 million Toric  32  of CVI  revenues totaled  163 1 million  up 8  on a pro forma basis Multifocal  10  of CVI  generated revenues of  52 4 million  up 2  at pro forma and down 1  year over year Non single use sphere  29  of CVI  revenues came in at  147 3 million  up 9  at pro forma and 6  from the year ago quarter Geographically  the segment witnessed an improvement in revenues in the Americas  38  of CVI   up 5  at pro forma and 6  year over year to  195 million EMEA revenues  39  of CVI  totaled  196 million  up 3  at pro forma but down 2  from the prior year quarter Asia Pacific sales  23  of CVI  rose 13  at pro forma and 12  year over year to  118 1 million The Cooper Companies  Inc  Price  Consensus and EPS Surprise
    CooperSurgical  CSI This segment posted revenues of  170 3 million  up 2  at pro forma and flat year over year Sub segment Office and Surgical products  62  of CSI  accounted for  106 3 million revenues  up 2  on a year over year basis Fertility  38  of CSI  revenues were  64 million  down 4  year over year but up 5  at pro forma Margin AnalysisIn the fiscal third quarter  gross profit was  450 7 million  up 5 6  year over year   Gross margin was 66 3  of net revenues  up 160 basis points  bps  year over year On an adjusted basis  gross margin was 67   flat year over year Operating income in the quarter was  142 2 million  up 23  year over year  Adjusted operating margin was 28   flat when compared to the prior year quarter FY19 View UpdatedFor fiscal 2019  Cooper Companies expects revenues within  2 635  2 655 million  calling for pro forma growth of 6 7   The Zacks Consensus Estimate is pegged at  2 65 billion  the high end of the guided range Notably  CVI revenues are expected within  1 966  1 976 million  reflecting 7 8  of pro forma growth  CSI revenues are projected between  669 million and  679 million  mirroring 4 6  of pro forma growth Adjusted EPS is expected within  12 27  12 35  The Zacks Consensus Estimate is pinned at  12 28  within the guided range  The mid point of  12 31 is higher than that of the previously stated guidance of  12 15  12 35 For fiscal fourth quarter  revenues are projected within  674  694 million  calling for 5 8  growth at pro forma  The Zacks Consensus Estimate stands at  684 4 million  within the guided range CVI revenues are expected within  503  513 million  indicating 6 8  growth at pro forma  CSI revenues are expected between  171 million and  181 million  reflecting 1 7  growth at pro forma Fourth quarter EPS is expected within  3 22  3 30  The Zacks Consensus Estimate is pegged at  3 29  the high end of the guided range Wrapping UpCooper Companies exited the fiscal third quarter on a mixed note  The company saw solid gains from its core CVI unit  which performed impressively in the United States  the EMEA and the Asia Pacific with high pro forma growth Apart from these  Cooper Companies continues to gain from the PARAGARD acquisition  which has been consistently driving CSI s performance  Management is also optimistic about the Clarity  MyDay and Biofinity suite of products  The company s portfolio of daily silicone hydrogel lenses makes it one of the leaders in the soft contact lens market On the flip side  Cooper Companies  soft Fertility sales in the quarter are a concern  EMEA revenues also fell year over year in the quarter under review  Moreover  a series of acquisitions pose significant integration risks  Stiff competition in the MedTech space adds to the woes Earnings of Other MedTech Majors at a GlanceSome better ranked stocks which posted solid results this earning season are Masimo Corporation   NASDAQ MASI    Baxter International Inc    NYSE BAX   and Intuitive Surgical  Inc    NASDAQ ISRG    each carrying a Zacks Rank  2  You can see  Masimo delivered second quarter 2019 adjusted EPS of 76 cents  beating the Zacks Consensus Estimate of 73 cents  Revenues of  229 7 million surpassed the Zacks Consensus Estimate of  223 million Baxter delivered second quarter 2019 adjusted EPS of 89 cents  which surpassed the Zacks Consensus Estimate of 81 cents by 9 9   Revenues of  2 84 billion outpaced the Zacks Consensus Estimate of  2 79 billion by 1 9  Intuitive Surgical reported second quarter 2019 adjusted EPS of  3 25  which beat the Zacks Consensus Estimate of  2 85  Revenues were  1 1 billion  surpassing the Zacks Consensus Estimate of  1 03 billion Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-08-30,Zacks Investment Research,https://www.investing.com/analysis/cooper-companies-coo-q3-earnings-beat-revenues-rise-yy-200460227,200460227
111587,333102,ISRG,Intuitive Surgical plans three for one stock split,news,Investing com    Intuitive Surgical Inc   NASDAQ ISRG  announced that its Board of Directors has approved a three for one split of the company s common stock  The split is subject to shareholder approval  Shareholders will vote on the split at the Special Meeting of Stockholders  which is currently scheduled to take place on September 22  2017 ,2017-08-11,Investing.com,https://www.investing.com/news/stock-market-news/intuitive-surgical-plans-threeforone-stock-split-517804,517804
111589,333104,ISRG,ETFs To Gain As Surgical Robots Rise In Popularity,opinion,Russia s first humanoid robot    Final Experimental Demonstration Object Research    was recently sent into space  Meanwhile  the CorPath GRX robot assisted a surgeon in the first remote heart operation on a patient 20 miles away in   These highlight the fact that we are living in an era that is largely dominated by AI applications and technological advancements  One field that is rapidly picking up pace and touching all the corners of our lives is   robotics  read    In fact  a report states that the global robotics market is expected to see a CAGR of 25  between 2019 and 2024  Now the application of robots is not just limited to industrial use but a plethora of other areas like healthcare  entertainment  retail  automobile and defense Surgical Robots and HealthcareThe rise of medical mechatronics  powerful computing  improved sensing  microfabrication and molecular imaging has enabled new approaches to age old problems faced by healthcare companies  The growing adoption of robot assisted surgeries is being observed in the healthcare platform  In fact  per a   for every three surgeries conducted in the United States  one will be performed with robotic systems by 2021  Accordingly  is expected to see a CAGR of 10 4  to reach a value of  6 5 billion between 2018 and 2023 The growing need for automation in   rising occurrences of chronic diseases  ageing population  complexities in surgical procedures  and the expanding demand for non invasive surgeries with more accuracy and flexibility are factors driving the market Notably  Intuitive Surgical s   NASDAQ ISRG   robot based da Vinci surgical system enables minimally invasive surgery that reduces trauma associated with open surgery  The da Vinci System is powered by robotic technology which has provided the company with solid exposure to medical mechatronics  robotics and AI for healthcare  The company launched an upgrade to its flagship Vinci Xi technology   da Vinci X  In recent times  Stryker   NYSE SYK   launched the robotic arm assisted total knee arthroplasty application for use with its Mako System  Notably  this is the first and only robotic technology which can be used for total knee  hip and partial knee replacement procedures  Mako Total Knee utilizes both Stryker s robotic platform and its Triathlon Total Knee System  guided through CT based 3D modeling of bone anatomy Verb Surgical  a joint venture between Alphabet  NASDAQ GOOGL  and Johnson   Johnson  NYSE JNJ   is also said to be working on integrating big data and machine learning with robotic surgery  In a bid to grow in the field of robotics spine surgery  Medtronic   NYSE MDT   acquired Mazor Robotics  an Israel based robotic surgical guidance systems company  Following the completion of the transaction  Medtronic launched the Mazor X Stealth Edition robotics guidance platform in January 2019 and has already received positive feedback for this capability The University of Oxford has conducted a trial of   In the trial  robotic surgeries were as successful or in some cases even more effective compared to   Encouragingly  the medical fraternity is also planning to use surgical robots to provide gene therapy to the  Another surgical robotics platform     includes flexible robotics  micro instrumentation  data science  and other technologies for therapeutic and diagnostic bronchoscopic procedures ETFs to ShineWe highlight some ETFs that can benefit from the current trends in the surgical robots market Global X Robotics   Artificial Intelligence ETF The fund seeks to replicate the investment results that correspond generally to the price and yield performance  before fees and expenses  of the Indxx Global Robotics   Artificial Intelligence Thematic Index  It holds 37 holdings in its basket with healthcare sector making 13  of the total weight  The fund has amassed  1 39 billion in assets under management and charges a fee of 68 basis points  The fund has gained 17 4  year to date ROBO Global Healthcare Technology and Innovation ETF The fund replicates the investment results that  before fees and expenses  correspond generally to the price and yield performance of the ROBO Global Healthcare Technology and Innovation Index  It holds around 85 stocks in its basket  It has amassed  2 4 million in assets under management and charges a fee of 68 basis points  The fund has lost 2  since its launch on Jun 25  2019 Want key ETF info delivered straight to your inbox Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ,2019-09-11,Zacks Investment Research,https://www.investing.com/analysis/etfs-to-gain-as-surgical-robots-rise-in-popularity-200463869,200463869
111590,333105,ISRG,Transenterix won t compete head on with Intuitive Surgical  CEO,news,By Ankur Banerjee  Reuters    Transenterix Inc s chief executive played down on Tuesday the threat posed by his company s surgical robotic system to market leader  Intuitive Surgical Inc   NASDAQ ISRG   saying he did not expect the two to compete head on   The U S  Food and Drug Administration cleared Transenterix s Senhance System for use at the end of last week  triggering a surge in the company s share price and a fall in Intuitive Surgical s as investors worried about impending competition   But Transenterix CEO Todd Pope said Senhance had a lot of ground to cover before it might have to compete directly with Intuitive s Da Vinci device  which has dominated robotic surgery purchasing since it was approved in 2000   We feel like we have got a lot of open field running ahead of us   said Pope   We are not going to be competing head on with Intuitive    Intuitive  which shipped 166 of its flagship da Vinci Surgical Systems in the second quarter  is scheduled to report third quarter results on Thursday   Senhance on Friday was approved for use in colorectal and gynecological surgery  helped by features including eye sensing camera control and haptic feedback which surgeons have long sought from robots  Pope said Transenterix would look to convert delicate laparoscopic surgery  which involves making tiny and precise incisions in the abdomen and in its current form is extremely wearing on surgeons  over to Senhance  Analysts have said they don t expect Transenterix pursuing the urological or prostate indications in which Intuitive Surgical specializes    I think in the U S  there s less than 100 000 prostates a year  our current indications give us 1 5 million procedures to go after  outside of that    Pope said   It s really not a focus of ours  ,2017-10-17,Reuters,https://www.investing.com/news/stock-market-news/transenterix-wont-compete-headon-with-intuitive-surgical-ceo-542917,542917
111592,333107,ISRG,Ecolab s  ECL  Nalco Water Opens Customer Experience Center,opinion,Ecolab Inc  s   NYSE ECL   Nalco Water recently opened a customer experience center at its production plant  Notably  the company aims to demonstrate how the company s technologies can reduce water use and optimize costs  This is expected to boost Ecolab s Global Industrial segment Per management  a full range of Nalco s cutting edge water technologies is utilized at the plant that produces water treatment chemistries  The system uses reverse osmosis  ultrafiltration membranes and Nalco Water s 3D TRASAR to treat waste water from different locations  This causes an overall reduction of freshwater use by 20  For investors  notice  3D TRASAR Technology for Cooling Water was launched by Nalco in 2015 to address complex water management needs of the industry  The system delivers the appropriate chemistry response to ensure a balanced  efficient and safe cooling system Ecolab s Water Treatment Offerings at a GlanceEcolab is a leading provider of water  hygiene and energy technologies and services  The company s Global Industrial segment consists of Water  Food   Beverage  Paper and Textile Care operating units and is one of the major revenue drivers  The segment contributed 36 7  of total revenues in the last reported quarter Notably  Ecolab offers treatment services for raw water  cooling water and waste water through real time data monitoring and water management software tools In June  Nalco unveiled a new offering  LegionGuard LG25  which is designed to lower the waterborne pathogen Legionella pneumophila in drinking water systems   Read More   Freshwater Crisis Goes GlobalThe world is currently struggling with dwindling water resources  threatening a staggering number of lives Libya  Yemen and Jordan are already facing severe water scarcity and the United States might also face the same  Notably  states like Texas  Oklahoma  Arizona  Kansas  New Mexico and Nevada are apprehended to be running out of water Per management  demand for freshwater is expected to outpace supply by 40  by 2030 Reflective of these  the global water treatment systems market size is anticipated to be valued at  44 01 billion by 2025 at a CAGR of 7 1   per   Hence  Ecolab s latest developments have been well timed Price PerformanceIn a year s time  shares of this Zacks Rank  3  Hold  company have rallied 26  against the  s 4 4  decline Key PicksA few better ranked stocks in the broader medical sector are Baxter International   NYSE BAX    Intuitive Surgical   NASDAQ ISRG   and Masimo Corporation   NASDAQ MASI    each carrying a Zacks Rank  2  Buy   You can see Baxter s long term earnings are expected to grow 12 8  Intuitive Surgical s long term earnings are projected to increase 12 8  Masimo s long term earnings are estimated to rise 20 5  Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ,2019-09-11,Zacks Investment Research,https://www.investing.com/analysis/ecolabs-ecl-nalco-water-opens-customer-experience-center-200464160,200464160
111593,333108,ISRG,ETFs Investing in Robotics  Automation and Artificial Intelligence Beat Broader Mark ,news,"Investing com   With South Korea s LG Electronics set to unveil three new robot types at the CES electronics show in Las Vegas next week  investors may be curious about how to capitalize on the emerging technology 
Two major investment vehicles focusing on robotics  automation and artificial intelligence stand out  Both are exchanged traded funds  or ETFs  The larger of the two is the Global Robotics   Automation Index ETF  whose stock ticker is ROBO  The other  also sometimes referred to by its catchy ticker  BOTZ  is the Global X Robotics   Artificial Intelligence ETF 
Both BOTZ and ROBO rose sharply in 2017  more than doubling the 20  gain of the benchmark S P 500 
ROBO owns shares in 88 different companies  while BOTZ has 28 holdings in its portfolio  Familiar names include iRobot  Rockwell Automation  NYSE ROK   Nvidia and Intuitive Surgical  NASDAQ ISRG   Many of the companies are not based in the U S  Japan  for one  is well represented 
Given their focus  the ETFs are relatively small by industry standards  ROBO has about  2 billion in assets under management  while BOTZ is closer to  1 5 billion 
Though new and small  they are growing quickly  Investor inflows surged in 2017 ",2018-01-08,Investing.com,https://www.investing.com/news/cryptocurrency-news/etfs-investing-in-robotics-automation-and-artificial-intelligence-beat-broader-mark-1076093,1076093
111594,333109,ISRG,Medidata  MDSO  Collaborates With Mapi Research To Boost Rave,opinion,Medidata Solutions  Inc    NASDAQ MDSO   announced its collaboration with Mapi Research Trust to build a digital library of pre configured and pre approved electronic clinical outcomes assessment  eCOA  questionnaires  Per management  this will enable Medidata Rave eCOA to collect COA data from hundreds of studies each year for better patient outcomes Apart from boosting Medidata s Rave platform  the collaboration is expected to solve major eCOA implementation struggles that affect the pharmaceutical industry  Mapi Research s licensing and author relationships  combined with Medidata s expertise and eCOA solution  will make study management more efficient So  the new eCOA library will include more than 470 questionnaires and pre approved agreements with instrument authors for faster study start acceleration Medidata s Rave at a GlanceMedidata Rave is a cloud based clinical data management system used to electronically capture  manage and report clinical research data  It enables the user to record patient information using forms that are customized for each study The company is witnessing substantial growth with Rave through the attachment of more products  Notably  Medidata serves more than 1200 active customers Market ProspectsAn article by Globenewswire suggests that the global eCOA market is expected to reach a worth of  2 52 billion at a CAGR of 17 6   Notably  strict regulatory norms were imposed on the pharmaceutical and biotech industries during the 2016 2017 period  This compelled the drug manufacturing companies to digitalize the process of their clinical trial outcomes  which drove market growth Hence  Medidata s latest alliance is well timed Medidata Getting AcquiredFor investors  notice  management at Medidata recently announced that the company is being acquired by French technology stalwart   Dassault Syst mes   in an all cash transaction at a price of  92 25 per share  The figure represents an enterprise value of  5 8 billion  The acquisition is expected to close by the end of 2019 Price PerformanceIn the past year  shares of this Zacks Rank  3  Hold  company have rallied 13 9  against the  s 12 8  decline Key PicksA few better ranked stocks in the broader medical sector are Baxter International   NYSE BAX    Intuitive Surgical   NASDAQ ISRG   and Masimo Corporation   NASDAQ MASI    While Baxter and Masimo carry a Zacks Rank  2  Buy   Intuitive Surgical  sports a  Zacks Rank  1  Strong Buy   You can see Baxter s long term earnings are expected to grow 12 8  Intuitive Surgical s long term earnings are projected to increase 12 8  Masimo s long term earnings are estimated to rise 20 5  Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-09-13,Zacks Investment Research,https://www.investing.com/analysis/medidata-mdso-collaborates-with-mapi-research-to-boost-rave-200464370,200464370
111596,333111,ISRG,Intuitive Surgical sees thinner profit margins in 2018  shares fall,news,"By Manas Mishra  Reuters     Intuitive Surgical Inc   O ISRG  said on Thursday it would continue to spend heavily on research and development in 2018  seeking to fend off competition and maintain its dominance in the surgical robotic systems market  Company executives also forecast profit margins for 2018 below 2017 levels on a call with analysts after Intuitive reported better than expected earnings for the fourth quarter  Sunnyvale  California based Intuitive s shares  which hit a record high earlier in the day  fell 3 percent in after hours trading  Excluding a  318 million tax expense  Intuitive reported earnings of  2 54 per share  The result exceeded analysts  average estimate by 30 cents  according to Thomson Reuters I B E S  But investors  who sent the company s stock up 73 percent last year and 23 percent in 2018  may have been expecting a bigger earnings outperformance  said Brandon Henry  an analyst at RBC Capital Markets  Intuitive has enjoyed a near monopoly in the market for robots used in abdominal surgery since launching its flagship device called da Vinci in 2000  But the company has ramped up spending on product development in recent months to remain ahead of competition  The FDA approved Transenterix Inc s  A TRXC  surgical robot for abdominal surgery in October  The news weighed on Intuitive s stock price even though the device was not expected to compete directly with da Vinci  Intuitive said operating expenses rose 16 6 percent year over year to  306 3 million in the fourth quarter ended Dec  31  Operating expenses this year will rise 16 to 18 percent above 2017 levels  as the company continues to invest in emerging markets and new technology including computer assisted surgery  executives said  Analysts said the expense forecast was slightly higher than expected  Intuitive expects a 2018 gross profit margin of 70 percent to 71 5 percent of revenue  lower than the 71 9 percent it recorded in 2017   They don t have big deals on the horizon  and they should be investing internally   said RBC s Henry  The higher spending comes amid strong demand for Intuitive s surgical robots   Intuitive shipped 216 da Vinci systems in the quarter  compared with 163 in the prior year period  The number of surgical procedures using its products rose about 17 percent in the fourth quarter  The company expects the number of procedures to rise 11 15 percent in 2018  Reflecting the tax expense  Intuitive reported a net loss of  38 8 million in the quarter  compared with a profit of  204 million a year earlier  
Total revenue rose 17 9 percent to  892 4 million ",2018-01-25,Reuters,https://www.investing.com/news/technology-news/intuitive-surgical-posts-fourthquarter-loss-on-tax-expense-1153565,1153565
111598,333113,ISRG,After Hours Gainers   Losers  04 17 2018 ,news,Top gainers  TLGT  12 6   ISRG  5 7   CSX  3 7   UAL  2 9   STG  1 6  Top losers  INFN  5 2   IBM  5 3   BMI  5 0   SJI  4 1   LRCX  4 1   Now read ,2018-04-17,Seeking Alpha,https://www.investing.com/news/stock-market-news/after-hours-gainers--losers-04172018-1399912,1399912
111599,333114,ISRG,Here s Why You Should Snap Up Baxter International  BAX  Now,opinion,Baxter International Inc    NYSE BAX   is expected to gain from a solid second quarter show and new developments Over the past year  shares of this Zacks Rank  2  Buy  company have rallied 19 1  compared with the  s 3 8  rise  The current level also compares favorably with the S P 500 index s 1 3  decline What s Favoring the Stock Solid Q2 EarningsIn the recently reported second quarter  Baxter delivered adjusted earnings of 89 cents per share and revenues worth  2 84 billion  Notably  both the metrics outpaced the consensus estimate Given the strong second quarter performance  Baxter raised the 2019 earnings per share guidance to the band of  3 34  3 40  from the previous  3 27  3 35 The company projects sales growth in the range of 1 2  on a reported basis  and about 4  on both cc and operational basis For the third quarter of 2019  management at Baxter expects revenues to grow in the range of 3 4  on a reported basis  and approximately 5  on both cc and operational basis  Adjusted earnings are projected in the range of 82 84 cents per diluted share Baxter International Inc  Price and Consensus   DevelopmentsBaxter and COSMED srl  a worldwide leader in the design of metabolic systems  have announced an agreement to commercialize Q NRG   a metabolic monitoring device utilizing indirect calorimetry technology  This agreement will enable Baxter to introduce Q NRG  to 18 key countries  thereby expanding its global footprint Additionally  Baxter has announced that Hamilton Health Care System will now be the first health system in the United States to utilize its new PrisMax system  This advanced technology is expected to enhance Baxter s Acute Therapies business  Notably  for the Acute Therapies business  Baxter  which is a worldwide leading player in acute care  expects growth of approximately 7  to 8  on a year over year basis in 2019   Read More   Which Way Are Estimates Headed The Zacks Consensus Estimate for third quarter earnings is pegged at 84 cents  suggesting year over year growth of 5   The same for revenues is pinned at  2 86 billion  calling for a decline of 3 5  year over year The Zacks Consensus Estimate for 2019 revenues is at  11 29 billion  indicating a rise of 1 5  year over year  The same for earnings stands at  3 37  calling for growth of 10 49  year over year Other Key PicksOther top ranked stocks in the broader medical space are Intuitive Surgical   NASDAQ ISRG    Stryker Corporation   NYSE SYK   and DENTSPLY SIRONA   NASDAQ XRAY    each carrying a Zacks Rank  2  You can see  Intuitive Surgical s long term earnings growth rate is expected to be 13 3  Stryker s long term earnings growth rate is anticipated to be 10  DENTSPLY s long term earnings growth rate is projected at 11 5  Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-08-15,Zacks Investment Research,https://www.investing.com/analysis/heres-why-you-should-snap-up-baxter-international-bax-now-200455811,200455811
111600,333115,ISRG,Medtronic  MDT  Beats On Q1 Earnings  Ups FY20 EPS Guidance,opinion,"Medtronic plc   NYSE MDT   reported first quarter fiscal 2020 adjusted earnings per share  EPS  of  1 26  beating the Zacks Consensus Estimate by 6 8   Adjusted earnings also rose 7 7  year over year After adjusting the foreign exchange headwind of 2 cents  adjusted EPS increased 9  year over year Without the adjustments  net earnings were 64 cents per share  reflecting an 18 9  decline from the year ago quarter Total RevenuesWorldwide revenues in the reported quarter grossed  7 49 billion  up 3 5  at constant exchange rate or CER  up 1 5  on a reported basis   The top line also exceeded the Zacks Consensus Estimate by 1 1   Revenues at CER in the quarter include adjustments for a  146 million negative impact from foreign currency Medtronic PLC Price  Consensus and EPS Surprise
     In the quarter under review  U S  sales  52  of total revenues  inched up 1 4  year over year on a reported basis to  3 92 billion  While non U S  developed market revenues summed  2 38 billion  32  of total revenues   depicting a 1 2  dip reportedly  up 2 6  at CER   Again the emerging market revenues  16  of total revenues  amounted to  1 19 billion  up 7 5  reportedly  up 12 5  at CER  Segment DetailsThe company currently generates revenues from four major groups  namely Cardiac and Vascular Group  CVG   Minimally Invasive Therapies Group  MITG   Restorative Therapies Group  RTG  and Diabetes Group CVG comprises Cardiac Rhythm   Heart Failure  CRHF   Coronary   Structural Heart  CSH  and Aortic   Peripheral Vascular divisions  APV   MITG includes the Surgical Innovations  SI  and the Respiratory  Gastrointestinal   Renal  RGR  divisions  RTG consists of the Spine  Brain Therapies  Specialty Therapies and Pain Therapies segments while the Diabetes Group incorporates the Intensive Insulin Management  IIM   Non Intensive Diabetes Therapies  NDT  and Diabetes Service   Solutions  DSS  divisions In the fiscal first quarter  CVG revenues improved 1 4  at CER  down 0 7  as reported  to  2 79 billion  driven by mid single digit growth in CSH and low single digit growth in APV  offset by a low single digit decline in CRHF  all at CER CRHF sales totaled  1 38 billion  down 1 2  year over year at CER  down 3 1  as reported   The mid single digits  growth in Arrhythmia Management was countered by a low double digit fall in Heart Failure CSH revenues were up 5 2  at CER  up 2 6  as reported  to  941 million  driven by mid teens  growth in transcatheter aortic valves  The company reported low single digits  year over year deterioration in drug eluting stents sales in the quarter APV revenues registered 1 7  growth at CER  down 0 2  as reported  to  467 million  boosted by high single digits  growth in Venous and mid single digits  rise in Aortic  both partially offset by high single digits  decline in Peripheral In MITG  worldwide sales totaled  2 1 billion  marking a 4 8  year over year increase at CER  up 2 3  on a reported basis   banking on mid single digit growth in both SI  Surgical Innovations  and RGR  Respiratory  Gastrointestinal   Renal  In RTG  worldwide revenues of  2 01 billion were up 4 6  year over year at CER  up 3 2  as reported  on low double digit growth in Brain Therapies  mid single digit growth in Specialty Therapies and low single digit growth in the Spine business  offset by mid single digit declines in Pain Therapies Moreover  revenues at the Diabetes group increased 5 4  at CER  up 3 5  as reported  to  592 million MarginsGross margin in the reported quarter contracted 173 basis points  bps  to 68 4  on a 7 4  rise in the cost of revenues to  2 37 billion  Adjusted operating margin expanded 193 bps year over year to 26 7   Meanwhile  there was a 2  slip in selling  general and administrative expenses  to  2 54 billion  while research and development expenses edged up 0 3   to  587 million   Other income in the quarter under discussion totaled  22 million against the  151 million expense a year ago Fiscal 2020 Guidance UpdatedThe company has reiterated its fiscal 2020 revenue outlook  For the full year  organic revenue growth is expected to be 4   Adverse currency fluctuation is projected to affect the top line by 0 8 1 2   The current Zacks Consensus Estimate for revenues is pegged at  31 44 billion Fiscal 2020 adjusted EPS view has been raised to the range of  5 54  5 60  earlier range was  5 44  5 50   Currency fluctuation is expected to have a 10 cent adverse impact on the full year adjusted EPS  The Zacks Consensus Estimate of  5 47 for the metric is below the guided range Our TakeMedtronic exited the first quarter of fiscal 2020 on a promising note with better than expected numbers  The company has demonstrated improved performances at CER  banking on growth in all major business segments and geographies  This in turn  highlighted sustainability across groups and regions in addition to displaying a successful integration and achievement of synergy targets  Apart from product innovation  the company is focusing on geographical diversification of its businesses On the flip side  escalating costs persistently put pressure on the gross margin  Unfavorable currency movement once again deterred growth during the quarter Zacks Rank   Other Key PicksMedtronic has a Zacks Rank  2  Buy   Some other top ranked stocks having posted solid results this earning season are Integra LifeSciences Holdings Corporation   NASDAQ IART    Baxter International Inc    NYSE BAX   and Intuitive Surgical  Inc    NASDAQ ISRG    each carrying the same favorable Zacks Rank as Medtronic   You can see  Integra LifeSciences delivered second quarter 2019 adjusted EPS of 73 cents  beating the Zacks Consensus Estimate by 12 3   Revenues of  383 6 million also surpassed the Zacks Consensus Estimate by 2 7  Baxter delivered second quarter 2019 adjusted EPS of 89 cents  which trumped the Zacks Consensus Estimate of 81 cents by 9 9   Revenues of  2 84 billion too outpaced the Zacks Consensus Estimate of  2 79 billion by 1 9  Intuitive Surgical reported second quarter 2019 adjusted EPS of  3 25  which beat the Zacks Consensus Estimate of  2 85  Further  revenues of  1 1 billion topped the Zacks Consensus Estimate of  1 03 billion Legalizing THIS Could Be Even Bigger than MarijuanaAmericans spend an estimated  150 billion in this industry every year  more than twice as much as they spend on marijuana Now that 8 states have fully legalized it  with several more states following close behind   Zacks has identified 5 stocks that could soar in response to the powerful demand  One industry insider described the future as  mind blowing    and early investors can still get in ahead of the surge ",2019-08-19,Zacks Investment Research,https://www.investing.com/analysis/medtronic-mdt-beats-on-q1-earnings-ups-fy20-eps-guidance-200456756,200456756
111601,333116,ISRG,Intuitive Surgical raises 2017 procedure growth forecast,news,By Bill Berkrot  Reuters     Intuitive Surgical Inc   NASDAQ ISRG   on Tuesday increased its 2017 forecast for growth in procedures using its da Vinci surgical robots after reporting higher than expected first quarter revenue and profit  and its shares rose nearly 4 percent  Da Vinci procedures grew almost 18 percent worldwide  with a 28 percent jump reported outside the United States  driven by prostatectomies and strong growth in U S  hernia procedures  Intuitive said it now expected full year procedure growth of 12 14 percent  up from its prior view of 9 12 percent  The company said average revenue per procedure for the quarter was  1 840   Procedure growth of about 18 percent was one of the strongest we have seen so far   Evercore ISI analyst Vijay Kumar said in a note  The company said it was unsure if growth in a wide range of procedures in the United States was driven by patients seeking care ahead of any healthcare reform under which they could lose insurance coverage  Intuitive  which has virtually no competition for its surgical robots  sold 133 da Vinci systems in the first quarter  up from 110 in the year ago period  The systems cost about  1 5 million each  Instrument and accessory revenue rose 18 percent to  381 million for the quarter   We feel our Q1 results were exceptional   Chief Executive Gary Guthart said on a conference call  The company said price per da Vinci placement was likely to trend lower going forward as it began to offer lower priced and refurbished older systems to cost sensitive markets  Intuitive also said Asian sales could be constrained until China approved the purchase of more da Vinci systems and Japan expanded reimbursement for additional procedures  Excluding items  Intuitive had adjusted earnings of  5 09 per share  beating analysts  average estimate by 12 cents  according to Thomson Reuters I B E S  Net profit rose to  180 million  or  4 67 per share  from  136 million  or  3 54 per share  a year ago  Revenue for the quarter rose 13 percent to  674 million  topping Wall Street s estimate of  666 5 million  Intuitive said it deferred  23 million in first quarter revenue under a new program in which some customers were offered the opportunity to trade products purchased in the first quarter of this year for products expected to be launched in the future  Intuitive Surgical shares rose to  787 in extended trading from a Nasdaq close at  759 34 ,2017-04-18,Reuters,https://www.investing.com/news/stock-market-news/intuitive-surgical-raises-2017-procedure-growth-forecast-475173,475173
111602,333117,ISRG,Veeva  VEEV  Introduces MuleSoft Connector For Vault Platform,opinion,Veeva Systems Inc    NYSE VEEV   recently announced the availability of the MuleSoft Connector for its flagship Vault platform  Notably  MuleSoft  a Salesforce   NYSE CRM   company  is working with Veeva to make it faster and easier for healthcare companies to connect Veeva Vault applications with other enterprise systems  The latest move expands offerings for Veeva and Salesforce s joint customers Additionally  it fortifies Veeva s foothold in the healthcare IT   HCIT   space For investors  notice  the MuleSoft Connector lets customers easily integrate Veeva Vault platform to third party vendors using connector operations in Mule Flow  The MuleSoft Connector for Veeva Vault is developed and supported by MuleSoft and technically certified by both MuleSoft and Veeva to drive joint customer success Into Veeva VaultVeeva Vault is a cloud based content management platform that offers a suite of applications to help healthcare companies increase business agility  It not only manages regulated documents but also tracks critical information ranging from product development to commercialization Notably  the Veeva Vault suite comprises a large spectrum of services like Veeva Vault Submissions  Vault RIM  Vault PromoMats  Veeva CRM  Veeva Network and VeevaOpenData It is encouraging to note that in recent times  Veeva s Vault platform has seen positive developments For instance  Early Access Care Limited recently selected Veeva Vault CDMS  Veeva Vault Clinical Data Management System  to provide electronic data capture  coding and data cleaning for their upcoming expanded access study Earlier this month  Veeva announced that Vault Safety AI  a new AI application  offers the first integrated suite of cloud applications on a common platform to manage the end to end drug safety lifecycle Last month  Alcon  a global medical device company  chose Veeva Vault CDMS as its enterprise clinical data management system for electronic data capture Additionally  Celltrion  a South Korean biopharmaceutical company  implemented Veeva Vault eTMF  trial master file  to improve oversight across its trial master file processes and achieve greater compliance   Read More   Market ProspectsA  article suggests that the global HCIT market is projected to reach  390 7 billion by 2024 from its current worth of  187 6 billion  at a CAGR of 15 8   The growing volume of patient data  surge in technological know how and demand for quick and efficient healthcare processes fuel market growth Hence  the latest developments have been profitable ones for Veeva Price PerformanceReflective of these  shares of this Zacks Rank  3  Hold  company have skyrocketed 58 5  compared with the  s 5 4  rise  The current level also compares favorably with the S P 500 index s 0 3  rally Key PicksA few better ranked stocks in the broader medical space are Intuitive Surgical   NASDAQ ISRG   and Baxter International   NYSE BAX    each carrying a Zacks Rank  2  Buy   You can see  Intuitive Surgical s long term earnings growth rate is estimated at 13 3  Baxter s long term earnings growth rate is projected at 12 8  Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2019-08-22,Zacks Investment Research,https://www.investing.com/analysis/veeva-veev-introduces-mulesoft-connector-for-vault-platform-200458046,200458046
111603,333118,ISRG,Money flow into Intuitive Surgical ripples out to Mazor Robotics  shares up 5 ,news,Investors  giddy over Intuitive Surgical s  ISRG  6 8   Q1 beat  are moving into Mazor Robotics  MZOR  4 9    Shares are up on almost a 14x surge in volume Mazor builds robotic systems used in spine surgery   Medtronic   NYSE MDT  owns a 10  stake which would increase to 15  if it chooses to invest an additional  20M under the companies  agreement inked about a year ago Standpoint Research is trying to rain on the parade with its downgrade of Mazor to Reduce ,2017-04-19,Seeking Alpha,https://www.investing.com/news/stock-market-news/money-flow-into-intuitive-surgical-ripples-out-to-mazor-robotics;-shares-up-5-475454,475454
111605,333120,ISRG,Phibro s  PAHC  Q4 Earnings Miss Estimates  Revenues Fall Y Y,opinion,"Phibro Animal Health Corporation   NASDAQ PAHC   reported adjusted earnings per share  EPS  of 33 cents in the fourth quarter of fiscal 2019  showing a 28  drop from the year ago number  The figure missed the Zacks Consensus Estimate by 2 9  Meanwhile  without adjustments  reported EPS was 22 cents  reflecting a fall of 60  from the year ago count For fiscal 2019  adjusted EPS came in at  1 53  down 12  from the year ago figure  The metric beat the consensus mark by 0 7  Net SalesIn the quarter under review  net sales totaled  203 9 million  down 3 7  year over year owing to substantially lower sales at two core segments   Animal Health and Mineral Nutrition For 2019  net sales totaled  828 million  up 1  from the year ago tally  However  the figure missed the Zacks Consensus Estimate by 0 2  Phibro Animal Health Corporation Price  Consensus and EPS Surprise
     Segmental Sales Break UpDuring the fourth quarter  Animal Health net sales declined 4  to  132 million  Within this segment  the company registered  86 3 million in sales  reflecting a 6  decline in medicated feed additives  MFAs   This was on account of lower demand owing to African swine fever outbreak in China and consistently lower domestic demand from the poultry and swine sectors  Nutritional specialty product sales rose 1  to  28 6 million  asconsistently dismal domestic dairy conditions and lowered demand from poultry customers was offset by international volume growth in dairy products  Apart from this  net vaccine sales totaled  17 2 million  showing a drop of 1  year over year due to the loss of a domestic distribution arrangement and the continued impact of turbulent economic conditions in certain foreign markets Net sales at the Mineral Nutrition segment fell 7  year over year to  56 million owing tounfavorable product mix and lower average selling prices Net sales at the Performance Products segment rose 15  to  15 9 million backed by higher volumes of personal care products Operational UpdatePhibro s fourth quarter gross profit declined 3 3  year over year to  65 3 million  Gross margin expanded 16 basis points  bps  to 32  Selling  general and administrative expenses in the reported quarter came in at  53 2 million  up 28 5  from the year ago quarter   Operating profit declined 53 6  year over year to  12 1 million and operating margin contracted 639 bps to 5 9  in the quarter under review Financial UpdateThe company exited fiscal 2019 with net cash used by operating activities of  14 1 million  down from the year ago  84 6 million  Capital expenditure amounted to  10 1 million in this quarter  reflecting an increase from  5 5 million in the prior year quarter FY20 OutlookThe company has initiated its guidance for fiscal 2020  Net sales are projected in the range of  833 863 million  an increase of 1 4    Adjusted EPS is estimated in the band of  1 08 1 15 The Zacks Consensus Estimate for fiscal revenues 2020 is pegged at  862 6 million  within the guided range  The same for adjusted EPS is pegged at  1 61  above the guided range Our TakePhibro ended fiscal 2019 on a disappointing note as earnings missed the consensus mark  Moreover  revenue decline across two of the core segments and contraction in operating margin are concerning  On an optimistic note  the company witnessed double digit revenue growth at its Performance Products segment  Strong international volume growth in dairy products contributed to the rise in Nutritional specialty product sales  The company is upbeat about its long term prospects within the animal health segment and has invested in strategic acquisitions like Osprey Biotechnics Zacks Rank and Key PicksPhibro currently carries a Zacks Rank  3  Hold  A few better ranked companies  which posted solid results this earnings season  are Stryker Corporation   NYSE SYK    Baxter International Inc    NYSE BAX   and Intuitive Surgical  Inc    NASDAQ ISRG   Baxter delivered second quarter 2019 adjusted EPS of 89 cents  which surpassed the Zacks Consensus Estimate of 81 cents by 9 9   Revenues of  2 84 billion beat the consensus estimate of  2 79 billion by 1 9   The company holds a Zacks Rank  2  Buy   You can see  Stryker delivered second quarter 2019 adjusted EPS of  1 98  beating the Zacks Consensus Estimate by 2 6   Revenues of  3 65 billion surpassed the Zacks Consensus Estimate by 1 4   The company carries a Zacks Rank of 2 Intuitive Surgical reported second quarter 2019 adjusted EPS of  3 25  which beat the Zacks Consensus Estimate of  2 85  Revenues were  1 1 billion  surpassing the Zacks Consensus Estimate of  1 03 billion  The company has a Zacks Rank  2 Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana  Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2019-08-28,Zacks Investment Research,https://www.investing.com/analysis/phibros-pahc-q4-earnings-miss-estimates-revenues-fall-yy-200459309,200459309
111606,333121,ISRG,IBM sends S P 500  Dow lower  Nasdaq advances,news,By Chuck Mikolajczak NEW YORK  Reuters    The S P 500 and Dow closed lower and the Nasdaq advanced on Wednesday as investors digested the latest round of earnings  while a drop in oil prices weighed on the energy sector   IBM   N IBM  sank 4 9 percent to  161 69 after the company reported a bigger than expected decline in revenue for the first time in five quarters  The stock was the biggest drag on the S P and the price weighted Dow   Usually the bigger names are the bellwethers  people look to them for some signals on the overall health  and sometimes the companies that report later that beat are lost in that shuffle   said Peter Jankovskis  co chief investment officer at OakBrook Investments LLC in Lisle  Illinois   The energy sector  SPNY  slumped 1 4 percent for its fifth drop in six sessions as oil prices settled nearly 4 percent lower   U S  data showed a counter seasonal build in gasoline inventories and a smaller than expected decline in overall crude stocks and sent U S  crude below the  52 a barrel mark for the first time in two weeks    Certainly oil has been weakening for a couple of days and that has been putting some pressure on things   said Jankovskis    Morgan Stanley   N MS  rose 2 percent after posting a surge in quarterly profit  taking some of the sting out of a disappointing report from Goldman Sachs  NYSE GS  on Tuesday  Of the 57 companies in the S P 500 that have reported earnings through Wednesday morning  75 4 percent have topped expectations  according to Thomson Reuters data  above the 71 percent average for the past four quarters   Overall  profits of S P 500 companies are estimated to have risen 10 8 percent in the quarter   the best since 2011  The Dow Jones Industrial Average  DJI  fell 119 13 points  or 0 58 percent  to 20 404 15  the S P 500  SPX  lost 4 03 points  or 0 17 percent  to 2 338 16 and the Nasdaq Composite  IXIC  added 13 56 points  or 0 23 percent  to 5 863 03  The S P 500 failed to climb above its 50 day moving average  a level which has acted as resistance since the benchmark index fell below it last week   With Wall Street near record levels and worries over President Donald Trump s ability to carry out his pro growth promises  investors are hoping first quarter earnings will be strong enough to justify pricey market valuations  Mounting tension between North Korea and the United States  along with political uncertainty in Europe ahead of the French presidential elections  have also served to keep investors cautious  Intuitive Surgical  O ISRG  gained 6 4 percent at  807 94 to help lift the Nasdaq after the company reported higher than expected first quarter revenue and profit  The stock was on track for its best day in nearly two years  The U S  economy expanded at a modest to moderate pace between mid February and the end of March  but inflation pressures remained in check despite more difficulties in attracting and retaining workers  the Federal Reserve said  Declining issues outnumbered advancing ones on the NYSE by a 1 12 to 1 ratio  on Nasdaq  a 1 52 to 1 ratio favored advancers  The S P 500 posted 21 new 52 week highs and 3 new lows  the Nasdaq Composite recorded 80 new highs and 39 new lows   About 6 60 billion shares changed hands in U S  exchanges  above the 6 31 billion daily average over the last 20 sessions ,2017-04-19,Reuters,https://www.investing.com/news/stock-market-news/futures-rise-as-earnings-take-center-stage-475334,475334
111608,333123,ISRG,Veeva Systems  VEEV  Q2 Earnings And Revenues Beat Estimates,opinion,"Veeva Systems Inc    NYSE VEEV   reported second quarter fiscal 2020 earnings per share  EPS  of 55 cents  well ahead of the Zacks Consensus Estimate of 49 cents  The metric shot up 41  on a year over year basis This Zacks Rank  3  Hold  company s revenues totaled  266 9 million  outpacing the Zacks Consensus Estimate of  259 3 million  On a year over year basis  the top line improved 27 3  Segmental DetailsSubscription ServiceSecond quarter subscription service revenues summed  217 3 million  up 28 1  year over year  Per management  the solid momentum in bookings was maintained in the quarter Professional Service and OthersProfessional Service revenues rose almost 23 9  to  49 6 million from the figure registered in the year ago quarter Per management  outperformance by Veeva Commercial Cloud and Veeva Vault drove revenues across all segments Veeva Systems Inc  Price  Consensus and EPS Surprise
     Margin DetailsIn the reported quarter  adjusted gross profit increased 31 2  year over year to  202 4 million  Adjusted gross margin was 75 9   which expanded 230 basis points  bps  Adjusted operating income totaled  103 7 million  up 39 4  year over year  In the quarter under review  adjusted operating margin improved 330 bps to 38 8  Meanwhile  operating expenses totaled  122 8 million  up 25 9  year over year GuidanceFor the fiscal third quarter  Veeva expects revenues between  274 million and  275 million  The Zacks Consensus Estimate is pegged at  268 9 million  below the projected range Adjusted EPS is anticipated within 54 55 cents  The Zacks Consensus Estimate is pinned at 51 cents  lower than the guided range  Adjusted operating margin is projected between  103 million and  104 million For fiscal 2020  Veeva has raised its revenue guidance Notably  the company projects revenues within  1 062 million and  1 065 million  compared with the earlier communicated range of  1 045  1 050 million  The Zacks Consensus Estimate stands at  1 05 billion  below the guided range Adjusted EPS is anticipated within  2 11 and  2 13  The Zacks Consensus Estimate is pinned at  2 02  much below the guided range  Adjusted operating margin is projected between  401 million and  404 million Wrapping UpVeeva Systems ended the fiscal second quarter on a strong note  Core Subscription business segment performed impressively in the quarter  An impressive guidance and a raised view for fiscal 2020 buoy optimism in the stock Apart from these  the company continues to benefit from its flagship Vault platform  In fact  Veeva Vault s customer count has increased manifold in recent times  Markedly  Veeva Systems  unique solutions include Veeva Vault  Veeva CRM  Veeva Network and Veeva OpenData  The company s new CRM Sunrise UI and Nitro look promising as well  In Commercial Cloud  Veeva Systems has secured a number of deals  The company is confident about growth in new markets with products like EDC  Safety  Nitro and Vault On the flip side  high expenses on the operational side are worrisome  Also  intense competition and a saturating life sciences market remain potent threats  Volatility in the foreign currency exchange rate is an added concern Earnings of Other MedTech Majors at a GlanceSome better ranked stocks which posted solid results this earning season are Stryker Corporation   NYSE SYK    Baxter International Inc    NYSE BAX   and Intuitive Surgical  Inc    NASDAQ ISRG    each carrying a Zacks Rank  2  Buy   You can see  Stryker delivered second quarter 2019 adjusted EPS of  1 98  beating the Zacks Consensus Estimate by 2 6   Revenues of  3 65 billion surpassed the Zacks Consensus Estimate by 1 4  Baxter delivered second quarter 2019 adjusted EPS of 89 cents  which surpassed the Zacks Consensus Estimate of 81 cents by 9 9   Revenues of  2 84 billion outpaced the Zacks Consensus Estimate of  2 79 billion by 1 9  Intuitive Surgical reported second quarter 2019 adjusted EPS of  3 25  which beat the Zacks Consensus Estimate of  2 85  Revenues were  1 1 billion  surpassing the Zacks Consensus Estimate of  1 03 billion Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2019-08-28,Zacks Investment Research,https://www.investing.com/analysis/veeva-systems-veev-q2-earnings-and-revenues-beat-estimates-200459418,200459418
111609,333124,ISRG,DexCom  DXCM  Scales 52 Week High  What s Driving The Stock ,opinion,On Aug 28  shares of DexCom  Inc    NASDAQ DXCM   reached a 52 week high of  178 45  closing the session marginally lower at  175 19 Over the past year  shares of DexCom have rallied 46 2  compared with the  s growth of 10 5   The current level is also higher than the S P 500 index s rally of 13  The company  being a major player in developing continuous glucose monitoring  CGM  systems for diabetic people and healthcare providers  is expected to scale new highs in the near term  It has average positive earnings surprise of 183 3  for the trailing four quarters The estimate revision trend for the current year is impressive as well  Over the past 30 days  the Zacks Consensus Estimate for the company s earnings has risen 17 5  to 94 cents Per our   DexCom has Growth Score of A  which is reflective of its solid prospects  Our research shows that stocks with a Growth Style Score of A or B combined with a Zacks Rank  1  Strong Buy  or 2  Buy  offer the best upside potential The company currently carries a Zacks Rank  3  Hold   Factors Driving DexComStrong Segmental Growth Drives Share  The market seems to be upbeat about the company registering strong segmental growth in the last reported quarter  Rise in all channels and geographies along with increased volume contributed to its growth  The company is consistently growing in terms of patient addition  which also buoys optimism Revenue Guidance Upbeat  Exiting a robust first half of 2019 and observing a steady demand for DexCom real time CGM  it raised its yearly revenue guidance by more than 10  indicating that this momentum will continue throughout the rest of the year  This also increased investors  optimism on the stock Series of Developments Buoys Optimism  The market also seems upbeat about DexCom s series of developments  In June  the company announced collaboration with Companion Medical  Inc  to allow a direct exchange of CGM data from Dexcom with insulin data from InPen into both companies  software applications  The agreement is the first of its kind and it paves the way for advanced diabetes decision support  which is an important tool for insulin users On the regulatory front  in February DexCom reached a milestone  with the receipt of Health Canada approval for its next generation Dexcom G6 CGM System for people with diabetes  aged two years and up   thus making it available in Canada Strong International Presence  Investors also seem bullish on strong adoption of Dexcom G6 in the European market  The company is targeting sizeable markets of Korea  India  China and Japan  In this regard  the industry is expected to reach approximately  1325 9 million globally at a CAGR of 15 8  between 2019 and 2025 Stocks to ConsiderSome better ranked stocks in the broader medical space are Integer Holdings Corporation   NYSE ITGR    Intuitive Surgical  Inc    NASDAQ ISRG   and Masimo Corporation   NASDAQ MASI   Integer Holdings currently sports a Zacks Rank  1  Its third quarter earnings growth rate is projected at 7 7  Intuitive Surgical s long term expected earnings growth rate is 13 3   The stock currently carries a Zacks Rank of 2  You can see Masimo s long term expected earnings growth rate is 20 5   The stock has a Zacks Rank  2 at present Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ,2019-08-29,Zacks Investment Research,https://www.investing.com/analysis/dexcom-dxcm-scales-52week-high-whats-driving-the-stock-200459769,200459769
111610,333125,ISRG,Dow sheds more than 100 points for second straight day,news,"Investing com   U S  equities closed lower on Wednesday  as weaker than expected earnings from  IBM  and a slump in oil prices weighed on sentiment 
The Dow posted a more than 100 point drop for the second straight session not least because corporate earnings continued to disappoint  after IBM posted mixed results 
International Business Machines  NYSE IBM  earnings per share beat expectations but revenue fell short of Wall Street estimates for the 20th straight quarter on a year over year basis 
Meanwhile  a slumped in energy stocks weighed on upside momentum  after crude prices fell by nearly 4   the biggest one day decline since March 
On the New York Mercantile Exchange crude futures for May delivery fell by  2 05 to settle at  50 44 a barrel 
In what was quiet day for top tier economic data  investors focused on comments from Federal Reserve officials  Eric Rosengren and Stanley Fisher 
Boston Fed President Eric Rosengren said on Wednesday  the Federal Reserve should start to shrink its balance sheet  relatively soon  but take a gradual approach to ensure planned rate hikes remained on track 
Meanwhile  Federal Reserve Vice Chairman Stanley Fisher maintained his view that U S  policy normalization is likely to be gradual and said that spillovers from tightening   will be manageable  
On the political front  U S  Secretary of State Rex Tillerson stoked U S    Iran tensions  after he said that the United States will conduct a  comprehensive review  of its policy toward Iran while warning that  unchecked Iran  could follow the path of North Korea 
The Dow Jones Industrial Average closed 0 58  lower at 20 404  The S P 500 dipped 0 17  and the Nasdaq Composite traded 0 23  higher at 5849 
S P 500  movers and shakers 
The top S P 500 gainers included   Lam Research Corp   NASDAQ LRCX  up 6 9   and  Intuitive Surgical Inc   NASDAQ ISRG  up 6 4   while  WestRock Co   NYSE WRK  added 4 5  
International Business Machines  NYSE IBM  down 4 9    Marathon Oil  Corporation  NYSE MRO  down 4 3  and Newfield Exploration Company  NYSE NFX  down 3 5   were among the worst S P 500 performers of the session ",2017-04-19,Investing.com,https://www.investing.com/news/stock-market-news/dow-drops-100-points-for-second-straight-day-475571,475571
111611,333126,ISRG,Intuitive Surgical s new da Vinci X CE Mark d,news,Intuitive Surgical  NASDAQ ISRG  announces that its new robotic surgical system  the da Vinci X  has receive CE Mark certification  The company says the new device will provide surgeons and hospitals with access to some of the most advanced robotic assisted surgery technology at a lower cost Now read  IHI  Keep Riding The Medical Devices Momentum,2017-04-26,Seeking Alpha,https://www.investing.com/news/stock-market-news/intuitive-surgical's-new-da-vinci-x-ce-mark'd-477491,477491
111614,333129,ISRG,Sell siders bullish on Intuitive Surgical after Q2 beat  shares down 4 ,news,On cue  sell side shops make bullish revisions to their models for Intuitive Surgical  ISRG  3 5   after it posted better than expected Q2 numbers Stifel  price target raised to  1 100 from  850 based on upward revision to procedure growth RBC Capital  price target raised to  1 000 from  950 citing pipeline progress and accelerating robotics adoption Cantor  price target raised to  1 050 from  1 000 Source  BloombergPreviously  Intuitive Surgical Q2 top line up 13   earnings up 20   shares up 1  after hours  July 20 Previously  Intuitive Surgical beats by  0 16  beats on revenue  July 20 Now read ,2017-07-21,Seeking Alpha,https://www.investing.com/news/stock-market-news/sell-siders-bullish-on-intuitive-surgical-after-q2-beat;-shares-down-4-508493,508493
111621,333136,ISRG,Inogen  INGN  Q2 Earnings Miss Estimates  2019 View Lowered,opinion,"Inogen  Inc    NASDAQ INGN   reported second quarter 2019 earnings per share  EPS  of 45 cents  which missed the Zacks Consensus Estimate of 50 cents  The bottom line also plunged 30 8  year over year Revenues of this Zacks Rank  4  Sell  company came in at  101 1 million  missing the Zacks Consensus Estimate by 5 6   On a year over year basis  the top line climbed 3 9  Segmental DetailsSales revenues amounted to  95 9 million in the quarter under review  up 4 2  on a year over year basis Rental revenues totaled  5 2 million  down 1  Inogen  Inc Price  Consensus and EPS Surprise
    Revenues by Region and CategoryBusiness to business revenues in the United States summed  29 7 million  down 10  on a year over year basis  Internationally  this segment recorded revenues of  22 6 million  up 8 7  and 14 7  at constant currency  on continued adoption by the company s European partners Direct to consumer revenues rose 14  year over year to  43 6 million in the quarter under review on higher sales representative productivity MarginsIn the quarter under review  gross profit was  50 2 million  up 3 6  year over year  Gross margin came in at 49 7   down 10 basis points  bps  Operating income was  12 1 million  down 13 4  year over year  Operating margin came in at 12  of net revenues  down a substantial 240 bps in the prior year quarter Guidance SlashedInogen slashed its 2019 revenue guidance to  370  375 million from the earlier  405  415 million  calling for year over year growth of 3 3 4 7   The Zacks Consensus Estimate for the same is pegged at  408 7 million  above the guided range  Per management  the company has slashed expectations for the direct to consumer sales channel  primarily because of a drop in sales headcount Additionally  third quarter 2019 revenues are expected to decline on a year over year basis Inogen also cut its 2019 operating income guidance to  26  28 million from the previous band of  42  44 million Wrapping UpInogen ended the second quarter on a mixed note  Solid business to business international revenues buoy optimism  Apart from these  the company s direct to consumer unit performed exceedingly well in the quarter  The company is also optimistic about international revenues  which witnessed solid growth in Europe during the second quarter On the flip side  Inogen s rental revenues declined on a year over year basis in the second quarter  In fact  the company s U S  business to business revenues also deteriorated in the quarter  Moreover  operating margin contraction is worrisome  Inogen lowered its guidance for 2019  which is disheartening  The company also expects revenues in the third quarter to remain subdued Earnings of MedTech Majors at a GlanceA few top ranked companies  which posted solid results this earnings season  are Stryker Corporation   NYSE SYK    Baxter International Inc    NYSE BAX   and Intuitive Surgical  Inc    NASDAQ ISRG    each carrying a Zacks Rank  2  Buy   You can see  Stryker delivered second quarter 2019 adjusted EPS of  1 98  beating the Zacks Consensus Estimate by 2 6   Its revenues of  3 65 billion surpassed the consensus estimate by 1 4  Baxter delivered second quarter 2019 adjusted EPS of 89 cents  which surpassed the Zacks Consensus Estimate of 81 cents by 9 9   Its revenues of  2 84 billion outpaced the consensus estimate of  2 79 billion by 1 9  Intuitive Surgical reported second quarter 2019 adjusted EPS of  3 25  which beat the Zacks Consensus Estimate of  2 85  Its revenues of  1 1 billion surpassed the Zacks Consensus Estimate of  1 03 billion Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2019-08-08,Zacks Investment Research,https://www.investing.com/analysis/inogen-ingn-q2-earnings-miss-estimates-2019-view-lowered-200453602,200453602
111623,333138,ISRG, Nevro  NVRO  Q2 Loss Wider Than Expected  Revenues Down Y Y,opinion,"Nevro Corp    NYSE NVRO   reported second quarter 2019 loss of 91 cents per share  wider than the Zacks Consensus Estimate of a loss of 89 cents  The company had incurred loss per share of 35 cents in the year ago quarter The Zacks Rank  4  Sell  company posted revenues of  93 6 million  outpacing the Zacks Consensus Estimate of  88 million  The figure also surpassed the company s expectations  However  revenues dropped 2 6  year over year Quarter HighlightsIn the quarter under review  international revenues were  15 5 million  down 4  year over year but up 2  at constant currency  cc  U S  revenues for the quarter totaled  78 1 million  reflecting a 2  year over year drop  The decline was due to the company s decision to diminish the impact of high volume product orders in the quarter Nevro Corp  Price  Consensus and EPS Surprise
    MarginsGross profit totaled  63 9 million  down 5 6  year over year  Gross margin was 68 3   down 240 basis points Operating expenses rose 18 9  year over year to  90 5 million  Research and development expenses totaled  14 9 million  up 30 8  year over year Sales  general and administrative expenses were up 16 8  year over year to  75 6 million GuidanceFor 2019  Nevro expects worldwide revenues between  368 million and  374 million  The Zacks Consensus Estimate for the same is pegged at  367 9 million  within the projected range SummaryNevro exited the second quarter on a weak note  The company s domestic and international revenues deteriorated year over year  Loss per share widened on a year over year basis  Significant contraction in gross margin raises concern  Surge in operating expenses adds to the woes On the bright side  increased R D expenses reflect focus on innovation  The guidance for 2019 is also promising Earnings of MedTech Majors at a GlanceA few top ranked companies  which posted solid results this earnings season  are Stryker Corporation   NYSE SYK    Baxter International Inc    NYSE BAX   and Intuitive Surgical  Inc    NASDAQ ISRG    each carrying a Zacks Rank  2  Buy   You can see  Stryker delivered second quarter 2019 adjusted earnings per share of  1 98  beating the Zacks Consensus Estimate by 2 6   Its revenues of  3 65 billion surpassed the consensus estimate by 1 4  Baxter delivered second quarter 2019 adjusted earnings per share of 89 cents  which surpassed the Zacks Consensus Estimate of 81 cents by 9 9   Its revenues of  2 84 billion outpaced the consensus estimate of  2 79 billion by 1 9  Intuitive Surgical reported second quarter 2019 adjusted earnings per share of  3 25  which beat the Zacks Consensus Estimate of  2 85  Its revenues of  1 1 billion surpassed the Zacks Consensus Estimate of  1 03 billion Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2019-08-08,Zacks Investment Research,https://www.investing.com/analysis/nevro-nvro-q2-loss-wider-than-expected-revenues-down-yy-200453720,200453720
111626,333141,ISRG,Tandem  TNDM  Q2 Loss Narrower Than Expected  Sales Top Mark,opinion,"Tandem Diabetes Care  Inc    NASDAQ TNDM   reported loss per share of 3 cents in second quarter 2019  significantly narrower than the year ago loss of  1 17   The figure was also narrower than the Zacks Consensus Estimate of a loss of 23 cents Revenues in DetailRevenues in the quarter totaled  93 3 million  surpassing the Zacks Consensus Estimate by 33 3   The top line skyrocketed 173  from the year earlier period on strong domestic demand for the t slim X2 insulin pump Per management  the rollout of t slim X2 with Basal IQ technology  increased supply capacity and renewal sales along with its international launch strengthened the company s core business and considerably drove top line growth in the second quarter In the quarter  Tandem Diabetes  global pump shipments soared 290  year over year to 21  258 pumps  Of these  8459 pumps were shipped to international markets  Accordingly  Tandem Diabetes registered international sales of  22 9 million in the period Domestic pump shipments surged 135  year over year to 12 799 pumps  Domestic sales came in at  70 4 million  up 106  year over year Tandem Diabetes Care  Inc  Price  Consensus and EPS Surprise
    Interestingly  the company began shipping pumps to select geographies for commencing international operations last August MarginsGross profit in the reported quarter came in at  49 9 million  up a significant 230 8  from the prior year period  Gross margin came in at 53 5   expanding 930 basis points  bps  Total operating expenses came in at  51 8 million  up 77 9  year over year  Operating loss in the quarter under review was  1 9 million compared with  13 9 million a year ago GuidanceBanking on a promising second quarter show  Tandem raised its full year sales projection to  350 365 million from the earlier range of  300  315 million  The raised range indicates annual sales growth of around 90 99   The Zacks Consensus Estimate for the top line is pegged at  359 3 million  significantly above management s projected range Our TakeTandem Diabetes delivered better than expected results in the second quarter  Strength in the t slim X2 Insulin pump s domestic sales  the company s expansion in international markets as well as a robust product pipeline drove the top line significantly during the quarter  We are impressed with the strong surge in global pump shipments  The company s raised sales forecast for 2019 also looks promising  On the flip side  its heavy dependence on the sale of insulin pumps and recurring operating losses pose a big threat Zacks Rank and Other Key PicksTandem Diabetes currently carries a Zacks Rank  2  Buy  A few other top ranked companies  which posted solid results this earnings season  are Stryker Corporation   NYSE SYK    Baxter International Inc    NYSE BAX   and Intuitive Surgical  Inc    NASDAQ ISRG   Baxter delivered second quarter 2019 adjusted EPS of 89 cents  which surpassed the Zacks Consensus Estimate of 81 cents by 9 9   Revenues of  2 84 billion beat the Zacks Consensus Estimate of  2 79 billion by 1 9   The company holds a Zacks Rank  2  You can see  Stryker delivered second quarter 2019 adjusted EPS of  1 98  beating the Zacks Consensus Estimate by 2 6   Revenues of  3 65 billion surpassed the Zacks Consensus Estimate by 1 4   The company carries a Zacks Rank of 2 Intuitive Surgical reported second quarter 2019 adjusted EPS of  3 25  which beat the Zacks Consensus Estimate of  2 85  Revenues were  1 1 billion  surpassing the Zacks Consensus Estimate of  1 03 billion  The company has a Zacks Rank  2  Wall Street s Next Amazon  NASDAQ AMZN  Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2019-08-09,Zacks Investment Research,https://www.investing.com/analysis/tandem-tndm-q2-loss-narrower-than-expected-sales-top-mark-200453535,200453535
111630,333145,ISRG,Allscripts  MDRX  Q2 Earnings Top Estimates  Revenues Lag,opinion,Allscripts Healthcare Solutions  Inc    NASDAQ MDRX   reported second quarter 2019 adjusted earnings per share  EPS  of 17 cents  which beat the Zacks Consensus Estimate by 6 3   However  the bottom line declined 10 5  on a year over year basis On a non GAAP basis  revenues totaled  445 million  which missed the Zacks Consensus Estimate by 0 7   The top line also fell 0 9  year over year  However  on a reported basis  revenues amounted to  444 5 million in the quarter  reflecting year over year improvement of 0 7  Bookings came in at  276 million  significantly up by 30 8  from the prior year quarter s tally Segment DetailsIn a bid to focus on the payer and life sciences market and evolution of the healthcare IT industry  the company realigned its segment reporting structure by divesting its investment in Netsmart on Dec 31  2018 The new Provider segment consists of the core integrated clinical software applications  financial management and patient engagement solutions targeted at clients across the entire continuum of care  Meanwhile  the new Veradigm segment mainly focuses on the payer and life sciences market Software delivery  Support and MaintenanceIn the quarter under review  revenues at the segment grossed  285 million on a reported basis  up 0 2  from the year ago quarter s tally Client ServicesAt this segment  revenues totaled  159 5 million  up 1 6  from the year ago quarter s figure Allscripts Healthcare Solutions  Inc  Price  Consensus and EPS Surprise    MarginsGross profit in the second quarter was  184 1 million  up 6  from the year ago quarter s level  As a percentage of revenues  gross margin was 41 4   up 210 bps from the year ago figure Adjusted gross profit amounted to  196 4 million  down 4 8  year over year  Adjusted gross margin was 44 1   down 180 bps from the prior year quarter Adjusted operating income in the quarter was  44 8 million  down 6 5  year over year  Adjusted operating margin was 10 1   as a percentage of revenues  down 60 bps from the prior year quarter Financial UpdateAs of Jun 30  2019  cash and cash equivalents totaled  138 9 million  down 20 3  from 2018 end level Net cash from operating activities for the three months ended Jun 30  2019  amounted to   7 7  million  against  8 2 million from the prior year quarter Guidance RevisedFor 2019  adjusted EPS are expected in the range of 65 70 cents  The Zacks Consensus Estimate is pegged at 68 cents  within the projected range For the third quarter of 2019  adjusted revenues are expected between  445 million and  455 million  The Zacks Consensus Estimate is pegged at  450 1 million  within management s guided range Full year bookings are anticipated between  1 05 billion and  1 10 billion  up from the previously guided range of  900 million and  1 billion  Summing UpAllscripts ended the second quarter on a mixed note  The company continues to gain from the core Client Services unit  which displayed better performance in the quarter  Significant growth in second quarter bookings also buoys optimism  The company continues to maintain momentum in its Provider business on the back of key client wins across solution set  The company remains confident about its near and long term outlook as it anticipates to benefit from a number of differentiated growth opportunities in both its Provider and Veradigm businesses Meanwhile  the company witnessed a contraction in operating margin in the reported quarter  Moreover  Allscripts is exposed to integration risks  Intense competition in the niche space is an added concern Zacks RankCurrently  Allscripts carries a Zacks Rank  2  Buy  Earnings of Other MedTech Majors at a GlanceSome other top ranked stocks which reported solid results this earning season are Stryker Corporation   NYSE SYK    Baxter International Inc    NYSE BAX   and Intuitive Surgical  Inc    NASDAQ ISRG    each carrying a Zacks Rank  2  Buy   You can see  Stryker delivered second quarter 2019 adjusted earnings per share of  1 98  beating the Zacks Consensus Estimate by 2 6   Revenues of  3 65 billion surpassed the Zacks Consensus Estimate by 1 4  Baxter delivered second quarter 2019 adjusted earnings of 89 cents per share  which surpassed the Zacks Consensus Estimate of 81 cents by 9 9   Revenues of  2 84 billion outpaced the Zacks Consensus Estimate of  2 79 billion by 1 9  Intuitive Surgical reported second quarter 2019 adjusted earnings per share of  3 25  which beat the Zacks Consensus Estimate of  2 85  Revenues were  1 1 billion  outpacing the Zacks Consensus Estimate of  1 03 billion Wall Street s Next Amazon  NASDAQ AMZN  Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2019-08-09,Zacks Investment Research,https://www.investing.com/analysis/allscripts-mdrx-q2-earnings-top-estimates-revenues-lag-200453558,200453558
111633,333148,ISRG,Glaukos  GKOS  Q2 Loss Wider Than Estimates   19 View Raised,opinion,"Glaukos Corporation   NYSE GKOS   posted second quarter loss per share of 11 cents  wider than the Zacks Consensus Estimate of a loss of 10 cents  This compares to a loss per share of 15 cents a year ago The Zacks Rank  4  Sell  company s quarterly sales totaled  58 6 million  which beat the Zacks Consensus Estimate by 4 3   On a year over year basis  revenues surged 35 8  Quarter DetailsGross profit in the second quarter was  50 7 million  up 37 1  year over year  Gross margin quarter was 86 6  of net revenues  up 90 basis points on a year over year basis Operating expenses increased 38 1  to  57 million on a year over year basis driven by growth in domestic sales as well as higher marketing and administrative personnel and expenses  These apart  Glaukos  expansion of global direct sales infrastructure and increased spending associated with pharmaceutical research and clinical trials drove operating expenses Glaukos Corporation Price  Consensus and EPS Surprise
     Guidance RaisedGlaukos now expects revenues within  226 million  231 million  up from the previously stated  225  230 million  The Zacks Consensus Estimate is pegged at  228 2 million  within the guided range Our TakeGlaukos exited the second quarter on a tepid note  However  a raised guidance instils optimism in the stock  Also  the company is currently progressing with the U S  commercial rollout of its next generation iStent inject Trabecular Micro Bypass device  For iDose Travoprost  Glaukos targets to file an FDA approval in the near future  Expansion in gross margin is a positive  Management is optimistic about the recent Avedro buyout On the flip side  surging operating expenses raise concern  Glaukos also faces cut throat competition in the Medical Devices space  Further  an overtly stringent regulatory approval process for the iDose platform is concerning Earnings of MedTech Majors at a GlanceA few top ranked companies  which posted solid results this earnings season  are Stryker Corporation   NYSE SYK    Baxter International Inc    NYSE BAX   and Intuitive Surgical  Inc    NASDAQ ISRG    each carrying a Zacks Rank  2  Buy   You can see  Stryker delivered second quarter 2019 adjusted earnings per share of  1 98  beating the Zacks Consensus Estimate by 2 6   Its revenues of  3 65 billion surpassed the consensus estimate by 1 4  Baxter delivered second quarter 2019 adjusted earnings per share of 89 cents  which surpassed the Zacks Consensus Estimate of 81 cents by 9 9   Its revenues of  2 84 billion outpaced the consensus estimate of  2 79 billion by 1 9  Intuitive Surgical reported second quarter 2019 adjusted earnings per share of  3 25  which beat the Zacks Consensus Estimate of  2 85  Its revenues of  1 1 billion surpassed the consensus mark of  1 03 billion Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-08-12,Zacks Investment Research,https://www.investing.com/analysis/glaukos-gkos-q2-loss-wider-than-estimates-19-view-raised-200454107,200454107
111634,333149,ISRG,Accuray  ARAY  Reports Loss In Q4  Revenues Beat Estimates,opinion,Accuray Incorporated   NASDAQ ARAY   reported fourth quarter fiscal 2019 adjusted loss of 2 cents per share against the Zacks Consensus Estimate of earnings per share  EPS  of 3 cents  The company had reported a loss of a penny in the year ago quarter Net revenues of the Zacks Rank  3  Hold  company totaled  117 4 million  surpassing the Zacks Consensus Estimate by 1 1   On a year over year basis  revenues climbed 3 2  FY19 at a GlanceFor fiscal 2019  revenues totaled  418 8 million  beating the Zacks Consensus Estimate of  417 5 million and increasing 3 4  year over year Adjusted net loss for fiscal 2019 was 19 cents per share  wider than the Zacks Consensus Estimate of a loss of 16 cents  The year ago figure was a loss of 28 cents Accuray reports through two major segments   Product and Service For the fiscal year  Product revenues were  196 7 million  47  of net sales   up 6 9  year over year  Service revenues were  222 1 million  53    up 0 5  Fiscal Q4 DetailsProduct Revenues  Product revenues increased 11  year over year to  60 6 million in the reported quarter on strong demand for the Radixact system Service Revenues  Service revenues totaled  56 8 million  down 4  from the year ago quarter Gross Order Update  Gross orders in the fiscal fourth quarter totaled  97 2 million  up 0 8  year over year  The upside was driven by strong demand for Radixact  CyberKnife and TomoTherapy platforms  Radixact accounted for approximately 60  of total gross orders while CyberKnife grew double digits U S  gross orders declined in the reported quarter while that in EMEA grew mid single digits Accuray Incorporated Price  Consensus and EPS Surprise    MarginsGross profit in the fiscal fourth quarter totaled  45 9 million  down 4 3  on a year over year basis  Gross margin was 39 1   highlighting a contraction of 310 basis points  bps  year over year Research and development expenses rose 10  year over year to  16 1 million  Selling and marketing expenses declined 11 5  to  14 9 million  General and administrative expenses contracted 13  to  11 7 million Fourth quarter operating profit was  3 3 million  up 5 3  from the year ago quarter  Operating margin was 2 8   up 10 bps year over year Cash PositionThe company exited fourth quarter fiscal 2019 with total cash  cash equivalents  and short term restricted cash of  87 million  compared with  22 4 million at the end of Mar 31  2019 FY20 GuidanceFor fiscal 2020  Accuray expects revenues within  410  420 million  The Zacks Consensus Estimate for the same is pegged at  434 1 million  much higher than the projected range  Per management  Accuray has slashed its guidance by 1 5   The company expects revenues from EMEA and Japan to remain flat or slightly below the fiscal 2019 levels  In the United States  Accuray expects modest revenue growth in fiscal 2020 Our TakeAccuray wrapped up the fiscal fourth quarter on a mixed note  However  solid demand for the company s Radixact  CyberKnife and TomoTherapy platforms has continued to boost business  We are also upbeat to note that this was the company s fifth consecutive quarter of double digit growth in gross orders  which was driven by continued strength in China  Accuray has also significantly operationalized its China joint venture agreement  which was signed earlier this year  A promising pipeline is expected to broaden the company s product portfolio in the near term On the flip side  declining gross orders in United States raise concern  Gross margin significantly contracted in the quarter  Additionally  Accuray s Service revenues were soft in the fiscal fourth quarter  A dull guidance for fiscal 2020 adds to the woes Earnings of Other MedTech Majors at a GlanceSome better ranked stocks which posted solid results this earning season are Stryker Corporation   NYSE SYK    Baxter International Inc    NYSE BAX   and Intuitive Surgical  Inc    NASDAQ ISRG    each carrying a Zacks Rank  2  Buy    You can see  Stryker delivered second quarter 2019 adjusted EPS of  1 98  beating the Zacks Consensus Estimate by 2 6   Revenues of  3 65 billion surpassed the Zacks Consensus Estimate by 1 4  Baxter delivered second quarter 2019 adjusted EPS of 89 cents   which surpassed the Zacks Consensus Estimate of 81 cents by 9 9   Revenues of  2 84 billion outpaced the Zacks Consensus Estimate of  2 79 billion by 1 9  Intuitive Surgical reported second quarter 2019 adjusted EPS of  3 25  which beat the Zacks Consensus Estimate of  2 85  Revenues were  1 1 billion  surpassing the Zacks Consensus Estimate of  1 03 billion Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-08-15,Zacks Investment Research,https://www.investing.com/analysis/accuray-aray-reports-loss-in-q4-revenues-beat-estimates-200455813,200455813
111635,333150,ISRG,Medtronic expects revenue from surgical robot in fiscal 2019,news,By Susan Kelly  Reuters     Medtronic   NYSE MDT  Plc  the world s largest standalone medical device maker  said on Monday it expects a robotic surgical system it is developing to make a meaningful contribution to company revenue beginning in fiscal 2019  Medtronic will launch the surgical robot before the 2019 fiscal year  with the first systems to roll out in India  said Bryan Hanson  head of the minimally invasive therapies group  The robot will generate  material revenue  in fiscal 2019  Hanson said in the company s investor day presentation   In robotically assisted surgery  the surgeon guides the robot s mechanical arms from a computer console  The approach requires smaller incisions than traditional open surgery and is increasingly used in procedures such as prostate removal and hysterectomy  When launched  Medtronic s robot will compete with Intuitive Surgical  NASDAQ ISRG  Inc s da Vinci system  the only robot for abdominal surgery now on the market  It is also expected to face competition from Verb Surgical  a startup backed by Johnson   Johnson  NYSE JNJ  and Alphabet  NASDAQ GOOGL  Inc s Google that is developing its own robot   Medtronic s offering will aim to lower costs associated with robotic surgery   It is costly today  We are going to be looking to eliminate that as a barrier   Hanson said   Minneapolis based Medtronic has 150 employees working on its robotic system across locations in Massachusetts  Connecticut  Colorado  and Germany  he added  The company  whose products range from pacemakers and heart valves to spinal implants  also announced plans to introduce its first hip and knee replacement devices as part of an Orthopedic Solutions offering for hospitals adjusting to a new Medicare bundled payment program   The Medicare plan ties reimbursement to quality and spending targets for the procedure and a recovery period after the patient leaves the hospital  Medtronic said it has acquired a company  Responsive Orthopedics  that will make the devices  It expects to have a knee available in the first half of 2017 and a hip the following year  The company is providing input to the Centers for Medicare and Medicaid Services on a possible bundled payment plan for cardiovascular surgery  with the aim of reducing hospital re admissions through better patient monitoring  executives said  In diabetes management  Medtronic said it plans to apply by the end of June for U S  approval to sell the first  hybrid closed loop  insulin pump that adjusts insulin delivery when a high glucose reading is detected and suspends it in response to a low level ,2016-06-06,Reuters,https://www.investing.com/news/technology-news/medtronic-expects-revenue-from-surgical-robot-in-fiscal-2019-406822,406822
111636,333151,ISRG,New crop of robots to vie for space in the operating room,news,"By Susan Kelly CHICAGO  Reuters    Even though many doctors see need for improvement  surgical robots are poised for big gains in operating rooms around the world  Within five years  one in three U S  surgeries   more than double current levels   is expected to be performed with robotic systems  with surgeons sitting at computer consoles guiding mechanical arms  Companies developing new robots also plan to expand their use in India  China and other emerging markets  Robotic surgery has been long dominated by pioneer  Intuitive Surgical Inc   NASDAQ ISRG   which has more than 3 600 of its da Vinci machines in hospitals worldwide and said last week the number of procedures that used them jumped by 16 percent in the second quarter compared to a year earlier  The anticipated future growth   and perceived weaknesses of the current generation of robots   is attracting deep pocketed rivals  including  Medtronic  Inc  NYSE MDT  and a startup backed by Johnson   Johnson  NYSE JNJ  and Google  NASDAQ GOOGL   Developers of the next wave aim to make the robots less expensive  more nimble and capable of performing more types of procedures  company executives and surgeons told Reuters  Although surgical robots run an average of  1 5 million and entail ongoing maintenance expenses  insurers pay no more for surgeries that utilize the systems than for other types of minimally invasive procedures  such as laparoscopy   Still  most top U S  hospitals for cancer treatment  urology  gynecology and gastroenterology have made the investment  The robots are featured prominently in hospital marketing campaigns aimed at attracting patients  and new doctors are routinely trained in their use  Surgical robots are used in hernia repair  bariatric surgery  hysterectomies and the vast majority of prostate removals in the United States  according to Intuitive Surgical data  Doctors say they reduce fatigue and give them greater precision  But robot assisted surgery can take more of the surgeon s time than traditional procedures  reducing the number of operations doctors can perform  That s turned off some like Dr  Helmuth Billy   Billy was an early adopter of Intuitive s da Vinci system 15 years ago  But equipping its arms with instruments slowed him down  He rarely uses it now   I like to do five operations a day   Billy said   If I have to constantly dock and undock da Vinci  it becomes cumbersome    SURGEONS  WISH LIST To gain an edge  new robots will need to outperform laparoscopic surgery  said Dr  Dmitry Oleynikov  who heads a robotics task force for the Society of American Gastrointestinal and Endoscopic Surgeons  Surgeons told Reuters they want robots to provide a way to feel the body s tissue remotely  called haptic sensing  and better camera image quality  New systems also will need to be priced low enough to entice hospitals and outpatient surgical centers that have not yet invested in a da Vinci  as well as convince those with established robotic programs to consider a second vendor or switching suppliers altogether   That is where competitors can differentiate   said Vik Srinivasan of the Advisory Board Co  a research and consulting firm that advises hospitals  Developers say they are paying attention  Verb Surgical  the J J Google venture that is investing about  250 million in its project  said creating a faster and easier to use system is a priority   Verb also envisions a system that is  always there  always on   enabling the surgeon to use the robot for parts of a procedure as needed  said Chief Executive Scott Huennekens  Intuitive said it too is looking to improve technology at a reasonable cost  but newcomers will face the same challenges   As competitors come in  they are going to have to work within that same framework   CEO Gary Guthart said in an interview  Device maker Medtronic has said it expects to launch its surgical robot before mid 2018 and will start in India  Others developing surgical robots include TransEnterix Inc and Canada s Titan Medical Inc  An RBC Capital Markets survey found that U S  surgeons expect about 35 percent of operations will involve robots in five years  up from 15 percent today   J J  which hopes to be second to market with a product from Verb  has said it sees robotics as a multibillion dollar market opportunity  Huennekens said Verb s surgical robot will differ from another Google robotics effort  the driverless car  in one important aspect  
 There will always be a surgeon there   he said ",2016-07-28,Reuters,https://www.investing.com/news/technology-news/new-crop-of-robots-to-vie-for-space-in-the-operating-room-417047,417047
111637,333152,ISRG,Intuitive Surgical sees slower 2017 procedure growth  buys back shares,news," Reuters     Intuitive Surgical Inc   O ISRG  on Tuesday posted fourth quarter profit that beat Wall Street expectations  but cautioned that growth in use of its da Vinci surgical robots will be slower next year at the same time research and development costs will increase 
Intuitive also announced an accelerated plan to buy back  2 billion of its common stock  and shares were up 1 percent at  673 after hours 
On a conference call with investors  Intuitive said procedures using the da Vinci system rose 15 percent year over year in 2016  but that growth will slow to between 9 and 12 percent this year due to changes in hospital trends and competitive factors 
The company also said its pro forma gross profit margins will drop modestly to between 69 and 71 percent this year  compared with 71 6 percent in 2016  due to higher spending on research and development  unfavorable foreign exchange rates and other factors 
For the fourth quarter  Intuitive reported adjusted earnings of  6 09 per share  compared with the average Wall Street estimate of  5 99  according to Evercore ISI ",2017-01-24,Reuters,"https://www.investing.com/news/stock-market-news/intuitive-surgical-sees-slower-2017-procedure-growth,-buys-back-shares-455431",455431
111643,333158,ISRG,Shares in Intuitive Surgical surge 7  after 3Q earnings  revenue beat,news,"Investing com    Shares in  Intuitive Surgical Inc   O ISRG  surged more than 7  in after hours trading after the manufacturer of robotic assisted systems used in minimally invasive surgeries beat analysts  forecasts with its revenues and earnings last quarter  
During the company s third quarter  which ended in late September  Intuitive Surgical reported earnings of  167 3 million or 4 40 per share  up from net profits of  123 7 million or 3 35 per share in the same quarter last year  It came as the number of procedures for the company s Da Vinci Surgical System rose by roughly 15  on a yearly basis  driven primarily by growth in U S  general surgery procedures and broad based procedure growth in Asia  
In addition  the Sunnyvale  California based company shipped 117 Da Vinci systems over the three month period  up from 11 during the same quarter last year  Approved by the U S  Food and Drug Administration in 2000  the system is commonly used for the treatment of prostate and hysterectomy removals  
On average  the  Si version   or most advanced platform of the surgical system can cost a hospital upwards of  1 5 million per unit  
 We are pleased with our third quarter procedure growth and financial results   Dr  Gary Guthart  president and CEO of Intuitive Surgical said in a statement   We believe our customers benefit from a large community of users and our technology ecosystem  
On a GAAP basis  Intuitive Surgical s revenue for the quarter grew by 7  to  590 million  amid a considerable increase in sales among its instrument and accessory division  Non GAAP revenue  which excludes the proceeds from the Da Vinci Xi system trade out offers  increased by roughly 10  for the period  
Moving forward  the company awaits approval on applications regarding its Single Site instruments and 30mm EndoWrist stapler products for the da Vinci Xi Surgical System  after filing for 510 k  clearances with the FDA earlier in the third quarter  
Shares in Intuitive Surgical soared 35 99 or 7 61  in after hours trading to 509 00 ",2015-10-20,Investing.com,"https://www.investing.com/news/stock-market-news/shares-in-intuitive-surgical-surge-7-after-3q-earnings,-revenue-beat-367127",367127
111645,333160,ISRG,Shares in Intuitive Surgical flat in spite of strong fourth quarter,news,"Investing com    Shares in  Intuitive Surgical Inc   O ISRG  were relatively flat in after hours trading after the California based advanced robotic surgical system manufacturer reported stronger than expected quarterly results and announced it has received regulatory approval for an integrated table motion product 
For the company s fourth quarter  which ended in late January  Intuitive Surgical reported net earnings of  190 million  or  4 99 a share  up from  146 8 million  or  3 94 a share during the same period in 2014  Adjusted earnings per share  excluding one time items increased by nearly 20  on the quarter 4 92 to 5 89
It came as worldwide procedures for its Da Vinci minimally invasive robotic surgeries increased 15  for the quarter  due primarily to a surge in worldwide urologic procedures and general surgeries in the U S  The company also shipped 158 surgical systems for the quarter  representing an increase of 35  from the previous quarter and 15  on an annual basis 
As a result  Intuitive Surgical had  677 million in revenues on the quarter  up 13  from sales of  601 million during the fourth quarter of 2014  Analysts expected the company to report adjusted per share earnings of 5 04 on revenues of  654 7 million 
For the year as a whole  the company finished with GAAP revenue of  2 4 billion  up from  2 1 billion in 2014  The company also reported full year diluted per share earnings of  15 54  compared to  11 11 in 2014 
  It  was a good year for Intuitive with increased used of our products around the globe and solid operation focus in 2015   CEO Gary Gunthart said in a conference call on Thursday   Our focus was to drive adoption of our platform in general surgery and expand our DaVinci surgical system product line  increase our organizational capability and performance in international markets and improve contribution margins for our newly launched products  
 Themes that emerged at the close of 2014  continued in 2015 with strong performance in general surgery and international procedure growth  
Also on Thursday  Intuitive Surgical announced that the U S  Food and Drug Administration cleared the company s proposal to combine the DaVinci surgical system with Trumpf Medical s advanced operating table  the TruSystem 7000 dv  The integration  according to the company  will help surgeons and anesthesiologists make table adjustments more easily and efficiently 
Shares in Intuitive Surgical rose 1 90 or 0 34  to 557 50 in after hours trading ",2016-01-21,Investing.com,https://www.investing.com/news/stock-market-news/shares-in-intuitive-surgical-flat-in-spite-of-strong-fourth-quarter-381206,381206
111646,333161,ISRG,Becton  Dickinson  BDX  Beats On Q3 Earnings And Revenues,opinion,"Becton  Dickinson and Company   NYSE BDX   reported third quarter fiscal 2019 earnings per share  EPS  of  3 08  which beat the Zacks Consensus Estimate of  3 05  The bottom line also improved 5 8  on a year over year basis and rose 14 8  at constant currency  cc  Becton Dickinson  also known as BD  raked in revenues of  4 35 billion  surpassing the Zacks Consensus Estimate by 0 06   The reported figure increased 0 6  from the year ago quarter  At cc  revenues rose 5 7  Segment DetailsBD MedicalIn the quarter under review  the Zacks Rank  3  Hold  company reported worldwide revenues of  2 31 billion  up 2 9  from the year ago quarter and 6  at cc  Per management  the segment s results were driven by performance in the Medication Management Solutions  Medication Delivery Solutions and Pharmaceutical Systems units BD Life SciencesWorldwide revenues in the segment totaled  1 06 billion  down 1 9  year over year but increased 5 4  at cc BD InterventionalThis segment generated worldwide revenues of  0 98 billion  up 2 8  from the year ago quarter  At cc  revenues grew 5 2   The segment s results reflect strong performance by the Urology and Critical Care and Surgery sub units Becton  Dickinson and Company Price  Consensus and EPS Surprise
    Geographic ResultsUSIn the fiscal third quarter  revenues in the United States improved 4 4  to  2 44 billion  Revenues grew 5  at cc  Per management  growth in the United States was driven by performance of the BD Medical and BD Interventional segments InternationalRevenues outside the United States grossed  1 91 billion  down 1 6  from the year ago quarter  At cc  the segment grew 6 5   Per management  international revenue growth in the third quarter was strong in China and EMEA Margin AnalysisIn the quarter  gross profit amounted to  2 07 billion  up 2 9  from the prior year quarter tally  Gross margin was 47 7   up 60 bps from the prior year quarter Operating income in the quarter grossed  626 million  down 22 3  from the year ago quarter  As a percentage of revenues  operating margin in the quarter was 14 4   up 240 bps year over year Adjusted operating income amounted to  716 million  up 9 6  from the year ago figure Guidance ReaffirmedFor 2019  the company continues to expect revenue growth of 8 9   At cc  revenues are anticipated to increase 5 6   The Zacks Consensus Estimate stands at  17 28 billion Adjusted EPS is expected between  11 65 and  11 75  indicating growth of 12  at cc  The Zacks Consensus Estimate is pegged at  11 68  within the projected range  However  this includes unfavorable impact of foreign currency Wrapping UpBD exited the fiscal third quarter on a strong note  Strong performance at the core BD Medical and Interventional segments instills optimism in the stock  Domestic revenues increased year over year in the quarter under review  driven by segmental strength  Growth in China and EMEA is a positive  Expansion in gross and operating margins is also encouraging  BD has kept fiscal 2019 guidance intact Meanwhile  sluggishness in the core Life Sciences unit raises concern  International sales also declined in the quarter  Contraction in operating margins in the quarter remains a concern  Management expects unfavorable foreign currency to partially mar BD s bottom line in fiscal 2019  Stiff competition in the MedTech space adds to woes Earnings of Other MedTech Majors at a GlanceSome better ranked companies  which posted solid results this earnings season  are Stryker Corporation   NYSE SYK    Baxter International Inc    NYSE BAX   and Intuitive Surgical  Inc    NASDAQ ISRG    each carrying a Zacks Rank  2  Buy   You can see  Stryker delivered second quarter 2019 adjusted EPS of  1 98  beating the Zacks Consensus Estimate by 2 6   Its revenues of  3 65 billion surpassed the Zacks Consensus Estimate by 1 4  Baxter delivered second quarter 2019 adjusted EPS of 89 cents  which surpassed the Zacks Consensus Estimate of 81 cents by 9 9   Its revenues of  2 84 billion outpaced the consensus estimate of  2 79 billion by 1 9  Intuitive Surgical reported second quarter 2019 adjusted EPS of  3 25  which beat the Zacks Consensus Estimate of  2 85  Its revenues of  1 1 billion surpassed the Zacks Consensus Estimate of  1 03 billion The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2019-08-06,Zacks Investment Research,https://www.investing.com/analysis/becton-dickinson-bdx-beats-on-q3-earnings-and-revenues-200451310,200451310
111649,333164,ISRG,Henry Schein  HSIC  Q2 Earnings Beat Estimates  Revenues Miss,opinion,"Henry Schein  Inc    NASDAQ HSIC   reported adjusted earnings per share  EPS  from continuing operations of 84 cents in the second quarter of 2019  up 10 5  year over year  Adjusted EPS beat the Zacks Consensus Estimate by 1 2  on revenue growth across global Medical and Technology and Value added Services businesses On a reported basis  EPS from continuing operations was 78 cents  showing an 8 3  improvement on a year over year basis Revenues in DetailHenry Schein reported net sales of  2 45 billion in the second quarter  up 5 6  year over year  The metric missed the Zacks Consensus Estimate by 1 2   The year over year improvement came on the back of 3 5  internal sales growth in local currencies along with acquisition growth of 4 3   The top line was adversely impacted by 2 1  owing to unfavorable foreign currency exchange 
 Henry Schein  Inc  Price  Consensus and EPS Surprise
     Excluding  23 9 million in corporate revenues from product sales to Covetrus under the transition services agreement related to Henry Schein s Animal Health spin off  normalized internal sales growth in local currencies was 2 4  In the quarter under review  the company recorded sales of  1 76 billion in the North American market  up 7 5  year over year  Sales totaled  683 8 million in the international market  up 1 4  year over year Segment Analysis    Henry Schein derives revenues from four operating segments  Dental  Medical and Technology and Value added Services In the second quarter  the company derived  1 60 billion of global Dental sales  down 0 7  year over year  This includes 2 1  growth in local currencies and 2 8  adverse impact from foreign currency exchange  At local currencies  internally generated sales increased 0 7  and acquisition growth was 1 4  Worldwide Medical revenues climbed 13 6  year over year to  697 6 million  Growth in local currencies was 13 8  while there was a 0 2  decline related to foreign exchange headwind Revenues from global Technology and Value added Services grew 39 9  to  125 1 million  This included 41 2  growth in local currencies and 1 3  decrease owing to adverse currency movements Margin Trend         Gross profit increased 6 8  to  767 4 million in the reported quarter  Gross margin expanded 34 basis points  bps  from the year ago quarter to 31 4  The company reported a 7 3  rise in selling  general   administrative expenses to  593 2 million in the second quarter  However  adjusted operating income improved 5 2  year over year to  174 2 million  Adjusted operating margin contracted 3 bps to 7 1  Financial PositionThe company exited second quarter 2019 with cash and cash equivalents of  84 9 million  compared with  88 1 million at the end of the first quarter  Year to date net cash provided by operating activities from continuing operations was  298 8 million compared with 111 9 million in the year  ago period During the quarter under review  Henry Schein repurchased 1 2 million shares of its common stock for approximately  77 million  At the end of the second quarter  the company had  173 million authorized for repurchase of common stock 2019 GuidanceThe company reaffirmed its EPS guidance for 2019  It expects adjusted EPS in the range of  3 38  3 50  reflecting 7 10  growth from 2018  The Zacks Consensus Estimate for 2019 adjusted EPS of  3 46 is within the guided range Our TakeHenry Schein exited the second quarter of 2019 on a mixed note  The company saw solid performance by the global Medical and Technology and Value added Services businesses during the second quarter  Henry Schein s strong share gains in the North American market raise optimism  Year over year revenue growth is also encouraging  Nonetheless  we are disappointed with the sluggish dental sales and the contraction in adjusted operating margin in the reported quarter Zacks Rank   Key PicksHenry Schein currently carries a Zacks Rank  3  Hold  A few better ranked companies  which posted solid results this earnings season  are Stryker Corporation   NYSE SYK    Baxter International Inc    NYSE BAX   and Intuitive Surgical  Inc    NASDAQ ISRG   Baxter delivered second quarter 2019 adjusted EPS of 89 cents  which surpassed the Zacks Consensus Estimate of 81 cents by 9 9   Revenues of  2 84 billion beat the Zacks Consensus Estimate of  2 79 billion by 1 9   The company holds a Zacks Rank  2  Buy   You can see  Stryker delivered second quarter 2019 adjusted EPS of  1 98  beating the Zacks Consensus Estimate by 2 6   Revenues of  3 65 billion surpassed the Zacks Consensus Estimate by 1 4   The company carries a Zacks Rank of 2 Intuitive Surgical reported second quarter 2019 adjusted EPS of  3 25  which beat the Zacks Consensus Estimate of  2 85  Revenues were  1 1 billion  surpassing the Zacks Consensus Estimate of  1 03 billion  The company sports a Zacks Rank  2 The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2019-08-06,Zacks Investment Research,https://www.investing.com/analysis/henry-schein-hsic-q2-earnings-beat-estimates-revenues-miss-200451423,200451423
111650,333165,ISRG,Avanos  AVNS  Q2 Earnings Beat Estimates  Revenues Miss,opinion,Avanos Medical  Inc    NYSE AVNS   reported adjusted earnings of 28 cents per share in second quarter 2019  which beat the Zacks Consensus Estimate by 12   However  the bottom line plunged 41 7  year over year Revenues of  172 2 million missed the Zacks Consensus Estimate by 0 3   However  the figure improved 7  on a year over year basis Q2 Segmental AnalysisChronic CareNet revenues at this segment amounted to  102 3 million  up 5 4  year over year Pain ManagementThe segment reported net revenues of  69 9 million  The metric advanced 9 6  on a year over year basis AVANOS MEDICAL  INC  Price  Consensus and EPS Surprise    Margin AnalysisAdjusted gross profit came in at  103 4 million  up 7 4  from the prior year quarter figure  Adjusted gross margin was 60  of net revenues  up 10 bps year over year Research and development expenses totaled  9 5 million  down 12  year over year  Selling  general and administrative expenses amounted to  94 7 million  up 18 7  year over year Adjusted operating profit in the second quarter was  19 5 million  improving 25  on a year over year basis The company reported operating loss of  9 8 million in the quarter under review  against the year ago quarter s operating income of  8 8 million Financial UpdateAs of Jun 30  2019  cash and cash equivalents totaled  288 1 million  down 25 1  from 2018 end level Net cash from operating activities for the three months ended Jun 30  2019  amounted to   31 9  million  narrower than   96 7  million from the prior year quarter Guidance RevisedFor 2019  Avanos now projects adjusted earnings per share to range between  1 15 and  1 25 compared to the prior guided range of  1 15  1 35 Avanos anticipates 2019 net revenues to increase 8 10  year over year  up from the previously guided estimate of 6 8    on a constant currency basis  including Game Ready and now NeoMed  Notably  the other key planning assumptions that management provided in the 2018 conference call remain unchanged Zacks RankCurrently  Avanos carries a Zacks Rank  3  Hold  Summing UpAvanos exited the second quarter on a mixed note  wherein the bottom line beat the consensus mark  while the top line missed the same  The company continues to gain from its core segments   Chronic Care and Pain Management  Notably  it completed the NeoMed  Inc  buyout and also entered into an agreement to acquire Summit Medical Products   a leading developer and manufacturer of electronic infusion pumps  which complements the company s Acute Pain business  Moreover  gross margin expansion is an added positive However  Avanos  Acute Pain unit has been witnessing weak performance in recent times  In fact  the company anticipates the headwinds impacting this unit to persist throughout the remaining portion of the year  Moreover  being a pure play MedTech company  it faces stiff competition from other bigwigs in the industry Earnings of Other MedTech Majors at a GlanceSome other top ranked stocks which reported solid results this earning season are Stryker Corporation   NYSE SYK    Baxter International Inc    NYSE BAX   and Intuitive Surgical  Inc    NASDAQ ISRG    each carrying a Zacks Rank  2  Buy   You can see  Stryker delivered second quarter 2019 adjusted earnings per share of  1 98  beating the Zacks Consensus Estimate by 2 6   Revenues of  3 65 billion surpassed the Zacks Consensus Estimate by 1 4  Baxter delivered second quarter 2019 adjusted earnings of 89 cents per share  which surpassed the Zacks Consensus Estimate of 81 cents by 9 9   Revenues of  2 84 billion outpaced the Zacks Consensus Estimate of  2 79 billion by 1 9  Intuitive Surgical reported second quarter 2019 adjusted earnings per share of  3 25  which beat the Zacks Consensus Estimate of  2 85  Revenues were  1 1 billion  outpacing the Zacks Consensus Estimate of  1 03 billion This Could Be the Fastest Way to Grow Wealth in 2019 Research indicates one sector is poised to deliver a crop of the best performing stocks you ll find anywhere in the market  Breaking news in this space frequently creates quick double  and triple digit profit opportunities These companies are changing the world   and owning their stocks could transform your portfolio in 2019 and beyond  Recent trades from this sector have generated  98    119 and  164 gains in as little as 1 month ,2019-08-06,Zacks Investment Research,https://www.investing.com/analysis/avanos-avns-q2-earnings-beat-estimates-revenues-miss-200452210,200452210
111654,333169,ISRG,CVS Health  CVS  Beats On Q2 Earnings  Raises  19 Guidance,opinion,CVS Health Corporation s   NYSE CVS   second quarter 2019 adjusted earnings per share  EPS  of  1 89 increased 11 8  year over year and also exceeded the Zacks Consensus Estimate by 11 2   The quarter s adjusted EPS considered certain transaction and integration costs pertaining to the buyout of Aetna  NYSE AET  On a reported basis  the company registered earnings of  1 49 per share against the year ago loss of  2 52 Moreover  total revenues in the second quarter surged 35 2  year over year  after adjusting the interest income on financing the Aetna acquisition  adjusted revenues increased 35 8  year over year  to  63 43 billion  The same also topped the Zacks Consensus Estimate of  62 61 billion by 1 3  CVS Health Corporation Price  Consensus and EPS Surprise   The year over year revenue rise was primarily driven by the acquisition of Aetna  expanded volume and the brand name drug price inflation in both the Pharmacy Services and Retail LTC segments  partially offset by a persistent reimbursement pressure in the Retail LTC  price compression in the Pharmacy Services segment and an increased generic dispensing rate Quarter in Detail     In the second quarter of 2019  the company realigned the composition of its segments  As a result of this move  the company s SilverScript Medicare Part D prescription drug plan  PDP  was shifted from the Pharmacy Services segment to the Health Care Benefits one  In addition  the mail order and specialty pharmacy operations of Aetna were transitioned from the Health Care Benefits segment to the Pharmacy Services one Pharmacy Services revenues inched up 4 2  to  34 84 billion in the reported quarter  driven by growth in total pharmacy claims volume and the brand name drug price inflation  This was  however  partially offset by a continued client price compression and a hiked generic dispensing rate Total pharmacy claims processed rose 4  on a 30 day equivalent basis  attributable to net new business and the steady adoption of Maintenance Choice offerings Revenues from CVS Health s Retail LTC were nudged up 3 7  year over year to  21 45 billion  Per the company  the result was based on higher prescription volume and branded drug price inflation  partially offset by a relentless reimbursement pressure and the impact of recent generic introductions  Front store revenues represented 22 7  of total Retail LTC revenues in the reported quarter  primarily banking on improved health product sales Total prescription volume grew 5 9  on a 30 day equivalent basis  boosted by the steady uptake of patient care programs and collaborations with PBMs as well as the preferred status in a number of Medicare Part D networks Within Health Care Benefits segment  the company registered revenues of  17 40 billion in the June quarter Gross profit skyrocketed 204  to  24 46 billion  Accordingly  gross margin expanded 2141 bps to 38 6   Adjusted operating margin in the quarter under review also grew 1911 bps to 25 9  despite 65 2  escalation in operating expenses to  8 04 billion OutlookCVS Health has updated its 2019 guidance Adjusted EPS expectation has been raised to the band of  6 89  7 from the earlier provided range of  6 75  6 90  The Zacks Consensus Estimate for earnings is pegged at  6 84  lower than the company s guided range  This apart  the company s 2019 adjusted operating profit estimate has been lifted to the  15 2  15 4 billion band from the previous view of 15  15 2 billion Further  the company has upped its cash flow from operations guidance to  10 1  10 6 billion from  9 8  10 3 billion The company has also issued view for the third quarter of 2019  Adjusted EPS is projected in the range of  1 75  1 79  The Zacks Consensus Estimate for earnings of  1 67 remains below the guided range Our TakeCVS Health ended the second quarter on a promising note with both earnings and revenues trumping the respective Zacks Consensus Estimate  Moreover  year over year growth in the top line was driven by a strong Pharmacy Services segment  benefiting from the upside in specialty services  The company s recently introduced Health Care Benefits segment following the Aetna acquisition also holds immense promise Additionally  solid year over year Retail LTC comparisons were encouraging  The raised EPS projection for 2019 further buoys optimism on the stock  However  the LTC business is facing some industry wide challenges Zacks Rank   Key PicksCVS Health currently carries a Zacks Rank  3  Hold   A few better ranked companies flaunting solid results this earnings season are Stryker Corporation   NYSE SYK    Baxter International Inc    NYSE BAX   and Intuitive Surgical  Inc    NASDAQ ISRG   Stryker delivered second quarter 2019 adjusted EPS of  1 98  beating the Zacks Consensus Estimate by 2 6   Revenues of  3 65 billion too exceeded the Zacks Consensus Estimate by 1 4   The company carries a Zacks Rank of 2 Baxter delivered second quarter 2019 adjusted EPS of 89 cents  which surpassed the Zacks Consensus Estimate of 81 cents by 9 9   Revenues of  2 84 billion also beat the Zacks Consensus Estimate of  2 79 billion by 1 9   The company holds a Zacks Rank  2  Buy   You can see  Intuitive Surgical reported second quarter 2019 adjusted EPS of  3 25  which beat the Zacks Consensus Estimate of  2 85  Moreover  revenues were  1 1 billion  topping the Zacks Consensus Estimate of  1 03 billion  The company is Zacks  2 Ranked This Could Be the Fastest Way to Grow Wealth in 2019 Research indicates one sector is poised to deliver a crop of the best performing stocks you ll find anywhere in the market  Breaking news in this space frequently creates quick double  and triple digit profit opportunities  These companies are changing the world   and owning their stocks could transform your portfolio in 2019 and beyond  Recent trades from this sector have generated  98    119  and  164  gains in as little as 1 month ,2019-08-06,Zacks Investment Research,https://www.investing.com/analysis/cvs-health-cvs-beats-on-q2-earnings-raises-19-guidance-200452371,200452371
111657,333172,ISRG,Syneos Health  SYNH  Q2 Earnings Beat Estimates   19 View Up,opinion,Syneos Health Inc    NASDAQ SYNH   reported second quarter 2019 adjusted earnings per share  EPS  of 74 cents  which beat the Zacks Consensus Estimate by 5 7   The metric also improved 19 4  from the year ago tally Reported EPS share came in at 11 cents  down 15 4  from the year ago figure Revenues in DetailService revenues in the quarter totaled  1 17 billion  The top line increased 8 8  year over year and beat the Zacks Consensus Estimate by 1 7   Per management  revenue growth across key segments drove the top line Segmental DetailsThe Clinical Solutions segment delivered service revenues of  849 9 million in the second quarter  up 8 4  year over year  adjusted revenues up 9 4  at CER   The upside was led by net new business growth favorable revenue mix and higher growth in reimbursable expenses  partially offset by the adverse impact of foreign currency fluctuation Commercial Solutions service revenues came in at  316 9 million in the reported quarter  up 9 8  year over year  adjusted revenues up 10 3  at CER   Net new business growth and the company s buyout of Kinapse in the third quarter of 2018 drove Commercial Solutions service revenues in the quarter under review Margin DetailsDirect cost  excluding depreciation and amortization  increased 8 3  to  917 5 million in the quarter  Selling  general and administrative expenses rose 10 6  year over year to  110 9 million  Adjusted operating margin  excluding depreciation  amortization  transaction and integration related and restructuring and other expenses  expanded 22 basis points from the year ago quarter to 11 9  Financial DetailsSyneos Health exited the second quarter of 2019 with cash  cash equivalents  and restricted cash of  107 3 million compared with  107 9 million at the end of the first quarter  Year to date  net cash provided by operating activities was  83 5 million compared with  65 2 million a year ago Guidance UpdatedFor 2019  the company raised the adjusted service revenue guidance to  4 64 4 75 billion  compared with the earlier projection of  4 62  4 73 billion  The Zacks Consensus Estimate is pegged at  4 67 billion  within the guided range For 2019  the company has also raised its adjusted EPS guidance to the range of  3 08 3 26 from the earlier  3 03  3 23  The Zacks Consensus Estimate for the same is pegged at  3 12  well within the guided range Our TakeSyneos Health exited the second quarter of 2019 on a solid note  We are upbeat about the strong year over year revenue growth across both operating segments  The company has been strengthening its unique end to end market position by consistently innovating and expanding its Syneos One product  Strong RFP flow  a diverse portfolio of clinical and commercial initiatives and sustained customer interest in the company s integrated offerings buoy optimism  Expansion in both margins is impressive as well  The raised 2019 guidance is indicative of continued bullish performance by the company Zacks Rank   Other Key PicksSyneos Health currently carries a Zacks Rank  2  Buy  A few other top ranked companies  which posted solid results this earnings season  are Stryker Corporation   NYSE SYK    Baxter International Inc    NYSE BAX   and Intuitive Surgical  Inc    NASDAQ ISRG   Baxter delivered second quarter 2019 adjusted EPS of 89 cents  which surpassed the Zacks Consensus Estimate of 81 cents by 9 9   Revenues of  2 84 billion beat the Zacks Consensus Estimate of  2 79 billion by 1 9   The company holds a Zacks Rank  2  You can see  Stryker delivered second quarter 2019 adjusted EPS of  1 98  beating the Zacks Consensus Estimate by 2 6   Revenues of  3 65 billion surpassed the Zacks Consensus Estimate by 1 4   The company carries a Zacks Rank of 2 Intuitive Surgical reported second quarter 2019 adjusted EPS of  3 25  which beat the Zacks Consensus Estimate of  2 85  Revenues were  1 1 billion  surpassing the Zacks Consensus Estimate of  1 03 billion  The company has a Zacks Rank  2 This Could Be the Fastest Way to Grow Wealth in 2019 Research indicates one sector is poised to deliver a crop of the best performing stocks you ll find anywhere in the market  Breaking news in this space frequently creates quick double  and triple digit profit opportunities  These companies are changing the world   and owning their stocks could transform your portfolio in 2019 and beyond  Recent trades from this sector have generated  98    119  and  164  gains in as little as 1 month ,2019-08-07,Zacks Investment Research,https://www.investing.com/analysis/syneos-health-synh-q2-earnings-beat-estimates-19-view-up-200452147,200452147
111659,333174,ISRG,AMN Healthcare  AMN  Q2 Earnings And Revenues Top Estimates,opinion,"AMN Healthcare Services Inc    NYSE AMN   reported second quarter 2019 adjusted earnings per share  EPS  of 77 cents  which outpaced the Zacks Consensus Estimate of 70 cents  However  the bottom line declined 7 2  year over year The Zacks Rank  1  Strong Buy  company reported revenues worth  535 2 million  which surpassed the Zacks Consensus Estimate of  527 1 million  However  on a year over year basis  revenues dropped 4 1  Segment DetailsNurse and Allied SolutionsIn the second quarter of 2019  the segment s revenues totaled  331 6 million  down 0 3  year over year Locum Tenens SolutionsThe segment s revenues amounted to  82 1 million  down 23 5  from the prior year quarter Other Workforce SolutionsIn the quarter under review  the segment s revenues came in at  121 5 million  up 2 9  year over year AMN Healthcare Services Inc Price  Consensus and EPS Surprise
    MarginIn the second quarter  gross profit totaled  179 5 million  down 0 8  year over year  As a percentage of revenues  gross margin was 33 5  which expanded 110 basis points  bps  Total operating expenses in the quarter were  131 7 million  up 16 9  year over year  Operating income in the quarter was  134 4 million  up 6 5   As a percentage of revenues  operating margin was 8 4   down 140 bps GuidanceFor the third quarter of 2019  AMN Healthcare expects revenues within  560  566 million  The Zacks Consensus Estimate of  557 3 million lies below the projected range Gross margin is expected at 33  while operating margin is estimated at 7 7  Adjusted EBITDA is projected at 12  Our TakeAMN Healthcare exited the second quarter on a solid note  The company gained from its core Other Workforce Solutions unit in the quarter  Management is upbeat about the latest Advanced Medical buyout  which is expected to expand the company s travel as well as school therapy and travel nurse staffing capabilities  Expansion in gross margin is also encouraging  A solid view for the third quarter buoys optimism However  lackluster performance by the company s Nurse and Allied as well as Locum Tenens Solutions is worrisome  In the second quarter  the company s top and bottom line declined on a year over year basis primarily due to labor disruption in the Nurse and Allied segment as well as lower contribution from the Locum Tenens unit  Contraction in operating margin adds to the woes Other Key PicksA few other top ranked companies  which posted solid results this earnings season  are Stryker Corporation   NYSE SYK    Baxter International Inc    NYSE BAX   and Intuitive Surgical  Inc    NASDAQ ISRG    each carrying a Zacks Rank  2  Buy   You can see  Stryker delivered second quarter 2019 adjusted EPS of  1 98  beating the Zacks Consensus Estimate by 2 6   Its revenues of  3 65 billion surpassed the Zacks Consensus Estimate by 1 4  Baxter delivered second quarter 2019 adjusted EPS of 89 cents  which surpassed the Zacks Consensus Estimate of 81 cents by 9 9   Its revenues of  2 84 billion outpaced the consensus estimate of  2 79 billion by 1 9  Intuitive Surgical reported second quarter 2019 adjusted EPS of  3 25  which beat the Zacks Consensus Estimate of  2 85  Its revenues of  1 1 billion surpassed the Zacks Consensus Estimate of  1 03 billion This Could Be the Fastest Way to Grow Wealth in 2019Research indicates one sector is poised to deliver a crop of the best performing stocks you ll find anywhere in the market  Breaking news in this space frequently creates quick double  and triple digit profit opportunities These companies are changing the world   and owning their stocks could transform your portfolio in 2019 and beyond  Recent trades from this sector have generated  98    119  and  164  gains in as little as 1 month ",2019-08-07,Zacks Investment Research,https://www.investing.com/analysis/amn-healthcare-amn-q2-earnings-and-revenues-top-estimates-200452229,200452229
111663,333178,ISRG,U S  futures lower  focus on E Z  worries  Dow Jones down 0 02 ,news,Investing com   U S  stock futures were lower on Wednesday  as sustained concerns over the debt crisis in the euro zone continued to dominate market sentiment Ahead of the open  the Dow Jones Industrial Average futures pointed to a decline of 0 02   S P 500 futures signaled a 0 06  fall  while the Nasdaq 100 futures indicated 0 02  loss Sentiment remained under pressure ahead of a critical auction of two and 10 year Spanish government bonds on Thursday  amid uncertainty over whether the government will be able to reduce one of the euro zone s largest budget deficits in the face of a looming recession Meanwhile  concerns over Portugal s economic health intensified after Prime Minister Pedro Passos Coelho said Wednesday there were  no guarantees  that the country would meet its commitment to return to the international capital markets before September 2013 The Internet sector was expected to be active after Yahoo reported higher than estimated first  quarter sales  fueling optimism that a turnaround effort by Chief Executive Officer Scott Thompson may succeed  The company said its revenue  excluding sales passed on to partner sites  rose 1  to USD1 08 billion  sending shares up 3 40  in pre market trade IBM saw shares tumble 1 43  in pre market trade  however  after reporting first quarter sales of USD24 7 billion  below analysts  estimates and the smallest increase for the company since the third quarter of 2009 Holding company Berkshire Hathaway was also likely to be in focus  as shares declined 1 11  in after hour trade after Chairman Warren Buffett said he was diagnosed with stage 1 prostate cancer Elsewhere  pharmaceuticals were slated to move during Wednesday s session  The maker of artificial hips and knees Stryker Corp  gained 1 37  in after hour trade after reporting first quarter sales of USD2 16 billion  topping the average analyst estimate of USD2 12 billion Intuitive Surgical Inc  also surged 5 95  as the producer of a robotic system to perform surgery reported first quarter adjusted profit of USD3 50 a share  surpassing the average analyst estimate of USD3 12 In corporate news  Swiss food giant Nestle was nearing a deal to buy Pfizer s baby formula business for around USD9 billion  according to the Wall Street Journal Other stocks in focus included BlackRock  Bank of New York Mellon and Halliburton  due to report earnings before the bell Across the Atlantic  European stock markets were lower  The EURO STOXX 50 tumbled 1 16   France s CAC 40 dropped 1 26   Germany s DAX retreated 0 61   while Britain s FTSE 100 fell 0 20  During the Asian trading session  Hong Kong s Hang Seng Index rose 1 2   while Japan s Nikkei 225 Index rallied 2 1  Later in the day  the U S  was to produce government data on crude oil stockpiles ,2012-04-18,Investing.com,https://www.investing.com/news/forex-news/u.s.-futures-lower-in-risk-off-trade;-dow-jones-down-0.02-232711,232711
111668,333183,ISRG,Teleflex  TFX  Q2 Earnings Top Estimates  Margins Improve,opinion,"Teleflex Incorporated   NYSE TFX   reported earnings per share  EPS  from continuing operations of  2 66 for the second quarter of 2019  up 7 7  year over year  The bottom line also surpassed the Zacks Consensus Estimate by 2 7  
Reported EPS came in at  1 77 against a loss of 6 cents in the prior year quarter 
Net revenues from continuing operations in the second quarter rose 7  year over year to  652 5 million  On a year over year basis  the company saw organic constant currency revenue growth of 9 6   The top line surpassed the Zacks Consensus Estimate by 2 5  
Revenues in Detail
In the second quarter  the Vascular Access segment recognized net revenues of  153 6 million  up 12  year over year at CER  The company registered strong growth in PICC  Peripherally Inserted Central Catheters   CVCs and EZ IO Teleflex Incorporated Price  Consensus and EPS Surprise
 

   The Interventional business registered net revenues of  104 8 million  reflecting an 8 8  rise on a year over year basis at CER  This upside was backed by higher sales of complex catheters  biologics on control and intra aortic balloon products 
Within the Anesthesia segment  net revenues declined 0 9  at CER to  85 7 million primarily due to sluggish sales of airway and pain management products 
Surgical segment recorded net revenues of  95 6 million  reflecting a 9  rise at CER on increased sales of ligation clips and surgical instruments 
Revenues at the Interventional Urology segment saw growth of 42 7  at CER to  67 9 million  The segment of OEM products recorded net revenues of  56 4 million  showing an 8 5  rise at CER 
Meanwhile  EMEA recorded revenue growth of 1 9  at CER to  147 1 million  driven by increased sales of Vascular Access and Interventional Access products 
Asia  OEM and Americas registered net revenues of  75 2 million   56 4 million and  373 8 million  respectively  corresponding top line growth of 10   8 5  and 13 1  each at CER   in the quarter under review 
Margin
Gross margin of 57 2  in the quarter under discussion expanded 62 basis points  bps  year over year on an 8 2  improvement in gross profits to  372 9 million  Adjusted operating margin expanded 216 bps to 16 7  on a 3 1  rise in operating expenses to  263 8 million 
Liquidity Position
The company exited the second quarter of 2019 with cash and cash equivalents of  303 9 million compared with  271 2 million at the end of the first quarter  Year to date net cash provided by operating activities was  157 3 million compared with  181 6 million a year ago 
2019 Outlook
Teleflex has raised its 2019 revenue guidance  Revenues are expected to increase 6 6 5  compared to the earlier projection of 5  to 6   This reflects an 1 5  unfavorable impact of foreign exchange translation  Moreover  the company raised its 2019 revenue guidance on a constant currency basis to a range of 7 5  8   from earlier projected range of 6 7   The Zacks Consensus Estimate for revenues is pegged at  2 59 billion 
The company reaffirms full year adjusted earnings per share from continuing operations at the  10 90  11 10 band  suggesting an increase of 10 1  to 12 1  over 2018 and indicating a 3 5  negative impact from foreign exchange translation  The Zacks Consensus Estimate for the same is pegged at  11 06  near the high end of the company s guided range 
Our Take
Teleflex exited the second quarter of 2019 on a solid note  We are encouraged by the company s robust improvement in revenues on balanced growth across majority of segments and all geographies  The continued Urolift momentum in the second quarter is impressive  Expansion of both margins also buoys optimism  A raised revenue guidance is an added positive 
Zacks Rank   Other Key Picks
Teleflex has a Zacks Rank  2  Buy  
Some other top ranked companies  which posted solid results this earnings season  are Stryker Corp    NYSE SYK    Baxter International Inc    NYSE BAX   and Intuitive Surgical  Inc    NASDAQ ISRG   
Stryker delivered second quarter 2019 adjusted EPS of  1 98  beating the Zacks Consensus Estimate by 2 6   Revenues of  3 65 billion surpassed the Zacks Consensus Estimate by 1 4   The company carries a Zacks Rank of 2  You can see  
Baxter delivered second quarter 2019 adjusted EPS of 89 cents  which surpassed the Zacks Consensus Estimate of 81 cents by 9 9   Revenues of  2 84 billion beat the Zacks Consensus Estimate of  2 79 billion by 1 9   The company holds a Zacks Rank  2 
Intuitive Surgical reported second quarter 2019 adjusted EPS of  3 25  which beat the Zacks Consensus Estimate of  2 85  Revenues were  1 1 billion  surpassing the Zacks Consensus Estimate of  1 03 billion  The company sports a Zacks Rank  1 
Breakout Biotech Stocks with Triple Digit Profit Potential 
The biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases 
Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ",2019-08-02,Zacks Investment Research,https://www.investing.com/analysis/teleflex-tfx-q2-earnings-top-estimates-margins-improve-200450285,200450285
111669,333184,ISRG,Bruker  BRKR  Q2 Earnings Beat Estimates  Margins Expand,opinion,"Bruker Corporation   NASDAQ BRKR   delivered adjusted earnings per share  EPS  of 33 cents in the second quarter of 2019  up 32  from the year ago figure  The figure surpassed the Zacks Consensus Estimate by 6 5  On a reported basis  earnings were 23 cents a share compared with the year earlier figure of 20 cents Revenues in DetailBruker registered revenues of  490 2 million in the second quarter  up 10 5  year over year  The top line also surpassed the Zacks Consensus Estimate by 2 7  Excluding a positive effect of 8 7  from acquisitions and a 3  negative impact from changes in foreign currency rates  Bruker recorded organic revenue growth of 4 8  year over year Bruker Corporation Price  Consensus and EPS Surprise
    The company s organic revenue growth was driven by strength in Bruker Scientific Instruments  BSI  and BEST segments Geographically  the United States saw 16 4  growth in the reported quarter  Meanwhile  European revenues rose 3 4  year over year  Also  Asia Pacific revenues grew 13 5   In Other category  revenues rose 12 6  During the second quarter  Bruker s BioSpin Group revenues increased 7 9  from the year ago quarter  Revenues in the NANO group rose 12 3   fueled by a strong uptrend in the academic research and industrial research markets  CALID revenues were up 9 8  year over year Margin TrendGross margin in the quarter under review expanded 75 basis points  bps  to 47   Meanwhile  selling  general   administrative expenses climbed 12 6  to  124 5 million  Research and development expenses went up 11 2  year over year to  48 5 million  Overall  adjusted operating margin expanded 22 bps to 11 7  Financial PositionBruker exited the second quarter of 2019 with cash and cash equivalents of  282 5 million  down from  298 8 million at the end of the first quarter  Year to date net cash provided by operating activities was  24 8 million in comparison to  79 9 million a year ago 2019 GuidanceBruker reaffirmed its 2019 outlook  For the full year  the company reiterates revenue growth projection at 7 8   including nearly 4 5 5 5  organic revenue rise and an estimated 2 5  headwind from adverse foreign currency translation  The Zacks Consensus Estimate for the metric is  2 04 billion The company continues to envision year over year expansion of 90 120 bps in adjusted operating margin over its fiscal 2018 non GAAP operating margin of 16 8   For 2019  Bruker maintains adjusted EPS view at the range of  1 57  1 61  The Zacks Consensus Estimate of  1 62 is above the guided range Our TakeBruker ended the second quarter on a positive note with earnings and revenues beating the consensus mark  A strong year over year uptrend in constant currency revenues was encouraging  Additionally  the improvement in gross and operating margins buoys optimism in the stock  The year over year revenue growth across all geographies has also been impressive  The company s strategic acquisition activities also raise optimism  Further  we are upbeat about its current focus on product development through higher R D investment  On the flip side  a competitive landscape and macroeconomic woes pose persistent challenges to the company Zacks Rank   Other Key PicksBruker has a Zacks Rank  2  Buy  A few other top ranked companies  which posted solid results this earnings season  are Stryker Corporation   NYSE SYK    Baxter International Inc    NYSE BAX   and Intuitive Surgical  Inc    NASDAQ ISRG   Stryker delivered second quarter 2019 adjusted EPS of  1 98  beating the Zacks Consensus Estimate by 2 6   Revenues of  3 65 billion surpassed the Zacks Consensus Estimate by 1 4   The company carries a Zacks Rank of 2  You can see  Baxter delivered second quarter 2019 adjusted EPS of 89 cents  which surpassed the Zacks Consensus Estimate of 81 cents by 9 9   Revenues of  2 84 billion beat the Zacks Consensus Estimate of  2 79 billion by 1 9   The company holds a Zacks Rank  2 Intuitive Surgical reported second quarter 2019 adjusted EPS of  3 25  which beat the Zacks Consensus Estimate of  2 85  Revenues were  1 1 billion  surpassing the Zacks Consensus Estimate of  1 03 billion  The company sports a Zacks Rank  1 Breakout Biotech Stocks with Triple Digit Profit Potential The biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases  Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ",2019-08-02,Zacks Investment Research,https://www.investing.com/analysis/bruker-brkr-q2-earnings-beat-estimates-margins-expand-200449895,200449895
111674,333189,ISRG, DENTSPLY SIRONA  XRAY  Q2 Earnings Beat  Revenues Fall Y Y,opinion,"DENTSPLY SIRONA Inc    NASDAQ XRAY   reported adjusted earnings per share  EPS  of 66 cents in the second quarter of 2019  beating the Zacks Consensus Estimate of 62 cents  The bottom line rose 10  from the prior year quarter  The Zacks Rank  2  Buy  company s revenues declined 3 1  year over year to  1 01 billion and lagged the Zacks Consensus Estimate of  1 03 billion  Per management  internal sales growth was 3  Business Details Net sales Excluding Precious Metal Content Net sales  excluding precious metal content  came in at  1 billion  down 3 1  year over year  For investors  notice  DENTSPLY s precious metal dental alloy products   used by third parties to construct crown and bridge materials   are subject to certain risks of price fluctuations  Technology   EquipmentPer management  Technology   Equipment revenues rose 0 9  year over year in the second quarter  Revenues in the segment totaled  558 4 million  Consumables DENTSPLY s Consumable revenues declined 7 8  year over year to  451 million in the reported quarter 
DENTSPLY SIRONA Inc  Price  Consensus and EPS Surprise
    
Revenues by Geography In the United States  revenues fell 2 6  and 1 5  on an internal basis  Rest of World revenues declined 6 9  on a reported basis but grew 2 4  on an internal sales growth basis  European revenues declined 1 1  with foreign exchange accounting for 6 9  of the European revenue decline  However  on an internal sales growth basis  European revenues increased 7 1   Margin Analysis Gross profit in the reported quarter amounted to  540 8 million  down 2 2  on a year over year basis  Gross margin was 53 6   up 60 basis points  bps   Excluding precious metal content  gross margin came in at 54 1   which also expanded 60 bps  Operating income totaled  67 5 million  improving significantly from an operating loss in the year ago quarter  Operating margin in the quarter was 0 7  Financial Condition DENTSPLY exited the second quarter with cash and cash equivalents of  250 1 million  Guidance For 2019  DENTSPLY continues to expect revenues within  3 95  4 05 billion  This represents internal sales growth of 4  and 5   The Zacks Consensus Estimate is pegged at  4 01 billion  near the high end of the guided range However  portfolio shaping initiatives and continued acquisitions are expected to reduce 2019 revenues by  60 million The company also raised the 2019 guidance range for adjusted EPS to  2 35  2 45 from the previous range of  2 30 to  2 40  The Zacks Consensus Estimate is pinned at  2 35  at the low end of the company s projected range Adjusted operating margin is expected between 18  and 19   up from the previously communicated range of 17 18  The company expects operating expenses below 2018 levels ConclusionDENTSPLY ended the second quarter on a tepid note  The company gained from its core Technology   Equipment unit which witnessed a year over year upside in the quarter  Overall sales grew on an internal basis  Revenues in Europe surged on an internal basis  A raised guidance for EPS and operating margin for 2019 is indicative of bright prospects  Expansion in margins is an added positive  Meanwhile  DENTSPLY s Consumable revenues witnessed a year over year downside in the quarter  In fact  the company s quarterly revenues declined in the quarter under review  U S  and International revenues also deteriorated on a year over year basis  Additionally  unfavorable foreign currency exchange and restructuring costs are expected to mar DENTSPLY s top line Earnings of Other MedTech Majors at a GlanceOther top ranked companies  which posted solid results this earnings season  are Stryker Corporation   NYSE SYK    Baxter International Inc    NYSE BAX   and Intuitive Surgical  Inc    NASDAQ ISRG   Stryker delivered second quarter 2019 adjusted EPS of  1 98  beating the Zacks Consensus Estimate by 2 6   Its revenues of  3 65 billion surpassed the Zacks Consensus Estimate by 1 4   The company currently carries a Zacks Rank of 2  You can see  Baxter delivered second quarter 2019 adjusted EPS of 89 cents  which surpassed the Zacks Consensus Estimate of 81 cents by 9 9   Its revenues of  2 84 billion outpaced the Zacks Consensus Estimate of  2 79 billion by 1 9   The company currently has a Zacks Rank  2 Intuitive Surgical reported second quarter 2019 adjusted EPS of  3 25  which beat the Zacks Consensus Estimate of  2 85  Its revenues of  1 1 billion surpassed the Zacks Consensus Estimate of  1 03 billion  The company sports a Zacks Rank  1 at present Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ",2019-08-02,Zacks Investment Research,https://www.investing.com/analysis/dentsply-sirona-xray-q2-earnings-beat-revenues-fall-yy-200449878,200449878
111675,333190,ISRG,Intersect  XENT  Q2 Loss Wider Than Estimates  Revenues Miss,opinion,"Intersect ENT Inc    NASDAQ XENT   reported second quarter 2019 loss per share of 36 cents  wider than the Zacks Consensus Estimate of a loss of 34 cents  The reported loss was also a massive 157  wider than the year ago loss of 14 cents Reported revenues in the second quarter grew 1 5  year over year to  26 7 million but missed the Zacks Consensus Estimate by 1 1   The upside can be attributed to higher uptake of the SINUVA Sinus Implant  SINUVA accounted for around 4  of second quarter 2019 revenues MarginsCost of sales during the reported quarter was  5 million  down 9 2  year over year  Gross margin came in at 81 1   reflecting a 221 basis point  bps  expansion year over year Selling  general and administrative expenses were up 31 4  to  27 6 million in the quarter under review  Research and development expenses were  6 million  up 38 1  year over year  The company reported operating loss of  12 million as compared with the year ago operating loss of  4 6 million Intersect ENT  Inc  Price  Consensus and EPS Surprise
    Cash PositionIntersect ENT exited the second quarter of 2019 with cash  cash equivalents and short term investments of  93 5 million compared with  97 6 million at the end of the first quarter 2019 GuidanceIntersect ENT slashed its 2019 revenue view to  108 5 million from the prior  113  117 million  The Zacks Consensus Estimate for the metric is pegged at  114 7 million  which is above the provided guidance The company s 2019 outlook for the gross margin has been reaffirmed at 80 81  Our TakeIntersect ENT ended the second quarter on a dismal note  The updated guidance for 2019 also lacks luster However  we are upbeat about the company s revenue growth on increased adoption of the SINUVA Sinus Implant  Management is optimistic that renewed focus on PROPEL market development should enhance SINUVA product access  The preliminary decision by CMS to assign a J code and the solid potential of SINUVA buoy optimism as well Zacks Rank   Key PicksIntersect ENT has a Zacks Rank  4  Sell  A few better ranked companies  which posted solid results this earnings season  are Stryker Corporation   NYSE SYK    Baxter International Inc    NYSE BAX   and Intuitive Surgical  Inc    NASDAQ ISRG   Baxter delivered second quarter 2019 adjusted earnings per share  EPS  of 89 cents  which surpassed the Zacks Consensus Estimate of 81 cents by 9 9   Revenues of  2 84 billion beat the Zacks Consensus Estimate of  2 79 billion by 1 9   The company holds a Zacks Rank  2  Buy  You can see  Stryker delivered second quarter 2019 adjusted EPS of  1 98  beating the Zacks Consensus Estimate by 2 6   Revenues of  3 65 billion surpassed the Zacks Consensus Estimate by 1 4   The company carries a Zacks Rank of 2 Intuitive Surgical reported second quarter 2019 adjusted EPS of  3 25  which beat the Zacks Consensus Estimate of  2 85  Revenues were  1 1 billion  surpassing the Zacks Consensus Estimate of  1 03 billion  The company sports a Zacks Rank  1 Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3   This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-08-04,Zacks Investment Research,https://www.investing.com/analysis/intersect-xent-q2-loss-wider-than-estimates-revenues-miss-200450768,200450768
111676,333191,ISRG,HMS Holdings  HMSY  Q2 Earnings And Revenues Top Estimates,opinion,HMS Holdings Corp    NASDAQ HMSY   reported adjusted earnings of 34 cents per share in second quarter 2019  which surpassed the Zacks Consensus Estimate of 26 cents by 30 8   The bottom line also surged 36  from the year ago quarter Revenues totaled  168 2 million  which beat the Zacks Consensus Estimate by 5 5   Moreover  the top line improved 14 6  on a year over year basis Q2 Segmental Analysis by ProductAnalytical ServicesRevenues at this segment were  63 1 million in the second quarter  up 37 2  year over year Within Analytical Services  PI revenues  excluding Medicare RAC  amounted to  38 6 million  up 23 7  year over year PHM revenues totaled  14 million in the quarter under review  down 5 4  on a year over year basis COB Revenues at the COB segment grossed  105 1 million in the second quarter  up 4 3  year over year HMS Holdings Corp Price  Consensus and EPS Surprise    Margin AnalysisTotal cost of services in the reported quarter was  99 6 million  down 1 4  year over year Gross profit came in at  68 6 million  which surged 49 9  from the prior year quarter figure  Gross margin was 40 8  of net revenues  up 960 bps year over year Selling  general and administrative expenses totaled  28 million  up 5 7  year over year  Operating income in the second quarter was  40 5 million  against operating loss of  0 8 million in the year ago quarter Financial UpdateCash and cash equivalents amounted to  268 7 million  up 50 1  from the year end 2018 Net cash provided by operating activities for the six months ended Jun 30  2019  came in at  78 1 million  compared with  23 7 million from the year ago quarter Guidance RaisedFor 2019  the company now anticipates revenues between  650 million and  660 million  up from the previously guided range of  640  650 million   This depicts year over year growth in the band of 8 6 10 3   The mid point of  655 million is above the Zacks Consensus Estimate of  646 9 million Net income is expected in the band of  85  90 million  up from the prior band of  64  70 million   indicating growth in the range of 54 5 63 6  year over year Adjusted EBITDA is expected in the range of  185  190 million  up from the previously guided range of  170  175 million   suggesting improvement of 14 17  Summing UpHMS Holdings ended the second quarter of 2019 on a solid note  beating the Zacks Consensus Estimate on both counts  The stock continues to benefit from Analytical Services and COB units  Additionally  gross margin expansion is a positive  Raised 2019 outlook also buoys optimism for the stock However  cut throat competition in the U S  medical cost containment space remains a concern Zacks RankCurrently  HMS Holdings carries a Zacks Rank  3  Hold  Earnings of Other MedTech Majors at a GlanceSome better ranked stocks which reported solid results this earning season are Stryker Corporation   NYSE SYK    Baxter International Inc    NYSE BAX   and Intuitive Surgical  Inc    NASDAQ ISRG   Stryker delivered second quarter 2019 adjusted earnings per share of  1 98  beating the Zacks Consensus Estimate by 2 6   Revenues of  3 65 billion surpassed the Zacks Consensus Estimate by 1 4   The company carries a Zacks Rank of 2  Buy   You can see  Baxter delivered second quarter 2019 adjusted earnings of 89 cents per share  which surpassed the Zacks Consensus Estimate of 81 cents by 9 9   Revenues of  2 84 billion outpaced the Zacks Consensus Estimate of  2 79 billion by 1 9   The company carries a Zacks Rank  2 Intuitive Surgical reported second quarter 2019 adjusted earnings per share of  3 25  which beat the Zacks Consensus Estimate of  2 85  Revenues were  1 1 billion  surpassing the Zacks Consensus Estimate of  1 03 billion  The company sports a Zacks Rank  1 Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-08-04,Zacks Investment Research,https://www.investing.com/analysis/hms-holdings-hmsy-q2-earnings-and-revenues-top-estimates-200450848,200450848
111677,333192,ISRG,Integer Holdings  ITGR  Q2 Earnings Beat  Revenues Miss,opinion,Integer Holdings Corporation   NYSE ITGR   reported second quarter 2019 adjusted earnings of  1 23 per share  which surpassed the Zacks Consensus Estimate of  1 06  The bottom line also advanced 16  on a year over year basis Revenues improved 0 1  year over year to  314 2 million on a reported basis  However  the top line missed the Zacks Consensus Estimate by 1 7  Segmental AnalysisInteger Holdings operates through two segments   Medical Sales and Non Medical Sales Medical SalesAt the segment  reported revenues were  297 5 million  down 0 6  year over year  Revenues remained flat year over year on an organic basis Medical Sales has three sub segments   Advanced Surgical  Orthopedics and Portable Medical  AS O   Cardio and Vascular  and Cardiac Neuromodulation Advanced Surgical  Orthopedics and Portable MedicalInteger Holdings  Advanced Surgical  Orthopedics   Portable Medical segment has been divested to Viant  Consequently  revenues at the segment include net sales from the acquirer Viant under supply agreements associated with the divestiture Revenues amounted to  32 6 million  down 6 1  from the prior year quarter  Further  the metric deteriorated 2 3  on an organic basis  Per management  growth in Portable Medical was offset by a decline in advanced surgical and orthopedics products Cardio and VascularRevenues at the segment totaled  150 4 million  up 1 1  from the prior year quarter and 1 6  organically  Per management  revenues increased on the back of solid peripheral vascular and structural heart growth  However  the estimated impact of an electrophysiology program maturing life cycle and supplier quality related delay offset the upside  Cardiac Neuromodulation Revenues at this segment totaled  114 5 million  down 1 3  from the prior year quarter and also on an organic basis due to soft performance at neuromodulation Non Medical SalesReported revenues at the segment totaled  16 7 million  up 11  on both year over year and organic basis Integer Holdings Corporation Price  Consensus and EPS Surprise    Margin AnalysisInteger Holdings generated a gross profit of  96 9 million in the second quarter  down 1 8  year over year  As a percentage of revenues  gross margin in quarter contracted 50 bps to 30 9  Selling  general and administrative expenses  SG A  were  33 1 million  down 9 9  year over year  Research  development and engineering costs grossed  11 4 million in the quarter  down 11 9  year over year Total operating income amounted to  49 3 million  up 11 2  year over year  Adjusted income from operations totaled  40 6 million  improving 16 9  year over year Operating margin in the quarter under review was 15 7   up 160 bps year over year Guidance RevisedFor 2019  adjusted earnings are expected in the range of  4 25  4 45  up from the previously guided range of  4 15  4 35 per share   indicating an improvement of 12 17  from the previous year  The mid point of the latest guidance range of  4 35 is lower than the Zacks Consensus Estimate of  4 40 On a reported basis  Integer Holdings expects 2019 earnings to range between  2 89 and  3 09  up from the prior band of  2 87  3 07 per share   suggesting a whopping growth of 101 115  year over year For 2019  Integer Holdings expects reported revenues between  1 27 billion and  1 28 billion  reflecting year over year growth of 4 5   On an adjusted basis  the company expects revenues in the same band  indicating an improvement of 4 6  from the previous year  Notably  the mid point of the guidance is in line with the Zacks Consensus Estimate of  1 28 billion Adjusted income from operations is anticipated between  140 million and  147 million  up from the previously guided range of  137  144 million   indicating year over year improvement of 13 18  Summing UpInteger Holdings exited the second quarter on a mixed note  wherein the bottom line beat the Zacks Consensus Estimate  while the top line missed the same The company continues to gain from its Cardio   Vascular product line  Strong demand across key areas like structural heart and peripheral vascular is an added positive  Management is optimistic about the divestiture of its AS O product line  An upbeat outlook for 2019 and expansion in operating margin buoy optimism on the stock  Integer Holdings also paid portion of its debt in the quarter under review Meanwhile  Integer Holdings  Advanced Surgical  Orthopedics and Portable Medical exhibited a dismal performance in the quarter under review  Gross margin contraction added to woes Zacks RankCurrently  Integer Holdings sports a Zacks Rank  1  Strong Buy  Earnings of Other MedTech Majors at a GlanceSome other top ranked stocks which reported solid results this earning season are Stryker Corporation   NYSE SYK    Baxter International Inc    NYSE BAX   and Intuitive Surgical  Inc    NASDAQ ISRG   Stryker delivered second quarter 2019 adjusted earnings per share of  1 98  beating the Zacks Consensus Estimate by 2 6   Revenues of  3 65 billion surpassed the Zacks Consensus Estimate by 1 4   The company carries a Zacks Rank of 2  Buy   You can see  Baxter delivered second quarter 2019 adjusted earnings of 89 cents per share  which surpassed the Zacks Consensus Estimate of 81 cents by 9 9   Revenues of  2 84 billion outpaced the Zacks Consensus Estimate of  2 79 billion by 1 9   The company carries a Zacks Rank  2 Intuitive Surgical reported second quarter 2019 adjusted earnings per share of  3 25  which beat the Zacks Consensus Estimate of  2 85  Revenues were  1 1 billion  surpassing the Zacks Consensus Estimate of  1 03 billion  The company sports a Zacks Rank  1 Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-08-04,Zacks Investment Research,https://www.investing.com/analysis/integer-holdings-itgr-q2-earnings-beat-revenues-miss-200450846,200450846
111682,333197,ISRG,Hill Rom  HRC  Beats On Q3 Earnings  Tightens  19 Guidance,opinion,Hill Rom Holdings  Inc    NYSE HRC   delivered third quarter fiscal 2019 adjusted earnings per share  EPS  of  1 23 excluding certain special items  This figure improved 6 9  from the year ago quarter and also surpassed the Zacks Consensus Estimate of  1 21 by 1 7  Moreover  revenues in the quarter came in at  726 8 million  reflecting a 2 6  increase from the year ago period  The top line also beat the Zacks Consensus Estimate of  719 million by 1 1  Geographically  U S  revenues grew 7 2  in the reported quarter while the metric outside the United States declined 8 1   down 4 2  at constant exchange rate or CER   Core revenue growth  after excluding foreign currency  divestitures and non strategic assets the company may exit including the Surgical Solutions international OEM business  was 6   exceeding the company s guidance of 4 5  growth Segment DetailsIn the quarter under review  Patient Support Systems revenues rose 6  year over year  up 7  at CER  to  375 million  This segment s domestic revenues were up 8 3   representing solid performance across the company s diverse and differentiated portfolio of connected solutions and services  which include smart beds  clinical workflow solutions and mobile communications platform  Voalte Hill Rom Holdings  Inc  Price  Consensus and EPS Surprise   Outside the United States  core Patient Support Systems revenues declined 8 1   down 4 2  at CER   Revenues at the Front Line Care segment inched up 2 3  to  244 4 million  up 3 3  at CER   banking on revenue contribution from new products resulting in double digit growth in vision and respiratory care  Further  robust growth of certain physical assessment and diagnostic tools aided the top line within this segment  Domestic revenues grew 5 3  while there was a 5  decrease in international revenues  down 1 4  at CER  The Surgical Solutions segment revenues slipped 1 8   up 0 2  at CER  to  107 9 million  While domestic revenues grew 8 3   there was a 12 2  fall in international revenues  down 8 1  at CER  Cash PositionThe company exited the third quarter of fiscal 2019 with a cash and cash equivalent of  202 6 million compared with  187 million at the end of the sequential quarter  Year to date  net cash provided by operating activities was  301 1 million compared with  249 8 million at the end of the year ago period Guidance   Hill Rom has updated its 2019 outlook  Adjusted EPS is now expected in the  5 03 5 05 range excluding special items  which is narrower than the earlier band of  5 02 5 06  The Zacks Consensus Estimate for fiscal 2019 earnings stands at  5 04  within the company s guided band The company tapers its revenue expectation for the full year to 2   at CER 3   from the earlier projected range of 2 3   earlier range was 3 4  at CER   Core revenues are now projected to grow at 6  rate  earlier range was 5 6    The Zacks Consensus Estimate for fiscal 2019 revenues is pegged at  2 90 billion For fourth quarter fiscal 2019  revenues are expected to grow 1  on constant currency basis  Core revenue growth is predicted at 5   The Zacks Consensus Estimate for quarterly revenues is pegged at  780 38 million Adjusted earnings in the fiscal fourth quarter  are estimated in the range of  1 64  1 66 per share  The Zacks Consensus Estimate for the same stands at  1 67  above the company s guided band Our TakeHill Rom exited the third quarter of fiscal 2019 on a strong note with better than expected results  The company saw a solid year over year increase in revenues on robust domestic growth  driven by sturdy performances in Patient Support Systems and Front Line Care We are also upbeat to note the company s strong momentum across its diversified product portfolio  which includes Centrella Smart  bed  Welch AllynConnex Spot Monitor  Monarch Airway Clearance System and Integrated Table Motion for the da Vinci Xi Surgical System  Additionally  the acquisition of Voalte buoys optimism as it boosts Hill Rom s digital and mobile communications platform On the flip side  international revenues of each of the company s key segments have declined at CER Zacks Rank and Key PicksHill Rom currently holds a Zacks Rank  4  Sell  Some better ranked stocks boasting solid results this earnings season are Stryker Corporation   NYSE SYK    Baxter International Inc    NYSE BAX   and Intuitive Surgical  Inc    NASDAQ ISRG   Stryker delivered second quarter 2019 adjusted earnings per share of  1 98  beating the Zacks Consensus Estimate by 2 6   Further  revenues of  3 65 billion surpassed the Zacks Consensus Estimate by 1 4   The company carries a Zacks Rank  2 Baxter posted second quarter 2019 adjusted earnings of 89 cents per share  outpacing the Zacks Consensus Estimate of 81 cents by 9 9   Moreover  revenues of  2 84 billion trumped the Zacks Consensus Estimate of  2 79 billion by 1 9   The company has a Zacks Rank of 2 Intuitive Surgical reported second quarter 2019 adjusted earnings per share of  3 25  topping the Zacks Consensus Estimate of  2 85  Also  revenues of  1 1 billion exceeded the Zacks Consensus Estimate of  1 03 billion  The company sports a Zacks Rank  1  You can see  Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-08-04,Zacks Investment Research,https://www.investing.com/analysis/hillrom-hrc-beats-on-q3-earnings-tightens-19-guidance-200450825,200450825
111685,333200,ISRG,PRA Health  PRAH  Q2 Earnings Beat  EPS Guidance Narrowed,opinion,"PRA Health Sciences  Inc    NASDAQ PRAH   reported second quarter 2019 adjusted earnings per share  EPS  of  1 22  which outpaced the Zacks Consensus Estimate of  1 20  The bottom line rose 22  from the prior year quarter s tally The Zacks Rank  3  Hold  registered revenues of  763 3 million in the quarter under review  up 5 6  year over year and 6 8  on a constant currency  cc  basis  However  the figure missed the Zacks Consensus Estimate by 0 1  Q2 in DetailSegmental AnalysisNet new business at the Clinical Research segment came in at  670 7 million in the second quarter  Through this segment  the company receives contracts from customers to provide clinical research services with payments based on fixed fee or fee for service arrangements Revenues at the Clinical Research segment and Data Solutions segment amounted to  702 2 million and  61 1 million  respectively  in the quarter under review  The company provides weekly  monthly or quarterly data reports and analytics to customers PRA Health Sciences  Inc  Price  Consensus and EPS Surprise
    Direct CostsDirect costs totaled  386 2 million in the quarter  up 1 2  year over year  Per management  the increase in direct costs was primarily driven by an increase in labor related costs in the Clinical Research segment Margin TrendOperating profit in the quarter was  88 million  up 19 3  from the year ago quarter  Operating margin in the quarter was 11 5   down significantly from the year ago quarter s 19 3  Financial UpdateCash and cash equivalents came in at  141 9 million  down 1 6  from the 2018 end level GuidanceFor 2019  PRA Health expects revenues within  3 02 billion  3 10 billion  representing reported growth of 5 8  and 6 8  at cc  Notably  this is lower than the earlier provided range of  3 09  3 20 billion  representing reported and cc growth of 8 11   respectively  The Zacks Consensus Estimate of  3 05 billion is within the guided range Adjusted EPS is expected between  4 98 and  5 08  calling for year over year growth of 16 19   Notably  the view has been narrowed from the previously communicated range of  4 93 to  5 08  The mid point of  5 03 is in line with the Zacks Consensus Estimate Our TakePRA Health ended the second quarter on a mixed note  A solid EPS view for 2019 instils optimism  Strong performance by the Clinical Research segment is a positive  PRA Health continues to gain from large pharmaceutical companies  which contributed substantially to its top line in recent times  Management is optimistic about the integration of Symphony Health  With this buyout  PRA Health expects to enhance ability in the field of data and analytics  The company is also poised well on CRO market prospects On the flip side  direct costs shot up in the quarter under review  A slashed revenue guidance for 2019 also raises concern Earnings of Other MedTech Majors at a GlanceSome better ranked companies  which posted solid results this earnings season  are Stryker Corporation   NYSE SYK    Baxter International Inc    NYSE BAX   and Intuitive Surgical  Inc    NASDAQ ISRG   Stryker delivered second quarter 2019 adjusted EPS of  1 98  beating the Zacks Consensus Estimate by 2 6   Its revenues of  3 65 billion surpassed the Zacks Consensus Estimate by 1 4   The company currently carries a Zacks Rank of 2  Buy   You can see  Baxter delivered second quarter 2019 adjusted EPS of 89 cents  which surpassed the Zacks Consensus Estimate of 81 cents by 9 9   Its revenues of  2 84 billion outpaced the consensus estimate of  2 79 billion by 1 9   The company currently has a Zacks Rank  2 Intuitive Surgical reported second quarter 2019 adjusted EPS of  3 25  which beat the Zacks Consensus Estimate of  2 85  Its revenues of  1 1 billion surpassed the Zacks Consensus Estimate of  1 03 billion  The company sports a Zacks Rank  1 at present Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-08-05,Zacks Investment Research,https://www.investing.com/analysis/pra-health-prah-q2-earnings-beat-eps-guidance-narrowed-200450695,200450695
111686,333201,ISRG,STERIS  STE  Q1 Earnings Surpass Estimates  Margins Rise,opinion,"STERIS plc   NYSE STE   reported first quarter fiscal 2020 adjusted earnings per share  EPS  of  1 23  up 23  year over year  The metric beat the Zacks Consensus Estimate by 10 8  Reported EPS came in at 99 cents  up 20 7  year over year Revenues of  696 8 million in the quarter rose 9 1  year over year and topped the Zacks Consensus Estimate by 3 4  Quarter in DetailOrganic revenue growth at constant currency was 10  year over year in the first quarter  mainly driven by growth across all segments The company operates through four segments  Healthcare Products  Healthcare Specialty Services  Applied Sterilization Technologies and Life Sciences Revenues at Healthcare Products increased 6 1  year over year to  309 8 million  up 6 7  on a constant currency organic basis   In the quarter under review  service revenues grew 2  and capital equipment revenues rose 7   Meanwhile  consumable revenues grew 8  on divestitures limiting growth STERIS plc Price  Consensus and EPS Surprise
    Revenues at the Healthcare Specialty Services segment were up 11 2  to  135 9 million  up 13 2  on a constant currency organic basis  Revenues at Applied Sterilization Technologies rose 10 6  to  154 3 million  up 13 1  at CER organic basis  backed by increased demand from core medical device customers Revenues at Life Sciences segment rose 13 9  to  96 8 million  up 15 3  at CER organic basis  on 9  growth in consumable revenues along with a 1  rise in service revenues and 40  year over year growth in capital equipment revenues MarginsAdjusted gross margin  after excluding cost of revenues for restructuring  expanded 177 basis points  bps  year over year to 43 9  in the reported quarter STERIS witnessed a 12 9  year over year rise in selling  general and administrative expenses to  178 8 million  Research and development expenses declined 3 9  to  15 6 million  Overall  adjusted operating margin expanded 122 bps on a year over year basis to 15 9  in the reported quarter Financial DetailsSTERIS exited first quarter of fiscal 2020 with cash and cash equivalents of  238 1 million compared with  220 6 million at the end of fiscal 2019  The company had long term debt of  1 21 billion at the end of the first quarter compared with  1 18 billion at the end of fiscal 2019 Year to date  net cash provided by operations was  109 3 million  compared with  100 8 million at the end of the year ago period 2020 Guidance STERIS has updated its projections for fiscal 2020 constant currency organic revenue growth at around 6 7  compared with the previous projection of 5 6   The Zacks Consensus Estimate for fiscal 2020 revenues is pegged at  2 94 billion The company has also raised its projection for fiscal 2020 adjusted EPS in the range of  5 38 5 53 from the earlier estimated  5 28 5 43  The Zacks Consensus Estimate for fiscal 2020 adjusted EPS lies at  5 37  below the guided range Our TakeSTERIS exited first quarter fiscal 2020 on a strong note  We are encouraged to note that the company witnessed solid revenue growth across each of its operating segments  The company s raised guidance for fiscal 2020 is indicative of brighter prospects  Contributions from elevated consumer demand  broader portfolio of products and services as well as additional volume and enhanced productivity buoy optimism for the company Zacks Rank   Key PicksSTERIS currently carries a Zacks Rank  3  Hold  A few better ranked companies  which posted solid results this earnings season  are Stryker Corporation   NYSE SYK    Baxter International Inc    NYSE BAX   and Intuitive Surgical  Inc    NASDAQ ISRG   Baxter delivered second quarter 2019 adjusted EPS of 89 cents  which surpassed the Zacks Consensus Estimate of 81 cents by 9 9   Revenues of  2 84 billion beat the Zacks Consensus Estimate of  2 79 billion by 1 9   The company holds a Zacks Rank  2  Buy   You can see  Stryker delivered second quarter 2019 adjusted EPS of  1 98  beating the Zacks Consensus Estimate by 2 6   Revenues of  3 65 billion surpassed the Zacks Consensus Estimate by 1 4   The company carries a Zacks Rank of 2 Intuitive Surgical reported second quarter 2019 adjusted EPS of  3 25  which beat the Zacks Consensus Estimate of  2 85  Revenues were  1 1 billion  surpassing the Zacks Consensus Estimate of  1 03 billion  The company sports a Zacks Rank  2 The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2019-08-05,Zacks Investment Research,https://www.investing.com/analysis/steris-ste-q1-earnings-surpass-estimates-margins-rise-200451361,200451361
111687,333202,ISRG,Insulet  PODD  Misses On Q2 Earnings  Ups  19 Revenue View ,opinion,Insulet Corporation   NASDAQ PODD   reported earnings per share  EPS  of 2 cents in second quarter 2019 against a net loss of 3 cents in the prior year quarter  The figure  however  missed the Zacks Consensus Estimate for earnings of 3 cents by 33 3  Revenues in DetailRevenues in the second quarter totaled  177 1 million  beating the Zacks Consensus Estimate by 8 6   Moreover  the top line surged 42 5  from the year ago number and also exceeded the company s projected band of  160 165 million for second quarter revenues Insulet delivered second quarter U S  Omnipod revenues of  98 1 million  reflecting an increase of 26  year over year Insulet Corporation Price  Consensus and EPS Surprise   International Omnipod revenues of  56 9 million were up 48  The Drug Delivery business  revenues totaled  62 7 million  up 120  year over year MarginsGross profit in the reported quarter was  116 4 million  up 41 8  from the prior year quarter  However  gross margin of 65 7  contracted 33 basis points  bps  due to the impact of the highly automated US manufacturing line in Massachusetts that has just begun operations Although total operating expenses of  108 8 million escalated 39 9  from the year ago figure  the operating margin expanded 81 bps to 4 3  in the second quarter 2019 GuidanceFor 2019  the company has raised its revenue expectation to the range of  700  715 million from the prior estimate of  667  690 million  This  in turn  suggests growth of roughly 24 27  from the level achieved in 2018  earlier expected growth rate was 18 22    The Zacks Consensus Estimate for revenues is pegged at  683 3 million  near the upper end of the guided range For the third quarter of 2019  Insulet expects revenues in the band of  174 181 million  indicating an approximate increase of 15 20  from the year ago reported number  The Zacks Consensus Estimate for the metric is pegged at  172 3 million  lower than the guided range Our TakeInsulet exited the second quarter on a mixed note as earnings lagged but revenues exceeded the respective Zacks Consensus Estimate  We are encouraged by the year over year improvement in revenues on the solid uptake of Omnipod system both in the United States and across international markets  We are also upbeat about Insulet s solid revenue growth within its Drug Delivery segment The lifted outlook for 2019 and the company s announcement to be on track for meeting its 2021 financial targets buoy optimism on the stock Nonetheless  Insulet is exposed to risks associated with a weaker global economy and lower reimbursement rates  Zacks Rank and Key PicksInsulet currently carries a Zacks Rank  3  Hold   Some better ranked stocks flaunting solid results this earnings season are Stryker Corporation   NYSE SYK    Baxter International Inc    NYSE BAX   and Intuitive Surgical  Inc    NASDAQ ISRG   Stryker delivered second quarter 2019 adjusted earnings per share of  1 98  beating the Zacks Consensus Estimate by 2 6   Further  revenues of  3 65 billion surpassed the Zacks Consensus Estimate by 1 4   The company carries a Zacks Rank  2 Baxter posted second quarter 2019 adjusted earnings of 89 cents per share  outpacing the Zacks Consensus Estimate of 81 cents by 9 9   Moreover  revenues of  2 84 billion trumped the Zacks Consensus Estimate of  2 79 billion by 1 9   The company has a Zacks Rank of 2 Intuitive Surgical reported second quarter 2019 adjusted earnings per share of  3 25  topping the Zacks Consensus Estimate of  2 85  Also  revenues of  1 1 billion exceeded the Zacks Consensus Estimate of  1 03 billion  The company sports a Zacks Rank  1  You can see  The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2019-08-05,Zacks Investment Research,https://www.investing.com/analysis/insulet-podd-misses-on-q2-earnings-ups-19-revenue-view-200451619,200451619
111727,333242,ISRG,Luminex  LMNX  Reports Q2 Loss  Beats Revenue Estimates,opinion,Luminex Corporation   NASDAQ LMNX   reported second quarter 2019 loss of 10 cents per share  EPS   against the Zacks Consensus Estimate of a break even  Notably  the company reported earnings of 15 cents per share in the year ago quarter Revenues in DetailRevenues came in at  83 1 million  beating the Zacks Consensus Estimate by 1 7   On a year over year basis  the top line improved 4 9  Total sample to answer franchise revenues grew 29  from the prior year quarter Luminex Corporation Price  Consensus and EPS Surprise    Segmental AnalysisSystem SalesRevenues at this segment totaled  18 6 million  surging 57 3  from the year ago quarter Consumable SalesThis segment accounted for  12 7 million of revenues  up 16 1  year over year Royalty RevenuesRoyalty revenues totaled  12 8 million  up 11  on a year over year basis Assay RevenuesThis segment reported revenues worth  31 4 million  down 21 9  on a year over year basis Service RevenuesRevenues in the segment grossed  6 million  up 97 9  from the year ago quarter OtherOther revenues came in at  1 5 million  down 25 3  from a year ago Business DetailsPer management  this Texas based company placed 48 sample to answer molecular systems under contract during the second quarter  Active sample to answer customers totaled 640 in the quarter under review Financial UpdateAs of Jun 30  2019  cash and cash equivalents totaled  63 3 million  down 17 2  from 2018 end level Cash flow from operating activities for the three months ended Jun 30  2019  came in at  5 8 million  down 66 4  from the year ago quarter MarginsGross profit in the reported quarter was  45 2 million  down 8 3  year over year  Gross margin was 54 5   contracting 740 bps Research and development expenses grossed  14 9 million  up 28 4  year over year  Selling  general and administrative expenses in the second quarter were  33 1 million  up 20 1  year over year  Total operating expenses amounted to  50 9 million  up 23  from the year ago reported figure The company incurred operating loss of  5 8 million  against the year ago quarter s operating income of  7 9 million GuidanceFor the third quarter of 2019  the company anticipates revenues between  80 million and  83 million  The mid point of the latest guidance of  81 5 million lies below the Zacks Consensus Estimate of  82 9 million Notably  the company reiterated 2019 revenue outlook  which is estimated in the band of  337  343 million  The mid point of the latest guidance of  340 million is slightly below the Zacks Consensus Estimate of  340 5 million In ConclusionLuminex exited the second quarter on a mixed note  The company continues to gain from its flagship ARIES and VERIGENE platforms that currently have a strong customer base  Revenues at System sales  Consumable Sales and Royalty revenues also improved significantly  Management remains optimistic about the acquisition of the flow cytometry asset of MilliporeSigma  Robust guidance for the third quarter of 2019 raises optimism in the stock Meanwhile  the company s assay and other revenues declined in the reported quarter  Contraction in gross margin add to woes Zacks RankCurrently  Luminex carries a Zacks Rank  5  Strong Sell  Earnings of Other MedTech Majors at a GlanceSome better ranked stocks which reported solid results this earning season are Stryker Corporation   NYSE SYK    Baxter International Inc    NYSE BAX   and Intuitive Surgical  Inc    NASDAQ ISRG   Stryker delivered second quarter 2019 adjusted earnings per share of  1 98  beating the Zacks Consensus Estimate by 2 6   Revenues of  3 65 billion surpassed the Zacks Consensus Estimate by 1 4   The company carries a Zacks Rank of 2  Buy   You can see  Baxter delivered second quarter 2019 adjusted earnings of 89 cents per share  which surpassed the Zacks Consensus Estimate of 81 cents by 9 9   Revenues of  2 84 billion outpaced the Zacks Consensus Estimate of  2 79 billion by 1 9   The company carries a Zacks Rank  2 Intuitive Surgical reported second quarter 2019 adjusted earnings per share of  3 25  which beat the Zacks Consensus Estimate of  2 85  Revenues were  1 1 billion  surpassing the Zacks Consensus Estimate of  1 03 billion  The company sports a Zacks Rank  1 Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2019-07-31,Zacks Investment Research,https://www.investing.com/analysis/luminex-lmnx-reports-q2-loss-beats-revenue-estimates-200449267,200449267
111728,333243,ISRG,McKesson  MCK  Q1 Earnings And Revenues Surpass Estimates,opinion,McKesson Corporation s   NYSE MCK   first quarter fiscal 2020 earnings of  3 31 per share beat the Zacks Consensus Estimate by 8 9   Further  the bottom line improved 14 1  from the year ago quarter Revenues came in at  55 73 billion  which surpassed the Zacks Consensus Estimate by 3 3  and improved 5 9  year over year Q1 Segmental AnalysisRevenues at the U S  Pharmaceutical and Specialty Solutions segment totaled  44 17 billion  up 7 8  year over year  Per management  the upside was primarily driven by market growth  However  branded to generic conversions partially offset the downside At the European Pharmaceutical Solutions segment  revenues amounted to  6 71 billion  down 3 2  year over year  However  the metric rose 3  at constant currency  cc  on the back of market growth in the pharmaceutical distribution business Revenues at the Medical Surgical Solutions segment amounted to  1 90 billion  up 11 7  year over year  Acquisition and growth in the Primary Care and Extended Care businesses drove the upside Revenues at the Other segment were  2 95 billion in the fiscal first quarter  down 1 4  year over year but up 2  at cc McKesson Corporation Price  Consensus and EPS Surprise    MarginsGross profit in the reported quarter was  2 79 billion  up 0 3  on a year over year basis  Meanwhile  gross margin was 5  of net revenues  down 30 bps Operating income in the quarter was  634 million  which improved significantly from the year ago quarter s figure of  83 million The U S  Pharmaceutical and Specialty Solutions segment reported adjusted operating profit of  600 million  Adjusted operating margin was 1 4  at the segment Adjusted operating profit at the European Pharmaceutical Solutions segment amounted to  35 million  while adjusted operating margin was 0 5  The Medical Surgical segment had adjusted operating profit of  159 million  Adjusted operating margin was 8 4  at the segment Adjusted operating profit was  279 million at the Other segment Fiscal 2020 Guidance RaisedFor fiscal 2020  McKesson now expects adjusted earnings per share in the range of  14  14 60  up from the previously guided range of  13 85  14 45  Change Healthcare UpdateAfter the completion of the Change Healthcare  Inc  IPO  McKesson is the owner of around 58 5  of Change Healthcare  down from 70   McKesson will continue to report the equity income from its interest in Change Healthcare based on its revised equity ownership percentage and with one month lag McKesson reiterated the outlook for adjusted equity earnings from Change Healthcare of around  250 million to  270 million in fiscal 2020 Financial UpdateIn the quarter under review  cash and cash equivalents came in at  1 9 million  down 34 7  sequentially Cash flow from operating activities stood at   51  million  narrower than that of the year ago quarter s reported figure of   1 1  billion Summing UpMcKesson exited the fiscal first quarter on a strong note  wherein both the bottom line and the top line beat the consensus mark  Strong first quarter show by core U S  Pharmaceutical and Specialty  and Medical Surgical Solutions segments buoy optimism  Further  management remains optimistic about the 10 year partnership signed with Rite Aid  These apart  the company raised fiscal 2020 adjusted earnings outlook  which is a positive Meanwhile  McKesson s European Pharmaceutical Solutions witnessed soft first quarter owing to challenges in the U K  Moreover  contraction in gross margin adds to woes  Price fluctuation of generic pharmaceuticals and stiff competition in the MedTech space are added concerns Zacks RankCurrently  McKesson carries a Zacks Rank  2  Buy    Earnings of Other MedTech Majors at a GlanceOther top ranked stocks which posted solid results this earning season are Stryker Corporation   NYSE SYK    Baxter International Inc    NYSE BAX   and Intuitive Surgical  Inc    NASDAQ ISRG   Stryker delivered second quarter 2020 adjusted earnings per share of  1 98  beating the Zacks Consensus Estimate by 2 6   Revenues of  3 65 billion surpassed the Zacks Consensus Estimate by 1 4   The company carries a Zacks Rank of 2  Buy   You can see  Baxter delivered second quarter 2020 adjusted earnings of 89 cents per share  which surpassed the Zacks Consensus Estimate of 81 cents by 9 9   Revenues of  2 84 billion outpaced the Zacks Consensus Estimate of  2 79 billion by 1 9   The company has a Zacks Rank  2 Intuitive Surgical reported second quarter 2020 adjusted earnings per share of  3 25  which beat the Zacks Consensus Estimate of  2 85  Revenues were  1 1 billion  surpassing the Zacks Consensus Estimate of  1 03 billion  The company sports a Zacks Rank  1 Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2019-07-31,Zacks Investment Research,https://www.investing.com/analysis/mckesson-mck-q1-earnings-and-revenues-surpass-estimates-200449263,200449263
111729,333244,ISRG,Hologic  HOLX  Beats On Q3 Earnings  Ups  19 Revenue View,opinion,Hologic  Inc    NASDAQ HOLX   reported third quarter fiscal 2019 adjusted earnings per share  EPS  of 63 cents  up 8 6  year over year  The bottom line also surpassed the Zacks Consensus Estimate by 3 3  However  on a reported basis  the company s earnings of 35 cents per share reflect a 14 6  drop from the year ago quarter Revenues in DetailRevenues grossed  852 4 million in the reported quarter  up 3 4  year over year  up 4 7  at constant exchange rate or CER   Excluding the divested Blood Screening business  total revenues came in at  838 2 million  up 4 1 year over yearand 5 3  at CER The Zacks Consensus Estimate for third quarter total revenues is pegged at  834 63 million Hologic  Inc  Price  Consensus and EPS Surprise   U S  revenues of  642 5 million increased 4 2   Additionally  international revenues of  209 9 million inched up 1 3  or 6 2  in constant currency Geographically  revenues in the United States rose 4 2  year over year to  642 5 million in the quarter  Global revenues were up 1 3   up 6 2  at CER  to  209 9 million as well  primarily on the back of strong contributions from the Diagnostics and GYN Surgical businesses Segments in DetailRevenues at the Diagnostics segment rose 3 8  year over year  up 5 1  at CER  to  305 4 million in the quarter under review with Molecular Diagnostics being the major driver  Molecular Diagnostics revenues of  170 9 million climbed 10 6   up 11 7  at CER   marking the third consecutive quarter of double digit constant currency growth despite a challenging prior year comp  However  Cytology and Perinatal revenues of  120 3 million registered a 0 7  dip  up 1 3  at CER  Revenues at the Breast Health segment increased 5 7   up 6 7  at CER  to  325 4 million  While domestic sales drove Breast Health growth in the quarter with 8 9  revenue rise year over year  outside the United States  Breast Health sales dipped 1 5   primarily due to the challenges in Latin America Although revenues at the GYN Surgical business grew 4 2   up 5 2  at CER  to  112 2 million  Medical Aesthetic business revenues of  85 million reflects a 7 3  decline  down 5 5  at CER  in the reported quarter Revenues at Skeletal Health fell 8 2   up 9 8  at CER  to  24 4 million Operational UpdateIn the fiscal third quarter  Hologic s adjusted gross margin contracted 114 basis points  bps  to 61 4   This downside was primarily due to the strong U S  dollar  trade tariffs in China  an adverse product sales mix  especially related to Cynosure s performance  and increased service costs Adjusted operating expenses amounted to  239 million  up 2 1  year over year  Also  adjusted operating margin contracted 36 bps to 27 9  Financial UpdateHologic exited the third quarter of fiscal 2019 with cash and cash equivalents of  427 9 million compared with  401 million at the end of second quarter fiscal 2019  Total long term debt was  3 05 billion in the reported quarter compared with  3 09 million at the end of the year ago quarter Year to date  net cash provided by operating activities was  401 8 million compared with  500 5 million a year ago Guidance UpdatedHologic has updated its fiscal 2019 financial guidance  The company now expects adjusted revenues in the range of  3 33  3 35 billion  up from the earlier announced band of  3 32  3 34 billion  a projection of 4 7 5 2  growth at CER  The Zacks Consensus Estimate for revenues stands at  3 33 billion  in line with the lower end of the guided range The company envisions adjusted EPS of  2 42  2 44 narrowed from  2 41  2 44 guided previously  a projection of 8 5 9 4  growth rate   The consensus mark for the metric is pinned on  2 42 within the estimated range For fourth quarter fiscal 2019  Hologic anticipates adjusted revenues of  834  849  indicating 3 5 5 3  growth at CER  The consensus estimate for revenues stands at  847 76 million within the forecast range Adjusted EPS is predicted at 64 66 cents  suggesting growth of 10 3 13 8  from the year ago period  The Zacks Consensus Estimate for fourth quarter fiscal adjusted EPS is pegged at 65 cents within the company s expected range Our TakeHologic exited the third quarter of fiscal 2019 on a solid note  Strong top line growth was led by a solid year over year rise in core businesses like Breast Health and Molecular Diagnostics  We are also upbeat about the recent launches like Aptima BV and Aptima CV TV assays in the United States  the Trident HD specimen radiography system in the United States  Europe and Canada  and the ThinPrep Genesis processor for cytology slide and molecular test preparation in Europe On the flip side  both margins contracted in the quarter under review Zacks Rank and Other Key PicksHologic currently carries a Zacks Rank  2  Buy   Some other top ranked stocks  which reported solid results this earnings season are Stryker Corporation   NYSE SYK    Baxter International Inc    NYSE BAX   and Intuitive Surgical  Inc    NASDAQ ISRG   Stryker delivered second quarter 2019 adjusted earnings per share of  1 98  beating the Zacks Consensus Estimate by 2 6   Revenues of  3 65 billion also surpassed the Zacks Consensus Estimate by 1 4   The company carries a Zacks Rank of 2  You can see  Baxter delivered second quarter 2019 adjusted earnings of 89 cents per share  which surpassed the Zacks Consensus Estimate of 81 cents by 9 9   Moreover  revenues of  2 84 billion outpaced the Zacks Consensus Estimate of  2 79 billion by 1 9   The company is a Zacks  2 Ranked player Intuitive Surgical reported second quarter 2019 adjusted earnings per share of  3 25  which beat the Zacks Consensus Estimate of  2 85  Further  revenues were  1 1 billion  surpassing the Zacks Consensus Estimate of  1 03 billion  The company sports a Zacks Rank  1 Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2019-07-31,Zacks Investment Research,https://www.investing.com/analysis/hologic-holx-beats-on-q3-earnings-ups-19-revenue-view-200449336,200449336
111730,333245,ISRG, Masimo  MASI  Earnings And Revenues Beat Estimates In Q2,opinion,"Masimo Corporation   NASDAQ MASI   reported second quarter 2019 adjusted earnings per share  EPS  of 76 cents  which surpassed the Zacks Consensus Estimate of 73 cents  Earnings improved from the year ago quarter by 24 6  The Zacks Rank  3  Hold  company s revenues improved 8 5  year over year to  229 7 million and edged past the Zacks Consensus Estimate of  223 million Segmental AnalysisMasimo reports through two segments   Product revenues and Royalty  and Other Product RevenuesProduct revenues in the second quarter came in at  229 5 million  up 13 6  from the year ago quarter and 15  at constant currency  cc   Per management  the company shipped 60 400 technology boards and monitors in the quarter Royalty and Other RevenuesRevenues at the segment totaled  0 1 million  significantly down from the year ago quarter s  9 6 million Margin AnalysisIn the quarter under review  gross profit totaled  154 3 million  up 8 8  year over year  Gross margin was 67 2   flat on a year over year basis Adjusted operating income in the quarter totaled  53 million  up 24 6  from a year ago  Per management  adjusted operating margin improved 200 basis points to 23 1  in the quarter Research and development expenses totaled  24 2 million  up 20 4  SG A expenses in the quarter were  78 2 million  up 10 9  Masimo Corporation Price  Consensus and EPS Surprise
    Guidance RaisedMasimo has raised its 2019 guidance The company expects adjusted revenues of  925 million  compared with the earlier communicated figure of  918 million  Notably  this calls for reported growth of 11 5  and cc growth of 12 2   The Zacks Consensus Estimate is pegged at  919 4 million  much below the guided range Adjusted EPS is now expected at  3 15 compared with the previously stated figure of  3 12  The Zacks Consensus Estimate stands at  3 12  in line with the company s expectations In ConclusionMasimo exited the second quarter on a strong note  The company continues to gain from its key Product segment  which witnessed solid growth in the quarter  Notably  the company s non invasive technology shipments surged in the quarter  In fact  management foresees increased shipments in the quarters ahead  A raised guidance for 2019 buoys optimism as well  Management is optimistic about Masimo s recent initiative for hospital automation  Recent regulatory approvals and product launches also buoy optimism On the flip side  Masimo s Royalty and Other segment saw significant softness in the quarter  In fact  management expects no meaningful contribution from the unit in 2019  Furthermore  Masimo expects foreign currency headwinds in 2019 to impact its top line  The company faces fierce competition from MedTech bigwigs Earnings of Other MedTech Majors at a GlanceSome better ranked stocks  which posted solid results this earnings season  are Stryker Corporation   NYSE SYK    Baxter International Inc    NYSE BAX   and Intuitive Surgical  Inc    NASDAQ ISRG   Stryker delivered second quarter 2019 adjusted EPS of  1 98  beating the Zacks Consensus Estimate by 2 6   Its revenues of  3 65 billion surpassed the Zacks Consensus Estimate by 1 4   The company currently carries a Zacks Rank of 2  Buy   You can see  Baxter delivered second quarter 2019 adjusted EPS of 89 cents  which surpassed the Zacks Consensus Estimate of 81 cents by 9 9   Its revenues of  2 84 billion outpaced the Zacks Consensus Estimate of  2 79 billion by 1 9   The company currently has a Zacks Rank  2 Intuitive Surgical reported second quarter 2019 adjusted EPS of  3 25  which beat the Zacks Consensus Estimate of  2 85  Its revenues of  1 1 billion surpassed the Zacks Consensus Estimate of  1 03 billion  The company sports a Zacks Rank  1 at present Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2019-08-01,Zacks Investment Research,https://www.investing.com/analysis/masimo-masi-earnings-and-revenues-beat-estimates-in-q2-200448903,200448903
111731,333246,ISRG,Bio Rad  Bio  Q2 Earnings Beat Estimates  Margins Expand,opinion,"Bio Rad Laboratories  Inc    NYSE BIO   posted second quarter 2019 adjusted earnings per share  EPS  of  1 57  which beat the Zacks Consensus Estimate by 12 9   The bottom line however fell 4 3  from the prior year quarter Reported EPS in the quarter was  19 86 compared with  8 87 a year ago Revenues in DetailRevenues in the quarter totaled  572 6 million  beating the Zacks Consensus Estimate by 1 7   Revenues fell 0 6  from the year ago quarter  up 2 7  at constant currency or cc  Per management  solid demand across many of its key product lines led to growth across most geographical regions Bio Rad Laboratories  Inc  Price  Consensus and EPS Surprise
    Segmental AnalysisSales at the Life Sciences segment in the second quarter totaled  212 4 million  down 2 5  year over year and 0 1  at cc  Excluding Process Media sales  the Life Science business saw 7 5  year over year growth on a currency neutral basis Net sales at Clinical Diagnostics segment totaled  357 1 million  up 0 9  on a year over year basis and 4 8  at cc  This upside was primarily driven by solid growth in Quality Controls  Immunology  and Diabetes product lines across all three geographies MarginsGross profit in the reported quarter totaled  307 8 million  up 2  from the prior year quarter  Gross margin came in at 53 7   expanding 137 basis points  bps   Operating margin was 9 8   up 224 bps 2019 Guidance ReaffirmedFor 2019  the company has reaffirmed its revenue growth guidance at 4 4 5   cc   The Zacks Consensus Estimate for the same is pegged at  2 35 billion Our TakeBio Rad exited the second quarter of 2019 with better than expected results  The company also witnessed solid revenue growth at the Clinical Diagnostics segment  Further  strength in many of the company s key product lines across major geographic regions buoys optimism  The solid expansion in both margins is also impressive On the flip side  the year over year fall in earnings and a decline at the Life Sciences segment revenues are worrying Zacks Rank   Key PicksBio Rad has a Zacks Rank  3  Hold  Some better ranked companies  which posted solid results this earnings season  are Stryker Corporation   NYSE SYK    Baxter International Inc    NYSE BAX   and Intuitive Surgical  Inc    NASDAQ ISRG   Stryker delivered second quarter 2019 adjusted EPS of  1 98  beating the Zacks Consensus Estimate by 2 6   Revenues of  3 65 billion surpassed the Zacks Consensus Estimate by 1 4   The company carries a Zacks Rank of 2  Buy   You can see  Baxter delivered second quarter 2019 adjusted EPS of 89 cents  which surpassed the Zacks Consensus Estimate of 81 cents by 9 9   Revenues of  2 84 billion beat the Zacks Consensus Estimate of  2 79 billion by 1 9   The company holds a Zacks Rank  2 Intuitive Surgical reported second quarter 2019 adjusted EPS of  3 25  which beat the Zacks Consensus Estimate of  2 85  Revenues were  1 1 billion  surpassing the Zacks Consensus Estimate of  1 03 billion  The company sports a Zacks Rank  1 
Breakout Biotech Stocks with Triple Digit Profit Potential 
The biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases 
Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ",2019-08-01,Zacks Investment Research,https://www.investing.com/analysis/biorad-bio-q2-earnings-beat-estimates-margins-expand-200449973,200449973
111732,333247,ISRG,DexCom  DXCM  Q2 Earnings And Revenues Surpass Estimates,opinion,DexCom  Inc    NASDAQ DXCM   reported adjusted earnings of 8 cents per share in the second quarter of 2019  beating the Zacks Consensus Estimate of a break even  Notably  the company reported a loss of 7 cents per share in the year ago quarter Total revenues surged 38 7  to  336 4 million on a year over year basis and also surpassed the Zacks Consensus Estimate by 11 4   Rising volumes across all channels and increasing global awareness of the benefits of real time CGM contributed to the upside  Segmental DetailsRevenues at the Sensor segment  77  of total revenues  surged 45 2  on a year over year basis to  260 4 million  Transmitter revenues  17   increased 31 2  year over year to  57 6 million  Receiver revenues  5   declined 3 7  year over year to  18 4 million DexCom  Inc  Price  Consensus and EPS Surprise    Geographical DetailsU S  revenues  79  of total revenues  surged 40 5  on a year over year basis to  266 3 million  International revenues  21   improved 32 5  year over year to  70 1 million Margin Analysis Gross profit in the quarter under review totaled  206 5 million  up 34 4  year over year  However  DexCom generated gross margin  as a percentage of revenues  of 61 4   which contracted 190 bps year over year  Research and development  R D  expenses amounted to  69 million in the quarter  up 46 2  year over year  Selling  general and administrative expenses totaled  138 3 million in the reported quarter  up 24 3  year over year  The company reported total operating expenses of  207 3 million  up 30 8  year over year The company reported operating income of  6 2 million  against an operating loss of  2 2 million in the year ago quarter  Financial Position As of Jun 30  2019  DexCom had  1 38 billion in cash and marketable securities  Total cash and cash equivalents came in at  709 2 million  down 37 6  from 2018 end level  2019 Guidance Revised DexCom now expects revenues in the range of  1 33  1 38 billion  up from the previously guided range of  1 25  1 3 billion   The Zacks Consensus Estimate for revenues is currently pegged at  1 29 billion  which is below the lower end of the guided range  Gross profit margin is projected to be 64  to 65  of net revenues  While adjusted operating margin is expected to be about 7  of net revenues  up from the previous projection of 6    adjusted EBITDA margin is anticipated to be 18 5   up from the prior estimate of 18    Wrapping Up DexCom exited the second quarter on a strong note  wherein both the top and bottom line beat the Zacks Consensus Estimate  Impressive contributions from the Sensor and Transmitter segments were key catalysts  Strong guidance also instills investors  optimism in the stock  Additionally  the glucose monitoring market presents significant commercial opportunity for this company  DexCom s opportunities in alternative markets such as the non intensive diabetes management space  the hospital  gestational  pre diabetes and obesity are likely to provide it a competitive edge in the MedTech space  Aided by the solid performance  the company has commenced 2019 on a good note and is optimistic about the future results  DexCom s growth is a testament to the increasing awareness and excitement revolving real time CGM and DexCom s new G6 technology  Meanwhile  cutthroat competition in the market for blood   glucose monitoring devices is worrisome  We believe that the company s margins will continue to remain under pressure in the upcoming quarters owing to high product development costs and rising expenditures on the R D front  Zacks Rank Currently  DexCom sports a Zacks Rank of 2  Buy  Earnings of Other MedTech Majors at a GlanceOther top ranked stocks which posted solid results this earning season are Stryker Corporation   NYSE SYK    Baxter International Inc    NYSE BAX   and Intuitive Surgical  Inc    NASDAQ ISRG   Stryker delivered second quarter 2019 adjusted earnings per share of  1 98  beating the Zacks Consensus Estimate by 2 6   Revenues of  3 65 billion surpassed the Zacks Consensus Estimate by 1 4   The company carries a Zacks Rank of 2  Buy   You can see  Baxter delivered second quarter 2019 adjusted earnings of 89 cents per share  which surpassed the Zacks Consensus Estimate of 81 cents by 9 9   Revenues of  2 84 billion outpaced the Zacks Consensus Estimate of  2 79 billion by 1 9   The company has a Zacks Rank  2 Intuitive Surgical reported second quarter 2019 adjusted earnings per share of  3 25  which beat the Zacks Consensus Estimate of  2 85  Revenues were  1 1 billion  surpassing the Zacks Consensus Estimate of  1 03 billion  The company sports a Zacks Rank  1 Breakout Biotech Stocks with Triple Digit Profit Potential The biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119 and  164 in as little as 1 month  The stocks in this report could perform even better ,2019-08-01,Zacks Investment Research,https://www.investing.com/analysis/dexcom-dxcm-q2-earnings-and-revenues-surpass-estimates-200449952,200449952
111733,333248,ISRG,Genomic Health  GHDX  To Join Exact Sciences  Posts Q2 Results,opinion,Genomic Health  Inc    NASDAQ GHDX   recently entered into a definitive agreement with cancer diagnostics major Exact Sciences Corp   wherein the latter will buy the former for a deal value of  2 8 billion  Genomic Health with a market cap of  2 71 billion expects this consolidation to form a high growth entity in the field of cancer diagnostics Since the news of the company s sell off plan surfaced on Jul 29  shares of Genomic Health climbed 6 3  to  72 99 at yesterday s close Under terms of the deal  shareholders of Genomic Health will receive  27 50 in cash and  44 50 in Exact Sciences stock for a total consideration of  72 per share Notably  the merger will combine two of the strongest brands in cancer diagnostics  Cologuard and OncotypeDX  providing platform for growth  The transaction  which has been unanimously approved by both companies  boards  is expected to be completed by the end of 2019 A Strategic Fit for Genomic Health According to Genomic Health  the integration will establish a best in class commercial  R D and clinical organization to provide global infrastructure for accelerating availability of new innovative cancer diagnostics to patients Genomic Health  Inc  Price  Consensus and EPS Surprise   Per Surveillance  Epidemiology and End Results  SEER  data  colorectal  breast and prostate tumors represent nearly 40  of all solid tumor incidences in the United States  Post consolidation  Exact Sciences and Genomic Health with their Cologuard  addressing the colorectal cancer  and Oncotype DX will address  20 billion global colorectal  breast and prostate cancer markets Integration Synergy at a GlanceOn an adjusted basis  the combined company is expected to generate revenues of  1 6 billion and a gross profit of  1 2 billion in 2020  Annualized cost synergies of approximately  25 million are expected within the third year from the closure date of the deal  primarily via reduction of public company costs and purchase optimization A Look Into Genomic Health s Q2 ResultsIn a separate press release  Genomic Health announced second quarter 2019 financial results The company delivered second quarter 2019 earnings per share  EPS  of 42 cents  registering an 82 6  surge from the year ago result  The bottom line also surpassed the Zacks Consensus Estimate by 20  Revenues in DetailTotal revenues in the second quarter rose 19 4  year over year to  114 1 million  beating the Zacks Consensus Estimate by 2 8   On adjusted constant currency  cc  basis  revenues shot up 20 1  Growth in the United States and international markets drove the company s top line  A solid U S  invasive breast cancer revenue uptick was also recorded Geographically  second quarter product revenues in the United States rose 17 9  to  96 million  The U S  product revenue rise was fueled by a 13 4  ascent in U S  invasive breast revenues from Oncotype DX Breast Recurrence Score tests and a 42 3  surge in U S  prostate test revenues from Oncotype DX Genomic Prostate Score  GPS  tests International product revenues totaled  17 8 million in the reported quarter  up 27 7  year over year  up 32 7  at adjusted cc  During the second quarter  the company delivered more than 37 470 Oncotype DX test results  up 14 5  year over year 2019 Guidance RevisedThe company has raised its 2019 revenue guidance to  448  452 million  earlier expected range was  436  448 million   indicating growth of 14 15   past projected growth rate was 11 14   from the prior year reported figure  The Zacks Consensus Estimate of  449 5 million remains close to the lower end of the guided range Full year EPS estimate has also been lifted to  1 44  1 54   1 23 1 38   The Zacks Consensus Estimate of  1 50 falls within the guided range Our TakeWe believe  the consolidation with Exact Sciences will prove perfectly strategic for Genomic Health Built on two of the strongest and fastest growing brands in the cancer diagnostics industry   Cologuard and Oncotype DX   the combined business will gain an even stronger platform for continued growth of both companies  marketed products and the development of their robust pipelines Meanwhile  Genomic Health exited the second quarter on a solid note with better than expected earnings results  The company has demonstrated strength across its entire business  driven by impressive performances in the United States and internationally  Within the prostate cancer space  the company is witnessing a robust improvement in volume as Oncotype DX GPS test results consistently lead the market in low  and intermediate risk prostate cancer test adoption  The company also saw buoyant global demand for Oncotype DX Breast Recurrence Score test usage  Moreover  it progressed in terms of reimbursement update in Germany for Oncotype DX Breast Recurrence Score test Zacks Rank and Other Key PicksGenomic Health currently holds a Zacks Rank  2  Buy   Some other top ranked stocks boasting solid results this earnings season are Stryker Corporation   NYSE SYK    Baxter International Inc    NYSE BAX   and Intuitive Surgical  Inc    NASDAQ ISRG   Stryker delivered second quarter 2019 adjusted earnings per share of  1 98  beating the Zacks Consensus Estimate by 2 6   Further  revenues of  3 65 billion surpassed the Zacks Consensus Estimate by 1 4   The company carries a Zacks Rank  2  You can see  Baxter delivered second quarter 2019 adjusted earnings of 89 cents per share  outpacing the Zacks Consensus Estimate of 81 cents by 9 9   Additionally  revenues of  2 84 billion outpaced the Zacks Consensus Estimate of  2 79 billion by 1 9   The company has a Zacks Rank of 2 Intuitive Surgical reported second quarter 2019 adjusted earnings per share of  3 25  topping the Zacks Consensus Estimate of  2 85  Also  revenues of  1 1 billion exceeded the Zacks Consensus Estimate of  1 03 billion  The company sports a Zacks Rank  1 Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ,2019-08-01,Zacks Investment Research,https://www.investing.com/analysis/genomic-health-ghdx-to-join-exact-sciences-posts-q2-results-200450080,200450080
111734,333249,ISRG,Globus Medical  GMED  Q2 Earnings In Line  Revenue View Up,opinion,Globus Medical  Inc    NYSE GMED   reported second quarter 2019 adjusted earnings per share  EPS  of 41 cents  in line with the Zacks Consensus Estimate  Meanwhile  the metric missed the year ago figure by 6 8  On a reported basis  the company registered earnings of 38 cents per share  reflecting a 13 6  decline from the year ago quarter Revenue DetailsSecond quarter 2019 worldwide sales summed  194 5 million  up 12 2   up 12 7  at constant exchange rate or CER  year over year  The figure also exceeded the Zacks Consensus Estimate by 5 9  During the quarter under review  sales generated in the United States including robotic improved 10  year over year  However  quarterly seasonality and longer sales cycles partially dampened robotic sales in the reported period Globus Medical  Inc  Price  Consensus and EPS Surprise   Meanwhile  international sales rose 23 3  from the year earlier quarter  up 26 7  at CER  Moreover  musculoskeletal solutions products generated revenues of  182 5 million  up 14 3  year over year  However  Enabling Technologies products revenues of  12 million in the quarter represented a 12 7  decline from the prior year period Cash PositionGlobus Medical exited the second quarter with cash and cash equivalents and short term marketable securities of  240 4 million compared with  320 7 million at the end of the first quarter  Year to date  net cash provided by the operating activities was  61 8 million compared with  85 6 million a year ago 2019 Guidance UpdatedThe company reaffirmed its 2019 adjusted EPS guidance at  1 72  matching the current Zacks Consensus Estimate for the metric However  2019 sales guidance has been raised to  775 million from  770 million predicted earlier  The Zacks Consensus Estimate for revenues is pegged at  767 5 million  lower than the company s projection Our TakeGlobus Medical posted a mixed second quarter performance with earnings meeting the Zacks Consensus Estimate while revenues beating the mark  Enabling Technologies registered strong sequential growth  Also  global spine business demonstrated a strong year over year improvement  An upped sales outlook for 2019 is indicative of this bullish trend to continue through the remaining year Zacks Rank   Key PicksGlobus Medical carries a Zacks Rank  4  Sell  Some better ranked stocks having reported solid results this earnings season are Stryker Corporation   NYSE SYK    Baxter International Inc    NYSE BAX   and Intuitive Surgical  Inc    NASDAQ ISRG   Stryker delivered second quarter 2019 adjusted earnings per share of  1 98  topping the Zacks Consensus Estimate by 2 6   Further  revenues of  3 65 billion surpassed the Zacks Consensus Estimate by 1 4   The company carries a Zacks Rank  2  Buy   You can see  Baxter delivered second quarter 2019 adjusted earnings of 89 cents per share  which surpassed the Zacks Consensus Estimate of 81 cents by 9 9   Additionally  revenues of  2 84 billion outpaced the Zacks Consensus Estimate of  2 79 billion by 1 9   The company has a Zacks Rank of 2 Intuitive Surgical reported second quarter 2019 adjusted earnings per share of  3 25  which exceeded the Zacks Consensus Estimate of  2 85  Also  revenues of  1 1 billion came ahead of the Zacks Consensus Estimate of  1 03 billion  The company sports a Zacks Rank  1 Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ,2019-08-01,Zacks Investment Research,https://www.investing.com/analysis/globus-medical-gmed-q2-earnings-in-line-revenue-view-up-200450079,200450079
111768,333283,ISRG,PerkinElmer  PKI  Q2 Earnings And Revenues Miss Estimates,opinion,PerkinElmer  Inc    NYSE PKI   reported second quarter 2019 adjusted earnings per share  EPS  of  1  which missed the Zacks Consensus Estimate of  1 01 per share by 0 9   However  the bottom line improved 9 9  from the year ago quarter Based in Waltham  MA  this leading MedTech company reported revenues of  722 5 million  up 2 7  from the year ago quarter and improved 5  organically  Adjusted revenues in the quarter came in at  722 7 million  up 2 7  year over year  However  the top line lagged the Zacks Consensus Estimate of   730 3 million by 1 1  Segment DetailsDASAt this segment  revenues totaled  434 million  reflecting an improvement of 0 8  from the year ago quarter  Organically  the segment grew 2  in the quarter under review  Per management  the second quarter performance was affected by soft performance in applied markets  However  solid show by life sciences contributed to organic revenue growth Coming to profits at the DAS segment  the company reported second quarter 2019 adjusted operating income of  81 5 million  up 6 7  from the year ago quarter Diagnostics segmentRevenues at this segment amounted to  288 6 million  up 5 8  on a year over year basis  Adjusted revenues in the segment totaled  288 7 million  up 5 8  from the prior year quarter  Organically  the segment grew 9  in the second quarter  Per management  the upside can be attributed to strength across reproductive health  and immunodiagnostics business lines Adjusted operating income in the segment totaled  79 7 million  up 3 2  from the year ago quarter PerkinElmer  Inc  Price  Consensus and EPS Surprise    Geographical DetailsPer management  the major geographies witnessed a mixed second quarter  with high single digit organic revenue growth in the United States  mid single digit organic revenue growth in Asia Pacific  APAC  and low single digit organic revenue growth in Europe Margin AnalysisGross profit in the quarter came in at  347 8 million  up 2 2  year over year  Adjusted gross margin  as a percentage of revenues  was 51   down 30 bps year over year Adjusted operating margin was  146 million  up 5 6  year over year  Adjusted operating margin  as a percentage of revenues  was 20 2  in the quarter  up 50 bps Financial UpdateIn the second quarter  cash and cash equivalents came in at  150 million  down 8  from that of 2018 end level During the reported quarter  net cash provided by operating activities stood at  46 9 million  down 35 8  from the year ago quarter 2019 Guidance ReiteratedPerkinElmer continues to expect 2019 adjusted EPS in the range of  4 02  4 07  Notably  the Zacks Consensus Estimate of  4 05 lies within the guided range ConclusionPerkinElmer exited the second quarter on a weak note  with both EPS and revenues missing the consensus mark  Nonetheless  the company witnessed strong performances by its core Diagnostics units in the quarter under review  Strength in reproductive health and immunodiagnostics business lines led to the impressive performance  Modest growth in international markets is also encouraging Further  expansion in operating margins buoys optimism  Solid show by Tulip and EUROIMMUN also paints a bright picture However  negative currency movements impacted the company s top line in the quarter under review  Furthermore  PerkinElmer continues its acquisition spree  which increases integration risks Zacks RankCurrently  PerkinElmer carries a Zacks Rank  4  Sell  Earnings of Other MedTech Majors at a GlanceOther top ranked stocks which posted solid results this earning season are Stryker Corporation   NYSE SYK    Baxter International Inc    NYSE BAX   and Intuitive Surgical  Inc    NASDAQ ISRG   Stryker delivered second quarter 2019 adjusted earnings per share of  1 98  beating the Zacks Consensus Estimate by 2 6   Revenues of  3 65 billion surpassed the Zacks Consensus Estimate by 1 4   The company carries a Zacks Rank of 2  Buy   You can see  Baxter delivered second quarter 2019 adjusted earnings of 89 cents per share  which surpassed the Zacks Consensus Estimate of 81 cents by 9 9   Revenues of  2 84 billion outpaced the Zacks Consensus Estimate of  2 79 billion by 1 9   The company has a Zacks Rank  2 Intuitive Surgical reported second quarter 2019 adjusted earnings per share of  3 25  which beat the Zacks Consensus Estimate of  2 85  Revenues were  1 1 billion  surpassing the Zacks Consensus Estimate of  1 03 billion  The company sports a Zacks Rank  1 Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-07-29,Zacks Investment Research,https://www.investing.com/analysis/perkinelmer-pki-q2-earnings-and-revenues-miss-estimates-200447466,200447466
111769,333284,ISRG,Surmodics  SRDX  Q3 Earnings Beat Estimates  Guidance Raised,opinion,"Surmodics  Inc    NASDAQ SRDX   delivered adjusted earnings per share  EPS  of 15 cents in third quarter fiscal 2019 which surpassed the Zacks Consensus Estimate by a whopping 200   The bottom line however declined 44 4  from the year ago quarter Reported EPS came in at 11 cents against reported loss per share of 20 cents a year ago Revenues in the quarter increased 9 5  year over year to  24 3 million  This figure outpaced the Zacks Consensus Estimate by 6 6  Fiscal Q3 HighlightsIn the quarter under review  Product sales were  9 9 million  down 5 7  year over year  Royalty and license fee revenues totaled  11 6 million  up 20 8  from the prior year quarter  Research  development and other were  2 9 million  up 31 8  year over year In the reported quarter  enrolments under Surmodics  TRANSCEND clinical trial continued and 90  of it was completed Surmodics  Inc  Price  Consensus and EPS Surprise
    Segmental AnalysisMedical DeviceIn the reported quarter  sales at the segment rose 13  to  18 9 million  including  2 million from the SurVeil agreement with Abbott  The Medical Device business unit recorded  0 8 million of operating income in the third quarter against an operating loss of  6 2 million a year ago In Vitro DiagnosticsIn the quarter under review  sales declined 2  to  5 4 million  Operating income at the segment was  2 5 million in the reported quarter  up 13 6  from the same period last year Operational DetailsGross profit rose 15 8  to  20 9 million during the quarter  Gross margin expanded 465 bps to 86 2  Surmodics registered Product costs of  3 4 million in the quarter  down 18  year over year The company s research and development costs totaled  13 3 million  up 36 2  year over year Selling  general and administrative expenditures were almost  5 9 million  down 0 6  from the prior year quarter Adjusted operating costs and expenses in the quarter were  19 3 million  up 22 2  year over year  Adjusted operating margin contracted 359 bps to 7 1  Fiscal 2019 Guidance RaisedSurmodics raised its fiscal 2019 revenue expectation to  92 94 million from the earlier  88 5 91 5 million  The Zacks Consensus Estimate for the metric is pegged at  91 2 million  below the guided range Adjusted EPS is now projected between 41 cents and 49 cents compared with the previous projection of 26 36 cents  The Zacks Consensus Estimate for the metric is pegged at 30 cents  much below the guided range Our TakeSurmodics exited the fiscal third quarter on a strong note with EPS and revenues outpacing estimates  The company continues to gain from its core Medical Devices unit  which saw significant contribution from the SurVeil deal with Abbott in the quarter  Management is also upbeat about the ongoing TRANSCEND enrolment  A raised guidance for fiscal 2019 buoys optimism On the flip side  surging operating expenses raise concern  Softness in IVD and product sales are disheartening as well  Contraction in operating margin adds to the woes Zacks Rank   Other Key PicksSurmodics currently carries a Zacks Rank  2  Buy  Some other top ranked stocks  which posted solid results this earning season  are Stryker Corporation   NYSE SYK    Baxter International Inc    NYSE BAX   and Intuitive Surgical  Inc    NASDAQ ISRG   Stryker delivered second quarter 2019 adjusted EPS of  1 98  beating the Zacks Consensus Estimate by 2 6   Revenues of  3 65 billion surpassed the Zacks Consensus Estimate by 1 4   The company carries a Zacks Rank of 2  You can see  Baxter delivered second quarter 2019 adjusted EPS of 89 cents  which surpassed the Zacks Consensus Estimate of 81 cents by 9 9   Revenues of  2 84 billion beat the Zacks Consensus Estimate of  2 79 billion by 1 9   The company holds a Zacks Rank  2 Intuitive Surgical reported second quarter 2019 adjusted EPS of  3 25  which beat the Zacks Consensus Estimate of  2 85  Revenues were  1 1 billion  surpassing the Zacks Consensus Estimate of  1 03 billion  The company sports a Zacks Rank  1 Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana  Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2019-07-31,Zacks Investment Research,https://www.investing.com/analysis/surmodics-srdx-q3-earnings-beat-estimates-guidance-raised-200448986,200448986
111770,333285,ISRG,IDEXX  IDXX  Beats Q2 Earnings Estimates  Lifts EPS Guidance,opinion,"IDEXX Laboratories  Inc    NASDAQ IDXX   posted second quarter 2019 earnings per share  EPS  of  1 43  reflecting a 16 3  year over year rise on a reported basis and 19  growth at comparable constant exchange rate  CER   The figure also surpassed the Zacks Consensus Estimate by 4 4  Revenues in DetailSecond quarter revenues increased 6 8  year over year  up 9  on an organic basis  to  620 1 million  The metric however missed the Zacks Consensus Estimate by 1 3  The year over year upside was primarily driven by strong global gains from Companion Animal Group  CAG  Diagnostics  recurring revenues Segmental AnalysisIDEXX derives revenues from four operating segments  CAG  Water  Livestock  Poultry and Dairy  LPD  and Other  In the second quarter  CAG revenues climbed 8   up 10  organically  year over year to  547 3 million  Water segment s revenues were up 6  from the prior year quarter  up 10  organically  to  30 3 million  LPD revenues dropped 5   flat organically  to  31 5 million  Revenues at the Other segment also slipped 12 5  on a reported basis to  4 9 million IDEXX Laboratories  Inc  Price  Consensus and EPS Surprise
    MarginsGross profit in the second quarter rose 7 6  to  357 9 million in spite of a 5 6  rise in cost of revenues to  262 3 million  Accordingly  gross margin expanded 47 basis points  bps  to 57 7  Sales and marketing expenses rose 5 3  to  101 3 million while general and administrative expenses slid 1 8  to  59 9 million  Additionally  research and development expenses increased 9 3  to  32 3 million  Operating margin in the quarter expanded 142 bps to 26 5  Financial PositionIDEXX exited the second quarter of 2019 with cash and cash equivalents of   110 8 million compared with  116 6 million at the end of the first quarter of 2019  Year to date net cash provided by operating activities was  171 5 million compared with  153 7 million in the year ago period 2019 Outlook UpdatedIDEXX slightly narrowed its revenue guidance for 2019  Full year revenues are now estimated in the range of  2 38  2 41 billion   from the past projection of  2 38 2 42 billion   indicating organic revenue growth of 9 5 10 5   reported revenue growth of 7 5 9       Meanwhile  EPS projection has been raised to the  4 82 4 92  from the past projection of  4 76  4 88  band  suggesting annualized growth of 17 20  at CER  The current Zacks Consensus Estimate for EPS stands at  4 82 on revenues of  2 41 billion Our TakeIDEXX exited the second quarter on a mixed note as EPS beat while revenues missed estimates  Solid organic revenues growth and a lifted EPS view for 2019 are encouraging  We are upbeat to note that the top line in the quarter was driven by strong sales at the CAG business  Specifically  the company witnessed sturdy gains from CAG Diagnostics in the quarter under review Management s innovative multi modality global strategy  enabled by an enhanced commercial capability  accelerated CAG Diagnostics  recurrent revenue growth  Expansion of strategic initiatives like IDEXX Preventive Care enabled faster growth of diagnostic testing during the second quarter Zacks Rank   Other Key PicksIDEXX has a Zacks Rank  2  Buy  Some other top ranked companies  which posted solid results this earnings season  are Stryker Corporation   NYSE SYK    Baxter International Inc    NYSE BAX   and Intuitive Surgical  Inc    NASDAQ ISRG   Stryker delivered second quarter 2019 adjusted EPS of  1 98  beating the Zacks Consensus Estimate by 2 6   Revenues of  3 65 billion surpassed the Zacks Consensus Estimate by 1 4   The company carries a Zacks Rank of 2  You can see  Baxter delivered second quarter 2019 adjusted EPS of 89 cents  which surpassed the Zacks Consensus Estimate of 81 cents by 9 9   Revenues of  2 84 billion beat the Zacks Consensus Estimate of  2 79 billion by 1 9   The company holds a Zacks Rank  2 Intuitive Surgical reported second quarter 2019 adjusted EPS of  3 25  which beat the Zacks Consensus Estimate of  2 85  Revenues were  1 1 billion  surpassing the Zacks Consensus Estimate of  1 03 billion  The company sports a Zacks Rank  1 Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana  Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2019-07-31,Zacks Investment Research,https://www.investing.com/analysis/idexx-idxx-beats-q2-earnings-estimates-lifts-eps-guidance-200448975,200448975
111771,333286,ISRG,ABIOMED  ABMD  Q1 Earnings Top Estimates  Sales Rise In Japan,opinion,"ABIOMED  Inc    NASDAQ ABMD   reported first quarter fiscal 2020 earnings per share  EPS  of  1  which beat the Zacks Consensus Estimate by a penny  The figure rose 28 2  year over year The Zacks Rank  4  Sell  company s revenues came in at  207 7 million  missing the Zacks Consensus Estimate of  210 6 million  However  the metric improved 15 4  from the prior year quarter Fiscal Q1 in DetailWorldwide Impella heart pump revenues in the reported quarter totaled  199 9 million  reflecting an increase of 15  year over year U S  Impella product revenues totaled  168 3 million  an increase of 11  year over year  Per management  U S  patient usage of the Impella heart pumps rose 13  in the quarter Outside the United States  Impella product revenues totaled  31 5 million  highlighting an increase of 44  year over year  Japan revenues were  8 5 million in the quarter  up a substantial 227  year over year ABIOMED  Inc  Price  Consensus and EPS Surprise
    Margin TrendIn the quarter under review  gross profit totaled  170 6 million  up 14 4  year over year  Gross margin in the quarter was 82 1  of net revenues  down 80 basis points  bps  year over year  Research   Development  R D  costs grossed  23 8 million  up 11 8  year over year Operating income totaled  60 7 million  up 30  on a year over year basis  Operating margin was 29 2   up 320 bps Financial ConditionABIOMED s balance sheet remains debt free  The company ended the fiscal first quarter with  526 7 million of cash and marketable securities Guidance SlashedFor fiscal 2020  ABIOMED expects total revenues in the range of  885  925 million  an increase of 15  to 20  year over year  This range is below the earlier provided guidance range of  900  945 million  calling for a year over year increase of 17 23   The Zacks Consensus Estimate for the same stands at  925 3 million  slightly above the projected range Summing UpABIOMED exited the fiscal first quarter on a mixed note  The company continues to gain from its flagship Impella  which saw a strong quarter  Impella s patient success stories and increasing global adoptions are added positives  Revenues from Japan skyrocketed in the quarter  Considerable expansion in the operating margin buoys optimism  Meanwhile  surging R D expenses show increasing focus on innovation  Recent product launches and regulatory approvals buoy optimism  Considerable expansion in operating margin is a positive On the flip side  the drop in gross margin is disheartening  A slashed guidance for fiscal 2020 adds to the woes Earnings of Other MedTech Majors at a GlanceSome better ranked stocks  which posted solid results this earnings season  are Stryker Corporation   NYSE SYK    Baxter International Inc    NYSE BAX   and Intuitive Surgical  Inc    NASDAQ ISRG   Stryker delivered second quarter 2019 adjusted EPS of  1 98  beating the Zacks Consensus Estimate by 2 6   Its revenues of  3 65 billion surpassed the Zacks Consensus Estimate by 1 4   The company currently carries a Zacks Rank of 2  Buy   You can see  Baxter delivered second quarter 2019 adjusted EPS of 89 cents  which surpassed the Zacks Consensus Estimate of 81 cents by 9 9   Its revenues of  2 84 billion outpaced the Zacks Consensus Estimate of  2 79 billion by 1 9   The company currently has a Zacks Rank  2 Intuitive Surgical reported second quarter 2019 adjusted EPS of  3 25  which beat the Zacks Consensus Estimate of  2 85  Its revenues of  1 1 billion surpassed the Zacks Consensus Estimate of  1 03 billion  The company sports a Zacks Rank  1 at present Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2019-07-31,Zacks Investment Research,https://www.investing.com/analysis/abiomed-abmd-q1-earnings-top-estimates-sales-rise-in-japan-200448953,200448953
111772,333287,ISRG,Which Healthcare Mutual Fund Should You Buy  FBIOX Or PRHSX ,opinion,Often  the healthcare sector is relied on for safeguarding investments  This is because demand for healthcare services does not vary so much with market conditions and investments in the sector provide sufficient protection to the capital invested Many pharmaceutical companies also offer regular dividends  Companies that pay out consistent dividends are financially stable and generate consistent cash flows irrespective of market conditions  Mutual funds are perfect choices for investors looking to enter this sector since they possess the advantages of wide diversification and analytical insight The U S  healthcare sector has performed decently so far this year  The Health Care Select Sector SPDR Fund  XLV  has gained 6 4  year to date despite fears related to a slowdown in the global economy as well as trade tensions So far this year  mega scale healthcare mergers  corporate restructuring as well as FDA approvals have buoyed gains for the space  As a matter of fact  America s healthcare sector is being anticipated to experience a major revolution in the days to come  With an uptick in over the counter drug sales coupled with major breakthroughs in the treatment of rare conditions  the healthcare space is deemed to gain big Under such circumstances  investing in healthcare mutual funds seems prudent  However  choosing the right mutual funds for your portfolio can become cumbersome  Let us  therefore  discuss which of these two funds are better for you Fidelity Select Biotechnology Portfolio   The fund mostly invests in common stocks of companies that are engaged in research  development  manufacture and distribution of biotechnological products  processes and related services  The fund seeks appreciation of capital This Sector Health product has a history of positive total returns for over 10 years  Specifically  the fund s returns are 11 7  over the 3 year and 7 5  of the 5 year period  To see how this fund performed compared in its category  and other  1 and  2 Ranked Mutual Funds     The Fidelity Select Biotechnology Portfolio fund  as of the last filing  allocates its assets in top two major groups   Small Growth and Foreign Stock  Further  as of the last filing  Amgen Inc  NASDAQ AMGN   Abbvie Inc and Gilead Sciences Inc  NASDAQ GILD  were the top holdings for FBIOX This Zacks Mutual Fund Rank  2  Buy  was incepted in December 1985 and is managed by   FBIOX carries an expense ratio of 0 72  and requires a minimal initial investment of  0 T  Rowe Price Health Sciences Fund   The fund seeks appreciation of capital in the long term  It invests a minimum of 80  of its assets in common stocks of companies which are involved in research  development  production and distribution of products and services which are related to healthcare  medicine or life sciences  The fund mostly invests in mid  and large capitalization companies This Sector Health product has a history of positive total returns for over 10 years  Specifically  the fund s returns over the 3 and 5 year benchmarks are14 2  and 12 9   respectively  To see how this fund performed compared in its category  and other  1 and  2 Ranked Mutual Funds     T  Rowe Price Health Sciences Fund  as of the last filing  allocates its assets in the top two major groups   Small Growth and Intermediate Bond  Further  as of the last filing  Unitedhealth Group Inc and Intuitive Surgical Inc  NASDAQ ISRG  were the top holdings for PRHSX This Zacks Rank  1  Strong Buy  was incepted in December 1995 and is managed by   PRHSX carries an expense ratio of 0 77  and requires a minimal initial investment of  2 500 To ConcludeWhile both FBIOX and PRHSX are recommended buys  upon having a closer look  we find that the former is a clear winner  PRHSX is much more expensive compared to FBIOX  it has a minimum initial investment  2 500 compared to FBIOX s  0   Further  its administrative and other operating expenses are also higher compared to FBIOX  So  one should clearly bet on FBIOX for higher returns on low investments Want key mutual fund info delivered straight to your inbox Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing mutual funds  each week ,2019-07-31,Zacks Investment Research,https://www.investing.com/analysis/which-healthcare-mutual-fund-should-you-buy-fbiox-or-prhsx-200449268,200449268
111793,333308,ISRG,Intuitive Surgical  ISRG  Down 7 2  Since Last Earnings Report  Can It Rebound ,opinion,"A month has gone by since the last earnings report for Intuitive Surgical  NASDAQ ISRG   Shares have lost about 7 2  in that time frame  underperforming the S P 500 
Will the recent negative trend continue leading up to its next earnings release  or is Intuitive Surgical due for a breakout  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important drivers  Intuitive Surgical Q1 Earnings Miss Estimates  Grows GloballyIntuitive Surgical reported adjusted earnings of  2 61 per share in the first quarter of 2019  which fell short of the Zacks Consensus Estimate of  2 70  Adjusted earnings improved 7  year over year The company recorded revenues of  973 7 million which improved 14 9  from the prior year quarter  However  the figure missed the Zacks Consensus Estimate of  980 million Segment DetailsInstruments   AccessoriesRevenues at the segment came in at  552 3 million  reflecting year over year increase of 20   The improvement primarily reflects increased use of Intuitive Surgical s advanced instruments SystemsIn the reported quarter  System revenues increased 5 5  year over year to  247 5 million  Per management  Intuitive Surgical placed 235 da Vinci Surgical Systems in the first quarter compared with 185 systems in the year ago quarter Per management  the install base of da Vinci systems expanded 13  on a year over year basis to approximately 5 110 ServicesServices revenues came in at  173 9 million  up 13 9  from the year ago quarter International Sales UpOutside the United States  revenues totaled  282 million  up 3  on a year over year basis but down 8  sequentially  The year over year improvement can be attributed to a greater proportion of da Vinci X systems and a higher mix of distributor arrangements Outside the United States  Intuitive Surgical placed 81 systems in the first quarter compared with 73 in the first quarter of 2019  Of these  49 were in Europe  13 in Japan  eight in Brazil and three in China MarginsAdjusted gross profit in the reported quarter was  692 9 million  up 14 2  year over year  As a percentage of revenues  adjusted gross margin in the quarter was 71 2   down 40 basis points  bps  Adjusted operating income totaled  361 5 million  up 4 4  year over year  As a percentage of revenues  adjusted operating margin in the quarter was 37 1   down 380 bps 2019 Outlook ImpressiveIntuitive Surgical now forecasts 2019 procedure growth in the range of 15  to 17   compared with the previous 13  to 17  
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed a downward trend in fresh estimates  The consensus estimate has shifted  10 26  due to these changes 
VGM Scores
At this time  Intuitive Surgical has a nice Growth Score of B  though it is lagging a lot on the Momentum Score front with a D  Following the exact same course  the stock was allocated a grade of D on the value side  putting it in the bottom 40  for this investment strategy 
Overall  the stock has an aggregate VGM Score of D  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been broadly trending downward for the stock  and the magnitude of these revisions indicates a downward shift  Notably  Intuitive Surgical has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2019-05-17,Zacks Investment Research,https://www.investing.com/analysis/intuitive-surgical-isrg-down-72-since-last-earnings-report-can-it-rebound-200422764,200422764
111794,333309,ISRG,Medical Products Industry Outlook  Growth Prospects Radiant,opinion,The Zacks  industry comprises companies that provide medical products and top notch technologies for diagnosis  observation  consultation  treatment and other healthcare services  Focus on research and development is the primary area of focus for companies in the space The industry caters to important therapeutic areas like cardiovascular devices  nephrology and urology devices  ophthalmic devices  neurological devices  dermatological devices  respiratory devices  skin care devices  dental devices  orthopedic devices and gastrointestinal devices Let us take a look at the three major themes in the industry AI  Medical Mechatronics   Robotics  The growing prevalence of minimally invasive robot assisted surgeries  self automated home based care  use of IT for quick and improved patient care  and shift of the payment system to a value based model indicate the growing significance of AI in the Medical Products space  Mechatronics   a high end technology incorporating electronics  machine learning and mechanical engineering   also characterizes the industry now  Intuitive Surgical  NASDAQ ISRG   ISRG  deserves a mention with respect to AI  robotics and medical mechatronics  The company designs  manufactures and markets the da Vinci surgical system   an advanced robot assisted surgical platform  This Mechatronic based platform enables minimally invasive surgery that helps reduce trauma associated with open surgery  Rampant M As  In recent times  there has been a pickup in M A activities in this space  This strategy has been aiding dominant Medical Products players to expand customer bases and gain leverage apart from lessening pricing pressure and competition  Of the recent ones  Aurora Cannabis Inc  s  ACB  acquisition of Whistler Medical Marijuana Corporation deserves a mention  The buyout is expected to provide Aurora with an exceptional and differentiated organic certified product portfolio  This in turn will expand both its medical and consumer offerings  and fortify Aurora s presence in the already strong West Coast cannabis market  Emerging Markets Hold Promise  Given the rising medical awareness and economic prosperity  emerging economies have been witnessing solid demand for medical products  An aging population  relaxed regulations  cheap skilled labor  increasing wealth and government focus on healthcare infrastructure make these markets a happy hunting ground for global medical device players Zacks Industry Rank Indicates Bright ProspectsThe Zacks Medical Products industry falls within the broader Zacks  sector  It carries a Zacks Industry Rank  97  which places it in the top 38  of more than 250 Zacks industries The group s   which is basically the average of the Zacks Rank of all the member stocks  indicates bright near term prospects  Our research shows that the top 50  of the Zacks ranked industries outperforms the bottom 50  by a factor of more than 2 to 1 Before we present a few insurance broker stocks that you may want to consider for your portfolio  let s take a look at the industry s recent stock market performance and valuation picture Industry s Stock Market PerformanceThe industry has outperformed both its sector and the Zacks S P 500 composite in the past year The industry has increased 4 1  over this period compared with the S P 500 s growth of 2 4   However  the broader sector has declined 4 9  One Year Price PerformanceIndustry s Current ValuationOn the basis of the forward 12 month price to earnings  P E  ratio  which is commonly used for valuing medical stocks  the industry is currently trading at 24 38X compared with the sector s 20 14X and the S P 500 s 16 70X Over the past five years  the industry has traded as high as 25 04X and as low as 16 77X  with the median being at 19 44X as the charts show below Price to Earnings Forward Twelve Months  F12M Price to Earnings Forward Twelve Months  F12M Bottom LineGiven the bipartisan two year suspension of a 2 3  excise tax on Medical Products and Medical Device manufacturers at the beginning of 2018  the industry witnessed massive investments  The reintroduction of the controversial 2 3  medical device tax  repeal by the Senate in April 2019 has bolstered optimism Meanwhile  per a CISION report  the United States remains the largest Medical Products market in the world with a market size of approximately  156 billion  The industry has been raking in more than  180 billion a year due to rising research and development activities and growing exposure to AI Here  we present three stocks that sport a Zacks Rank  1  Strong Buy   These stocks are well positioned to grow in the near term  You can see  Cardiovascular Systems  Inc   CSII Cardiovascular Systems  Inc  is a medical device manufacturer that develops and commercializes innovative solutions to treat patients suffering from peripheral and coronary arterial diseases  including those with arterial calcium The company delivers a unique  patented Orbital Atherectomy System  OAS  of products that remove calcified and fibrotic plaque in arterial vessels throughout the leg and heart in very short treatment time For this St  Paul  MN based company  the Zacks Consensus Estimate for 2019 revenues indicates year over year improvement of 13 3   It has an average positive earnings surprise of 77 08  in the trailing four quarters Price and Consensus  CSIIHaemonetics Corporation  HAE Haemonetics Corporation  HAE  provides blood management solutions to customers including blood and plasma collectors  hospitals and health care providers globally  The company s portfolio of integrated devices  information management  and consulting services offers blood management solutions for each facet of the blood supply chain  resulting in better clinical outcomes For this Braintree  MA based company  the Zacks Consensus Estimate for 2019 revenues indicates year over year improvement of 4 2   It has an average positive earnings surprise of 15 47  in the trailing four quarters Price and Consensus  HAEQuidel Corporation  QDEL Quidel Corporation discovers  develops  manufactures and markets point of care  rapid diagnostic tests for detection of medical conditions and illnesses  These products provide accurate  rapid and cost effective diagnostic information for acute and chronic conditions that affect women s health throughout the phases of their lives including reproductive status  pregnancy management and osteoporosis For this San Diego  CA based company  the Zacks Consensus Estimate for 2019 revenues indicates year over year improvement of 1 6   It has an average positive earnings surprise of 24 76  in the trailing four quarters Price and Consensus  QDEL Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-06-13,Zacks Investment Research,https://www.investing.com/analysis/medical-products-industry-outlook-growth-prospects-radiant-200431345,200431345
111795,333310,ISRG,Intuitive Surgical  ISRG  Earnings Expected To Grow  Should You Buy ,opinion,"Intuitive Surgical  NASDAQ ISRG  is expected to deliver a year over year increase in earnings on higher revenues when it reports results for the quarter ended June 2019  This widely known consensus outlook gives a good sense of the company s earnings picture  but how the actual results compare to these estimates is a powerful factor that could impact its near term stock price 
The stock might move higher if these key numbers top expectations in the upcoming earnings report  which is expected to be released on July 18  On the other hand  if they miss  the stock may move lower 
While management s discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations  it s worth having a handicapping insight into the odds of a positive EPS surprise 
Zacks Consensus Estimate
This robotic surgery system company is expected to post quarterly earnings of  2 84 per share in its upcoming report  which represents a year over year change of  2 9  
Revenues are expected to be  1 03 billion  up 12 8  from the year ago quarter 
Estimate Revisions Trend
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days  This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period 
Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change 
Price  Consensus and EPS Surprise

Earnings Whisper
Estimate revisions ahead of a company s earnings release offer clues to the business conditions for the period whose results are coming out  Our proprietary surprise prediction model    the Zacks Earnings ESP  Expected Surprise Prediction     has this insight at its core 
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Thus  a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate  However  the model s predictive power is significant for positive ESP readings only 
A positive Earnings ESP is a strong predictor of an earnings beat  particularly when combined with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold   Our research shows that stocks with this combination produce a positive surprise nearly 70  of the time  and a solid Zacks Rank actually increases the predictive power of Earnings ESP 
Please note that a negative Earnings ESP reading is not indicative of an earnings miss  Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and or Zacks Rank of 4  Sell  or 5  Strong Sell  
How Have the Numbers Shaped Up for Intuitive Surgical 
For Intuitive Surgical  the Most Accurate Estimate is the same as the Zacks Consensus Estimate  suggesting that there are no recent analyst views which differ from what have been considered to derive the consensus estimate  This has resulted in an Earnings ESP of 0  
On the other hand  the stock currently carries a Zacks Rank of  3 
So  this combination makes it difficult to conclusively predict that Intuitive Surgical will beat the consensus EPS estimate 
Does Earnings Surprise History Hold Any Clue 
While calculating estimates for a company s future earnings  analysts often consider to what extent it has been able to match past consensus estimates  So  it s worth taking a look at the surprise history for gauging its influence on the upcoming number 
For the last reported quarter  it was expected that Intuitive Surgical would post earnings of  2 70 per share when it actually produced earnings of  2 61  delivering a surprise of  3 33  
Over the last four quarters  the company has beaten consensus EPS estimates two times 
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower  Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors  Similarly  unforeseen catalysts help a number of stocks gain despite an earnings miss 
That said  betting on stocks that are expected to beat earnings expectations does increase the odds of success  This is why it s worth checking a company s Earnings ESP and Zacks Rank ahead of its quarterly release  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported 
Intuitive Surgical doesn t appear a compelling earnings beat candidate  However  investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release ",2019-07-10,Zacks Investment Research,https://www.investing.com/analysis/intuitive-surgical-isrg-earnings-expected-to-grow-should-you-buy-200438972,200438972
111796,333311,ISRG,Should You Buy Intuitive Surgical  ISRG  Ahead Of Earnings ,opinion,Investors are always looking for stocks that are poised to beat at earnings season and Intuitive Surgical  Inc    NASDAQ ISRG   may be one such company  The firm has earnings coming up pretty soon  and events are shaping up quite nicely for their report That is because Intuitive Surgical is seeing favorable earnings estimate revision activity as of late  which is generally a precursor to earnings beat  After all  analysts raising estimates right before earnings   with the most up to date information possible   is a pretty good indicator of some favorable trends underneath the surface for ISRG in this report In fact  the Most Accurate Estimate for the current quarter is currently at  2 86 per share for ISRG  compared to a broader Zacks Consensus Estimate of  2 85 per share  This suggests that analysts have very recently bumped up their estimates for ISRG  giving the stock a Zacks Earnings ESP of  0 31  heading into earnings season Intuitive Surgical  Inc  Price and EPS Surprise   Why is this Important A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises  and outperforming the market  Our recent 10 year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank  3  Hold  or better show a positive surprise nearly 70  of the time  and have returned over 28  on average in annual returns  see more   Given that ISRG has a Zacks Rank  3 and an ESP in positive territory  investors might want to consider this stock ahead of earnings  You can see  Clearly  recent earnings estimate revisions suggest that good things are ahead for Intuitive Surgical  and that a beat might be in the cards for the upcoming report Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-07-17,Zacks Investment Research,https://www.investing.com/analysis/should-you-buy-intuitive-surgical-isrg-ahead-of-earnings-200440635,200440635
111797,333312,ISRG,Will Intuitive Surgical  ISRG  Gain On Rising Earnings Estimates ,opinion,"Intuitive Surgical  NASDAQ ISRG  could be a solid addition to your portfolio given a notable revision in the company s earnings estimates  While the stock has been gaining lately  the trend might continue since its earnings outlook is still improving 
The upward trend in estimate revisions for this robotic surgery system company reflects growing optimism of analysts on its earnings prospects  which should get reflected in its stock price  After all  empirical research shows a strong correlation between trends in earnings estimate revisions and near term stock price movements  This insight is at the core of our stock rating tool    the Zacks Rank 
The five grade Zacks Rank system  which ranges from a Zacks Rank  1  Strong Buy  to a Zacks Rank  5  Strong Sell   has an impressive externally audited track record of outperformance  with Zacks  1 Ranked stocks generating an average annual return of  25  since 2008 
For Intuitive Surgical  there has been strong agreement among the covering analysts in raising earnings estimates  which has helped push consensus estimates considerably higher for the next quarter and full year 
The chart below shows the evolution of forward 12 month Zacks Consensus EPS estimate 
12 Month EPS

Current Quarter Estimate Revisions
The company is expected to earn  2 96 per share for the current quarter  which represents a year over year change of  4 59  
Over the last 30 days  the Zacks Consensus Estimate for Intuitive Surgical has increased 5 27  because five estimates have moved higher while one has gone lower 
Current Year Estimate Revisions
The company is expected to earn  12 01 per share for the full year  which represents a change of  9 28  from the prior year number 
There has been an encouraging trend in estimate revisions for the current year as well  Over the past month  10 estimates have moved up for Intuitive Surgical versus no negative revisions  This has pushed the consensus estimate 8 04  higher 
Favorable Zacks Rank
Thanks to promising estimate revisions  Intuitive Surgical currently carries a Zacks Rank  1  Strong Buy   The Zacks Rank is a tried and tested rating tool that helps investors effectively harness the power of earnings estimate revisions and make the right investment decision  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
Our research shows that stocks with Zacks Rank  1  Strong Buy  and 2  Buy  significantly outperform the S P 500 
Bottom Line
Intuitive Surgical shares have added 5 7  over the past four weeks  suggesting that investors are betting on its impressive estimate revisions  So  you may consider adding it to your portfolio right away to benefit from its earnings growth prospects ",2019-07-24,Zacks Investment Research,https://www.investing.com/analysis/will-intuitive-surgical-isrg-gain-on-rising-earnings-estimates-200445222,200445222
111825,333340,ISRG,Quick Look At Health Care Heading Into Q1  19 Earnings,opinion,"Every Thursday night  Bespoke publishes a YTD return for all 11 sectors of the SP 500  and last Thursday night s bar chart shows that the Health Care sector was now negative for 2019 YTD  dramatically underperforming the SP 500 YTD 
Using IBES by Refinitiv actual earnings and revenue growth for the sector  here are the historical growth rates for the Health Care sector 
Earnings Growth 

1 year   16 1  avg
3 year   10 8  avg
5 year   12 4  avg
29 mos   10 2  avg

Revenue Growth 

1 year   7 5  avg
3 year   6 8  avg
5 year   8 1  avg
25 mos   7 9  avg

But here is what is interesting for readers  looking at the sector growth rate revisions since April 1   19  both Q1 and Q2  19 Health Care revisions have been higher 

expected Q1  19 Health Care earnings growth has been revised from 4 5  as of April 1 to  5 1  as of April 19  2019 
expected Q2  19 Health Care earnings growth has been revised from 3  as of April 1 to  3 4  as of April 19  2019 
Quarter s 3   4 of 2019 have been revised slightly lower 

But here is what was really surprising  expected Health Care sector revenue growth is 13 3  for Q1  19 and  12 4  for Q2  19 
Those revenue growth rates are well above the historical averages shown above 
Here was a snippet cut and pasted from  This Week in Earnings  on Health Care revenue growth 
 The health care sector has the highest  expected  revenue growth rate  13 3   of any sector  It is expected to earn  506 4B in 19Q1  compared to revenue of  447 1B in 18Q1  All of the 10 sub industries in the sector are anticipated to see higher revenue than a year ago  The health care services  56 4   and managed health care  13 5   sub industries have the highest revenue growth in the sector  If these sub industries are removed  the growth rate declines to 3 1     The one flaw to this blog is that I don t have access to those  sub sector  growth rates or revisions on a weekly basis  I ve asked frequently   
Summary conclusion  Has the drop in Health Care been a head fake for 2019 or is there some worries over  Medicare for All  and nationalized medicine as the Presidential rhetoric heats up  During the Spring and Summer of 2016  when it was widely thought that Hillary Clinton would be our next President  the Health Care sector didn t trade well into the election 
Clients are long biotech in the form of the IBB and the XBI  which didn t really get hit until last week  probably since the sector is below it s all time highs last seen in 2015  and the fact is biotech does seem to correlate with the Russell 2000 which has lagged for some time too  so I felt biotech was a safer way to play Health Care for clients  and whether that was a smart allocation remains to be seen  Our largest single stock position in Health care is Pfizer  NYSE PFE  since it and Merck  NYSE MRK  are working off the 20 year bases formed after the drop from the year 2000 highs  Both pharma giants have substantial free cash generation  good dividends and from a sentiment perspective are completely unloved and unwanted  although Merck  which was added to on Thursday  has seen some success with Keytruda 
So is the Health Care under performance peril or opportunity  As Bespoke noted earlier in the week in one of their research hits  under performing sectors like Health Care  when within a bull market   usually remain under performers  but I d suggest readers look at your favorite names and watch and see what Q1  19 earnings look like and what happens with earnings revisions 
Intuitive Surgical  NASDAQ ISRG  reported Thursday night after the bell and it might drop on Monday  but bear markets in sectors tend to compress P E multiples on growth stocks even when the underlying business is fine  so use the selloff in strong healthcare names as a long term opportunity ",2019-04-21,Brian Gilmartin,https://www.investing.com/analysis/quick-look-at-health-care-headed-into-q1-19-earnings-200408851,200408851
111826,333341,ISRG,Intuitive Surgical  ISRG  Q1 Earnings  Revenues Lag Estimates,opinion,"Intuitive Surgical  Inc    NASDAQ ISRG   reported adjusted earnings of  2 61 per share in the first quarter of 2019  which fell short of the Zacks Consensus Estimate of  2 70  Adjusted earnings improved 7  year over year The Zacks Rank  4  Sell  company recorded revenues of  973 7 million which improved 14 9  from the prior year quarter  However  the figure missed the Zacks Consensus Estimate of  980 million Segment DetailsInstruments   AccessoriesRevenues at the segment came in at  552 3 million  reflecting year over year increase of 20   The improvement primarily reflects increased use of Intuitive Surgical s advanced instruments SystemsIn the reported quarter  System revenues increased 5 5  year over year to  247 5 million  Per management  Intuitive Surgical placed 235 da Vinci Surgical Systems in the first quarter compared with 185 systems in the year ago quarter Per management  the install base of da Vinci systems expanded 13  on a year over year basis to approximately 5 110 ServicesServices revenues came in at  173 9 million  up 13 9  from the year ago quarter Intuitive Surgical  Inc  Price  Consensus and EPS Surprise
    International Sales UpOutside the United States  revenues totaled  282 million  up 3  on a year over year basis but down 8  sequentially  The year over year improvement can be attributed to a greater proportion of da Vinci X systems and a higher mix of distributor arrangements Outside the United States  Intuitive Surgical placed 81 systems in the first quarter compared with 73 in the first quarter of 2018  Of these  49 were in Europe  13 in Japan  eight in Brazil and three in China MarginsAdjusted gross profit in the reported quarter was  692 9 million  up 14 2  year over year  As a percentage of revenues  adjusted gross margin in the quarter was 71 2   down 40 basis points  bps  Adjusted operating income totaled  361 5 million  up 4 4  year over year  As a percentage of revenues  adjusted operating margin in the quarter was 37 1   down 380 bps 2019 Outlook ImpressiveIntuitive Surgical now forecasts 2019 procedure growth in the range of 15  to 17   compared with the previous 13  to 17  Wrapping UpIntuitive Surgical ended the first quarter on a dull note  However  the flagship da Vinci procedures recorded solid growth in the quarter  In fact  management expects strong procedure growth in 2019  The company looks to accelerate its business in China  following the clearance of da Vinci Xi  Sales outside the United States surged in the quarter  Management is also optimistic about the recent approvals for the Ion endoluminal system  IRIS augmented reality product and the da Vinci SP Surgical System  Meanwhile  the newly formed Intuitive Foundation is expected to improve patient outcome On the flip side  contraction in the gross and operating margin is worrisome  Additionally  the da Vinci system is in the early stages of adoption in some of the markets outside the United States which is likely to impede placements  Intense competition in the global MedTech space is concerning as well Key PicksA few better ranked stocks in the broader Medical space are Penumbra   NYSE PEN    Wright Medical   NASDAQ WMGI   and Masimo Corporation   NASDAQ MASI    each carrying a Zacks Rank  2  Buy   You can see  Penumbra has a long term earnings growth rate of 20 9  Wright Medical s long term earnings growth is projected at 11 3  Masimo s long term earnings are expected to grow 15 6  Is Your Investment Advisor Fumbling Your Financial Future See how you can more effectively safeguard your retirement with a new Special Report   4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future  ",2019-04-22,Zacks Investment Research,https://www.investing.com/analysis/intuitive-surgical-isrg-q1-earnings-revenues-lag-estimates-200409064,200409064
111827,333342,ISRG,Where To Find Great Investment Ideas,opinion," 0 30    Where To Find Stock Ideas  2 30    Newspaper Sources  Using Wall Street Journal and Financial Times 12 45    Is Barron s A Good Stock Market Source   15 00    Finding Stock Market Information From Magazines  Business Week and The Economist 25 15    Episode Roundup  FIVE  ISRG  UFO  IRBO  FINX  FIVG  BYND  K Welcome to Episode  175 of the Zacks Market Edge Podcast 
Every week  host and Zacks stock strategist  Tracey Ryniec  will be joined by guests to discuss the hottest investing topics in stocks  bonds and ETFs and how it impacts your life 
In this episode  Tracey is joined by Zacks Director of ETF Research  Neena Mishra  to talk about what newspapers and magazines they read to discover new investing ideas 
You don t have to read the paper versions  as digital will work just fine  but both newspapers and magazines provide a plethora of investing ideas for both stocks and ETFs 
Newspapers  Old Fashioned or a Great Source  
No one does it better than some of the large international newspapers like the Wall Street Journal and the Financial Times 
They have hundreds of reporters around the globe covering businesses and economic trends 
Both offer some free articles every month before you need to subscribe  Also  look for subscriber deals 
Neena uses the Financial Times to find ETF ideas in Space  Robotics and FinTech 
Some ETFs in those areas that stand out include the Procure Space ETF   LON UFO   and the Global X FinTech ETF   NS FINX   
What about Barron s 
This weekly paper offers some great stock lists  It s especially good at targeting small cap stocks you might not have heard of like Five Below   NASDAQ FIVE   
Top Magazines for Stock Ideas
Despite being left for dead  people are still reading magazines 
Bloomberg Businessweek is great at covering trending topics like pot  social media and beauty 
It will also drill down into a company so investors can get a better idea of the business 
Recently  it featured Intuitive Surgical s   NASDAQ ISRG   growth plan which was a real eye opener for Tracey 
But what about finding investing ideas in your everyday reading 
Readers of Eating Well magazine wouldn t be surprised by the mania in meatless products as the magazine recently featured 5 of the healthiest store bought veggie burgers 
Included on the list was Beyond Meat s   NASDAQ BYND   burger 
But what about the others on the list  Who makes the other meatless burgers  You might be surprised about what investing ideas lurk there   
What else should you know about finding investing ideas in newspapers and magazines 
Listen to this week s podcast to find out 
Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ",2019-05-07,Zacks Investment Research,https://www.investing.com/analysis/where-to-find-great-investment-ideas-200418945,200418945
111828,333343,ISRG,Zacks Market Edge Highlights  UFO  FINX  FIVE And ISRG,opinion,"For Immediate Release
Chicago  IL   May 9  2019   Zacks Market Edge is a podcast hosted weekly by cks Stock Strategist Tracey Ryniec  Every week  Tracey will be joined by guests to discuss the hottest investing topics in stocks  bonds and ETFs and how it impacts your life  To listen to the podcast  click here 

Where to Find Great Investment Ideas
Welcome to Episode  175 of the Zacks Market Edge Podcast 
Every week  host and Zacks stock strategist  Tracey Ryniec  will be joined by guests to discuss the hottest investing topics in stocks  bonds and ETFs and how it impacts your life 
In this episode  Tracey is joined by Zacks Director of ETF Research  Neena Mishra  to talk about what newspapers and magazines they read to discover new investing ideas 
You don t have to read the paper versions  as digital will work just fine  but both newspapers and magazines provide a plethora of investing ideas for both stocks and ETFs 
Newspapers  Old Fashioned or a Great Source  
No one does it better than some of the large international newspapers like the Wall Street Journal and the Financial Times 
They have hundreds of reporters around the globe covering businesses and economic trends 
Both offer some free articles every month before you need to subscribe  Also  look for subscriber deals 
Neena uses the Financial Times to find ETF ideas in Space  Robotics and FinTech 
Some ETFs in those areas that stand out include the Procure Space ETF   LON UFO   and the Global X FinTech ETF   NS FINX    
What about Barron s 
This weekly paper offers some great stock lists  It s especially good at targeting small cap stocks you might not have heard of like Five Below   NASDAQ FIVE   
Top Magazines for Stock Ideas
Despite being left for dead  people are still reading magazines 
Bloomberg Businessweek is great at covering trending topics like pot  social media and beauty 
It will also drill down into a company so investors can get a better idea of the business 
Recently  it featured Intuitive Surgical s   NASDAQ ISRG   growth plan which was a real eye opener for Tracey 
But what about finding investing ideas in your everyday reading 
Readers of Eating Well magazine wouldn t be surprised by the mania in meatless products as the magazine recently featured 5 of the healthiest store bought veggie burgers 
Included on the list was Beyond Meat s burger 
But what about the others on the list  Who makes the other meatless burgers  You might be surprised about what investing ideas lurk there   
What else should you know about finding investing ideas in newspapers and magazines 
Listen to this week s podcast to find out 
Breakout Biotech Stocks with Triple Digit Profit Potential
The biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases 
Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better 
See these 7 breakthrough stocks now   
Follow us on Twitter   
Join us on Facebook  NASDAQ FB    
Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates 
Media Contact
Zacks Investment Research
800 767 3771 ext  9339


Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ",2019-05-08,Zacks Investment Research,https://www.investing.com/analysis/zacks-market-edge-highlights-ufo-finx-five-and-isrg-200419632,200419632
111853,333368,ISRG,Intuitive Surgical Gets FDA Nod For Ion Endoluminal System,opinion,Intuitive Surgical  Inc    NASDAQ ISRG   announced that the U S  FDA has granted 501 k  clearance for the Ion endoluminal system to enable minimally invasive biopsy in the peripheral lung  The company plans a limited rollout of the platform in the United States  with customer shipments to commence during the second quarter of 2019 About IonIon is a new robotic endoluminal platform in development for peripheral lung biopsy  The system features an ultra thin  ultra maneuverable catheter that allows navigation far into the peripheral lung  Moreover  its unprecedented stability enables the precision needed for biopsy Apart from lung nodule biopsy  Ion integrates existing imaging technology including fluoroscopy  radial endobronchial ultrasound  and cone beam CT Market ProspectsThe Ion platform represents Intuitive Surgical s solid focus on minimally invasive care  Per Mordor Intelligence  the global minimally invasive devices market is expected to multiply at a CAGR of nearly 8  during the 2018 2023 time frame  Apart from Intuitive Surgical  Abbot Laboratories   NYSE ABT   and Medtronic   NYSE MDT   are the other key players in this space The latest development also provides Intuitive Surgical a favorable exposure in the peripheral lung biopsy markets  Per GlobeNewswire  Lung Cancer Diagnostics market size is projected to reach a worth of  3 64 billion by 2024  Notably  the market is consolidated in nature  In 2018  Qiagen N V    NYSE QGEN     a global player in the niche space   received the FDA approval to expand the usage of EGFR test in lung cancer A Plethora of Regulatory ApprovalsFavorable tidings on the regulatory front have always favored Intuitive Surgical  Of the latest ones  the company submitted 510 k  for the second indication of TransOral Robotic Surgery  It is also working through supply chain optimization as Intuitive Surgical begins to ramp up production for SP Further  a suite of regulatory approvals for the Vessel Sealer Extend   the da Vinci SP Surgical System   and the Sure Form 60 buoys optimism Intuitive Surgical gained significantly on the CE Mark approval for da Vinci X in Europe  The stock has got a further boost from the recent FDA approval of the same Price PerformanceIntuitive Surgical outperformed its  in a year s time  The Zacks Rank  3  Hold  company has gained 40   comparing favorably with the industry s 9 9  growth  The current level is also higher than the S P 500 s decline of 6 1  over the same time frame  You can see   Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  would you like to know about our 10 finest buy and holds for the year Who wouldn t  Our annual Top 10s have beaten the market with amazing regularity  In 2018  while the market dropped  5 2   the portfolio scored well into double digits overall with individual stocks rising as high as  61 5   And from 2012 2017  while the market boomed  126 3  Zacks  Top 10s reached an even more sensational  181 9  ,2019-02-19,Zacks Investment Research,https://www.investing.com/analysis/intuitive-surgical-gets-fda-nod-for-ion-endoluminal-system-200390265,200390265
111854,333369,ISRG,Intuitive Surgical  ISRG  Up 2 9  Since Last Earnings Report  Can It Continue ,opinion,"It has been about a month since the last earnings report for Intuitive Surgical  NASDAQ ISRG   Shares have added about 2 9  in that time frame  underperforming the S P 500 
Will the recent positive trend continue leading up to its next earnings release  or is Intuitive Surgical due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at its most recent earnings report in order to get a better handle on the important drivers  
Intuitive Surgical Q4 Earnings Miss  da Vinci Performs WellIntuitive Surgicalreported adjusted earnings of  2 96 per share in the fourth quarter of 2018  which fell short of the Zacks Consensus Estimate of  2 99  Adjusted earnings improved 13 8  year over year 
Revenues totaled  1 05 billion improved 17 3  from the prior year quarter and surpassed the Zacks Consensus Estimate of  1 04 billion 
Segment Details
Instruments   Accessories
Revenues at the segment came in at   539 3 million  which reflects year over year increase of 18   The uptick was primarily driven by 19  growth in worldwide da Vinci procedure volumes 
Systems
In the reported quarter  System revenues increased 19 7  year over year to  340 6 million  Per management  Intuitive Surgical shipped 290 da Vinci Surgical Systems in the fourth quarter compared with 216 systems in the year ago quarter 
Per management  the install base of da Vinci systems increased 13  on a year over year basis 
Services
Services revenues came in at  166 6 million  up 10 8  from the year ago quarter 
International Sales Up
Outside the United States  revenues totaled  307 million  up 24  on a year over year basis and 25  sequentially  The upside can be attributed to a 24  increase in international procedures 
Outside the United States  Intuitive Surgical placed 115 systems in the reported quarter compared with 86 in the fourth quarter of 2017  Of these  35 were X systems  This included 55 in Europe  31 in Japan  and nine in Brazil 
Margins
Adjusted gross profit in the reported quarter was  751 2 million  up 16 3  year over year  As a percentage of revenues  adjusted gross margin in the quarter was 71 8  which contracted 60 basis points  bps   Per management  the downside reflects product mix in costs associated with new products 
Adjusted operating income totaled  411 8 million  up 6 7  year over year  As a percentage of revenues  adjusted operating margin in the quarter was 39 4   down 390 bps 
For investors  notice  Intuitive Surgical s fourth quarter operating expenses include a  25 million contribution to the newly formed Intuitive Foundation 
2019 Outlook
Intuitive Surgical did not issue any guidance 
However  management expects 2019 procedure growth in the range of 13 17   driven by U S  general surgery and procedures  Adjusted operating expenses are expected to rise 20 28  
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed an upward trend in fresh estimates 
VGM Scores
Currently  Intuitive Surgical has a nice Growth Score of B  though it is lagging a bit on the Momentum Score front with a C  Charting a somewhat similar path  the stock was allocated a grade of D on the value side  putting it in the bottom 40  for this investment strategy 
Overall  the stock has an aggregate VGM Score of D  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been trending upward for the stock  and the magnitude of this revision looks promising  Notably  Intuitive Surgical has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2019-02-22,Zacks Investment Research,https://www.investing.com/analysis/intuitive-surgical-isrg-up-29-since-last-earnings-report-can-it-continue-200391809,200391809
111855,333370,ISRG,Top Stock Reports For Visa  Honeywell   Biogen,opinion,"Tuesday  March 12  2019
The Zacks Research Daily presents the best research output of our analyst team  Today s Research Daily features new research reports on 16 major stocks  including Visa  V   Honeywell  HON  and Biogen  BIIB   These research reports have been hand picked from the roughly 70 reports published by our analyst team today 
You can see 
Visa s shares have outperformed the Zacks Financial Transaction Services industry over the past year   22 3  vs   14 3    Visa s results were driven by growth in payments volume  cross border volume and processed transactions  and a lower tax rate  The Zacks analyst thinks numerous strategic acquisitions and alliances  technology upgrades and effective marketing have paved the way for long term growth and consistent increase in revenues  
Visa is well poised to gain from growing electronic payment processing and a solid brand name  Its strong capital position enables investments in business  Nevertheless  high client incentives and operating expenses  and foreign exchange volatility might put pressure on margins  Softness in cross border volumes is another concern 
 You can   
Shares of Honeywell have underperformed the Zacks Diversified Operations industry in the past three months  gaining  10 3  vs  a  12 8  increase  Honeywell believes that strength in its commercial aftermarket and sensing businesses as well as solid demand for its productivity and commercial fire products will boost its revenues in the quarters ahead  
The Zacks analyst thinks stronger sales volumes  increased productivity and ongoing commercial effectiveness actions will likely boost near term profitability  Notably  the company anticipates generating organic sales growth in the range of 2 5  in 2019  Rising costs of revenues are a worry for the company s gross margin  
Also  analysts have become increasingly bearish on the company over the past couple of months  Increases in debt levels can increase its financial obligations 
 You can   
Biogen s shares have underperformed the Zacks Biomedical and Genetics industry year to date   3 5  vs   11 9    Biogen has a strong position in the MS market with a wide range of products  The Zacks analyst likes its efforts to diversify beyond MS to other areas like Alzheimer s  Parkinson s and stroke  among others  Meanwhile  its newest drug Spinraza is performing well and has multi billion dollar potential  
Biogen s efforts to regularly in license assets to build its pipeline are encouraging with several having transformative potential  Multiple data readouts are expected in 2019 with multiple potential launches in the early 2020s  However  its core MS business  excluding Ocrevus royalties  has been largely flat 
Also  potential competition to Spinraza from competitors  gene therapy programs for SMA is a concern  Though Biogen s CNS pipeline is attractive  it is a high risk area 
 You can   
Other noteworthy reports we are featuring today include Intuitive Surgical  NASDAQ ISRG   Humana  HUM  and EOG Resources  NYSE EOG  
Today s Best Stocks from Zacks 
Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  
This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year 

Mark VickerySenior Editor
Note  Sheraz Mian heads the Zacks Equity Research department and is a well regarded expert of aggregate earnings  He is frequently quoted in the print and electronic media and publishes the weekly and reports  If you want an email notification each time Sheraz publishes a new article  please 
Today s Must Read
Growing Top line Aids Visa  V   Escalating Expenses Hurt


Aerospace Segment Drives Honeywell  HON   High Costs Hurt


Biogen  BIIB  Rides on Spinraza and In Licensing Agreements


Featured Reports
EOG Resources  EOG  Gains on Eagle Ford  Well Expenses High
Huge inventory of premium drilling wells in the Eagle Ford shale will contribute to EOG Resources  oil production  But  escalating lease and well operating costs are a concern  per the Zacks analyst 

Solid Acquisitions Aid Humana  HUM   Rising Expenses Hurt 
Per the Zacks analyst  acquisitions have helped Humana expand its portfolio  which in turn  aided its top line 

Ongoing Investments  New Water Segment Aids Eversource  ES 
Per the Zacks analyst  Eversource Energy s  12 8 billion investment in the 2019 2023 period to strengthen infrastructure and new water operations will boost performance 

Apache  NYSE APA  Banks on Permian Prowess Amid Debt Concerns
Apache s sharp focus on the prolific Permian region  especially Alpine High  is likely to buoy production  However  high leverage of 53  limits the firm s financial flexibility  per the Zacks analyst 

Acquisitions Buoy C H  Robinson  CHRW  Amid Capex Woes
The Zacks analyst appreciates the company s growth by acquisition strategy  which is boosting the top line by expanding its portfolio 

Industrial  Flex Demand Aids PS Business Parks  PSB  Growth
Per the Zacks analyst  PS Business Parks is likely to ride high on the growth curve via demand for flex and industrial real estates and strategic buyouts in core markets 

Marcellus Acres Aids EQT Corp  NYSE EQT   Gathering Expenses Ail
Per the Zacks analyst  EQT Corp s presence in the prolific Marcellus play will support natural gas production growth 

New Upgrades
PACCAR  NASDAQ PCAR  Rides on Rising Demand for Class 8 Trucks
PACCAR s Class 8 truck s retail sales are rising  Per the Zacks analyst  demand for trucks is rising due to strong European economic growth and higher freight activity  

Nasdaq  NDAQ  Continues to Gain from Strategic Buyouts
Per the Zacks analyst  prudent acquisitions  such as the eVestment buyout  will continue to be accretive to Nasdaq s operational performance  thereby resulting in overall growth 

Kohl s  KSS  Top Line Likely to Benefit From Sturdy Comps
Kohl s has been posting positive comps for six straight quarters  Per the Zacks analyst  Kohl s omnichannel efforts  Greatness Agenda strategy and merchandising plans are likely to keep driving comps 

New Downgrades
Competition   Contraction in Margins Hurt Intuitive  ISRG 
Intense competition in the global MedTech space hurts Intuitive Surgical  The Zacks analyst believes contraction in Intuitive Surgical s gross and operating margins in recent times is a concern 

Higher SG A Cost and Softer Demand to Hurt Watsco  WSO 
Per the Zacks analyst  higher SG A cost  due to health related costs and greater technology spending  along with soft demand in Florida and Latin America are hurting Watsco s bottom line 

Hawaiian Holdings  HA  Stung By Capacity   Competition Woes
The Zacks analyst is worried about capacity overexpansion at the company  With Southwest to begin Hawaiian operations from Mar 17  competition is likely to intensify in Hawaiian Holdings  main market ",2019-03-12,Zacks Investment Research,https://www.investing.com/analysis/top-stock-reports-for-visa-honeywell--biogen-200397049,200397049
111856,333371,ISRG,RTI Surgical Buys Paradigm Spine  Adds Coflex To Portfolio,opinion,RTI Surgical Holdings  Inc    NASDAQ RTIX   announced that it has recently closed the deal to acquire Paradigm Spine  LLC  This acquisition  which was initiated back in November 2018  aligns with RTI s goal of expanding its spine portfolio Over the years  RTI has earned a reputation as one of the pioneers in the field of surgical implant procedures  Paradigm Spine happens to be a key market player in motion preservation and non fusion spinal implant technology  with its primary product being the coflex Interlaminar Stabiliization device About the AcquisitionThe acquisition of Paradigm Spine by RTI should enable the latter to invest in differentiated products and build scale within its business  The highlight of this buyout is the integration of the Paradigm Spine s coflex device into RTI s prevailing spine portfolio  which comprises top notch hardware  interbody and biologic options  How Strategic is the Deal Coflex is a differentiated  minimally invasive motion preserving stabilization implant  This device has already received the PMA  Pre Market Approval  by the FDA for the treatment of lumbar spinal stenosis  LSS  combined with decompression  LSS is a highly incapacitating disease  affecting 1 6 million patients every year in the United States Hence  the integration of Paradigm Spine s coflex will enhance RTI s existing spine portfolio  thereby boosting the company s top line  going forward Market ProspectsThe global market for spinal implants and devices is projected to reach a total value of  13 38 billion  progressing at a CAGR of 4 6  during the forecast period of 2015 2022  Considering the abundant market prospects  this acquisition is strategically timed Recent Developments by RTIIn August 2018  RTI announced partnership with Aziyo Biologics for the distribution of ViBone for spine and other orthopedic procedures  Earlier that year  RTI featured next generation spine implant technologies at NSS 2018  Early 2018  RTI also acquired Zyga Technology to integrate the latter s Simmetry Sacroiliac joint fusion system  Further  RTI launched Fortilink  TS and  LIBF systems with TETRAfuse 3D technology The company is gradually strengthening its foothold in the exponentially growing spine surgery market  banking on these product launches and strategic expansions  However  imminent threat is from giant players like Intuitive Surgical Inc   NASDAQ ISRG    Zimmer Biomet Holdings  Inc    NYSE ZBH   and Stryker Corporation   NYSE SYK    RTI needs to constantly introduce or acquire new products to withstand this competitive pressure and maintain its market share Price performanceOver the past year  RTI s shares have rallied 15 5   outperforming the  s growth of 6   Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  wouldn t you like to know about our 10 finest buy and holds for the year  From more than 4 000 companies covered by the Zacks Rank  these 10 were picked by a process that consistently beats the market  Even during 2018 while the market dropped  5 2   our Top 10s were up well into double digits  And during bullish 2012   2017  they soared far above the market s  126 3   reaching  181 9   This year  the portfolio features a player that thrives on volatility  an AI comer  and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs ,2019-03-13,Zacks Investment Research,https://www.investing.com/analysis/rti-surgical-buys-paradigm-spine-adds-coflex-to-portfolio-200397426,200397426
111857,333372,ISRG,Intuitive Surgical Da Vinci SP Gets FDA Nod  Prospects Bright,opinion,Intuitive Surgical  Inc    NASDAQ ISRG   recently announced FDA clearance for the use of da Vinci SP surgical system in certain transoral otolaryngology procedures in adults  Surgeons can now utilize da Vinci SP robotic assisted surgery to conduct radical tonsillectomy and tongue base resection  This fortifies Intuitive Surgical s hold in the global robotic surgery market However  post the announcement  shares of the Zacks Rank  4  Sell  company fell 0 4  to  558 21 at close It is encouraging to note that last month  the FDA granted 510 k  approval to Intuitive Surgical s Ion endoluminal system to enable minimally invasive biopsy in the peripheral lung   Read More   About da Vinci SPCleared for urology procedures by the FDA in 2018  the da Vinci SP system provides surgeons with robotic assisted technology designed for deep and narrow access to tissue in the body  The system includes three  multi jointed  wristed instruments and a fully wristed 3D HD camera Intuitive Surgical shipped 15 da Vinci SP systems in 2018 and a few hundred procedures have been performed to date Robotics Shaping Up MedTechThe use of AI and robotically assisted medical devices has created a revolution  courtesy of rising need for precision in surgeries and a spur in research and development  R D  activities by MedTech companies  Notably  R D activity has been fueled by a 2 3  Medical Device tax suspension made in early 2018 Per a Cision report  the global medical robotic systems market will see a CAGR of 20 5  by 2024 Other key players in the robotic surgery market are Accuray Incorporated   NASDAQ ARAY   and Stryker Corporation   NYSE SYK    Accuray s fully robotic CyberKnife radiosurgery and stereotactic body radiation therapy systems and Stryker s flagship Mako  a robotic arm assisted surgery platform  are currently much in demand Price PerformanceOver the past year  shares of Intuitive Surgical have rallied 30 7  compared with the  s 10 1  gain  The current level is also higher than the S P 500 index s 4 3  rally Key PickA better ranked stock from the broader medical space is Veeva Systems   NYSE VEEV   Veeva Systems  long term earnings growth rate is projected at 14 8   The stock carries a Zacks Rank  2  Buy   You can see  Is Your Investment Advisor Fumbling Your Financial Future See how you can more effectively safeguard your retirement with a new Special Report   4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future  ,2019-03-18,Zacks Investment Research,https://www.investing.com/analysis/intuitive-surgical-da-vinci-sp-gets-fda-nod-prospects-bright-200398667,200398667
111858,333373,ISRG,Intuitive Surgical  ISRG  Reports Next Week  Wall Street Expects Earnings Growth,opinion,"The market expects Intuitive Surgical  NASDAQ ISRG  to deliver a year over year increase in earnings on higher revenues when it reports results for the quarter ended March 2019  This widely known consensus outlook is important in assessing the company s earnings picture  but a powerful factor that might influence its near term stock price is how the actual results compare to these estimates 
The earnings report  which is expected to be released on April 18  2019  might help the stock move higher if these key numbers are better than expectations  On the other hand  if they miss  the stock may move lower 
While the sustainability of the immediate price change and future earnings expectations will mostly depend on management s discussion of business conditions on the earnings call  it s worth handicapping the probability of a positive EPS surprise 
Zacks Consensus Estimate
This robotic surgery system company is expected to post quarterly earnings of  2 70 per share in its upcoming report  which represents a year over year change of  10 7  
Revenues are expected to be  980 40 million  up 15 7  from the year ago quarter 
Estimate Revisions Trend
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days  This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period 
Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts 
Price  Consensus and EPS Surprise

Earnings Whisper
Estimate revisions ahead of a company s earnings release offer clues to the business conditions for the period whose results are coming out  This insight is at the core of our proprietary surprise prediction model    the Zacks Earnings ESP  Expected Surprise Prediction  
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Thus  a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate  However  the model s predictive power is significant for positive ESP readings only 
A positive Earnings ESP is a strong predictor of an earnings beat  particularly when combined with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold   Our research shows that stocks with this combination produce a positive surprise nearly 70  of the time  and a solid Zacks Rank actually increases the predictive power of Earnings ESP 
Please note that a negative Earnings ESP reading is not indicative of an earnings miss  Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and or Zacks Rank of 4  Sell  or 5  Strong Sell  
How Have the Numbers Shaped Up for Intuitive Surgical 
For Intuitive Surgical  the Most Accurate Estimate is higher than the Zacks Consensus Estimate  suggesting that analysts have recently become bullish on the company s earnings prospects  This has resulted in an Earnings ESP of  0 96  
On the other hand  the stock currently carries a Zacks Rank of  4 
So  this combination makes it difficult to conclusively predict that Intuitive Surgical will beat the consensus EPS estimate 
Does Earnings Surprise History Hold Any Clue 
Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings  So  it s worth taking a look at the surprise history for gauging its influence on the upcoming number 
For the last reported quarter  it was expected that Intuitive Surgical would post earnings of  2 99 per share when it actually produced earnings of  2 96  delivering a surprise of  1  
Over the last four quarters  the company has beaten consensus EPS estimates three times 
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower  Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors  Similarly  unforeseen catalysts help a number of stocks gain despite an earnings miss 
That said  betting on stocks that are expected to beat earnings expectations does increase the odds of success  This is why it s worth checking a company s Earnings ESP and Zacks Rank ahead of its quarterly release  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported 
Intuitive Surgical doesn t appear a compelling earnings beat candidate  However  investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release ",2019-04-10,Zacks Investment Research,https://www.investing.com/analysis/intuitive-surgical-isrg-reports-next-week-wall-street-expects-earnings-growth-200405960,200405960
111871,333386,ISRG,Medical Products Industry Outlook  Plenty Of Upside Left,opinion,"The Zacks  industry consists of companies that provide medical products and top notch technologies for diagnosis  observation  consultation  treatment along with other healthcare services  Focus on research and development is a key growth strategy for companies in the space 
The industry serves important therapeutic areas like cardiovascular devices  nephrology and urology devices  ophthalmic devices  neurological devices  dermatological devices  respiratory devices  skin care devices  dental devices  orthopedic devices and gastrointestinal devices 
Here are the three major industry themes AI  Medical Mechatronics   Robotics  The growing prevalence of minimally invasive robot assisted surgeries  self automated home based care  use of IT for quick and improved patient care and shift of the payment system to a value based model indicate the high prevalence of AI in the Medical Products space  Mechatronics   a high end technology incorporating electronics  machine learning and mechanical engineering  also characterizes the industry now  Intuitive Surgical  NASDAQ ISRG   ISRG  is worth a mention when it comes to AI  robotics and medical mechatronics  The company designs  manufactures and markets the da Vinci surgical system   an advanced robot assisted surgical platform  This Mechatronic based platform enables minimally invasive surgery that helps reduce the trauma associated with open surgery  Rampant M As  Of late  there has been a pickup in M A activities in this space  This strategy has been helping dominant Medical Products players to expand customer bases and gain leverage apart from lessening pricing pressure and competition  Of the recent ones  Stryker s SYK  acquisition of K2M Group Holdings deserves a mention  In fact  MedTech behemoth Medtronic  NYSE MDT   MDT  has also taken over Mazor Robotics  an Israel based robotic surgical guidance systems company  to boost its spine surgery business  Emerging Markets Hold Promise  Backed byrising medical awareness and economic prosperity  emerging economies are witnessing solid demand for medical products  Anaging population  relaxed regulations  cheap skilled labor  increasing wealth and government focus on healthcare infrastructure make these markets a happy hunting ground for global medical device players  Zimmer Biomet Holdings  ZBH  has been adopting strategic initiatives to strengthen its foothold in emerging markets that provide long term opportunities  The company s investments in these regions to improve operational and sales performance are yielding results  Following the integration of Biomet  the combined company has started to benefit from its solid presence in emerging markets with an expanded portfolio that includes upper and lower joints Zacks Industry Rank Indicates Bright Prospects
The Zacks Medical Products industry falls within the broader Zacks  sector  It carries a Zacks Industry Rank  83  which places it in the top 33  of more than 250 Zacks industries 
The group s Zacks Industry Rank  which is basically the average of the Zacks Rank of all the member stocks  indicates bright near term prospects  Our research shows that the top 50  of the Zacks ranked industries outperforms the bottom 50  by a factor of more than 2 to 1 
We will present a few stocks that have the potential to outperform the market based on a strong earnings outlook  But it s worth taking a look at the industry s shareholder returns and current valuation first 
Industry s Stock Market Performance 
The industry has outperformed the Zacks S P 500 composite but has lagged its own sector in the past year 
The industry has declined 6 3  over this period compared with the S P 500 s 6 5  fall  However  the broader sector has returned 3 4  in a year s time 
One Year Price Performance

 
Industry s Current Valuation
On the basis of the forward 12 month price to earnings  P E  ratio  which is commonly used for valuing medical stocks  the industry is currently trading at 19 59X compared with the sector s 16 84X and the S P 500 s 16 15X 
Over the past five years  the industry has traded as high as 54 63X  as low as  3 10X  and at the median of 23 00X as the charts show below 
Price to Earnings Forward Twelve Months  F12M 

Price to Earnings Forward Twelve Months  F12M 

 
Bottom Line
Apart from the trends discussed above  a bipartisan two year suspension of a 2 3  excise tax on Medical Products and Medical Device manufacturers at the beginning of 2018 has encouraged massive investments in the sector 
Meanwhile  per a CISION report  the United States remains the largest Medical Products market in the world  raking in more than  180 billion a year owing to rising research and development activities and growing exposure to AI 
Here  we present three stocks that have a Zacks Rank  2  Buy   These stocks are well positioned to grow in the near term  You can see  
Abbott Laboratories  NYSE ABT   ABT 
Abbott s performance in emerging markets has been impressive  We are optimistic about the strong and consistent performance by the company s EPD and Medical Devices segments organically  Meanwhile  the company has been hogging the limelight within the Diabetes Care segment 
Within the Structural Heart unit  worldwide strong demand of MitraClip improves further following the FDA approval of its upgraded version  These apart  synergies from Alere consolidation  in the form of revenues from Rapid Diagnostics  have been driving growth 
The Zacks Consensus Estimate for the company s full year sales is pegged at  31 92 billion  mirroring a 4  rise year over year  The same for adjusted earnings stands at  3 20  reflecting an increase of 11 1  year over year 
The company has returned 10 6  in a year s time 
Price and Consensus   ABT

 
BioLife Solutions  Inc   BLFS 
BioLife s flagship products like CryoStor and HypoThermosol have been raking in huge profits 
Management further stated that the company s proprietary biopreservation media products have been used in multiple customer clinical applications  including dozens of CAR T cell and other T cell immunotherapies targeting blood cancers and solid tumors 
The Zacks Consensus Estimate for the company s full year sales is pegged at  19 8 million  The same for adjusted earnings is pinned at 15 cents  reflecting an increase of 171 4  year over year 
The company has returned 140 3  in a year s time 
Price and Consensus   BLFS

 
Meridian Bioscience Inc   VIVO 
The company s solid focus on R D investment is likely to be beneficial in fiscal 2020 and 2021  Recently  Meridian has also received approval for Novel molecular CMB assay for newborns  In addition  the company established a strategic partnership with the DiaSorin to drive sales of HPSA assay leveraging on DiaSorin liaison instrument 
The Zacks Consensus Estimate for the company s full year sales is pegged at  220 7 million  up 3 3  year over year  The same for adjusted earnings stands at 76 cents  indicating a 2 7  increase year over year 
The company has returned 1 5  in a year s time 
Price and Consensus   VIVO

 
Wall Street s Next Amazon  NASDAQ AMZN 
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2019-01-29,Zacks Investment Research,https://www.investing.com/analysis/medical-products-industry-outlook-plenty-of-upside-left-200380877,200380877
111878,333393,ISRG,The Zacks Analyst Blog Highlights  United Technologies  Lockheed Martin And NextEra Energy,opinion,For Immediate ReleaseChicago  IL   January 31  2019   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include  United Technologies   NYSE UTX    Lockheed Martin   NYSE LMT   and NextEra Energy   NYSE NEE   Here are highlights from Wednesday s Analyst Blog  Top Stock Reports for UTX  Lockheed Martin and NextEraThe Zacks Research Daily presents the best research output of our analyst team  Today s Research Daily features new research reports on 16 major stocks  including United Technologies  Lockheed Martin and NextEra Energy  These research reports have been hand picked from the roughly 70 reports published by our analyst team today You can see Buy rankedUnited Technologies  shares have lost 5 1  over the past three months  underperforming the Zacks Diversified Operations industry  which has declined 1 8  over the same period  However  United Technologies  fourth quarter 2018 earnings and revenues surpassed expectations by a wide margin The Zacks analyst thinks strength in commercial and military aftermarket businesses and impressive contribution from its acquired Rockwell Collins  NYSE COL  business sales will likely continue to boost United Technologies  near term revenues  Also  improved revenues and cost cutting measures are expected to enhance profitability  going forward Backed by these positives  the company has given bullish full year 2019 revenue guidance  Further  the Rockwell Collins buyout is likely to boost sales in 2019  Moreover  separation of the company s existing business will create higher values and customer satisfaction Shares of Lockheed Martin have lost 17 7  in the past year  underperforming the Zacks Aerospace Defense sector  which has declined 8 8  over the same period  Lockheed Martin ended 2018 on a mixed note  While the company s fourth quarter earnings came in line with the Zacks Consensus Estimate  revenues surpassed the consensus mark  Year over year results were impressive The Zacks analyst thinks that being the largest defense contractor in the world  Lockheed enjoys strong demand for its high end military equipment in domestic and international markets  Consequently  strong order growth has been a primary growth driver for this company  The F 35 program continues to be a primary growth driver for the company However  it faces intense competition for its broad portfolio of products and services in both domestic and international markets  It remains subject to interest rate risk related to the issuance of debt  With current U S  economic conditions favoring higher rates  the credit market may not be favorable for Lockheed Martin Buy rankedNextEra Energy s shares have outperformed the Zacks Electric Power industry in the past year  gaining 9 1  vs 3 4   However  NextEra Energy s fourth quarter earnings and total revenues missed expectations  But strong execution of operational and financial plans allowed NextEra Energy to report solid year over year results The Zacks analyst thinks investments to strengthen its infrastructure and ongoing capital projects  on completion  will help in serving the expanding customer base more efficiently  The expansion of business through strategic acquisitions positively impacted earnings The company s nature of business is subject to complex and comprehensive federal  state and other regulations  Substantial investments are undertaken to ensure the safety of nuclear operations  That said  the risk of unplanned outages remains  which could derail its normal operations and impact profitability Other noteworthy reports we are featuring today include NVIDIA  NASDAQ NVDA  and Intuitive Surgical  NASDAQ ISRG  Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  wouldn t you like to know about our 10 finest buy and holds for the year From more than 4 000 companies covered by the Zacks Rank  these 10 were picked by a process that consistently beats the market  Even during 2018 while the market dropped  5 2   our Top 10s were up well into double digits  And during bullish 2012   2017  they soared far above the market s  126 3   reaching  181 9  This year  the portfolio features a player that thrives on volatility  an AI comer  and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs  Media ContactZacks Investment Research800 767 3771 ext  9339  Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit for information about the performance numbers displayed in this press release ,2019-01-31,Zacks Investment Research,https://www.investing.com/analysis/the-zacks-analyst-blog-highlights-united-technologies-lockheed-martin-and-nextera-energy-200381748,200381748
111889,333404,ISRG,Intuitive Surgical Shares March Higher  Can It Continue ,opinion,As of late  it has definitely been a great time to be an investor in Intuitive Surgical  Inc    NASDAQ ISRG    The stock has moved higher by 0 4  in the past month  while it is also above its 20 Day SMA too  This combination of strong price performance and favorable technical  could suggest that the stock may be on the right path We certainly think that this might be the case  particularly if you consider ISRG s recent earnings estimate revision activity  From this look  the company s future is quite favorable  as ISRG has earned itself a Zacks Rank  1  Strong Buy   meaning that its recent run may continue for a bit longer  and that this isn t the top for the in focus company  You can see  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2019-01-17,Zacks Investment Research,https://www.investing.com/analysis/intuitive-surgical-shares-march-higher-can-it-continue-200377018,200377018
111890,333405,ISRG,Ericsson  ERIC  To Report Q4 Earnings  What s In The Cards ,opinion,Ericsson  BS ERICAs    NASDAQ ERIC   is scheduled to report fourth quarter 2018 financial results before the opening bell on Jan 25  In the last reported quarter  the company delivered a positive earnings surprise of 200  The company is likely to report higher revenues in the to be reported quarter on the back of healthy growth dynamics  Whether this can result into an earnings beat remains to be seen Let s find out how things are shaping up prior to the announcement Factors at PlayEricsson conducted 4G LTE trial using 600 MHz of spectrum  together with Agri Valley Services and NewCore Wireless  in the beginning of the fourth quarter  The trial  which took place in Caro  MI  represents the first of its kind with a regional carrier in the United States  The 600 MHz low band spectrum enables operators to extend coverage by utilizing low band radio wave propagation  resulting in more coverage per cell site in rural areas  This is considered to be a major step forward by Ericsson in offering 600 MHz 4G LTE coverage to its rural customers on existing network infrastructure During the fourth quarter  the Swedish firm entered into a strategic partnership with Fujitsu   a leading Japanese information and communication technology company   to deliver 5G network solutions and related services  They jointly aim to develop their combined portfolios  covering radio access and core network  for the 5G market in Japan and connect communications service providers to the global 5G ecosystem  Moreover  Ericsson inked a new deal with Telenor Group   a Norwegian multinational telecommunications company   to transform the latter s core network in Sweden  Denmark and Norway  by deploying Ericsson Cloud Core solutions for 5G across multiple data centers During the quarter  Ericsson was chosen by Volvo Car Group under a five year contract to provide the industrialized Ericsson Connected Vehicle Cloud platform to facilitate the latter s digital vehicle services in more than 120 markets worldwide  Notably  the deal  which would enable Volvo Car Group to provide car owners with its latest developments in connected car digital services  is the largest to date for Ericsson Connected Vehicle Cloud Further  Ericsson was chosen by Swisscom   the largest telecommunications service provider in Switzerland   to augment the latter s customer experience through deployment of the Ericsson Expert Analytics solution into its existing Big Data ecosystem  Ericsson also secured a multi year contract from Millicom s commercial brand   TIGO  Per the deal  Ericsson will work on modernizing TIGO s radio access network across Honduras and Paraguay  involving the rollout of Ericsson Radio System The healthy demand for Ericsson services is likely to translate into higher revenues in the quarter  However  management expects flat business from North America while the rest of the world is likely to deliver normal seasonality  For the fourth quarter  the Zacks Consensus Estimate for total revenues stands at  6 884 million  up from  6 881 million reported in the year earlier quarter  Adjusted earnings per share are pegged at 15 cents  The company incurred a loss of 14 cents a year ago What Our Model SaysOur proven model does not conclusively show that Ericsson is likely to beat earnings this quarter as it does not possess both the two key components  A stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  This is not the case here as you will see below Earnings ESP  Ericsson s Earnings ESP  which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate  is 0 00  as both are pegged at 15 cents  You can uncover the best stocks to buy or sell before they re reported with our  Ericsson Price and EPS Surprise   Zacks Rank  Ericsson currently carries a Zacks Rank  2  which increases the predictive power of ESP  However  the company s 0 00  Earnings ESP makes surprise prediction difficult Note that we caution against stocks with a Zacks Rank  4 or 5  Sell rated  going into the earnings announcement  especially when the company is seeing a negative estimate revisions momentum Stocks to ConsiderHere are some companies that you may want to consider  as our model shows that these have the right combination of elements to post an earnings beat this quarter Meridian Bioscience  Inc    NASDAQ VIVO   has an Earnings ESP of  1 89  and a Zacks Rank  1  You can see  Intuitive Surgical  Inc    NASDAQ ISRG   has an Earnings ESP of  2 63  and a Zacks Rank  2   Alaska Air Group  Inc    NYSE ALK   has an Earnings ESP of  2 23  and a Zacks Rank  2   Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2019-01-21,Zacks Investment Research,https://www.investing.com/analysis/ericsson-eric-to-report-q4-earnings-whats-in-the-cards-200377900,200377900
111891,333406,ISRG,Why Earnings Season Could Be Great For Intuitive Surgical  ISRG ,opinion,Investors are always looking for stocks that are poised to beat at earnings season and Intuitive Surgical  Inc    NASDAQ ISRG   may be one such company  The firm has earnings coming up pretty soon  and events are shaping up quite nicely for their report That is because Intuitive Surgical is seeing favorable earnings estimate revision activity as of late  which is generally a precursor to an earnings beat  After all  analysts raising estimates right before earnings   with the most up to date information possible   is a pretty good indicator of some favorable trends underneath the surface for ISRG in this report In fact  the Most Accurate Estimate for the current quarter is currently at  3 07 per share for ISRG  compared to a broader Zacks Consensus Estimate of  2 99 per share  This suggests that analysts have very recently bumped up their estimates for ISRG  giving the stock a Zacks Earnings ESP of  2 63  heading into earnings season Intuitive Surgical  Inc  Price and EPS Surprise   Why is this Important A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises  and outperforming the market  Our recent 10 year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank  3  Hold  or better show a positive surprise nearly 70  of the time  and have returned over 28  on average in annual returns  see more   Given that ISRG has a Zacks Rank  2  Buy  and an ESP in positive territory  investors might want to consider this stock ahead of earnings  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here Clearly  recent earnings estimate revisions suggest that good things are ahead for Intuitive Surgical  and that a beat might be in the cards for the upcoming report Zacks  Top 10 Stocks for 2019 In addition to the stocks discussed above  wouldn t you like to know about our 10 finest buy and holds for the year From more than 4 000 companies covered by the Zacks Rank  these 10 were picked by a process that consistently beats the market  Even during 2018 while the market dropped  5 2   our Top 10s were up well into double digits  And during bullish 2012   2017  they soared far above the market s  126 3   reaching  181 9  This year  the portfolio features a player that thrives on volatility  an AI comer  and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs ,2019-01-22,Zacks Investment Research,https://www.investing.com/analysis/why-earnings-season-could-be-great-for-intuitive-surgical-isrg-200378244,200378244
111892,333407,ISRG,Can Diagnostic Revenues Fuel PerkinElmer s  PKI  Q4 Earnings ,opinion,"PerkinElmer  Inc    NYSE PKI   is expected to release fourth quarter 2018 results on Jan 31  after market close  The quarterly result should reflect steady growth in the core Diagnostics business  Meanwhile  a raised earnings view for 2018 is encouraging Q3 Results at a GlancePerkinElmer reported third quarter 2018 adjusted earnings per share of 90 cents  which fell short of the Zacks Consensus Estimate by 2 2   However  the bottom line grew 23 3  from the year ago quarter figure Revenues in the quarter came in at  674 3 million  missing the Zacks Consensus Estimate by 0 02  but improved 21 7  on a year over year basis  Adjusted revenues totaled  674 5 million  which increased 21 6  year over year In the trailing four quarters  PerkinElmer delivered average positive earnings surprise of 2 5  Which Way Are Estimates Treading For the quarter to be reported  the Zacks Consensus Estimate for earnings per share is pegged at  1 16  mirroring 19 6  improvement year over year  The same for revenues stands at  746 2 million  reflecting growth of 16 3  year over year Let s see how things are shaping up before the earnings results PerkinElmer  Inc  Price and EPS Surprise
    Diagnostics Revenues  A Key CatalystWe expect PerkinElmer s Diagnostics segment to be the major growth driver for fourth quarter 2018 results  Notably  the company s immunodiagnostics and applied genomics business lines are the key contributors to Diagnostics revenues  Acquisitions of Tulip and Haoyuan should also play a major role  PerkinElmer also provides digital x ray flat panel detectors and infectious disease testing solutions in its Diagnostics portfolio In the last reported quarter  the segment accounted for 38 8  of total revenues  which grew 58 8  on a year over year basis It is encouraging to note that for the fourth quarter  the Zacks Consensus Estimate for the segment s revenues is pinned at  290 million  mirroring 50 3  improvement year over year Other Factors at PlayFourth Quarter GuidanceFor the fourth quarter of 2018  management forecasts reported revenues of  745 million  representing 16  year over year growth  The guidance assumes approximately 5  core organic revenue growth and  102 million sales from EUROIMMUN Earnings is predicted to come in at  1 16  indicating 20  increase on a year over year basis  This forecast includes an additional 4 cent headwind from foreign exchange DAS   A Key ContributorPerkinElmer has been consistently experiencing strong customer uptake of both new imaging and analytical instrumentation in the Discovery   Analytical Solutions  DAS  segment  This trend is likely to continue in the to be reported quarter as well Additionally  the fourth quarter is likely to witness strength in life sciences and applied end markets in DAS  Life sciences strength is likely to be driven by solid performance in the pharma biotech end market  Notably  PerkinElmer s new in vivo imaging products  launched in late 2017  should also bolster the DAS segment s performance in the fourth quarter For investors  notice  DAS accounted for 60 2  of revenues in the last reported quarter  Revenues at this segment totaled  406 2 million  reflecting a 5 4  rise from the year ago quarter  Per management  the segment saw organic growth of 7  in the third quarter For the quarter to be reported  the Zacks Consensus Estimate for the segment s revenues stands at  457 million  reflecting a 2  improvement year over year What Does Our Model Say Per our proven model  a stock needs to have a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  to deliver a positive earnings surprise  This is precisely the case here Earnings ESP  PerkinElmer has an Earnings ESP of  0 77   You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  PerkinElmer carries a Zacks Rank  3 Please note that we caution against stocks with a Zacks Rank  4 or 5  Sell rated  going into the earnings announcement  especially when the company is seeing negative estimate revision Stocks Worth a LookHere are a few medical stocks worth considering as they also have the right combination of elements to post an earnings beat this quarter Intuitive Surgical  Inc    NASDAQ ISRG   has an Earnings ESP of  2 63  and a Zacks Rank  2 Illumina  Inc    NASDAQ ILMN   has an Earnings ESP of  1 83  and a Zacks Rank  3  You can see  DexCom   NASDAQ DXCM   has an Earnings ESP of  0 90  and a Zacks Rank  2 Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  wouldn t you like to know about our 10 finest buy and holds for the year From more than 4 000 companies covered by the Zacks Rank  these 10 were picked by a process that consistently beats the market  Even during 2018 while the market dropped  5 2   our Top 10s were up well into double digits  And during bullish 2012   2017  they soared far above the market s  126 3   reaching  181 9  This year  the portfolio features a player that thrives on volatility  an AI comer  and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs ",2019-01-22,Zacks Investment Research,https://www.investing.com/analysis/can-diagnostic-revenues-fuel-perkinelmers-pki-q4-earnings-200378342,200378342
111895,333410,ISRG,ISRG  RMD Earnings On Jan 24  Here Are The Key Predictions,opinion,The earnings season has seen releases from 55 members of the S P 500 index till Jan 18 Performances of these index participants indicate a 16 9  increase in total earnings on 9  higher revenues  Per the latest   the beat ratio is impressive with 70 9  companies surpassing bottom line expectations and 56 4  outperforming on the top line front The fourth quarter of 2018 is expected to register healthy double digit percentage growth for eight of the 16 Zacks sectors  By the end of the season  earnings of the S P 500 companies  as a whole  are expected to grow 10 7  from the year ago quarter on a 5 3  rise in revenues Earnings Expectations From the Medical Sector   one of the 16 Zacks sectors   is expected to record solid earnings growth this reporting cycle  For the quarter under review  the projected earnings growth rate for the sector is 7 2  on 6 1  revenue growth The MedTech companies  within the broader Medical sector  are likely to put up a superb show this earnings season  Favorable exposure to AI based applications  medical mechatronics  robotics  cloud computing  big data applications  gene editing  DNA sequencing and EHRs have favored the MedTech space  Currently  these companies are benefiting from R D innovation courtesy of the 2 3  Medical Device tax abolition earlier in 2018 However  the U S  MedTech industry has confronted short term hurdles pertaining to the trade war with China  According to a survey conducted by the Medical Imaging   Technology Alliance  MITA   tariffs will cost the MedTech companies nearly  138 million every year What Our Model SaysAccording to the Zacks model  a company with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  has a good chance of beating estimates if it also has a positive   Conversely  Zacks Rank  4  Sell  or 5  Strong Sell  stocks are best avoided  especially if the companies are witnessing negative estimate revisions  You can uncover the best stocks to buy or sell before they re reported with our  Considering the above factors  we take a look at the two MedTech behemoths that are set to release results on Jan 24 Intuitive Surgical Inc   NASDAQ ISRG   expects steady growth at the Instruments and Accessories segment in the fourth quarter of 2018  Revenues from other segments are also likely to bolster the company s performance in the to be reported quarter The Zacks Consensus Estimate for fourth quarter revenues is pinned at  917 million  indicating a year over year increase of 13 8   The same for earnings is pegged at  2 65  reflecting a 4 3  decline year over year  In the trailing four quarters  the company exceeded the consensus mark  the average being 13 2   read more    Our model predicts a positive earnings surprise by Intuitive Surgical this season  This is because the stock has an Earnings ESP of  1 34  and a Zacks Rank  2  You can see  Intuitive Surgical  Inc  Price and EPS Surprise    ResMedInc   NYSE RMD    is expected to gain from a strong performance on the domestic as well as international front in the second quarter of fiscal 2019 For the quarter to be reported  the Zacks Consensus Estimate for earnings is pegged at 93 cents  down 7  year over year  The same for revenues is pinned at  667 1 million  mirroring an increase of 11  year over year The company has a Zacks Rank  3 and an Earnings ESP of 0 00   a combination that hints at slim chances of a beat this reporting cycle ResMed Inc  Price and EPS Surprise    Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  wouldn t you like to know about our 10 finest buy and holds for the year From more than 4 000 companies covered by the Zacks Rank  these 10 were picked by a process that consistently beats the market  Even during 2018 while the market dropped  5 2   our Top 10s were up well into double digits  And during bullish 2012   2017  they soared far above the market s  126 3   reaching  181 9  This year  the portfolio features a player that thrives on volatility  an AI comer  and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs ,2019-01-23,Zacks Investment Research,https://www.investing.com/analysis/isrg-rmd-earnings-on-jan-24-here-are-the-key-predictions-200378292,200378292
111922,333437,ISRG,Intuitive Surgical  ISRG  Up On Solid Preliminary Q4 Results,opinion,"Intuitive Surgical  Inc    NASDAQ ISRG   recently announced preliminary results for fourth quarter 2018  wherein the top line surpassed the Zacks Consensus Estimate Revenues are anticipated to total  1 05 billion  up 17  year over year and well above the Zacks Consensus Estimate of  1 02 billion The company is scheduled to release full financial results on Jan 24 Shares UpIntuitive Surgical s fourth quarter preliminary results boosted its shares  which climbed 3 2  to  517 11 at close  following the announcement Notably  the Zacks Rank  2  Buy  stock rallied 22 7  compared with the  s 0 7  growth in a year s time  The current level also compares favorably with the S P 500 index s 6 7  decline HighlightsPreliminary instrument and accessory revenues increased approximately 18  in fourth quarter 2018 to approximately  539 million  up 17 9  year over year  driven primarily by growth of the da Vinci procedure In the fourth quarter  the company contributed  25 million to establish the Intuitive Foundation to help reduce the global burden of disease and suffering through research  education and philanthropy Intuitive Surgical  Inc  Price and Consensus
    Full Year ResultsOn a full year basis  revenues are expected to be approximately  3 72 billion  marking an increase of approximately 19  from the prior year quarter  The Zacks Consensus Estimate pegs revenues of  3 70 billion Preliminary instrument and accessory revenues for 2018 increased approximately 20  year over year to  1 962 billion  Preliminary service revenues for 2018 increased approximately 11  year over year to  635 million da Vinci UpdateFourth quarter worldwide da Vinci procedures increased approximately 19  from the year ago quarter  Notably  the company shipped 290 da Vinci Surgical Systems in the fourth quarter compared with 216 in the year ago period  Intuitive Surgical expects da Vinci procedures to grow approximately 13 17  in 2019 It is also encouraging to note that in recent times  the China National Health Commission has announced a new quota to allow the sale of 154 new surgical robots into China through 2020  which includes da Vinci Surgical Systems  In late 2018  Intuitive Surgical also obtained clearance for the da Vinci Xi Surgical System in China Moreover  Intuitive Surgical began direct operations for da Vinci products and services in Taiwan in late 2018 Our TakeIntuitive Surgical is set to report a solid fourth quarter performance  Notably  the company s projected top line beats the consensus mark   If Intuitive Surgical manages to outpace the Zacks Consensus Estimate in the fourth quarter  it will mark a consecutive beat since the last reported quarter Flagship da Vinci system is also expected to have put up a solid show in the fourth quarter  Additionally  Intuitive Surgical enjoys a strong presence in China  where it received clearance for the da Vinci Xi Surgical System  Commencement of da Vinci sale in Taiwan also adds to the positives  Management expects strong contributions from da Vinci in 2019  However  the company has not issued any guidance for 2019 Other Key PicksA few other top ranked stocks in the broader medical space are Veeva Systems Inc   NYSE VEEV    Penumbra  Inc    NYSE PEN   and OPKO Health  Inc   NASDAQ OPK    While Veeva Systems and OPKO Health currently sport a Zacks Rank  1  Strong Buy   Penumbra carries a Zacks Rank  2  You can see  Veeva Systems  long term earnings growth rate is projected at 19 5  Penumbra has a long term earnings growth rate of 20  OPKO Health s long term earnings growth rate is projected at 12  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2019-01-10,Zacks Investment Research,https://www.investing.com/analysis/intuitive-surgical-isrg-up-on-solid-preliminary-q4-results-200374321,200374321
111923,333438,ISRG,Why The Earnings Surprise Streak Could Continue For Intuitive Surgical  ISRG ,opinion,"Have you been searching for a stock that might be well positioned to maintain its earnings beat streak in its upcoming report  It is worth considering Intuitive Surgical  NASDAQ ISRG   which belongs to the Zacks Medical   Instruments industry 
When looking at the last two reports  this robotic surgery system company has recorded a strong streak of surpassing earnings estimates  The company has topped estimates by 9 04   on average  in the last two quarters 
For the last reported quarter  Intuitive Surgical came out with earnings of  2 83 per share versus the Zacks Consensus Estimate of  2 65 per share  representing a surprise of 6 79   For the previous quarter  the company was expected to post earnings of  2 48 per share and it actually produced earnings of  2 76 per share  delivering a surprise of 11 29  
Price and EPS Surprise

Thanks in part to this history  there has been a favorable change in earnings estimates for Intuitive Surgical lately  In fact  the Zacks Earnings ESP  Expected Surprise Prediction  for the stock is positive  which is a great indicator of an earnings beat  particularly when combined with its solid Zacks Rank 
Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank  3  Hold  or better produce a positive surprise nearly 70  of the time  In other words  if you have 10 stocks with this combination  the number of stocks that beat the consensus estimate could be as high as seven 
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Intuitive Surgical has an Earnings ESP of  1 34  at the moment  suggesting that analysts have grown bullish on its near term earnings potential  When you combine this positive Earnings ESP with the stock s Zacks Rank  2  Buy   it shows that another beat is possibly around the corner  The company s next earnings report is expected to be released on January 24  2019 
When the Earnings ESP comes up negative  investors should note that this will reduce the predictive power of the metric  But  a negative value is not indicative of a stock s earnings miss 
Many companies end up beating the consensus EPS estimate  though this is not the only reason why their shares gain  Additionally  some stocks may remain stable even if they end up missing the consensus estimate 
Because of this  it s really important to check a company s Earnings ESP ahead of its quarterly release to increase the odds of success  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported ",2019-01-10,Zacks Investment Research,https://www.investing.com/analysis/why-the-earnings-surprise-streak-could-continue-for-intuitive-surgical-isrg-200374856,200374856
111924,333439,ISRG,The Zacks Analyst Blog Highlights  Morgan Stanley  Intuitive Surgical  Colgate Palmolive  Keurig Dr Pepper And Prudential Financial,opinion,For Immediate ReleaseChicago  IL   January 11  2019   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include  Morgan Stanley   NYSE MS    Intuitive Surgical  Inc    NASDAQ ISRG    Colgate Palmolive Company   NYSE CL    Keurig Dr Pepper   NYSE KDP   and Prudential Financial   NYSE PRU   Here are highlights from Thursday s Analyst Blog  Top Research Reports for Morgan Stanley  Intuitive Surgical and Colgate PalmoliveThe Zacks Research Daily presents the best research output of our analyst team  Today s Research Daily features new research reports on 16 major stocks  Morgan Stanley  Intuitive Surgical  Inc  and Colgate Palmolive Company  These research reports have been hand picked from the roughly 70 reports published by our analyst team today You can see Morgan Stanley s shares have lost 12 6  in the last six months  outperforming the Zacks Investment Banking industry  which has lost 16 2  over the same period  The company possesses an impressive earnings surprise history  beating the Zacks Consensus Estimate in each of the trailing four quarters The company s efforts to strengthen wealth management business  focus on corporate lending  steady loan growth  higher interest rates and normalized levels of trading activities will further support revenues  Also  its steady capital deployment plan reflects strong balance sheet position However  a slowdown in debt originations will hamper underwriting fee income growth  Further  mounting operating expenses is a major near term concern for the company  Shares of Buy ranked Intuitive Surgical have gained  2 6  in the last six months  outperforming the Zacks Medical Instruments industry which has lost  4 9  over the same period  The company s robotic platform   da Vinci System   recorded solid growth in recent times  This is led by strong performance in U S  general surgery procedures and global urologic procedures  Management expects strong contributions from da Vinci in 2019 as well  Commencement of da Vinci sale in Taiwan also adds to the positives Management is also optimistic about the company s collaboration with InTouch Health  On the negative side  the company expects outside U S  sales to be a bit lumpy in the quarters ahead  These markets are in early stages of adoption Shares of Colgate Palmolive have underperformed the Zacks Consumer Staples industry over the past three months   1 7  vs   8 1    Colgate is smoothly progressing with its cost savings program  Notably  the Global Growth and Efficiency Program and Funding the Growth initiative are delivering impressive results Management approved an expansion and extension of the program through Dec 31  2019  which will enable it to take advantage of the incremental opportunities while streamlining operations  Further  the company s meet or beat earnings long track record remains impressive It also provided a favorable earnings view for 2018  However  the stock has lagged the industry in the past three months  It has a dismal sales trend  missing estimates in 21 of the last 22 quarters  Management anticipates a tough backdrop due to uncertain global markets and slowing category growth worldwide Other noteworthy reports we are featuring today include Keurig Dr Pepper and Prudential Financial Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look  Media ContactZacks Investment Research800 767 3771 ext  9339  Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ,2019-01-11,Zacks Investment Research,https://www.investing.com/analysis/the-zacks-analyst-blog-highlights-morgan-stanley-intuitive-surgical-colgatepalmolive-keurig-dr-pepper-and-prudential-financial-200374653,200374653
111925,333440,ISRG,Intuitive Surgical  ISRG  Stock Moves  0 52   What You Should Know,opinion,"Intuitive Surgical  NASDAQ ISRG  closed at  502 71 in the latest trading session  marking a  0 52  move from the prior day  This change was narrower than the S P 500 s 0 53  loss on the day  Meanwhile  the Dow lost 0 36   and the Nasdaq  a tech heavy index  lost 0 94  
Prior to today s trading  shares of the robotic surgery system company had lost 1 35  over the past month  This has was narrower than the Medical sector s loss of 3 96  and the S P 500 s loss of 1 47  in that time 
ISRG will be looking to display strength as it nears its next earnings release  which is expected to be January 24  2019  On that day  ISRG is projected to report earnings of  2 98 per share  which would represent year over year growth of 17 32   Meanwhile  our latest consensus estimate is calling for revenue of  1 04 billion  up 16 57  from the prior year quarter 
Investors should also note any recent changes to analyst estimates for ISRG  These recent revisions tend to reflect the evolving nature of short term business trends  As such  positive estimate revisions reflect analyst optimism about the company s business and profitability 
Our research shows that these estimate changes are directly correlated with near term stock prices  Investors can capitalize on this by using the Zacks Rank  This model considers these estimate changes and provides a simple  actionable rating system 
The Zacks Rank system  which ranges from  1  Strong Buy  to  5  Strong Sell   has an impressive outside audited track record of outperformance  with  1 stocks generating an average annual return of  25  since 1988  Within the past 30 days  our consensus EPS projection has moved 0 1  higher  ISRG is currently a Zacks Rank  2  Buy  
Valuation is also important  so investors should note that ISRG has a Forward P E ratio of 40 24 right now  For comparison  its industry has an average Forward P E of 31 37  which means ISRG is trading at a premium to the group 
Meanwhile  ISRG s PEG ratio is currently 2 77  The PEG ratio is similar to the widely used P E ratio  but this metric also takes the company s expected earnings growth rate into account  Medical   Instruments stocks are  on average  holding a PEG ratio of 2 36 based on yesterday s closing prices 
The Medical   Instruments industry is part of the Medical sector  This industry currently has a Zacks Industry Rank of 93  which puts it in the top 37  of all 250  industries 
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
Be sure to follow all of these stock moving metrics  and many more  on Zacks com ",2019-01-14,Zacks Investment Research,https://www.investing.com/analysis/intuitive-surgical-isrg-stock-moves-052-what-you-should-know-200375415,200375415
111926,333441,ISRG,Will Instruments Fuel Intuitive Surgical  ISRG  Q4 Earnings ,opinion,Intuitive Surgical Inc   NASDAQ ISRG   is scheduled to release fourth quarter 2018 results on Jan 24  after market close  The company expects steady growth in the Instruments and Accessories segment Revenues from other segments are likely to bolster the company s performance in the to be reported quarter Third Quarter ResultsIntuitive Surgical reported adjusted earnings of  2 83 per share in the third quarter of 2018  which surpassed the Zacks Consensus Estimate of  2 65  Adjusted earnings improved 1 8  year over year  Revenues amounted to  920 9 million  up 14  from the prior year quarter number  The figure also surpassed the Zacks Consensus Estimate of  918 6 million In the trailing four quarters  the company exceeded the consensus mark  the average being 13 2  Which Way Are Estimates Treading For the fourth quarter  the Zacks Consensus Estimate for revenues is pinned at  917 million  indicating a year over year increase of 13 8   The same for earnings is pegged at  2 65  reflecting a 4 3  decline year over year Let s delve deeper Instruments   Accessories   A Key CatalystThe Instruments and Accessories segment is expected to deliver solid performance in the fourth quarter  Not to forget  the segment performed impressively in the last reported quarter as well  contributing 52 8  to total revenues  Markedly  the flagship da Vinci surgical system continues to be a revenue driver for the segment   In the third quarter  da Vinci procedures grew approximately 21 2  fromyear ago quarter s figure The Zacks Consensus Estimate for Instruments   Accessories fourth quarter revenues in the United States is pegged at  407 million  mirroring a 10 6  rise on a sequential basis Other Factors at PlayPreliminary Results Intuitive Surgicalrecently announced preliminary results for fourth quarter 2018  Revenues are anticipated to total  1 05 billion  up 17  year over year  Preliminary instrument and accessory revenues increased approximately 18  to approximately  539 million  up 17 9  year over year driven primarily by growth of the da Vinci procedure  Moreover  the company contributed  25 million for establishing the Intuitive Foundation to help reduce the global burden of disease and suffering through research  education and philanthropy Fourth quarter worldwide da Vinci procedures increased approximately 19  from the year ago quarter  Notably  the company shipped 290 da Vinci Surgical Systems in the quarter compared with 216 in the year ago period  In 2019  Intuitive Surgical expects da Vinci procedures to grow approximately 13 17  It is also encouraging to note that the China National Health Commission recently announced a new quota to allow the sale of 154 new surgical robots into China through 2020  which includes da Vinci Surgical Systems  Additionally  Intuitive Surgical obtained clearance for the da Vinci Xi Surgical System in China in late 2018 In Taiwan  Intuitive Surgical began direct operations for da Vinci products and services in late 2018 The Services SegmentIntuitive Surgical s fourth quarter results are expected to witness strong contribution from the Services segment as well The Zacks Consensus Estimate for net revenues at this segment is pegged at  168 million  up 5  year over year  In the last reported quarter  Services revenues came in at  160 million  up 2 7  from the year ago quarter s tally For Services revenues in the United States  the consensus mark is pinned at  120 million  reflecting an increase of 7 1  on a sequential basis What Does Our Model Say Per our proven model  a stock needs to have both   a positive and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold    for an earnings beat  This is exactly the case here as you will see below You can see  Earnings ESP  Intuitive Surgical has an Earnings ESP of  1 34   You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Intuitive Surgical carries a Zacks Rank  2 We caution against stocks with a Zacks Rank  4 or 5  Sell rated  going into the earnings announcement  especially when the company is seeing negative estimate revision Intuitive Surgical  Inc  Price and EPS Surprise    Stocks Worth a LookHere are a few medical stocks worth considering as they have the right combination of elements to post an earnings beat this quarter PerkinElmer   NYSE PKI   has an Earnings ESP of  0 77  and a Zacks Rank  3 Baxter International   NYSE BAX   has an Earnings ESP of  1 15  and a Zacks Rank  3 DexCom   NASDAQ DXCM   has an Earnings ESP of  23 03  and a Zacks Rank  2 Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana      Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2019-01-14,Zacks Investment Research,https://www.investing.com/analysis/will-instruments-fuel-intuitive-surgical-isrg-q4-earnings-200375640,200375640
111927,333442,ISRG,5 Great Medical Stocks To Buy Ahead Of Q4 Earnings  ,opinion,In 2018  health care stocks emerged as some of the best performers for the S P 500  which itself closed the year in the red  Looking ahead  multiple headwinds are clouding the market outlook for the year 2019  These include the ongoing trade war with China  the interest rate situation and concerns about an impending global slowdown In the absence of a strong aggressive strategy to boost gains  it is better to adopt a strong defensive tactic to shore up hard won profits  Health care fits the bill perfectly  since it offers defensive growth over the longer term  This is why it is a good idea to pick up select stocks from the sector that are likely to outperform their earnings estimates Most Favored S P 500 Sector of the YearA Reuters review of 13 prominent Wall Street Research firms reveals that health care is the most favored of the S P 500 s 11 major sectors at the start of 2019  These firms issue recommendations about what weight is to be assigned to these groups in investment portfolios Notably  in 2018  health care stocks in the S P 500 gained 4 7   Along with utilities  it was only of the two S P 500 sectors to close 2018 in the green  The benchmark itself lost 6 2  last year A large section of analysts think the sector s attractive valuations  sturdy balance sheets and steady dividends are major factors working in its favor  The group s positive earnings outlook is another major positive even as it remains less vulnerable to cyclical downtrends compared to other sectors When the economy faces a slowdown  most investors avoid sectors that benefit from an upswing  However  they do not want to adopt an ultra defensive stance  Health care fits the bill nicely with its diversified earnings stream  which helps in striking a healthy balance between risk and returns Diversified Earnings Stream Strikes Healthy BalanceThe diverse nature of health care s earnings stream stems from the variety of business under its huge umbrella  The sector s width spans prescription drug makers  medical device manufacturers  medical insurers  hospitals and tool providers for scientific research In simple terms  this means that along with rock steady options  large cap pharma companies  the sector also includes such fast growing categories as biotechs  Sectors such as these offer appreciably higher returns  along with a jump in risk  of course However  earnings and revenue growth for sectors across the board are expected to decelerate appreciably in the fourth quarter  For medical stocks  total Q3 earnings were up 13 2  on 7 6  higher revenues But total Q4 earnings for the sector are expected to be up 7 1  on 6  higher revenues  This represents a considerable decline in pace  but is still better than autos  conglomerates and utilities  Earnings growth for these sectors is set to decline 13 8   13 1  and 6 3   respectively Notably  utilities stocks were among the best performers for the S P 500 last year  The relatively superior earnings prospects of health care stocks bear out their favored status among the broader benchmark s sectors this year  For the S P 500 index as a whole  total Q4 earnings are expected to be up 10 5  from the same period last year on 5 3  higher revenues   Read   Our ChoicesIt comes as no surprise that health care has emerged as a favorable option for investors  The sector continues to offer the prospect of high quality  market beating growth  It is also relatively resistant to the multiple macroeconomic headwinds the economy and equity markets are facing at the moment   is our proprietary methodology for identifying stocks that have high chances of surprising with their next earnings announcement  It shows the percentage difference between the Most Accurate Estimate and the Zacks Consensus Estimate  You can uncover the best stocks to buy or sell before they re reported with our  You could further narrow down the list of choices by looking at stocks that have a favorable Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold   You can see  Our research shows that for stocks with this combination  the chance of a positive earnings surprise is as high as 70  Intuitive Surgical Inc    NASDAQ ISRG   designs  manufactures and markets the da Vinci surgical system and related instruments and accessories  which is an advanced robot assisted surgical system Intuitive Surgical beat the Zacks Consensus Estimate for earnings in the last four consecutive quarters  with an average positive earnings surprise of 13 2  Powered with the right combination of the two key ingredients   an Earnings ESP of  1 34  and a Zacks Rank of 2   our proven model shows that an earnings beat is expected for Intuitive Surgical in the to be reported quarter as well The company is expected to report fourth quarter 2018 results on Jan 24 Illumina  Inc    NASDAQ ILMN   is a life sciences company which provides tools and integrated systems for analysis of genetic variation and function Illumina surpassed the Zacks Consensus Estimate for earnings in the last four consecutive quarters  with an average positive earnings surprise of 27 3  Powered with the right combination of the two key ingredients   an Earnings ESP of  0 90  and a Zacks Rank of 2   our proven model shows that an earnings beat is expected for Illumina in the to be reported quarter as well The company is expected to report fourth quarter 2018 results on Jan 29 HCA Healthcare  Inc    NYSE HCA   is the largest non governmental operator of acute care hospitals in the United States HCA Healthcare beat the Zacks Consensus Estimate for earnings in the last four consecutive quarters  with an average positive earnings surprise of 11 2  Powered with the right combination of the two key ingredients   an Earnings ESP of  2 09  and a Zacks Rank of 1   our proven model shows that an earnings beat is expected for HCA Healthcare in the to be reported quarter The company is expected to report fourth quarter 2018 results on Jan 29 Elanco Animal Health Incorporated   NYSE ELAN   operates as an animal health care company  It develops  manufactures and markets products for companion and food animals Powered with the right combination of the two key ingredients   an Earnings ESP of  2 86  and a Zacks Rank of 2   our proven model shows that an earnings beat is expected for Elanco Animal Health in the to be reported quarter as well The company is expected to report fourth quarter 2018 results on Feb 5 Humana Inc    NYSE HUM   is one of the largest health care plan providers in the United States Humana topped the Zacks Consensus Estimate for earnings in the last four consecutive quarters  with an average positive earnings surprise of 4 7  Powered with the right combination of the two key ingredients   an Earnings ESP of  0 22  and a Zacks Rank of 2   our proven model shows that an earnings beat is expected for Humana in the to be reported quarter as well The company is expected to report fourth quarter 2018 results on Feb 6 Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana      Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2019-01-15,Zacks Investment Research,https://www.investing.com/analysis/5-great-medical-stocks-to-buy-ahead-of-q4-earnings-200375538,200375538
111928,333443,ISRG,The Zacks Analyst Blog Highlights  Intuitive Surgical  Illumina  HCA  Elanco Animal And Humana,opinion,For Immediate ReleaseChicago  IL  January 16  2019   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include  Intuitive Surgical Inc    NASDAQ ISRG    Illumina  Inc    NASDAQ ILMN    HCA Healthcare  Inc    NYSE HCA    Elanco Animal Health Inc    NYSE ELAN   and Humana Inc    NYSE HUM   Here are highlights from Tuesday s Analyst Blog  5 Great Medical Stocks to Buy Ahead of Q4 EarningsIn 2018  health care stocks emerged as some of the best performers for the S P 500  which itself closed the year in the red  Looking ahead  multiple headwinds are clouding the market outlook for the year 2019  These include the ongoing trade war with China  the interest rate situation and concerns about an impending global slowdown In the absence of a strong aggressive strategy to boost gains  it is better to adopt a strong defensive tactic to shore up hard won profits  Health care fits the bill perfectly  since it offers defensive growth over the longer term  This is why it is a good idea to pick up select stocks from the sector that are likely to outperform their earnings estimates Most Favored S P 500 Sector of the YearA Reuters review of 13 prominent Wall Street Research firms reveals that health care is the most favored of the S P 500 s 11 major sectors at the start of 2019  These firms issue recommendations about what weight is to be assigned to these groups in investment portfolios Notably  in 2018  health care stocks in the S P 500 gained 4 7   Along with utilities  it was only of the two S P 500 sectors to close 2018 in the green  The benchmark itself lost 6 2  last year A large section of analysts think the sector s attractive valuations  sturdy balance sheets and steady dividends are major factors working in its favor  The group s positive earnings outlook is another major positive even as it remains less vulnerable to cyclical downtrends compared to other sectors When the economy faces a slowdown  most investors avoid sectors that benefit from an upswing  However  they do not want to adopt an ultra defensive stance  Health care fits the bill nicely with its diversified earnings stream  which helps in striking a healthy balance between risk and returns Diversified Earnings Stream Strikes Healthy BalanceThe diverse nature of health care s earnings stream stems from the variety of business under its huge umbrella  The sector s width spans prescription drug makers  medical device manufacturers  medical insurers  hospitals and tool providers for scientific research In simple terms  this means that along with rock steady options  large cap pharma companies  the sector also includes such fast growing categories as biotechs  Sectors such as these offer appreciably higher returns  along with a jump in risk  of course However  earnings and revenue growth for sectors across the board are expected to decelerate appreciably in the fourth quarter  For medical stocks  total Q3 earnings were up 13 2  on 7 6  higher revenues But total Q4 earnings for the sector are expected to be up 7 1  on 6  higher revenues  This represents a considerable decline in pace  but is still better than autos  conglomerates and utilities  Earnings growth for these sectors is set to decline 13 8   13 1  and 6 3   respectively Notably  utilities stocks were among the best performers for the S P 500 last year  The relatively superior earnings prospects of health care stocks bear out their favored status among the broader benchmark s sectors this year  For the S P 500 index as a whole  total Q4 earnings are expected to be up 10 5  from the same period last year on 5 3  higher revenues   Read   Our ChoicesIt comes as no surprise that health care has emerged as a favorable option for investors  The sector continues to offer the prospect of high quality  market beating growth  It is also relatively resistant to the multiple macroeconomic headwinds the economy and equity markets are facing at the moment   is our proprietary methodology for identifying stocks that have high chances of surprising with their next earnings announcement  It shows the percentage difference between the Most Accurate Estimate and the Zacks Consensus Estimate  You can uncover the best stocks to buy or sell before they re reported with our  You could further narrow down the list of choices by looking at stocks that have a favorable Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold   You can see  Our research shows that for stocks with this combination  the chance of a positive earnings surprise is as high as 70  Intuitive Surgical Inc  designs  manufactures and markets the da Vinci surgical system and related instruments and accessories  which is an advanced robot assisted surgical system Intuitive Surgical beat the Zacks Consensus Estimate for earnings in the last four consecutive quarters  with an average positive earnings surprise of 13 2  Powered with the right combination of the two key ingredients   an Earnings ESP of  1 34  and a Zacks Rank of 2   our proven model shows that an earnings beat is expected for Intuitive Surgical in the to be reported quarter as well The company is expected to report fourth quarter 2018 results on Jan 24 Illumina  Inc  is a life sciences company which provides tools and integrated systems for analysis of genetic variation and function Illumina surpassed the Zacks Consensus Estimate for earnings in the last four consecutive quarters  with an average positive earnings surprise of 27 3  Powered with the right combination of the two key ingredients   an Earnings ESP of  0 90  and a Zacks Rank of 2   our proven model shows that an earnings beat is expected for Illumina in the to be reported quarter as well The company is expected to report fourth quarter 2018 results on Jan 29 HCA Healthcare  Inc  is the largest non governmental operator of acute care hospitals in the United States HCA Healthcare beat the Zacks Consensus Estimate for earnings in the last four consecutive quarters  with an average positive earnings surprise of 11 2  Powered with the right combination of the two key ingredients   an Earnings ESP of  2 09  and a Zacks Rank of 1   our proven model shows that an earnings beat is expected for HCA Healthcare in the to be reported quarter The company is expected to report fourth quarter 2018 results on Jan 29 Elanco Animal Health Inc  operates as an animal health care company  It develops  manufactures and markets products for companion and food animals Powered with the right combination of the two key ingredients   an Earnings ESP of  2 86  and a Zacks Rank of 2   our proven model shows that an earnings beat is expected for Elanco Animal Health in the to be reported quarter as well The company is expected to report fourth quarter 2018 results on Feb 5 Humana Inc  is one of the largest health care plan providers in the United States Humana topped the Zacks Consensus Estimate for earnings in the last four consecutive quarters  with an average positive earnings surprise of 4 7  Powered with the right combination of the two key ingredients   an Earnings ESP of  0 22  and a Zacks Rank of 2   our proven model shows that an earnings beat is expected for Humana in the to be reported quarter as well The company is expected to report fourth quarter 2018 results on Feb 6 Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana      Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look   Media ContactZacks Investment Research800 767 3771 ext  9339  Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ,2019-01-15,Zacks Investment Research,https://www.investing.com/analysis/the-zacks-analyst-blog-highlights-intuitive-surgical-illumina-hca-elanco-animal-and-humana-200376080,200376080
111929,333444,ISRG,What Makes Intuitive Surgical  ISRG  A Strong Momentum Stock  Buy Now ,opinion,"Momentum investing revolves around the idea of following a stock s recent trend in either direction  In the  long  context  investors will be essentially be  buying high  but hoping to sell even higher   With this methodology  taking advantage of trends in a stock s price is key  once a stock establishes a course  it is more than likely to continue moving that way  The goal is that once a stock heads down a fixed path  it will lead to timely and profitable trades 
Even though momentum is a popular stock characteristic  it can be tough to define  Debate surrounding which are the best and worst metrics to focus on is lengthy  but the Zacks Momentum Style Score  part of the Zacks Style Scores  helps address this issue for us 
Below  we take a look at Intuitive Surgical  NASDAQ ISRG   which currently has a Momentum Style Score of A  We also discuss some of the main drivers of the Momentum Style Score  like price change and earnings estimate revisions 
It s also important to note that Style Scores work as a complement to the Zacks Rank  our stock rating system that has an impressive track record of outperformance  Intuitive Surgical currently has a Zacks Rank of  2  Buy   Our research shows that stocks rated Zacks Rank  1  Strong Buy  and  2  Buy  and Style Scores of A or B outperform the market over the following one month period 
You can see the current list of Zacks  1 Rank Stocks here    
Set to Beat the Market 
Let s discuss some of the components of the Momentum Style Score for ISRG that show why this robotic surgery system company shows promise as a solid momentum pick 
A good momentum benchmark for a stock is to look at its short term price activity  as this can reflect both current interest and if buyers or sellers currently have the upper hand  It is also useful to compare a security to its industry  as this can help investors pinpoint the top companies in a particular area 
For ISRG  shares are up 7 13  over the past week while the Zacks Medical   Instruments industry is up 2 36  over the same time period  Shares are looking quite well from a longer time frame too  as the monthly price change of 9 33  compares favorably with the industry s 4 29  performance as well 
Considering longer term price metrics  like performance over the last three months or year  can be advantageous as well  Over the past quarter  shares of Intuitive Surgical have risen 6 79   and are up 19 68  in the last year  In comparison  the S P 500 has only moved  6 46  and  3 85   respectively 
Investors should also pay attention to ISRG s average 20 day trading volume  Volume is a useful item in many ways  and the 20 day average establishes a good price to volume baseline  a rising stock with above average volume is generally a bullish sign  whereas a declining stock on above average volume is typically bearish  ISRG is currently averaging 815 189 shares for the last 20 days 
Earnings Outlook
The Zacks Momentum Style Score also takes into account trends in estimate revisions  in addition to price changes  Please note that estimate revision trends remain at the core of Zacks Rank as well  A nice path here can help show promise  and we have recently been seeing that with ISRG 
Over the past two months  2 earnings estimates moved higher compared to none lower for the full year  These revisions helped boost ISRG s consensus estimate  increasing from  10 97 to  11 01 in the past 60 days  Looking at the next fiscal year  4 estimates have moved upwards while there have been no downward revisions in the same time period 
Bottom Line
Taking into account all of these elements  it should come as no surprise that ISRG is a  2  Buy  stock with a Momentum Score of A  If you ve been searching for a fresh pick that s set to rise in the near term  make sure to keep Intuitive Surgical on your short list ",2019-01-16,Zacks Investment Research,https://www.investing.com/analysis/what-makes-intuitive-surgical-isrg-a-strong-momentum-stock-buy-now-200376763,200376763
111930,333445,ISRG,Intuitive Surgical  ISRG  Earnings Expected To Grow  What To Know Ahead Of Next Week s Release,opinion,"Wall Street expects a year over year increase in earnings on higher revenues when Intuitive Surgical  NASDAQ ISRG  reports results for the quarter ended December 2018  While this widely known consensus outlook is important in gauging the company s earnings picture  a powerful factor that could impact its near term stock price is how the actual results compare to these estimates 
The stock might move higher if these key numbers top expectations in the upcoming earnings report  which is expected to be released on January 24  On the other hand  if they miss  the stock may move lower 
While management s discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations  it s worth having a handicapping insight into the odds of a positive EPS surprise 
Zacks Consensus Estimate
This robotic surgery system company is expected to post quarterly earnings of  2 98 per share in its upcoming report  which represents a year over year change of  17 3  
Revenues are expected to be  1 04 billion  up 16 8  from the year ago quarter 
Estimate Revisions Trend
The consensus EPS estimate for the quarter has been revised 0 64  higher over the last 30 days to the current level  This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period 
Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change 
Price  Consensus and EPS Surprise

Earnings Whisper
Estimate revisions ahead of a company s earnings release offer clues to the business conditions for the period whose results are coming out  Our proprietary surprise prediction model    the Zacks Earnings ESP  Expected Surprise Prediction     has this insight at its core 
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a version of the Zacks Consensus whose definition is subject to change  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Thus  a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate  However  the model s predictive power is significant for positive ESP readings only 
A positive Earnings ESP is a strong predictor of an earnings beat  particularly when combined with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold   Our research shows that stocks with this combination produce a positive surprise nearly 70  of the time  and a solid Zacks Rank actually increases the predictive power of Earnings ESP 
Please note that a negative Earnings ESP reading is not indicative of an earnings miss  Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and or Zacks Rank of 4  Sell  or 5  Strong Sell  
How Have the Numbers Shaped Up for Intuitive Surgical 
For Intuitive Surgical  the Most Accurate Estimate is higher than the Zacks Consensus Estimate  suggesting that analysts have recently become bullish on the company s earnings prospects  This has resulted in an Earnings ESP of  1 34  
On the other hand  the stock currently carries a Zacks Rank of  2 
So  this combination indicates that Intuitive Surgical will most likely beat the consensus EPS estimate 
Does Earnings Surprise History Hold Any Clue 
Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings  So  it s worth taking a look at the surprise history for gauging its influence on the upcoming number 
For the last reported quarter  it was expected that Intuitive Surgical would post earnings of  2 65 per share when it actually produced earnings of  2 83  delivering a surprise of  6 79  
Over the last four quarters  the company has beaten consensus EPS estimates four times 
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower  Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors  Similarly  unforeseen catalysts help a number of stocks gain despite an earnings miss 
That said  betting on stocks that are expected to beat earnings expectations does increase the odds of success  This is why it s worth checking a company s Earnings ESP and Zacks Rank ahead of its quarterly release  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported 
Intuitive Surgical appears a compelling earnings beat candidate  However  investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release ",2019-01-16,Zacks Investment Research,https://www.investing.com/analysis/intuitive-surgical-isrg-earnings-expected-to-grow-what-to-know-ahead-of-next-weeks-release-200376695,200376695
111962,333477,ISRG,4 Stocks To Watch  RUN  VSLR  MED PII ,opinion,"Sunrun Inc  NASDAQ RUN  is yet another solar stock  that not only broke out through the declining topsline on Tuesday  but lateral resistance at the very bottom  jumping 1 08  or 8 29   to 14 11  on 3 3 million shares  It needs to get to 14 14 45  and then it may make a run to 16 1 4 
Vivint Solar Inc  NYSE VSLR  broke out on Monday  and followed through on Tuesday  popping 52 cents  or 8   to 7 00  on 2 4 million shares  It had a nice run to a double top  no less  I m looking for a move to about the 8 1 4 1 2 area  If it gets through that  we re looking at 10 10 1 2 
Stocks on the Short Side  
MEDIFAST INC  NYSE MED  was down another 5 86  or 4   to 143 27  on 354 114 shares traded on Tuesday  That was the lowest close in seven months  It looks like it s in falling mode  and appears to be headed to 115  and probably at some point lower than that 
Polaris Industries Inc  NYSE PII  which I put a swing on Tuesday  continues to fall  dropped 2 12  or 2   to 95 38  on 368 804 shares traded  I like the looks of the break down  flag  and then the break down  wedge  The next target is around 78 80 
Stocks on the long side included Advanced Micro Devices  Inc   NASDAQ AMD   Sphere 3D Corp   ANY   Darling Ingredients Inc   DAR   Frontline Ltd   FRO   First Solar  Inc   NASDAQ FSLR   Houghton Mifflin Harcourt Company  HMHC   Intelsat S A   I   JinkoSolar Holding Co   Ltd   JKS   Maxim Integrated Products  Inc   NASDAQ MXIM   Natural Grocers by Vitamin Cottage  Inc   NGVC   Renewable Energy Group  Inc   REGI   Sunrun Inc   RUN   Spirit Airlines  Inc   SAVE   Tesaro  Inc   TSRO   and Vivint Solar  Inc   VSLR  
On the short side  stocks included Axon Enterprise  Inc   AAXN   Editas Medicine  Inc   EDIT   IntriCon Corporation  IIN   Intuitive Surgical  Inc   NASDAQ ISRG   Medifast  Inc   MED   Polaris Industries Inc   PII   PVH Corp   NYSE PVH   and Vicor Corporation  VICR  
Watch video here ",2018-11-27,Harry Boxer,https://www.investing.com/analysis/run-vslr-med-pii-200362909,200362909
111963,333478,ISRG,Intuitive Surgical  ISRG  Stock Moves  0 18   What You Should Know,opinion,"Intuitive Surgical  NASDAQ ISRG  closed the most recent trading day at  520 97  moving  0 18  from the previous trading session  This move was narrower than the S P 500 s daily loss of 0 22   Elsewhere  the Dow lost 0 11   while the tech heavy Nasdaq lost 0 25  
Heading into today  shares of the robotic surgery system company had gained 0 14  over the past month  lagging the Medical sector s gain of 6 05  and the S P 500 s gain of 3 57  in that time 
ISRG will be looking to display strength as it nears its next earnings release  which is expected to be January 24  2019  On that day  ISRG is projected to report earnings of  2 96 per share  which would represent year over year growth of 16 54   Our most recent consensus estimate is calling for quarterly revenue of  1 02 billion  up 14 49  from the year ago period 
Looking at the full year  our Zacks Consensus Estimates suggest analysts are expecting earnings of  10 97 per share and revenue of  3 70 billion  These totals would mark changes of  22 02  and  18 23   respectively  from last year 
Any recent changes to analyst estimates for ISRG should also be noted by investors  These recent revisions tend to reflect the evolving nature of short term business trends  As such  positive estimate revisions reflect analyst optimism about the company s business and profitability 
Based on our research  we believe these estimate revisions are directly related to near team stock moves  Investors can capitalize on this by using the Zacks Rank  This model considers these estimate changes and provides a simple  actionable rating system 
The Zacks Rank system  which ranges from  1  Strong Buy  to  5  Strong Sell   has an impressive outside audited track record of outperformance  with  1 stocks generating an average annual return of  25  since 1988  Within the past 30 days  our consensus EPS projection remained stagnant  ISRG currently has a Zacks Rank of  3  Hold  
Looking at its valuation  ISRG is holding a Forward P E ratio of 47 58  This valuation marks a premium compared to its industry s average Forward P E of 33 94 
Investors should also note that ISRG has a PEG ratio of 3 28 right now  The PEG ratio is similar to the widely used P E ratio  but this metric also takes the company s expected earnings growth rate into account  Medical   Instruments stocks are  on average  holding a PEG ratio of 2 42 based on yesterday s closing prices 
The Medical   Instruments industry is part of the Medical sector  This group has a Zacks Industry Rank of 71  putting it in the top 28  of all 250  industries 
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
You can find more information on all of these metrics  and much more  on Zacks com ",2018-11-29,Zacks Investment Research,https://www.investing.com/analysis/intuitive-surgical-isrg-stock-moves-018-what-you-should-know-200363742,200363742
111964,333479,ISRG,Has Intuitive Surgical  ISRG  Outpaced Other Medical Stocks This Year ,opinion,"Investors interested in Medical stocks should always be looking to find the best performing companies in the group  Has Intuitive Surgical  NASDAQ ISRG  been one of those stocks this year  Let s take a closer look at the stock s year to date performance to find out 
Intuitive Surgical is a member of the Medical sector  This group includes 840 individual stocks and currently holds a Zacks Sector Rank of  2  The Zacks Sector Rank considers 16 different sector groups  The average Zacks Rank of the individual stocks within the groups is measured  and the sectors are listed from best to worst 
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions  highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months  ISRG is currently sporting a Zacks Rank of  2  Buy  
The Zacks Consensus Estimate for ISRG s full year earnings has moved 2 25  higher within the past quarter  This is a sign of improving analyst sentiment and a positive earnings outlook trend 
Based on the most recent data  ISRG has returned 26 01  so far this year  At the same time  Medical stocks have lost an average of 5 81   As we can see  Intuitive Surgical is performing better than its sector in the calendar year 
To break things down more  ISRG belongs to the Medical   Instruments industry  a group that includes 93 individual companies and currently sits at  63 in the Zacks Industry Rank  This group has gained an average of 4 17  so far this year  so ISRG is performing better in this area 
ISRG will likely be looking to continue its solid performance  so investors interested in Medical stocks should continue to pay close attention to the company ",2018-12-20,Zacks Investment Research,https://www.investing.com/analysis/has-intuitive-surgical-isrg-outpaced-other-medical-stocks-this-year-200370241,200370241
111966,333481,ISRG,Here s Why You Should Buy Intuitive Surgical  ISRG  Now,opinion,"Intuitive Surgical  Inc    NASDAQ ISRG   is one of the top performing stocks in the MedTech space now  A solid outlook for 2018 and strength in robotics currently favor the stock Price PerformanceIn a year s time  shares of Intuitive Surgical have rallied 27  compared with the  s 1 8  growth  The current level also compares favorably with the S P 500 index s decline of 8  The stock currently carries a Zacks Rank  2  Buy  What Makes the Stock an Attractive Pick Bullish OutlookIntuitive Surgical forecasts 2018 procedure growth in the range of 17 18   up from 14 5 16 5  projected earlier For 2018  the company expects adjusted gross profit margin in the band of 70 5 71 5  of net revenues Operating expenses are anticipated to rise 15 5 17  compared with 16 18  estimated earlier Strength in RoboticsIntuitive Surgical s robot based da Vinci surgical system enables minimally invasive surgery that reduces the trauma associated with open surgery and has consistently driven the company s top line  The da Vinci System is powered by robotic technology which has provided the company with solid exposure to medical mechatronics  robotics and Artificial Intelligence for healthcare In the last reported quarter  da Vinci procedures increased approximately 20  from the year ago quarter  Notably  mature procedure growth in the United States includes prostatectomy and hysterectomy  In Japan  procedures grew above 40  year over year  However  European procedure performance has been in line with solid strength in the United Kingdom Intuitive Surgical  Inc  Price and Consensus
    Which Way Are Estimates Treading For the fourth quarter  the Zacks Consensus Estimate for earnings is pegged at  2 96  reflecting year over year growth of 16 5   The same for revenues stands at  1 02 billion  mirroring a 14 5  improvement year over year For 2018  the Zacks Consensus Estimate for earnings is pinned at  10 97  reflecting 22  growth from the previous year number  The same for revenues is pegged at  3 7 billion  indicating a rise of 18 2  Other Key PicksOther top ranked stocks in the broader medical space are Veeva Systems Inc    NYSE VEEV    Integer Holdings Corporation   NYSE ITGR   and OPKO Health  Inc    NASDAQ OPK   Veeva Systems  long term earnings growth rate is projected at 19 5   The stock currently flaunts a Zacks Rank  1  Strong Buy   You can see  Integer projects earnings growth rate of 31 2  for the fourth quarter  It currently carries a Zacks Rank  1 OPKO Health s long term earnings growth rate is projected at 12   The stock presently sports a Zacks Rank of 2  Buy  Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ",2018-12-27,Zacks Investment Research,https://www.investing.com/analysis/heres-why-you-should-buy-intuitive-surgical-isrg-now-200371556,200371556
111967,333482,ISRG,Intuitive Surgical  ISRG  Outpaces Stock Market Gains  What You Should Know,opinion,"Intuitive Surgical  NASDAQ ISRG  closed the most recent trading day at  478 44  moving  1 43  from the previous trading session  The stock outpaced the S P 500 s daily gain of 0 7   Elsewhere  the Dow gained 0 42   while the tech heavy Nasdaq added 1 26  
Heading into today  shares of the robotic surgery system company had lost 9 13  over the past month  lagging the Medical sector s loss of 6 76  and the S P 500 s loss of 6 13  in that time 
ISRG will be looking to display strength as it nears its next earnings release  which is expected to be January 24  2019  On that day  ISRG is projected to report earnings of  2 97 per share  which would represent year over year growth of 16 93   Meanwhile  the Zacks Consensus Estimate for revenue is projecting net sales of  1 02 billion  up 14 48  from the year ago period 
Investors might also notice recent changes to analyst estimates for ISRG  These recent revisions tend to reflect the evolving nature of short term business trends  As such  positive estimate revisions reflect analyst optimism about the company s business and profitability 
Our research shows that these estimate changes are directly correlated with near term stock prices  We developed the Zacks Rank to capitalize on this phenomenon  Our system takes these estimate changes into account and delivers a clear  actionable rating model 
The Zacks Rank system  which ranges from  1  Strong Buy  to  5  Strong Sell   has an impressive outside audited track record of outperformance  with  1 stocks generating an average annual return of  25  since 1988  Over the past month  the Zacks Consensus EPS estimate remained stagnant  ISRG is currently sporting a Zacks Rank of  3  Hold  
Investors should also note ISRG s current valuation metrics  including its Forward P E ratio of 37 57  Its industry sports an average Forward P E of 29 77  so we one might conclude that ISRG is trading at a premium comparatively 
Investors should also note that ISRG has a PEG ratio of 2 59 right now  This popular metric is similar to the widely known P E ratio  with the difference being that the PEG ratio also takes into account the company s expected earnings growth rate  ISRG s industry had an average PEG ratio of 2 27 as of yesterday s close 
The Medical   Instruments industry is part of the Medical sector  This industry currently has a Zacks Industry Rank of 95  which puts it in the top 38  of all 250  industries 
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
Be sure to follow all of these stock moving metrics  and many more  on Zacks com ",2019-01-07,Zacks Investment Research,https://www.investing.com/analysis/intuitive-surgical-isrg-outpaces-stock-market-gains-what-you-should-know-200373441,200373441
111982,333497,ISRG,DexCom  DXCM  Beats Q3 Earnings Estimates  Raises  18 View,opinion,"DexCom  Inc    NASDAQ DXCM    reported adjusted earnings of 17 cents per share in the third quarter of 2018  beating the Zacks Consensus Estimate of a loss of 12 cents  Also  the figure improved from a loss of 4 cents in the year ago quarter The stock sports a Zacks Rank  1  Strong Buy  Total revenues rallied 44 5  to  266 7 million on a year over year basis  The figure surpassed the Zacks Consensus Estimate of  242 million DexCom  Inc  Price and Consensus
    Segmental DetailsRevenues in the Sensor segment  73  of total revenues  surged 47  on a year over year basis to  194 million  Transmitter revenues  18   increased 27  year over year to  48 5 million  Receiver revenues  9   rallied 68  year over year to  24 2 million Geographical DetailsU S  revenues  76  of total revenues  surged 34  on a year over year basis to  202 4 million  International revenues  24   rocketed 93  year over year to  64 3 millionOperational Details Gross Profit in the quarter totaled  168 6 million  up 32 8  year over year DexCom generated gross margin  as a percentage of revenues  of 63 2   which contracted 560 basis points  bps  year over year  Margins were under pressure due to an inventory change as well as shift toward OUS and Medicare Research and development  R D  expenses totaled  50 1 million in the quarter  up 15 7  year over year  Selling  general and administrative expenses totaled  104 6 million in the reported quarter  up 24 2  year over year The company reported net operating expenses of  154 7 million  up 21  year over year  As a percentage of revenues  DexCom generated operating margin of 5 2  in the third quarter GuidanceDexCom raised 2018 guidance The company expects revenues of  975 million  up from the previous projection of  925 million  Meanwhile  the Zacks Consensus Estimate for revenues is currently pegged at  967 4 million  which is significantly lower than the guidance Reported operating expenses  excluding investments in non intensive programs  are expected to increase 18  from 2017 level  The estimate is significantly higher than the previous forecast of 14  However  gross profit margin is projected to be 64   in line with the prior guidance Wrapping UpDexCom exited the third quarter on a strong note  beating the Zacks Consensus Estimate for earnings and revenues  Impressive contributions from the Sensor  Transmitter and Receiver segments are key catalysts  A raised guidance instills investors  optimism  The glucose monitoring market presents significant commercial opportunity for DexCom  The company s opportunities in alternative markets such as the non intensive diabetes management space  the hospital  gestational  pre diabetes and obesity are likely to provide it a competitive edge in the MedTech space On the flip side  cutthroat competition in the market for blood   glucose monitoring devices is a headwind  We believe that the company s margins will continue to remain under pressure in the upcoming quarters  thanks to high product development costs and rising expenditures on the R D front  Lower expected margins on transmitter sales are add to the concerns Q3 Earnings of MedTech Majors at a GlanceOther top ranked stocks from the broader Medical space that delivered robust results this earnings season are Intuitive Surgical   NASDAQ ISRG    Stryker Corporation   NYSE SYK   and Merit Medical Systems  Inc   NASDAQ MMSI    Notably  each of the stocks carry a Zacks Rank  2  Buy   You can see  Intuitive Surgical reported third quarter 2018 adjusted earnings per share  EPS  of  2 83  which beat the Zacks Consensus Estimate of  2 65  Revenues totaled  920 9 million  which outpaced the consensus mark of  918 6 million Stryker posted third quarter 2018 adjusted EPS of  1 69  which outpaced the Zacks Consensus Estimate by a penny  Operating margin was 17 8   up 30 bps Merit Medical reported third quarter 2018 adjusted EPS of 47 cents  which trumped the Zacks Consensus Estimate of 42 cents  Revenues of  221 6 million edged past the consensus mark of  218 million 
The Hottest Tech Mega Trend of All
Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce   the world s first trillionaires    but that should still leave plenty of money for regular investors who make the right trades early ",2018-11-13,Zacks Investment Research,https://www.investing.com/analysis/dexcom-dxcm-beats-q3-earnings-estimates-raises-18-view-200358576,200358576
111983,333498,ISRG,Looking For A Growth Stock  Why It Is Time To Focus On Intuitive Surgical  ISRG ,opinion,Growth stocks can be some of the most exciting picks in the market  as these high flyers can captivate investors  attention  and produce big gains as well  However  they can also lead on the downside when the growth story is over  so it is important to find companies which are still seeing strong growth prospects in their businesses One such company that might be well positioned for future earnings growth is Intuitive Surgical  Inc    NASDAQ ISRG    This firm  which is in the Medical   Instruments industry  saw EPS growth of 20 6  last year  and is looking great for this year too In fact  the current growth estimate for this year calls for earnings per share growth of 22   Furthermore  the long term growth rate is currently an impressive 15 6   suggesting pretty good prospects for the long haul Intuitive Surgical  Inc  Price and Consensus   And if this wasn t enough  the stock has actually seen estimates rise over the past month for the current fiscal year by about 1 9   Thanks to this rise in earnings estimates  ISRG has a Zacks Rank  2  Buy  which further underscores the potential for outperformance in this company  You can see  So  if you are looking for a fast growing stock that is still seeing plenty of opportunities on the horizon  make sure to consider ISRG  Not only does it have double digit earnings growth prospects  but its impressive Zacks Rank suggests that analysts believe better days are ahead for ISRG as well 3 Medical Stocks to Buy NowThe greatest discovery in this century of biology is now at the flashpoint between theory and realization  Billions of dollars in research have poured into it  Companies are already generating revenue  and cures for a variety of deadly diseases are in the pipeline So are big potential profits for early investors  Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it ,2018-11-13,Zacks Investment Research,https://www.investing.com/analysis/looking-for-a-growth-stock-why-it-is-time-to-focus-on-intuitive-surgical-isrg-200359107,200359107
111984,333499,ISRG,GNC Holdings  GNC  Q3 Earnings Miss On Soft U S  Retail,opinion,GNC Holdings  Inc    NYSE GNC   reported third quarter 2018 adjusted earnings per share  EPS  of 2 cents  reflecting a 93 8  year over year plunge  Adjusted EPS also missed the Zacks Consensus Estimate of 4 cents  A significant year over year decline in revenues along with escalating costs impedes the bottom line growth in the reported quarter RevenuesRevenues in the quarter under review declined 5 4  year over year to  580 2 million  Excluding the contribution from Lucky Vitamin  sold in September 2017   which is reflected in the year ago quarter s tally  revenues slipped 2  year over year due to lower sales associated with certain store closures at the end of the respective lease term  Notably  this is a component of the company s store portfolio optimization strategy However  the quarterly revenues exceeded the Zacks Consensus Estimate of  575 million Same store sales slid 2 1  in domestic company owned stores  including GNC com sales  in the quarter under discussion  In domestic franchise locations  same store sales dipped 4 1  Segmental DetailsGNC Holdings reports operations under three segments  U S    Canada  including company owned stores in the United States  Puerto Rico and Canada  franchise stores in the United States and e commerce   International  inclusive of franchise locations in approximately 50 countries  The Health Store and China operations  and Manufacturing Wholesale  comprising manufactured products sold to other segments  third party contract manufacturing and sales to wholesale partners  GNC Holdings  Inc  Price  Consensus and EPS Surprise   During the reported quarter  GNC Holdings  revenues from the U S    Canada segment fell 3 2  to  476 5 million  E commerce sales accounted for 7 2  of U S  and Canada revenues  mirroring a 1  increase year over year In domestic franchise locations  revenues dropped  3 6 million due to soft retail same store sales  partially offset by a  7 5 million rise relating to the company s loyalty programs  PRO Access paid membership fees and the myGNC Rewards change in deferred points liability Revenues at the International segment grew 6 1  to  51 4 million  driven by solid sales at the company s international franchisees Revenues at the Manufacturing Wholesale segment  excluding intersegment revenues  were up 1 9  to  52 3 million owing to higher third party contract manufacturing sales  However  Intersegment sales rose  5 7 million  courtesy of the company s raised focus on proprietary products  MarginGross profit declined 8 2  in the third quarter to  184 7 million  Gross margin contracted 100 basis points  bps  to 31 8  Selling  general and administrative expenses slid 3 9  to  149 9 million  Accordingly  adjusted operating margin declined 138 bps to 5 9  Financial PositionGNC Holdings exited third quarter 2018 with cash and cash equivalents of  33 3 million  down from  43 4 million at the end of the second quarter  Long term debt was  1 04 billion in the quarter under consideration compared with  1 05 billion at second quarter end  Year to date  net cash flow from operating activities totaled  55 7 million compared with  149 6 million a year ago Further  the company generated free cash flow of  60 6 million compared with  124 8 million in the prior year period Our Take        GNC Holdings exited the third quarter of 2018 on a mixed note with earnings lagging the Zacks Consensus Estimate and revenues exceeding the mark  The year over year lower than expected adjusted earnings and revenues are dampening  While domestic retail comps were soft  GNC registered a strong performance in e commerce business as well as at International segment In fact  GNC Holdings is pulling out all the stops to strengthen its international presence  In this regard  the company s plan is well in place to expand its footprint in China and India and also to enter the Australian market with strategies to leverage its alternative channels of distribution Zacks Rank   Key PicksGNC Holdings has a Zacks Rank  3  Hold   A few better ranked stocks in the broader medical space  which reported solid earnings this season  are Intuitive Surgical   NASDAQ ISRG    Stryker Corporation   NYSE SYK   and Merit Medical Systems  Inc    NASDAQ MMSI    All the stocks carry a Zacks Rank  2  Buy   You can see  Intuitive Surgical reported third quarter 2018 adjusted EPS of  2 83  which beat the Zacks Consensus Estimate of  2 65  Revenues totaled  920 9 million  also surpassing the consensus estimate of  918 6 million Stryker posted third quarter 2018 adjusted EPS of  1 69  outpacing the Zacks Consensus Estimate of  1 68  Operating margin was 17 8   up 30 bps Merit Medical reported third quarter 2018 adjusted EPS of 47 cents  which trumped the Zacks Consensus Estimate of 42 cents  Revenues of  221 6 million edged past the consensus estimate of  218 million 3 Medical Stocks to Buy NowThe greatest discovery in this century of biology is now at the flashpoint between theory and realization  Billions of dollars in research have poured into it  Companies are already generating revenue  and cures for a variety of deadly diseases are in the pipeline So are big potential profits for early investors  Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it ,2018-11-13,Zacks Investment Research,https://www.investing.com/analysis/gnc-holdings-gnc-q3-earnings-miss-on-soft-us-retail-200359208,200359208
111985,333500,ISRG,4 Stocks To Watch Today  AXGN  EDIT  ISRG  MED,opinion,"Stocks on the Short Side   
Axogen Inc  NASDAQ AXGN  broke a wedge this week  and it looks like it s coming down hard  dropping 1 11  or 3 34   to 32 17  on 360 219 shares traded on Wednesday  Should it break underneath support at 31  potentially  we re looking at 29 range short term 
Editas Medicine Inc  NASDAQ EDIT  is also backing off resistance at the declining topsline  dropping 2 09  or 7   to 26 90  on 648 815 shares traded on Wednesday  It seems to be headed down to the low 20 s 
Intuitive Surgical  Inc   NASDAQ ISRG  has rolled over the last five sessions  it snapped back to resistance  and came down pretty hard  It closed on the gap on Wednesday  dropping another 4 80  or 1   to 498 64  on shares traded  The bottom line to test now is 470 00  455 00  and eventually 430 00 
MEDIFAST INC  NYSE MED  broke down hard in a beautiful bear wedge  dropping another 5 58  or 3 44   to 156 47  on 209 456 shares traded on Wednesday  I have to put a swing on this one because it looks like it s going to 115 00 
Stocks on the long side included Advanced Micro Devices  Inc   NASDAQ AMD   Covia Holdings Corporation  CVIA   Canada Goose Holdings Inc   GOOS   Hutchison China MediTech Limited  HCM   Imprimis Pharmaceuticals  Inc   IMMY   Kornit Digital Ltd   KRNT   Micro Focus International plc  MFGP    MACOM Technology Solutions  MTSI   Qiwi plc  QIWI   VelocityShares 3x Long Natural Gas ETN  UGAZ   and United States Natural Gas  UNG  
On the short side  stocks included Axon Enterprise  Inc   AAXN   AxoGen  Inc   AXGN   BlackLine  Inc   BL   CRISPR Therapeutics AG  CRSP   Editas Medicine  Inc   EDIT   Guidewire Software  Inc   GWRE   IntriCon Corporation  IIN   IRadimed Corporation  IRMD   Intuitive Surgical  Inc   ISRG   Medifast  Inc   MED   MGP Ingredients  Inc   MGPI   PTC Inc   PTC   Qualys  Inc   QLYS   SiteOne Landscape Supply  Inc   SITE   Vicor Corporation  VICR   Wayfair Inc   W   and Wix com Ltd   WIX  
Watch video here ",2018-11-14,Harry Boxer,https://www.investing.com/analysis/axgn-edit-isrg-med-200359363,200359363
111986,333501,ISRG,Intuitive Surgical  ISRG  Down 0 7  Since Last Earnings Report  Can It Rebound ,opinion,"It has been about a month since the last earnings report for Intuitive Surgical  NASDAQ ISRG   Shares have lost about 0 7  in that time frame  outperforming the S P 500 
Will the recent negative trend continue leading up to its next earnings release  or is Intuitive Surgical due for a breakout  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important catalysts  Intuitive Surgical Q3 Earnings Beat  da Vinci Drives GrowthIntuitive Surgical reported adjusted earnings of  2 83 per share in the third quarter of 2018  which beat the Zacks Consensus Estimate of  2 65  Adjusted earnings improved 1 8  year over year Revenues totaled  920 9 million  up 14  from the prior year quarter  The figure also surpassed the Zacks Consensus Estimate of  918 6 million  The upside was backed by higher worldwide da Vinci procedures led by growth in U S  general surgery procedures and global urologic procedures Segment DetailsInstruments   AccessoriesRevenues in the segment came in at  486 3 million  which reflects year over year increase of 21 2   The uptick in instrument accessory revenues was primarily driven by procedure growth and favorable customer buying pattern SystemsIn the reported quarter  System revenues increased 4 8  year over year to  274 6 million  Notably  231 da Vinci Surgical systems were shipped by the company compared with 169 in the third quarter of 2017 In the quarter under review  shipments included 58 systems under operating lease arrangements compared with 20 in the year ago quarter ServicesServices revenues came in at  160  up 2 7  from the year ago quarter International Sales UpOutside the United States  revenues totaled  244 million  up 15  on a year over year basis  The upside can be attributed to an increase in instruments and accessories revenues of  30 million Outside of the United States  Intuitive Surgical placed 75 systems in the reported quarter compared with 62 in the third quarter of 2017  This included 30 into Europe and 30 into Japan  X systems comprised 36 of the 75 systems placed in the third quarter MarginsGross profit in the reported quarter was  642 3 million  up 13 1  year over year  As a percentage of revenues  gross margin contracted 63 basis points  bps  to 69 7  in the quarter  The downside primarily indicates lower system ASPs and unfavorable revenue mix OutlookFor 2018  Intuitive Surgical continues to expect adjusted gross profit margin in the range of 70 5 71 5  compared with the previous guidance of 70 71 5  of net revenues Intuitive Surgical expects operating expense growth between 15 5  and 17  compared with the previously guided range of 16  and 18  Management at Intuitive Surgical expects non cash stock compensation expenses between  255 million and  260 million compared with the previous guidance of  245 million and  255 million Intuitive Surgical forecasts 2018 procedure growth in the range of 17 18   up from the previous band of 14 5 16 5  
How Have Estimates Been Moving Since Then 
Fresh estimates followed an upward path over the past two months 
VGM Scores
At this time  Intuitive Surgical has a subpar Growth Score of D  however its Momentum Score is doing a bit better with a C  Charting a somewhat similar path  the stock was allocated a grade of D on the value side  putting it in the bottom 40  for this investment strategy 
Overall  the stock has an aggregate VGM Score of D  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Intuitive Surgical has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2018-11-16,Zacks Investment Research,https://www.investing.com/analysis/intuitive-surgical-isrg-down-07-since-last-earnings-report-can-it-rebound-200360249,200360249
111988,333503,ISRG,4 Stocks To Watch Today  DAR  LCI  AXGN  ISRG,opinion,"Darling Ingredients Inc  NYSE DAR   one of our swing trades  popped and pulled back and ran up nicely on Monday  In a market like this  and to go up 1 41  or 7   to 21 47  on 2 2 million shares on Monday  shows that this stock has outstanding relative strength  If it gets above 22  the targets going forward are 24 and 28 
Lannett Com  NYSE LCI   another one of our swing trades  was up 22 cents  or 4   to 6 19  on 4 3 million shares o Monday  It is up against the gap  If it gets through it  you re looking at 7 1 2  8 1 2  and eventually 12 as targets 
Stocks on the Short Side  
Axogen Inc  NASDAQ AXGN  is rolling over hard  It broke the trendline  formed a rising wedge  a second wedge  a larger wedge  and then it rolled over hard  dropping 3 59  or 11   to 28 37  on 812 621 shares traded on Monday  It s now below everything and is likely headed for 24 1 2 
Intuitive Surgical  Inc   NASDAQ ISRG  got slammed dunked for 35 87  or 7   to 482 67  on 1 1 million shares on Monday  That s bad news  folks  If you re short  stay short  It looks like it may make a run at 450 455  and below that 430 
Stocks on the long side included Darling Ingredients Inc   DAR   IDT Corporation  IDT   Lannett Company  Inc   LCI   NIO Inc   NIO   Origin Agritech Limited  SEED   Synchronoss Technologies  Inc   SNCR   VelocityShares Daily 2x VIX ST ETN  TVIX   ProShares Ultra VIX Short Term Futures  UVXY   Yulong Eco Materials Limited  YECO   and YETI Holdings  Inc   YETI  
On the short side  stocks included AxoGen  Inc   AXGN   Copart  Inc   CPRT   Daqo New Energy Corp   DQ   Editas Medicine  Inc   EDIT   Fortinet  Inc   FTNT   GrubHub Inc   GRUB   Guidewire Software  Inc   GWRE   IntriCon Corporation  IIN   IRadimed Corporation  IRMD   Intuitive Surgical  Inc   ISRG   Medifast  Inc   MED   Nutanix  Inc   NTNX   PTC Inc   PTC   Qualys  Inc   QLYS   Ferrari N V   NYSE RACE   SiteOne Landscape Supply  Inc   SITE   Vicor Corporation  VICR   Wayfair Inc   W   Wix com Ltd   WIX   Weight Watchers International  Inc   WTW   and World Wrestling Entertainment  Inc   WWE  
Watch video here ",2018-11-19,Harry Boxer,https://www.investing.com/analysis/dar-lci-axgn-isrg-200360812,200360812
111992,333507,ISRG,Intuitive Surgical  ISRG  Gains As Market Dips  What You Should Know,opinion,"Intuitive Surgical  NASDAQ ISRG  closed at  485 24 in the latest trading session  marking a  0 53  move from the prior day  This move outpaced the S P 500 s daily loss of 1 82   Meanwhile  the Dow lost 2 21   and the Nasdaq  a tech heavy index  lost 1 7  
Prior to today s trading  shares of the robotic surgery system company had lost 5 62  over the past month  This has lagged the Medical sector s loss of 1 44  and the S P 500 s loss of 2 57  in that time 
ISRG will be looking to display strength as it nears its next earnings release  which is expected to be January 24  2019  The company is expected to report EPS of  2 96  up 16 54  from the prior year quarter  Meanwhile  our latest consensus estimate is calling for revenue of  1 02 billion  up 14 49  from the prior year quarter 
Looking at the full year  our Zacks Consensus Estimates suggest analysts are expecting earnings of  10 97 per share and revenue of  3 70 billion  These totals would mark changes of  22 02  and  18 23   respectively  from last year 
Any recent changes to analyst estimates for ISRG should also be noted by investors  These revisions help to show the ever changing nature of near term business trends  As such  positive estimate revisions reflect analyst optimism about the company s business and profitability 
Based on our research  we believe these estimate revisions are directly related to near team stock moves  To benefit from this  we have developed the Zacks Rank  a proprietary model which takes these estimate changes into account and provides an actionable rating system 
The Zacks Rank system  which ranges from  1  Strong Buy  to  5  Strong Sell   has an impressive outside audited track record of outperformance  with  1 stocks generating an average annual return of  25  since 1988  The Zacks Consensus EPS estimate remained stagnant within the past month  ISRG is holding a Zacks Rank of  2  Buy  right now 
Looking at its valuation  ISRG is holding a Forward P E ratio of 44  This valuation marks a premium compared to its industry s average Forward P E of 32 91 
Meanwhile  ISRG s PEG ratio is currently 2 81  This metric is used similarly to the famous P E ratio  but the PEG ratio also takes into account the stock s expected earnings growth rate  ISRG s industry had an average PEG ratio of 2 46 as of yesterday s close 
The Medical   Instruments industry is part of the Medical sector  This industry currently has a Zacks Industry Rank of 77  which puts it in the top 30  of all 250  industries 
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
To follow ISRG in the coming trading sessions  be sure to utilize Zacks com ",2018-11-20,Zacks Investment Research,https://www.investing.com/analysis/intuitive-surgical-isrg-gains-as-market-dips-what-you-should-know-200361230,200361230
111994,333509,ISRG,Medtronic Gets Health Canada License For Visualase System,opinion,Medtronic plc s   NYSE MDT   Canadian subsidiary Medtronic of Canada Ltd   recently announced the receipt of Health Canada license for its MRI guided laser ablation technology for use in cranial neurosurgery procedures The Visualase MRI Guided Laser Ablation System allows to accurately target while ablating undesirable and damaging soft tissues without harming the adjacent healthy tissues  We believe the recent development will aid in boosting top line contributions from the Brain Therapies division of Medtronic Market PotentialAccording to the Canadian Cancer Society  around 3 000 Canadians were diagnosed with brain and spinal cord cancer  Per Mordor Intelligence report  the Canadian minimally invasive devices market is likely to reach a worth of  4 59 billion in 2019  at a CAGR of 8 5  between 2014 and 2019  In view of the data  the receipt of license is expected to help Medtronic cash in on the bountiful opportunities in the niche market A Glimpse of the Brain Therapies ArmIn Brain Therapies  which now includes Neurovascular and Neurosurgery businesses  the company has been witnessing sturdy growth  The Neurovascular business grew mid teens on high twenties constant currency growth of stents for acute ischemic stroke  including the Solitaire Platinum  in the recently reported quarter  The company also witnessed strong growth in neuro access products  coils and intrasaccular therapies  flow diversion products The Neurosurgery business grew in the high single digits on solid capital equipment sales of the StealthStation S8 surgical navigation system  Visualase MRI Guided Laser Ablation System and Mazor X robotic guidance systems for spine surgeries Medtronic has been consistently trying to strengthen its Brain Therapies unit  In April  the company had announced the CE Mark receipt and launch of the Visualase MRI Guided Laser Ablation System in Europe Medtronic also announced the U S  launch and receipt of FDA approval for its Deep Brain Stimulation Clinician Programmer and Activa Programming Application in June  Notably  the product has been made available in Europe Share Price MovementMedtronic has been gaining investor confidence on consistently positive results  Over a year s time  the company s share price has outperformed its   The stock has gained 11 7  against the industry s 2 8  decline  Zacks Rank   Key PicksMedtronic currently carries a Zacks Rank  3  Hold  A few better ranked stocks in the broader medical space are Intuitive Surgical  Inc    NASDAQ ISRG    Illumina  Inc   NASDAQ ILMN   and Veeva Systems   NYSE VEEV   Intuitive Surgical has long term expected earnings growth rate of 15 6  and a Zacks Rank  2  Buy   You can see  Illumina s long term earnings growth rate is projected at 23 4   The stock carries a Zacks Rank  2 Veeva Systems  long term earnings growth rate is estimated at 19 3   The stock carries a Zacks Rank  2 Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2018-11-22,Zacks Investment Research,https://www.investing.com/analysis/medtronic-gets-health-canada-license-for-visualase-system-200361982,200361982
111995,333510,ISRG,Medtronic s Deal With Nutrino Health To Boost Diabetes Arm,opinion,Recently  Medtrnic  plc   NYSE MDT   entered into a definitive agreement to acquire nutrition related data services  analytics and technologies provider Nutrino Health Ltd  This development is part of the company s efforts to expand its diabetes management business While financial terms of the deal remain undisclosed  Medtronic expects this transaction to culminate in third quarter fiscal 2019  ending Jan 25  2019  subject to certain customary closing conditions Notably  Nutrino is working on the improvement of universal health by enabling artificial intelligence  AI  led analysis of how nutritional intake will affect a person s health  The company has created a food database and nutrition data insights platform  collating data from millions of access points and food items globally According to Medtronic  based on the fact that food and nutrition are major components in effective diabetes management  the union with Nutrino will improve clinical outcomes for diabetic patients  Post completion of the transaction  Nutrino s extensive food analysis infrastructure  nutrition science expertise and AI driven personalized insights will integrate with Medtronic s technology and future innovations Significantly  bringing Nutrino under Medtronic s Diabetes Group will help the company accelerate its progress in this business  In this regard  this is not the first time that Medtronic has inked a strategic deal with Nutrino  The relationship dates back to 2016  Nutrino has played a vital role in Medtronic s recent product introductions in the United States including the updated iPro2 myLog app used with professional CGM solutions as well as the Sugar IQ diabetes assistant app used with the Guardian Connect smart CGM system Market PotentialAgeing population  unhealthy lifestyle  rising awareness and higher expenditure in healthcare are likely to drive the highly competitive diabetes market Per a report by Mordor Intelligence  the global market for diabetes care devices is projected to reach a value of  30 25 billion by 2021 at a CAGR of 5 93   Considering this bullish market trend  we believe that the latest development is a strategic fit for the company Share Price Movement Medtronic has been gaining investor confidence from consistently positive results  Over the past three months  the company s share price has outperformed its   The stock has lost 2 8   comparing favorably with the industry s 7 7  decline Zacks Rank   Key PicksMedtronic currently carries a Zacks Rank  3  Hold   A few better ranked stocks in the broader medical space are Intuitive Surgical  Inc    NASDAQ ISRG    Illumina  Inc   NASDAQ ILMN   and Veeva Systems   NYSE VEEV   Intuitive Surgical has an expected long term earnings growth rate of 15 6  and a Zacks Rank  2  Buy   You can see  Illumina s long term earnings growth rate is projected at 23 4   The stock carries a Zacks Rank of 2 Veeva Systems  long term earnings growth rate is estimated at 19 3   The stock is a Zacks  2 Ranked player Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2018-11-22,Zacks Investment Research,https://www.investing.com/analysis/medtronics-deal-with-nutrino-health-to-boost-diabetes-arm-200362002,200362002
112002,333517,ISRG,RTI Surgical Gains From HealthPartners  Nod For SI Surgery,opinion,RTI Surgical  Inc    NASDAQ RTIX   recently announced HealthPartners  positive coverage decision for its minimally invasive sacroiliac  SI  joint fusion surgery  Notably  this will increase access to the company s SImmetry System for HealthPartners members considering treatment of SI joint pain or dysfunction  This is likely to fortify RTI Surgical s foothold in the minimally invasive devices industry Following the news  shares of RTI Surgical inched up by a penny to  4 30 at close For investors  notice  HealthPartners is the largest consumer governed nonprofit health care organization in the United States More on SImmetry SystemRTI Surgical s SImmetry System is a minimally invasive surgical solution  providing long term pain relief through decortication technology  bone graft and threaded fixation Notably  the system currently sees robust demand and contributed significantly to RTI Surgical s Spine business in the recently reported third quarter 2018 Booming Minimally Invasive Surgery MarketReduced stay at hospital and lower healthcare costs  pain  scarring and tissue damage are a few benefits of opting for minimally invasive surgery over traditional procedures  Such surgical methods are currently raking in billions in the surgical industry Some of the MedTech bigwigs  deserving special mention in this regard are  Intuitive Surgical   NASDAQ ISRG   and Medtronic plc   NYSE MDT    Intuitive Surgical s much coveted da Vinci surgical system   an advanced robot assisted surgical platform   and Medtronic s Minimally Invasive Therapies Group currently witness robust demand  worldwide BIS Research projects the global minimally invasive surgical systems market to reach a value of  40 52 billion by 2025 at a CAGR of 10 9  Hence  RTI Surgical s latest development seems a well timed one Price PerformanceWe believe that such positive developments are likely to drive the shares of RTI Surgical and help the stock rebound as it has declined 9 5  against the  s rally of 8 2  in a year s time  The current level is also lower than the S P 500 index s 1 9  gain The stock has a Zacks Rank  3  Hold  Key PickA better ranked stock from the broader medical space is Surmodics  Inc    NASDAQ SRDX   Surmodics has an expected long term earnings growth rate of 10   The stock carries a Zacks Rank  2  Buy   You can see  Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2018-11-22,Zacks Investment Research,https://www.investing.com/analysis/rti-surgical-gains-from-healthpartners-nod-for-si-surgery-200361996,200361996
112008,333523,ISRG,Inogen  INGN  Q3 Earnings Beat  2018 Revenue Guidance Up,opinion,"Inogen  Inc    NASDAQ INGN   posted third quarter 2018 earnings per share of 73 cents  which surpassed the Zacks Consensus Estimate by 40 4   The bottom line also improved a whopping 121 1  from the figure registered in the year ago quarter Revenues totaled  95 3 million  which trumped the Zacks Consensus Estimate of  91 million  On a year over year basis  the top line climbed 38  In a year s time  this Zacks Rank  3  Hold  stock has gained 24 3  compared with the  s 20 9  growth and  the S P 500 index s 8 5  rise Segmental DetailsSales revenues totaled  89 7 million  up 42 1  on a year over year basis Business to business revenues in the United States amounted to  30 3 million  up 32  on a year over year basis  The uptick was primarily driven by increased sales representative headcount and additional consumer advertising Internationally  this segment recorded revenues of  21 1 million  up 23  year over year  courtesy of continued adoption from the company s European partners Inogen  Inc Price  Consensus and EPS Surprise
    Direct to consumer revenues in the United States grossed  38 3 million in the third quarter  This reflects an increase of 66 3  from the prior year quarter  The upside can be attributed to continued adoption by traditional home medical equipment providers and internet resellers Rental revenues totaled  5 6 million  down 5 3  on a year over year basis  Per management  the downturn was primarily due to a decline in net rental patients MarginsIn the quarter under review  gross profit was  48 8 million  up 47 2  year over year  Gross margin came in at 51 2   which expanded 310 basis points  bps  Adjusted operating profit was  10 4 million  up 24 8  year over year  Adjusted operating margin came in at 10 9   down 120 bps from the prior year quarter Adjusted EBITDA was  16 3 million  up 16 2  on a year over year basis 2018 GuidanceInogen raised its 2018 revenue guidance  The company expects revenues to be within  345  355 million  up from the previously guided  340  350 million  Notably  this reflects a year over year growth of 38 3 42 3   The Zacks Consensus Estimate is pegged at  347 9 million  within the guided range However  Inogen expects its rental revenues to decline by 10  on a year over year basis in 2018 The company envisions adjusted net income between  46 million and  48 million compared with  45 million and  48 million projected earlier  This represents a year over year growth of 119 128 5  Furthermore  2018 EBITDA is expected to be within  60  62 million  down from the earlier issued guidance of  65  69 million  representing a year over year growth of 18 22  2019 ViewInogen provided an outlook for 2019 as well  Revenues are expected between  430 million and  440 million  representing 22 9 25 7  growth over 2018  The Zacks Consensus Estimate stands at  432 7 million  within the guided range Full year adjusted EBITDA is projected between  67 million and  71 million  representing 9 8 16 4  growth over 2018 Our TakeInogen wrapped up the third quarter on a solid note delivering better than expected performance  Solid business to business revenues also buoy optimism  These apart  the company s direct to consumer unit performed exceedingly well in the quarter  In fact  management expects the unit to be the fastest growing one in 2019  Moreover  the company remains optimistic about its international revenues  which saw solid growth in Europe in the third quarter  The raised revenue guidance for 2018 is an added positive  Inogen issued a bullish guidance for 2019 as well  A considerable expansion in gross margin is also encouraging On the flip side  Inogen s rental revenues declined on a year over year basis in the third quarter  In fact  the company expects rental revenues to be down in 2018 and grow modestly in 2019  Moreover  contraction in operating margin is worrisome  Rising operating expenses are discouraging as well Earnings of MedTech Majors at a GlanceSome better ranked stocks from the broader Medical space that delivered robust results this earnings season are Intuitive Surgical   NASDAQ ISRG    Stryker Corporation   NYSE SYK   and Merit Medical Systems  Inc    NASDAQ MMSI    Notably  each of the stocks carries a Zacks Rank  2  Buy   You can see  Intuitive Surgical reported third quarter 2018 adjusted earnings per share of  2 83  which exceeded the Zacks Consensus Estimate of  2 65  Revenues totaled  920 9 million  which outpaced the consensus mark of  918 6 million Stryker posted third quarter 2018 adjusted earnings per share of  1 69  which outpaced the Zacks Consensus Estimate by a penny  Operating margin was 17 8   up 30 bps Merit Medical reported third quarter 2018 adjusted earnings per share of 47 cents  which trumped the Zacks Consensus Estimate of 42 cents  Revenues of  221 6 million edged past the consensus mark of  218 million The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2018-11-08,Zacks Investment Research,https://www.investing.com/analysis/inogen-ingn-q3-earnings-beat-2018-revenue-guidance-up-200357578,200357578
112009,333524,ISRG,Wright Medical  WMGI  Reports Q3 Loss  Raises  18 Guidance,opinion,Wright Medical Group N V    NASDAQ WMGI   reported third quarter 2018 adjusted loss of 9 cents  narrower than the Zacks Consensus Estimate of a loss of 15 cents  Notably  the company reported loss of 16 cents in the year ago quarter Third quarter revenues came in at  194 1 million  which beat the Zacks Consensus Estimate by 4 2   Revenues also improved 13 8  year over year  The stock sports a Zacks Rank  1  Strong Buy  Segment DetailsLower ExtremitiesThis segment posted worldwide revenues of  71 1 million  up 8 8  year over year  Sales in the United States increased 12  to  57 6 million on a year over year basis  International sales totaled  13 5 million  down 3 3  year over year Wright Medical Group N V  Price and Consensus    Upper ExtremitiesRevenues in the segment totaled  91 million  up 19 8  from the prior year quarter s level  In the United States  sales were up 19 2  on a year over year basis to  65 3 million  Internationally  the segment raked in revenues worth  25 7 million  up 21 2  year over year BiologicsWorldwide Biologics sales were  27 2 million  up 14 1  on a year over year basis  While international revenues in the segment rose 26 1  to  6 5 million  U S  sales were  20 7 million  up 10 8  year over year Sports Med   OtherThe segment posted worldwide sales of  4 8 million  down 9 8  on a year over year basis  The segment s U S  sales declined 2 2  to  1 9 million  while international sales sunk 14 5  to  2 8 million Margin AnalysisIn the quarter under review  gross profit totaled  139 2 million  up 5 9  year over year  Gross margin was 77 2  of net revenues  which contracted 30 basis points  bps  from the year ago quarter s level Selling  general and administrative expenses were  140 8 million  up 7 7  year over year Research and development expenses were  14 7 million  up 15 3  year over year Adjusted operating expenses in the third quarter of 2018 were  153 1 million  up 6 8  year over year Guidance RaisedWright Medical increased revenue guidance in the band of  825  828 million  up from the previous guidance of approximately  812  822 million  This represents growth of 11 12  on a constant currency basis  For 2018  the Zacks Consensus Estimate for revenues is pegged at  821 1 million  below the guidance The company expects 2018 adjusted loss per share within 8 3 cents  narrower than the previous guidance of 14 21 cents  The Zacks Consensus Estimate for the same is pinned at a loss of 15 cents  wider than the projected range Full year adjusted EBITDA is anticipated in the range of  110  116 million  higher than the previous range of  106  113 million  The guidance has approximately 0 5  cushion from foreign currency exchange rates In ConclusionWright Medical exited the third quarter on a promising note  The company s loss was narrower than the consensus mark and revenues beat the same  Solid performance in the upper and the lower extremity segments buoy optimism  The FDA approval of the AUGMENT Injectable Bone Graft is also a major positive  The company has also witnessed strong growth in the Perform Reversed Glenoid platform  Further  contribution from the company s SIMPLICITI shoulder system is noteworthy  Management is optimistic about the recent acquisition of BLUEPRINT  Wright Medical also launched INVISION Total Ankle Revision System On the flip side  the company s rising operating expenses are a concern  Soft show by the sports business is discouraging  Distribution issues in Europe and Asia as well as foreign currency volatility add to the woes  Increased costs related to product launch and re building infrastructure is expected to keep the margins under pressure Earnings of Other MedTech Majors at a GlanceOther top ranked stocks in the broader medical space that also reported solid earnings this season are Intuitive Surgical   NASDAQ ISRG    Stryker Corporation   NYSE SYK   and Merit Medical Systems  Inc    NASDAQ MMSI    Each of the stocks carry a Zacks Rank  2  Buy   You can see  Intuitive Surgical reported third quarter 2018 adjusted EPS of  2 83  which beat the Zacks Consensus Estimate of  2 65  Revenues totaled  920 9 million  which beat the consensus estimate of  918 6 million Stryker posted third quarter 2018 adjusted EPS of  1 69  beating the Zacks Consensus Estimate by a penny  Operating margin was 17 8   up 30 bps Merit Medical reported third quarter 2018 adjusted EPS of 47 cents  which trumped the Zacks Consensus Estimate of 42 cents  Revenues of  221 6 million edged past the consensus estimate of  218 million Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana      Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2018-11-08,Zacks Investment Research,https://www.investing.com/analysis/wright-medical-wmgi-reports-q3-loss-raises-18-guidance-200357693,200357693
112012,333527,ISRG,DENTSPLY SIRONA  XRAY  Q3 Earnings   Revenues Miss Estimates,opinion,DENTSPLY SIRONA Inc    NASDAQ XRAY   reported adjusted earnings per share  EPS  of 38 cents in the third quarter of 2018  missing the Zacks Consensus Estimate by 15 6   The bottom line also deteriorated significantly by 45 7  from the prior year quarter number Net revenues declined 8  year over year to  928 4 million and fell short of the Zacks Consensus Estimate of  952 8 million  At constant currency  cc   the metric declined 5 9  In a year s time  this Zacks Rank  4  Sell  stock has declined 43 9  against the  s 4 3  growth  The current level is also lower than the S P 500 index s rally of 8 5  Business DetailsNet sales Excluding Precious Metal ContentNet sales  excluding precious metal content  came in at  920 3 million  down 7 9  year over year For investors  notice  DENTSPLY s precious metal dental alloy products   used by third parties to construct crown and bridge materials   are subject to certain risks of price fluctuations Per management  DENTSPLY s Healthcare business grew by mid single digits in the quarter under review DENTSPLY SIRONA Inc  Price  Consensus and EPS Surprise   Technology   EquipmentPer management  Technology   Equipment revenues declined 11 3  year over year  in the third quarter  Notably  revenues in the segment totaled  495 million  It was further stated that a significant amount of inventory destocking in the reported quarter led to decrease in revenues ConsumablesDENTSPLY s Consumable growth was impacted by a short term disruption from its distribution infrastructure in Venlo  Netherlands  Consumable revenues declined 3 9  year over year to  433 2 million in the quarter Restructuring PlanDENTSPLY announced a comprehensive plan to accelerate revenue growth  expand margins and simplify its business  The plan includes a restructuring that is anticipated to achieve  200  225 million in net annual cost savings by 2021 through streamlining the organization and consolidating functions  Furthermore  this strategy is expected to boost the top line by 3 4  and deliver an adjusted operating income margin of 20  by the end of 2020 and 22  by 2022 Revenues by GeographyRevenues from the United States totaled  328 7 million  which fell 9 6  year over year In Europe  revenues declined 9 8  on a year over year basis to  3 4 8 million in the third quarter  The downside can be primarily attributed to the revenue shortfall with regards to Venlo and some softness in the equipment markets in Central Europe Revenues from the Rest of the World  ROW  also inched down 3 1  to  250 9 million  However  the company foresees high single digit growth opportunities in Latin America and China Margin AnalysisGross profit in the reported quarter summed  476 1 million  down 14 8  on a year over year basis  Gross margin was 51 3   down 410 basis points  bps  Excluding precious metal content  gross margin came in at 51 7   which also contracted 420 bps Adjusted operating income totaled  57 6 million  down significantly by 55 1  year over year Adjusted operating margin in the quarter was 6 2   down 650 bps from the year ago period Excluding precious metal content  adjusted operating margin came in at 6 3   down 660 bps in the third quarter Financial ConditionDENTSPLY exited the third quarter with cash and cash equivalents of  233 1 million  Operating cash flow amounted to  126 million in the quarter GuidanceFor 2018  DENTSPLY anticipates adjusted EPS at or slightly below the low end of the previously announced guided range of  2 00  2 15 per share  The Zacks Consensus Estimate is pegged at  2 07  above the lower end of the projected range The 2018 revenue guidance assumes a decline of 2  at cc  The Zacks Consensus Estimate is pinned at  3 99 billion ConclusionDENTSPLY ended the third quarter on a dull note  with both earnings and revenues missing the consensus mark  Both the metrics also declined on a year over year basis  The company s Technology   Equipment and Consumable growth was marred by factors like inventory destocking and disruption from its distribution infrastructure in Venlo  Significant contractions in gross and operating margins also add to the woes  A lowered guidance for 2018 is worrisome On the flip side  DENTSPLY continues to gain from its Healthcare business  The company also announced its restructuring plan  which is expected to boost top line  In the fourth quarter  DENTSPLY expects to see normal revenue growth in Europe  Management also foresees high single digit growth opportunities in Latin America and China Earnings of MedTech Majors at a GlanceSome stocks from the broader Medical space that delivered robust results this earnings season are Intuitive Surgical   NASDAQ ISRG    Stryker Corporation   NYSE SYK   and Merit Medical Systems  Inc    NASDAQ MMSI    Notably  each of the stocks carries a Zacks Rank  2  Buy   You can see  Intuitive Surgical reported third quarter 2018 adjusted earnings per share of  2 83  which exceeded the Zacks Consensus Estimate of  2 65  Revenues totaled  920 9 million  which outpaced the consensus mark of  918 6 million Stryker posted third quarter 2018 adjusted earnings per share of  1 69  which beat the Zacks Consensus Estimate by a penny  Operating margin was 17 8   up 30 bps Merit Medical reported third quarter 2018 adjusted earnings per share of 47 cents  which trumped the Zacks Consensus Estimate of 42 cents  Revenues of  221 6 million edged past the consensus mark of  218 million The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2018-11-08,Zacks Investment Research,https://www.investing.com/analysis/dentsply-sirona-xray-q3-earnings--revenues-miss-estimates-200357670,200357670
112016,333531,ISRG,Haemonetics  HAE  Earnings   Revenues Beat Estimates In Q2,opinion,"Haemonetics Corporation   NYSE HAE   reported adjusted earnings per share  EPS  of 56 cents in the second quarter of fiscal 2019  reflecting a 16 7  rise year over year  The bottom line surpassed the Zacks Consensus Estimate of 54 cents by 3 7  On a reported basis  net income came in at 35 cents per share  down 7 9  year over year Total RevenuesRevenues rose 7 2  year over year  same at constant exchange rate or CER  to  241 6 million in the quarter under review  Moreover  the top line exceeded the Zacks Consensus Estimate by 3 2  Revenues by Product CategoriesAt Plasma  reported revenues of  124 4 million  accounting for 51 5  of total revenues  rose 13 3  year over year  same at CER   Plasma revenue growth in North America was 17   including 16 2  growth in disposables along with strength in software revenues 
Haemonetics Corporation Price  Consensus and EPS Surprise
    Revenues at BloodCenter  28 2  of total revenues  dropped 4 8   down 4 7  at CER  to  68 2 million Hospital revenues  contributing to 20 3  of total revenues  rose 11 6   up 11 3  at CER  to  49 million  MarginsAdjusted gross margin was 48 2   up 170 basis points  bps  year over year on favorable revenue volume  price and product mix and currency movements along with savings from Complexity Reduction Initiative Adjusted operating income was  38 9 million in the quarter under discussion  showing a 6 4  rise year over year  Meanwhile  adjusted operating margin contracted 10 bps year over year to 16 1  Financial PositionHaemonetics exited the second quarter of fiscal 2019 with cash and cash equivalents of  199 8 million compared with  192 1 million at the end of first quarter of fiscal 2019 The company generated operating cash flow of  80 5 million in the first six months of the fiscal compared with  97 3 million a year ago  The company also reported free cash flow  before restructuring and turnaround costs  of  20 8 million during the same period compared with  75 3 million a year ago  Capital expenditures totaled  75 3 million in the period  higher than  27 8 million in the same period last year Fiscal 2019 GuidanceHaemonetics updated its fiscal 2019 revenue guidance at CER  The company now expects full year revenue growth of 6 8  compared with 3 5  stated previously  Coming to segmental revenues  Plasma revenue growth is expected in the 14 16  band  7 10  stated earlier  while Hospital revenues are estimated to increase 6 9   5 8    However  Blood Center revenues are likely to decline 3 6   The Zacks Consensus Estimate for fiscal 2019 revenues is pegged at  972 5 million The company predicts 2019 adjusted EPS in the range of  2 25  2 35 compared with the prior range of  2  2 30  The consensus estimate of  2 33 is within this guided range Our TakeHaemonetics exited second quarter fiscal 2019 on a promising note  Per the company  benefits from complexity reduction and investments along with strength in market demand and success from early launches helped the company put up an impressive performance  Continued momentum in new business generation and geographical expansion has contributed to the results as well However  we are displeased with the company s sluggish Blood Center business moderating overall growth despite encouraging progress in Plasma and Hospitals  Meanwhile  we are upbeat about the company s steady progress with the ongoing rollout of NexSys PCS devices and NexLynk DMS donor management software Zacks Rank   Other Key PicksHaemonetics has a Zacks Rank  2  Buy   Other top ranked stocks in the broader medical space which reported solid earnings this season are Intuitive Surgical   NASDAQ ISRG    Stryker Corporation   NYSE SYK   and Merit Medical Systems  Inc    NASDAQ MMSI    All the stocks carry a Zacks Rank  2  You can see  Intuitive Surgical reported third quarter 2018 adjusted EPS of  2 83  which beat the Zacks Consensus Estimate of  2 65  Revenues totaled  920 9 million  also surpassing the consensus estimate of  918 6 million Stryker posted third quarter 2018 adjusted EPS of  1 69  outpacing the Zacks Consensus Estimate of  1 68  Operating margin was 17 8   up 30 bps Merit Medical reported third quarter 2018 adjusted EPS of 47 cents  which trumped the Zacks Consensus Estimate of 42 cents  Revenues of  221 6 million edged past the consensus estimate of  218 million The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2018-11-12,Zacks Investment Research,https://www.investing.com/analysis/haemonetics-hae-earnings--revenues-beat-estimates-in-q2-200358749,200358749
112017,333532,ISRG,Athenahealth  ATHN  Q3 Earnings Beat  Bookings Down Y Y,opinion,"athenahealth Inc    NASDAQ ATHN   reported adjusted earnings of  1 08 per share in the third quarter of 2018  which beat the Zacks Consensus Estimate by 10 2   Adjusted earnings in the year ago quarter were 56 cents The Watertown  MA based maker of billing and medical practice management software posted revenues of  329 5 million  missing the Zacks Consensus Estimate of  337 million  Revenues increased 8 2  year over year For investors  notice  the company adopted a new revenue recognition standard on Jan 1  2018  Total revenues prior to the impact of the new revenue recognition standard were  331 4 million  up 8 8  year over year Over the past year  the Zacks Rank  3  Hold  stock has rallied 5 1  against the  s 4 9  decline  The current level is however lower than the S P 500 index s 5 4  rise Q3 DetailsSegment DetailsExcluding the impact of the new revenue recognition standard  revenues at the Business and Services unit were  322 7 million  up 9 1  from the year ago quarter However  revenues at the Implementation and other segment were  8 7 million  down slightly from the year ago  8 8 million athenahealth  Inc  Price  Consensus and EPS Surprise
    Network ExpansionPer management  the company expanded its network across ambulatory and hospital platforms The company s network has 120 194 Collector Providers  67 667 Clinical Providers and 78 290 Communicator Providers  up 13   17  and 16   respectively  on a year over year basis In the athenaOne  Hospital  platform  number of discharged beds surged a whopping 101  year over year However  in the Population Health platform  number of covered lives dropped 5  year over year BookingsIn the reported quarter  athenahealth s total bookings were  46 6 million  down a significant 29 1   Per management  third quarter bookings included a large enterprise client chargeback originally signed in 2016 Margin AnalysisConsidering the new revenue recognition standard  gross profit in the quarter was  175 1 million  up 9  year over year  As a percentage of revenues  reported gross margin in the third quarter was 53 1   up 40 basis points  bps   Per management  adjusted gross margin in the reported quarter was 54 9   up 90 bps Considering the new revenue recognition standard  athenahealth s adjusted operating income increased 105 4  year over year to  38 2 million in the third quarter  Adjusted operating margin was 11 6   up considerably from 5 1  of the prior year quarter Per management  athenahealth s adjusted operating income in the quarter was  61 million or 18 5  of revenues Guidance IntactUnder the new revenue recognition standard  athenahealth expects 2018 revenues in the range of  1 34  1 37 billion  Meanwhile  the Zacks Consensus Estimate for revenues is pegged at  1 35 billion  within the guided range The company expects adjusted operating income in the range of  244  270 million for 2018 Adjusted operating margin is expected in the band of 18 3 19 8  of net revenues for 2018 In Conclusionathenahealth exited the third quarter of 2018 on a solid note  We believe unique applications like athenaClinicals  athenaClinicals Streamlined  athenaInsight  athenaCommunicator and athenaOne favor the company  Strength in core ambulatory services and client base have been key catalysts for athenahealth  Business and Services revenues have been consistently growing On the flip side  lackluster performance by the Implementation and other segment has been a concern  Further  athenahealth failed to meet its bookings goals in the quarter  Population Health performance also saw a soft third quarter  Among other concerns  athenahealth s EHR solution faces stiff competition from Allscripts Healthcare Solutions and more Earnings of MedTech Majors at a GlanceA few better ranked stocks in the broader medical space that reported impressive earnings this season are Intuitive Surgical   NASDAQ ISRG    Stryker Corporation   NYSE SYK   and Merit Medical Systems  Inc    NASDAQ MMSI    each carrying a Zacks Rank  2  Buy   You can see  Intuitive Surgical reported third quarter 2018 adjusted earnings per share of  2 83  which exceeded the Zacks Consensus Estimate of  2 65  Revenues came in at  920 9 million  surpassing the consensus estimate of  918 6 million Stryker posted third quarter 2018 adjusted earnings per share of  1 69  which beat the Zacks Consensus Estimate by a penny  Operating margin was 17 8   up 30 bps Merit Medical reported third quarter 2018 adjusted earnings per share of 47 cents  which trumped the Zacks Consensus Estimate of 42 cents  Revenues of  221 6 million edged past the consensus estimate of  218 million The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2018-11-12,Zacks Investment Research,https://www.investing.com/analysis/athenahealth-athn-q3-earnings-beat-bookings-down-yy-200358748,200358748
112020,333535,ISRG,OPKO Health  OPK  Incurs Loss In Q3  Lags Revenue Estimates,opinion,"OPKO Health  Inc    NASDAQ OPK   incurred loss of 5 cents per share in third quarter 2018  narrower than the Zacks Consensus Estimate of a loss of 8 cents  The company had incurred a loss of 8 cents per share in the year ago quarter Revenues totaled  249 8 million  missing the Zacks Consensus Estimate of  263 million  However  on a year over year basis  the top line increased 1 5  OPKO Health carries a Zacks Rank  3  Hold  Segment DetailsThis Florida based diagnostics and pharmaceuticals company reports through three major segments   services  products and transfer of intellectual property Revenues from services grossed  202 8 million in the reported quarter  up 0 9  year over year Revenues from products increased 11  to  25 4 million  Per management  revenues from products include  5 8 million contribution from RAYALDEE Revenues from transfer of intellectual property came in at  21 6 million  down 3 1  year over year OPKO Health  Inc  Price and Consensus
    RAYALDEE UpdatePer management  total RAYALDEE prescriptions improved 222  year over year in the third quarter  OPKO Health initiated the Phase 2 clinical trial of RAYALDEE as a new treatment for secondary hyperparathyroidism  SHPT  in adults with vitamin D insufficiency and those suffering from stage 5 chronic kidney disease Margin AnalysisAdjusted gross profit in the reported quarter came in at  98 9 million  up 4 4  from the prior year quarter  Adjusted gross margin was 60 4   down 110 basis points  bps  Selling  general and administrative expenses totaled  84 1 million  down 18 5  year over year Research and development expenses amounted to  30 2 million  down 7 1  year over year                   In the third quarter  OPKO Health incurred an operating loss of  33 5 million  which narrowed considerably from the year ago quarter s  47 8 million GuidanceOPKO Health did not provide any guidance for 2018 However  for the fourth quarter of 2018  management expects revenues from services between  185 million and  205 million Product revenues are expected within  28  32 million  including revenues for RAYALDEE between  6 5 million and  7 1 million Revenues from transfer of intellectual property are anticipated in the band of  18  23 million The company expects costs and expenses to be between  280 million and  290 million  including research and development expenses of  33  38 million in the fourth quarter Summing UpOPKO Health exited the third quarter on a mixed note  While loss per share was narrower than expected  revenues topped the Zacks Consensus Estimate  Contribution from RAYALDEE was significant  Furthermore  OPKO Health s utilization of the 4Kscore remains strong  with 8 700 tests registered in the third quarter OPKO has also completed a Premarket Approval  PMA  submission for Claros point of care PSA test to the FDA  Additionally  tests like testosterone and Vitamin D utilizing the Claros platform are advancing toward a 510 k  submission to the FDA These apart  the company s clinical development programs look promising with a robust pipeline of candidates  Several metabolic and endocrinology programs that are underway  are likely to provide OPKO Health a competitive advantage Meanwhile  the margins look pressed at the moment  Also  the company s core segmental revenues remain weak in the quarter  Moreover  the decline in R D expenses indicates reduced focus on innovation Q3 Earnings of MedTech Majors at a GlanceA few better ranked stocks from the broader Medical space that delivered robust results this earnings season are Intuitive Surgical   NASDAQ ISRG    Stryker Corporation   NYSE SYK   and Merit Medical Systems  Inc   NASDAQ MMSI    each carrying a Zacks Rank  2  Buy   You can see  Intuitive Surgical reported third quarter 2018 adjusted earnings per share  EPS  of  2 83  which exceeded the Zacks Consensus Estimate of  2 65  Revenues totaled  920 9 million  which outpaced the consensus mark of  918 6 million Stryker posted third quarter 2018 adjusted EPS of  1 69  which outpaced the Zacks Consensus Estimate by a penny  Operating margin was 17 8   up 30 bps Merit Medical reported third quarter 2018 adjusted EPS of 47 cents  which trumped the Zacks Consensus Estimate of 42 cents  Revenues of  221 6 million edged past the consensus mark of  218 million The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce   the world s first trillionaires    but that should still leave plenty of money for regular investors who make the right trades early ",2018-11-12,Zacks Investment Research,https://www.investing.com/analysis/opko-health-opk-incurs-loss-in-q3-lags-revenue-estimates-200358722,200358722
112050,333565,ISRG,Becton  Dickinson  BDX  Q4 Earnings Beat  FY19 View Strong,opinion,Becton  Dickinson and Company   NYSE BDX   posted fourth quarter fiscal 2018 earnings of per share  2 93  which surpassed the Zacks Consensus Estimate by a penny  The bottom line also improved 22 1  on a year over year basis and 24 6  at constant currency  cc  Becton Dickinson  also known as BD  raked in revenues of  4 4 billion and outpaced the Zacks Consensus Estimate of  4 36 billion  The reported figure surged 39  from the year ago quarter number  primarily owing to the acquisition of C  R  Bard  At cc  revenues rose 8 4  In a year s time  the Zacks Rank  3  Hold  stock has rallied 7 3   outperforming the  s 3  growth and the S P 500 index s 5 8  gain Fiscal 2018 at a GlanceFor fiscal 2018  BD s worldwide revenues totaled  15 98 billion  which trumped the Zacks Consensus Estimate of  15 94 billion  The top line increased 32 2  from the prior year s tally  courtesy of the acquisition of C R  Bard  At cc  revenues grew 5 8  Adjusted earnings per share of  11 01 came in line with the Zacks Consensus Estimate  The metric also surged 16 1  from the year ago figure and 12 3  at cc BD Medical posted revenues of  8 62 billion for the full year  53 9  of net sales   while BD Life Sciences revenues grossed  4 33 billion  27 1  of net sales   BD Interventional revenues came in at  3 04 billion  19  of net sales  Becton  Dickinson and Company Price  Consensus and EPS Surprise   Segment DetailsBD MedicalIn the quarter under review  BD Medical posted worldwide revenues of  2 35 billion  up 20 7  from the year ago quarter and 10 1  at cc  The upside was driven by strength in the Medication Delivery Solutions  Medication Management Solutions and Pharmaceutical systems  Per management  the improvement can be attributed to the C R  Bard acquisition BD Life SciencesWorldwide revenues in the segment totaled  1 11 billion  up 5 4  year over year and 6 9  at cc  Per management  revenues were strong across the Preanalytical Systems  Diagnostic Systems and Biosciences units BD InterventionalThis segment posted worldwide revenues of  0 95 billion  significantly up from the year ago figure of  172 million  At cc  the segment grew 6   Surgery  Peripheral Intervention and Urology and Critical care revenues skyrocketed in the fourth quarter Geographic ResultsUSIn the reported quarter  revenues in the United States shot up 48 9  to  2 45 billion  Revenues grew 8 7  at cc  Per management  revenue growth in the United States was primarily driven by very strong performance in the Medication Management Solutions and Pharmaceutical Systems units within the BD Medical segment For full year  domestic revenues totaled  8 77 billion  up 34 8  on a year over year basis and 5  at cc InternationalRevenues outside the United States grossed  1 95 billion  up 28 4  from the year ago quarter and 7 9  at cc  Per management  overseas revenue growth was backed by strong performance across all three segments in the fourth quarter For the full year  international revenues totaled  7 22 billion  up 29 1  on a year over year basis and 7  at cc Margin AnalysisIn the fiscal fourth quarter  gross profit amounted to  2 09 billion  up 34 6  from the prior year quarter tally  Gross margin was 47 5   down 160 basis points  bps  Operating income in the quarter grossed  570 million  reflecting an improvement of 28 7  from the prior year quarter Adjusted operating income summed  710 million  up 27  on a year over year basis  As a percentage of revenues  operating margin in the quarter was 16 1   which contracted 160 bps year over year GuidanceOn a reported basis  BD expects fiscal 2019 revenues to increase 8 5 9 5   primarily owing to the C  R  Bard acquisition  At cc  the same metric is anticipated to increase 5 6   The Zacks Consensus Estimate is pegged at  17 71 billion For fiscal 2019  adjusted earnings per share are projected between  12 05  12 15  reflecting growth of 13 14  at cc  Notably  the Zacks Consensus Estimate is pinned at  12 62  above the guided range Notably  fiscal 2019 earnings per share expectations include high single digit accretion from the C  R  Bard buyout Summing UpBecton  Dickinson wrapped up the fiscal fourth quarter on a solid note  with both earnings and revenues beating the consensus mark  Also  the company continues to gain from its C R  Bard acquisition  Notably  BD expects the buyout to contribute significantly to earnings in fiscal 2019  Strong performance by the core BD Medical and Life Sciences segment buoys too optimism  Domestic and international revenues also increased year over year in the quarter under review  A bullish guidance for fiscal 2019 is also indicative of brighter prospects ahead On the flip side  gross and operating margin contraction raise concerns  Management foresees a sales impact from Hurricane Maria in Puerto Rico and negative impact from foreign currency on Bard s business in first quarter of fiscal 2019  Stiff competition also adds to the woes Earnings of MedTech Majors at a GlanceA few better ranked stocks in the broader medical space that reported impressive earnings this season are Intuitive Surgical   NASDAQ ISRG    Stryker Corporation   NYSE SYK   and Merit Medical Systems  Inc    NASDAQ MMSI    each carrying a Zacks Rank  2  Buy   You can see  Intuitive Surgical reported third quarter 2018 adjusted earnings per share of  2 83  which exceeded the Zacks Consensus Estimate of  2 65  Revenues came in at  920 9 million  surpassing the consensus estimate of  918 6 million Stryker posted third quarter 2018 adjusted earnings per share of  1 69  came ahead of the Zacks Consensus Estimate by a penny  Operating margin was 17 8   up 30 bps Merit Medical reported third quarter 2018 adjusted earnings per share of 47 cents  which trumped the Zacks Consensus Estimate of 42 cents  Revenues of  221 6 million edged past the consensus estimate of  218 million Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2018-11-05,Zacks Investment Research,https://www.investing.com/analysis/becton-dickinson-bdx-q4-earnings-beat-fy19-view-strong-200355571,200355571
112051,333566,ISRG,CVS Health s  CVS  Q3 Earnings Top Estimate  Gross Margin Up,opinion,"CVS Health Corporation s   NYSE CVS   third quarter 2018 adjusted earnings per share  EPS  of  1 73 surged 15 3  year over year and exceeded the Zacks Consensus Estimate of  1 71  The quarter s adjusted EPS considered certain transaction and integration costs related to the proposed acquisition of Aetna  NYSE AET  and the purchase of Omnicare 
On a reported basis  earnings came in at  1 36 per share in the quarter  a 7 9  improvement year over year 
Net revenues in the third quarter increased 2 4  year over year to  47 27 billion  This surpassed the Zacks Consensus Estimate by 0 2  
Quarter in Details                                
Pharmacy Services revenues increased 2 6  to  33 8 billion in the reported quarter  driven by growth in pharmacy network and mail choice claim volume as well as brand inflation  This was  however  partially offset by continued price compression 
Pharmacy network claims processed during the quarter climbed 5 4  to 394 5 million on a 30 day equivalent basis  backed by net new business growth  Also  the Mail Choice claim processed count was 71 8 million  up 7 4  on a 30 day equivalent basis on continued adoption of Maintenance Choice offeringsand an increase in specialty pharmacy claims CVS Health Corporation Price  Consensus and EPS Surprise
   Revenues from CVS Health s Retail LTC were up by 6 4  year over year to  20 9 billion  According to the company  a 9 2  increase in same store prescriptions on a 30 day equivalent basis  continued adoption of Patient Care Programs  alliances with PBMs and health plans  inclusion in a number of additional Medicare Part D networks and brand inflation were partially offset by continued reimbursement pressure 
Front store same store sales were up 0 8  year over year on continued to benefit from strength in the company s consumer health care and beauty care categories 
Pharmacy same store sales increased 8 7  in the reported quarter driven by the increase in pharmacy same store prescription volumes  partially offset by continued reimbursement pressure and a negative impact of approximately 190 basis points due to recent generic introductions 
The generic dispensing rate  the proportion of all generic prescriptions to total number of prescriptions dispensed  increased approximately 20 bps to 87 2  at the Pharmacy Services segment and improved around 10 bps to 87 3  at the Retail LTC segment 
Gross profit improved 2 9  to  7 3 billion  Accordingly  gross margin expanded 9 bps to 15 5   Adjusted operating margin in the quarter however  contracted 43 bps to 4 9  
CVS Health exited the third quarter 2018 with cash and cash equivalents and short term investments of  41 7 billion compared with  43 9 billion at the end of the second quarter  Year to date  net cash provided by operating activities was  6 4 billion  as compared to  8 1 billion a year ago 
Outlook
CVS Health reaffirmed its earlier projection to deliver full year 2018 adjusted EPS in the band of  6 98 to  7 08  The Zacks Consensus Estimate for earnings is pegged at  7 05 per share  within but near to the upper end of the company s guided range  This apart  its 2018 adjusted operating profit growth guidance still remains in the range of  0 75   to up 0 75  
Further  the company expects cash flow from operations of  9 billion and free cash flow of  7 billion in 2018 
Aetna Acquisition Update
CVS Health noted that  the regulatory approval process for the company s impending acquisition of Aetna is progressing as per expectation  On Oct 10  2018  both the companies entered into a consent decree with the United States Department of Justice  DOJ  that allows the acquisition to proceed  provided Aetna agrees to sell its individual standalone Medicare Part D prescription drug plans 
Following this  Aetna has recently entered into an asset purchase agreement with a subsidiary of WellCare Health Plans  Inc  for the aforesaid divestiture  Closing of this divestiture is subject to the closing of the proposed acquisition 
Our Take
CVS Health ended the third quarter of 2018 on promising note with earnings and revenues both ahead of the respective Zacks Consensus Estimate  The year over year growth in the top line was driven by a strong Pharmacy Services segment  benefiting from the upside in the specialty services 
Also  strong year over year Retail LTC comparisons were encouraging  The company currently is moving forward towards the completion of the Aetna deal 
Zacks Rank   Key Picks
CVS Health currently carries a Zacks Rank  3  Hold  
A few better ranked stocks in the broader medical space  which reported solid earnings this season  are Intuitive Surgical   NASDAQ ISRG    Stryker Corp    NYSE SYK   and Merit Medical Systems  Inc    NASDAQ MMSI    All the stocks carry a Zacks Rank  2  Buy   You can see  
Intuitive Surgical reported third quarter 2018 adjusted earnings per share of  2 83  which beat the Zacks Consensus Estimate of  2 65  Revenues totaled  920 9 million  also surpassing the consensus estimate of  918 6 million 
Stryker posted third quarter 2018 adjusted earnings per share of  1 69  beating the Zacks Consensus Estimate of  1 68  Operating margin was 17 8   up 30 bps 
Merit Medical reported third quarter 2018 adjusted earnings per share of 47 cents  which trumped the Zacks Consensus Estimate of 42 cents  Revenues of  221 6 million edged past the consensus estimate of  218 million 
Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6  and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2018-11-06,Zacks Investment Research,https://www.investing.com/analysis/cvs-healths-cvs-q3-earnings-top-estimate-gross-margin-up-200355738,200355738
112052,333567,ISRG,Luminex s  LMNX  Q3 Earnings And Revenues Miss Estimates,opinion,Luminex Corporation   NASDAQ LMNX   reported third quarter 2018 earnings of 5 cents per share  which fell short of the Zacks Consensus Estimate by 37 5   The bottom line also plummeted 61 5  on a year over year basis Revenues in DetailIn the reported quarter  revenues came in at  72 4 million missing the Zacks Consensus Estimate of  74 million  On a year over year basis  the top line dipped 2 3  Total sample to answer molecular product revenues grew 15  from the prior year quarter to  13 6 million However  per management  revenues in the reported quarter were negatively impacted by the LabCorp departure Luminex s MDx franchise revenues also declined by 10   year over year Luminex Corporation Price  Consensus and EPS Surprise   Segmental AnalysisSystem SalesRevenues at this segment totaled  10 million  up 1 2  from the year ago quarter Consumable SalesThis segment accounted for  11 6 million of revenues  up 9 5  year over year  The upside can be primarily attributed to higher bulk purchases by a large HLA partner Royalty RevenuesRoyalty revenues summed  12 1 million  up 9 8  on a year over year basis Assay RevenuesThis segment posted revenues worth  33 7 million  which decreased 11  on a year over year basis Service RevenuesRevenues in the segment grossed  3 million  which inched up 4 2  from the year ago quarter number OtherOther revenues came in at  1 9 million  up 8 2  from a year ago Business DetailsPer management  this Texas based company secured 81 sample to answer molecular systems under contract in the quarter under review  Active sample to answer customers were about 560 by the end of the third quarter Sample to answer utilization per VERIGENE customer grew 7  to  104 000  while the same for ARIES grew 28  to  55 000 from the year ago quarter level The company also shipped 284 multiplexing analyzers  comprising MAGPIX systems  LX systems and FLEXMAP 3D systems Last month  Luminex entered into a definitive agreement with EMD Millipore Corporation to acquire the latter s flow cytometry portfolio valued at  75 million MarginsGross profit in the reported quarter was  44 3 million  down 3 4  year over year  Gross margin was 61 1   which contracted 70 basis points  bps  Operating expenses totaled  40 5 million  reflecting an increase of 3 1  on a year over year basis Adjusted operating income amounted to  5 9 million  down significantly by 31 2  from the previous year number As a percentage of revenues  operating margin was 8 2   down 340 bps on a year over year basis Research and development expenses grossed  12 million  up 12 4  year over year Selling  general and administrative expenses in the third quarter were  26 3 million  down slightly by 0 4  year over year GuidanceLuminex anticipates fourth quarter 2018 revenues to be within  77  79 million  The Zacks Consensus Estimate is pegged at  77 7 million  within the guided range For 2018  the company expects revenues to be within its guidance of  310  316 million  The Zacks Consensus Estimate is pinned at  313 9 million  within the projected range Our TakeLuminex exited the third quarter on a dull note  with both earnings and revenues missing the consensus mark  However  the company continues to gain from its flagship ARIES and VERIGENE platforms that currently have a strong customer base  The company s System  Consumables and Royalty revenues also improved significantly in the quarter under review  These apart  Luminex s efforts in controlling operating expenses are noteworthy  Management also remains optimistic about the recent EMD Millipore acquisition  which is expected to contribute significantly to the company s top line in 2019 On the flip side  year over year declines in Luminex s revenues and earnings are worrisome  The company s assay revenues also declined in the third quarter  Per management  the departure of LabCorp in the quarter has significantly impacted Luminex s top line performance  Additionally  the company s MDx franchise revenues fell significantly  Contraction in gross and operating margins add to the woes Earnings of MedTech Majors at a GlanceSome stocks from the broader Medical space that delivered robust earnings this season are Intuitive Surgical   NASDAQ ISRG    Stryker Corporation   NYSE SYK   and Merit Medical Systems  Inc    NASDAQ MMSI   Intuitive Surgical reported third quarter 2018 adjusted earnings per share of  2 83  which exceeded the Zacks Consensus Estimate of  2 65  Revenues totaled  920 9 million  which outpaced the consensus mark of  918 6 million Stryker posted third quarter 2018 adjusted earnings per share of  1 69  which came ahead of the Zacks Consensus Estimate by a penny  Operating margin was 17 8   up 30 bps Merit Medical reported third quarter 2018 adjusted earnings per share of 47 cents  which trumped the Zacks Consensus Estimate of 42 cents  Revenues of  221 6 million edged past the consensus mark of  218 million Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2018-11-06,Zacks Investment Research,https://www.investing.com/analysis/luminexs-lmnx-q3-earnings-and-revenues-miss-estimates-200356326,200356326
112053,333568,ISRG,STERIS  STE  Q2 Earnings   Revenues Beat Estimates  Rise Y Y,opinion,"STERIS plc   NYSE STE   reported second quarter fiscal 2019 adjusted earnings per share  EPS  of  1 10  up 17  year over year  The metric surpassed the Zacks Consensus Estimate of  1 08 by 1 9   Reported EPS came in at 91 cents  up from the year ago 75 cents STERIS generated revenues of  679 million in the fiscal second quarter  up 7 1  year over year  Revenues also topped the Zacks Consensus Estimate by 3 4  Quarter in DetailOrganic revenue growth at constant currency was 9  year over year in the fiscal second quarter  mainly driven by growth across all segments The company operates through four segments  Healthcare Products  Healthcare Specialty Services  Applied Sterilization Technologies and Life Sciences Revenues at Healthcare Products increased 6  year over year to  321 5 million  up 11  on a constant currency organic basis   In the quarter under review  service revenues grew 6  and capital equipment revenues rose 12   Meanwhile  consumable revenues grew 1  on divestitures limiting growth 
STERIS plc Price  Consensus and EPS Surprise
    Revenues at the Healthcare Specialty Services segment were up 7  to  124 6 million  up 7  on a constant currency organic basis  Revenues at Applied Sterilization Technologies rose 7  to  135 7 million  up 8   backed by increased demand from core medical device customers Revenues at Life Sciences segment rose 9  to  97 2 million  up 9   on 27  growth in capital equipment revenues along with 2  rise in service and consumable revenues  MarginsAdjusted gross margin declined 10 basis points  bps  year over year to 41 9  in the reported quarter  Per STERIS  shift of revenue mix toward capital equipment and investments along with outsourced reprocessing in the United States led to the decline in gross margin  However  benefits from favorable currency movement and price along with gains from divestitures had partially offset the decline STERIS witnessed a 5 5  year over year rise in selling  general and administrative expenses to  162 3 million  Research and development expenses rose 12 9  to  15 8 million  However  adjusted operating margin expanded 20 bps on a year over year basis to 15 7  in the reported quarter Financial DetailsSTERIS exited second quarter fiscal 2019 with cash and cash equivalents of  209 9 million compared with  218 5 million at the end of first quarter fiscal 2018  The company had long term debt of  1 27 billion at the end of the second quarter compared with  1 32 billion at the end of first quarter fiscal 2018 For the first six months of fiscal 2019  the company generated  226 7 million in cash flow from operations  up from  217 4 million in the year ago period  Further  free cash flow in the same period was  169 7 million compared with  144 million a year ago 2019 Guidance RevisedBased on the results for the first half of fiscal 2019  STERIS updated its full year projections for constant currency organic revenue growth to 5 6  from 4 5   The Zacks Consensus Estimate for fiscal 2019 revenues is pegged at  2 73 billion The company also revised the adjusted EPS guidance for fiscal 2019 to the range of  4 74  4 84 compared with  4 63  4 75  stated previously  The consensus estimate for fiscal 2019 adjusted EPS lies within the guided range at  4 71 Our TakeSTERIS exited second quarter fiscal 2019 on a promising note  We are also encouraged by the favorable underlying market trends along with new product and service offerings  Further  growth in free cash flow reserve is indicative of the company s strong cash balance  The company raising its overall guidance for fiscal 2019 is also indicative of brighter prospects  STERIS has also made certain divestments and organizational changes  which are expected to better align with its operations Zacks Rank   Other Key PicksSTERIS has a Zacks Rank  2  Buy  Other top ranked stocks in the broader medical space which reported solid earnings this season are Intuitive Surgical   NASDAQ ISRG    Stryker Corporation   NYSE SYK   and Merit Medical Systems  Inc    NASDAQ MMSI    All the stocks carry a Zacks Rank  2  You can see  Intuitive Surgical reported third quarter 2018 adjusted EPS of  2 83  which beat the Zacks Consensus Estimate of  2 65  Revenues totaled  920 9 million  also surpassing the consensus estimate of  918 6 million Stryker posted third quarter 2018 adjusted EPS of  1 69  outpacing the Zacks Consensus Estimate of  1 68  Operating margin was 17 8   up 30 bps Merit Medical reported third quarter 2018 adjusted EPS of 47 cents  which trumped the Zacks Consensus Estimate of 42 cents  Revenues of  221 6 million edged past the consensus estimate of  218 million Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2018-11-07,Zacks Investment Research,https://www.investing.com/analysis/steris-ste-q2-earnings--revenues-beat-estimates-rise-yy-200356913,200356913
112054,333569,ISRG,Cardinal Health  CAH  Surpasses Earnings Estimates In Q1,opinion,Cardinal Health Inc    NYSE CAH   delivered first quarter fiscal 2019 adjusted earnings of  1 29 per share  which beat the Zacks Consensus Estimate of  1 06  Adjusted earnings increased 18  year over year Revenues increased 7 9  on a year over year basis to  35 21 billion and beat the Zacks Consensus Estimate of  33 54 billion Cardinal Health currently has a Zacks Rank  4  Sell  Segmental AnalysisPharmaceutical SegmentIn the fiscal first quarter  pharmaceutical revenues increased 8 6  to  31 42 billion on a year over year basis  The segment witnessed strong growth in the Specialty business and gained a large number of Pharmaceutical Distribution customers However  strong growth in the segment was partially offset by the divestiture of the company s China distribution business Pharmaceutical witnessed a 12 8  decline in profits to  409 million  thanks to generic pharmaceutical pricing Medical SegmentIn the quarter under review  revenues in the segment improved 2 1  to  3 80 billion  courtesy of the Patient Recovery business acquisition Medical segment profits increased 4 7  to  135 million Cardinal Health  Inc  Price  Consensus and EPS Surprise    Margin AnalysisGross Profit inched down 0 3  year over year to  1 67 billion As a percentage of revenues  gross margin in the quarter was 4 7   down 40 basis points  bps  on a year over year basis Distribution  selling  general and administrative expenses were  1 16 billion in the quarter under review  up 8 8  year over year  Adjusted operating margin for Cardinal Health in the quarter under review was 3 3  of net revenues  flat year over year GuidanceThe company reiterated guidance for fiscal 2019 adjusted earnings per share Adjusted earnings from continuing operations are expected in the range of  4 90  5 15  The Zacks Consensus Estimate was pegged at  5 02  which lies within the guidance In ConclusionCardinal Health exited the fiscal first quarter on a solid note  with adjusted earnings and revenues beating the consensus mark  The Pharmaceutical segment registered strong growth in the Specialty business and gained a number of Pharmaceutical Distribution customers  Cardinal Health also inked a partnership with Clayton  Dubilier   Rice to accelerate growth of naviHealth  a market leader in post acute care management Despite growth in business  profits in the Pharmaceutical segment were hurt by generic pharmaceutical pricing  Huge investments in Pharmaceutical IT platform and lackluster generics performance are likely to mar Cardinal Health s operational efficiencies in the upcoming quarters  Intense competition and customer concentration are other bottlenecks  Recently  the company closed the divestiture of Cardinal Health China distribution Earnings of Other MedTech Majors at a GlanceA few better ranked stocks in the broader medical space which also reported solid earnings this season are Intuitive Surgical   NASDAQ ISRG    Stryker Corporation   NYSE SYK   and Merit Medical Systems  Inc    NASDAQ MMSI    Each of the stocks carry a Zacks Rank  2  You can see  Intuitive Surgical reported third quarter 2018 adjusted EPS of  2 83  which beat the Zacks Consensus Estimate of  2 65  Revenues totaled  920 9 million  also surpassing the consensus estimate of  918 6 million Stryker posted third quarter 2018 adjusted EPS of  1 69  beating the Zacks Consensus Estimate by a penny  Operating margin was 17 8   up 30 basis points  bps  Merit Medical reported third quarter 2018 adjusted EPS of 47 cents  which trumped the Zacks Consensus Estimate of 42 cents  Revenues of  221 6 million edged past the consensus estimate of  218 million Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana      Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2018-11-07,Zacks Investment Research,https://www.investing.com/analysis/cardinal-health-cah-surpasses-earnings-estimates-in-q1-200357051,200357051
112055,333570,ISRG,Myriad Genetics  MYGN  Beats On Earnings In Q1  Revenues Lag,opinion,"Myriad Genetics  Inc    NASDAQ MYGN   reported adjusted earnings per share  EPS  of 43 cents in the first quarter of fiscal 2019  up 48 3  year over year  Moreover  adjusted EPS beat the Zacks Consensus Estimate of 30 cents by 43 3  and exceeded the company s guided range of 28 30 cents Meanwhile  on a reported basis  the company incurred loss per share of a penny as against earnings of  1 12 a year ago RevenuesTotal revenues were up 13 1  year over year to  202 3 million in the quarter under review and were almost in line with the high end of the company s guidance of  200  202 million  The figure  however  missed the Zacks Consensus Estimate by 0 8  The year over year growth was driven by growing new product and hereditary cancer volumes  offsetting adverse impacts from price reductions in long term contracts related to Hereditary cancer testing  Moreover  this was the seventh consecutive quarter in which the company witnessed year over year Hereditary cancer testing volume growth 
Myriad Genetics  Inc  Price  Consensus and EPS Surprise
    Quarter in DetailSegment wise  Molecular diagnostic tests  93 4  of total revenues  recorded total revenues of  189 million  up 12 9  year over year   Hereditary Cancer testing revenues declined by 0 6  to  116 3 million  Furthermore  Hereditary Cancer testing revenues declined due to price reductions in long term contracts EndoPredict testing revenues rose 33 3  year over year to  2 4 million in the reported quarter  Vectra DA testing revenues were  13 million  down 7 1  year over year while other testing revenues rose 94 7  to  3 7 million  Further  GeneSight testing revenues rose 1 7  year over year to  29 3 million in the reported quarter  Prolaris tests raked in revenues of  6 2 million  up 59  year over year  Prenatal testing revenues came in at  18 1 million Pharmaceutical and clinical service revenues  accounting for the rest  in the quarter under review totaled  13 3 million  reflecting a year over year increase of 16 7  Margin TrendsGross margin in the quarter under review contracted 60 basis points  bps  to 75 4   However  adjusted gross margin came in at 77 1   up 100 bps year over year  According to management  the gross margin performance was led by reduction in reagent costs derived by initiating new process enhancement for the DNA  RNA  and protein laboratories Adjusted operating income was  1 6 million  down 85 2  year over year  Research and development  R D  expenses rose 18 5  year over year  to  21 1 million  along with a 21 2  increase in selling  general and administrative  SG A  expenses  to  129 9 million  in the reported quarter  The adjusted operating margin came in at 0 8   compared with operating margin of 6  a year ago Financial PositionMyriad Genetics exited first quarter fiscal 2019 with cash  cash equivalents and marketable securities of  167 5 million compared with  180 6 million at the end of fiscal 2018  For the three months ending Sep 30  2018  cash flow from operations totaled  7 8 million compared with  23 5 million a year ago  Further  the company registered free cash flow of  6 5 million in the same period  compared with  21 9 million a year ago Guidance UpdatedMyriad Genetics has updated the guidance for the fiscal 2019 revenues  The company now expects fiscal 2019 revenues in the range of  855  865 million compared with  880  890 million stated previously  The Zacks Consensus Estimate of  901 9 million lies above the guided range On the bottom line front  the company continues to expect adjusted EPS of  1 70  1 75  The current Zacks Consensus Estimate of  1 73 is within the company s guided range Management has provided the guidance for the second quarter of fiscal 2019  The company estimates adjusted EPS of 36 38 cents on total revenues of  216  218 million  The Zacks Consensus Estimate for adjusted EPS is 43 cents and revenues is  226 2 million  Our estimates for both the metrics are above the company s guided range Our ViewMyriad Genetics started off fiscal 2019 on a mixed note  The company observed strong growth in GeneSight  EndoPredict and Prolaris testing revenues  The recent FDA approvals and encouraging test results buoy optimism  Further  management believes that Hereditary cancer pricing has remained stable on a sequential basis for four consecutive quarters  We are upbeat about Myriad Genetics  expectation to witness a stable pricing trend in the same to continue throughout fiscal 2019 Moreover  the company seems to be well positioned to deliver strong financial results in fiscal 2019  on solid performance by new products  a re designed cost structure  synergies from the Counsyl buyout along with augmenting reimbursements for the tests On the flip side  unfavorable foreign currency translation continues to pose a threat  With a considerable portion of its revenues coming from outside the United States  the company faces the risk of exchange rate fluctuations Zacks Rank   Key PicksMyriad Genetics currently has a Zacks Rank  3  Hold  A few better ranked stocks in the broader medical space which reported solid earnings this season are Intuitive Surgical   NASDAQ ISRG    Stryker Corporation   NYSE SYK   and Merit Medical Systems  Inc    NASDAQ MMSI    All the stocks carry a Zacks Rank  2  Buy   You can see  Intuitive Surgical reported third quarter 2018 adjusted EPS of  2 83  which beat the Zacks Consensus Estimate of  2 65  Revenues totaled  920 9 million  also surpassing the consensus estimate of  918 6 million Stryker posted third quarter 2018 adjusted EPS of  1 69  outpacing the Zacks Consensus Estimate by a penny  Operating margin was 17 8   up 30 bps Merit Medical reported third quarter 2018 adjusted EPS of 47 cents  which trumped the Zacks Consensus Estimate of 42 cents  Revenues of  221 6 million edged past the consensus estimate of  218 million Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2018-11-07,Zacks Investment Research,https://www.investing.com/analysis/myriad-genetics-mygn-beats-on-earnings-in-q1-revenues-lag-200357047,200357047
112056,333571,ISRG,Hologic  HOLX  Q4 Earnings Miss  Revenues Top Estimates,opinion,Hologic  Inc    NASDAQ HOLX   reported fourth quarter fiscal 2018 adjusted earnings per share  EPS  of 58 cents  up 16  year over year  However  the bottom line missed the Zacks Consensus Estimate by a penny and met the lower end of the company s guided range of 58 60 cents On a reported basis  the company recorded net income of 18 cents per share compared with 29 cents in the year ago period Revenues in DetailRevenues grossed  813 5 million in the reported quarter  up 1 3  year over year  up 1 7  at constant exchange rate or CER   The top line also surpassed the Zacks Consensus Estimate of  805 million as well as the lower end of the company s projection of  800  815 million Notably  Hologic sprior year numbers were benefited  by higher sales from the company s divested Blood Screening business and its non recurring royalty revenues of  9 5 million in Molecular Diagnostics  which more than offset an extra selling day in the reported quarter Hologic  Inc  Price  Consensus and EPS Surprise   Geographically  revenues in the United States inched up 0 3  year over year to  615 1 million in the fiscal fourth quarter  International revenues were up 4 5   up 6 3  at CER  to  207 2 million  primarily on a strong contribution from the Molecular Diagnostics  Breast Health and and Surgical business Segments in DetailRevenues at the Diagnostics segment  representing 35 5  of total revenues  slid 1  year over year  up 0 5  at CER  to  288 9 million in the quarter under review  Under this segment  Molecular Diagnostics revenues of  158 million increased 2 9   up 3 4  at CER  fueled by strong international performance However  Cytology and Perinatal revenues with  118 million showed a 1 8  slip  down 1 2  at CER  Revenues at the Breast Health segment  39 6   increased 7 1   up 7 4  at CER  to  322 2 million  This metric in the United States grew 5 4   registering the best growth rate over the last seven quarters  Internationally  Breast Health revenue growth was in the mid teens   Revenues at the GYN Surgical business  13 2   grew 2 6   up 3 1  at CER  to  107 4 million  Medical Aesthetic business in the reported quarter logged revenues of  70 6 million  reflecting a 12 9  decline Revenues at Skeletal Health  accounting for the rest  inched up  8   up 1 4  at CER  to  24 4 million Operational UpdateIn the fiscal fourth quarter  Hologic s adjusted gross margin contracted 25 basis points  bps  to 61 7   This downside was primarily due to an adverse geographic and product sales mix  non recurring royalties included in the prior year period plus refunds and rebates associated with the company s TempSure Vitalia products Hologic s adjusted operating expenses amounted to  304 million  up 4 6  year over year  Adjusted operating margin contracted 144 bps to 24 3  Financial UpdateHologic exited fiscal 2018 with cash and cash equivalents of  666 7 million compared with  540 6 million at the end of fiscal 2017  Total long term debt was  3 30 billion at the end of fiscal 2018 compared with  3 32 billion a year ago At the end of the full year  the company generated operating cash flow of  732 9 million compared with  8 3 million in the prior year period  GuidanceHologic has provided its fiscal 2019 financial guidance  The company expects adjusted revenues of  3 29  3 33 billion  expected growth rate of 2 8 4 2  at CER   The Zacks Consensus Estimate for revenues is pegged at  3 32 billion  within but near to the upper end of the guided range The company also envisions adjusted EPS of  2 38  2 42  a projection of 6 7 8 5  growth rate   The consensus mark for the metric stands at  2 41  falling within the estimated range For first quarter fiscal 2019  Hologic anticipates adjusted revenues of  800  815 million  indicating 1 6 3 5  expected growth at CER  The consensus estimate for revenues is  822 2 million  lying above the projected range Adjusted EPS is predicted at 55 57 cents  reflecting annualized growth of 0 3 6   The Zacks Consensus Estimate for first quarter adjusted EPS is pegged at 59 cents  higher than the company s forecast Our TakeHologic exited the fiscal 2018 on a mixed note with fourth quarter earnings missing the Zacks Consensus Estimate while revenues exceeding the mark  Tough year ago comparison along with sluggish Diagnostics sales in the reported quarter hampered the overall performance for the company  On a positive note  a solid uptick in its international business buoys optimism  Also  an improvement in the Surgical and Cynosure businesses is encouraging Zacks Rank   Key PicksHologic carries a Zacks Rank  4  Sell  A few better ranked stocks in the broader medical space  which reported solid earnings this season  are Intuitive Surgical   NASDAQ ISRG    Stryker Corporation   NYSE SYK   and Merit Medical Systems  Inc    NASDAQ MMSI    each carrying a Zacks Rank  2  Buy   You can see  Intuitive Surgical reported third quarter 2018 adjusted EPS of  2 83  which beat the Zacks Consensus Estimate of  2 65  Revenues totaled  920 9 million  also surpassing the consensus estimate of  918 6 million Stryker posted third quarter 2018 adjusted EPS of  1 69  outpacing the Zacks Consensus Estimate of  1 68  Operating margin was 17 8   up 30 bps Merit Medical delivered third quarter 2018 adjusted EPS of 47 cents  which trumped the Zacks Consensus Estimate of 42 cents  Revenues of  221 6 million edged past the consensus estimate of  218 million Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2018-11-07,Zacks Investment Research,https://www.investing.com/analysis/hologic-holx-q4-earnings-miss-revenues-top-estimates-200356986,200356986
112057,333572,ISRG,DaVita s  DVA  Q3 Earnings Lag Estimates  Kidney Care Down,opinion,DaVita Inc   NYSE DVA   reported third quarter 2018 adjusted operating earnings per share of 56 cents  which missed the Zacks Consensus Estimate by 37 1   The figure also declined 34 1  on a year over year basis Total revenues in the quarter improved 3  year over year to  2 85 billion  also missing the Zacks Consensus Estimate of  2 92 billion Per management  DaVita incurred additional expenses in the reported quarter which significantly impacted earnings These expenses include  45 million of advocacy costs in countering union policy efforts and equity compensation of  23 million  Additionally  the company recognized restructuring charges of  11 million and asset impairment charges of  6 million in the reported quarter DaVita Inc  Price  Consensus and EPS Surprise   Over the past year  the Zacks Rank  3  Hold  stock has rallied 40  compared with the  s 11  rise  The current level is also higher than the S P 500 index s increase of 6 3  Business DetailsNet dialysis and related lab patient service revenues in the third quarter totaled  2 66 billion  up 8 9  on a year over year basis  Other revenues were  188 6 million  down a significant 41 6  year over year Per management  in the quarter under review  the company provided dialysis services to a total of 226 000 patients at 2 876 outpatient dialysis centers  Of these 2 625 centers were located in the United States and 251 centers were in 10 countries outside  Moreover  DaVita opened a total of 47 new dialysis centers and acquired three dialysis centers in the United States However  DaVita posted lackluster results in the Kidney Care business in the third quarter  Net consolidated revenues at the segment totaled  2 85 billion  down 1 4  year over year  Consolidated Kidney Care operating income was  289 million  down 34  from the year ago quarter  As an operating division of the company  DaVita Kidney Care focuses on setting worldwide standards for clinical  social and operational practices in kidney care U S  dialysis and related lab services revenues grossed  2 58 billion  down 0 4  from the prior year quarter  International dialysis patient service and other revenues totaled  113 million  up 5 6  year over year For investors  notice  the company is on track to divest the major segment   DaVita Medical Group  DMG    to Optum  a subsidiary of UnitedHealth Group Inc  NYSE UNH   This transaction is subject to regulatory approvals and other customary closing conditions  The results of DMG business  operations have been reported as discontinued Share Repurchase UpdateDuring the third quarter  DaVita repurchased a total of 4 8 million shares for approximately  344 million  at an average price of  70 86 a share As of Nov 5  2018  DaVita has repurchased 16 8 million shares for  1 15 billion on a year to date basis Financial ConditionDaVita exited the third quarter with operating cash flow of  362 million and free cash flow of  226 million GuidanceFor 2018  DaVita expects Kidney Care adjusted consolidated operating income in the range of  1 5  1 53 billion  lower than the earlier band of  1 5  1 6 billion  which excluded advocacy costs Operating cash flow in 2018 is anticipated within  1 4  1 6 billion Effective income tax rate on income from continuing operations attributable to the company is projected between 30 5  and 31 5  for 2018 Our TakeDaVita ended the third quarter on a dull note  with earnings and revenues missing the consensus mark  Earnings declined year over year  The company s Kidney Care revenues also inched down  In fact  dialysis services in the United States saw a relatively soft quarter  Notably  DaVita incurred significant advocacy and impairment costs in the quarter  which negatively impacted results  Adoption of executive retirement policy also led to additional expenses for the company  Sluggishness in Other business has been another headwind  A narrowed guidance for 2018 adds to the woes On the brighter side  DaVita s international dialysis revenues rose year over year in the quarter  The company is on track to acquire an increasing number of dialysis centers in the United States  Additionally  the recent win against the union backed ballot in California is indicative of brighter prospects Earnings of MedTech Majors at a GlanceSome stocks from the broader Medical space that delivered robust results this earnings season are Intuitive Surgical   NASDAQ ISRG    Stryker Corporation   NYSE SYK   and Merit Medical Systems  Inc    NASDAQ MMSI    Notably  each of the stocks carries a Zacks Rank  2  Buy   You can see  Intuitive Surgical reported third quarter 2018 adjusted earnings per share of  2 83  which exceeded the Zacks Consensus Estimate of  2 65  Revenues totaled  920 9 million  which outpaced the consensus mark of  918 6 million Stryker posted third quarter 2018 adjusted earnings per share of  1 69  which beat the Zacks Consensus Estimate by a penny  Operating margin was 17 8   up 30 bps Merit Medical reported third quarter 2018 adjusted earnings per share of 47 cents  which trumped the Zacks Consensus Estimate of 42 cents  Revenues of  221 6 million edged past the consensus mark of  218 million Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2018-11-07,Zacks Investment Research,https://www.investing.com/analysis/davitas-dva-q3-earnings-lag-estimates-kidney-care-down-200357062,200357062
112058,333573,ISRG,Intuitive Surgical  ISRG  Dips More Than Broader Markets  What You Should Know,opinion,"In the latest trading session  Intuitive Surgical  NASDAQ ISRG  closed at  540 02  marking a  1 04  move from the previous day  This change lagged the S P 500 s daily loss of 0 25   At the same time  the Dow added 0 04   and the tech heavy Nasdaq lost 0 53  
Heading into today  shares of the robotic surgery system company had gained 6 53  over the past month  outpacing the Medical sector s loss of 1 06  and the S P 500 s loss of 2 35  in that time 
ISRG will be looking to display strength as it nears its next earnings release  which is expected to be January 24  2019  In that report  analysts expect ISRG to post earnings of  2 96 per share  This would mark year over year growth of 16 54   Our most recent consensus estimate is calling for quarterly revenue of  1 02 billion  up 14 49  from the year ago period 
Looking at the full year  our Zacks Consensus Estimates suggest analysts are expecting earnings of  10 97 per share and revenue of  3 70 billion  These totals would mark changes of  22 02  and  18 23   respectively  from last year 
It is also important to note the recent changes to analyst estimates for ISRG  These recent revisions tend to reflect the evolving nature of short term business trends  As a result  we can interpret positive estimate revisions as a good sign for the company s business outlook 
Research indicates that these estimate revisions are directly correlated with near term share price momentum  To benefit from this  we have developed the Zacks Rank  a proprietary model which takes these estimate changes into account and provides an actionable rating system 
The Zacks Rank system  which ranges from  1  Strong Buy  to  5  Strong Sell   has an impressive outside audited track record of outperformance  with  1 stocks generating an average annual return of  25  since 1988  Within the past 30 days  our consensus EPS projection has moved 1 69  higher  ISRG is currently sporting a Zacks Rank of  2  Buy  
Valuation is also important  so investors should note that ISRG has a Forward P E ratio of 49 75 right now  Its industry sports an average Forward P E of 33 62  so we one might conclude that ISRG is trading at a premium comparatively 
It is also worth noting that ISRG currently has a PEG ratio of 3 18  This popular metric is similar to the widely known P E ratio  with the difference being that the PEG ratio also takes into account the company s expected earnings growth rate  The Medical   Instruments industry currently had an average PEG ratio of 2 66 as of yesterday s close 
The Medical   Instruments industry is part of the Medical sector  This group has a Zacks Industry Rank of 92  putting it in the top 36  of all 250  industries 
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
To follow ISRG in the coming trading sessions  be sure to utilize Zacks com ",2018-11-08,Zacks Investment Research,https://www.investing.com/analysis/intuitive-surgical-isrg-dips-more-than-broader-markets-what-you-should-know-200357240,200357240
112059,333574,ISRG,Genomic Health  GHDX  Q3 Earnings And Revenues Top Estimates,opinion,"Genomic Health  Inc    NASDAQ GHDX   reported third quarter 2018 adjusted earnings per share  EPS  of 35 cents compared with the year ago adjusted EPS of 3 cents  The bottom line also surpassed the Zacks Consensus Estimate of 7 cents Reported net income came in at 32 cents per share against the year ago net loss of 6 cents Revenues in DetailTotal revenues in the quarter rose 20 9  year over year to  101 3 million  beating the Zacks Consensus Estimate by 7 2   Growth in the United States and international markets drove the top line  Solid U S  invasive breast cancer growth was also recorded in the quarter Geographically  third quarter product revenues in the United States rose 23  to  85 8 million from the year ago pre 606 adjusted revenues  The U S  product revenue growth was fueled by a 24  rise in U S  invasive breast revenues from Oncotype DX Breast Recurrence Score tests and a 28  surge in U S  prostate test revenues from Oncotype DX Genomic Prostate Score  GPS  tests 
Genomic Health  Inc  Price  Consensus and EPS Surprise
    International product revenues totaled  15 5 million in the quarter under review  up 22  year over year  up 20  at adjusted constant currency  from the year ago pre 606 adjusted tally During the third quarter  the company delivered more than 34 810 Oncotype DX test results  up 10  year over year Margin TrendGenomic Health s gross margin expanded 70 basis points  bps  year over year to 84 7  in the third quarter The company also saw a 1 2  rise in operating expenses to  74 million on a 4 7  rise in selling and marketing expenses to  40 1 million and a 5 7  increase in general and administrative expenses to  18             5 million  However  research and development expenses declined 10 5  to  15 4 million In the reported quarter  Genomic Health s operating income came in at  11 8 million against the year ago operating loss of  2 6 million Financial UpdateGenomic Health exited the third quarter of 2018 with cash and cash equivalents and short term marketable securities of  183 2 million  highlighting an improvement from  152 9 million at the end of second quarter 2018 2018 Guidance UpdatedGenomic Health now expects full year revenues in the range of  389  391 million as against the prior  366  382 million  reflecting growth of 17   from 10 15  growth stated earlier   The Zacks Consensus Estimate is pegged at  392 3 million  above the guided range Our TakeGenomic Health exited third quarter 2018 on a promising note We are also encouraged by the year over year rise in revenues  driven by solid performances in the United States and internationally  Per the company  within prostate cancer space  the company saw increasing private coverage for the Oncotype DX GPS test  Moreover  Genomic Health recently announced the publication of real world clinical data supporting the use of the Oncotype DX GPS test  which has resulted in substantially greater use of active surveillance compared to no testing  Results of this new study were published in Reviews in Urology Another independent study was published by University of California  San Francisco  UCSF  researchers in the Journal of Urology The company also witnessed a series of developments for its Oncotype DX Breast Recurrence Score tests  In this regard  Genomic Health recently announced a positive development with regard to the newly updated National Comprehensive Cancer Network  NCCN  2018 guidelines for invasive breast cancer chemotherapy treatment  Per the company  its Oncotype DX Breast Recurrence Score test has been identified as the only  preferred  test for making decisions regarding chemotherapy treatment for patients suffering from node negative early stage breast cancer Furthermore  Oncotype DX has been elevated into the algorithm for chemotherapy treatment of patients with micrometastases and one to three positive lymph nodes However  Genomic Health s sole reliance on the Breast Oncotype DX test is concerning Zacks Rank   Other Key PicksGenomic Health carries a Zacks Rank  1  Strong Buy  Other top ranked stocks in the broader medical space which reported solid earnings this season are Intuitive Surgical   NASDAQ ISRG    Stryker Corporation   NYSE SYK   and Merit Medical Systems  Inc    NASDAQ MMSI    All the stocks carry a Zacks Rank  2  Buy   You can see  Intuitive Surgical reported third quarter 2018 adjusted EPS of  2 83  which beat the Zacks Consensus Estimate of  2 65  Revenues totaled  920 9 million  also surpassing the consensus estimate of  918 6 million Stryker posted third quarter 2018 adjusted EPS of  1 69  outpacing the Zacks Consensus Estimate of  1 68  Operating margin was 17 8   up 30 bps Merit Medical reported third quarter 2018 adjusted EPS of 47 cents  which trumped the Zacks Consensus Estimate of 42 cents  Revenues of  221 6 million edged past the consensus estimate of  218 million The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2018-11-08,Zacks Investment Research,https://www.investing.com/analysis/genomic-health-ghdx-q3-earnings-and-revenues-top-estimates-200357561,200357561
112091,333606,ISRG,Abiomed  ABMD  Q2 Earnings Beat  Impella Maintains Momentum,opinion,"Abiomed  Inc    NASDAQ ABMD   reported second quarter fiscal 2019 earnings per share of 81 cents  which surpassed the Zacks Consensus Estimate by 11   Adjusted earnings skyrocketed 84 1  from the year ago quarter 
Revenues in the reported quarter came in at  181 8 million  outpacing the Zacks Consensus Estimate of  175 3 million  Revenues also improved 36 9  from the prior year quarter 
Meanwhile  the Zacks Rank  1  Strong Buy  stock has rallied 98 3  compared with the  s 17 8  in a year s time  The current level is also higher than the S P 500 index s rise of 6 4  ABIOMED  Inc  Price  Consensus and EPS Surprise

   Q2 in Detail
Geographic Analysis
Per management  U S  revenues rose 33  year over year to  158 million  driven by a 29  increase in overall patient utilization in the second quarter  Outside the United States  revenues were  24 million  up 67  from the year ago quarter 
European revenues increased 38   with German revenues up 33  year over year 
Additionally  the company recorded revenues of  4 1 million in Japan 
Impella Sustains Momentum
Abiomed s flagship Impella heart pump revenues totaled  175 3 million in the second quarter  globally  Per management  this shows a year over year upside of 38  
U S  Impella heart pump revenues totaled  152 2 million in the reported quarter  reflecting an increase of 34  from the prior year quarter 
Outside the United States  Impella heart pump revenues totaled  23 1 million  up 67  
Furthermore  the Impella 2 5 and CP were placed at approximately 1 250 sites in the United States by the end of the reported quarter  Additionally  the Impella 5 0 and RP were placed at 559 and 368 sites  respectively 
Margin Trend
In the quarter under review  gross margin was 83 6   down 10 basis points  bps  year over year  Per management  the benefit from higher volume was offset by manufacturing investments such as direct labor hires to support growth 
Research   Development  R D  costs in the second quarter grossed  22 7 million  up 17 2  year over year 
Operating income in the quarter totaled  50 3 million  up 58 6  on a year over year basis  Operating margin was 27 7   up 380 bps 
Financial Condition
Abiomed s cash and marketable securities for the fiscal second quarter were  410 4 million  The company currently has no debt 
FY19 Outlook
Abiomed raised its fiscal 2019 guidance 
For fiscal 2019  the company expects revenues in the band of  765  770 million  showing an increase of 29 30  from the previous fiscal  This compares to the earlier guidance of  755  770 million  showing a year over year rise of 27 30  
Notably  the Zacks Consensus Estimate is pegged at  768 2 million  within the guided range 
Abiomed expects to see strong contribution from its core Impella product lines in the quarters ahead 
Summing Up
Abiomed wrapped up the second quarter of fiscal 2019 on a solid note  The company continues to gain from its flagship Impella which saw a strong quarter in the United States  Impella s patient success stories and increasing global adoptions are major positives  Revenues from Germany and Japan shot up in the quarter 
Raised guidance for fiscal 2019 is indicative of brighter prospects  Considerable expansion in the operating margin also buoys optimism  Meanwhile  surging R D expenses show increasing focus on innovation  In fact  the company continues to invest in training and education  Abiomed s balance sheet remains debt free 
However  contraction in the company s gross margin raises concern  Intense competition in the industry is likely to mar prospects  Abiomed has significant international presence that exposes it to fluctuations in currency exchange rates 
Earnings of Other MedTech Majors at a Glance
Other top ranked stocks in the broader medical space which also reported solid earnings this season are Intuitive Surgical   NASDAQ ISRG    Stryker Corp    NYSE SYK   and Merit Medical Systems  Inc    NASDAQ MMSI    Each of the stocks carries a Zacks Rank  2  Buy   You can see  
Intuitive Surgical reported third quarter 2018 adjusted earnings per share of  2 83  which beat the Zacks Consensus Estimate of  2 65  Revenues totaled  920 9 million  also surpassing the consensus estimate of  918 6 million 
Stryker posted third quarter 2018 adjusted earnings per share of  1 69  steering past the Zacks Consensus Estimate by a penny  Operating margin was 17 8   up 30 bps 
Merit Medical reported third quarter 2018 adjusted earnings per share of 47 cents  which trumped the Zacks Consensus Estimate of 42 cents  Revenues of  221 6 million edged past the consensus estimate of  218 million 
Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2018-11-02,Zacks Investment Research,https://www.investing.com/analysis/abiomed-abmd-q2-earnings-beat-impella-maintains-momentum-200354254,200354254
112092,333607,ISRG,Allscripts  MDRX  Misses Q3 Earnings And Revenue Estimates,opinion,"Allscripts Healthcare Solutions  Inc    NASDAQ MDRX   posted third quarter 2018 adjusted earnings per share of 18 cents  which missed the Zacks Consensus Estimate by a penny  Earnings also improved 12 5  on a year over year basis Revenues in the quarter came in at  535 8 million on a non GAAP basis  which missed the Zacks Consensus Estimate of  546 million  However  the figure improved 18 8  year over year  On a reported basis  revenues totaled  522 million in the quarter  reflecting an increase of 16  year over year Bookings in the reported quarter came in at  246 million  significantly down from the prior year quarter s tally of  304 million  In fact  management expects to some volatility in bookings in the quarters ahead The stock carries a Zacks Rank  4  Sell  Allscripts Healthcare Solutions  Inc  Price and Consensus
    Segment DetailsSoftware delivery  Support and MaintenanceRevenues in the segment grossed  330 4 million on a reported basis  up 14 3  from the year ago quarter s tally Client servicesRevenues in the segment came in at  191 9 million  up 19 7  from the year ago quarter s figure MarginsIn the quarter under review  gross profit totaled  218 4 million  up 8 1  from the year ago quarter s level  As a percentage of revenues  gross margin was 41 8   down from 69 8  in the year ago quarter  The lackluster performance was primarily caused by decline in non recurring software license revenues Selling  general and administrative expenses in the quarter totaled  133 2 million  up 13 5  year over year  Research and development expenses totaled  69 7 million  up 36 4  year over year Adjusted operating income in the quarter was  15 5 million  down 53 7  year over year  Adjusted operating margin was 3   as a percentage of revenues GuidanceOn an adjusted basis  Allscripts expects 2018 revenues in the lower end of  2 15 billion and  2 25 billion  up 17 22  year over year  The Zacks Consensus Estimate is pegged at  2 17 billion  within the guided range Adjusted earnings per share  EPS  are expected in the lower end of 72 cents and 82 cents  reflecting an increase of 16  to 32  year over year  The Zacks Consensus Estimate is at 75 cents  within the projected range Adjusted EBITDA is anticipated between  420 million and  460 million  up 12  to 23  year over year Summing UpAllscripts ended the third quarter on a tepid note  missing the Zacks Consensus Estimate for both the counts  The company s margins are under pressure due to decline in non recurring software license revenues  Year over year decline in bookings is a concern  In fact  management expects to some volatility in bookings in the quarters ahead  Additionally  the company witnessed significant contraction in margins  The company is also exposed to integration risks  Intense competition in the niche space adds to the woes On the positive side  the company continues to gain from the core software  delivery  support and maintenance units  which projected solid growth  The company s growth in revenue cycle services and acquisition of McKesson s EIS business have lent it a competitive edge  The recently closed acquisition of HealthGrid is likely to boost the company s FollowMyHealth patient engagement platform  Management is also optimistic about benefits from the sale of OneContent  which was closed earlier this year Q3 Earnings of MedTech Majors at a GlanceA few better ranked stocks in the broader medical space  having reported solid earnings this season  are Stryker Corporation   NYSE SYK    Intuitive Surgical  Inc   NASDAQ ISRG   and Merit Medical Systems  Inc   NASDAQ MMSI   All the three stocks carry a Zacks Rank  2  Buy   You can see  Intuitive Surgical reported adjusted earnings of  2 83 per share in the third quarter of 2018  which beat the Zacks Consensus Estimate of  2 65  Adjusted earnings improved 1 8  year over year Stryker delivered third quarter 2018 adjusted EPS of  1 69  which beat the Zacks Consensus Estimate of  1 68  Earnings improved 11 2  year over year  within the company s guidance Merit Medical reported third quarter 2018 adjusted EPS of 47 cents  beating the Zacks Consensus Estimate of 42 cents  Adjusted earnings improved 46 9  from the year ago quarter s tally Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana      Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2018-11-04,Zacks Investment Research,https://www.investing.com/analysis/allscripts-mdrx-misses-q3-earnings-and-revenue-estimates-200354734,200354734
112093,333608,ISRG,Integer Holdings  ITGR  Beats On Q3 Earnings And Revenues,opinion,Integer Holdings Corporation   NYSE ITGR   reported third quarter 2018 adjusted earnings of  1 06 per share  outpacing the Zacks Consensus Estimate by 15 2   Earnings rose 16 5  on a year over year basis Revenues improved 6 9  year over year to  305 1 million on a reported basis and surpassed the Zacks Consensus Estimate of  292 million Meanwhile  the Zacks Rank  1  Strong Buy  stock has rallied 81 4  compared with the  s 16 2  in a year s time  The current level is also higher than the S P 500 index s rise of 5 2  Integer Holdings Corporation Price  Consensus and EPS Surprise   Segmental AnalysisInteger Holdings operates through two segments   Medical Sales and Non Medical Sales Medical SalesReported sales at the segment were  292 6 million  up 8  year over year  Revenues increased 8 7  on an organic basis Medical Sales has three sub segments   Advanced Surgical  Orthopedics and Portable Medical  AS O   Cardio and Vascular  and Cardiac Neuromodulation Advanced Surgical  Orthopedics and Portable MedicalRevenues amounted to  32 8 million  up 3 4  from the prior year quarter  Notably  the segment grew 8 9  on an organic basis  Per management  the upside was driven by solid market demand Cardio and VascularRevenues at the segment totaled  150 2 million  up 9 1  from the prior year quarter and 9 2  organically  Per management  sales increased primarily on continued strong demand in the electrophysiology market and product launches Cardiac NeuromodulationRevenues at this segment totaled  109 6 million  up 7 9  from the prior year quarter  On an organic basis  the segment grew 7 9   However  management expects a drop in sales in the fourth quarter of 2018 Non Medical SalesReported sales in the segment totaled  12 4 million  down 17 7  on both year over year and organic basis  Per management  the deterioration was caused due to North American drilling activity and planned phase out of certain rechargeable battery pack products Margin AnalysisInteger Holdings generated gross profit of  91 9 million in the third quarter  up 3 1  year over year  As a percentage of revenues  gross margin in quarter contracted 110 basis points  bps  to 30 1  Selling  general and administrative expenses  SG A  were  34 1 million  down 2 8  year over year Research  development and engineering costs totaled  12 2 million in the quarter  up 0 1  year over year Total operating income in the quarter under review was  41 5 million  up 15 7  year over year  Adjusted income from operations totaled  45 6 million  up 8 8  year over year Adjusted operating margin was 14 9   up 30 bps year over year Financial ConditionInteger Holdings exited the third quarter with cash and cash equivalents of  22 9 million  The company paid down  595 million of debt  of which  548 million was used from the divestiture of the AS O Product Line GuidanceFor 2018  Integer Holdings expects reported revenues between  1 197 million and  1 212 million  reflecting year over year growth of 5 7   On an adjusted basis  the company expects revenues in the band of  1 195  1 210 million  showing growth of 6 7  from the previous year The Zacks Consensus Estimate is pegged at  1 24 billion Adjusted earnings per share are expected within  3 55 to  3 70  indicating a rise of 15 20  from the previous year  The Zacks Consensus Estimate is pinned at  3 62  within the guided range Adjusted income from operations is anticipated between  117 million and  122 million showing year over year rise of 18  23  Adjusted EBITDA is projected between  255 million and  265 million  up 9 13  year over year Summing UpInteger Holdings wrapped up the third quarter on a solid note  with earnings and revenues beating the consensus mark  The company continues to gain from its Cardio   Vascular product line  Strong demand across key areas like electrophysiology  structural heart and peripheral vascular is a major positive  Management is optimistic about the divestiture of its AS O product line  A solid outlook for 2018 and expansion in operating margin buoy optimism as well  Integer Holdings also paid down its debt significantly in the quarter On the flip side  Integer Holdings  Non Medical segment continues to see market softness  Management expects segment sales to be flat year over year in the fourth quarter  Additionally  a lackluster guidance for the Cardiac Neuromodulation s fourth quarter sales is discouraging  Contraction in gross margin adds to the woes Earnings of Other MedTech Majors at a GlanceOther top ranked stocks in the broader medical space which also reported solid earnings this season are Intuitive Surgical   NASDAQ ISRG    Stryker Corporation   NYSE SYK   and Merit Medical Systems  Inc    NASDAQ MMSI    Each of the stocks carries a Zacks Rank  2  Buy   You can see  Intuitive Surgical reported third quarter 2018 adjusted earnings per share of  2 83  which beat the Zacks Consensus Estimate of  2 65  Revenues totaled  920 9 million  also surpassing the consensus estimate of  918 6 million Stryker posted third quarter 2018 adjusted earnings per share of  1 69  beating the Zacks Consensus Estimate by a penny  Operating margin was 17 8   up 30 bps Merit Medical reported third quarter 2018 adjusted earnings per share of 47 cents  which trumped the Zacks Consensus Estimate of 42 cents  Revenues of  221 6 million edged past the consensus estimate of  218 million Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2018-11-04,Zacks Investment Research,https://www.investing.com/analysis/integer-holdings-itgr-beats-on-q3-earnings-and-revenues-200354893,200354893
112094,333609,ISRG,Hill Rom  HRC  Q4 Earnings Top Estimates On All Line Growth,opinion,Hill Rom Holdings  Inc    NYSE HRC   delivered fourth quarter fiscal 2018 adjusted earnings per share  EPS  of  1 63  reflecting a 23 5  increase from the year ago quarter  The bottom line also exceeded the Zacks Consensus Estimate by 7 9  and was well above the company s projected range of  1 50  1 53 as well The strong performance was backed by a solid core revenue rise  continued margin expansion and growth driving strategic investments  This in turn  marked the 13th straight quarter of double digit earnings growth for the company Full year adjusted EPS came in at  4 75  a 23  rise from the year ago period Revenue DetailsRevenues in the fiscal fourth quarter climbed 3  year over year to  759 2 million  same at constant exchange rate or CER   The top line also exceeded the Zacks Consensus Estimate of  751 million on sturdy growth in core business  Full year worldwide revenues were  2 85 billion  up 4   improving 2  at CER  compared with the prior year figure Geographically  U S  revenues grew 7  to  544 million in the reported quarter while the metric outside the United States declined 6   down 4  at CER  to  215 million  Core revenue growth was 4  at CER Segmental PerformanceIn the quarter under review  Patient Support Systems revenues inched up 2 5  year over year  up 3 1  at CER  to  380 4 million  This segment s domestic core revenues were up 10   representing solid performances across all key capital product categories  This is the second consecutive quarter with double digit growth in med surg bed systems  Clinical Workflow Solutions and safe patient handling equipment  However  outside the United States  core Patient Support Systems revenues fell 6  Hill Rom Holdings  Inc  Price  Consensus and EPS Surprise    Revenues at the Front Line Care segment increased 5 4  to  258 7 million  up 5 9  at CER   Domestic growth of 9  was driven by the contribution from new products including the Connex Spot Monitor  the Monarch Mobile Vest and our Vision Care portfolio  International revenues dipped 1   primarily due to a drop in sales in Asia Pacific  However  the company registered a solid performance across Europe  Canada and the Middle East The Surgical Solutions segment revenues slipped 1 4   down 0 7  at CER  to  120 1 million MarginsReported gross margin in the fiscal fourth quarter was 49 6   up 45 bps year over year  Adjusted gross margin grew 30 bps  buoyed by a positive contribution from product mix  primarily related to portfolio optimization initiatives and new products as well as benefits from manufacturing productivity and procurement efforts  Adjusted operating margin expanded 209 bps to 16 6  in the reported quarter OutlookHill Rom has provided its fiscal 2019 financial guidance  The company expects revenues to rise 1 2  on a reported basis  up 2 3  at CER  and core revenues to grow 4 5   The Zacks Consensus Estimate for fiscal 2019 revenues is pegged at  2 92 billion Adjusted EPS for the year is expected in the  5 08  5 16 range  The Zacks Consensus Estimate for fiscal 2019 earnings stands at  5 10  within the company s guided band For the first quarter fiscal 2019  Hill Rom expects a revenue rise of around 1  on a reported basis  or up 2  at CER   Core revenues are expected to increase 4  year over year   The company estimates adjusted earnings per share of  0 97  0 99  The Zacks Consensus Estimate for first quarter earnings is  1 04 on revenues of  684 3 million Our TakeHill Rom exited the fiscal 2018 on a strong note  The company saw a solid year over year increase in revenues on robust domestic growth  driven by a sturdy performance in Patient Support Systems and Front Line Care The company is currently focusing on product innovation through research and development  Year to date  it has achieved more than  180 million as new product revenues Zacks Rank   Key PicksHill Rom carries a Zacks Rank  4  Sell  A few better ranked stocks in the broader medical space  which reported solid earnings so far this reporting season  are Intuitive Surgical   NASDAQ ISRG    Stryker Corporation   NYSE SYK   and Merit Medical Systems  Inc    NASDAQ MMSI    All stocks carry a Zacks Rank  2  Buy   You can see  Intuitive Surgical reported third quarter 2018 adjusted EPS of  2 83  which beat the Zacks Consensus Estimate of  2 65  Revenues totaled  920 9 million  also surpassing the consensus estimate of  918 6 million Stryker posted third quarter 2018 adjusted EPS of  1 69  steering past the Zacks Consensus Estimate of  1 68  Operating margin was 17 8   up 30 bps Merit Medical reported third quarter 2018 adjusted EPS of 47 cents  which trumped the Zacks Consensus Estimate of 42 cents  Revenues of  221 6 million edged past the consensus estimate of  218 million Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2018-11-04,Zacks Investment Research,https://www.investing.com/analysis/hillrom-hrc-q4-earnings-top-estimates-on-allline-growth-200354865,200354865
112095,333610,ISRG,PRA Health s  PRAH  Q3 Earnings Top  Revenues Lag Estimates,opinion,"PRA Health Sciences  Inc    NASDAQ PRAH   posted third quarter 2018 adjusted earnings per share  EPS  of  1 13  which surpassed the Zacks Consensus Estimate of  1 08  EPS and rose 28 4  from the prior year quarter s tally  For investors  notice  PRA Health Sciences witnessed an increase in direct costs this season  which included a favorable foreign currency effect of  6 1 million 
PRA Health registered revenues of  717 6 million in the third quarter  up 23 3  year over year  However  the figure missed the Zacks Consensus Estimate by 1 9  
The stock has a Zacks Rank  2  Buy  
Q3 in Detail
Segmental Analysis
The company is managed through two reportable segments   the Clinical Research and the Data Solutions 
Net new business in the Clinical Research segment came in at  657 2 million in the third quarter  Through this segment  the company receives contracts from customers to provide clinical research services with payments based on fixed fee or fee for service arrangements 
Revenues in the Data Solutions segment amounted to  60 6 million in the quarter under review  The company provides weekly  monthly or quarterly data reports and analytics to customers 
PRA Health Sciences  Inc  Price and Consensus
   Direct Costs
Direct costs totaled  371 4 million in the quarter  13 6  year over year 
In the Clinical Research segment  direct costs consist primarily of labor related charges  Notably  labor related costs rose  11 1 million in the segment 
In the Data Solutions segment  direct costs consist primarily of data costs  The segment witnessed  29 4 million of incremental direct costs year over year 
Margin Trend
Gross profit  after excluding direct costs  came in at  346 2 million  up 35 7  from the prior year quarter s figure  Gross margin  as a percentage of revenues  came in at 48 2   up 440 basis points  bps  year over year 
Net income from operations  after excluding selling  general and administrative expenses from gross profit  came in at  253 6 million  up 44 2  from the year ago quarter s level  Adjusted operating margin  as a percentage of revenues  came in at 35 3   up 510 bps 
Guidance 
PRA Health reiterated 2018 revenue guidance in the range of  2 87  2 92 billion  representing growth of 47  50   The Zacks Consensus Estimate is currently pegged at  2 91 billion  which is within the guidance 
Moreover  the company raised EPS view  Adjusted EPS is expected between  4 22 and  4 27 compared with the previous range of  4 13 and  4 23  The Zacks Consensus Estimate is currently pegged at  4 20  which is within the guidance 
Wrapping Up
PRA Health ended the third quarter on a mixed note  where in adjusted earnings beat the consensus mark  while revenues missed the same  A raised EPS view for 2018 instils optimism  Strong performance in the Clinical Research segment is a positive 
PRA Health continues to gain from large pharmaceutical companies  which contributed substantially to its top line growth in recent times  Management is optimistic about the integration of Symphony Health  With this buyout  PRA Health expects to enhance ability in the field of data and analytics  The company also rides high on CRO market prospects 
On the flip side  escalating direct costs are headwinds  For investors  notice  management claims that the increase in direct costs was primarily related to a hike in labor related costs  specifically in the Clinical Research segment 
Q3 Earnings of MedTech Majors at a Glance
A few other top ranked stocks in the broader medical space  having reported solid earnings this season  are Stryker Corp    NYSE SYK    Intuitive Surgical  Inc    NASDAQ ISRG   and Merit Medical Systems  Inc    NASDAQ MMSI   
All the three stocks carry a Zacks Rank  2  You can see  
Intuitive Surgical reported adjusted earnings of  2 83 per share in the third quarter of 2018  which beat the Zacks Consensus Estimate of  2 65  Adjusted earnings improved 1 8  year over year 
Stryker delivered third quarter 2018 adjusted EPS of  1 69  which beat the Zacks Consensus Estimate of  1 68  Earnings improved 11 2  year over year  within the company s guidance 
Merit Medical reported third quarter 2018 adjusted EPS of 47 cents  beating the Zacks Consensus Estimate of 42 cents  Adjusted earnings improved 46 9  from the year ago quarter s tally 
Looking for Stocks with Skyrocketing Upside 
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana 
Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2018-11-05,Zacks Investment Research,https://www.investing.com/analysis/pra-healths-prah-q3-earnings-top-revenues-lag-estimates-200354951,200354951
112096,333611,ISRG,Masimo  MASI  Beats On Q3 Earnings  2018 Guidance Impressive,opinion,"Masimo Corporation   NASDAQ MASI   reported third quarter 2018 adjusted earnings of 71 cents per share  which surpassed the Zacks Consensus Estimate by 4 4   Earnings rose 26 8  on a year over year basis Revenues improved 8 9  year over year to  210 6 million in the quarter and surpassed the Zacks Consensus Estimate of  206 3 million Meanwhile  in the past year  the Zacks Rank  2  Buy  stock has rallied 28 2  against the  s 16 1  rise  The current level is also higher than the S P 500 index s rise of 5 3  Segmental AnalysisProduct RevenuesProduct revenues came in at  202 1 million  up 12 4  from the year ago quarter and 12 8  at constant currency  cc   Per management  the year over year upside can be attributed to strong customer demand in both Masimo s direct and OEM businesses  Worldwide non invasive technology shipments rose 16  year over year Masimo also continues to see strong growth in its rainbow platform Royalty and Other RevenuesRevenues at the segment totaled  8 5 million  down 37 7  from the prior year quarter Masimo Corporation Price  Consensus and EPS Surprise
    Margin AnalysisIn the quarter under review  gross profit totaled  140 8 million  up 13 5  year over year  Gross margin was 66 8   up 270 basis points  bps  Adjusted operating income in the quarter totaled  48 6 million  up 13  from a year ago  Adjusted operating margin was 23 1   which expanded 80 bps Research and development expenses totaled  19 4 million  up 27 1  year over year SG A expenses in the quarter were  72 7 million which shot up 10 7  from the year ago quarter GuidanceBuoyed by a solid third quarter  Masimo raised its 2018 guidance for revenues and earnings Revenues are expected at  854 million  up from the previously issued  850 million  The Zacks Consensus Estimate is pegged at  850 2 million  below the projected figure Product revenues are anticipated at  826 million  up from the previously stated figure of  822 million  Per management  this reflects year over year growth of approximately 11 9  and 11 3  at cc  Meanwhile  expectations from Royalty and Other revenues remain unchanged at  28 million Full year earnings per share are expected at  2 92  up from the earlier projection of  2 90  The Zacks Consensus Estimate is pegged at  2 92  in line with the guided figure Masimo s guidance for adjusted gross margin remains unchanged at 24 4   The same for EBITDA is also pegged at 29 9  For 2018  Masimo expects estimated tax rate of 24  Our TakeMasimo exited the third quarter on a solid note  Strong Product revenues buoy optimism  In the quarter  Masimo saw strong demand for its SET pulse oximetry products and rainbow platform  Considerable expansion in the company s gross and operating margins is another positive  Management is optimistic about Masimo s alliance with Philips  Increased R D expenses imply greater focus on innovation  Management is also hopeful about receiving FDA clearance for Ori  A raised guidance for 2018 paints a bright picture On the flip side  Masimo s Royalty and Other segment saw a soft third quarter  Furthermore  the company faces fierce competition from OEM distributors and medical device bigwigs that might mar the top line over the long haul Earnings of Other MedTech Majors at a GlanceOther top ranked stocks in the broader medical space which also reported solid earnings this season are Intuitive Surgical   NASDAQ ISRG    Stryker Corporation   NYSE SYK   and Merit Medical Systems  Inc    NASDAQ MMSI    Each of the stocks carries a Zacks Rank  2  You can see  Intuitive Surgical reported third quarter 2018 adjusted earnings per share of  2 83  which beat the Zacks Consensus Estimate of  2 65  Revenues totaled  920 9 million  also surpassing the consensus estimate of  918 6 million Stryker posted third quarter 2018 adjusted earnings per share of  1 69  beating the Zacks Consensus Estimate by a penny  Operating margin was 17 8   up 30 bps Merit Medical reported third quarter 2018 adjusted earnings per share of 47 cents  which trumped the Zacks Consensus Estimate of 42 cents  Revenues of  221 6 million edged past the consensus estimate of  218 million Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2018-11-05,Zacks Investment Research,https://www.investing.com/analysis/masimo-masi-beats-on-q3-earnings-2018-guidance-impressive-200354671,200354671
112097,333612,ISRG,Tandem Diabetes  TNDM  Reports Loss In Q3  Revenues Beat,opinion,"Tandem Diabetes Care  Inc    NASDAQ TNDM   reported loss per share of 62 cents in third quarter 2018 compared with net loss of  3 09 a year ago The company s adjusted loss was 30 cents a share  The Zacks Consensus Estimate was pegged at a loss of 34 cents Revenues in DetailRevenues in the quarter totaled  46 3 million  beating the Zacks Consensus Estimate by 12 9   The top line improved 71 5  from the year ago quarter Per management  launch of the t slim X2 with Basal IQ technology  increased supply capacity and renewal sales strengthening the company s core business along with the international launch drove the upside in revenues Tandem Diabetes  pump shipments rose 118  year over year to 8 434 pumps from 3 868 
Tandem Diabetes Care  Inc  Price  Consensus and EPS Surprise
    Interestingly  the company had begun shipping pumps to select geographies for commencing international operations in August 2018  As a result  of the 8 434 pumps shipped  1 055 pumps were shipped to locations outside the United States  Accordingly  Tandem Diabetes recorded international sales of  2 5 million in the third quarter MarginsGross profit in the reported quarter grossed  21 8 million  up 83 2  from the prior year quarter  Gross margin came in at 47 1   up 300 basis points  bps  on benefits from increased production volumes to meet growing demand and a significant contribution from sales of high margin pumps Total operating expenses came in at  37 5 million compared with  25 million in the prior year quarter  Operating loss in the reported quarter was  15 7 million  compared with operating loss of  13 2 million             a year ago Guidance RevisedFor 2018  the company raised its revenue guidance to a range of  160  165 million from  150  158 million  reflecting annual sales growth of around 49 53  from 2017  The Zacks Consensus Estimate for revenues is pegged at  155 7 million  below the guided range Our TakeTandem Diabetes posted better than expected top line results for the third quarter  Strength in domestic sales along with the recent launch of the t slim X2 Insulin Pump in select international markets bodes well for the company  Encouragingly  this was Tandem Diabetes  highest sales in a quarter  The company s raising of sales guidance for 2018 buoys optimism  We are upbeat about the company s receipt of Heath Canada Medical Device License for the t slim X2 Insulin Pump   Also  favorable demographics in the diabetes market are expected to boost demand for Tandem Diabetes  products However  heavy dependence on sales of insulin pumps and recurring operating losses are threats to the company Zacks Rank   Key PicksTandem Diabetes currently carries a Zacks Rank  3  Hold  A few better ranked stocks in the broader medical space  which reported solid earnings this season  are Intuitive Surgical   NASDAQ ISRG    Stryker Corporation   NYSE SYK   and Merit Medical Systems  Inc    NASDAQ MMSI    All the stocks carry a Zacks Rank  2  Buy   You can see  Intuitive Surgical reported third quarter 2018 adjusted earnings per share of  2 83  which beat the Zacks Consensus Estimate of  2 65  Revenues totaled  920 9 million  also surpassing the consensus estimate of  918 6 million Stryker posted third quarter 2018 adjusted earnings per share of  1 69  beating the Zacks Consensus Estimate of  1 68  Operating margin was 17 8   up 30 bps Merit Medical reported third quarter 2018 adjusted earnings per share of 47 cents  which trumped the Zacks Consensus Estimate of 42 cents  Revenues of  221 6 million edged past the consensus estimate of  218 million 
Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2018-11-05,Zacks Investment Research,https://www.investing.com/analysis/tandem-diabetes-tndm-reports-loss-in-q3-revenues-beat-200354668,200354668
112098,333613,ISRG,Henry Schein s  HSIC  Q3 Earnings Top  Revenues Lag Estimates,opinion,"Henry Schein  Inc    NASDAQ HSIC   reported adjusted earnings per share  EPS  of  1 03 in the third quarter of 2018  up 18 4  year over year  Adjusted EPS beat the Zacks Consensus Estimate of  1 01 by 2   driven by revenue growth across all business segments On a reported basis  EPS came in at 79 cents in the third quarter  down 9 2  year over year Revenues in DetailHenry Schein reported net sales of  3 28 billion in the third quarter  up 3 8  year over year  However  the metric missed the Zacks Consensus Estimate by 2 1    The year over year improvement came on the back of 3 2  internal sales growth in local currencies along with acquisition growth of 1 9  in the quarter  The top line edged down 1 3  owing to unfavorable foreign currency exchange In the quarter under review  the company recorded sales of  2 24 billion in the North American market  up 5 7  year over year  Sales totaled  1 04 billion in the international market  down 0 3  year over year Segment Analysis    Henry Schein derives revenues from four operating segments  Dental  Medical  Animal Health and Technology and Value added services 
Henry Schein  Inc  Price  Consensus and EPS Surprise   In the third quarter  the company derived  1 51 billion in revenues from global Dental sales  up 2 4  year over year  This includes 4 4  growth in local currencies and 2  adverse impact from foreign currency exchange  At local currencies  internally generated sales increased 3 5  and acquisition growth was 0 9   Internal growth at local currencies included 4 7  improvement in North America and 1 6  growth internationally The company s global Animal Health segment witnessed a 1 9  rise in revenues to  899 3 million  This includes 3 4  growth in local currencies and 1 5  adverse impact from foreign currency exchange  At local currencies  internally generated sales inched up 1 1  and acquisition growth was 2 3   The internal growth in local currencies included 0 4  rise in North America and 1 8  improvement internationally Worldwide Medical revenues climbed 4 5  year over year to  721 9 million  Growth in local currencies was 4 5  Revenues from global Technology and Value added Services grew 32  to  143 9 million  This included 32 6  growth in local currencies and 0 6  decrease from adverse currency movements  Acquisitions contributed 24 8  in the quarter under review Margin Trend         Gross profit increased 6 3  to  888 6 million in the reported quarter  However  gross margin expanded 60 basis points  bps  from the year ago quarter to 27 1  despite a 2 6  escalation in cost of sales   Despite a 7 3  rise in selling  general   administrative expenses of  668 million  adjusted operating income improved 3 3  year over year to  220 6 million  Nonetheless  adjusted operating margin shrunk 10 bps year over year to 6 7  in the Sep end quarter Financial PositionHenry Schein exited the third quarter of 2018 with cash and cash equivalents of  119 7 million compared with  111 3 million at the end of second quarter 2018  For the first nine months of 2018  net operating cash flow was  390 8 million compared with  307 5 million in the year ago period During the quarter under review  Henry Schein repurchased 777 000 shares of its common stock for approximately  61 million  At the close of the third quarter  the company had  86 million authorized for repurchase of common stock 2018 Guidance ReiteratedThe company has reiterated its 2018 EPS guidance  It continues to expect EPS in the range of  4 06  4 14  reflecting 13 15  growth from the 2017 adjusted EPS figure of  3 60  The Zacks Consensus Estimate for 2018 adjusted EPS of  4 12 is within the guided range Our TakeHenry Schein exited the third quarter of 2018 on a mixed note  All of the company s operating segments recorded year over year growth  Henry Schein s strong share gains in the North American markets raise optimism  Year over year improvement in gross margin also encourages us Nonetheless  we are disappointed with the year over year deterioration in operating margin due to higher expenses Meanwhile  we are looking forward to Henry Schein recently entering into a new exclusive distribution agreement with Sprig Oral Health Technologies Inc  Per the agreement  Henry Schein will distribute Sprig s products to help its customers place crowns We currently await the completion of the company s global Animal Health business  planned spin off  This business contributes nearly 30  to the company s top line  The spin off  accordingly  is expected to bring major changes to Henry Schein s overall operating results According to the company  following the spin off  the Animal Health business will merge with privately held Vets First Choice to form a new public entity called Vets First Corp  We believe  this initiative is part of Henry Schein s 2018 2020 Strategic Plan to focus more on dental and medical businesses Zacks Rank   Key PicksHenry Schein carries a Zacks Rank  3  Hold   currently A few better ranked stocks in the broader medical space  which reported solid earnings this season  are Intuitive Surgical   NASDAQ ISRG    Stryker Corporation   NYSE SYK   and Merit Medical Systems  Inc    NASDAQ MMSI    All the stocks carry a Zacks Rank  2  Buy   You can see  Intuitive Surgical reported third quarter 2018 adjusted EPS of  2 83  which beat the Zacks Consensus Estimate of  2 65  Revenues totaled  920 9 million  also surpassing the consensus estimate of  918 6 million Stryker posted third quarter 2018 adjusted EPS of  1 69  outpacing the Zacks Consensus Estimate of  1 68  Operating margin was 17 8   up 30 bps Merit Medical reported third quarter 2018 adjusted EPS of 47 cents  which trumped the Zacks Consensus Estimate of 42 cents  Revenues of  221 6 million edged past the consensus estimate of  218 million Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2018-11-05,Zacks Investment Research,https://www.investing.com/analysis/henry-scheins-hsic-q3-earnings-top-revenues-lag-estimates-200355374,200355374
112131,333646,ISRG,Baxter  BAX  Earnings Beat  Revenues Lag Estimates In Q3,opinion,Baxter International Inc    NYSE BAX   reported third quarter 2018 adjusted earnings per share of 80 cents  which surpassed the Zacks Consensus Estimate by 8 1  and improved from the year ago quarter by 25  In the last four quarters  the company delivered positive earnings surprises  the average being 9 6  Baxter posted sales of  2 77 billion  which marginally missed the Zacks Consensus Estimate of  2 79 billion  Revenues improved 2 2  on a year over year basis and 3  at constant currency  cc  Growth was backed by strong revenues from the company s Renal Care  Pharmaceuticals  Advanced Surgery and Acute Therapies businesses  However  per management  these businesses were impacted by market disruptions due to Hurricane Maria This Zacks Rank  2  Buy  company s shares have rallied roughly 6 5  in a year s time and the  has gained 0 6   The current level is also higher than the S P 500 index s rally of 4 3  Baxter International Inc  Price  Consensus and EPS Surprise   Geographical DetailsBaxter reports operating results through three geographic segments  Americas  North and South America   EMEA  Europe  Middle East and Africa  and APAC  Asia Pacific  In Americas  Baxter recorded sales of  1 5 billion  up 2 7  on a year over year basis and 4  at cc In EMEA  sales totaled  707 million  up 3 7  from the year ago quarter and 4  at cc In APAC  sales of  563 million declined 0 7  from the prior year quarter and were flat at cc Segmental DetailsRenal CareThis segment recorded sales of  910 million in the reported quarter  up 1 6  year over year  Sales at the segment increased 3  at cc Medication DeliverySales at the segment grossed  652 million  down 4  from the year ago quarter  Sales at the segment inched down 3  at cc PharmaceuticalsSales in the segment were  519 million  up 4 2  from the year ago quarter and 5  at cc Clinical NutritionSales in the segment were  218 million  down 2 2  from the year ago quarter s tally  At cc  revenues fell 2  Advanced SurgerySales in the segment were  200 million  up 14 3  from the year ago quarter and 15  at cc Acute TherapiesSales in the segment were  122 million  up 8 9  from the prior year quarter and 10  at cc OtherSales in the segment were  146 million  up 17 7  on a year over year basis  At cc  revenues increased an impressive 17  in the quarter Margin AnalysisBaxter registered adjusted gross profit of  1 28 billion in the third quarter  up 4 4  year over year  As a percentage of revenues  adjusted gross margin expanded 100 basis points  bps  to 46 3  in the third quarter Adjusted operating income increased 12 5  year over year to  505 million in the quarter  As a percentage of revenues  operating margin expanded 170 bps to 18 3  in third quarter 2018 GuidanceFor fourth quarter 2018  Baxter expects sales growth of 1  on a reported basis and 3 4  at cc  Adjusted earnings per share are projected in the band of 71 73 cents  The Zacks Consensus Estimate is pegged at 77 cents  above the guided range For 2018  Baxter expects adjusted earnings per share within  2 98 to  3  Notably  the company has lifted the low end of the  previously issued guidance  The Zacks Consensus Estimate is pegged at  2 98  at the low end of the guided range Revenues are expected to grow 5  on a reported basis and 4  at cc in 2018  This is marginally lower than the earlier provided view of 6  on a reported basis and 5  at cc Wrapping UpBaxter ended the third quarter of 2018 on a mixed note  While earnings surpassed the consensus mark  revenues missed the same  However  the company continues to gain from its Renal Care  Pharmaceuticals  Advanced Surgery and Acute Therapies businesses  Solid growth in the United States and EMEA also buoys optimism  The company also received regulatory approvals for its PrisMax system  Actifuse and ALTAPORE bone graft systems which paints a bright picture  New addition to the company s parenteral nutrition portfolio and collaboration with Mayo Clinic are heartening developments  Considerable expansion in the company s gross and operating margins is encouraging as well  Baxter raised the low end of its earnings per share guidance for 2018  However  a weak revenue guidance for the upcoming quarter is indicative of headwinds ahead  Notably  Baxter s Medication Delivery and Clinical Nutrition saw a soft third quarter  Market disruptions due to Hurricane Maria continue to plague the company  Sales in the APAC region declined which is worrisome Earnings of MedTech Majors at a GlanceA few top ranked stocks in the broader medical space which reported solid earnings this season are Intuitive Surgical   NASDAQ ISRG    Stryker Corporation   NYSE SYK   and Merit Medical Systems  Inc    NASDAQ MMSI    Each of the stocks carries a Zacks Rank  2  You can see  Intuitive Surgical reported third quarter 2018 adjusted earnings per share of  2 83  which beat the Zacks Consensus Estimate of  2 65  Revenues totaled  920 9 million  also surpassing the consensus estimate of  918 6 million Stryker posted third quarter 2018 adjusted earnings per share of  1 69  steering past the Zacks Consensus Estimate of  1 68  Operating margin was 17 8   up 30 bps Merit Medical reported third quarter 2018 adjusted earnings per share of 47 cents  which trumped the Zacks Consensus Estimate of 42 cents  Revenues of  221 6 million edged past the consensus estimate of  218 million 3 Medical Stocks to Buy NowThe greatest discovery in this century of biology is now at the flashpoint between theory and realization  Billions of dollars in research have poured into it  Companies are already generating revenue  and cures for a variety of deadly diseases are in the pipeline So are big potential profits for early investors  Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it ,2018-10-30,Zacks Investment Research,https://www.investing.com/analysis/baxter-bax-earnings-beat-revenues-lag-estimates-in-q3-200352471,200352471
112132,333647,ISRG,Accuray  ARAY  Q1 Loss Wider Than Expected  Gross Orders Rise,opinion,Accuray Incorporated   NASDAQ ARAY   reported first quarter fiscal 2019 adjusted loss of 7 cents per share  wider than the Zacks Consensus Estimate of a loss of 6 cents  Notably  the company had reported a loss of 7 cents in the year ago quarter The company posted net revenues worth  95 83 million  marginally beating the Zacks Consensus Estimate of  95 million  On a year over year basis  revenues climbed 5 4  in the quarter The stock carries a Zacks Rank  3  Hold  Q1 DetailsProduct Revenues  Product revenues increased 6 7  year over year to  41 5 million in the reported quarter Service Revenues  Service revenues totaled  54 3 million  which rose 4 4  from the year ago quarter s tally  The upside can be attributed to Accuray s recent software releases Gross Order Update  Gross orders in the first quarter of fiscal 2019 totaled  61 4 million  up 10 4  on a year over year basis Radixact UpdatePer management  gross orders for Accuray s flagship Radixact System more than doubled on a year over year basis in the fiscal first quarter  Accuray registered approximately 25 system orders Radixact represented approximately 85  of TomoTherapy platform orders Accuray Incorporated Price and Consensus     Cost Saving InitiativeManagement has implemented a new initiative to reduce operating costs  This is expected to have a non recurring charge of  1 5 million to  2 million in the second quarter of fiscal 2019 For investors  notice  the company expects annualized cost savings of approximately  15 million compared with fiscal 2018 The benefit of the initiative is projected to be realized by the fourth quarter of fiscal 2019 MarginsGross profit in the fiscal first quarter totaled  37 9 million  down 0 6  on a year over year basis  Gross margin in the quarter was 39 5  of net revenues  down 240 basis points  bps  Research and development expenses inched down 1 4  year over year to  13 9 million  Selling and marketing expenses fell 11 7  year over year to  13 million  General and administrative expenses rallied 38 3  year over year to  15 6 million First quarter operating loss was  4 7 million compared with a loss of  2 1 million in the year ago quarter GuidanceAccuray reiterated fiscal 2019 revenue guidance and updated EBITDA guidance For fiscal 2019  product revenue growth is expected between 4 8  and service revenue growth is projected at approximately 2   resulting in total revenues between  415 million and  425 million  The Zacks Consensus Estimate is pegged at  413 3 million  below the guidance Adjusted EBITDA is projected between  23 million to  29 million  higher than the previous range of  21 million to  27 million  This represents growth of 35 70  year over year  significantly higher than the previously estimated growth rate of 23 58  Wrapping UpAccuray exited the fiscal fourth quarter on a tepid note  Loss per share was wider than estimates and revenues surpassed the consensus mark The company continues to gain from the flagship Radixact platform  which garnered sizeable orders and drove the company s TomoTherapy platform recently  A regulatory approval for Radixact X9 system in India buoys optimism  Gross orders rose in the United States and EMEA  Accuray s service revenues also improved year over year  Significant expansion in gross margin is a positive However  decline in orders in the APAC region owing to China issues  long sales and implementation cycle of the CyberKnife and TomoTherapy systems are headwinds  Furthermore  unfavorable product mix  sluggish macroeconomic conditions and pricing headwinds are concerns Earnings of MedTech Majors at a GlanceA few better ranked stocks in the broader medical space  which reported solid earnings this season are  Stryker Corporation   NYSE SYK    Intuitive Surgical  Inc   NASDAQ ISRG   and Merit Medical Systems  Inc   NASDAQ MMSI   All the three stocks carry a Zacks Rank  2  Buy   You can see  Intuitive Surgical reported adjusted earnings of  2 83 per share in the third quarter of 2018  which beat the Zacks Consensus Estimate of  2 65  Adjusted earnings improved 1 8  year over year Stryker delivered third quarter 2018 adjusted earnings per share  EPS  of  1 69  which beat the Zacks Consensus Estimate of  1 68  Earnings improved 11 2  year over year  within the company s guidance Merit Medical reported third quarter 2018 adjusted EPS of 47 cents  beating the Zacks Consensus Estimate of 42 cents  Adjusted earnings improved 46 9  from the year ago quarter s tally Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2018-10-31,Zacks Investment Research,https://www.investing.com/analysis/accuray-aray-q1-loss-wider-than-expected-gross-orders-rise-200353020,200353020
112133,333648,ISRG,Intuitive Surgical  ISRG  Stock Sinks As Market Gains  What You Should Know,opinion,"In the latest trading session  Intuitive Surgical  NASDAQ ISRG  closed at  518 61  marking a  0 49  move from the previous day  This change lagged the S P 500 s daily gain of 0 65   Meanwhile  the Dow gained 0 79   and the Nasdaq  a tech heavy index  added 1 01  
Coming into today  shares of the robotic surgery system company had lost 7 18  in the past month  In that same time  the Medical sector lost 9 59   while the S P 500 lost 6 82  
Wall Street will be looking for positivity from ISRG as it approaches its next earnings report date  This is expected to be January 24  2019  On that day  ISRG is projected to report earnings of  2 96 per share  which would represent year over year growth of 16 54   Meanwhile  the Zacks Consensus Estimate for revenue is projecting net sales of  1 02 billion  up 14 49  from the year ago period 
Looking at the full year  our Zacks Consensus Estimates suggest analysts are expecting earnings of  10 97 per share and revenue of  3 70 billion  These totals would mark changes of  22 02  and  18 23   respectively  from last year 
Any recent changes to analyst estimates for ISRG should also be noted by investors  Recent revisions tend to reflect the latest near term business trends  As a result  we can interpret positive estimate revisions as a good sign for the company s business outlook 
Based on our research  we believe these estimate revisions are directly related to near team stock moves  Investors can capitalize on this by using the Zacks Rank  This model considers these estimate changes and provides a simple  actionable rating system 
The Zacks Rank system  which ranges from  1  Strong Buy  to  5  Strong Sell   has an impressive outside audited track record of outperformance  with  1 stocks generating an average annual return of  25  since 1988  Over the past month  the Zacks Consensus EPS estimate has moved 2 25  higher  ISRG is holding a Zacks Rank of  2  Buy  right now 
Digging into valuation  ISRG currently has a Forward P E ratio of 47 51  For comparison  its industry has an average Forward P E of 31 34  which means ISRG is trading at a premium to the group 
Meanwhile  ISRG s PEG ratio is currently 3 04  The PEG ratio is similar to the widely used P E ratio  but this metric also takes the company s expected earnings growth rate into account  Medical   Instruments stocks are  on average  holding a PEG ratio of 2 7 based on yesterday s closing prices 
The Medical   Instruments industry is part of the Medical sector  This industry currently has a Zacks Industry Rank of 98  which puts it in the top 38  of all 250  industries 
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
To follow ISRG in the coming trading sessions  be sure to utilize Zacks com ",2018-11-01,Zacks Investment Research,https://www.investing.com/analysis/intuitive-surgical-isrg-stock-sinks-as-market-gains-what-you-should-know-200353591,200353591
112134,333649,ISRG,Express Scripts  ESRX  Tops Q3 Earnings   Revenue Estimates ,opinion,"Express Scripts Holding Company   NASDAQ ESRX   posted third quarter 2018 adjusted earnings of  2 43 per share  which beat the Zacks Consensus Estimate of  2 42  Further  adjusted earnings improved 27 9  year over year Revenues of  25 56 billion surpassed the Zacks Consensus Estimate of  24 99 billion and inched up 3 6  year over year  The upside was driven by operational cost improvement backed by focus on technology  digital tools  home delivery and specialty services The stock has a Zacks Rank  3  Hold  Q3 Patient Claim Volume DetailsDuring the quarter  Express Scripts witnessed year over year declines in patient claims Adjusted network claims were 260 2 million  up 0 3  year over year  Adjusted home delivery and specialty claims were 74 4 million in the reported quarter  down 11 5  year over year As a result  net adjusted claims in the third quarter were 334 6 million  down 2 6  year over year  The decline was primarily caused by the loss of certain public sector clients Express Scripts Holding Company Price and Consensus
    Core Business UpdateDuring the third quarter  Express Scripts generated  1 39 billion of core business adjusted EBITDA  up 4 1  year over year Growth in the core business can be attributed to supply chain initiatives  strong performance by SafeguardRx suite of solutions  contributions from eviCore and Accredo However  lower claims volume and delays in specialty generic launches partially offset growth in the core business Margin DetailsAdjusted gross profit in the third quarter was  2 35 billion  up 5 1  year over year  As a percentage of revenues  adjusted gross margin was 9 2  of net revenues  The figure improved 10 basis points  bps  year over year Adjusted selling  general and administrative  SG A  expenses were  862 8 million  up 13 6  from the prior year quarter s figure  As a percentage of revenues  adjusted SG A margin was 3 4  of net revenues  The figure was up 30 bps year over year Operating income in the quarter came in at  1 49 billion  up 0 7  year over year Impending Acquisition by CignaIntegrating medical care and pharmacy benefits under one roof  Express Scripts announced that it is getting acquired by Cigna Corporation  NYSE CI   a global health insurance company   In September  the U S  Department of Justice sanctioned the proposed buyout  The acquisition is expected to be completed by Dec 31  2018 For investors  notice  Express Scripts will no longer provide financial guidance because of the acquisition agreement Summing UpExpress Scripts ended the third quarter on a solid note  beating the Zacks Consensus Estimate for both the counts  The company has been gaining from strong performance by the core PBM unit  Further  its recently acquired eviCore s complementary medical benefit solutions is likely to build a comprehensive PBM solution worldwide  Developments by the company s Inside Rx program buoys optimism However  Express Scripts currently faces persistent drug pricing issue  The company is also getting acquired by Cigna by December 2018  Express Scripts announced that its biggest customer and leading health insurer Anthem  NYSE ANTM  is not likely to extend the PBM agreement with the company anymore  Furthermore  the company has currently suspended share repurchase program because of the merger agreement with Cigna  Express Scripts has not provided any guidance for 2018 Q3 Earnings of MedTech Majors at a GlanceA few better ranked stocks in the broader medical space  which reported solid earnings this season are  Stryker Corporation   NYSE SYK    Intuitive Surgical  Inc   NASDAQ ISRG   and Merit Medical Systems  Inc   NASDAQ MMSI   All the three stocks carry a Zacks Rank  2  Buy   You can see  Intuitive Surgical reported adjusted earnings of  2 83 per share in the third quarter of 2018  which beat the Zacks Consensus Estimate of  2 65  Adjusted earnings improved 1 8  year over year Stryker delivered third quarter 2018 adjusted earnings per share  EPS  of  1 69  which beat the Zacks Consensus Estimate of  1 68  Earnings improved 11 2  year over year  within the company s guidance Merit Medical reported third quarter 2018 adjusted EPS of 47 cents  beating the Zacks Consensus Estimate of 42 cents  Adjusted earnings improved 46 9  from the year ago quarter s tally Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2018-11-01,Zacks Investment Research,https://www.investing.com/analysis/express-scripts-esrx-tops-q3-earnings--revenue-estimates-200352950,200352950
112135,333650,ISRG,Bio Rad  BIO  Earnings Miss Estimates In Q3  Revenues Beat,opinion,"Bio Rad Laboratories  Inc    NYSE BIO   posted third quarter 2018 adjusted earnings per share  EPS  of 91 cents  which missed the Zacks Consensus Estimate of  1 16 by 21 6   Earnings declined 10 8  from the prior year quarter Revenues in DetailRevenues in the quarter totaled  545 1 million  beating the Zacks Consensus Estimate by 1 1   Revenues improved 2 1  from the year ago quarter and rose 3 4  at constant currency  cc  Per management  solid demand across many of its key product lines led to growth across most geographical regions Segmental AnalysisSales at the Life Sciences segment totaled  206 6 million  up 7 1  year over year and 8  at cc  Per management  the upside reflects higher sales in the cell biology  droplet Digital PCR and food safety product lines  Further  the company continues to see increased demand for its process media product lines On a geographic basis  sales at cc were particularly strong in the United States  China and India 
Bio Rad Laboratories  Inc  Price  Consensus and EPS Surprise
    Net sales at Clinical Diagnostics in the third quarter totaled  334 million  down 1 2  on a year over year basis  However  sales were up 0 5  at cc  The upside in the currency neutral sales indicates growth in immunology  diabetes monitoring  blood typing and quality control product lines Geographically  sales rose in the Americas and Asia  partially offset by a decline in Europe MarginsGross profit in the reported quarter totaled  286 7 million  down 4 1  from the prior year quarter  Gross margin came in at 52 6   down 340 basis points  bps   Per the company  changes in product mix  high service  warranty and reagent rental costs  along with extra inventory related expenses led to the decline in gross margin Adjusted gross margin came in at 53 5   down 340 bps year over year Operating income grossed  36 3  down 6 4  from the year ago quarter Guidance UpdatedFor 2018  the company reiterated revenue growth guidance at 4 4 5   cc   The Zacks Consensus Estimate for the same is pegged at  2 72 billion Full year operating margin is now projected in the 8 9  range from 10  stated earlier Our TakeBio Rad exited third quarter 2018 on mixed note  We are however encouraged with the year over year rise in earnings and revenues  Sales growth at the Clinical Diagnostics segment was impressive as well  The company also saw strong growth in the Life Science segment and cell biology  Digital PCR and food safety product lines  Further  solid revenue growth in geographies like North America  China and Asia Pacific buoys optimism We are also upbeat about the company s recent 510 k  clearance from the FDA for the IH Reader 24  a semi automated blood typing instrument designed for medium  to small volume laboratories However  challenges associated with the implementation of the global ERP system raise concerns Zacks Rank   Key PicksBio Rad has a Zacks Rank  3  Hold  A few better ranked stocks in the broader medical space  which reported solid earnings this season  are Intuitive Surgical   NASDAQ ISRG    Stryker Corporation   NYSE SYK   and Merit Medical Systems  Inc    NASDAQ MMSI    All the stocks carry a Zacks Rank  2  Buy   You can see  Intuitive Surgical reported third quarter 2018 adjusted EPS of  2 83  which beat the Zacks Consensus Estimate of  2 65  Revenues totaled  920 9 million  also surpassing the consensus estimate of  918 6 million Stryker posted third quarter 2018 adjusted EPS of  1 69  steering past the Zacks Consensus Estimate of  1 68  Operating margin was 17 8   up 30 bps Merit Medical reported third quarter 2018 adjusted EPS of 47 cents  which trumped the Zacks Consensus Estimate of 42 cents  Revenues of  221 6 million edged past the consensus estimate of  218 million Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2018-11-01,Zacks Investment Research,https://www.investing.com/analysis/biorad-bio-earnings-miss-estimates-in-q3-revenues-beat-200354169,200354169
112136,333651,ISRG,Insulet  PODD  Beats Earnings And Revenue Estimates In Q3,opinion,Insulet Corporation   NASDAQ PODD   reported earnings per share  EPS  of 3 cents in third quarter 2018 against net loss of 4 cents a year ago  The figure also surpassed the Zacks Consensus Estimate of 2 cents by 50  Revenues in DetailRevenues in the third quarter totaled  151 1 million  beating the Zacks Consensus Estimate by 1 7   Moreover  the top line improved 24 1  from the year ago quarter Per management  the company s direct European operations  progress in market access initiatives  build out of the U S  manufacturing facility and the limited commercial launch of the Omnipod DASH system drove the upside in revenues  An expanding global customer base also played a role Insulet reported U S  Omnipod revenues of  82 million  reflecting an increase of 17  year over year International Omnipod revenues of  50 2 million rose 55  Insulet Corporation Price  Consensus and EPS Surprise    Revenues at the Drug Delivery business totaled  18 9 million  down 2  year over year MarginsGross profit in the reported quarter grossed  102 million  up 38 6  from the prior year quarter  Gross margin came in at 67 5   up 700 basis points  bps  on continuous improvement in manufacturing and supply chain operations  Furthermore  successful transition to direct operations in Europe led to an added benefit of 400 bps to the gross margin Total operating expenses came in at  95 1 million compared with  71 6 million in the prior year quarter  Operating income in the reported quarter was  6 9 million  up from  2 million in the year earlier quarter Guidance RevisedFor 2018  the company raised the low end of its revenue guidance to a range of  558  563 million from  547  562 million expected earlier  reflecting growth of around 20 21  from  463 8 million reported in 2017  The Zacks Consensus Estimate for revenues is pegged at  557 3 million  below the guided range For the fourth quarter of 2018  Insulet expects revenues in the band of  159 164 million  reflecting growth of approximately 22 26  compared with  130 5 million in the year ago quarter  The Zacks Consensus Estimate for the metric is pegged at  155 million  below the guided range Our TakeInsulet exited third quarter 2018 on a solid note  We are encouraged by the year over year improvement in results on solid uptake of Omnipod system in the United States  Encouragingly  the company recorded net income in the quarter for the first time  An expanding global customer base also drove revenues  Furthermore  an improvement in the gross margin buoys optimism  We are also upbeat about Insulet s solid progress with respect to its four pillar strategy At the end of the quarter under review  the company secured approximately a third of Medicare Part D covered lives for both Omnipod and Omnipod DASH systems  This also includes large Part D providers like Optum  Express Scripts  NASDAQ ESRX  and Magellan  Meanwhile  Insulet is exposed to risks associated with a weaker global economy and lower reimbursement rates  Zacks Rank   Key PicksInsulet currently carries a Zacks Rank  3  Hold  A few better ranked stocks in the broader medical space  which reported solid earnings this season  are Intuitive Surgical   NASDAQ ISRG    Stryker Corporation   NYSE SYK   and Merit Medical Systems  Inc    NASDAQ MMSI    All the stocks carry a Zacks Rank  2  Buy   You can see  Intuitive Surgical reported third quarter 2018 adjusted EPS of  2 83  which beat the Zacks Consensus Estimate of  2 65  Revenues totaled  920 9 million  also surpassing the consensus estimate of  918 6 million Stryker posted third quarter 2018 adjusted EPS of  1 69  steering past the Zacks Consensus Estimate of  1 68  Operating margin was 17 8   up 30 bps Merit Medical reported third quarter 2018 adjusted EPS of 47 cents  which trumped the Zacks Consensus Estimate of 42 cents  Revenues of  221 6 million edged past the consensus estimate of  218 million Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2018-11-01,Zacks Investment Research,https://www.investing.com/analysis/insulet-podd-beats-earnings-and-revenue-estimates-in-q3-200354166,200354166
112137,333652,ISRG,Teleflex  TFX  Q3 Earnings Surpass Estimates  EPS View Up,opinion,Teleflex Incorporated   NYSE TFX   announced earnings per share  EPS  from continuing operations of  2 52 for the third quarter of 2018  up 18 9  year over year  Also  the bottom line surpassed the Zacks Consensus Estimate by 4 6  Net revenues in the reported quarter rose 14  year over year to  609 7 million  Moreover  the top line edged past the Zacks Consensus Estimate by a marginal 0 07  On a year over year basis  the company saw organic constant currency revenue growth of 5 6  including a benefit of 1  from increased sales of Vascular Solutions products and a contribution of 4 6  from legacy Teleflex product line Revenues in DetailTeleflex s Vascular North America segment recognized net revenues of  80 7 million  up 7 8  year over year at constant exchange rate or CER  Despite a decrease in sales volumes of existing products  the growth was primarily attributable to improved sales volumes of existing products and better new product sales The Interventional North America business registered net revenues of  66 7 million  a 9 9  rise on a year over year basis at CER  This upside was fueled by increased sales volumes of existing products and higher new product sales Teleflex Incorporated Price  Consensus and EPS Surprise   Within Anesthesia North America  net revenues climbed 4 8  at CER to  53 2 million  Growth in sales volumes of existing products and stronger new product sales during the third quarter were partially offset by price declines Surgical North America realized net revenues of  42 5 million  a 4 6  rise at CER on increased sales volumes of existing products and a climb in new product sales Meanwhile  EMEA grossed revenue growth of 2 9  at CER to  139 6 million  driven by a beneficial price improvement and more solid new product sales  However  this was partially offset by lower sales volumes of existing products Asia  OEM and All Other logged net revenues of  76 5 million   54 9 million and  95 6 million  respectively  corresponding top line growth of 6 7   13 1  and 103  each at CER   in the quarter under review MarginGross margin of 56 2  during the quarter under discussion was up 98 basis points  bps  year over year on 16  improvement in gross profits  Adjusted operating margin contracted 400 bps to 16 6  on 30 4  escalation in operating cost Liquidity PositionThe company exited the third quarter with cash and cash equivalents of  356 3 million compared with  346 3 million at the end of the second quarter  Year to date  net cash provided by operating activities was  302 9 million compared with  319 7 million in the year ago period OutlookTeleflex lowered its guidance for 2018 revenue growth to a range of 13 5 14 5  from the earlier announced band of 14 15   This revision reflects an anticipated 1 5  favorable impact of foreign exchange translation  earlier  the projection was a 2  conducive effect   On constant currency basis  the company reaffirmed its full year view of 12 13  over the prior year s expected range The company  however  raised its forecast for full year adjusted earnings per share from continuing operations in the  9 80  9 95 band  earlier prediction was  9 70  9 90   representing an approximately 5  positive impact from forex fluctuations Our TakeNotably Teleflex continues to report a robust improvement in revenues  banking on balanced growth across all segments and geographies  The company s newly acquired NeoTract has started to contribute to its top line quite handsomely  We are also upbeat about Urolift that has continued with its sturdy momentum in the third quarter  delivering  49 million to revenues  an approximate 45  increase compared with the prior year period s tally Zacks Rank   Key PicksTeleflex carries a Zacks Rank  3  Hold   A few better ranked stocks in the broader medical space  which have already reported better than expected earnings this reporting cycle  are Intuitive Surgical   NASDAQ ISRG    Stryker Corporation   NYSE SYK   and Merit Medical Systems  Inc    NASDAQ MMSI    All stocks hold a Zacks Rank  2  Buy   You can see  Intuitive Surgical reported third quarter 2018 adjusted EPS of  2 83  which beat the Zacks Consensus Estimate of  2 65  Revenues summed  920 9 million  also surpassing the consensus estimate of  918 6 million Stryker posted third quarter 2018 adjusted EPS of  1 69  steering past the Zacks Consensus Estimate of  1 68  Operating margin was 17 8   up 30 bps Merit Medical released third quarter 2018 adjusted EPS of 47 cents  which trumped the Zacks Consensus Estimate of 42 cents  Revenues of  221 6 million slightly outperformed the consensus estimate of  218 million Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2018-11-02,Zacks Investment Research,https://www.investing.com/analysis/teleflex-tfx-q3-earnings-surpass-estimates-eps-view-up-200354146,200354146
112138,333653,ISRG,Bruker  BRKR  Q3 Earnings Surpass Estimates  Guidance Up,opinion,"Bruker Corporation   NASDAQ BRKR   reported adjusted earnings per share  EPS  of 37 cents in the third quarter of 2018  up 27 6  from the year ago figure  Adjusted EPS also exceeded the Zacks Consensus Estimate by 23 3  
On a reported basis  earnings came in at 28 cents a share  a 21 7  surge on a year over year basis 
Revenues in Detail
Bruker registered revenues of  466 6 million in the third quarter  up 7 1  year over year  Moreover  the top line surpassed the Zacks Consensus Estimate of  452 5 million 
Excluding 1 5  positive effect from acquisitions and a 1 4  favorable impact from changes in foreign currency rates  Bruker generated higher organic revenues of 7  year over year 
The company s organic revenue growth is driven by the strength in Bruker Scientific Instruments  BSI  and BEST segments Bruker Corporation Price  Consensus and EPS Surprise

   Geographically  European revenues declined 5 4  year over year in the reported quarter while North America revenues were up 20 6   In Asia Pacific  APAC   revenue uptick was 14 7  
Bruker s BioSpin Group revenues inched up 0 5  above the year ago quarter s level 
Revenues in the NANO group increased 13 9   fueled by a strong uptrend in academic research and industrial research markets  CALID revenues were up 6 6  year over year 
Margin Trend
Gross margin in the quarter under review expanded 205 basis points  bps  to 47 7   While selling  general   administrative expenses climbed 3 7  to  106 5 million  Research and development expenses rose 2 9  year over year to  41 8 million  Overall  adjusted operating margin improved 316 bps to 15 9  
Financial Position
Bruker exited third quarter 2018 with cash and cash equivalents plus short term investments of  270 1 million  up from  258 7 million at the end of the second quarter  Year to date  operating cash inflow was  107 4 million in comparison to  50 7 million in the year ago period 
2018 Guidance
Bruker updated its expectations for 2018  For the full year  the company projects revenue growth of approximately 6 5 7  including nearly 3 5 4  of organic revenue rise  The figure compares favorably with the earlier prediction of 6 5  revenue growth comprising 3 5  organic increase  The company projects a year over year expansion of 80 bps in adjusted operating margin including an estimated 70 bps headwind from foreign currency translation 
For 2018  Bruker raised its adjusted EPS view to a range of  1 36  1 40  up 12 16  from the previous year s rally  earlier projection was 1 34  1 38  an estimated 11 14  rise from the year ago period   The Zacks Consensus Estimate of  1 38 remains under the company s current forecast 
Our Take
Bruker exited the third quarter on a solid note with a strong year over year increase in revenues as well as earnings  Additionally  the improvement in gross and operating margins buoys optimism  The company s strategic acquisition activity has also been encouraging  Further  we are upbeat about the company s current focus on product development through higher R D investment  
On the flip side  a competitive landscape and macroeconomic woes persistently pose challenges to the company 
Zacks Rank   Key Picks
Bruker carries a Zacks Rank  3  Hold   A few better ranked stocks in the broader medical space  which reported solid earnings so far this season  are Intuitive Surgical   NASDAQ ISRG    Stryker Corp    NYSE SYK   and Merit Medical Systems  Inc    NASDAQ MMSI    All stocks carry a Zacks Rank  2  Buy   You can see  
Intuitive Surgical reported third quarter 2018 adjusted EPS of  2 83  which beat the Zacks Consensus Estimate of  2 65  Revenues totaled  920 9 million  also surpassing the consensus estimate of  918 6 million 
Stryker posted third quarter 2018 adjusted EPS of  1 69  steering past the Zacks Consensus Estimate of  1 68  Operating margin was 17 8   up 30 bps 
Merit Medical reported third quarter 2018 adjusted EPS of 47 cents  which trumped the Zacks Consensus Estimate of 42 cents  Revenues of  221 6 million edged past the consensus estimate of  218 million 
Today s Stocks from Zacks  Hottest Strategies
It s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6  and  67 1  
And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2018-11-02,Zacks Investment Research,https://www.investing.com/analysis/bruker-brkr-q3-earnings-surpass-estimates-guidance-up-200354230,200354230
112166,333681,ISRG,Cardinal Health  CAH   CD R To Jointly Invest In NaviHealth,opinion,Cardinal Health  Inc    NYSE CAH   and Clayton  Dubilier   Rice  CD R  recently announced a joint investment plan in naviHealth  Notably  71  of Tennessee based naviHealth was acquired by Cardinal Health in 2015 for a deal value of  290 million  The company had a goal of acquiring the entire business after four years naviHealth currently serves more than two million insured members and manages care transitions for approximately 800 acute hospitals and 11 000 post acute care facilities across the United States  Meanwhile  CD R is one of the oldest private equity firms in the world  specializing in buyouts and growth capital financings Post the above announcement  shares of Cardinal Health inched up 0 7  to  54 62 at close  However  the stock has declined 12 5  against the  s increase of 5 9  in the past six months  The stock currently carries a Zacks Rank  5  Strong Sell  Coming back to the news  the CD R managed funds will acquire approximately a 55  ownership stake in naviHealth while Cardinal Health will retain roughly 45  interest in the business  Additionally  Cardinal Health will reserve a call right to reacquire the business  The transaction is expected to be completed during the third quarter of 2018 The latest strategic move will enable the Ohio based distributor of healthcare services to deliver improved post acute care across the United States Market ProspectsPer Frost   Sullivan  the post acute healthcare industry can expect a surge of approximately  40 billion in revenues in 2018  This upside is attributable to a shift of medically complex patients toward post acute care settings Hence  it can be concluded that Cardinal Health s decision has been timely and strategic Cardinal Health s Acute Patient SolutionsCardinal Health offers a broad range of acute patient care solutions Previously acquired naviHealth coordinates care in the acute and post acute setting apart from enabling providers to customize patient specific care plans  The company also analyzes data and discovers patterns to optimize workflows Furthermore  Cardinal Health s Outpatient Pharmacy Solutions enable healthcare providers to boost patient population health management  It plays a critical role in continuing patient care beyond discharge from hospitals to homes The company has also launched a line of Cardinal Health Hospital Quality at Home consumer products  This allows patients and caregivers to buy the same products used in the hospital to support continuity of care  The list includes products related to bath safety and daily living aids Key PicksSome better ranked stocks in the broader medical space are Abiomed  Inc    NASDAQ ABMD    Stryker Corporation   NYSE SYK   and Intuitive Surgical Inc    NASDAQ ISRG   Abiomed has a projected long term earnings growth rate of 27   The stock sports a Zacks Rank  1  Strong Buy   You can see  Stryker has a projected long term earnings growth rate of 9 7   The stock carries a Zacks Rank  2  Buy  Intuitive Surgical has an expected long term earnings growth rate of 12 1  and a Zacks Rank of 1 Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2018-06-15,Zacks Investment Research,https://www.investing.com/analysis/cardinal-health-cah-cdr-to-jointly-invest-in-navihealth-200325247,200325247
112167,333682,ISRG,Haemonetics  Plasma Momentum Solid  Margins Gain Traction,opinion,On Jun 15  we issued an updated research report on Haemonetics Corporation   NYSE HAE    The company has been benefiting from continued momentum in new business generation and expanding geographies  The stock carries a Zacks Rank  2  Buy  Shares of this leading provider of hematology products and solutions have outperformed its  over the last three months  The stock has rallied 24 8  compared with the industry s 5 6  rise Haemonetics exited fourth quarter fiscal 2018 on a promising note with earnings and revenues beating the Zacks Consensus Estimate  Consistent momentum in new business formation along with widening global footprint has also helped the company deliver strong results  Moreover  the gross and operating margin growth buoys optimism among investors about the stock Additionally  we are upbeat about Haemonetics  flourish in the Plasma franchise  For solid end market demand for plasma derived biopharmaceuticals continues to drive growth  Haemonetics is also confident about maintaining progress in the commercial Plasma collection business Further  the fiscal 2019 guidance looks promising  In addition  the company s strong cash position boosts investors  confidence On the flip side  Haemonetics operates in a fiercely competitive environment with respect to manual and automated systems including the likes of MAK Systems Moreover  the company has been witnessing sluggish revenue growth at the Blood Center franchise  significantly affecting its results over the past few quarters  Also  management doesn t expect any quick recovery in the Blood Center s outcome  which further adds to our concerns Other Key PicksSome other top ranked stocks in the broader medical space are Abiomed  Inc    NASDAQ ABMD    Stryker Corporation   NYSE SYK   and Intuitive Surgical Inc    NASDAQ ISRG   Abiomed has a projected long term earnings growth rate of 27   The stock sports a Zacks Rank  1  Strong Buy  Stryker has an estimated long term earnings growth rate of 9 7   The stock holds a Zacks Rank of 2 Intuitive Surgical has an expected long term earnings growth rate of 12 1  and a Zacks Rank of 1  You can see  Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2018-06-17,Zacks Investment Research,https://www.investing.com/analysis/haemonetics-plasma-momentum-solid-margins-gain-traction-200325794,200325794
112168,333683,ISRG,ISRG Or ITGR  Which Is A Better Medical Instrument Stock ,opinion,"Rise in ageing population and a long track record of chronic diseases make the United States the world s largest medical device market  Furthermore  the market is currently riding on the recent suspension of the infamous 2 3  Medical Device tax  The tax deferral for another two years is likely to prove beneficial for the companies over the long haul  as it will significantly boost their R D prospects Per a research by Emergo  the U S  Medical Device industry is projected to reach a market value of  173 billion by 2019 Intuitive Surgical  Inc   ISRG  and Integer Holdings Corporation  ITGR  are two close contenders in this space Notably  Intuitive Surgical sports a Zacks Rank  1  Strong Buy  while Integer Holdings carries a Zacks Rank  2  Buy   This instils investors  confidence in the stocks  Intuitive Surgical has Growth Score of C and the same for Integer Holdings is B  indicating the latter s better prospects over the long haul Our research shows that stocks with a Growth Score of A or B  when combined with a Zacks Rank  1 or 2  are profitable picks  You can see the complete list of today s Zacks  1 Rank stocks here Here  we make a detailed analysis of the companies  fundamentals to determine which stock is currently positioned better in the Medical Instruments space With a market cap of  55 57 billion  Intuitive Surgical engages in designing and manufacturing of the coveted da Vinci surgical systems Based in Texas  Integer Holdings manufactures and develops medical devices and components primarily for original equipment manufacturers  The company has a market cap of  2 08 billion Price PerformanceIn the past six months  shares of Integer Holdings have rallied 39 7  compared with Intuitive Surgical s gain of 33 5  against the industry s decline of 4 4  The stockshave also outperformed the S P 500 Index s return of 3 5  over the same time frame Thus  when price performance is considered  Integer Holdings is in an advantageous position Earnings Growth ProjectionsThe Zacks Consensus Estimate for Intuitive Surgical s current year earnings is pegged at  10 26  reflecting a projected growth rate of 14 1  The same for Integer Holdings stands at  3 37 indicating growth of 19 9  Thus  Integer Holdings wins this round as well Sales Growth ProjectionsThe Zacks Consensus Estimate for Intuitive Surgical s current year revenues is pegged at  3 61 billion  showing an anticipated growth of 15 2  The same for Integer Holdings stands at  1 53 billion  reflecting growth of 4 9  Here  Intuitive Surgical scores over Integer Holdings Factors Driving the StocksIntuitive SurgicalCA based Intuitive Surgical rides on the solid performance of its noted da Vinci surgical system  Notably  this system enables minimally invasive surgery that helps avoid the trauma associated with open surgery In a recent study  it was also found that patients undergoing robotic assisted surgery using da Vinci surgical system had lesser complications In the first quarter of 2018  the da Vinci installed base grew 13  on year over year basis Furthermore  the company recently began direct operations in India  through its distributor  Vattikuti Technologies Pvt  Ltd   Read more  Intuitive Surgical Commences Direct Operations in India  Integer HoldingsThe company recently signed an agreement to divest its core Advanced Surgical and Orthopaedics unit   AS O   to MedPlast  LLC for  600 million  Management expects the deal to unlock significant value in the long run Notably  in the first quarter of 2018  the AS O segment generated revenues of  121 8 million  up 15 8  from the prior year quarter  Revenues witnessed organic growth of 11 5   year over year  Furthermore  the company rides on a strong guidance for 2018 It expects adjusted earnings per share within  3 20 3 20  reflecting growth of 14 25  Revenues are anticipated to be between  1 51 billion and  1 55 billion  indicating growth of 3 6  In ConclusionOur comparative analysis indicates that Integer Holdings is positioned better than Intuitive Surgical  considering price performance  style score and earnings growth projections Other Key PicksA couple of other top ranked stocks in the broader medical space are Genomic Health  GHDX  and Abiomed  inc   ABMD  Genomic Health has an expected earnings growth rate of 187 5  for the current quarter  The stock flaunts a Zacks Rank  1 Abiomed has an expected long term earnings growth rate of 27  and sports a Zacks Rank  1 Today s Stocks from Zacks  Hottest Strategies It s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1   And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation  See Them Free  Rise in ageing population and a long track record of chronic diseases make the United States the world s largest medical device market  Furthermore  the market is currently riding on the recent suspension of the infamous 2 3  Medical Device tax  The tax deferral for another two years is likely to prove beneficial for the companies over the long haul  as it will significantly boost their R D prospects  Per a research by Emergo  the U S  Medical Device industry is projected to reach a market value of  173 billion by 2019  Intuitive Surgical  Inc    NASDAQ ISRG   and Integer Holdings Corporation   NYSE ITGR   are two close contenders in this space  Notably  Intuitive Surgical sports a Zacks Rank  1  Strong Buy  while Integer Holdings carries a Zacks Rank  2  Buy   This instils investors  confidence in the stocks  Intuitive Surgical has  of C and the same for Integer Holdings is B  indicating the latter s better prospects over the long haul Our research shows that stocks with a Growth Score of A or B  when combined with a Zacks Rank  1 or 2  are profitable picks  You can see   Here  we make a detailed analysis of the companies  fundamentals to determine which stock is currently positioned better in the Medical Instruments space  With a market cap of  55 57 billion  Intuitive Surgical engages in designing and manufacturing of the coveted da Vinci surgical systems  Based in Texas  Integer Holdings manufactures and develops medical devices and components primarily for original equipment manufacturers  The company has a market cap of  2 08 billion  Price Performance In the past six months  shares of Integer Holdings have rallied 39 7  compared with Intuitive Surgical s gain of 33 5  against the  s decline of 4 4  The stocks have also outperformed the S P 500 Index s return of 3 5  over the same time frame    Thus  when price performance is considered  Integer Holdings is in an advantageous position  Earnings Growth Projections The Zacks Consensus Estimate for Intuitive Surgical s current year earnings is pegged at  10 26  reflecting a projected growth rate of 14 1   The same for Integer Holdings stands at  3 37 indicating growth of 19 9   Thus  Integer Holdings wins this round as well  Sales Growth Projections The Zacks Consensus Estimate for Intuitive Surgical s current year revenues is pegged at  3 61 billion  showing an anticipated growth of 15 2   The same for Integer Holdings stands at  1 53 billion  reflecting growth of 4 9   Here  Intuitive Surgical scores over Integer Holdings  Factors Driving the Stocks Intuitive Surgical CA based Intuitive Surgical rides on the solid performance of its noted da Vinci surgical system  Notably  this system enables minimally invasive surgery that helps avoid the trauma associated with open surgery  In a recent study  it was also found that patients undergoing robotic assisted surgery using da Vinci surgical system had lesser complications  In the first quarter of 2018  the da Vinci installed base grew 13  on year over year basis  Furthermore  the company recently began direct operations in India  through its distributor  Vattikuti Technologies Pvt  Ltd   Read more    Intuitive Surgical  Inc  Price and Consensus
 

   
Integer HoldingsThe company recently signed an agreement to divest its core Advanced Surgical and Orthopaedics unit   AS O   to MedPlast  LLC for  600 million  Management expects the deal to unlock significant value in the long run  Notably  in the first quarter of 2018  the AS O segment generated revenues of  121 8 million  up 15 8  from the prior year quarter  Revenues witnessed organic growth of 11 5   year over year  Furthermore  the company rides on a strong guidance for 2018  It expects adjusted earnings per share within  3 20 3 20  reflecting growth of 14 25  Revenues are anticipated to be between  1 51 billion and  1 55 billion  indicating growth of 3 6  Integer Holdings Corporation Price and Consensus
     In Conclusion Our comparative analysis indicates that Integer Holdings is positioned better than Intuitive Surgical  considering price performance  style score and earnings growth projections  Other Key Picks A couple of other top ranked stocks in the broader medical space are Genomic Health   NASDAQ GHDX   and Abiomed  inc    NASDAQ ABMD    Genomic Health has an expected earnings growth rate of 187 5  for the current quarter  The stock flaunts a Zacks Rank  1  Abiomed has an expected long term earnings growth rate of 27  and sports a Zacks Rank  1  Today s Stocks from Zacks  Hottest Strategies It s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1   And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2018-06-18,Zacks Investment Research,https://www.investing.com/analysis/isrg-or-itgr-which-is-a-better-medical-instrument-stock-200325786,200325786
112169,333684,ISRG,Walgreens Boots  Retail Pharmacy Strong Despite Several Woes,opinion,On Jun 19  we issued an updated research report on Walgreens Boots Alliance  Inc    NASDAQ WBA    We are currently looking forward to the company s modified Rite Aid contract  expected to benefit the company in the long run  The stock carries a Zacks Rank  3  Hold  We are encouraged by the company s consistent sales increase in the Retail Pharmacy International business  Moreover  Walgreens Boots has been gaining traction from a slew of strategic tie ups  which brought more patients to its U S  pharmacies We are also upbeat about the company s alliance with Express Scripts  via which  both companies aim to expand respective existing group purchasing efforts  This latest pact is expected to improve Express Scripts  supply chain and make medicines including biosimilars affordable and accessible to patients Walgreens Boots Alliance  Inc  Price    The above positives apart  Walgreens Boots  decision to buy a 40  stake in China s Sinopharm Holding Guoda Drugstores looks promising as that should provide a strong impetus to the company s worldwide retail pharmacy business  The limited number of Rite Aid stores  acquisitions also impresses us for which  the company has recently secured a regulatory approval However  Walgreens Boots faces headwinds in the form of fierce competition and tough industry conditions  Even though the company continues to reap benefits from its growth initiatives  major business tycoons are already advancing in pharmacy businesses with a fair market share Notably  a slowdown in generic introduction over the last few years has been affecting Walgreens Boots  margins  Also  an escalated reimbursement pressure and a generic drug cost inflation have been hampering Walgreens Boots  margins significantly Over the past three months  shares of Walgreens Boots have underperformed the   The stock has lost 3 2  against the industry s 5 6  increase Key PicksSome better ranked stocks in the broader medical sector are Illumina  Inc   NASDAQ ILMN    Intuitive Surgical   NASDAQ ISRG   and Chemed Corporation   NYSE CHE    While Illumina and Intuitive Surgical sport a Zacks Rank  1  Strong Buy   Chemed carries a Zacks Rank  2  Buy   You can see  Illumina expects long term earnings growth of 19 3  Intuitive Surgical has an expected long term earnings growth rate of 12 1  Chemed has an expected long term earnings growth rate of 10  Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2018-06-19,Zacks Investment Research,https://www.investing.com/analysis/walgreens-boots-retail-pharmacy-strong-despite-several-woes-200326464,200326464
112170,333685,ISRG,Polaris  58 com  BlackRock  Intuitive Surgical  Medtronic And NuVasive As Zacks Bull And Bear Of The Day,opinion,For Immediate Release         Chicago  IL   June 29  2018    highlights Polaris Industries   NYSE PII   as the Bull of the Day and BlackRock Capital   NASDAQ BKCC   as the Bear of the Day  In addition  Zacks Equity Research provides analysis onIntuitive Surgical  Inc    NASDAQ ISRG    Medtronic plc   NYSE MDT   and NuVasive  Inc    NASDAQ NUVA   Here is a synopsis of all four stocks                                                 Recent headlines have highlighted the issues some American companies are having with recent tariffs imposed on imports and the retaliatory tariffs imposed by our trading partners on goods exported from the U S  to other markets Harley Davidsonhas been specifically singled out by President Trump for its decision to shift some manufacturing overseas in order to sell its motorcycles to European markets while avoiding approximately  2 200 per vehicle in tariffs While sales of motorcycles and other recreational equipment are on the rise in the U S  thanks to a strong economy and record low unemployment  manufacturers who have the smallest reliance on imported raw materials or sales outside the country will be in an advantaged position to continue to operate normally with minimal regard for tariffs and could even gain market share and or pricing power versus imported products Polaris Industriesmanufactures and sells Powersports equipment primarily in the U S  including Motorcycles  Off Road ATVs  Snowmobiles and a wide range of parts and accessories  Through its brands Polaris  Ranger RZR and Indian motorcycles  Polaris is far and away the leader in sales of Powersports equipment in North America It s worth noting that Indian Motorcycles   a revival of an iconic American brand produced from 1901 to 1953   makes large V Twin road cycles that compete directly with Harley Davidson s products Polaris operates 16 In House manufacturing facilities worldwide  10 of which are in the U S   as well as 1 in Mexico  3 in France  1 in Poland and 1 in China  In the current environment  managers of public companies have a difficult job weighing the cost benefits of manufacturing overseas  while minimizing the negative effects of taxes and tariffs   and now  apparently even avoiding the ire of the President Polaris recently opened a new manufacturing plant in Alabama and announced plans for a new distribution center in Nevada Their diverse manufacturing footprint allows Polaris to continue producing good for the U S  in the U S   while serving while serving markets abroad   which are growing at an annual rate of 27    with goods manufactured in jurisdictions which minimize tariffs  BlackRock Capital is a class of investment known as a  Business Development Company   BDC  which were created by a 1980 amendment to the Investment Company Act of 1940  BDCs are unregulated closed end investment companies that invest in small and mid sized businesses  They are similar to Private Equity or Venture Capital Funds  except that they are usually traded on an exchange like a stock  instead of being open only to very wealthy investors BlackRock Capital provides middle market companies with flexible financing solutions  including senior and junior  unsecured and subordinated debt securities and loans and equity securities  Unlike a traditional private equity firm  BlackRock Capital makes non control investments in middle market companies The goal of a BDC is to invest in non public companies that investors would not otherwise have access to and to provide cash distributions to shareholders based on the cash flows of its investments  Taxed as a Regulated Investment Company  RIC   BlackRock Capital pays little or no corporate income tax as long as it passes through at least 90  of taxable income as dividends to investors Unfortunately  credit quality across the middle market lending space has been declining lately and BDCs like BlackRock Capital have seen a smaller pool of poorer performing loans than in the past  In their most recent earnings press release  Chairman and interim CEO James Keenan commented   Generally speaking  the loan market remains issuer friendly with tighter spreads  higher leverage levels and weaker structures  which is a continuation of market conditions seen over the last 12 18 months  This is a familiar sentiment across the middle market lending sector  As large investment vehicles with cumulative trillions of dollars that need to be invested   like Pensions  Public Retirement Funds and Endowments   reach for yield in a low interest rate environment  loan quality is getting squeezed  with less deserving issuers getting more attractive deals BlackRock Capital Shares have declined nearly 40  over the past 4 years as the company has missed numerous quarterly estimates  even as the consensus has steadily declined  Due to declining earnings estimates  BlackRock Capital is a Zacks Rank  5  Strong Sell  3 Stocks to Tap the Minimally Invasive Surgery Market BoomThe United States has hit rough waters of late  Few analysts label the troubles as self invited while others foresee a revolution  Rising trade war tensions between the United States and China are showing no signs of abatement  The issue has escalated to a point where imposition of tariffs and retaliatory tariffs may go up to  450 billion on both the sides Moreover  President Trump s mulling over a restriction for Chinese companies when it comes to investing in U S  tech firms to avert technology export is likely to worsen the scenario  If this wasn t enough  the United States is urging countries to stop importing oil from Iran by November  raising supply related concernsFurthermore  Trump s decision to impose tariffs on steel and aluminum imported from China  the European Union  Mexico and Canada along with threats of higher tariffs for imported cars and auto parts have raised concerns MedTech on Stable GroundIn the wake of such a rocky scenario  investors are consistently on the lookout for safer sectors  With tailwinds like favorable consumer behavior  growing demand for liquid biopsy tests along with deferred implementation of an industry wide Medical Device tax backing the sector  the medical device space seems to be in safer territories  Per Emergo  the U S  Medical Device industry is likely to be worth  173 billion by 2019 Minimally Invasive Surgical Device Market Hogs LimelightFor investors trying to pick a sub industry with booming prospects  the minimally invasive surgical device market is the final stop Reduced stay at hospital  lower healthcare costs and pain  scaring and tissue damage  are certain benefits of opting for minimally invasive surgery over the traditional process Persistence Market Research estimates the global minimally invasive surgical device market to value around  18 900 million in 2022  at a CAGR of 6 8  between 2017 and 2022  Per a report by Mordor intelligence  the U S  minimally invasive surgery device market is projected to see a CAGR of 8 65  between 2018 and 2023 Factors Driving the MarketThe minimally invasive surgical device market is largely dependent on the aging population  Per the U S  Census Bureau report  in 2050  people aged 65 or more are likely to total 83 7 million  almost double its estimated population of 43 1 million in 2012  Data also shows that the median age is increasing in most areas of the country and the global scenario is pretty similar Strengthening emerging markets have been contributing largely to the rise in demand for minimally invasive surgical devices  Geographically  the market is divided into North America  Europe  Latin America  Asia Pacific  and Middle East   Africa  Per Wise Guy Reports  the demand for minimally invasive surgical devices will be solid in the Asia Pacific region  the expected CAGR being 12 2  between 2016 and 2021 The growing dominance of AI applications in healthcare and technological revolution  new avenues and opportunities in the minimally invasive surgical devices space with robot assisted surgeries being in vogue  In this context  the first generation of surgical robots is being installed in a number of operating rooms globally Stocks to Watch Out ForWe have picked three companies  which we believe can help tap the booming prospects of the minimally invasive surgical devices market Intuitive Surgical  Inc   This Zacks Rank  3  Hold  company designs  manufactures and markets the da Vinci surgical system   an advanced robot assisted surgical platform  This Mechatronic based platform enables minimally invasive surgery that helps avoid the trauma associated with open surgery  You can see The company plans to expand the usage of da Vinci in general and thoracic surgery  colorectal surgery and hernia repair in the days to come Intuitive Surgical has an expected earnings growth rate of 14 1  for the current year  Over the past three months  Intuitive Surgical has outperformed its   The stock has gained 15 4  against the industry s 14 6  fall  Medtronic plc  This Zacks Rank  3 company has Minimally Invasive Therapies Group  formerly referred to as the Covidien Group following completion of the Covidien acquisition as one of the segments  The company offers ablation systems  acute care ventilation systems  brain and capnography monitoring systems along with a host of other products Medtronic has an expected earnings growth rate of 7 3  for the current year   The stock has delivered positive earnings surprises in all of the trailing four quarters  the average beat being 3 9  Over the past three months  Medtronic has outperformed its   The stock has risen 6 5  compared with the industry s 4 6   NuVasive  Inc   This Zacks Rank  3 company leads the global medical device spine market  focused on developing minimally disruptive surgical products and procedurally integrated solutions for the spine  The company s principal product includes a minimally disruptive surgical platform called Maximum Access Surgery  MAS   In the recent past  the company has launched XLIF Crestline  lateral ALIF and lateral MIS fixation NuVasive has an expected earnings growth rate of 28 3  for the current year  Over the past month  NuVasive has outperformed its   The stock has gained 3 4  compared with the industry s 0 2   5 Medical Stocks to Buy NowZacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia  AIDS  muscular dystrophy  hemophilia  and other conditions New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline  Early investors could realize exceptional profits Follow us on Twitter   Join us on Facebook  NASDAQ FB    Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates Media ContactZacks Investment Research800 767 3771 ext  9339Zacks com provides investment resources and informs you of these resources  which you may choose to use in making your own investment decisions  Zacks is providing information on this resource to you subject to the Zacks  Terms and Conditions of Service  disclaimer   Past performance is no guarantee of future results  Inherent in any investment is the potential for loss This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ,2018-06-28,Zacks Investment Research,https://www.investing.com/analysis/polaris-58com-blackrock-intuitive-surgical-medtronic-and-nuvasive-as-zacks-bull-and-bear-of-the-day-200328662,200328662
112171,333686,ISRG,5 Trade Ideas For Monday  Anthem  Apache  Costco  DaVita And Intuitive Surgical,opinion,"Anthem  NYSE ANTM 

Anthem  ANTM  ran higher  peaking at the end of January  It pulled back and then settled into a 5 month consolidation with a slight upward drift  Recently it pulled back from making a higher high to a higher low  And Friday it started moving higher again  The RSI is rising in the bullish zone with the MACD level but positive  Look for continuation to participate higher 
Apache  NYSE APA 

Apache  APA  started higher in March and has continued to move up  Last week it closed a gap from January  ending the week at resistance  The RSI is in the bullish zone with the MACD positive and rising  Look for a push over resistance to participate to the upside 
Costco  NASDAQ COST 

Costco  COST  started higher out of consolidation in June and ran to an all time high toward the end of the month  It pulled back from there to the 20 day SMA in a bull flag  Friday saw it breaking the bull flag to the upside  The RSI is rising in the bullish zone with the MACD flat but positive  Look for continuation to participate higher 
DaVita HealthCare  NYSE DVA 

DaVita  DVA  moved higher over its 200 day SMA with a gap up in December  It ran to a top in January and then started to pullback  It bottomed as it moved under the 200 day SMA again and consolidated for a month  In May it started back higher again and is moving up in steps  Friday looks to have begun the next step up  The RSI is turning back up and the MACD leveling and positive  Look for continuation to participate 
Intuitive Surgical  NASDAQ ISRG 

Intuitive Surgical  ISRG  has continued to march higher but with some volatile pullbacks  It gapped higher in April and then refilled the gap before a push higher  The price paused in May and then made another move up in June to resistance  Friday it moved back to resistance after a minor pullback 2 weeks ago  The RSI is rising in the bullish zone with the MACD about to cross up and positive  Look for a push over resistance to participate 
After reviewing over 1 000 charts  I have found some good setups for the week  These were selected and should be viewed in the context of the broad Market Macro picture reviewed Friday which with the 4th of July behind  sees slow holiday trading ahead and it seems to be good for equities so far 
Elsewhere look for gold to bounce in its downtrend while Crude Oil may pause in its uptrend  The US Dollar Index is also pausing in its uptrend while US Treasuries are breaking out to the upside  The Shanghai Composite continues to look better lower but may have a short term pause while Emerging Markets may be reversing to the upside after a several months long pullback 
Volatility looks to continue to creep lower keeping the bias higher for the equity index ETF s SPY  IWM and QQQ  Their charts all look good in the long term with the IWM the strongest in the short run  but the SPY and QQQ reversing higher out of support 
Use this information as you prepare for the coming week and trad em well 
The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment  I or my affiliates may hold positions or other interests in securities mentioned in the Blog  please see my Disclaimer page for my full disclaimer 
Original post",2018-07-09,Gregory W. Harmon,https://www.investing.com/analysis/5-trade-ideas-for-monday-anthem-apache-costco-davita--intuitive-surgical-200329765,200329765
112202,333717,ISRG,Cooper Companies  COO  Q2 Earnings   Revenues Beat Estimates,opinion,"The Cooper Companies  Inc    NYSE COO   posted second quarter fiscal 2018 adjusted earnings of  2 86 per share  which beat the Zacks Consensus Estimate by 1 1   Earnings also increased 14 4  on a year over year basis The California based specialty medical device company reported revenues worth  631 3 million  which surpassed the Zacks Consensus Estimate by 0 8   Revenues improved 20 8  from the prior year quarter and 5  on a pro forma basis  defined as constant exchange rate and including acquisitions in both periods  Meanwhile  Cooper s shares have declined 0 8  against the  s rise of 5 7  in the past six months The stock currently carries a Zacks Rank  3  Hold  The Cooper Companies  Inc  Price  Consensus and EPS Surprise
    Segment DetailsCooper reports revenues in two major segments   CooperVision  CVI  and CooperSurgical  CSI  CVIThis segment garnered revenues worth  467 5 million  up 14  on a year over year basis and 6  at cc  Per management  overall CVI sales have been driven by strong performance by the silicone hydrogel portfolio of Clariti and MyDay Toric  32  of CVI  revenues raked in  150 8 million  up 8  at cc  while Multifocal  10   generated revenues worth  49 1 million  up 7  at cc Single use sphere  27   posted revenues worth  124 4 million  up 19  from the prior year quarter  Non single use sphere  31   revenues came in at  143 2 million  up 10  from a year ago Geographically  the segment saw a strong quarter  U S  revenues rose 7  to  183 6 million on a year over year basis and 6  at cc  Management expects the U S  growth momentum to be strong in the second half on fiscal 2018  with growth expected in upper single digits Revenues rose 20  on a year over year basis in both EMEA and Asia Pacific CSIThis segment posted revenues of  163 8 million  up 44  from a year ago and 3  at cc  Per management  growth was led by strength in PARAGARD and the fertility solutions product offerings Sub segment Office and Surgical products  60  of CSI  accounted for  97 9 million  up a whopping 86  year over year  Fertility  40   posted sales worth  65 9 million  up 8  year over year Margin AnalysisAs a percentage of revenues  adjusted gross margin at the CSI segment was 71  in the reported quarter  up 900 basis points  bps  compared with the prior year quarter As a percentage of revenues  adjusted gross margin at the CVI segment was 68  in the reported quarter  higher than 67  of revenues in the year ago quarter In the second quarter  gross profit as a whole for Cooper Companies  totaled  431 3 million  up 25  from the year ago quarter  Adjusted gross margin was 68 3   which expanded 230 bps Operating income in the quarter totaled  180 2 million  up 28 8  from the prior year figure  Adjusted operating margin was 28 5   up 170 bps Guidance UpdatedCooper updated its revenue guidance for fiscal 2018 The company now expects fiscal 2018 revenues within  2 515  2 550 million compared with the previous range of  2 510  2 560 million  Notably  the Zacks Consensus Estimate for the same is pegged at  2 53 billion  which lies within the projected range Revenues at the CVI segment are now estimated in the band of  1 870  1 890 million  compared with  1 870  1 890 million stated previously  However  CSI revenue range has been kept intact at  645  660 million Fiscal 2018 adjusted earnings per share are anticipated between  11 70 and  11 90  The Zacks Consensus Estimate for earnings is pinned at  11 80  within the projected range In ConclusionCooper wrapped up fiscal second quarter on a solid note  Strong performance by CooperVision buoys optimism  Geographically as well  the company put up a solid show  The acquisition of PARAGARD drove CooperSurgical revenues  Management is optimistic about the recently completed acquisition of LifeGlobal which is expected to enhance Cooper s fertility business  Further  the continued improvement in gross and operating margin is promising On the flip side  Cooper s long term debt has increased significantly  which raises concern  Moreover  continued acquisitions pose integration risks  Stiff competition in the niche space adds to the woes Key PicksA few better ranked stocks in the broader medical space which have reported solid results this season are Intuitive Surgical   NASDAQ ISRG    Chemed Corporation   NYSE CHE   and Baxter International Inc    NYSE BAX    While Intuitive Surgical sports a Zacks Rank  1  Strong Buy   Chemed and Baxter carry a Zacks Rank  2  Buy   You can see  Intuitive Surgical reported first quarter 2018 adjusted earnings per share of  2 44  which beat the Zacks Consensus Estimate by 22 6   Revenues totaled  848 million  also surpassing the consensus estimate by 10 6  Chemed posted first quarter 2018 adjusted earnings per share of  2 72  surpassing the Zacks Consensus Estimate of  2 37  Revenues came in at  439 2 million  beating the Zacks Consensus Estimate of  420 million Baxter posted first quarter 2018 adjusted earnings per share of 70 cents  which beat the Zacks Consensus Estimate by 12 9   Revenues of  2 68 billion also edged past the Zacks Consensus Estimate of  2 62 billion Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2018-06-07,Zacks Investment Research,https://www.investing.com/analysis/cooper-companies-coo-q2-earnings--revenues-beat-estimates-200323502,200323502
112203,333718,ISRG,Corindus Vascular Robotics  CVRS  Soars  Stock Adds 14 2  In Session,opinion,"Corindus Vascular Robotics  Inc    NYSE CVRS   was a big mover last session  as the company saw its shares rise more than 14  on the day  The move came on solid volume too with far more shares changing hands than in a normal session  This reverses the recent trend for the company as the stock is now up 2 4  in the past one month time frame The stock gained after the developer of precision vascular robotics reported that it has obtained PMDA approval for the commercialization of its CorPath GRX System in Japan  which is one of the largest percutaneous coronary interventions  PCI  markets in the world The company has seen no changes when it comes to estimate revision over the past few weeks  while the Zacks Consensus Estimate for the current quarter has also remained unchanged  The recent price action is encouraging though  so make sure to keep a close watch on this firm in the near future Corindus Vascular Robotics currently has a Zacks Rank  3  Hold  while its  is 0 00    Corindus Vascular Robotics  Inc  Price
   Investors interested in the Medical   Instruments industry may consider Intuitive Surgical  Inc    NASDAQ ISRG    which has a Zacks Rank  1  Strong Buy   You can see the complete list of today s Zacks  1 Rank stocks here 
Is CVRS going up  Or down  Predict to see what others think Up or DownThe Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2018-06-11,Zacks Investment Research,https://www.investing.com/analysis/corindus-vascular-robotics-cvrs-soars-stock-adds-142-in-session-200323906,200323906
112204,333719,ISRG,Momentum Monday   Bull Markets Correct Through Sector Rotation ,opinion,"Recent Chinese IPOs have gone wild  Many of them have doubled in a month or two  Highly shorted stocks are forcing short sellers out of their positions  Many momentum tech stocks are looking dangerously extended  but other sectors are starting to perk up and keep the stock market indexes afloat  Is the market running on fumes or sector rotation will save the day again and keep pushing higher 
We cover QQQ  MSFT  ETSY  MMYT  ROKU  TSLA  ISRG  TWTR  BABA  RH  MA  V  and many others 
Disclaimer  Everything on this show is for informational and educational purposes only  The ideas presented are not recommendations to buy or sell stocks  The material presented here might not take into account your specific investment objectives  I may or I may not own some of the securities mentioned  Consult your investment advisor before acting on any of the information provided here ",2018-06-11,Ivaylo Ivanhoff,https://www.investing.com/analysis/momentum-monday--bull-markets-correct-through-sector-rotation-200324054,200324054
112205,333720,ISRG,Market Overlooks Summit To Focus On The Fed,opinion,"Programming Note  Sheraz Mian  the Director of Research here at Zacks  was talking about the Q2 earnings season on WGN Radio s The Opening Bell this morning  Check out his appearance right here  
	As expected  the meeting between President Trump and North Korean leader Kim Jong un didn t have much of an impact on the market  The agreement signed at the summit proved to be too vague to cause much of a reaction 
	The market is more interested in tomorrow s Fed announcement  A rate hike on Wednesday is a foregone conclusion  but the focus will be on the Dot Plot  Are we still set for only three hikes this year  one more after tomorrow   Or is a fourth hike still on the table  We ll see   
	Unlike yesterday  the major indices moved sharply higher in the final hour of Tuesday s session  The NASDAQ finished with a 0 57  advance to a new high of 7703 8 and the S P climbed 0 17  to 2786 9  However  the Dow couldn t make it all the way back and finished with a slight 0 01  slip to 25320 7  Despite the media coverage of the meeting between Kim and Trump  the summit had little effect on the markets   said Jeremy in Counterstrike   The Fed is really all that matters  We will likely see a rate hike again tomorrow  but what will be more important is what kind of language will be used  For short term trading reasons  anything taken as dovish will likely help rip markets above 2800  
	Other than the summit  the biggest news today didn t come until after the close  A federal judge approved the  85 billion acquisition of Time Warner by AT T  NYSE T   Now  the market is getting ready for a deluge of new M A coming down the pike 
	The portfolios were very active today and included a lot of profit taking  Stocks Under  10 cashed in a triple digit winner to make room for a new buy  while Surprise Trader secured a double digit return in less than a week  Meanwhile  Counterstrike sold all or parts of three positions to fit in a new buy  while Short List swapped out four names  Read more in the highlights section below  Today s Portfolio Highlights  Stocks Under  10  The portfolio is completely full  so Brian Bolan needs to sell a name before he can add a new one  Fortunately  the service is sitting on a triple digit winner in Extreme Networks  EXTR   a maker of wireless networking products and services  The stock was sold today for a profit of about 120  
	The move gives Brian a chance to take advantage of some shorts in the retail world  A lot of shorts have been getting squeezed in the last few days on some good reports from retailers  and the editor thinks the same thing is happening right now with Big 5 Sporting Goods  BGFV   The stock has a  ferociously high  short interest of 45  of the float  and Brian thinks those shorts have overstayed their welcome  He believes BGFV could be set to move to  11 or more on some good news  Read the full write up for more on today s moves Counterstrike  The rising market has Jeremy in a buying mood  but first he needs to clear some space and take a few profits  On Tuesday  the portfolio made these moves 
	  Sold half of Echo Global Logistics  ECHO  for a 10 8  return
	  Sold all of Intuitive Surgical  NASDAQ ISRG  for a 9 9  return
	  Sold a third of Salesforce com  NYSE CRM  for a 5  return
	These moves gave the editor enough space to add Parsley Energy  PE  with a 7  allocation  The stock has pulled back from a solid quarterly report in May that included a positive earnings surprise of 40   Jeremy thinks the stock has bottomed and is poised to move if crude oil ticks higher again  which it is likely to do this summer  Read the complete commentary for more specifics on all of today s moves Surprise Trader  The portfolio sold Restoration Hardware  RH  on Tuesday for a nice 40 7  profit IN LESS THAN ONE WEEK  Dave added this name last Wednesday in a  bet the jockey  not the horse  move due to his confidence in Chairman   CEO Gary Friedman  Well  shares of this upscale furniture retailer soared today after a positive earnings surprise in its latest quarterly report  which also included a strong outlook for this quarter  The editor says the shorts are getting routed  so this is a great time to cash in a double digit winner with RH 

Zacks Short List  The portfolio swapped out four names in this week s adjustment  The short covered stocks that left the portfolio today include 

  Applied Optoelectronics  AAOI   8 3  
	  MGM Resorts Intl  MGM 
	  Sina Corp  SINA 
	  Williams Partners  WPZ 

The new buys that replaced these names are 

  MercadoLibre Inc   MELI 
	  Schlumberger Limited  SLB 
	  TAL Education Group  TAL 
	  Zayo Group  ZAYO 

Learn more about this emotion free portfolio that takes advantage of falling and volatile markets by reading the Short List Trader Guide 

All the Best 
	Jim Giaquinto
Recommendations from Zacks  Private Portfolios   Believe it or not  this article is not available on the Zacks com website  The commentary is a partial overview of the daily activity from Zacks  private recommendation services  If you would like to follow our Buy and Sell signals in real time  we ve made a special arrangement for readers of this website  Starting today you can see all the recommendations from all of Zacks  portfolios absolutely free for 7 days  Our services cover everything from value stocks and momentum trades to insider buying and positive earnings surprises  which we ve predicted with an astonishing 80   accuracy    Click here to  test drive  Zacks Ultimate for FREE   ",2018-06-12,Zacks Investment Research,https://www.investing.com/analysis/market-overlooks-summit-to-focus-on-the-fed-200324404,200324404
112206,333721,ISRG,SYK Or SRDX  Which Is A Better Medical Product Stock ,opinion,The United States is the world s largest medical device market  which is expected to improve further aided by a long track record of chronic diseases  Also  with the suspension of the controversial 2 3  medical device tax for another two years  this industry is currently riding high on optimism  Per a research by Emergo  the U S  Medical Device industry is projected to reach a market value of  173 billion by 2019 Stryker Corporation   NYSE SYK   and Surmodics  Inc    NASDAQ SRDX   are two close contenders in this space Notably  both stocks carry a Zacks Rank  2  Buy   which raises investors  optimism  These stocks also have a  B  Our research shows that stocks with a VGM Score of A or B  when combined with a Zacks Rank  1  Strong Buy  or 2  are profitable picks Here  we make a detailed analysis of the companies  fundamentals to determine which stock is currently positioned better in the Medical Products space With a market cap of  60 74 billion  Stryker is one of the leading medical device companies operating in the global orthopedic market On the other hand  based in Minnesota  Surmodics is a leading provider of medical device and In Vitro Diagnostics  IVD  technologies  The company has a market cap of  723 9 million Price PerformanceIn the past year  Stryker s shares have gained 17 4  compared with the  s rise of 13   The stock has also surpassed the S P 500 index s increase of 14  Meanwhile  shares of Surmodics have skyrocketed 122 2  in this period Price ComparisonYou can see  Earnings GrowthThe Zacks Consensus Estimate for Stryker s current year earnings is pegged at  7 23 per share  which reflects projected growth of 11 4  The same for Surmodics is pegged at 2 cents  indicating decline of 103 9  Moreover  since 2009  Stryker s earnings per share have witnessed a CAGR of 10 4  to  6 49 in 2017  Surmodics  earnings projected a negative CAGR of 9  and totaled 51 cents in 2017 Hence  Stryker wins this round Sales GrowthThe Zacks Consensus Estimate for Stryker s current year revenues is pegged at  13 61 billion  showing growth of 9 3   The same for Surmodics is pinned at  78 4 million  reflecting growth of 7 3  Since 2009  Stryker s revenues witnessed a CAGR of 8  and reached  12 44 billion in 2017  Surmodics  revenues depicted a negative CAGR of 6 2  in 2017 Here too  Stryker wins over Surmodics Factors Driving the StocksStrykerStryker s robotic arm assisted Mako surgery platform has been consistently driving the top line  In the last reported quarter  the platform recorded 28 new robot installations  globally  Notably  the Mako TKA knee platform drove the Orthopaedic segment  which delivered an organic growth of 2 5  recently The company raised guidance for the second quarter of 2018  which buoys optimism Stryker Corporation Price and Consensus   SurmodicsSurmodics has been on an acquisition spree  Recently  the company announced that it has reached an agreement with Embolitech to acquire an innovative thrombectomy platform technology  This is likely to enhance the company s focus on developing highly differentiated whole product solutions for its medical device customers Recently  the company received approval from the FDA for its  018  Low Profile percutaneous transluminal angioplasty  PTA  balloon dilation catheter  Notably  the device is designed for a broad range of peripheral vascular applications Moreover  a partnership with the MedTech bigwig Abbott  is also a major positive Surmodics  Inc  Price and Consensus   In ConclusionOur comparative analysis indicates that Stryker is positioned better than Surmodics  considering price performance as well as earnings and sales growth Other Key PicksA few other top ranked stocks in the broader medical space are Genomic Health   NASDAQ GHDX   and Intuitive Surgical Inc   NASDAQ ISRG   Genomic Health has an expected earnings growth rate of 187 5   The stock flaunts a Zacks Rank of 1 Intuitive Surgical has an expected long term earnings growth rate of 12 1  and sports a Zacks Rank  1 5 Medical Stocks to Buy NowZacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia  AIDS  muscular dystrophy  hemophilia  and other conditions New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline  Early investors could realize exceptional profits ,2018-06-13,Zacks Investment Research,https://www.investing.com/analysis/syk-or-srdx-which-is-a-better-medical-product-stock-200324964,200324964
112207,333722,ISRG,Here s Why You Should Steer Clear Of Express Scripts For Now,opinion,Express Scripts Holding Company   NASDAQ ESRX   has underperformed the broader  in the last three months  The company s shares have gained 8 2  versus the industry s rally of 8 8  A rapidly changing healthcare environment in the United States  loss of clients and stiff competition in niche space are significant headwinds for the company Battered by such challenges  the Zacks Consensus Estimate for second quarter adjusted earnings is currently pegged at  2 20 per share  down 1 8  in the last two months  The same for revenues is pinned at  25 34 billion  reflecting a year over year decline of 0 01  The stock has a Zacks Rank  4  Sell  Below we take a sneak peek at the major issues plaguing Express Scripts Loss of Patient ClaimsThe MO based pharmacy benefit manager lost certain public sector clients  which resulted in a 1 6  year over year decline in adjusted network claims in the last reported quarter Moreover  adjusted home delivery and specialty claims totaled 77 3 million in the quarter  down 8 6  year over year Express Scripts Getting AcquiredExpress Scripts recently announced that it is getting acquired by Cigna Corporation  NYSE CI   a global health insurance company  The acquisition is expected to be concluded by Dec 31  2018  Cigna will take over Express Scripts in a cash and stock transaction worth  67 billion Competition RifeExpress Scripts faces intense competition in the Patient Benefit Management industry from independent PBMs like MedImpact and Navitus Health Solutions  Moreover  the PBM space is dominated by bigwigs like CVS  Aetna  NYSE AET  and Cigna  among others Guidance DownbeatFor 2018  Express Scripts  adjusted earnings per share are estimated in the band of  9 to  9 14  significantly below the previous range of  9 27  9 47 Key PicksSome better ranked stocks in the broader medical space are Abiomed  Inc    NASDAQ ABMD    Stryker Corporation   NYSE SYK   and Intuitive Surgical Inc    NASDAQ ISRG   Intuitive Surgical has an expected long term earnings growth rate of 12 1   The stock sports a Zacks Rank  1  Strong Buy   You can see  Stryker has a projected long term earnings growth rate of 9 7   The stock carries a Zacks Rank  2  Buy  Abiomed has a projected long term earnings growth rate of 27   The stock holds a Zacks Rank  1 Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2018-06-14,Zacks Investment Research,https://www.investing.com/analysis/heres-why-you-should-steer-clear-of-express-scripts-for-now-200325361,200325361
112235,333750,ISRG,NuVasive s  NUVA  Global Prospects Solid  Competition Rife,opinion,On Jun 4  we issued an updated research report on NuVasive  Inc    NASDAQ NUVA    We are upbeat about the company s flourishing international business  which holds immense opportunity  However  a highly competitive landscape is a concern for this Zacks Rank  3  Hold  company This leading global medical device company in the global spine market  focused on developing minimally disruptive surgical products and procedurally integrated solutions for the spine  has been outperforming its over the past month  The stock has gained 5 8  compared with the industry s 4 5  rise We are upbeat about NuVasive s international business recording above 20  growth for the sixth consecutive quarter in the first quarter of 2018  The company saw strong sales growth across all geographies  Emerging markets also performed well  with strong growth in South Africa and Saudi Arabia  Asia Pacific grew in double digits with strong results from Japan s reintroduction of XLIF  Further  NuVasive s healthy cash balance should support its plans to pursue acquisitions and develop products Meanwhile  the presence of a large number of players has made the medical devices market intensely competitive  The orthopedic industry  in particular  is extremely competitive with the presence of bellwethers like Zimmer Biomet Holdings   NYSE ZBH   and Stryker Corporation   NYSE SYK    among others Also  margin drag  pricing pressure and reimbursement issues continue to be other major headwinds Key PickA better ranked stock in the broader medical sector is Intuitive Surgical   NASDAQ ISRG    which sports a Zacks Rank  1  Strong Buy   You can see  Intuitive Surgical has an expected long term earnings growth rate of 12 1  The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2018-06-04,Zacks Investment Research,https://www.investing.com/analysis/nuvasives-nuva-global-prospects-solid-competition-rife-200322288,200322288
112236,333751,ISRG,Why You Should Add IDEXX  IDXX  Stock To Your Portfolio ,opinion,IDEXX Laboratories  Inc    NASDAQ IDXX   has been gaining investor confidence from consistently solid results  The stock has rallied 28 1  over a year  ahead of the S P 500 s 13  growth and against the broader  s 1 1  decline Moreover  the company has a market cap of  19 07 billion  Its five year expected growth rate is also favorable at 20 2  compared with the industry s 16 7  tally Dwelling on solid prospects  this Zacks Rank  2  Buy  player is an attractive bet for investors at the moment The company s estimate revision trend for 2018 has also been positive  In the last 60 days  five analysts moved their estimates northward with no movement in the opposite direction  The consensus mark for current year earnings has been raised around 11 4  to  4 11 per share  Per our   IDEXX Laboratories sports a favorable Growth Score of B  reflective of the company s strong fundamentals  Our research shows that stocks with an impressive Growth Style Score of A or B combined with a bullish Zacks Rank  1  Strong Buy  or 2 offer the best upside potential Accordingly  IDEXX Laboratories has an encouraging net margin  net income sales  of 13 9  as well against the industry s negative 14 9   Also  the company s sale to assets ratio of 1 26 compared with the industry s 0 63 makes it a sturdy growth pick Let s find out is the recent positive momentum is sustainable or not The company is a leading manufacturer of products and services  primarily for the companion animal veterinary  livestock and poultry  It exited the first quarter of 2018 on a commendable note with better than expected earnings and revenue performances The stock s stellar performance was driven by robust sales at the CAG  Companion Animal Group  business  In the first quarter  CAG revenues rose 13  organically year over year  supported by CAG Diagnostics  recurring organic revenue growth Moreover  IDEXX VetLab consumables organic revenue growth was firm on the back of an expanding premium instrument base in the United States and the international markets  including growth in competitive instrument placements  increasing utilization and a consistent customer retention Notably  in January 2018  the company made Catalyst SDMA Test available in North America  With this  IDEXX s point of care customers will now be able to add SDMA as an essential element to the routine chemistry panel  Apart from the United States and Canada  IDEXX expects to launch the Catalyst SDMA Test in other parts of the world over the next several months Continuing with a slew of developments  IDEXX Laboratories entered into a global agreement in January with the diagnostic company called Applied BioCode  Per the deal  IDEXX Laboratories will bring its Reference Laboratories customers on the digital multiplex platform built by Applied BioCode  Management aims at commercially launching this technology in 2019 The companion animal market fundamentals remain consolidated on the global runway for tremendous growth  Management s innovation based  multi modality global strategy accelerated the recurrent CAG Diagnostics revenue growth in the reported quarter  Moreover  a substantial top line rise was contributed by considerable contributions from other business segments  Furthermore  a raised guidance for 2018 bottom line per share instills confidence in the stock We are also optimistic about the company witnessing double digit organic revenue growth in its international business  This upside indicated steady consumable revenue gains riding on Catalyst instrument base and average testing utilization Additionally  the company boasts a secure cash balance  allowing it to carry out share repurchases Meanwhile  IDEXX Laboratories  heavy dependence on third party distributors raises a concern  Moreover  a rigid competitive landscape in the domestic and overseas markets weighs on the company s margin Other Key PicksA few other top ranked stocks in the broader medical space are Abiomed  Inc    NASDAQ ABMD    Genomic Health  Inc    NASDAQ GHDX   and Intuitive Surgical   NASDAQ ISRG   Abiomed has an estimated long term earnings growth rate of 27   The stock sports a Zacks Rank  1  Strong Buy   You can see  Genomic Health has an expected earnings growth rate of 187 5   The stock has a Zacks Rank of 1 Intuitive Surgical has an expected long term earnings growth rate of 12 1  and is a Zacks  1 Ranked stock Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2018-06-06,Zacks Investment Research,https://www.investing.com/analysis/why-you-should-add-idexx-idxx-stock-to-your-portfolio-200323053,200323053
112237,333752,ISRG,Bio Rad Banks On Solid Global Scenario  Competition Rife ,opinion,On Jun 7  we initiated a research report on Bio Rad Laboratories  Inc    NYSE BIO    We are upbeat about the company delivering a robust performance overseas  while a tough competitive landscape is a concern  The stock carries a Zacks Rank  3  Hold  This California based manufacturer and global supplier of clinical diagnostics and life science research products has been outperforming its  over the past year  The stock has gained 30 7  versus the industry s 15 3  rise  Bio Rad kick started 2018 on a solid note  with earnings and revenues rising year over year in the first quarter  The company has been strongly progressing with its efforts to strengthen its hold in other geographies  In first quarter 2018  Bio Rad derived around 62  of its net sales globally  The company delivered robust performance  primarily in North America  China and the Asia Pacific region Further  constant currency sales at the Life Science segment were particularly strong in North America  China and Europe  while currency neutral sales at the company s Clinical Diagnostics segment saw strength in China  Asia Pacific and North America We are encouraged by the company s active portfolio expansion for the blood typing market  In January 2018  Bio Rad announced the receipt of 510 k  clearance from the FDA for the IH Incubator L and IH Centrifuge L instruments to be used with the complete range of Bio Rad s IH System Gel Reagents for manual blood typing methods Meanwhile  Bio Rad operates in a highly competitive environment dominated by firms varying from large multinational corporations to start ups  Also  the competitive and regulatory conditions in the markets where the company operates limit its ability to switch to strategies like price increases and other drivers of cost increases In the Life Science segment  Bio Rad primarily competes with the likes of Becton Dickinson and Thermo Fisher Scientific   NYSE TMO    among others  Again  some prominent competitors in the Clinical Diagnostics segment are Abbott Laboratories   NYSE ABT   and DiaSorin Further  Bio Rad is exposed to risks associated with a weaker global economy and lower reimbursement rates Key PicksA better ranked stock in the broader medical sector is Intuitive Surgical   NASDAQ ISRG    sporting a Zacks Rank  1  Strong Buy   You can see  Intuitive Surgical has a long term expected earnings growth rate of 12 1  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2018-06-07,Zacks Investment Research,https://www.investing.com/analysis/biorad-banks-on-solid-global-scenario-competition-rife-200323344,200323344
112270,333785,ISRG,US North Korea Summit Talks Resume  4 MedTech Stocks To Watch ,opinion,President Donald Trump s calling off of the summit with North Korean leader Kim Jong Un last Thursday was quite a shocker The abandonement of summit plans dealt a blow to the underpenetrated and emerging markets of Asia  which are a solid source of revenues for more than 80  of U S  based multinational companies  The effects of the political mayhem caused the MSCI s broadest index of Asia Pacific shares outside Japan  South Korea s KOSPI and Japan s Nikkei to plummet Major Wall Street indices  S P 500 and the Dow Jones Industrial Average  lost ground as well Considering this trend of downward movements  the White House decided to conduct the meeting  The United States announced its plans to send a  pre advance team  to Singapore to prepare for Trump Kim summit on Jun 12 MedTech appears to be one of the very few sectors that might shelter investors from the political tension  Shrugging off the current volatility  the Medical Products industry has returned 0 2  since the call off against the S P 500 s fall of 0 4   In fact  analysts believe that the MedTech sector will be able to strengthen its foothold at a faster rate if the meeting goes on as planned This is because there are a number of U S  based MedTech companies operating in Asia  Post the success of the summit  these companies will be able to spread their network in North Korea and augment overall production  Per research by Statista  the MedTech market in the Asia Pacific region is estimated to reach a worth of around  78 billion in 2018 Buoyed by the encouraging projections  it would rather be interesting to see how the  companies are placed amid the political turmoil 4 MedTech Stocks to GainMeanwhile  the Medical Product companies have already been gaining from organic growth  R D innovation  higher consolidation  tax abolition as well as focus on emerging markets including Japan  South Korea  China  Vietnam  India  Philippines and more In fact  stakeholders in the medical universe have been eyeing these markets over the last couple of years  These companies are bullish about growing medical awareness  economic prosperity  an aging population  increasing wealth  government s focus on healthcare infrastructure and expansion of medical insurance coverage in the APAC space Below  we take a look at four leading MedTech players that are gaining from the prospects in the APAC market Becton  Dickinson and Company   NYSE BDX    popularly known as BD  particularly focuses on broader emerging markets like India  China  Brazil and Turkey  whose economic and healthcare sectors are growing rapidly  In particular  safety engineered products continue to drive growth in the emerging markets  We believe that exposure in these markets will boost the top line  which in turn will accelerate EPS growth This Zacks Rank  3  Hold  company s shares have returned 16 2  in a year  significantly higher than the S P 500 index s gain of 11 4  Baxter International s   NYSE BAX   solid presence in Asia  precisely India  is worth a mention  The company has research hubs in Japan and China  Recently  Baxter completed the acquisition of India based Claris Injectables  a global generic injectables pharmaceutical company  for almost  625 million This Zacks Rank  2  Buy  stock has outperformed the S P 500 index in a year s time  The stock has returned 21   Intuitive Surgical Inc s   NASDAQ ISRG   growing interest in the emerging markets  specifically in the APAC region  bodes well  In the past two years  the company s procedure performance in Asia projected consistent strength  The company registered solid growth in China  Japan and Korea The Zacks Rank  1  Strong Buy  company s shares have returned 49 1  in a year  You can see  Boston Scientific Corporation s   NYSE BSX   growth strategy comprises the pursuit of development opportunities outside the United Station through strengthening of global presence  inclusive of emerging markets  Against the backdrop of flattening or declining sales growth in developed markets like the United States and Europe  Boston Scientific is fortifying its foothold in the emerging markets of Brazil  Russia  India and China  BRIC  In first quarter 2018  business from the emerging markets registered 17  growth  Business in China was once again remarkable  up 23  year over year   The company is currently projecting an improvement in performance in China banking on the recent approval of SYNERGY This Zacks Rank  2 stock has returned 11 7  in a year  Things to Remember Things are not so easy as they appear to be  Americans should never forget that former president George W  Bush referred North Korea as an  Axis of evil   as it sponsored terrorism and had solid access to nuclear weapons Further  North Korea s multiple trials of nuclear warheads have dampened the inter country relationship  Analysts believe that an unforeseen summit may not solve these age old problems  Further  no one can guarantee that Kim Jong Un s  tremendous anger and open hostility  will not offend Trump anymore as it did last week However  Trump s team is expecting to reach an agreement to settle the North Korean nuclear and other issues in the meeting Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2018-05-29,Zacks Investment Research,https://www.investing.com/analysis/usnorth-korea-summit-talks-resume-4-medtech-stocks-to-watch-200320484,200320484
112271,333786,ISRG,Is Intuitive Surgical  ISRG  Stock Outpacing Its Medical Peers This Year ,opinion,"Investors interested in Medical stocks should always be looking to find the best performing companies in the group  Is Intuitive Surgical  NASDAQ ISRG  one of those stocks right now  By taking a look at the stock s year to date performance in comparison to its Medical peers  we might be able to answer that question 
Intuitive Surgical is a member of our Medical group  which includes 763 different companies and currently sits at  10 in the Zacks Sector Rank  The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors 
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks  This system has a long record of success  and these stocks tend to be on track to beat the market over the next one to three months  ISRG is currently sporting a Zacks Rank of  1  Strong Buy  
The Zacks Consensus Estimate for ISRG s full year earnings has moved 12 66  higher within the past quarter  This means that analyst sentiment is stronger and the stock s earnings outlook is improving 
Our latest available data shows that ISRG has returned about 24 58  since the start of the calendar year  At the same time  Medical stocks have lost an average of 1 77   This means that Intuitive Surgical is performing better than its sector in terms of year to date returns 
Looking more specifically  ISRG belongs to the Medical   Instruments industry  which includes 88 individual stocks and currently sits at  101 in the Zacks Industry Rank  On average  this group has lost an average of 7 45  so far this year  meaning that ISRG is performing better in terms of year to date returns 
Investors with an interest in Medical stocks should continue to track ISRG  The stock will be looking to continue its solid performance ",2018-05-30,Zacks Investment Research,https://www.investing.com/analysis/is-intuitive-surgical-isrg-stock-outpacing-its-medical-peers-this-year-200320655,200320655
112332,333847,ISRG,QIAGEN  QGEN  Banks On Test Menu Expansion  Competition Stiff,opinion,On May 16  we issued an updated research report on QIAGEN N V    NYSE QGEN    We are upbeat about the company progressing with the testing menu expansion strategy  However  a tough competitive landscape is a concern  The stock carries a Zacks Rank  3  Hold  This Netherlands based molecular diagnostics provider offers innovative technologies and products for pre analytical sample preparation and molecular diagnostics solutions  The stock has been outperforming its  over the past six months  Per the latest stock movement  it has gained 12 2  against 8 1  decline of the broader industry QIAGEN ended the first quarter on a solid note  We are impressed with the year over year growth in majority of the segments  The company has been proceeding with its test menu expansion strategy  In this regard  in April  the company announced the receipt of pre market approval by the FDA for PartoSure  In the same month  the company launched QIAstat Dx in Europe following the closure of the recently announced Stat Dx acquisition and completion of defined development activities by Stat Dx  We are also upbeat about QIAGEN s Molecular Diagnostics sales that have been growing significantly  During the first quarter  the company witnessed double digit CER growth in revenues from the QuantiFERON latent TB test along with strength in Personalized Healthcare following rising sales of infectious disease testing products We also look forward to the implementation of the recently drawn strategies to boost top line contributions from the NGS portfolio Meanwhile  QIAGEN faces stiff competition from firms that provide competitive pre analytical solutions and other products  The markets for some of the company s products are very competitive and price sensitive  which add to the concerns Also  strong reliance on collaborations and declining HPV sales in the United States are other negatives A few better ranked stocks in the broader medical sector are Intuitive Surgical   NASDAQ ISRG    Illumina  Inc   NASDAQ ILMN   and The Cooper Companies  Inc    NYSE COO    While Intuitive Surgical and Illumina sport a Zacks Rank  1  Strong Buy   Cooper Companies carries a Zacks Rank  2  Buy   You can see  Intuitive Surgical has a long term expected earnings growth rate of 12 1  Illumina has a long term expected earnings growth rate of 20  Cooper Companies has a long term expected earnings growth rate of 10 8  Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2018-05-16,Zacks Investment Research,https://www.investing.com/analysis/qiagen-qgen-banks-on-test-menu-expansion-competition-stiff-200316961,200316961
112333,333848,ISRG,Intuitive Surgical  ISRG  Up 4 9  Since Earnings Report  Can It Continue ,opinion,"A month has gone by since the last earnings report for Intuitive Surgical  Inc    NASDAQ ISRG    Shares have added about 4 9  in that time frame 
Will the recent positive trend continue leading up to its next earnings release  or is ISRG due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important drivers 
Recent EarningsIntuitive Surgical reported first quarter 2018 adjusted earnings of  2 44 per share  which beat the Zacks Consensus Estimate by 22 6   Earnings also improved 42 7  on year over year basis Revenues totaled  848 million  up 24 7  from the prior year quarter  Revenues also surpassed the Zacks Consensus Estimate by 10 6  The solid performance was backed by higher worldwide da Vinci procedures led by growth in U S  general surgery procedures and global urologic procedures  Per management  revenues also gained from around a 2 5  drop in dollar Segment DetailsInstruments   AccessoriesRevenues came in at  460 3 million  which reflects a year over year increase of 20 9   Per management  15  growth in da Vinci procedure volume primarily drove the upside In Japan  12 da Vinci procedures within the specialties of general surgery  gynecology  and cardiothoracic surgery were granted a national reimbursement status SystemsIn the reported quarter  system revenues increased 45 8  year over year to  234 5 million  Notably  185 da Vinci Surgical systems were shipped by the company  up 39 1  year over year In the quarter under review  shipments included 43 systems under operating lease arrangements  compared with 21 in the year ago quarter ServicesServices revenues came in at  152 7  up 10 7  from a year ago International Sales UpOutside the United States  revenues totaled  275 million  up 49  on a year over year basis and 11  sequentially  The upside can be attributed to an increase in systems revenue of 55 million and higher instruments and accessories revenues of 30 million OUS procedures grew 18  year over year  with 73 system placements in the reported quarter  compared with 56 in the year ago quarter  The first quarter of 2018 placements include 45 in Europe and 9 in Japan MarginsGross margin was 71 6   down 40 basis points  bps  year over year In the first quarter of 2018  operating income increased 30 1  on a year over year basis to  346 million Financial ConditionThe company ended the first quarter with  4 1 billion in cash  cash equivalents and investments  reflecting an increase of  222 million in the quarter  primarily driven by cash generated from operations The company has not repurchased any share in the quarter and has approximately  718 million remaining under its board s buyback authorization OutlookThe company has not issued any guidance However  management feels that U S  revenues might experience a low single digit decline because of lackluster performance in the gynecology and benign hysterectomy market Management also feels that margins will fluctuate due to a mix of newer products of systems and accessory revenues 
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed an upward trend in fresh estimates  There have been eight revisions higher for the current quarter Intuitive Surgical  Inc  Price and Consensus
    VGM Scores
At this time  ISRG has a nice Growth Score of B  a grade with the same score on the momentum front  However  the stock was allocated a grade of F on the value side  putting it in the lowest quintile for this investment strategy 
Overall  the stock has an aggregate VGM Score of D  If you aren t focused on one strategy  this score is the one you should be interested in 
Zacks style scores indicate that the company s stock is suitable for growth and momentum investors 
Outlook
Estimates have been trending upward for the stock and the magnitude of these revisions looks promising  It comes with little surprise  ISRG has a Zacks Rank  1  Strong Buy   We expect an above average return from the stock in the next few months ",2018-05-17,Zacks Investment Research,https://www.investing.com/analysis/intuitive-surgical-isrg-up-49-since-earnings-report-can-it-continue-200317017,200317017
112334,333849,ISRG,ResMed Releases Positive U S    U K  Study Data On COPD,opinion,ResMed Inc    NYSE RMD   recently demonstrated a favorable outcome from two clinical analyses in the field of chronic obstructive pulmonary disease  COPD   These studies were conducted for the United Kingdom and the United States  highlighting the cost effectiveness of combining home oxygen therapy with home non invasive ventilation  NIV  therapy for persistent hypercapnia patients  who suffer exacerbation of COPD The combo regimen of Home Oxygen Therapy Home Mechanical Ventilation  a home NIV   together known as HOT HMV  has been presented at the American Thoracic Society 2018 International Conference  These are company sponsored health economic studies Going by the U K  study  HOT HMV treatment reduced exacerbation frequency and 28 day hospital readmission  Data from the analysis was used to develop an economic model from the U K  National Health Service perspective  While the U S  study demonstrated a 58 3  reduction in 30 day readmissions for HOT HMV patients compared with those on home oxygen alone  Evidently  this indicated the treatment to be hugely cost effective  Per ResMed  the U S  analysis was based on the U K  study  The study finds were utilized to build an economic model from the U S  payer perspective   We are optimistic about this entire development by ResMed  taking into consideration the widely growing market for COPD treatment  Per data provided by GBI Research  the global COPD market is currently worth  11 3 billion and is projected to reach a value of  15 6 billion by 2019  According to the research report  this gaping demand will be met through numerous new  efficient and convenient products making inroads into the market   Undoubtedly  ResMed s HOT HMV studies and the related favorable outcomes are a step forward for the company to intensify its footprint in the niche market Notably  ResMed achieved strong global revenue growth over the past few quarters  led by sales of sleep devices  respiratory care devices  mask systems as well as software solutions  We believe  ResMed s product launches and strategies will gain traction in the SDB market and are expected to drive growth for the company in the near term Among recent developments  the company informed about its first self branded portable oxygen concentrator Mobi  subject to a fiscal third quarter launch  It has also introduced AirMini  the world s smallest PAP  positive airway pressure  device In the past three months  ResMed has outperformed its   The stock has gained 9  compared with the 5 1  rise of the industry Zacks Rank   Key PicksResMed currently carries a Zacks Rank  3  Hold   A few better ranked stocks in the broader medical sector are Intuitive Surgical   NASDAQ ISRG    Illumina  Inc   NASDAQ ILMN   and The Cooper Companies  Inc    NYSE COO    While Intuitive Surgical and Illumina sport a Zacks Rank  1  Strong Buy   Cooper Companies carries a Zacks Rank  2  Buy   You can see  Intuitive Surgical has a long term expected earnings growth rate of 12 1  Illumina has a long term expected earnings growth rate of 20  The Cooper Companies has a long term expected earnings growth rate of 10 8  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana      Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2018-05-20,Zacks Investment Research,https://www.investing.com/analysis/resmed-releases-positive-us--uk-study-data-on-copd-200317935,200317935
112369,333884,ISRG,Penumbra  PEN  Q1 Earnings   Revenues Top Estimates  View Up,opinion,Penumbra  Inc    NYSE PEN   reported first quarter 2018 adjusted earnings per share of 6 cents against the adjusted loss of 10 cents in the year ago quarter  Moreover  the bottom line remained well ahead of the Zacks Consensus Estimate of a loss of 2 cents Total revenues in the reported quarter surged 40 3  year over year  up 36 2  at constant exchange rate or CER  to  102 7 million  exceeding the Zacks Consensus Estimate of  93 million Geographically  first quarter revenues in the United States  representing 64  of total sales  grossed  65 8 million  up 35 7  from the year ago period  Meanwhile  international sales  36  of total sales  improved 49 2  year over year  up 37 1  at CER  to  36 9 million Penumbra  Inc  Price  Consensus and EPS Surprise    Per the product category  revenues from neuro products grew 42 2   up 37 3  at CER  to  71 4 million in the quarter under review  Revenues from peripheral vascular product business rose to  31 3 million in the first quarter  reflecting an increase of 36 2   up 33 7  at CER  year over year Operational UpdatePenumbra s first quarter gross margin was 64 8   representing a 36 basis point  bps  contraction year over year  However  gross profit climbed 39 5  Research and development expenses totaled  8 million  up 13 9  while sales  general and administrative expenses amounted to  54 5 million  up 27 6  year over year  Operating profit in the reported quarter came in at  4 million versus the operating loss of  2 million in the prior year quarter Financial Update Penumbra exited the first quarter of 2018 with cash and cash equivalents of  52 8 million compared with  50 6 million at the end of 2017 OutlookPenumbra has raised its guidance for 2018 revenues  The company now expects total revenues in the range of  410  415 million compared with the earlier provided projection of  400  405 million  The Zacks Consensus Estimate of  404 1 million lags the guided range Our TakePenumbra exited first quarter 2018 with better than expected results  The year over year comparison of earnings was favorable  Moreover  the company witnessed strong growth across all geographies as well as product lines  The company is focusing on product innovation through research and development  On the flip side  escalating costs and expenses are weighing on the bottom line Penumbra is an active player in the fast growing interventional therapies space  In fact  the company s products primarily cater to the unmet clinical needs across the two major markets of neuro and peripheral vascular Zacks Rank   Key PicksPenumbra has a Zacks Rank  3  Hold   A few better ranked stocks in the broader medical space  which have reported solid financial figures this reporting cycle are  Intuitive Surgical   NASDAQ ISRG    Chemed Corp    NYSE CHE   and Baxter International Inc    NYSE BAX    While Intuitive Surgical sports a Zacks Rank  1  Strong Buy   Chemed and Baxter carry a Zacks Rank  2  Buy   You can see  Intuitive Surgical reported first quarter 2018 adjusted EPS of  2 44  which beat the Zacks Consensus Estimate by 22 6   Revenues totaled  848 million  also surpassing the consensus estimate by 10 6  Chemed posted first quarter 2018 adjusted EPS of  2 72  surpassing the Zacks Consensus Estimate of  2 37  Revenues came in at  439 2 million  beating the Zacks Consensus Estimate of  420 million Baxter posted first quarter 2018 adjusted EPS of 70 cents  which outpaced the Zacks Consensus Estimate by 12 9   Revenues of  2 68 billion also edged past the Zacks Consensus Estimate of  2 62 billion The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2018-05-08,Zacks Investment Research,https://www.investing.com/analysis/penumbra-pen-q1-earnings--revenues-top-estimates-view-up-200314823,200314823
112370,333885,ISRG,STERIS  STE  Q4 Earnings   Revenues Beat  Estimates  Up Y Y,opinion,STERIS plc   NYSE STE   reported fourth quarter fiscal 2018 adjusted earnings per share  EPS  of  1 24  up 11 7  year over year and 1 6  ahead of the Zacks Consensus Estimate  Reported EPS came in at 86 cents  a significant improvement from 31 cents a year ago The adjusted EPS figure for the full year was  4 15  up 10 4  from the year ago period and also above the Zacks Consensus Estimate by a couple of cents STERIS generated revenues of  715 9 million in the fiscal fourth quarter  up 5 1  year over year  Moreover  the top line exceeded the Zacks Consensus Estimate of  710 million  Fiscal 2018 revenues came in at  2 61 billion  a marginal 0 3  improvement from the year ago period  The annual figure is in line with the consensus mark Quarter in DetailOrganic revenue growth at constant currency was 5 2  year over year in the fiscal fourth quarter  mainly driven by balanced growth across all segments of the company STERIS plc Price  Consensus and EPS Surprise    The company operates through four segments  Healthcare Products  Healthcare Specialty Services  Applied Sterilization Technologies and Life Sciences Revenues at Healthcare Products increased 2  year over year to  360 million  up 4  on a constant currency organic basis   In the quarter under review  service revenues grew 7   consumable revenues rose 2  and capital equipment revenues were flat year over year Revenues at the Healthcare Specialty Services segment were up 7 1  to  122 1 million  up 5  on a constant currency organic basis   The fourth quarter registered the final impact from the linen business divestitures year over year  Revenues at Applied Sterilization Technologies rose 11  to  133 5 million  up 5    backed by increased demand from core medical device customers Revenues at Life Sciences segment grew 15  to  100 3 million  up 12   on 9  growth in Service revenues and a 46  rise in capital equipment revenues  Consumable revenues were flat year over year  MarginsAdjusted gross margin improved 70 basis points  bps  year over year to 42  in the reported quarter  Per STERIS  gross margin expansion was fueled by a favorable product mix and price along with a 60 basis point improvement from divestitures  Currency had an unfavorable impact of 60 basis points on the gross margin STERIS witnessed a 21 4  year over year decline in selling  general and administrative expenses to  161 6 million  Research and development expenses rose 11 7  to  15 2 million  Accordingly  adjusted operating margin expanded 280 bps on a year over year basis to 17 6  in the reported quarter Financial DetailsSTERIS exited the fiscal 2018 with cash and cash equivalents of  201 5 million compared with  282 9 million at the end of fiscal 2017  The company had long term debt of  1 32 billion at the end of the fiscal fourth quarter compared with  1 48 billion at the end of fourth quarter fiscal 2017 For the full year  the company generated  457 6 million in cash flow from operations  up 7 9  from the year ago period  While free cash flow was  294 3 million compared with  256 million in the prior year 2019 GuidanceSTERIS expects 4 5  of constant currency organic revenue growth in fiscal 2019 from the prior fiscal  The Zacks Consensus Estimate for fiscal 2019 revenues is pegged at  2 73 billion Adjusted EPS outlook for fiscal 2019 has been projected in the range of  4 63  4 75  The consensus estimate for fiscal 2019 adjusted EPS  lies within the guided range at  4 71 Our TakeSTERIS exited fourth quarter fiscal 2018 on a promising note with both earnings and revenues beating the respective Zacks Consensus Estimate  We are also encouraged by the favorable underlying market trends along with new product and service offerings  Further  growth in free cash flow reserve is indicative of the company s strong cash balance  The company has also made certain divestments and organizational changes  which are expected to better align with its operations Zacks Rank   Key PicksSTERIS has a Zacks Rank  3  Hold   Some better ranked stocks in the broader medical space  having reported solid results this earnings season are  Intuitive Surgical   NASDAQ ISRG    Chemed Corporation   NYSE CHE   and Baxter International Inc    NYSE BAX    While Intuitive Surgical sports a Zacks Rank  1  Strong Buy   Chemed and Baxter carry a Zacks Rank  2  Buy   You can see  Intuitive Surgical reported first quarter 2018 adjusted EPS of  2 44  which beat the Zacks Consensus Estimate by 22 6   Revenues totaled  848 million  also surpassing the consensus estimate by 10 6  Chemed posted first quarter 2018 adjusted EPS of  2 72  surpassing the Zacks Consensus Estimate of  2 37  Revenues came in at  439 2 million  outpacing the Zacks Consensus Estimate of  420 million Baxter posted first quarter 2018 adjusted bottom line of 70 cents  which beat the Zacks Consensus Estimate by 12 9   The top line came in at  2 68 billion  edging past the Zacks Consensus Estimate of  2 62 billion Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2018-05-09,Zacks Investment Research,https://www.investing.com/analysis/steris-ste-q4-earnings--revenues-beat--estimates-up-yy-200315024,200315024
112371,333886,ISRG,Here s Why You Should Invest In Intuitive Surgical Right Now,opinion,Intuitive Surgical  Inc    NASDAQ ISRG   is one of the top performing stocks in the U S  MedTech space  The company s solid revenue base  improving financial performance and unwavering focus on minimally invasive surgical methods are key catalysts The company has a positive average earnings surprise of 19 7  for the trailing four quarters  Moreover  in the last 60 days  the Zacks Consensus Estimate for earnings has improved 4 3  to  2 43  This reflects strong prospects of the company In the past year  shares of Intuitive Surgical have rallied 64 1  against the  s decline of 2 3   The current level is also higher than the S P 500 s gain of 11 6   If you want to cash in on the share price appreciation  it s time you add the stock to your portfolio  Intuitive Surgical sports a Zacks Rank  1  Strong Buy   What s Favoring the Stock Solid Q1 ResultsIntuitive Surgical delivered strong first quarter 2018 results  The company s flagship da Vinci procedures saw solid growth and holds tremendous potential  The company also saw expansion outside the United States  which buoys optimism  Both earnings and revenues surpassed the consensus mark Revenues totaled  848 million  up 24 7  from the prior year quarter  Meanwhile  earnings surged 42 7  on a year over year basis Outside the United States  revenues totaled  275 million  up 49  on a year over year basis and 11  sequentially  while OUS procedures rose 18  da Vinci Surgical Platform Holds PromiseIntuitive Surgical has of late been focusing on minimally invasive surgical procedures in order to avoid the trauma associated with open surgery  The da Vinci System is powered by robotic technology that allows the surgeon s hand movements to be translated into smaller  precise movements Notably  in the first quarter of 2018  da Vinci procedures grew approximately 15  on a year over year basis  Management replaced 185 da Vinci surgical systems  up from 133 in the year ago quarter  Furthermore  the company s installed base grew 13  from a year ago Strong Revenue BaseSince 2014  Intuitive Surgical has been delivering strong revenues  Till 2017  revenues saw a CAGR of 15 6  to  3 1 billion  Moreover  the company has a solid recurring revenue base  In the first quarter of 2018  total recurring revenues were  623 million  representing 73  of total revenues  Total recurring revenues in 2017 was  2 2 billion representing 72  of total revenues Other Key PicksOther top ranked stocks in the broader medical space are ABIOMED  Inc    NASDAQ ABMD    Genomic Health  Inc    NASDAQ GHDX   and Exelixis  Inc    NASDAQ EXEL   ABIOMED has a long term growth rate of 27   The stock sports a Zacks Rank  1  You can see  Genomic Health has an expected growth rate of 187 5  for the current quarter  The stock sports a Zacks Rank  1 Exelixis has a projected growth rate of 75  for the current quarter  The stock sports a Zacks Rank  1 Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2018-05-09,Zacks Investment Research,https://www.investing.com/analysis/heres-why-you-should-invest-in-intuitive-surgical-right-now-200315190,200315190
112372,333887,ISRG,Is Intuitive Surgical  ISRG  Outperforming Other Medical Stocks This Year ,opinion,"For those looking to find strong Medical stocks  it is prudent to search for companies in the group that are outperforming their peers  Has Intuitive Surgical  NASDAQ ISRG  been one of those stocks this year  Let s take a closer look at the stock s year to date performance to find out 
Intuitive Surgical is a member of our Medical group  which includes 764 different companies and currently sits at  10 in the Zacks Sector Rank  The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors 
The Zacks Rank is a successful stock picking model that emphasizes earnings estimates and estimate revisions  The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months  ISRG is currently sporting a Zacks Rank of  1  Strong Buy  
The Zacks Consensus Estimate for ISRG s full year earnings has moved 11 40  higher within the past quarter  This signals that analyst sentiment is improving and the stock s earnings outlook is more positive 
Based on the most recent data  ISRG has returned 28 35  so far this year  Meanwhile  stocks in the Medical group have lost about 2 08  on average  As we can see  Intuitive Surgical is performing better than its sector in the calendar year 
Looking more specifically  ISRG belongs to the Medical   Instruments industry  which includes 88 individual stocks and currently sits at  107 in the Zacks Industry Rank  On average  stocks in this group have lost 6 58  this year  meaning that ISRG is performing better in terms of year to date returns 
Investors with an interest in Medical stocks should continue to track ISRG  The stock will be looking to continue its solid performance ",2018-05-10,Zacks Investment Research,https://www.investing.com/analysis/is-intuitive-surgical-isrg-outperforming-other-medical-stocks-this-year-200315461,200315461
112373,333888,ISRG,Anatomy Of Success  Intuitive Surgical  ISRG ,opinion,"The Zacks Rank is a proven stock picking system that helps both beginning and experienced investors find strong companies at any given moment  The model  which emphasizes earnings estimates and estimate revisions  discovers companies of all shapes and sizes that are displaying the right characteristics to beat the market 
When a particular company earns the desired Zacks Rank  1  Strong Buy   it is on track to provide remarkable returns over the next one to three months  Of course  achieving this ideal rank is no easy task  Of the thousands of companies tracked by Zacks  only about 5  earn this designation 
Below  you will read about one specific company that helped prove the strength of the Zacks Rank  If investors had followed our model when it identified this futuristic healthcare technology manufacturer  they would have achieved massive profits 
Intuitive Surgical  NASDAQ ISRG   Inc   ISRG 
Intuitive Surgical is the global leader in minimally invasive robotic assisted surgery  The company is best known for its da Vinci Surgical System  which enables surgeons to operate through a few small incisions or the belly button from a nearby ergonomic console  The da Vinci System features a magnified 3D HD vision system and tiny wristed instruments that bend and rotate far greater than the human hand 
Over the past year  the Zacks Rank has spotted ISRG as a strong option multiple times  The stock first earned a Zacks Rank  1  Strong Buy  on June 9  2017  However  things really started picking up for the company directly after its next earnings report in July 
Intuitive posted earnings of  1 98 per share  topping the Zacks Consensus Estimate by five cents  The company also witnessed quarterly revenues of  756 million  cruising past our consensus estimate and improving nearly 13  on a year over year basis  ISRG would earn its second  1  Strong Buy  designation just one day after reporting 
Throughout the next few months  the stock would never dip below a Zacks Rank  3  Hold  and witnessed several stretches where it was a Zacks Rank  2  Buy   ISRG also briefly saw its third  1  Strong Buy  ranking on Dec  15  2017 
Intuitive earned its next  1  Strong Buy  designation on April 20  and it maintains that ranking today  This came on the back of another strong quarterly earnings report  which not only surpassed expectations  but also inspired positive revisions to forward looking estimates 
In its latest quarter  ISRG posted earnings of  2 44 per share  crushing the Zacks Consensus Estimate of  1 99 and improving more than 43  from the year ago period  Meanwhile  revenue of  848 million was well ahead of our consensus estimate of  767 million 
The below chart demonstrates the price performance for ISRG and 12 month forward looking EPS estimate  in red   starting from the time the stock first earned a Zacks Rank  1  Strong Buy  
As we can see  ISRG has been a massive winner for those that followed the Zacks Rank  The stock is currently up about 50 3  since earning a Zacks Rank  1  Strong Buy  last year  Investors should know that our model is the simplest way to identify elite stocks poised to beat the market on a consistent basis 
Want more market analysis from this author  Make sure to follow   on Twitter 
Looking for Stocks with Skyrocketing Upside 
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana 
Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2018-05-11,Zacks Investment Research,https://www.investing.com/analysis/anatomy-of-success-intuitive-surgical-isrg-200315658,200315658
112374,333889,ISRG,Orthofix  OFIX  Stock Declines 13  On  18 Earnings View Cut,opinion,"Shares of Orthofix International N V    NASDAQ OFIX   have lost 13  over the past two weeks since the company s first quarter 2018 earnings release on Apr 30  2018 
Despite better than expected bottom line numbers  shares dropped due to lowered earnings outlook for the company in 2018  Over this period  the company has also significantly underperformed the  it belongs to  The stock has lost 12 5  against the industry s 3 7  gain 
Let us delve deeper into the earnings details of Orthofix 
The company reported first quarter 2018 adjusted earnings per share  EPS  of 39 cents from continuing operations  The figure was ahead of the Zacks Consensus Estimate by 8 3   The bottom line surged 44 4  year over year primarily on strong sales growth at the company s BioStim  Extremity Fixation and Spine Fixation strategic business units  SBU  

 
Excluding one time items  net income from continuing operations in the first quarter came in at 27 cents per share versus the net loss from continuing operations of 13 cents  thereby showing a remarkable year over year improvement 
Sales Details
Orthofix s first quarter sales improved 5 8   up 3 3  at constant exchange rate or CER  to  108 7 million  almost in line with the Zacks Consensus Estimate of  109 million  As a result of the company s adoption of the revenue recognition accounting change at the beginning of 2018  Orthofix noted that if it converts the consolidated revenues of first quarter 2017 into the new standard  growth would have been 2 4  at CER in the reported quarter  Sales were primarily driven by a strong performance by the company s three SBUs  namely BioStim  Extremity Fixation and Spine Fixation  partly offset by a year over year decline in Biologics business 
SBU Details
For the first quarter  the company posted BioStim sales of  46 2 million  reflecting 3 6   same at CER  growth from the prior year period  
Extremity Fixation sales were  27 5 million in the quarter under review with 14 9  improvement  up 4 3  at CER  from first quarter 2017  The company realized a continued uptake of new products and a commendable performance in most of the company s global markets including the United States Orthofix International N V  Price  Consensus and EPS Surprise

   Orthofix reported Spine Fixation SBU sales of  20 7 million  reflecting 7 5   up 7 2  at CER  growth over the year earlier quarter  This uptick can be attributed to product launches and the adopted strategic initiatives 
Biologics SBU sales totaled  14 3 million  down 4 4   same at CER  from the year ago quarter  This decline resulted from the contractual reduction in the marketing service fee percentage that Orthofix receives from MTF Biologics 
Margins
In the first quarter  gross margin contracted 23 basis points  bps  to 77 8   Unfavorable sales mix impacted the quarterly gross margin 
Sales and marketing expenses rose 3 6  year over year to  50 2 million  General and Administrative expenses were up 6 6  to  19 5 million  The company witnessed a 6 6  decrease in research and development expenses to  6 9 million  Overall  adjusted operating margin expanded 148 bps to 7 2  owing to increased operating expenses 
Cash Position
Orthofix exited the first quarter of 2018 with cash and cash equivalents of  77 1 million compared with  81 2 million at the end of 2017  For the first quarter  net cash used in operating activities was  3 6 million compared with  10 8 million a year ago 
2018 Guidance
Orthofix has lowered its 2018 earnings view as it expects Biologic sales to be flat or less by low single digits for the full year due to contractual decrease in the marketing service fee the company is going to receive from MTF Biologics  Adjusted EPS from continuing operations are expected in the range of  1 58  1 78  falling below the earlier projected band of  1 76  1 84  The Zacks Consensus Estimate for full year adjusted EPS stands at  1 67  within the company s projected range 
Full year net sales projection has been increased to the band of  458  464 million  earlier prediction was  450  455 million   The Zacks Consensus Estimate for full year revenues is pegged at  462 7 million  lying within but near the upper end of the guided range 
Our Take
Orthofix exited the first quarter of 2018 on a mixed note  While earnings exceeded the Zacks Consensus Estimate  sales almost matched the consensus mark  Investors are upset about poor Biologics prospects  which will continue to be a drag on the overall performance throughout the remainder of the year  Accordingly  the company has to reduce its full year earnings expectation 
This apart  currency fluctuations  a competitive landscape and macroeconomic headwinds continue to pose challenges to the company  Moreover  higher costs and operating expenses are a matter of grave concern for Orthofix  Also  heavy dependence on a third party for final distribution of products exposes the company to heightened risks  
On a positive note  the top line was substantially driven by strength in Extremity Fixation as well as Spine Fixation businesses  which are expected to continue in the near term on the back of sales force enhancements  expanded distributorship network and introduction of products 
Zacks Rank   Key Picks
Orthofix carries a Zacks Rank  4  Sell   Some better ranked stocks in the broader medical space  having posted solid results this earnings season are  Intuitive Surgical   NASDAQ ISRG    Chemed Corp    NYSE CHE   and Baxter International Inc    NYSE BAX    While Intuitive Surgical sports a Zacks Rank  1  Strong Buy   Chemed and Baxter carry a Zacks Rank  2  Buy   You can see  
Intuitive Surgical reported first quarter 2018 adjusted EPS of  2 44  beating the Zacks Consensus Estimate by 22 6   Revenues totaled  848 million  also surpassing the consensus estimate by 10 6  
Chemed posted first quarter 2018 adjusted EPS of  2 72  outshining the Zacks Consensus Estimate of  2 37  Revenues came in at  439 2 million  outpacing the Zacks Consensus Estimate of  420 million 
Baxter posted first quarter 2018 adjusted bottom line of 70 cents  which exceeded the Zacks Consensus Estimate by 12 9   The top line came in at  2 68 billion  edging past the Zacks Consensus Estimate of  2 62 billion 
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia  AIDS  muscular dystrophy  hemophilia and other conditions New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline  Early investors could realize exceptional profits ",2018-05-14,Zacks Investment Research,https://www.investing.com/analysis/orthofix-ofix-stock-declines-13-on-18-earnings-view-cut-200316076,200316076
112375,333890,ISRG,Medtronic Initiates Study On DES For Expanded Use In The US,opinion,Medtronic plc   NYSE MDT   recently announced the initiation of a clinical study   The Bifurcation Cohort   to evaluate the efficiency and safety standards of drug eluting stents  DES  for treating bifurcation lesions Study in DetailsThe Bifurcation Cohort  part of the RESOLUTE ONYX Post Approval Study  will cover 250 patients with bifurcation lesions from 30 sites in the United States and Europe  It will be enrolling patients suffering with coronary artery disease  CAD  and receiving Resolute Onyx DES in diameter sizes varying from 2 0 5 0 mm  Notably  the Resolute Onyx DES is not approved for treating bifurcation lesions in the United States  Further  the primary endpoint for the study will be target vessel failure at 12 months Per Medtronic  data from the study will be submitted to the FDA for expanded indication approval including bifurcation lesions for the Resolute Onyx DES  Further  the company stated that bifurcation lesions are responsible for 20  of all percutaneous coronary interventions  Thus  we believe the positive data will provide impetus to the company s efforts to achieve expanded FDA approval for the Resolute Onyx DES and accelerate business growth CSH PerformanceMedtronic is consistently trying to enhance its Coronary   Structural Heart  CSH  segment  which is part of the Cardiac   Vascular Group  CVG  segment CSH revenues in third quarter fiscal 2018 were up 14  at CER  18  as reported  on low 30s constant currency growth in transcatheter aortic valves as a result of strong customer uptake of the CoreValve Evolut PRO platform and expanded FDA approval to include patients at intermediate risk Moreover  continued uptake of the Resolute Onyx drug eluting stent in the United States and Japan revived the business We encouragingly note that Medtronic recently received FDA nod for the U S  launch of the Resolute Onyx 2 0 mm drug eluting stent  The stent is the smallest in size in the market presently  The Resolute Onyx DES is available for use in all sizes in the United States  Europe and in countries that recognize the CE Mark Market PotentialMedtronic s strategy to gain traction in the CSH segment seems to be aligned with data provided by Transparency Market Research  Per the report  the global coronary stent market is expected to see a CAGR of 6 6  from 2013 to 2019 More specifically  the DES market within the Coronary stents market is expanding fast  It is estimated to witness a CAGR of 9 54  in the 2013 2019 period  The market is likely to expand 9  in the United States  10  in the Asia Pacific  and 3 1  in Europe as well as the Rest of the World Stock Performance Over the past three months  Medtronic has outperformed the   gaining 2 7  as compared with the industry s 1 8    Zacks Rank   Key PicksMedtronic currently carries a Zacks Rank   3  Hold  A few better ranked stocks in the broader medical sector are Intuitive Surgical   NASDAQ ISRG    Illumina  Inc   NASDAQ ILMN   and The Cooper Companies  Inc    NYSE COO    While Intuitive Surgical and Illumina sport a Zacks Rank  1  Strong Buy   Cooper Companies carries a Zacks Rank  2  Buy   You can see  Intuitive Surgical has a long term expected earnings growth rate of 12 1  Illumina has a long term expected earnings growth rate of 20  Cooper Companies has a long term expected earnings growth rate of 10 8  Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2018-05-16,Zacks Investment Research,https://www.investing.com/analysis/medtronic-initiates-study-on-des-for-expanded-use-in-the-us-200316970,200316970
112410,333925,ISRG,QIAGEN  QGEN  Beats Earnings  Revenue Estimates In Q1,opinion,"QIAGEN N V  s   NYSE QGEN   first quarter 2018 adjusted earnings per share  EPS  came in at 26 cents  up 18 2  year over year  The figure beat the Zacks Consensus Estimate of 24 cents  At constant exchange rate or CER  the company reported adjusted earnings of 25 cents 
Revenues in Detail
Net sales at actual rates in the first quarter grew 11 7  on a year over year basis to  343 6 million  6  at CER   Also  the top line surpassed the Zacks Consensus Estimate of  340 million 
Region wise  sales from the Americas  46  of revenues  grew 11  at CER  while revenues from Europe Middle East Africa  34   increased 4   Further  revenues from Asia Pacific Japan  20   rose 2  year over year  after excluding business portfolio changes  Sales in the top seven emerging markets  13   exhibited growth of 1  year over year at CER in the quarter under review 
QIAGEN N V  Price  Consensus and EPS Surprise   Segments in Detail
QIAGEN primarily generates revenues through Molecular Diagnostics  Applied Testing  Pharma and Academia  which represented 47   9   21  and 23  of net sales  respectively  during the reported quarter 
Molecular diagnostics sales were up 9  at CER  Sales derived from Applied Testing remained flat at CER  Pharma sales rose 8  at CER in the first quarter and Academia sales improved 3  on growing demand 
Operational Update
Adjusted operating income  excluding restructuring charges  increased 21  year over year to  77 2 million in the first quarter  Also  adjusted operating margin expanded 180 basis points to 22 5   
Financial Update
QIAGEN exited first quarter with cash and cash equivalents of  814 9 million  up from  657 7 million at the end of 2017  Net cash from operating activities in the reported quarter was  48 2 million  down from  60 2 million in the year ago quarter  Moreover  the company reported first quarter 2018 free cash flow of  29 3 million compared with  44 2 million in the year ago quarter 
QIAGEN announced a new commitment in January to return  200 million to shareholders via open market repurchases  after returning  300 million to shareholders by the end of 2017  Notably  shares will be repurchased on the Frankfurt Stock Exchange 
2018 Guidance
QIAGEN has maintained its 2018 guidance for total net sales growth at about 6 7  at CER  This guidance also includes decreased U S  HPV test sales to have an adverse impact of around 1 5  on total net sales growth in 2018  Further  sales of about  7 million during the second half of 2018 from the acquisition of STAT Dx was taken into account  The Zacks Consensus Estimate for 2018 revenues is pegged at  1 54 billion 
Moreover  the adjusted EPS guidance has been reiterated at  1 31  1 33 at CER  Our consensus estimate for 2018 earnings of  1 34 is above the guided range 
Further  favorable currency movements are expected to have a positive impact on 2018 net sales growth of 2 3  and of a penny to two cents per share on adjusted EPS 
The company also provided the financial guidance for the second quarter of 2018  Net sales are expected to grow 5 6  at CER  Adjusted EPS is expected at around 31 32 cents at CER on an underlying basis  The Zacks Consensus Estimate for earnings stands at 32 cents per share  coinciding with the high end of the company s guided range 
Further  favorable currency movements are expected to have a positive impact on the second quarter 2018 net sales growth of 2 3  and up to a penny on adjusted EPS 
Our Take
QIAGEN ended the first quarter on a solid note  We are impressed with the year over year growth in majority of the segments  The company also delivered a strong performance with respect to operating margin  Meanwhile  its commitment to return more to shareholders through increased repurchases reflects its solid cash position  Expectations of favorable currency movement in 2018 also buoy optimism 
We are also upbeat about QIAGEN s recent receipt of FDA pre market approval for PartoSure  Notably  this test helps in assessing the risk of spontaneous preterm birth in patients with symptoms of preterm labor  Further  the company plans to market the test in the United States in 2018  We encouragingly note that the PartoSure test has already been successfully launched in over 35 countries across Europe  the Middle East  Asia and Latin America 
On the flip side  a competitive landscape and strong reliance on collaborations remain major overhangs 
Zacks Rank   Key Picks
QIAGEN has a Zacks Rank  3  Hold  
A few better ranked stocks in the broader medical space which have reported solid results this season are Intuitive Surgical   NASDAQ ISRG    Chemed Corp    NYSE CHE   and Baxter International Inc    NYSE BAX    While Intuitive Surgical sports a Zacks Rank  1  Strong Buy   Chemed and Baxter carry a Zacks Rank  2  Buy   You can see  
Intuitive Surgical reported first quarter 2018 adjusted EPS of  2 44  which beat the Zacks Consensus Estimate by 22 6   Revenues totaled  848 million  also surpassing the consensus estimate by 10 6  
Chemed posted first quarter 2018 adjusted EPS of  2 72  surpassing the Zacks Consensus Estimate of  2 37  Revenues came in at  439 2 million  beating the Zacks Consensus Estimate of  420 million 
Baxter posted first quarter 2018 adjusted EPS of 70 cents  which beat the Zacks Consensus Estimate by 12 9   Revenues of  2 68 billion also edged past the Zacks Consensus Estimate of  2 62 billion 
Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2018-05-04,Zacks Investment Research,https://www.investing.com/analysis/qiagen-qgen-beats-earnings-revenue-estimates-in-q1-200313249,200313249
112411,333926,ISRG,IDEXX Laboratories  IDXX  Earnings  Revenues Rise In Q1 ,opinion,"IDEXX Laboratories  Inc    NASDAQ IDXX   reported first quarter 2018 earnings per share  EPS  of  1 01  up 31 2  year over year on a reported basis and 32  on a comparable constant exchange rate  CER  basis  The current Zacks Consensus Estimate for adjusted EPS is pegged at 93 cents 
Per the company  the upside in reported EPS was driven by revenue growth  solid operating margin gains and impressive benefits from the U S  tax reform 
Revenues in Detail
Revenues rose 16 4  year over year  up 12 3  on organic basis  to  537 7 million  surpassing the Zacks Consensus Estimate of  526 2 million by 2 2  
The upside was driven by strong global gains in Companion Animal Group   CAG   Diagnostics recurring revenues  including double digit organic revenue gains across consumable and reference lab as well as strong acceptance of rapid assays and veterinary software  services and diagnostic imaging systems  Further  steady overall growth contributed to the top line 
IDEXX Laboratories  Inc  Price  Consensus and EPS Surprise
   Segmental Analysis
IDEXX derives revenues from four operating segments  CAG  Water  Livestock  Poultry and Dairy   LPD    and Other 
In the first quarter  CAG revenues rose 16 8   up 13 1  organically  year over year to  470 8 million  Water segment s revenues were up 16 2  from the prior year quarter  up 11 8  organically  to  29 1 million  LPD revenues grew 10   up 2  organically  to  32 2 million  Revenues at the Other segment rose 23 6   up 22 3  organically  to  5 4 million 
Margins
Gross profit increased 17 4  to  303 1 million in the reported quarter  Further  gross margin expanded 50 basis points  bps  to 56 4  despite a 15 1  rise in cost of revenues to  234 6 million 
Sales and marketing expenses rose 14 8  to  100 1 million  while general and administrative expenses increased 15 1  to  60 9 million  Research and development expenses rose 12 4  to  29 million  Operating margin in the quarter improved 100 bps to 21  
Financial Position
IDEXX exited the first quarter of 2018 with cash and cash equivalents of  159 2 million  compared with  187 7 million at the end of 2017  Net cash provided by operating activities in the reported quarter was  34 9 million  compared with  31 3 million in the year ago quarter 
2018 Guidance
IDEXX has reaffirmed the 2018 revenue outlook at  2 205  2 245 million  The company has updated the 2018 revenue organic growth guidance to 10 5 12 5  from the previous 9 5 11 5   However  IDEXX continues to expect revenue growth of 12 14  on a reported basis  The Zacks Consensus Estimate for 2018 revenues is pegged at  2 22 billion  within the guided range 
Management also raised the EPS guidance to  4 06  4 20 from the earlier  4 04  4 18  supported by continued operating margin expansion aligned with its long term goals  The updated outlook represents EPS growth of 38 43  on a reported basis compared with 37 42  stated previously  The Zacks Consensus Estimate for 2018 adjusted EPS is pegged at  4 11 
Our Take
IDEXX exited the first quarter on a solid note  Moreover  solid year over year growth in organic revenues and a raised EPS guidance for 2018 are encouraging 
The stellar performance was driven by strong sales at the CAG business  The companion animal market fundamentals remain solid with tremendous global runway for growth  Management s innovation based  multi modality global strategy  enabled by enhanced commercial capability  accelerated recurring CAG Diagnostics revenue growth  Moreover  the strong top line growth in the quarter was driven by considerable contributions from the rest of the business segments 
Zacks Rank   Other Key Picks
IDEXX has a Zacks Rank  2  Buy   
A few other top ranked stocks in the broader medical space which have reported solid results this season are Intuitive Surgical   NASDAQ ISRG    Chemed Corp    NYSE CHE   and Baxter International Inc    NYSE BAX    While Intuitive Surgical sports a Zacks Rank  1  Strong Buy   Chemed and Baxter carry a Zacks Rank  2  You can see  
Intuitive Surgical reported first quarter 2018 adjusted EPS of  2 44  which beat the Zacks Consensus Estimate by 22 6   Revenues totaled  848 million  also surpassing the consensus estimate by 10 6  
Chemed posted first quarter 2018 adjusted EPS of  2 72  surpassing the Zacks Consensus Estimate of  2 37  Revenues came in at  439 2 million  beating the Zacks Consensus Estimate of  420 million 
Baxter posted first quarter 2018 adjusted EPS of 70 cents  which beat the Zacks Consensus Estimate by 12 9   Revenues of  2 68 billion also edged past the Zacks Consensus Estimate of  2 62 billion 
Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2018-05-04,Zacks Investment Research,https://www.investing.com/analysis/idexx-laboratories-idxx-earnings-revenues-rise-in-q1-200313247,200313247
112412,333927,ISRG,5 Stocks To Watch  CRM  IBKR  SRG  TIF  ZTS,opinion,"5 Trade ideas excerpted from the detailed analysis and plan for premium subscribers 
Salesforce com  NYSE CRM 
Salesforce com   CRM  moved steadily higher out of consolidation in August  continuing higher with tests at the 20 day SMA along the way  It made a top in March and pulled back through the 20 day SMA but then rose to a lower high  Another pullback to a higher low and it reversed to move back to the recent top  The RSI rising in the bullish zone with the MACD positive and moving up  Look for a push over the prior high to participate to the upside   
Interactive Brokers  Ticker   IBKR
Interactive Brokers   IBKR  had a strong run higher from June last year until making a top in March  It pulled back through the 20 day SMA from there to a low at the start of April before another leg higher to a slightly higher high a few weeks ago  It has consolidated there since  The RSI is in the bullish zone with the MACD trying to cross up again  Look for a push through resistance to participate higher   
Intuitive Surgical  NASDAQ ISRG 
Intuitive Surgical   ISRG  had a strong earnings report and the stock gapped higher 3 weeks ago  It then pulled back  filling the gap  and bounced  It settled there for a week before starting higher again Friday  The RSI is rising in the bullish zone with the MACD turning up after avoiding a cross  Look for continuation to participate higher   
Tiffany  Ticker   TIF
Tiffany   TIF  broke above consolidation in December and ran to a high at the end of January  It punctuated it with a Shooting Star reversal and price eventually fell back below the 200 day SMA  Last week it had pushed up to resistance but failed to move above it and pulled back to a higher low  It is moving up toward resistance again with the RSI bullish and rising along with the MACD positive and moving higher  Look for a push through resistance to participate higher   
Zoetis  Ticker   ZTS
Zoetis   ZTS  started moving higher at the beginning of the year  It paused along the way  most recently over support at 80  It gapped down last week following earnings and has started working back higher  The RSI is turning back up with the MACD now negative  Look for continuation to participate higher   
Up Next  Bonus Idea
After reviewing over 1 000 charts  I have found some good setups for the week  These were selected and should be viewed in the context of the broad  picture reviewed Friday which as May begins sees the equity market continuing to move sideways in consolidation without any energy  but a slightly improving picture 
Elsewhere look for Gold to hold or bounce off of support in its range while Crude Oil continues higher  The US Dollar Index continues to show strength in the short term moving higher while US Treasuries are consolidating at a lower high  a possible Dead Cat Bounce  The Shanghai Composite is consolidating in a downtrend clinging to support while Emerging Markets continue to retrench in the uptrend 
Volatility looks to remain low and more stable taking pressure off of the equity index ETF s SPY  NYSE SPY   IWM and QQQ  Their charts all ended the week stronger on the shorter timeframe and in consolidation near the top on the longer timeframe  In the short term the QQQ and IWM look a bit stronger than the SPY  Use this information as you prepare for the coming week and trad em well 
DISCLAIMER  The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment  I or my affiliates may hold positions or other interests in securities mentioned in the Blog  please see my  page for my full disclaimer ",2018-05-07,Gregory W. Harmon,https://www.investing.com/analysis/salesforce-interactive-brokers-intuitive-surgical-tiffany--zoetis-200313572,200313572
112413,333928,ISRG,PetMed  PETS  Q4 Earnings Top Estimates  Reorder Sales Solid,opinion,"PetMed Express  Inc    NASDAQ PETS   announced earnings per share  EPS  of 50 cents for the fourth quarter of fiscal 2018  up from the year ago quarter s 37 cents  Also  the bottom line surpassed the Zacks Consensus Estimate of 44 cents by 13 6   The year over year upside was driven by higher gross profit margin  Further  a tax cut owing to the recent U S  tax reform provided an impetus For the full year  EPS was  1 82  reflecting an increase of 55 6  from the year ago  1 17  The EPS figure also beat the Zacks Consensus Estimate of  1 77 Net sales in the reported quarter rose 6 8  year over year to  67 3 million  However  sales missed the consensus estimate of  68 1 million by 1 2  According to this leading pet pharmacy in the Americas  the sales upside was a result of increased reorders Net sales totaled  273 8 million in the full year  up 9 9  from a year ago  Net sales  however  missed the Zacks Consensus Estimate of  274 6 million 
PetMed Express  Inc  Price  Consensus and EPS Surprise
    In the reported quarter  reorder sales increased 9 4  to  57 million on a year over year basis  while new order sales declined 5  to  10 3 million Average order value was approximately  89 in the quarter compared with  86 in the year earlier quarter  We note that the variation in average order value was mainly because of a shift in sales to higher priced items Per the company  the seasonality in its business is mainly because of the proportion of flea  tick and heartworm medications in the product mix  Spring and summer are considered peak seasons  while fall and winter represent off seasons During the quarter under review  PetMed acquired 113 000 new customers  up from 126 000 a year ago  Roughly 85  of all orders was generated from its website  compared with 83  in the prior year quarter  Gross margin expanded 190 basis points  bps  year over year to 37  in the quarter under review  General and administrative expenses were up 8 9  year over year to  6 1 million  However  advertising expenses declined 2 3  to  4 3 million  Adjusted operating expenses  however  rose 4   without depreciation expense  to  10 4 million  Nevertheless  adjusted operating margin in the quarter expanded 210 bps to 21 5  from the year ago quarter PetMed exited the fiscal with cash and cash equivalents of  77 9 million  compared with  58 7 million at the end of fiscal 2017  The company also declared a quarterly dividend of 25 cents per share  payable to shareholders on record as of May 25  2018 Our TakePetMed exited the fiscal fourth quarter on a mixed note  However  we are encouraged by the growth in reorder sales in the quarter  Further  an expanding gross margin due to a shift to higher margin products like next generation medications buoys optimism The company is also striving to implement strategies to revitalize its top line  These include increased focus on advertising efficiency to boost new order sales as well as shifting sales to higher margin items while also expanding its product line Zacks Rank   Key PicksPetMed has a Zacks Rank  3  Hold  A few better ranked stocks in the broader medical space which have reported solid results this season are Intuitive Surgical   NASDAQ ISRG    Chemed Corporation   NYSE CHE   and Baxter International Inc    NYSE BAX    While Intuitive Surgical sports a Zacks Rank  1  Strong Buy   Chemed and Baxter carry a Zacks Rank  2  Buy   You can see  Intuitive Surgical reported first quarter 2018 adjusted EPS of  2 44  which beat the Zacks Consensus Estimate by 22 6   Revenues totaled  848 million  also surpassing the consensus estimate by 10 6  Chemed posted first quarter 2018 adjusted EPS of  2 72  surpassing the Zacks Consensus Estimate of  2 37  Revenues came in at  439 2 million  beating the Zacks Consensus Estimate of  420 million Baxter posted first quarter 2018 adjusted EPS of 70 cents  which beat the Zacks Consensus Estimate by 12 9   Revenues of  2 68 billion also edged past the Zacks Consensus Estimate of  2 62 billion Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2018-05-07,Zacks Investment Research,https://www.investing.com/analysis/petmed-pets-q4-earnings-top-estimates-reorder-sales-solid-200314152,200314152
112414,333929,ISRG,Phibro Animal  PAHC  Q3 Earnings Beat  Sales Improve Y Y,opinion,"Phibro Animal Health Corporation   NASDAQ PAHC   reported adjusted earnings per share  EPS  of 46 cents in the third quarter of fiscal 2018  up 24 3  year over year  Adjusted EPS surpassed the Zacks Consensus Estimate of 44 cents  According to the company  the year over year improvement was primarily driven by a higher gross profit  reduced interest expenses and a lower effective income tax rate Reported EPS of 49 cents was down 16 9  from the year ago quarter on lower net income Net SalesIn the reported quarter  net sales totaled  208 9 million  up 10  year over year  The improvement was driven by sales growth at the Animal Health  Mineral Nutrition and Performance Products segments Sales by SegmentsNet sales at the Animal Health segment increased 9  to  132 3 million in the reported quarter on volume increase at Nutritional specialty and Vaccine product groups within the segment  While Nutritional specialty products grew 14   principally on volume growth of products for poultry and dairy industries  Further  sales from Vaccines increased 6   majorly on global volume growth 
Phibro Animal Health Corporation Price  Consensus and EPS Surprise    Moreover  sales at Medicated feed additives  MFAs  and Other grew 9  primarily on strength in international business Domestic net sales at MFAs and Other rose  1 million on volume growth of certain products  International net sales increased by  5 6 million  driven by growth in most regions  including benefits from a recent buyout and additional penetration in the cattle sector Net sales at the Mineral Nutrition segment increased 10  to  62 9 million on higher average selling prices resulting from an increase in underlying raw material commodity price Net sales at the Performance Products segment rose 17  to  13 7 million on higher average selling prices and volumes of copper based products Operational UpdatePhibro s third quarter gross profit increased 14  year over year to  69 1 million  The gross margin expanded 120 basis points  bps  to 33 1  Selling  general and administrative expenses rose 39 2  to  42 6 million  Operating margin contracted 310 bps to 12 7  in the quarter Financial Update                                                             Year to date  Phibro generated  59 9 million in cash flow from operations compared with  84 8 million a year ago  Capital expenditure amounted to  13 million in this period  reflecting a reduction from  15 4 million in the year ago period FY18 View ReaffirmedPhibro has reaffirmed its guidance for fiscal 2018  The company expects to generate net sales of  800  825 million  The current Zacks Consensus Estimate of  811 million falls within the guided range Phibro projects adjusted EPS in the  1 66  1 71 band  The current Zacks Consensus Estimate of  1 69 is also within the company s guided range Our TakePhibro ended third quarter fiscal 2018 on a solid note  The company witnessed considerable improvement across all segments  Moreover  the company believes that continuous investments in portfolio enhancement and development of organizational capabilities have started to pay off  Further  an improved gross margin from favorable product mix buoys optimism Moreover  the company is busy arranging funds from third parties to invest in the development of technologies and products  We are also upbeat about Phibro foraying into the companion animal space with the signing of an agreement to develop an innovative product for a canine Lyme disease vaccine using a novel delivery method  Zacks Rank   Key PicksPhibro has a Zacks Rank  3  Hold  A few better ranked stocks in the broader medical space which have reported solid results this season are Intuitive Surgical   NASDAQ ISRG    Chemed Corporation   NYSE CHE   and Baxter International Inc    NYSE BAX    While Intuitive Surgical sports a Zacks Rank  1  Strong Buy   Chemed and Baxter carry a Zacks Rank  2  Buy   You can see  Intuitive Surgical reported first quarter 2018 adjusted EPS of  2 44  which beat the Zacks Consensus Estimate by 22 6   Revenues totaled  848 million  also surpassing the consensus estimate by 10 6  Chemed posted first quarter 2018 adjusted EPS of  2 72  surpassing the Zacks Consensus Estimate of  2 37  Revenues came in at  439 2 million  beating the Zacks Consensus Estimate of  420 million Baxter posted first quarter 2018 adjusted EPS of 70 cents  which beat the Zacks Consensus Estimate by 12 9   Revenues of  2 68 billion also edged past the Zacks Consensus Estimate of  2 62 billion Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2018-05-07,Zacks Investment Research,https://www.investing.com/analysis/phibro-animal-pahc-q3-earnings-beat-sales-improve-yy-200314125,200314125
112451,333966,ISRG,CVS Health s  CVS  Q1 Earnings Beat Estimate  Margins Grow,opinion,"CVS Health Corporation s   NYSE CVS   first quarter 2018 adjusted earnings per share  EPS  of  1 48 surged 26 5  year over year and exceeded the Zacks Consensus Estimate by 6 5   The quarter s adjusted EPS considered an additional adjustment for net interest expense from the proposed Aetna  NYSE AET  acquisition 
Reported EPS from continuing operations came in at 98 cents per share  a 6 5  surge from the year ago period 
Net revenues in the first quarter increased 2 6  year over year to  45 69 billion  However  it lagged the Zacks Consensus Estimate of  45 81 billion 
Quarter in Details
Pharmacy Services revenues increased 3 2  to  32 2 billion in the reported quarter  driven by growth in specialty claim volumes  higher pharmacy network volumes as well as brand inflation  This was  however  partially offset by increased generic dispensing and continued price compression CVS Health Corporation Price  Consensus and EPS Surprise

   Pharmacy network claims processed during the quarter climbed 6  to 399 5 million on a 30 day equivalent basis  backed by net new business growth  Also  the Mail Choice claim processed count was 69 3 million  up 8 9  on a 30 day equivalent basis on continued adoption of Maintenance Choice offerings 
Revenues from CVS Health s Retail LTC were up by 5 6  year over year to  20 4 billion  According to the company  a 8 5  increase in same store prescriptions on a 30 day equivalent basis  partnerships with PBM s and health plans  inclusion in a number of additional Medicare Part D networks this year and brand inflation were partially offset by continued reimbursement pressure and an increase in the generic dispensing rate 
Front end same store sales increased 1 6  year over year driven by a 90 basis pointsfavorable impactof the shift of sales associated with the Easter holiday to the first quarter of 2018 from the second quarter of 2017  This apart  seasonal cough and cold positively impacted the Front store sales by another 70 basis points approximately  However  this was adversely affected by soft customer traffic 
Pharmacy same store sales increased 7 3  in the reported quarter  The increase in pharmacy same store prescription volumes was driven by the increase in pharmacy same store prescription volumes  partially offset by a negative impact of approximately 280 basis points due to recent generic introductions 
The generic dispensing rate  the proportion of all generic prescriptions to total number of prescriptions dispensed  increased approximately 65 bps to 87 6  at the Pharmacy Services segment and around 60 bps to 88 1  at the Retail LTC segment 
Gross profit improved 4 3  to  6 9 billion  Accordingly  gross margin expanded 24 bps to 15   Total operating margin in the quarter expanded 22 bps to 4 3  
CVS Health exited the first quarter 2018 with cash and cash equivalents and short term investments of  42 1 billion compared with  1 81 billion at the end of 2017  At the end of the first quarter  net cash used in operating activities was  131 million  as compared to  537 million a year ago 
Outlook
CVS Health currently expects to deliver full year 2018 adjusted EPS in the band of  6 87 to  7 08  Also  it has reiterated its 2018 adjusted operating profit growth guidance in the range of  1 5   to 1 5  
The company has also provided guidance for second quarter 2018  CVS Health expects to deliver adjusted EPS in the range of of  1 59 to  1 64  This apart  adjusted operating profit growth is expected in the range of flat to up 3 25  
Our Take
CVS Health ended the first quarter of 2018 on a mixed note  While earnings were ahead of the Zacks Consensus Estimate  revenues remained behind the consensus number  However  the year over year growth in the top line was driven by a strong Pharmacy Services segment  benefiting from the upside in the specialty services  Also  strong year over year Retail LTC comparisons were encouraging  The company currently is moving forward towards the completion of the Aetna deal 
Zacks Rank   Key Picks
CVS Health has a Zacks Rank  3  Hold  
A few better ranked stocks in the broader medical sector which reported solid results this season are Intuitive Surgical   NASDAQ ISRG    Chemed Corp    NYSE CHE   and Baxter International Inc    NYSE BAX     While Intuitive Surgical sports a Zacks Rank  1  Strong Buy   Chemed and Baxter carry a Zacks Rank  2  Buy   You can see  
Intuitive Surgical reported first quarter 2018 adjusted earnings per share  EPS  of  2 44  which beat the Zacks Consensus Estimate by 22 6   Revenues of  848 million also surpassed the consensus estimate by 10 6  
Chemed posted first quarter 2018 adjusted EPS of  2 72  surpassing the Zacks Consensus Estimate of  2 37  Revenues came in at  439 2 million  beating the Zacks Consensus Estimate of  420 million 
Baxter posted first quarter 2018 adjusted EPS of 70 cents  which beat the Zacks Consensus Estimate by 12 9   Revenues of  2 68 billion also edged past the Zacks Consensus Estimate of  2 62 billion 
Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2018-05-02,Zacks Investment Research,https://www.investing.com/analysis/cvs-healths-cvs-q1-earnings-beat-estimate-margins-grow-200312029,200312029
112452,333967,ISRG,Becton  Dickinson  BDX  Beats On Q2 Earnings  Lifts  18 View,opinion,"Becton  Dickinson and Company   NYSE BDX   posted second quarter fiscal 2018 earnings of  2 65 which beat the Zacks Consensus Estimate of  2 61  Earnings also improved 7 8  at constant currency  cc  Becton Dickinson  also known as BD  posted revenues worth at  4 22 billion  surpassing the Zacks Consensus Estimate of  4 12 billion  Revenues rose 5 7  at cc  On a year over year basis  revenues surged 42 2  on the acquisition of C  R  Bard Meanwhile  BD s shares have gained 25 2   compared with the  s 12 6  BD currently carries a Zacks Rank  3  Hold  Becton  Dickinson and Company Price  Consensus and EPS Surprise
    Segment DetailsBD MedicalThe segment posted worldwide revenues of  2 17 billion  up 4 2  at cc  Per management  the strong results were driven by strength in the Medication Delivery Solutions  Diabetes Care and Pharmaceutical Systems units BD Life SciencesWorldwide revenues in this segment came in at  1 18 billion  reflecting an increase of 7 3  at cc Revenue growth reflects strong performance in the Diagnostic Systems and Biosciences units   However  growth in the Preanalytical Systems unit was negatively impacted by a production issue in one of its product lines which was resolved in the quarter The segment s growth was aided by flu related revenues in the Diagnostic Systems unit as a result of a stronger flu season in comparison to the prior year BD InterventionalIn the reported quarter  this segment posted worldwide revenues of around  1 billion  up 7 1  at cc  The segment s results reflect strong performance by the Peripheral Intervention and Urology and Critical Care units and solid growth in the Surgery unit Geographic ResultsUSSales in the United States came in at  2 33 billion  up 4  at cc in the second quarter The BD Medical segment accounted for revenues of  1 18 billion in the United States BD Life Sciences accounted for  498 million of revenues  while BD Interventional recorded  649 million in the United States InternationalSales outside the United States came in at  1 9 billion  up 7 9  at cc The upside was driven by strong performance by the BD Medical  BD Life Sciences and BD Interventional segments Internationally  BD Medical posted revenues worth  994 million  BD Life Sciences raked in international revenues of  600 million  while BD Interventional contributed  303 million Margin AnalysisIn the reported quarter  gross profit totaled  1 6 billion  up 14 8  year over year BD posted operating income of  183 million  down 59  on a year over year basis GuidanceBuoyed by the solid fiscal second quarter performance  BD raised its fiscal 2018 guidance  The company expects adjusted earnings per share within  10 9  11 05 on an increase in the estimated benefit from foreign currency  This represents growth of approximately 15 16 5  over fiscal 2017  Notably  the Zacks Consensus Estimate for earnings per share of  10 95 lies within the range The company raised the revenue growth guidance for fiscal 2018 to 5 5 5   which is also at a high end of the previous guidance Our TakeBecton  Dickinson ended the fiscal second quarter of 2018 on a promising note  Strong growth in BD Medical was primarily driven by Medication Delivery Solutions  Diabetes Care and Pharmaceutical Systems units  Meanwhile  the acquisition of C R  Bard has proven accretive to fiscal second quarter results  Internationally  BD posted strong revenues and has maintained its global foothold  However  declining margins raise concern  The recent product recalls and foreign exchange volatility are also likely to mar the company s prospects Key PicksA few better ranked stocks in the broader medical space which have reported solid results this season are Intuitive Surgical   NASDAQ ISRG    Chemed Corporation   NYSE CHE   and Baxter International Inc    NYSE BAX    While Intuitive Surgical sports a Zacks Rank  1  Strong Buy   Chemed and Baxter carry a Zacks Rank  2  Buy   You can see  Intuitive Surgical reported first quarter 2018 adjusted earnings per share of  2 44  which beat the Zacks Consensus Estimate by 22 6   Revenues totaled  848 million  also surpassing the consensus estimate by 10 6  Chemed posted first quarter 2018 adjusted earnings per share of  2 72  surpassing the Zacks Consensus Estimate of  2 37  Revenues came in at  439 2 million  beating the Zacks Consensus Estimate of  420 million Baxter posted first quarter 2018 adjusted earnings per share of 70 cents  which beat the Zacks Consensus Estimate by 12 9   Revenues of  2 68 billion also edged past the Zacks Consensus Estimate of  2 62 billion 5 Medical Stocks to Buy NowZacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia  AIDS  muscular dystrophy  hemophilia  and other conditions New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline  Early investors could realize exceptional profits ",2018-05-02,Zacks Investment Research,https://www.investing.com/analysis/becton-dickinson-bdx-beats-on-q2-earnings-lifts-18-view-200312416,200312416
112453,333968,ISRG,Pacific Biosciences  PACB  Loss Wider Than Expected In Q1,opinion,"Pacific Biosciences of California   NASDAQ PACB   reported first quarter adjusted loss of 20 cents per share  which is wider than the Zacks Consensus Estimate by a penny  The company reported loss of 26 cents per share in the year ago quarter Meanwhile  the stock has lost 33 3   compared with the  s decline of 5 4  in a year s time Pacific Biosciences carries a Zacks Rank  2  Buy  Revenue DetailsThe Menlo Park  CA based manufacturer of sequencing systems posted revenues of  19 4 million  which missed the Zacks Consensus Estimate by 21 1   Revenues also dropped 22 1  from the year ago quarter  primarily due to lower instrument revenues in the quarter under review Product revenues totaled  16 3 million  which deteriorated 23 5  from the prior year quarter Meanwhile  service and other revenues came in at  3 1 million  down 14 9  year over year  Pacific Biosciences of California  Inc  Price  Consensus and EPS Surprise
     Furthermore  instrument revenues came in at  7 2 million  compared with  12 6 million a year ago  Consumable revenues came in at  9 1 million  slightly up from the year ago  8 7 million Per management  Sequel instrument bookings were strong in the first quarter  with the highest number of instruments ordered since the introduction of the system  The orders include 10 instrument orders from both BGI and China  The growth in the Sequel business has partially offset the decline in the RS II Smart Cell usage Additionally  Alabama based HudsonAlpha Institute for Biotechnology has been using the company s flagship Sequel System and has been expanding its use into human clinical research Margin AnalysisGross profit in the first quarter of 2018 was  7 3 million  down 18 4  on a year over year basis Gross margin was 37 7  of total revenues  up 180 basis points  bps  year over year Operating expenses totaled  31 2 million  slightly down from  32 2 million in the prior year quarter The contraction was led by lower R D expenses  which totaled  16 3 million in the first quarter  Moreover  sales  general and administrative expenses in the quarter were  14 9 million  slightly lower than  15 2 million in the prior year quarter Financial ConditionPacific Biosciences  cash  cash equivalents and investments  excluding restricted cash  totaled  79 3 million in the reported quarter  The figure rose 26 1  year over year In ConclusionPacific Biosciences ended the first quarter on a dreary note  Product and service revenues fell on a year over year basis due to lower instrument revenues  However  this was partially offset by a strong Sequel performance  which witnessed record bookings in the quarter  The adoption of the system by HudsonAlpha is also a major positive  The continued instrument orders from BGI and China are encouraging  Furthermore  the company is well poised on expansion of SMRT Sequencing and product development activities  Meanwhile  a highly competitive environment raises concern  Falling consumer revenues adds to the woes Other Key PicksSome other top ranked stocks in the broader medical space which have reported solid results this season are Intuitive Surgical   NASDAQ ISRG    Chemed Corporation   NYSE CHE   and Baxter International Inc    NYSE BAX    While Intuitive Surgical sports a Zacks Rank  1  Strong Buy   Chemed and Baxter carry a Zacks Rank  2  You can see  Intuitive Surgical reported first quarter 2018 adjusted earnings per share of  2 44  which beat the Zacks Consensus Estimate by 22 6   Revenues totaled  848 million  also surpassing the consensus estimate by 10 6  Chemed posted first quarter 2018 adjusted earnings per share of  2 72  surpassing the Zacks Consensus Estimate of  2 37  Revenues came in at  439 2 million  beating the Zacks Consensus Estimate of  420 million Baxter posted first quarter 2018 adjusted earnings per share of 70 cents  which beat the Zacks Consensus Estimate by 12 9   Revenues of  2 68 billion also edged past the Zacks Consensus Estimate of  2 62 billion 5 Medical Stocks to Buy NowZacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia  AIDS  muscular dystrophy  hemophilia  and other conditions New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline  Early investors could realize exceptional profits ",2018-05-02,Zacks Investment Research,https://www.investing.com/analysis/pacific-biosciences-pacb-loss-wider-than-expected-in-q1-200312413,200312413
112454,333969,ISRG,Genomic Health  GHDX  Q1 Earnings Top Estimates  Margins Low,opinion,Genomic Health  Inc    NASDAQ GHDX   reported first quarter 2018 adjusted earnings of 13 cents per share against the year ago adjusted net loss of 8 cents  thereby reflecting a significant improvement  The bottom line also exceeded the Zacks Consensus Estimate of 2 cents Reported net loss came in at 11 cents per share  wider than a couple of cents a year ago Revenues in DetailIn the reported quarter  the company adopted the new ASC 606 accounting standard for calculating revenues using the modified retrospective method  Accordingly  the metric was  92 6 million  up 12 5  from the year ago pre 606 adjusted revenues  if the new ASC 606 standard had been applied as of Jan 1  2017  of  82 3 million  On an adjusted constant currency basis  the top line improved 12  year over year  The quarterly number also surpassed the Zacks Consensus Estimate of  89 million Genomic Health  Inc  Price  Consensus and EPS Surprise    Geographically  first quarter product revenues in the United States rose 14  to  78 9 million from the year ago pre 606 adjusted revenues  The U S  product revenue growth was fueled by a 12  rise inU S  invasive breast revenuesfrom Oncotype DX Breast Recurrence Score tests and a 75  surge in U S  prostate test revenues from Oncotype DX Genomic Prostate Score  GPS  tests International product revenues totaled  13 8 million in the quarter under review  up 5  year over year  up 1  atadjusted constant currency  from the year ago pre 606 adjusted tally During the first quarter  the company delivered more than 32 440 Oncotype DX test results  up 3  year over year Margin TrendGenomic Health s gross margin contracted 394 basis points  bps  year over year to 79 8  in the first quarter The company also witnessed a 7  rise in operating expenses to  78 3 million on a 12 9  escalation in research and development expenses to  16 8 million  17 7  uptick in general and administrative expenses to  19 7 million and a 0 6  increase in selling and marketing expenses to  41 8 million In the reported quarter  Genomic Health s operating loss came in at  4 4 million  wider than the year ago operating loss of  2 8 million  Accordingly  the operating margin contracted 137 bps Financial UpdateGenomic Health exited the first quarter of 2018 with cash and cash equivalents and short term marketable securities of  130 4 million  highlighting an improvement from  129 6 million recorded at the end of 2017 2018 GuidanceThe company has reaffirmed its earlier provided outlook for 2018  Genomic Health expects full year revenues in the range of  366  382 million  reflecting 10 15  growth  The Zacks Consensus Estimate of  373 4 million is within this guided range Our TakeGenomic Health exited first quarter 2018 on a promising note with both adjusted earnings and revenues outpacing the respective consensus mark We are also encouraged by the year over year rise in revenues  driven by solid performances in the United States and internationally  Per the company  within prostate cancer space  the strengthened NCCN  National Comprehensive Cancer Network  prostate cancer guidelines and additional new data are increasing private coverage for the Oncotype DX GPS test  Moreover  the company is upbeat about the U S  commercial launch of Oncotype DX AR V7 Nucleus Detect  a liquid biopsy test for metastatic prostate cancer  which is expected to contribute to this business growth in 2018 The company also witnessed a series of upsides for its Oncotype DX Breast Recurrence Score tests However  Genomic Health s sole reliance on the Breast Oncotype DX test is a concern  Moreover  the company s rising operating expenses pose a challenge Zacks Rank   Key PicksGenomic Health carries a Zacks Rank  3  Hold  A few better ranked stocks in the broader medical sector with solid results this earnings season are Intuitive Surgical   NASDAQ ISRG    Chemed Corp    NYSE CHE   and Baxter International Inc    NYSE BAX    While Intuitive Surgical sports a Zacks Rank  1  Strong Buy   Chemed and Baxter carry a Zacks Rank  2  Buy   You can see  Intuitive Surgical reported first quarter 2018 adjusted earnings per share  EPS  of  2 44  which beat the Zacks Consensus Estimate by 22 6   Revenues of  848 million also surpassed the consensus estimate by 10 6  Chemed posted first quarter 2018 adjusted EPS of  2 72  outshining the Zacks Consensus Estimate of  2 37  Revenues came in at  439 2 million  beating the Zacks Consensus Estimate of  420 million Baxter released first quarter 2018 adjusted EPS of 70 cents  which crossed the consensus mark by 12 9   Revenues of  2 68 billion also edged past the Zacks Consensus Estimate of  2 62 billion 5 Medical Stocks to Buy NowZacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia  AIDS  muscular dystrophy  hemophilia  and other conditions New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline  Early investors could realize exceptional profits ,2018-05-02,Zacks Investment Research,https://www.investing.com/analysis/genomic-health-ghdx-q1-earnings-top-estimates-margins-low-200312713,200312713
112494,334009,ISRG,Hill Rom  HRC  Earnings   Revenues Beat In Q2  Margins Up,opinion,"Hill Rom Holdings  Inc    NYSE HRC   reported second quarter fiscal 2018 adjusted earnings per share  EPS  of  1 05  reflecting a 19 3  increase from the year ago quarter  Adjusted earnings surpassed the Zacks Consensus Estimate by 2 9  and were well above the company s projected range of  1  1 02 The strong bottom line performance was backed by solid core revenue growth  continued margin expansion and strategic investments to drive growth This marked the 11th consecutive quarter of double digit earnings growth for the company Revenue DetailsRevenues in the second quarter increased 4 7  year over year to  710 5 million  up 1 8  at CER   The top line also exceeded the Zacks Consensus Estimate of  710 million on momentum in core business  Mortara acquisition and value added from new products Geographically  U S  revenues grew 1  to  466 million while revenues outside the United States increased 12 5   up 3 5  at CER  to  245 million  Core revenue growth was 2  at CER 
Hill Rom Holdings  Inc  Price  Consensus and EPS Surprise
    Segmental PerformanceIn the second quarter  Patient Support Systems revenues dropped 2 2  year over year  down 4 5  at CER  to  355 million  The segment s domestic revenues declined 5 5   However  after adjusting for divestitures  U S  core revenues decreased 5  from the prior year Revenues at the Front Line Care segment  which includes Welch Allyn  Respiratory Care and Mortara  increased 12 7  to  238 million  up 10 7  at CER   Apart from gains from Mortara  the performance was driven by contributions from new products  strong growth of thermometry and blood pressure monitoring devices and physical assessment tools plus double digit growth at respiratory care business The Surgical Solutions segment revenues increased 12   up 5 6  at CER  to  118 million on 18 4  international growth  driven by strong momentum in the Middle East and Europe  U S  revenues increased 5 4   The growth was backed by solid uptake of Integrated Table Motion and contribution from products like the iLED7 and the new TS 3000 Mobile Operating Table MarginsReported gross margin in the fiscal second quarter was 49 3   up 150 bps year over year  Despite a 1 6  increase in cost of revenue  the company witnessed gross margin expansion on account of a 4 7  rise in revenues  Adjusted gross margin grew 130 bps to 49 3  buoyed by the company s initiatives like portfolio diversification  benefits from cost and sourcing efficiencies and product launches  Adjusted operating margin improved 120 bps to 16 2  OutlookIn view of a promising second quarter performance  Hill Rom has updated its fiscal 2018 earnings guidance and has also provided the third quarter estimates For the full year  the company continues to expect revenue growth of 3 4  on a reported basis  up 2  to 3  at CER   Excluding foreign currency  Mortara  divestitures and other non strategic assets  the company continues to expect core revenue growth of 3   The Zacks Consensus Estimate for fiscal 2018 revenues is pegged at  2 85 billion Hill Rom now expects adjusted earnings per share for fiscal 2018 in the range of  4 60  4 65 compared with the previous range of  4 57  4 65  The Zacks Consensus Estimate for fiscal 2018 earnings is pegged at  4 62  within the company s guided range For the third quarter  Hill Rom expects revenue growth of around 3  on a reported basis  or approximately 1  at CER   Core revenues are expected to increase 3 4  year over year   The company expects adjusted earnings per share of  1 12  1 14  The Zacks Consensus Estimate for third quarter earnings stands at  1 18 on revenues of  709 9 million  Our consensus estimate for earnings is above the company s guided range Our TakeHill Rom exited the fiscal second quarter on a strong note  The company saw a solid year over year increase in revenues on strong international growth  The upside in international growth was driven by double digit growth in Canada and the Middle East  along with strength in Europe and Latin America  The company is also focusing on product innovation through research and development  In this regard  the company recently announced the upgrading of its Welch Allyn Spot Vision Screener  The latest version is capable of quickly and efficiently screening adult patients with pupil sizes as small as 3 mm to diagnose any vision related issue However  a decline in revenues at the Patient Support Systems segment is quite disappointing  Also  foreign exchange remains a concern Zacks Rank   Key PicksHill Romhas a Zacks Rank  4  Sell  A few better ranked stocks in the broader medical space  which reported solid earnings this season  are ResMed Inc    NYSE RMD    Chemed Corporation   NYSE CHE   and Intuitive Surgical  Inc    NASDAQ ISRG    While Intuitive Surgical sports a Zacks Rank  1  Strong Buy   ResMed and Chemed carry a Zacks Rank  2  Buy   You can see Intuitive Surgical reported first quarter 2018 adjusted EPS of  2 44  which beat the Zacks Consensus Estimate by 22 6   Revenues totaled  848 million  also surpassing the Zacks Consensus Estimate by 10 6  ResMed reported third quarter fiscal 2018 adjusted EPS of 92 cents  beating the Zacks Consensus Estimate by 10 8   Revenues came in at  591 6 million  exceeding the consensus estimate of  564 9 million Chemed posted first quarter 2018 adjusted EPS of  2 72  beating the Zacks Consensus Estimate of  2 37  Revenues came in at  439 2 million  steering past the Zacks Consensus Estimate of  420 million The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2018-04-29,Zacks Investment Research,https://www.investing.com/analysis/hillrom-hrc-earnings--revenues-beat-in-q2-margins-up-200310794,200310794
112495,334010,ISRG,Accuray  ARAY  Q3 Loss Wider Than Estimates  Revenues Top,opinion,"Accuray Incorporated   NASDAQ ARAY   reported a loss of 10 cents per share in the third quarter of fiscal 2018  7 cents wider than the Zacks Consensus Estimate and 4 cents wider than the year ago figure Total revenues in the quarter increased 2 6  year over year to  99 8 million  beating the Zacks Consensus Estimate of  98 2 million Segment DetailsProduct Revenues  Product revenues declined 10  to  43 2 million  The same from Japan declined roughly  10 million in the third quarter  Despite the year over year decline in total product revenues  the company continued to witness strength in Radixact Service Revenues  Service revenues amounted to  56 6 billion in the reported quarter  up 14 8  year over year  courtesy of increased upgrade purchase on service contract Gross Order Update  Gross Order performance in the third quarter of fiscal 2018 was  74 9 million  down 10 6  from the last quarter  Order growth was primarily driven by TomoTherapy array of products and Radixact system orders 
Accuray Incorporated Price  Consensus and EPS Surprise
    Other HighlightsRadixact Platform Drives Sales  Radixact is one of the company s latest devices  which contributed handsomely to revenues  The Radixact system accounted for 80  of all TomoTherpay orders in the quarter under review Further  the system is being accepted as a true workhorse product in the market  courtesy of its significantly improved product performance  functional efficacies and broad case mix versatility            Suite of Software Upgradation  A series of software upgradation has been another growth driver for Accuray  These upgrades were primarily focused on improvised imaging  faster planning capabilities as well as system connectivity  Further  software enhancements involved improvisation of CyberKnife treatment planning efficiency In this regard  Accuray had introduced CTrue iterative reconstruction  an enhanced CT imaging capability for Radixact in the annual ESTRO meeting  which was held in Barcelona in 2018 Geographical Gains Improve  Per management  revenue growth in the third quarter can attributed to the European  American and APAC regions  Contributions in order performance from the EMEA and Japan have also been strong Margin DetailsIn the quarter under review  total gross margin was 36 3   roughly flat year over year  Product gross margin increased 41 4  in the reported quarter  compared with 38 4  in the year ago quarter  This can be attributed to increased revenue contribution from CyberKnife Systems and Radixact Systems Service gross margin in the third quarter was 32 4   compared with 34 4  in the year ago quarter Operating expenses totaled  40 1 million versus  36 7 million in the year ago quarter  The increase was primarily led by investments in research and development and sales and marketing Financial ConditionAccuray exited the third quarter with  70 4 million of cash and cash equivalents  compared with  79 5 million in the second quarter of fiscal 2018 Guidance for 2018The company revised its previous guidance The company expects revenues between  395 million and  400 million from the previous range of  390 million to  400 million  The Zacks Consensus Estimate for fiscal 2018 revenues of  399 72 million is near the high end of the guided range The guidance for gross order growth has been maintained to rise at approximately 5  on a year over year basis The company expects adjusted EBITDA between  18 million and  20 million from the previously provided range of  25 million and  30 million Our TakeAccuray reported a mixed third quarter of fiscal 2018  Further  the company lowered the EBITDA expectations largely due to strategic investments and lower than expected gross margins  However  Accuray continues to rides on the market s solid response to the Radixact platform and the company s revamped software On the flip side  long sales and implementation cycles of the CyberKnife and TomoTherapy systems can majorly affect the company s top line  Increasing operating expenses as a result of research and development activity is also a concern Price PerformanceAccuray has been outperforming the  over the past six months  The stock has gained 4 7  against the industry s decline of 10 6  Zacks Rank   Key PicksAccuray carries a Zacks Rank  3  Hold  A few better ranked stocks in the broader medical sector which reported solid results this season are Intuitive Surgical   NASDAQ ISRG    Chemed Corporation   NYSE CHE   and Baxter International Inc    NYSE BAX    While Intuitive Surgical sports a Zacks Rank  1  Strong Buy   Chemed and Baxter carry a Zacks Rank  2  Buy   You can see  Intuitive Surgical reported first quarter 2018 adjusted earnings per share  EPS  of  2 44  which beat the Zacks Consensus Estimate by 22 6   Revenues totaled  848 million  also surpassing the consensus estimate by 10 6  Chemed posted first quarter 2018 adjusted EPS of  2 72  surpassing the Zacks Consensus Estimate of  2 37  Revenues came in at  439 2 million  beating the Zacks Consensus Estimate of  420 million Baxter posted first quarter 2018 adjusted EPS of 70 cents  which beat the Zacks Consensus Estimate by 12 9   Revenues of  2 68 billion also edged past the Zacks Consensus Estimate of  2 62 billion Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2018-04-30,Zacks Investment Research,https://www.investing.com/analysis/accuray-aray-q3-loss-wider-than-estimates-revenues-top-200311252,200311252
112496,334011,ISRG,Inogen  INGN  Beats Q1 Earnings Estimates  Lifts 2018 View,opinion,"Inogen  Inc    NASDAQ INGN   reported adjusted first quarter earnings per share of 48 cents  beating the Zacks Consensus Estimate by a whopping 77 8   Earnings also rose by the same margin from the year ago figure of 27 cents Total revenues in the reported quarter came in at  79 1 million  beating the Zacks Consensus Estimate by 26 4   Revenues surged 50 6  from the prior year quarter Notably  45 400 of total units were sold  reflecting an increase of 77 3  on a year over year basis Meanwhile  in the past six months  Inogen s shares have rallied 43 4   against the  s decline of 11 2  Inogen  Inc Price  Consensus and EPS Surprise
    Segmental AnalysisSales revenues came in at  73 6 million  up 60 1  year over year  while rental revenues totaled  5 5 million  down 16 3  Business to business domestic sales were  28 million  up 60 4  from a year ago  The upside can be attributed to the company s private label partner and traditional home medical equipment providers International sales in the segment came in at  16 9 million  up 48  on a year over year basis  primarily on continued adoption by the company s European partners and favorable currency rates Direct to consumer sales rose 67 8  year over year to  28 7 million  Per management  the upside can be attributed to increased sales representative headcount and associated consumer spending MarginsGross profit in the reported quarter was  37 7 million  down 46 5  year over year  Total gross margin was 47 7  of net revenues  down 130 basis points  bps  year over year  The contraction in gross margin was primarily led by lower sales revenue per unit and rental gross margin  partially offset by reduced cost of sales revenue per unit In the quarter under review  operating expenses increased 43 9  to  29 million  Operating margin  as a percentage of revenues contracted by 170 bps  This was mainly impacted by an upside in research and development  R D  expenses  which totaled  1 4 million in the quarter Adjusted EBITDA came in at  15 5 million  indicating year over year growth of 42 7  Financial ConditionInogen exited the quarter with cash  cash equivalents  and marketable securities worth  188 3 million  compared with  173 9 million in the last report GuidanceBuoyed by the solid first quarter results  Inogen raised the outlook for 2018  The revenue guidance range is  310 320 million  representing growth of 24 3 28 3  from 2017 results  Notably  the Zacks Consensus Estimate for full year revenues of  303 3 million lies below this range  Direct to consumer is expected to be the fastest growing channel for the company Net income guidance for the full year is  38  41 million  up from  36  39 million  representing growth of 80 9 95 2  from 2017 Inogen also raised the guidance for 2018 adjusted EBITDA to  62  67 million from  60  64 million  representing 22 0 31 8  growth from 2017 results The company further expects net positive cash flow for 2018 with no additional equity capital required to meet its current operating plan In ConclusionInogen exited the first quarter of 2018 on a solid note  beating the consensus mark for both the counts  Strong sales in the United States and Europe raise optimism  A raised guidance for 2018 also paints a bright picture  On the flip side  declining margins owing to surging R D expenses raise concern  The decline in rental revenues adds to the woes  Additionally  management expects rental revenues to decline around 10  in 2018 from 2017 Zacks Rank   Key PicksInogen carries a Zacks Rank  3  Hold  A few better ranked stocks in the broader medical sector which reported solid results this season are Intuitive Surgical   NASDAQ ISRG    Chemed Corporation   NYSE CHE   and Baxter International Inc    NYSE BAX    While Intuitive Surgical sports a Zacks Rank  1  Strong Buy   Chemed and Baxter carry a Zacks Rank  2  Buy   You can see  Intuitive Surgical reported first quarter 2018 adjusted earnings per share of  2 44  which beat the Zacks Consensus Estimate by 22 6   Revenues totaled  848 million  also surpassing the consensus estimate by 10 6  Chemed posted first quarter 2018 adjusted earnings per share of  2 72  surpassing the Zacks Consensus Estimate of  2 37  Revenues came in at  439 2 million  beating the Zacks Consensus Estimate of  420 million Baxter posted first quarter 2018 adjusted earnings per share of 70 cents  which beat the Zacks Consensus Estimate by 12 9   Revenues of  2 68 billion also edged past the Zacks Consensus Estimate of  2 62 billion Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2018-05-01,Zacks Investment Research,https://www.investing.com/analysis/inogen-ingn-beats-q1-earnings-estimates-lifts-2018-view-200311267,200311267
112529,334044,ISRG,MS  USB  ABT   TXT Leads Q1 Earnings,opinion,Triple digit gains in regular day Tuesday trading in both the Dow and Nasdaq were bolstered by a number of different things   strong housing starts and a lack of relative geopolitical tension early this week among them   but nothing so influential as a very strong Q1 earnings season  We are still in the early stages so far  only a week has passed since Delta Air Lines  NYSE DAL  beat estimates on both top and bottom lines   but overall results have been notably better than expected While after the bell earnings reports yesterday were better than expected across the board  some companies performed more impressively than others  While Intuitive Surgical   NASDAQ ISRG   posted a robust earnings beat  IBM   NYSE IBM   eked out a positive surprise on new corporate tax benefits alone   IBM s Watson enterprise has thus far failed to inspire fresh investment in Big Blue   As a result  IBM has shed more than 5  in today s pre market  while ISRG shares are up 5  this morning New Q1 earnings reports are following suit  starting with Morgan Stanley   NYSE MS    which left estimates in the dust this morning  This investment banking major posted  1 45 per share on  11 1 billion in quarterly revenues  outpacing the  1 28 and  10 5 billion in the Zacks consensus estimates  respectively  Net income grew 38  in Q1  whereas Sales   Trading rose 26   Fellow financial institution U S  Bank   NYSE USB   beat earnings estimates by a penny to 95 cents per share  but missed on revenue expectations  bringing in  5 47 billion as opposed to the  5 53 billion our analysts were looking for  This still represents good year over year growth from  5 29 billion in Q1 2017  but pre market trading shows USB shares slipping half a percentage point at this hour  Based on Chicago s North Shore  Abbott Labs   NYSE ABT   also topped earnings consensus by a penny to 59 cents per share  Revenues also slightly surpassed expectations in Q1  reporting  7 39 billion in sales  Guidance for full year 2018 has been posted at between  2 80 and  2 90 per share  and the Zacks consensus is roughly at the midpoint  Shares are off 1 3  ahead of today s opening bell  Defense components major Textron   NYSE TXT    however  performed much better this morning   76 cents per share blew away expectations of 46 cents  and more than double the 37 cents per share a year ago  Sales of  3 296 million also impressed  both above the estimated  3 114 million and the year ago figure of  3 093 million  Industrial sales perked up 14   and the company saw gains from its Arctic Cat acquisition  Shares are up 6 7  in today s pre market ,2018-04-17,Zacks Investment Research,https://www.investing.com/analysis/ms-usb-abt--txt-leads-q1-earnings-200306611,200306611
112530,334045,ISRG,Company News For Apr 19  2018,opinion,Textron Inc  s    NYSE TXT   shares increased 6 8  after reporting first quarter earnings of  0 72 surpassing the Zacks Consensus Estimate of  0 46U S  Bancorp s   NYSE USB   decline 2 after announcing first quarter revenues of  5 47 billion lagging the Zacks Consensus Estimate of  5 53 billionHancock Holding Co  s   NASDAQ HBHC   shares decreased 5 8  after posting first quarter revenues of  271 9 million lagging the Zacks Consensus Estimate of  281 7 millionShares of Intuitive Surgical Inc  s   NASDAQ ISRG   increased 8 2  after reporting first quarter  earnings of  2 44 outpacing the Zacks Consensus Estimate of  1 89,2018-04-18,Zacks Investment Research,https://www.investing.com/analysis/company-news-for-apr-19-2018-200306941,200306941
112531,334046,ISRG,Top Stock Reports For BlackRock  Charter Communications   Intuitive Surgical ,opinion,"Monday  April 23  2018
The Zacks Research Daily presents the best research output of our analyst team  Today s Research Daily features new research reports on 16 major stocks  including BlackRock  BLK   Charter Communications  NASDAQ CHTR  and Intuitive Surgical  NASDAQ ISRG   These research reports have been hand picked from the roughly 70 reports published by our analyst team today 
You can see 
BlackRock s shares have outperformed the Zacks Investment Management industry in the last six months    10 7  vs   1 5    This performance was supported by impressive earnings surprise history as the company surpassed expectations in three of the trailing four quarters  Its first quarter 2018 results were supported by higher revenues and growth in assets under management  AUM  
The company is undertaking initiatives to restructure its actively managed equities business and expand globally via acquisitions to further boost top line growth  Also  its efficient capital deployment activities will continue to enhance shareholder value  However  mounting expenses  mainly due to continued rise in marketing costs  might hurt the bottom line growth to some extent  The company s high dependence on overseas revenues remains a matter of concern 
 You can   
Shares of Charter Communications have outperformed the Zacks Cable TV industry over the past three months   17 4  vs   18 1    Charter s residential and commercial internet and voice customer growth continues to accelerate  which is evident from the revenue growth and subscriber gain  The Zacks analyst thinks the recently announced partnership with Comcast  NASDAQ CMCSA  to develop back end software to support services for Xfinity and Spectrum mobile offerings is significantly positive for the company s growth prospects 
The collaboration will help in saving costs for both the companies  However  the company continues to struggle due to sluggish growth in a saturated and competitive multi channel U S  video market  Charter also faces stiff competition from online TV streaming service providers  The company s high debt level and consolidation related woes are other potential hazards 
 You can   
Strong Buy ranked Intuitive Surgical s shares have outperformed the Zacks Medical Instruments industry over the last year  gaining  66 5  vs  1   Intuitive Surgical ended the first quarter of 2018 on a solid note  with both earnings and revenues surpassing expectations  The company s flagship da Vinci procedures recorded solid growth and holds promise for the quarters ahead  
The company also saw solid expansion outside the United States in the recent past  A suite of regulatory approvals buoys optimism  Solid growth in prostatectomy procedure volumes lent Intuitive Surgical a competitive edge in the broader prostate surgery market  However  the company expects U S  sales to decline in the quarters ahead  which raises concern 
Furthermore  looming foreign exchange volatility also adds to the woes  Intense competition in niche space and long sale and purchase order cycles of da Vinci unit has been currently plaguing the company 
 You can   
Other noteworthy reports we are featuring today include Statoil  OL STL   STO   Diageo  LON DGE   DEO  and Aon  AON  
Today s Stocks from Zacks  Hottest Strategies 
It s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  
And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation 

Mark Vickery
Senior Editor
Note  Sheraz Mian heads the Zacks Equity Research department and is a well regarded expert of aggregate earnings  He is frequently quoted in the print and electronic media and publishes the weekly and reports  If you want an email notification each time Sheraz publishes a new article  please 
Today s Must Read









Featured Reports

The Zacks analyst thinks that Nilit and Omni Plastics acquisitions as well as operational cost savings through productivity actions will drive Celanese s profitability in FY18 


According to the Zacks analyst  Valmont should gain from its restructuring actions that are geared to improve productivity amid headwinds from raw material cost inflation in 2018 


Per the Zacks analyst  improved store sales   digital initiatives are aiding CarMax s comparable store used vehicle sales  The rise in sales is getting complimented by aggressive store expansion   


Per a Zacks analyst  Stanley Black   Decker  NYSE SWK  s Nelson Fastener buyout will fortify its Engineered Fastening business and prove accretive to earnings in 2018  Commodity inflation remains a drag 


Per the Zacks analyst  Aon largely benefits from its partnerships  the recent one with HP to combat cyber attacks is worth a mention here 


Per Zacks analyst  BancorpSouth s efforts to drive operational efficiency through cost control measures and strategic deals remain encouraging 


Per the Zacks analyst  Skechers  international business remains a key sales driver  apart from product innovation 

New Upgrades

The Zacks analyst appreciates the company s efforts to reward shareholders  Improvement in the Rail International unit s profit is also encouraging 


Per the Zacks analyst WEC Energy s plans to invest  11 8B to fortify its electric and gas delivery operation and energy infrastructure by 2022  will help it to serve its rising customer base 


The Zacks analyst expects Statoil to generate significant cash flow from new upstream projects in the Norwegian Continental Shelf 

New Downgrades

Per Zacks analyst  Deutsche Bank s revenues continue to remain under pressure due to the prevailing low rate environment in the European economy  Also  pending legal matters will keep costs elevated 


Per the Zacks analyst DTE Energy faces stringent government regulations for curbing emissions  Such new legislation can change how the company operates its business and lead to additional expenses 


Diageo sales were hit by currency woes in first half fiscal 2018  given its solid global presence  Thus  the Zacks analyst expects adverse currency movements to remain a threat for Diageo s top line ",2018-04-23,Zacks Investment Research,https://www.investing.com/analysis/top-stock-reports-for-blackrock-charter-communications--intuitive-surgical-200308042,200308042
112532,334047,ISRG,Direxion Launches Leveraged Robotics ETF ,opinion,"Direxion launched a leveraged fund on Apr 19  focused on providing exposure to the global robotics and Artificial Intelligence  AI  space 
Direxion Daily Robotics  Artificial Intelligence   Automation Index Bull 3X Shares  seeks to track  before fees and expenses  the performance of the Indxx Global Robotics and Artificial Intelligence Thematic Index 
Fund Characteristics 
The market cap weighted index looks to provide exposure to exchange listed companies in developed markets that are poised to benefit from adoption of AI and robotics 
The fund charges a fee of 122 basis points a year and provides triple leveraged  300   exposure to its underlying index   The index s top three holdings include Intuitive Surgical Inc   NASDAQ ISRG    Nvidia Corp   NASDAQ NVDA   and Yaskawa Electric Corp  with 8 9   8 8  and 8 0  exposure  respectively 
How Does it Fit in a Portfolio 
The global robotics market is experiencing robust growth as demand for automation is increasing  With the advancement of technology and a drive toward more efficient business operations  robotics sector has garnered a lot of investor attention  as they seek to get a share of the pie of returns this sector offers 
Owing to the increased attention this sector has garnered  robotics ETFs are a great way to gain diversified exposure to the space   The robotics  artificial intelligence  and automation industries are rapidly growing and evolving   Sylvia Jablonski  Managing Director at Direxion said   The launch of UBOT allows traders to take a bold position in companies that are on the forefront of technology   she  
However  investors should note that leveraged ETFs are complex instruments and not suitable for long term buy and hold portfolios  These ETFs employ strategies to attain their goals on a daily basis  Hence  in a long term setting  performance of these funds might significantly differ from their stated objectives 
Other Funds in the Space
Although there are no other leveraged funds offering exposure to the space  below we discuss a few other regular ETFs that seek to provide exposure to the robotics sector  see   
ROBO Global Robotics and Automation Index ETF   NASDAQ ROBO  
This fund seeks to provide a diversified exposure to Robotics stocks and tracks the Robo Stox Global Robotics and Automation Index  It has AUM of  2 4 billion and charges a fee of 95 basis points a year 
The fund is heavily inclined toward Computing  Processing   AI  Manufacturing   Industrials and Actuation  with 18 0   16 0  and 14 0  exposure  respectively  The fund s top three holdings are Hiwin Technologies Corp  Fanuc Corp and Krones AG with 2 2   2 0  and 2 0  allocation  respectively  From a geographical perspective  the fund s top three allocations are to the United States  Japan and Germany  with 39 0   29 0  and 9  exposure  respectively  The fund has returned 34 2  in a year and 2 9  year to date 
Robotics   Artificial Intelligence ETF 
This fund seeks to invest in companies that have chances of benefitting from increased demand of robotics and AI  It tracks the same index as UBOT  The fund has AUM of  2 6 billion and charges a fee of 68 basis points a year 
The fund is heavily inclined toward Industrial Machinery  Electronic Components and Electronic Equipment   Instruments  with 28 4   13 7  and 12 4  exposure  respectively  The fund s top three holdings are Intuitive Surgical Inc  Nvidia Corp and Yaskawa Electric Corp  with 8 9   8 8  and 8 0  exposure  respectively  From a geographical perspective  the fund s top three allocations are to the Japan  United States and Switzerland  with 50 8   26 9  and 8 6  exposure  respectively   The fund has returned 41 3  in a year and 2 5  year to date 
Want key ETF info delivered straight to your inbox Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ",2018-04-23,Zacks Investment Research,https://www.investing.com/analysis/direxion-launches-leveraged-robotics-etf-200308060,200308060
112565,334080,ISRG,MedTech Stock Q4 Earnings Slated For Jan 30  SYK  ZBH  ALGN,opinion,The fourth quarter earnings season has commenced on a positive note for most sectors  with a decent picture from the 133 S P 500 participants that have reported till Jan 26  Total earnings for these companies are up 12 3  year over year on 8 8  higher revenues  with 81 2  beating earnings estimates and 78 9  surpassing top line expectations Notably  about 121 S P 500 companies are reporting their earnings this week Per the latest   overall earnings for the fourth quarter are expected to increase 11 6  on 7 5  growth in revenues  This indicates an improved growth projection from the previous quarter driven by a corporate tax overhaul and relatively healthy job data  These factors have boosted corporate earnings and stoked investments Based on this pattern  the fourth quarter is expected to register modest double digit percentage earnings growth on a year over year basis MedTech Earnings So FarMedical  one among the 16 Zacks sectors  is expected to stand out this quarter  The sector benefits from favorable consumer behavior  growing prevalence of minimally invasive surgeries  demand for liquid biopsy tests  use of IT for ensuring quick and improved patient care along with the shift of the payment system to a value based model This is evident from the results of MedTech heavyweights Abbott   NYSE ABT   and Intuitive Surgical   NASDAQ ISRG    The companies exited the fourth quarter on a solid note  beating the Zacks Consensus Estimate on both counts  An upbeat FY18 guidance also instills confidence For the fourth quarter  the earnings growth rate for the medical sector is pegged at 4 2  on 4 9  revenue growth Upcoming ReleasesLet s take a look at three major other MedTech stocks slated to release their quarterly reports on Jan 30  2018 Stryker Corporation s   NYSE SYK   results are scheduled for release after the market closes  Notably  the Zacks Consensus Estimate for fourth quarter revenues is pegged at  3 46 billion  up 9 5  year over year  The Zacks Consensus Estimate for fourth quarter earnings is  1 95  up 9 6  on a year over year basis Stryker recently announced better than expected preliminary net sales results for fourth quarter 2017  For full year 2017  net sales are estimated at  12 4 billion  up 9 8  from the year ago quarter on a constant currency basis  The figure beat the Zacks Consensus Estimate of  12 38 billion Buoyed by these prospects  our quantitative model indicates an earnings beat for Stryker this quarter  This is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  to be able to beat estimates  Stryker s Earnings ESP is  0 01   You can uncover the best stocks to buy or sell before they re reported with our   Stryker carries a Zacks Rank  3  read more    Stryker Corporation Price and Consensus    Zimmer Biomet Holdings  Inc   NYSE ZBH    is set to report results  before the market opens  Notably  the Zacks Consensus Estimate for fourth quarter revenues is pegged at  2 03 billion  up 0 9  year over year  The Zacks Consensus Estimate for fourth quarter earnings is projected at  2 10  down 1 9  on a year over year basis Despite solid prospects in the company s S E T   Surgical  Sports Medicine  Foot and Ankle  Extremities and Trauma  arm  macroeconomic uncertainties and unfavorable currency fluctuations have been denting sales over the past few quarters The company has been dealing with pricing pressure  In this regard  Zimmer Biomet witnessed negative pricing pressure of approximately 2 1  last quarter  In the absence of any favorable changes on these lines  these headwinds might reflect in the company s fourth quarter results  read more    As a result  our proven model does not conclusively show earnings beat for Zimmer Biomet this quarter  Zimmer Biomet has an Earnings ESP of  0 38   The stock carries a Zacks Rank  4  Sell  You can see  Zimmer Biomet Holdings  Inc  Price and Consensus    Align Technology  Inc   NASDAQ ALGN    is set to report results after the market closes  Notably  the Zacks Consensus Estimate for fourth quarter revenues is pegged at  395 5 million  up 34 9  year over year  The Zacks Consensus Estimate for fourth quarter earnings is at 96 cents  up 43 3  on a year over year basis Align Technology achieved a milestone of five million patients undergoing treatment with its flagship clear aligner system   InvisAlign   in November 2017  The company has been adopting several strategies to drive adoption of its core InvisAlign product line In 2017  the company received two U S  patents for Align Technology s SmartTrack aligner material that is exclusively used for InvisAlign aligner treatment  Moreover  in a bid to gain traction in the InvisAlign platform  Align Technology collaborated with Digital Smile Design in the recent past  read more    Despite the positive developments  our proven model does not conclusively show that Align Technology is likely to beat earnings this quarter  Align Technology has an Earnings ESP of  2 08   The stock carries a Zacks Rank  2 Align Technology  Inc  Price and Consensus    Zacks Top 10 Stocks for 2018In addition to the stocks discussed above  would you like to know about our 10 finest buy and hold tickers for the entirety of 2018  Last year s 2017 Zacks Top 10 Stocks portfolio produced double digit winners  including FMC Corp  NYSE FMC   and VMware which racked up stellar gains of  67 9  and  61   Now a brand new portfolio has been handpicked from over 4 000 companies covered by the Zacks Rank  Don t miss your chance to get in on these long term buys ,2018-01-28,Zacks Investment Research,https://www.investing.com/analysis/medtech-stock-q4-earnings-slated-for-jan-30-syk-zbh-algn-200284451,200284451
112566,334081,ISRG,Intuitive Surgical  ISRG  Down 5  Since Earnings Report  Can It Rebound ,opinion,"A month has gone by since the last earnings report for Intuitive Surgical  Inc    NASDAQ ISRG    Shares have lost about 5  in the past month  underperforming the market 
Will the recent negative trend continue leading up to its next earnings release  or is ISRG due for a breakout  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important catalysts 
Recent EarningsIntuitive Surgical posted adjusted earnings of  2 54 per share in the fourth quarter of 2017  which beat the Zacks Consensus Estimate of  2 27 and improved 25 1  year over year Revenues increased 17 9  year over year to  892 4 million  driven by growth in Instrument   Accessories  Services and Systems  Revenues also beat the Zacks Consensus Estimate of  864 million  FY17 at a GlanceIntuitive Surgical reported revenues of  3 12 billion in full year 2017  The company has three major revenue segments  Instruments and Accessories  52 3  of total revenues   Systems  29 1  of total revenues  and Services  18 6  of total revenues  Business HighlightsSolid Procedure TrendsIntuitive Surgical posted solid numbers in the quarter  courtesy of rising customer adoption of procedures and growth in system placements  The company outperformed in the Mature and Growth procedures  especially in general and thoracic surgery Precisely  fourth quarter procedures increased approximately 17  on a year over year basis  Procedure performance in Asia reflected persistent strength backed by solid growth in China  Japan and Korea  Added to this  growth in prostatectomy procedure volumes lent the company a competitive edge in the broader prostate surgery market in the fourth quarter Favorable Study ResultsIn November 2017  a team of investigators from the University of Southern California  the University of Michigan Ann Arbor  Penn State Health and Intuitive Surgical published a large scale study titled  Robotic Assisted  Video Assisted Thoracic and Open Lobectomy  Propensity Matched Analysis of Recent Premiere Data in the Annals of Thoracic Surgery  The results from this study demonstrated the increase in the number of robotic assisted lobectomies  Lobectomy can be defined as surgical excision of a lobe or an organ In the quarter under review  Intuitive Surgical submitted the 510 k  applications to the U S  FDA for its 60 millimeter stapler for da Vinci X and Xi platforms International SalesThe company has been gaining solid prominence globally  In fact  outside the United States  the company s procedures improved approximately 21  on a year over year basis  Intuitive Surgical s system placements included 47 in the Europe and 22 in Japan  Notably  25 of the 47 systems placed in Europe  were da Vinci X systems  However  as the OUS markets are in early stages of adoption  sales might lag estimates in the region Revenue SegmentsInstruments   AccessoriesRevenues in the segment rose 18  to  457 million in the quarter  on the back of strong procedure growth and increased sales of stapling and vessel sealing products  Revenues realized per procedure were approximately  1 910  flat year over year Systems Sales in the segment increased 20  to  283 million  buoyed by higher system placements and partially offset by lower average selling prices  Coming to the company s flagship da Vinci surgical platform  Intuitive Surgical shipped 216 systems compared with 163 in the prior year quarter ServicesThe company registered revenues of  153 million  up 13  on a year over year basis and backed by growth in the installed base of da Vinci systems Gross MarginIntuitive Surgical s adjusted gross margin in the reported quarter expanded 130 basis points  bps  to almost 71  of net revenues  The increase in margins indicates the company s consistent efforts to lower manufacturing cost Notably  management expects margins to fluctuate based on the company s mix of new products  reduction of product costs and the reinstatement of the medical device tax in 2018 Financial UpdateIntuitive Surgical ended the fourth quarter of 2017 with  3 8 billion in cash  cash equivalents  and investments  in line with the third quarter figure  Per management  this was offset by a final payment of  274 million associated with the accelerated share repurchase agreement initiated by the company in first quarter 2017 GuidanceFor 2018  Intuitive Surgical anticipates full year procedure growth within a range of 11  to 15   Procedure growth is expected to be driven by U S  general surgery and procedures outside the United States Management expects operating expenses to rise in the range of 16 18  in 2018  as the company continues to invest in emerging markets and new technology including computer assisted surgery Gross margin is expected within the range of 70 71 5  of net revenues in 2018 Incorporating projected impacts of the newly enacted U S  tax law  Intuitive Surgical expects 2018 income tax rate between 2  and 20  of net pre tax income  
How Have Estimates Been Moving Since Then 
Fresh estimates followed an upward path over the past two months Intuitive Surgical  Inc  Price and Consensus     
VGM Scores
At this time  ISRG has a nice Growth Score of B  though it is lagging a lot on the momentum front with a F  Following a similar course  the stock was allocated a grade of D on the value side  putting it in the bottom 40  for this investment strategy 
Overall  the stock has an aggregate VGM Score of D  If you aren t focused on one strategy  this score is the one you should be interested in 
The stock is suitable solely for growth based on our styles scores 
Outlook
ISRG has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2018-02-26,Zacks Investment Research,https://www.investing.com/analysis/intuitive-surgical-isrg-down-5-since-earnings-report-can-it-rebound-200294034,200294034
112567,334082,ISRG,Top Research Reports For UnitedHealth  Morgan Stanley   Anheuser Busch,opinion,"Tuesday  March 20  2018
The Zacks Research Daily presents the best research output of our analyst team  Today s Research Daily features new research reports on 16 major stocks  including UnitedHealth  UNH   Morgan Stanley  NYSE MS  and Anheuser Busch  BUD   These research reports have been hand picked from the roughly 70 reports published by our analyst team today 
You can see 
UnitedHealth s shares have marginally underperformed the Zacks Medical Insurance industry in the last one year  up  34 2  vs   34 5    The Zacks analyst likes the company s robust Government business and continued strong growth at Optum  Its international business and strong capital position that allows for business investment are other positives  
It has been witnessing an increase in membership over many years  The company raised its 2018 earnings guidance led by tax reform upside  The stock has seen the Zacks Consensus Estimate for current year earnings being revised 15 4  upward over the last 90 days  Nevertheless  membership loss in its fee based commercial business and Brazilian business will pull down overall membership growth 
 You can   
Shares of Morgan Stanley have outperformed the Zacks Investment Banking industry over the last three months   7 7  vs   6 1    supported by the company s impressive earnings surprise history  It surpassed the Zacks Consensus Estimate in each of the trailing four quarters 
The Zacks analyst likes the company s efforts to lower balance sheet risk  strengthen wealth management operations along with its cost saving initiatives  Further  lower tax rates will aid profitability in the quarters ahead  However  persistent fall in net interest income  despite rising interest rates  remains a concern  Also  overall trading weakness is expected to hurt the company s top line growth in the near term 
 You can   
Anheuser Busch s shares have underperformed the Zacks Alcoholic Beverages industry over the last three months  gaining  0 8  vs  an increase of  2 2   However  both top and bottom line outpaced estimates and improved year over year in the fourth quarter  In fact  the quarter marked earnings beat after seven consecutive negative surprises while revenues surpassed estimates after two straight misses  
The Zacks analyst likes its robust brand portfolio and solid geographical reach  The company keeps introducing near beer alternatives along with no  and low alcohol beers to resonate with changing demand  Further  SABMiller s buyout has enhanced its position in the global beer market  
Though the company anticipates delivering strong top line growth for 2018  backed by solid brands performance and robust commercial plans  it sees volatility in certain key markets  Moreover  it envisions a soft first quarter  owing to difficult comparisons  and phasing of marketing and sales initiatives 
 You can   
Other noteworthy reports we are featuring today include Cigna  CI   MetLife  NYSE MET  and Intuitive Surgical  NASDAQ ISRG  
Today s Stocks from Zacks  Hottest Strategies
It s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively 
And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation 

Mark Vickery
Senior Editor
Note  Sheraz Mian heads the Zacks Equity Research department and is a well regarded expert of aggregate earnings  He is frequently quoted in the print and electronic media and publishes the weekly and reports  If you want an email notification each time Sheraz publishes a new article  please 
Today s Must Read









Featured Reports

Per the Zacks analyst  Cigna s Global Healthcare unit has been performing strongly for the past many years leading to revenue growth  Its strong balance sheet supports strategic investments


Per the Zacks analyst  Ameren s multi billion  long run investment plan aids its system reliability and infrastructural improvements  Yet the recent tax reform may reduce its near term cash flows 


The Zacks analyst believes Eversource s planned  10 8 billion capital investment  intended to strengthen its operations  and cost savings initiatives will boost the performance of the company 


The Zacks analyst is concerned about the company s lower proved oil reserves which might affect output 


According to the Zacks analyst  Valmont should gain from its restructuring actions that are geared to improve productivity amid headwinds from raw material cost inflation in 2018 


Per the Zacks analyst  Nordstrom has been focusing on its store expansion strategy as part of its efforts to grow market share 


Per the Zacks analyst  Merrimack has a promising pipeline with candidates being developed in prospective indications 

New Upgrades

Per the Zacks analyst  Zumiez has recorded sales beat for seven straight quarters and delivered comps growth for six consecutive quarters  It expects this trend to persist and drive growth in 2018 


The Zacks analyst sees Wyndham s strategic acquisitions as a means of global expansion  Moreover  effective marketing campaigns are helping the company expand its presence and drive occupancy


Intuitive registered solid performance in the Mature   Growth procedures  especially in General and Thoracic surgery  The Zacks analyst is bullish on the company s product development initiatives 

New Downgrades

Per the Zacks analyst  investments in efficiency programs might weigh on MetLife s bottomline before generating returns  Exposure to catastrophe losses induces earnings volatility 


The Zacks analyst is concerned about capacity expansion outpacing traffic growth at Alaska Air Group  High labor and fuel costs are also likely to limit bottom line growth 


Per the Zacks analyst  First Data s top line growth is negatively impacted by frequent acquisitions and seasonality ",2018-03-20,Zacks Investment Research,https://www.investing.com/analysis/top-research-reports-for-unitedhealth-morgan-stanley--anheuserbusch-200299510,200299510
112568,334083,ISRG,Here s Why You Should Invest In Robotics   AI ETFs,opinion,"In this episode of ETF Spotlight  I talked with Jeremie Capron  Managing Partner   Director of Research at ROBO Global  Robo Global is the creator of the first index to track the global robotics  automation and artificial intelligence industry  This index is the benchmark for ROBO Global Robotics and Automation Index ETF   NASDAQ ROBO   
Robots and AI are improving and becoming an integral part of our lives  Almost every day  we learn about some new real life benefits of these innovative technologies 
Jeremie highlighted some of the key growth areas in this field and why investors should not ignore this rapidly evolving and exponentially growing space 
We then discussed the index created by Robo Global  The company has a team of experts that looks at the entire robotics and automation landscape to identify the companies to be included in the index 
Jeremie explained the process of selection of constituents bellwether as well as non bellwether   He also talked about the benefits of equal weighing approach  which largely eliminates single stock risk 
About 40  of ETF assets are invested in US companies and rest in international companies  Japanese companies get about 28  allocation  which makes sense since Japan has been a leader in robotics 
So  in addition to familiar US names like iRobot   NASDAQ IRBT    Intuitive Surgical   NASDAQ ISRG    Rockwell Automation   NYSE ROK   and Nvidia   NASDAQ NVDA    we see a lot of non US companies in the ETF 
Jeremie talked about some foreign companies that are at the forefront of these technologies 
Finally  we discussed impressive earnings growth of some of these companies  which resulted in the index s impressive return of 47  in 2017  Jeremie explained that despite this surge  many companies still look very attractive from valuation perspective 
To learn more about the world of robotics  automation   AI and the ROBO ETF  please listen to the podcast and visit  
And please visit the ETF section of for more information on this ETF and other ETFs 
Please make sure to tune in for our next podcast  If you have any comments or question  please email 
Disclosure  I own ROBO for the Zacks ETF Investor portfolio ",2018-03-23,Zacks Investment Research,https://www.investing.com/analysis/heres-why-you-should-invest-in-robotics--ai-etfs-200300361,200300361
112569,334084,ISRG,5 Of The Best Big Cap Earnings Charts ,opinion,"This is the first big week of earnings season and that means we ll get a lot of big cap companies reporting  including several Dow components 
These five companies  in various industries  lead off the charge as several have some of the best charts of not only this week  but of the entire earnings season 
It s not easy to beat every quarter for years  If they ve done it  it means surviving various economic conditions and having management with a forward thinking vision 
Can these five keep up their winning streaks 
5 of the Best Big Cap Earnings Charts
1     Johnson   Johnson   NYSE JNJ   has kept its earnings beat streak alive  It hasn t missed in over 5 years  Shares are off in 2018  as the stock market has pulled back  Will it get a boost from earnings 
2     UnitedHealth Group   NYSE UNH   has one of the best charts on all of Wall Street  Shares are off the recent all time highs  Is this a change in the growth stocks or is it just a pause as these big cap names move higher still 
3     IBM   NYSE IBM   has beat 13 quarters in a row but shares have been stagnant for several years on worries about revenue growth  Will blockchain be IBM s savior 
4     Intuitive Surgical   NASDAQ ISRG   has been one of the hottest medical stocks for the last two years  It has beat 11 quarters in a row  But shares have paused in 2018  Is this a buying opportunity 
5     Lam Research   NASDAQ LRCX   hasn t missed in five years  It was a great performer in 2017 but volatility has hit the shares in 2018  Will this earnings report be just the boost it needs 
Investor Alert  Breakthroughs PendingA medical advance is now at the flashpoint between theory and realization  Billions of dollars in research have poured into it  Companies are already generating substantial revenue  and even more wondrous products are in the pipeline Cures for a variety of deadly diseases are in sight  and so are big potential profits for early investors  Zacks names 5 stocks to buy now ",2018-04-16,Zacks Investment Research,https://www.investing.com/analysis/5-of-the-best-big-cap-earnings-charts-200305921,200305921
112570,334085,ISRG,Late Q1 Earnings Have Liftoff  IBM  UAL  LRCX  CSX   ISRG,opinion,After the closing bell Tuesday  a fresh wave of Q1 earnings reports have come out  across a wide swath of sectors  Among the big names posting actuals this afternoon  all came out with exclusively better than expected results IBM Corp    NYSE IBM    at first glance  appeared to accomplish what analyst had set out for it  a 5 cent earnings beat to  2 45 per share on  19 1 billion in sales  which surpassed the  18 7 analysts were looking for  These figures represent year over year revenue growth for the first time in 5 years  but after market trading is selling off IBM shares roughly 5   virtually wiping out the company s gains for all of 2018 so far This sell off may also provide a drag to the Dow index tomorrow morning  which had just finally dug itself out of its hole over the past month  IBM s guidance for full year 2018 was reaffirmed at  13 80 per share  apparently investors were looking for something a little stronger on this line United Continental   NYSE UAL   topped the Zacks consensus earnings estimate by a penny to 50 cents a share  with revenues for the quarter also edging out expectations to  9 03 billion  This marks a 23  upswing in earnings from the year ago quarter on PRASM metrics up 2 7  in Q1  Full year guidance have tightened to between  7 8 per share  and the company has beaten estimates on the bottom line for 5 straight quarters Lam Research   NASDAQ LRCX   also outperformed estimates  though not by as impressive of margins as some of these companies this afternoon  Headline numbers of  4 79 per share on  2 89 billion in sales also mark the fifth straight earnings beat  and revenue growth year over year was roughly 33   Yet late trading is selling the news following a strong regular session  down 2 6  since results were posted  CSX Corp    NASDAQ CSX   easily bettered expectations on the bottom line in its Q1    78 cents per share vs  66 cents expected  on  2 88 billion in revenues  better than the  2 83 billion expected  This company has also outperformed in the past 5 straight quarters  with a trailing 4 quarter average of over 10   Late trading is pushing up CSX shares 3 78  Finally  Intuitive Surgical   NASDAQ ISRG   posted arguably the most impressive Q1 report of the bunch  with  2 44 per share far outpacing the  1 99 expected  and revenues of  848 million solidly passing the  767 million in the Zacks consensus  Shares in late trading are up 5 6   putting the MedTech company up near record high trading territory Investor Alert  Breakthroughs PendingA medical advance is now at the flashpoint between theory and realization  Billions of dollars in research have poured into it  Companies are already generating substantial revenue  and even more wondrous products are in the pipeline Cures for a variety of deadly diseases are in sight  and so are big potential profits for early investors  Zacks names 5 stocks to buy now ,2018-04-17,Zacks Investment Research,https://www.investing.com/analysis/late-q1-earnings-have-liftoff-ibm-ual-lrcx-csx--isrg-200306365,200306365
112571,334086,ISRG,Q1 Earnings Keep Markets In The Green  MS  USB  ABT   TXT,opinion,Wednesday  April 18  2018Triple digit gains in regular day Tuesday trading in both the Dow and Nasdaq were bolstered by a number of different things   strong housing starts and a lack of relative geopolitical tension early this week among them   but nothing so influential as a very strong Q1 earnings season  We are still in the early stages so far  only a week has passed since Delta Air Lines  NYSE DAL  beat estimates on both top and bottom lines   but overall results have been notably better than expected While after the bell earnings reports yesterday were better than expected across the board  some companies performed more impressively than others  While Intuitive Surgical   NASDAQ ISRG   posted a robust earnings beat  IBM   NYSE IBM   eked out a positive surprise on new corporate tax benefits alone   IBM s Watson enterprise has thus far failed to inspire fresh investment in Big Blue   As a result  IBM has shed more than 5  in today s pre market  while ISRG shares are up 5  this morning New Q1 earnings reports are following suit  starting with Morgan Stanley   NYSE MS    which left estimates in the dust this morning  This investment banking major posted  1 45 per share on  11 1 billion in quarterly revenues  outpacing the  1 28 and  10 5 billion in the Zacks consensus estimates  respectively  Net income grew 38  in Q1  whereas Sales   Trading rose 26   Fellow financial institution U S  Bank   NYSE USB   beat earnings estimates by a penny to 95 cents per share  but missed on revenue expectations  bringing in  5 47 billion as opposed to the  5 53 billion our analysts were looking for  This still represents good year over year growth from  5 29 billion in Q1 2017  but pre market trading shows USB shares slipping half a percentage point at this hour  Based on Chicago s North Shore  Abbott Labs   NYSE ABT   also topped earnings consensus by a penny to 59 cents per share  Revenues also slightly surpassed expectations in Q1  reporting  7 39 billion in sales  Guidance for full year 2018 has been posted at between  2 80 and  2 90 per share  and the Zacks consensus is roughly at the midpoint  Shares are off 1 3  ahead of today s opening bell  Defense components major Textron   NYSE TXT    however  performed much better this morning   76 cents per share blew away expectations of 46 cents  and more than double the 37 cents per share a year ago  Sales of  3 296 million also impressed  both above the estimated  3 114 million and the year ago figure of  3 093 million  Industrial sales perked up 14   and the company saw gains from its Arctic Cat acquisition  Shares are up 6 7  in today s pre market  Mark VickerySenior EditorQuestions or comments about this article and or its author  Click here   Medical Stocks to Buy NowZacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia  AIDS  muscular dystrophy  hemophilia and other conditions New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline  Early investors could realize exceptional profits ,2018-04-17,Zacks Investment Research,https://www.investing.com/analysis/q1-earnings-keep-markets-in-the-green-ms-usb-abt--txt-200306500,200306500
112599,334114,ISRG,Will Intuitive Surgical  ISRG  Disappoint In Q4 Earnings ,opinion,"Intuitive Surgical Inc  s   NASDAQ ISRG   fourth quarter 2017 results  scheduled for release on Jan 25  are expected to show steady growth in instruments and accessories revenues   one of the major revenue components  While this could majorly drive earnings in the quarter under review  an expected improvement in revenues at all other segments should help the company generate solid results this season The Zacks Consensus Estimate for instrument and accessories revenues is pegged at  442 million for the fourth quarter  This reflects an increase of 19 5  from the year ago quarter It is important to note that Intuitive Surgical delivered positive earnings surprises in the past four quarters  the average being 12 8   Like the prior quarter  strong growth in U S  general surgery and worldwide urology  are said to be the supposed growth drivers Intuitive Surgical  Inc  Price and Consensus
     Upbeat Preliminary Results for Q4Intuitive Surgical has recently announced better than expected preliminary net sales results for fourth quarter 2017 The company expects net sales for fourth quarter 2017 to be approximately  892 million  up 18  on a year over year basis da Vinci procedures increased roughly by 17  in the fourth quarter of 2017 Preliminary fourth quarter 2017 revenues of the instrument and accessories segment increased approximately 18  to  457 million on a year over year basis  read more   Other Factors at PlayWe believe that the growing adoption of Intuitive Surgical s da Vinci system among physicians for general surgery  oncology  urology and gynecology procedures is a catalyst for the fourth quarter  The Zacks Consensus Estimate for revenues in the fourth quarter is  847 20 million  which grew 11 9  year over year Further  the Zacks Consensus Estimate for earnings in the fourth quarter is pegged at  2 25  which grew 10 8  year over year   Below are the other factors that might influence Intuitive Surgical s quarterly results this earnings season Solid Procedure Trends  Solid revenue performance of Product Instruments and Accessories is likely to boost the company s top line  Added to this  solid growth in da Vinci procedures is expected to lend Intuitive Surgical a competitive edge in the broader general surgery market In December 2017  the company filed form 510 k  with the FDA for the da Vinci Single Port Surgical System for certain urology procedures Further  Intuitive Surgical s procedure trends are expected to be solid globally  courtesy of stellar performances in the general surgery and global urology segments da Vinci   Service Units Hold Promise  Solid growth in the company s da Vinci and service segment is expected to drive the company s fourth quarter earnings  In fact  the Zacks Consensus Estimate for da Vinci system unit segment is pegged at  188 million  up 11 2  compared to the prior quarter  The increase is likely to stem from solid growth in da Vinci procedures  Coming to revenues at the services segment  the Zacks Consensus Estimate is  151 million  up 12 7  on a year over year basis Growth in System s Installed Base  Per the Zacks Consensus Estimate  the company s total systems installed base is expected to be 4400 units  driven by higher system placements and operating lease revenues  It is important to note that Intuitive Surgical generated approximately  7 million in revenues from operating leases last quarter  compared with  4 million in the third quarter and approximately  6 million in the second quarter of 2016 Here is what our quantitative model predicts Although Intuitive Surgical carries a Zacks Rank  2  Buy  it does not have a positive   for increasing the odds of an earnings beat Zacks ESP  The Earnings ESP for Intuitive Surgical is  0 73   as the Most Accurate estimate is  2 23 and the Zacks Consensus Estimates is pegged at  2 25  You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Intuitive Surgical increases the predictive power of ESP  However  we also need a positive ESP to be confident of earnings beat Stocks Worth a LookHere are a few medical stocks worth considering as they have the right combination of elements to post earnings beat this quarter Centene Corporation   NYSE CNC   has an Earnings ESP of  0 25  and a Zacks Rank  1  Strong Buy   You can see  Eiger BioPharmaceuticals Inc    NASDAQ EIGR   has an Earnings ESP of  0 73  and a Zacks Rank  2 Blueprint Medicines Corporation   NASDAQ BPMC   has an Earnings ESP of  2 44  and a Zacks Rank  3  Hold  Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2018-01-15,Zacks Investment Research,https://www.investing.com/analysis/will-intuitive-surgical-isrg-disappoint-in-q4-earnings-200280664,200280664
112600,334115,ISRG,Abiomed Hits New 52 Week High  3 Factors Driving The Stock,opinion,"Abiomed  Inc  s   NASDAQ ABMD   price scaled a new 52 week high of  228 08 on Jan 18  eventually closing a bit lower at  225 89  The company s shares have gained 56 5  in the last six months  compared with the broader  s 9 7  gain Headquartered in Danvers  MA  Abiomed is engaged in developing  manufacturing and marketing of medical products  designed to assist or replace the pumping function in cases of heart failure The stock has a market cap of  9 98 billion  It is currently one of the top performing stocks in the MedTech space  Improvement in price performance and strong fundamentals indicates the stock s bullish run  Therefore  if you haven t taken advantage of the price appreciation yet  it s time you add the stock to your portfolio  A long term expected earnings growth rate of 31 5  holds promise for the stock What s Driving the Stock Let s take a look at three major factors that have been boosting Abiomed lately Strong Preliminary ResultsAbiomed recently reported preliminary third quarter fiscal 2018 revenues of approximately  154 million  up 34  on a year over year basis  U S  revenues from Impella products are likely to be  130 7 million  up from from  100 3 million year over year  Further  preliminary fiscal 2018 guidance has been raised to approximately  582 million  up 31  from the prior year quarter Impella Product LineAbiomed s expanding product portfolio is expected to strengthen the company s foothold in the prophylactic high risk PCI and cardiogenic shock patient market  In this regard  the company s Impella line of products deserves a mention  Per management  Impella is the world s smallest heart pump  It is a support system of percutaneous  catheter based devices offering hemodynamic support to the heart Abiomed s Impella 2 5  Impella CP and Impella 5 0 are FDA approved pumps that treat cardiogenic shock  Further  the Impella 2 5 and Impella CP are approved to treat urgent percutaneous coronary interventions  PCI  such as stenting or balloon angioplasty and cure blocked coronary arteries  The company s right side heart pump  the Impella RP device  cures right heart failure ABIOMED  Inc  Price and Consensus
     The company also has an Automated Impella Controller  which is a primary user interface for the Impella platform featuring a highly exclusive 10 inch high resolution display Per bcc Research  the global market for cardiac medical devices is projected to reach  67 5 billion by 2019 at a CAGR of 5 3  during 2014 2019  Considering the prospects in the niche space  we expect Abiomed to gain solid market tractions in the years to come Northward Estimate RevisionOne estimate for the current year moved north in the past 60 days against no southward revisions  which indicates analysts  optimism in the company  The Zacks Consensus Estimate for adjusted earnings increased 0 8  for the current year  The positive trend signifies analyst s bullish sentiment  The company holds a Zacks Rank  2  Buy   which indicates robust fundamentals and expectations of outperformance in the near term  You can see The Zacks Consensus Estimate for fiscal 2018 revenues is pegged at  577 2 million  up 29 6  year over year  Moreover  revenues are expected to grow 27 1  in fiscal 2019 Other Key PicksOther top ranked stocks in the broader medical sector are Integer Holdings Corporation   NYSE ITGR    Bio Rad Laboratories  Inc    NYSE BIO   and Intuitive Surgical  Inc    NASDAQ ISRG   Bio Rad Laboratories flaunts a Zacks Rank  1  Strong Buy   The company has a long term expected earnings growth rate of 25  Integer Holdings has a long term expected earnings growth rate of 15   The stock carries a Zacks Rank  2 Intuitive Surgical has a long term expected earnings growth rate of 9 2   The stock carries a Zacks Rank  2 Will You Make a Fortune on the Shift to Electric Cars  Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ",2018-01-18,Zacks Investment Research,https://www.investing.com/analysis/abiomed-hits-new-52week-high-3-factors-driving-the-stock-200281777,200281777
112618,334133,ISRG,McKesson Buys RxCrossroads From CVS Health For  735 Million,opinion,"McKesson Corp    NYSE MCK   recently announced that it has completed the acquisition of RxCrossroads from CVS Health Corp  NYSE CVS   RxCrossroads is a provider of tailored services to pharmaceutical and biotechnology manufacturers  The transaction is valued at  735 million and has been entirely funded by cash on hand 
RxCrossroads will become part of McKesson s Specialty Health business  McKesson expects this transaction to be accretive to adjusted earnings per share by approximately 20 cents within the third year following the close of the transaction  McKesson s specialty pharma business will be a strong growth driver over the next several years 
The buyout is expected to enhance McKesson s existing commercialization solutions for manufacturers of branded  specialty  generic and biosimilar drugs  including comprehensive patient support services  custom pharmacy solutions and third party logistics  This will also allow the company to expand end to end offerings for manufacturers 
RxCrossroads was founded in 1986 as Medical Distribution company  which was later acquired by Omnicare in 2005 and then acquired by CVS Health in 2015 
McKesson has been actively pursuing deals  divestitures and acquisitions to drive growth  Recently  McKesson divested Enterprise Information segment recently for approximately  185 million in cash  which indicates the company s focus on core strength  Notably  the Enterprise Information Solutions portfolio included a robust set of clinical and financial solutions supporting full scope of care delivery processes including Paragon  EHR solution   STAR and HealthQuest  Revenue Cycle solutions   Lab Analytics and Blood Bank  and OneContent  Content Management solutions   The company also signed an agreement to acquire privately owned company CoverMyMeds for approximately  1 1 billion 
However  McKesson s pharmaceutical distribution business  which contributes almost 99  to the company s top line  is witnessing sluggish growth since the last few quarters due to weak pricing trends and customer consolidation  Distribution Solutions faces stiff competition in terms of price and service from various full line  short line and specialty wholesalers  service merchandisers  self warehousing chains  manufacturers engaged in direct distribution  third party logistics companies and large payer organizations 
Price Performance
Over the last three months  McKesson has been trading below the   The company s shares have gained 2 1   lower than the industry s rally of 5 4   The current level also is lower than the S P 500 index s return of just 6 6  
McKesson Corporation Price
   Zacks Rank   Other Picks
McKesson has a Zacks Rank  2  Buy  
Other top ranked stocks in the broader medical sector are Integer Holdings Corp    NYSE ITGR    Bio Rad Laboratories  Inc    NYSE BIO   and Intuitive Surgical  Inc    NASDAQ ISRG   
Bio Rad Laboratories flaunts a Zacks Rank  1  Strong Buy   You can see The company has a long term expected earnings growth rate of 25  
Integer Holdings has a long term expected earnings growth rate of 15   The stock carries a Zacks Rank  2 
Intuitive Surgical has a long term expected earnings growth rate of 9 2   The stock carries a Zacks Rank  2 
Zacks Editor in Chief Goes  All In  on This Stock 
Full disclosure  Kevin Matras now has more of his own money in one particular stock than in any other  He believes in its short term profit potential and also in its prospects to more than double by 2019  Today he reveals and explains his surprising move in a new Special Report ",2018-01-04,Zacks Investment Research,https://www.investing.com/analysis/mckesson-buys-rxcrossroads-from-cvs-health-for-735-million-200277742,200277742
112619,334134,ISRG,FDA Nod For Zimmer Biomet s Sidus  Aids Arthroplasty Arm ,opinion,Zimmer Biomet Holdings  Inc    NYSE ZBH   reached a new milestone in the field of total shoulder arthroplasty with the recent Food and Drug Administration  FDA  approval for its SidusStem Free Shoulder system in the United States  Following this approval  the Sidus system will be available in the country from the first quarter of 2018 This total shoulder arthroplasty solution claims to benefit patients with a good bone stock and also at the same time  complaining of either osteoarthritis  post traumatic arthrosis  focal avascular necrosis of the humeral head or for those having undergone previous surgeries of the shoulder that do not compromise the fixation Per Zimmer Biomet  the system is designed to restore a patient s anatomy  preserve bone stock and offers improved pre to post operative patient outcomes We are encouraged to note that the Sidus Stem Free Shoulder system offers minimal bone resection in total shoulder arthroplasty  Zimmer Biomet claimed that this advanced approach will reduce pain and restore a range of motions The Sidus system was first introduced in Europe in 2012 and the company initiated a clinical study in the United States in 2015  Going by the strong clinical performance that the Sidus Stem Free Shoulder system has demonstrated over time  Zimmer Biomet seems highly optimistic about showing the impression of customer adoption Per an article published in OrthoSpineNews  in 2016  the global shoulder arthroplasty market was valued at  1 090 0 million  By 2023  the same is expected to scale up to  1 866 3 million  registering a CAGR of 8 1  during the forecast period  This promising data indicates what a timely and strategic role the latest FDA approval is going to play in favor of Zimmer Biomet Solid Stock Performance In the last 30 days  Zimmer Biomet has been trading above the broader   The company has gained 11  versus the broader industry s 5 2  rise  Also  the company has outperformed the S P 500 s 3 1  gain over the same time frame Zacks Rank   Key PicksZimmer Biomet carries a Zacks Rank  4  Sell  Some better ranked stocks from the broader medical space are ABIOMED Inc    NASDAQ ABMD    Tactile Systems Technology   NASDAQ TCMD   and Intuitive Surgical Inc    NASDAQ ISRG    each carrying a Zacks Rank  2  Buy   You can see ABIOMED has a long term expected earnings growth rate of 31 5   The stock has rallied 72 8  in the last year Tactile Systems has a long term expected growth rate of 20   The stock has soared 81 5  in the last year Intuitive Surgical has a long term expected growth rate of 9 2   Over the last 6 months  the stock has rallied 20 1  5 Medical Stocks to Buy NowZacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia  AIDS  muscular dystrophy  hemophilia  and other conditions New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline  Early investors could realize exceptional profits ,2018-01-07,Zacks Investment Research,https://www.investing.com/analysis/fda-nod-for-zimmer-biomets-sidus-aids-arthroplasty-arm-200278387,200278387
112620,334135,ISRG,RTI Surgical  RTIX  To Acquire Zyga  Improve Spine Surgeries,opinion,"RTI Surgical Inc    NASDAQ RTIX   recently executed a deal to acquire Zyga Technology Inc   a privately held medical device company  based in Minnesota  However  successful closing of the deal is subject to filing with the state of Delaware   Currently  the Delaware Department of State is closed owing to unfavorable weather conditions 
Financial terms of the deal are still under wraps  Upon the closing of the deal  RTI Surgical will fund the acquisition through a combination of cash and borrowing under existing credit facility 
About Zyga
Zyga Technology is dedicated toward research  development and commercialization of surgical solutions  The company provides economic value in the treatment of underserved conditions of spine 
Zyga is known for two of primary medical devices   SImmetry Sacroiliac Joint Fusion System  SIJF  and Glyder Facet Restoration Device  SImmetry Sacroiliac Joint Fusion System is a minimally invasive spine surgery procedure designed to help stabilize the SI joint  The Glyder Facet Restoration Device is intended to provide relief from lumber facet pain and restoring facet joint function 
The company generated approximately  4 million in annual revenues 
RTI Surgical  Inc  Price and Consensus   A Strategic Move
RTI Surgical expects the Zyga Technology s SImmetry Sacroiliac Joint Fusion System to leverage the competency of Spine franchise  The acquisition is in line with the company s motto of strategic transformation toward increased operational excellence as it will lead to reduced complexities in the surgical procedures 
Market Prospect
The SIJF market has seen significant growth in the current years and its market is estimated to be  100 million in the United States  By 2024  the SIJF is expected to exceed  200 million  The growth can be attributed to an increase in procedure volumes and technology adoption by new surgeons  Per  iData Research  more than 80  of the U S  population is likely to suffer from lower back pain at some point in their lives 
Shares Look Up
Over the last year  RTI Surgical has had a smooth run on the bourse  The stock has rallied 34 8  compared with the  s gain of 25 6  
Zacks Ranks   Key Picks
RTI Surgical has a Zacks Rank  3  Hold  
A few better ranked stocks in the broader medical space are  ABIOMED Inc    NASDAQ ABMD    Tactile Systems Technology   NASDAQ TCMD   and Intuitive Surgical Inc    NASDAQ ISRG    each carrying a Zacks Rank  2  Buy   You can see  
ABIOMED s long term growth rate is expected to be an impressive 31 5   The stock has rallied 72 8  which is way above the industry s gain of 25 6   in the last year 
Tactile Systems has a long term growth rate of 20   The stock has rallied 81 5  and has outperformed the industry  over the last year 
Intuitive Surgical has a long term growth rate of 9 2   Over the last six months  the stock has rallied 20 1   surpassing the industry s gain of 6 7  
5 Medical Stocks to Buy NowZacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia  AIDS  muscular dystrophy  hemophilia  and other conditions New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline  Early investors could realize exceptional profits ",2018-01-07,Zacks Investment Research,https://www.investing.com/analysis/rti-surgical-rtix-to-acquire-zyga-improve-spine-surgeries-200278504,200278504
112621,334136,ISRG,NANO Arm Profits For Bruker  MERLIN Buyout Holds Promise,opinion,"On January 5th  we issued an updated research report on Bruker Corporation   NASDAQ BRKR    The stock carries a Zacks Rank  2  Buy  
Bruker has been trading above the broader  over the past three months  The stock has returned 18 7   higher than the 6  gain of the broader industry during the period 
In the last three quarters  Bruker s NANO Surfaces group business realized profitability owing to prior restructuring and cost actions  In the last reported third quarter 2017  high single digit growth was driven by contributions from Hysitron nanoindenting product s acquisition in January 2017 and improved results at the AXS business 

Moving on  the company s strategic acquisition activity has also been encouraging  For instance  the company recently announced the completion of its Germany based MERLIN s buyout  Products of the acquired company can complement Bruker s MALDI Biotyper platform 
More good news is that Bruker s MALDI Biotyper franchise has grown into an impressive system worth approximately  90 million per annum  We are happy to note that demand for the MALDI Biotyper is increasing in the applied markets  specifically for food  feed and beverage categories segments 
Based on recent developments witnessed in its product portfolio  management believes that Bruker is poised to double its microbiology business over the next four five years  The company s raised 2017 guidance is also indicative of brighter prospects 
On the flip side  Bruker conducts 80  of its business in the international markets  As a result  adverse currency fluctuations continue to incur losses for the company  Also  headwinds like unfavorable economic conditions and an intense competition continue to pose threats 
Other Key Picks
Some other top ranked stocks in the broader medical space are  ABIOMED Inc    NASDAQ ABMD    Tactile Systems Technology   NASDAQ TCMD   and Intuitive Surgical Inc    NASDAQ ISRG    each carrying a Zacks Rank  2  Buy   You can see  
ABIOMED has a long term expected earnings growth rate of 31 5   The stock has rallied 72 8  over the last year 
Tactile Systems has a long term expected growth rate of 20   The stock has soared 81 5  over the last year 
Intuitive Surgical has a long term expected growth rate of 9 2   Over the last 6 months  the stock has rallied 20 1  
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia  AIDS  muscular dystrophy  hemophilia and other conditions 
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline  Early investors could realize exceptional profits ",2018-01-08,Zacks Investment Research,https://www.investing.com/analysis/nano-arm-profits-for-bruker-merlin-buyout-holds-promise-200278473,200278473
112622,334137,ISRG,NuVasive Q4 Preliminary Results Fail To Cheer Investors,opinion,"The market is not content with NuVasive  Inc  s   NASDAQ NUVA   unimpressive preliminary results for the fourth quarter and 2017  After the results were announced on Jan 8  the stock lost 10 8  to close the session at  53 26 on the next day   Prelim Results at a GlanceWe believe the dull revenue expectation for the fourth quarter 2017 has dampened investors  spirits  NuVasive announced preliminary revenues of approximately  272 million for the quarter  flat year over year  The Zacks Consensus Estimate for fourth quarter revenues is pegged at  272 74 million Revenues for 2017 are expected at  1 03 billion  reflecting 7  year over year growth  The estimates happen to be in line with the company s guidance  The Zacks Consensus Estimate for 2017 revenues stands at  1 03 billion In view of the continued impact of hurricane Maria in Puerto Rico in the fourth quarter as well as an anticipated decline in U S  procedural volumes  NuVasive had issued an updated 2017 guidance during the third quarter 2017 earnings call The company had expected to report revenue growth of 7 2   at CER for 2017  The projected revenue figure was approximately  1 030 billion  NuVasive also projects its 2017 adjusted earnings per share  EPS  to be pegged at  1 91  Additionally  adjusted operating margin for the year is currently expected at 16 6   The Zacks Consensus Estimate for 2017 EPS stands at  1 91 However  the company continues to witness sequential growth in international revenues  Notably  on the back of continued innovation  NuVasive has witnessed more than 20  increase in international sales in the fourth quarter for the fifth sequential quarter 
NuVasive  Inc  Price and EPS Surprise
     Preliminary Outlook for 2018NuVasive has also provided the initial guidance for full year 2018 as well  The company expects mid single digit revenue growth in 2018 over the 2017 figure  The Zacks Consensus Estimate for 2018 revenues is pegged at  1 09 billion  Moreover  the company expects non GAAP operating margin expansion of approximately 100 basis points  Also  adjusted EBITDA is expected in the  290  300 million range The latest U S  tax legislation  which slashes corporate tax rates from 35  to 21   is expected to result in significant tax savings for NuVasive  Without the tax rate cut  the company would have to face a corporate tax rate of 33  on a non GAAP basis in 2018 The company will also take synergies from the December 2017 acquisition of privately held intraoperative neurophysiological monitoring  IONM  service provider SafePassage into account while issuing the guidance for 2018  The buyout is on track and is expected to close in January 2018 on fulfillment of certain customary closing conditions  Per NuVasive  the acquisition will strengthen the company s intraoperative neuromonitoring business line  The consolidated giant is expected to deliver services to more than 1 000 customers and 3 000 surgeons  Moreover  following the acquisition of SafePassage  NCS is likely to aid more than 100 000 IONM cases every year in the United States Post closure of the deal  the transaction is expected to prove accretive to the company s EPS in 2018 and beyond  It is also expected to support NuVasive s long term targets for revenue growth and expansion of adjusted operating and EBITDA margins Zacks Rank   Key PicksNuVasive carries a Zacks Rank  3  Hold  A few better ranked stocks in the broader medical sector are Integer Holdings Corporation   NYSE ITGR    Bio Rad Laboratories  Inc    NYSE BIO   and Intuitive Surgical  Inc    NASDAQ ISRG   Bio Rad Laboratories flaunts a Zacks Rank  1  Strong Buy   You can see  The company has a long term expected earnings growth rate of 25  Integer Holdings has a long term expected earnings growth rate of 15   The stock carries a Zacks Rank  2  Buy  Intuitive Surgical has a long term expected earnings growth rate of 9 2   The stock carries a Zacks Rank  2 Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2018-01-09,Zacks Investment Research,https://www.investing.com/analysis/nuvasive-q4-preliminary-results-fail-to-cheer-investors-200279167,200279167
112623,334138,ISRG,Intuitive Surgical  ISRG  Upbeat On Q4   2017 Sales Results,opinion,"Intuitive Surgical Inc    NASDAQ ISRG   recently announced better than expected preliminary net sales results for fourth quarter and full year 2017  The company is scheduled to report fourth quarter 2017 results on Jan 25  2018  Following the announcement  the stock closed at a value of  423 76 on Jan 10 The company expects net sales for fourth quarter 2017 to be approximately  892 million  up 18  on a year over year basis  The preliminary figure is higher than the Zacks Consensus Estimate of  845 7 million Full year 2017 revenues are expected to be approximately  3 1 billion  up 16  on a year over year basis  The company s preliminary figure compares favorably with the Zacks Consensus Estimate of  3 09 billion 
Intuitive Surgical  Inc  Price and Consensus
     Preliminary fourth quarter 2017 revenues of the instrument and accessories segment increased approximately 18  to  457 million on a year over year basis Per management  the anticipated revenue growth of the instruments and accessories segment is driven by da Vinci procedure growth The revenues from the da Vinci Surgical System is expected to be   283 million  up 20  on a year over year basis  The company shipped 216 da Vinci Surgical Systems during the quarter The number of da Vinci surgeries rose approximately 17   on a year over year basis in the fourth quarter  The upside can be attributed to the surge in general surgery procedures in the United States and worldwide urologic procedures Service revenues increased approximately 13  to  153 million on a year over year basis Share Price Looks UpIntuitive Surgical has had an outstanding performance on the bourses in the last year  The stock has gained 87 5   outperforming the  s rally of 27 2   Zacks Ranks   Other PicksIntuitive Surgical carries a Zacks Rank  2  Buy  
Other top ranked stocks in the broader medical space are Bio Rad Laboratories Inc    NYSE BIO    Centene Corporation   NYSE CNC   and Magellan Health Inc    NASDAQ MGLN    each sporting a Zacks Rank  1  Strong Buy   You can see  Bio Rad has a long term growth rate of 25   Over the last six months  the stock has rallied 10   much above the industry s gain of 5 8  Centene has a projected long term growth rate of 14   The stock has gained 28 3  over the last six months  much above the industry s gain of 18 7  Magellan has an impressive expected growth rate of 28 4  for the first quarter of 2018  The stock too gained 31  in the last six months and surpassed the broader industry Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2018-01-10,Zacks Investment Research,https://www.investing.com/analysis/intuitive-surgical-isrg-upbeat-on-q4--2017-sales-results-200279576,200279576
112626,334141,ISRG,Baxter  BAX  Launches Arisure Closed System Transfer Device,opinion,"In a bid to promote safe handling of hazardous drugs and maintain medication sterility  Baxter International Inc    NYSE BAX   recently announced a distribution agreement for the launch of the Arisure Closed System Transfer device in the United States  The platform prevents contamination of intravenous  IV  medication delivery system during drug preparation Per management  with the latest development  Baxter will be able to ensure safer drug preparation  transportation  administration and disposal  The system will reduce the risk of accidental exposure or contamination  for both patients and caregivers The Arisure Closed System Transfer device includes a closed vial adapter  an intravenous dry spike and a closed male Luer valve  The Arisure Closed Male Luer lowers the exposure risk of healthcare professionals to sharp needles  Further  the Arisure Closed Male Luer is compatible with Baxter s ONE LINK Needle free IV Connector and CLEARLINK Luer Activated Valve that paves way to initiate a mechanically and microbiologically closed system Broad Product SpectrumBaxter has an impressive product portfolio with convenient kidney dialysis solutions  regenerative tissue products and the next generation SIGMA Spectrum Infusion pump  The Sigma Spectrum Infusion System minimizes patient risk when administering vital fluids and medications  Recently  the company upgraded the SIGMA Spectrum Infusion System with the launch of DeviceVue Advanced Asset Tracking System Baxter International Inc  Price     
Baxter is the first and only smart infusion pump manufacturer to offer a tagless  end to end acid tracking application designed in consultation with potential customers to drive operational efficiencies and maximize the clinical value of their pump investments Of late  Baxter s needle free connector product lines have also been under focus  in which minimize hospital infections In acute therapies  Baxter launched the first 3 in 1 oXIRIS for continuous renal replacement therapy and sepsis management protocols  This adds to Baxter s multi organ therapy offering  utilizing the Prismaflex system Stock Performance SolidOver the past six months  Baxter has gained 9 8  comparing favorably with the  s rally of 5 7   Baxter is poised to gain from an expanding product portfolio and increasing penetration in international markets  Accretive acquisitions like these are also key catalysts in the long haul  The company s long term expected earnings growth rate of 12 3  holds promise in this regard Zacks Rank   Key PicksBaxter has a Zacks Rank  3  Hold  A few better ranked stocks in the broader medical sector are Integer Holdings Corporation   NYSE ITGR    Bio Rad Laboratories  Inc    NYSE BIO   and Intuitive Surgical  Inc    NASDAQ ISRG   Bio Rad Laboratories flaunts a Zacks Rank  1  Strong Buy   You can see  The company has a long term expected earnings growth rate of 25  Integer Holdings has a long term expected earnings growth rate of 15   The stock carries a Zacks Rank  2  Buy  Intuitive Surgical has a long term expected earnings growth rate of 9 2   The stock carries a Zacks Rank  2 Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2018-01-14,Zacks Investment Research,https://www.investing.com/analysis/baxter-bax-launches-arisure-closed-system-transfer-device-200280271,200280271
112650,334165,ISRG,Trump Focuses On APAC  4 MedTech Stocks To Watch,opinion,Asia Pacific  or APAC  is home to more than half of the world s population  so demand for healthcare is also exceptionally high in the region  Furthermore  the need for cutting edge MedTech products and services is significantly high across the world  with APAC being no exception In fact  a research report by McKinsey shows that APAC is expected to outpace the European Union as the world s second largest MedTech market pretty soon  after the United States   Almost 1 1 billion people in the region are expected to enter the 50 plus age group by 2025  indicating emerging demand for healthcare needs  Also  APAC accounts for two thirds of the global disease burden Further  a research report by Statista shows that the MedTech market in the Asia Pacific region is estimated to reach nearly  78 billion in 2018 Trump s Focus on AsiaWith the above data pointing toward the huge and unmet healthcare needs within the APAC market  investors may find President Trump s recent 12 day long Asia trip  with stops in Japan  South Korea  China  Vietnam and the Philippines  to be a positive sign Furthermore  his recent tweet    Our great country is respected again in Asia  You will see the fruits of our long but successful trip for many years to come   is indicative of a favorable Republican stance on APAC  especially with respect to business and trade Here we take a sneak peek at two major postulates of Trump s recent Asia visit Bilateral Trade AgreementTrump s promise to augment bilateral trade agreements with Indo Pacific nations instills our confidence in his APAC policies  However  Trump specifically mentioned that these agreements are bound to follow the  principles of fair and reciprocal trade   He also voiced for  free and open Indo Pacific trade   emphasizing on increased focus in the nations of Japan  Australia  and India Prospects in China Pacific is big enough to accommodate both China and the United States   said China s President Xi Jinping during Trump s visit China undoubtedly poses serious competitive threat to the United States  not just in the healthcare space  but also in electronic  semiconductors  retail  and other areas  Jinping s statements clearly hint at the possibility of the countries coexisting peacefully despite the political tensions  This might also be indicative of strategic mergers between companies in the two nations in order to enhance trade practices MedTech Companies Eye APACConsidering Trump s growing focus on APAC  the region seems to be poised to yield accretive returns in the long term  In fact  stakeholders in the medical universe have been eyeing the emerging market over the last couple of years  These companies are bullish on the growing medical awareness  economic prosperity  an aging population  increasing wealth  government focus on healthcare infrastructure  and the expansion of medical insurance coverage in the APAC space Meanwhile  despite the health policy debacle in the United States and deteriorating economic conditions in Europe  we can conclude that growth in the emerging markets of China  India  Japan  and others will bolster the global foothold for MedTech companies  Below  we take a look at four leading MedTech players that are tapping into and also gaining from the bountiful opportunities in the APAC market Baxter International   NYSE BAX  Baxter s solid presence in Asia  precisely in India  is worth a mention  the company has research hubs in Japan and China  In the just reported third quarter  Baxter completed the acquisition of India based Claris Injectables  a global generic injectables pharmaceutical company  for almost  625 million  In December 2016  Baxter had initiated the agreement  Per management  the acquisition will bolster Baxter s foothold in the generic pharmaceuticals space  In the second quarter of 2017  Baxter signed an agreement with India based Dorizoe Lifesciences for the expansion of its generic injectables pipeline  Further  Baxter s strong presence in peritoneal dialysis  nutrition  IV fluids  and anesthesia gases fortifies its footprint in China This Zacks Rank  2  Buy  stock has had an impressive run on the bourses in the last two years  The stock has returned 70 6   significantly higher than the broader industry s gain of 16 2    BostonScientific Corporation   NYSE BSX  An important part of Boston Scientific s growth strategy is to continue pursuing development opportunities outside the United States In the just reported third quarter 2017  business from the emerging markets registered an 18  organic growth rate  It remained above the company s target of reaching 15  of sales by 2017  from 8  in 2013   Business in China was also remarkable  up 23  year over year   The company is currently looking forward to an improved performance in China  banking on the recent approval of SYNERGY Boston Scientific is also optimistic about its core cardiology segment  which is gradually stabilizing with growth in the BRIC nations  The cardiology capacity in China is expected to double by 2017 end  In India  business is projected to grow more than 15  annually This Zacks Rank  3  Hold  stock has yielded a stellar return of 59 3  in the last two years  way ahead of the broader industry s 16 2  over the same time frame  You can see    Intuitive Surgical Inc    NASDAQ ISRG  Intuitive Surgical s growing interest in the emerging markets  specifically in the APAC region  bodes well  Over the last couple of years  the company s procedure performance in Asia showed continued strength  with solid growth in China  Japan  and Korea  In the just reported third quarter  Intuitive Surgical s system placements included 14 in Japan  five in India  four in New Mexico  and one in China This Zacks Rank  3  Hold  company has returned 135 4  over the last two years  much higher than the broader industry s 25  during the same period   Becton  Dickinson and Company   NYSE BDX  Becton  Dickinson and Company  or BD  is focused on geographical expansion in overseas markets  and in particular  emerging nations  We note that the company is especially focused on broader emerging markets like India and China  which are seeing rapid growth in economic and healthcare sectors  We believe that significant emerging market exposure will boost the company s top line  which in turn should lead to accelerated EPS growth BD revenues grew 6 9  in the just reported fourth quarter of fiscal 2017  Emerging market revenues grew a strong 12 7  year over year in the quarter at constant currency  driven by strong performance in greater Asia and China  where revenues saw double digit growth This leading player in the MedTech space is a Zacks Rank  3  Hold   The stock has returned 45 1  in the last two years  much higher than the broader industry s growth of 10    The ParadoxHowever  Trump s  Americafirst   pitch at the Asia Pacific Economic Cooperation summit  or APEC  which was held in Vietnam  November 6 11   has been a serious threat to U S  multilateral trade  It has been clearly portrayed that Trump s primary focus was  is  and will be the betterment of the United States Zacks  Best Private Investment IdeasWhile we are happy to share many articles like this on the website  our best recommendations and most in depth research are not available to the public Starting today  for the next month  you can follow all Zacks  private buys and sells in real time  Our experts cover all kinds of trades  from value to momentum       from stocks under  10 to ETF and option moves       from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises  You can even look inside exclusive portfolios that are normally closed to new investors ,2017-11-16,Zacks Investment Research,https://www.investing.com/analysis/trump-focuses-on-apac-4-medtech-stocks-to-watch-200265952,200265952
112651,334166,ISRG,The Zacks Analyst Blog Highlights  Baxter International  BostonScientific  Intuitive Surgical And Becton And Dickinson,opinion,For Immediate ReleaseChicago  IL   November 17  2017   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include Baxter International   NYSE BAX    BostonScientific Corporation   NYSE BSX    Intuitive Surgical Inc    NASDAQ ISRG   and Becton  Dickinson and Company   NYSE BDX   Today  Zacks is promoting its   Buy   stock recommendations   Here are highlights from Thursday s Analyst Blog  Trump Focuses on APAC  4 MedTech Stocks to WatchAsia Pacific  or APAC  is home to more than half of the world s population  so demand for healthcare is also exceptionally high in the region  Furthermore  the need for cutting edge MedTech products and services is significantly high across the world  with APAC being no exception In fact  a research report by McKinsey shows that APAC is expected to outpace the European Union as the world s second largest MedTech market pretty soon  after the United States   Almost 1 1 billion people in the region are expected to enter the 50 plus age group by 2025  indicating emerging demand for healthcare needs  Also  APAC accounts for two thirds of the global disease burden Further  a research report by Statista shows that the MedTech market in the Asia Pacific region is estimated to reach nearly  78 billion in 2018 Trump s Focus on AsiaWith the above data pointing toward the huge and unmet healthcare needs within the APAC market  investors may find President Trump s recent 12 day long Asia trip  with stops in Japan  South Korea  China  Vietnam and the Philippines  to be a positive sign Furthermore  his recent tweet    Our great country is respected again in Asia  You will see the fruits of our long but successful trip for many years to come   is indicative of a favorable Republican stance on APAC  especially with respect to business and trade Here we take a sneak peek at two major postulates of Trump s recent Asia visit Bilateral Trade AgreementTrump s promise to augment bilateral trade agreements with Indo Pacific nations instills our confidence in his APAC policies  However  Trump specifically mentioned that these agreements are bound to follow the  principles of fair and reciprocal trade   He also voiced for  free and open Indo Pacific trade   emphasizing on increased focus in the nations of Japan  Australia  and India Prospects in China Pacific is big enough to accommodate both China and the United States   said China s President Xi Jinping during Trump s visit China undoubtedly poses serious competitive threat to the United States  not just in the healthcare space  but also in electronic  semiconductors  retail  and other areas  Jinping s statements clearly hint at the possibility of the countries coexisting peacefully despite the political tensions  This might also be indicative of strategic mergers between companies in the two nations in order to enhance trade practices MedTech Companies Eye APACConsidering Trump s growing focus on APAC  the region seems to be poised to yield accretive returns in the long term  In fact  stakeholders in the medical universe have been eyeing the emerging market over the last couple of years  These companies are bullish on the growing medical awareness  economic prosperity  an aging population  increasing wealth  government focus on healthcare infrastructure  and the expansion of medical insurance coverage in the APAC space Meanwhile  despite the health policy debacle in the United States and deteriorating economic conditions in Europe  we can conclude that growth in the emerging markets of China  India  Japan  and others will bolster the global foothold for MedTech companies  Below  we take a look at four leading MedTech players that are tapping into and also gaining from the bountiful opportunities in the APAC market Baxter InternationalBaxter s solid presence in Asia  precisely in India  is worth a mention  the company has research hubs in Japan and China  In the just reported third quarter  Baxter completed the acquisition of India based Claris Injectables  a global generic injectables pharmaceutical company  for almost  625 million  In December 2016  Baxter had initiated the agreement  Per management  the acquisition will bolster Baxter s foothold in the generic pharmaceuticals space  In the second quarter of 2017  Baxter signed an agreement with India based Dorizoe Lifesciences for the expansion of its generic injectables pipeline Further  Baxter s strong presence in peritoneal dialysis  nutrition  IV fluids  and anesthesia gases fortifies its footprint in China This Zacks Rank  2  Buy  stock has had an impressive run on the bourses in the last two years  The stock has returned 70 6   significantly higher than the broader industry s gain of 16 2  BostonScientific CorporationAn important part of Boston Scientific s growth strategy is to continue pursuing development opportunities outside the United States In the just reported third quarter 2017  business from the emerging markets registered an 18  organic growth rate  It remained above the company s target of reaching 15  of sales by 2017  from 8  in 2013   Business in China was also remarkable  up 23  year over year   The company is currently looking forward to an improved performance in China  banking on the recent approval of SYNERGY Boston Scientific is also optimistic about its core cardiology segment  which is gradually stabilizing with growth in the BRIC nations  The cardiology capacity in China is expected to double by 2017 end  In India  business is projected to grow more than 15  annually This Zacks Rank  3  Hold  stock has yielded a stellar return of 59 3  in the last two years  way ahead of the broader industry s 16 2  over the same time frame  You can see  Intuitive Surgical Inc Intuitive Surgical s growing interest in the emerging markets  specifically in the APAC region  bodes well  Over the last couple of years  the company s procedure performance in Asia showed continued strength  with solid growth in China  Japan  and Korea  In the just reported third quarter  Intuitive Surgical s system placements included 14 in Japan  five in India  four in New Mexico  and one in China This Zacks Rank  3  Hold  company has returned 135 4  over the last two years  much higher than the broader industry s 25  during the same period Becton  Dickinson and CompanyBecton  Dickinson and Company  or BD  is focused on geographical expansion in overseas markets  and in particular  emerging nations  We note that the company is especially focused on broader emerging markets like India and China  which are seeing rapid growth in economic and healthcare sectors  We believe that significant emerging market exposure will boost the company s top line  which in turn should lead to accelerated EPS growth BD revenues grew 6 9  in the just reported fourth quarter of fiscal 2017  Emerging market revenues grew a strong 12 7  year over year in the quarter at constant currency  driven by strong performance in greater Asia and China  where revenues saw double digit growth This leading player in the MedTech space is a Zacks Rank  3  Hold   The stock has returned 45 1  in the last two years  much higher than the broader industry s growth of 10  The ParadoxHowever  Trump s  Americafirst   pitch at the Asia Pacific Economic Cooperation summit  or APEC  which was held in Vietnam  November 6 11   has been a serious threat to U S  multilateral trade  It has been clearly portrayed that Trump s primary focus was  is  and will be the betterment of the United States Zacks  Best Private Investment IdeasWhile we are happy to share many articles like this on the website  our best recommendations and most in depth research are not available to the public Starting today  for the next month  you can follow all Zacks  private buys and sells in real time  Our experts cover all kinds of trades  from value to momentum       from stocks under  10 to ETF and option moves       from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises  You can even look inside exclusive portfolios that are normally closed to new investors Today  Zacks is promoting its   Buy   stock recommendations   About Zacks Equity ResearchZacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long term Continuous coverage is provided for a universe of 1 150 publicly traded stocks  Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance  Recommendations and target prices are six month time horizons Strong Stocks that Should Be in the NewsMany are little publicized and fly under the Wall Street radar  They re virtually unknown to the general public  Yet today s 220 Zacks Rank  1  Strong Buys  were generated by the stock picking system that has nearly tripled the market from 1988 through 2015  Its average gain has been a stellar  26  per year Follow us on Twitter  Join us on Facebook  NASDAQ FB   Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates Media ContactZacks Investment Research800 767 3771 ext  9339Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ,2017-11-16,Zacks Investment Research,https://www.investing.com/analysis/the-zacks-analyst-blog-highlights-baxter-international-bostonscientific-intuitive-surgical-and-becton-and-dickinson-200266188,200266188
112652,334167,ISRG,Intuitive Surgical Hits A 52 Week High On Solid Prospects,opinion,Share price of Intuitive Surgical Inc   NASDAQ ISRG   scaled a new 52 week high of  400 on Nov 17  eventually closing a bit lower at  392 48  The company has gained 19 8  over the last three months  much better than the S P 500 s 6 4  rise and the broader  s gain of 6 3   Taking the stock s stable performance into consideration  we expect Intuitive Surgical to scale higher in the coming quarters  The company s long term growth of 9 2  also holds promise Average volume of shares traded over the last three months was remarkable at approximately 807 4K  The stock has a market cap of  43 9 billion  Over the last 60 days  four analysts have raised the earnings estimates for the current year  while one has slashed the same  The net effect has taken the Zacks Consensus Estimate to  8 60 from  7 87 per share for the period   CatalystsThe Sunnyvale  CA based company posted an impressive third quarter peformance with both earnings and revenues having registered a year over year increase in the quarter  The company also witnessed growth in all the segments  The international performance was encouraging too More good news is that the market is upbeat about Intuitive Surgical s procedure performance in Asia that showed continued strength with solid growth in China  Japan and Korea  The company gained significantly on the CE Mark approval for da Vinci X in Europe  The stock received further boost on the recent FDA approval of the same We believe that the increasing adoption of Intuitive Surgical s da Vinci system among physicians for general surgery  oncology  urology and gynecology procedures is a key growth catalyst  Also  growing procedural volumes outside the United States  open up considerable opportunities for the company Additionally  a solid outlook for the coming quarters raises investors  confidence in the stock  Further  incremental spending on product development and higher investments in international markets are prudent moves that are likely to drive long term growth  The company is also expected to enhance organizational capabilities and gain prominence in the markets of Europe and Asia Zacks Rank   Key PicksIntuitive Surgical carries a Zacks Rank  3  Hold   A few better ranked medical stocks are PetMed Express  Inc    NASDAQ PETS    Align Technology  Inc    NASDAQ ALGN   and Myriad Genetics  Inc    NASDAQ MYGN    each sporting a Zacks Rank  1  Strong Buy   You can see PetMed has a long term expected earnings growth rate of 10   The stock has rallied roughly 76 6  over a year Align Technologyhas a long term expected earnings growth rate of 28 9   The stock has soared 163 9  in a year s time Myriad Genetics has a long term expected earnings growth rate of 15   The stock has surged 91 6  in a year Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2017-11-19,Zacks Investment Research,https://www.investing.com/analysis/intuitive-surgical-hits-a-52week-high-on-solid-prospects-200266761,200266761
112653,334168,ISRG,6 MedTech Stocks Set To Crush The Market In 2018,opinion," America has the best doctors  the best nurses  the best hospitals  the best medical technology  the best medical breakthrough medicines in the world     Rep  Bill FristIn terms of market size  the U S  health care market is the largest in the world  A report by Health Access suggests that America s unparalleled purchasing power  massive demand for medical services and equipment  and opportunity for innovation has lent it a competitive edge Further  the markets got a boost after President Donald Trump   an ardent proponent of  living big  living large    came into power  His constant efforts to boost American lifestyle  focus on middle class and incorporate the best health care in America have been creating a stir Trump s efforts to eliminate the country s jobless stature are remarkable  Per reports  the U S  unemployment rate was pegged at 4 1  in November  the lowest since February 2001  Undoubtedly  Trump s  America first   pitch has been driving employment growth like never before Four Factors to Drive MedTech in 2018Increasing Consolidation in HealthcareThe latest trend of increasing consolidation in the healthcare space has led to a reduction in the number of players  greater market concentration and reduced competition as well as increasing barriers of entry in the industry  The companies will benefit from higher market cap  which will put them in a position to negotiate with suppliers and consumers The recent  69 billion deal between Aetna Inc    NYSE AET   and CVS Health   NYSE CVS   is a significant example  It qualifies as vertical integration  which will enable the newly formed entity to sell a range of services and products from drug to insurance cover President Trump s Focus on Emerging MarketsPer a recent BCG report  the share of emerging market revenues  which is less than a quarter of MedTech s global revenues  is likely to increase to nearly one third by 2022 Thus  the United States  trade plans with emerging countries are likely to favor the domestic companies In this regard  investors may find President Trump s 12 day Asia trip last month interesting  The visit was aimed at boosting inter country trade relations  particularly with the emerging nations  Trump s promise to augment bilateral trade agreements with Indo Pacific nations instills our confidence in his APAC policies  He also emphasized  free and open Indo Pacific trade  with a focus on the nations of Japan  Australia and India IVD   PBM Markets to Thrive A research report by EvaluateMedTech World Preview indicates that global MedTech sales are expected to witness a CAGR of 5 1  to  522 billion by 2022  with IVD  in Vitro diagnosis  raking in annual sales of  69 6 billion at a CAGR of 5 9   Increasing investments from government and private players in the form of reimbursement coverage and speedy patent approvals are driving demand The role of pharmacy benefit managers  PBM  in the U S  healthcare sector has been evolving  PBMs manage pharmaceutical spending and enhance health benefits for end users  Per a report by Market Research Reports biz  the global PBM market will see a CAGR of 7 16  between 2014 and 2019  Investing in PBM stocks can be a prudent move for registering solid gains in 2018  Looking for the Best Stocks for 2018  Be among the first to see our  Robot based Applications to Boost MedTechThe AI based applications have been enhancing the healthcare space with clinical applications  diagnostic support  operational efficiency  Electronic Health Record systems  practice workflows and supply chain management  The growing prevalence of minimally invasive robot assisted surgeries  self automated home based care  use of IT for quick and improved patient care and shift of the payment system to a value based model For example  MedTech major Intuitive Surgical  NASDAQ ISRG  designs  manufactures and markets the da Vinci surgical system   an advanced robot assisted surgical platform  This AI platform enables minimally invasive surgery that helps avoid the trauma associated with open surgery  The company plans to expand the usage of da Vinci in general and thoracic surgery  colorectal surgery and hernia repair in the days to come Picking the Right StocksBased on certain parameters  we have selected six MedTech growth stocks which are poised for impressive returns in 2017  These stocks carry a solid Zacks Rank  1  Strong Buy  or 2  Buy  along with a Growth Style Score of A or B We note that our Growth Style Score encompasses all the essential metrics from a company s financial statements to get a true sense of the quality and sustainability of growth  Our research shows that stocks with Growth Style Scores of  A  or  B  when combined with a Zacks Rank  1 or 2 offer the best investment opportunities in the growth investing space 6 Growth PicksChemed Corp    NYSE CHE    The stock has a Zacks Rank  2 and a Growth score of A  The Zacks Consensus Estimate for Chemed s sales is pegged at  1 73 billion for the next year  reflecting growth of 3 8  on a year over year basis  The stock has a market cap of  3 75 billion and a long term expected earnings growth rate of 10  Chemed s raised guidance banking on Roto Rooter business strength buoys optimism at the moment  Roto Rooter is currently the nation s leading provider of plumbing and drain cleaning services  Through its network of company owned branches  independent contractors and franchises  Roto Rooter offers plumbing and drain cleaning services to over 90  of the U S  population Chemed Corp  Price and Consensus     
athenahealth Inc    NASDAQ ATHN     The stock flaunts a Zacks Rank  1 and a Growth Score of B  The Zacks Consensus Estimate for athenahealth s sales is pegged at  1 36 billion for 2018  signifying growth of 11 7  on a year over year basis  The stock has a market cap of  5 35 billion and a long term expected earnings growth rate of 22 3  at the moment athenahealth s strong product portfolio   solid network expansion strategies and unique business model are key tailwinds  athenahealth s portfolio comprises a wide array of products that include electronic health records  revenue cycle management  medical billing  patient engagement  care coordination  population health management and Epocrates  Notably  the company launched athenaInsight  an online news hub reporting on U S  healthcare activities and trends of healthcare providers and  de identified patients  athenahealth  Inc  Price and Consensus     
Align Technology Inc     NASDAQ ALGN     The stock has a Zacks Rank  1 and a Growth score of B  The Zacks Consensus Estimate for Align Technology s sales is pegged at  1 79 billion for next year  signifying growth of 23 5  on a year over year basis in 2018  The stock has a market cap of  18 75 billion and a long term expected earnings growth rate of 28 9  now Align Technology s consistent efforts to boost product development  balanced growth across all channels and the focus in international markets bolster our confidence in the stock  We are encouraged by the company s strong InvisAlign Technology prospects and growth in North America and international regions  We are also upbeat about the company signing of a distribution agreement with Patterson Companies  NASDAQ PDCO  recently Align Technology  Inc  Price and Consensus     
IDEXX Laboratories  Inc    NASDAQ IDXX     The stock has a Zacks Rank  2 and a Growth Score of B  The Zacks Consensus Estimate for IDEXX Laboratories  sales pegs at  2 16 billion for the next year  reflecting growth of 10 7  on a year over year basis  The stock has a market cap of  18 75 billion and a long term expected earnings growth rate of 20 4  IDEXX Laboratories continues to depict solid growth globally on strong international expansion  Management s innovation based global strategy is leading to CAG Diagnostics growth  Notably  IDEXX widened cloud technology portfolio by adding rVetLink   Solid organic revenue growth along with a raised guidance for 2017 buoy optimism IDEXX Laboratories  Inc  Price and Consensus    Straumann Holding AG     The stock has a Zacks Rank  1 and a Growth score of B  The Zacks Consensus Estimate for Straumann Holding s sales pegs at  2 16 billion for the next year  signifying growth of 10 7  on a year over year basis  The stock has a market cap of  11 21 billion and a long term expected earnings growth rate of 15  now  You can see  Straumann Holding is a global leader in implant and restorative dentistry and oral tissue regeneration  The company collaborates with leading clinics  research institutes and universities to research  develop and manufacture dental implants  instruments  prosthetics and tissue regeneration products for use in tooth replacement and restoration solutions or prevent tooth loss Straumann Holding AG Price and Consensus    PRA Health Sciences  Inc     NASDAQ PRAH     The stock has a Zacks Rank  2 and a Growth Score of B  The Zacks Consensus Estimate for Straumann Holding s sales is pegged at  2 34 billion for the next year  signifying growth of 21 5  on a year over year basis  The stock has a market cap of  5 65 billion and a long term expected earnings growth rate of 18 1  now The company operates as a global contract research organization providing outsourced clinical development services to the biotechnology and pharmaceutical industries  It offers therapeutic services in the areas of cardio metabolic  biosimilars  infectious diseases  immunology  neurology and psychiatry  oncology and hematology  rare diseases and respiratory needs PRA Health Sciences  Inc  Price and Consensus    5 Medical Stocks to Buy NowZacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia  AIDS  muscular dystrophy  hemophilia  and other conditions New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline  Early investors could realize exceptional profits ",2017-12-20,Zacks Investment Research,https://www.investing.com/analysis/6-medtech-stocks-set-to-crush-the-market-in-2018-200274886,200274886
112654,334169,ISRG,Top Stock Reports For Nike  PayPal   BNY Mellon ,opinion,"Wednesday  December 20  2017
The Zacks Research Daily presents the best research output of our analyst team  Today s Research Daily features new research reports on 16 major stocks  including Nike  NYSE NKE   PayPal  PYPL  and BNY Mellon  BK   These research reports have been hand picked from the roughly 70 reports published by our analyst team today 
You can see 
Nike s shares have outperformed the Zacks Shoes and Retail Apparel industry over the last one year   22 8  vs   22 4    driven by strength in international business and the global Nike Direct business  Also  Nike has been focused on its Consumer Direct Offense plan  
Driven by its Triple Double strategy  this restructuring plan focuses on using digital methods for rapid innovation and product development  along with strengthening consumer relations by operating through core regions  It also has a positive record of earnings surprises in the recent quarters  
However  lackluster sales trend in the company s key North American market remains a headwind  Also  gross margin in the last quarter was hurt by currency woes and a higher mix of off price sales  Further  management anticipates near term results to be hurt by the tough retail environment  which led to a bleak second quarter view  Nevertheless  second quarter estimates have been stable ahead of the earnings release 
 You can   
Shares of Buy rated PayPal have outperformed the Zacks Internet Software industry in the year to date period   88 8  vs   32 9    PayPal is currently riding on partnerships and mobile centrism  The company continues to perform strongly in global payments  especially mobile  PayPal s ongoing strategic partnerships with Visa and MasterCard offer great flexibility and choice to consumers 
It recently extended its partnership with Mastercard in Europe  Latin America  Canada  Africa  the Caribbean and the Middle East  Partnerships with Google  NASDAQ GOOGL   Facebook  NASDAQ FB   Pinterest  Alibaba  NYSE BABA   Intuit  NASDAQ INTU  and other major retailers and financial institutions are also delivering positive results  However  continuous exposure to foreign exchange and interest rate risks are concerns 
 You can   
Buy rated BNY Mellon s shares have underperformed the Zacks Major Regional Banks industry in the last six months   9 3  vs   16 9    The company s earnings have surpassed expectations in two of the trailing four quarters  Easing margin pressure  driven by gradual rise in interest rates  and rising loan demand are expected to further aid revenue growth  
Also  potential lesser regulations and cost saving initiatives will likely drive profitability  Given a solid capital position  the company is expected to continue enhancing shareholder value through efficient capital deployment activities  However  concentration risk arising from significant dependence on fee based income remains a matter of concern in the near term 
 You can   
Other noteworthy reports we are featuring today include PPG Industries  NYSE PPG   Intuitive Surgical  NASDAQ ISRG  and CME Group  CME  
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia  AIDS  muscular dystrophy  hemophilia and other conditions 
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline  Early investors could realize exceptional profits 

Mark Vickery
Senior Editor
Note  Sheraz Mian heads the Zacks Equity Research department and is a well regarded expert of aggregate earnings  He is frequently quoted in the print and electronic media and publishes the weekly and reports  If you want an email notification each time Sheraz publishes a new article  please 
Today s Must Read









Featured Reports

Per the Zacks analyst  Nektar has a strong pipeline  with many updates lined up  However  it s PEGylation platform faces strong competition which may hamper the company s prospects in the near term 


Per the Zacks analyst  solid demand for commercial jets is boosting Spirit AeroSystems  growth in aerostructures manufacturing space  Yet the intense rivalry it faces may push up its revenue costs 


While the  6 billion Chicago Bridge buy will add onshore services to McDermott s offshore focused portfolio  the Zacks analyst is worried about increase in the combined company s debt load 


The Zacks analyst likes the growth in overall carload volumes  Improvement in operating ratio is also a positive for the company 


Per the Zacks analyst  the buyout deal of Signode will significantly boost Crown Holdings  free cash flow and add a portfolio of protective packaging franchises to metal packaging business 


Per the Zacks analyst  da Vinci X robotic platform has been boosting Intuitive Surgical s growth trajectory for long 


Per the Zacks analyst  CME Group s emphasis on expansion of derivative product lines will drive growth 

New Upgrades

Per Zacks analyst  Webster Financial s organic strength is reflected by rising loans and deposits balances  Also  easing margin pressure on rising interest rates is likely to support top line growth 


The Zacks analyst believes that attractive and economically viable oil reserves in the offshore Zama 1 exploration well will drive Stone Energy s future production 


The Zacks analyst believes that robust diagnostics and repair information products business  and accretive acquisitions like Norbar Torque   Car O Liner will continue to lend momentum to Snap On 

New Downgrades

Per the Zacks analyst  Arconic faces earnings headwind from sizable charges related to LIFO  last in  first out  method of accounting  It is also exposed to pricing pressure in GRP and EPS segments 


Per the Zacks analyst  PPG Industries is exposed to raw materials cost inflation and headwinds from unfavorable impacts of hurricanes  which may continue to affect its margins in Q4 


Per the Zacks analyst  dismal North American business remains a drag for Under Armour s top line  This has compelled management to trim full year sales view to low single digit growth from 9 11  ",2017-12-20,Zacks Investment Research,https://www.investing.com/analysis/top-stock-reports-for-nike-paypal--bny-mellon-200274944,200274944
112655,334170,ISRG,Intuitive Surgical Banks On Da Vinci X  Forex Woes Remain,opinion,On Dec 20  we issued an updated research report on Intuitive Surgical Inc    NASDAQ ISRG    Growing adoption of the company s da Vinci system  increasing procedure volumes  strategic acquisitions  continuous innovation and solid recurring revenue base are key catalysts  The stock has a Zacks Rank  3  Hold  Intuitive Surgical is the manufacturer of the da Vinci surgical system  an advanced robot assisted surgical system  and related instruments and accessories  The system enables minimally invasive surgery that helps avoid trauma associated with open surgery  In the last quarter  Intuitive Surgical launched two additional instruments and accessories for da Vinci X and Xi platforms in seven countries Notably  the company initiated a limited launch of a refined vessel sealer in Europe in the quarter  Management announced plans to file the first 510 k  for FDA approval of da Vinci SP program by 2017 and submissions for additional indications thereafter  For 2018  Intuitive Surgical has strong opportunities in the U S  general surgery market  particularly driven by procedures for hernia repair and colorectal surgery  Internationally  the company has significant opportunities in Japan  South Korea and China On the flip side  foreign exchange movements are affecting the company s results  Though Intuitive Surgical generates a major portion of revenues from the domestic market  continued investments in international businesses are widening the company s exposure to international markets  Hence  unfavorable foreign exchange is a major concern for 2018 Further  the Medical Product space  has been a precarious game for the Republicans since day one  courtesy of President Trump s repeated failure to repeal and replace Obamacare  However  major MedTech players like Intuitive Surgical have been pinning their hopes on Trump s promise to abolish the infamous 2 3  medical device sales tax  though its elimination is far from being achieved In this regard  let us not forget the massive chaos in the MedTech space triggered by the failure of the first Republican healthcare bill which was proposed this summer  The so called American Health Care Act  AHCA  failed to garner support in the House owing to solid opposition from conservative and moderate lawmakers  The persistent uncertainty has given rise to concerns regarding the sustainability of MedTech companies  including Intuitive Surgical Investors  optimism has been growing  thanks to President Trump s promise of  enactment of new tax reforms   However  the market has not benefited due to the lack of favorable developments in the regulatory front  Notably  this tax had been suspended for two years and is likely to be put into effect again on Jan 1  2018 Shares Shine BrightIntuitive Surgical s price movement has been robust over the last three months  The company represented a solid return of almost 6 8   comparing favorably with the r  s rally of just 2 9   The current level is a bit lower than the S P 500 index s gain of 8  Key PicksA few better ranked stocks in the broader medical sector are PetMed Express   NASDAQ PETS    Luminex Corporation   NASDAQ LMNX   and IDEXX Laboratories   NASDAQ IDXX   PetMed Express flaunts a Zacks Rank  1  Strong Buy   The company has a long term expected earnings growth rate of 10   You can see Luminex yielded a return of 6 4  over the last year  The stock flaunts a Zacks Rank  1 IDEXX Laboratories has a long term expected earnings growth rate of 19 8   The stock rose 39 2  over a year s time and carries a Zacks Rank  2  Buy  Zacks  Best Private Investment IdeasWhile we are happy to share many articles like this on the website  our best recommendations and most in depth research are not available to the public Starting today  for the next month  you can follow all Zacks  private buys and sells in real time  Our experts cover all kinds of trades  from value to momentum       from stocks under  10 to ETF and option moves       from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises  You can even look inside exclusive portfolios that are normally closed to new investors ,2017-12-20,Zacks Investment Research,https://www.investing.com/analysis/intuitive-surgical-banks-on-da-vinci-x-forex-woes-remain-200275118,200275118
112660,334175,ISRG,5 Reasons Why You Should Buy Abiomed  ABMD  Stock Right Now,opinion,Abiomed Inc    NASDAQ ABMD   is currently one of the top performing stocks in the MedTech space  Improvement in price performance and strong fundamentals signify the stock s bullish run  Therefore  if you haven t taken advantage of the share price appreciation yet  it s time you add the stock to your portfolio The company has performed impressively over the last year and has the potential to sustain the momentum in the upcoming period  A long term expected earnings growth rate of 31 5  holds promise for the stock Why an Attractive Pick Shares Shine BrightOver the last six months  Abiomed has gained 32  comparing favorably with the S P 500 index s rally of 12 1   The current level is also better than the  s gain of 4 3  The company s expanding product portfolio is a key catalyst in this regard  Also  cost savings efforts are encouraging factors  Northward Estimate RevisionsOne estimate for the current year moved north over the past 60 days against no southward revisions  reflecting analysts  optimism in the company  The Zacks Consensus Estimate for adjusted earnings increased 0 8  for the current year  The positive trend signifies analyst s bullish sentiment  The company holds a Zacks Rank  2  Buy   which indicates robust fundamentals and expectations of outperformance in the near term  You can see Strong Growth ProspectsThe company s Zacks Consensus Estimate of earnings of  2 42 for fiscal 2018 reflects year over year growth of 107   Moreover  earnings are expected to register 8  growth in fiscal 2018 The Zacks Consensus Estimate for fiscal 2018 revenues of  574 9 million reflects year over year improvement of 29 1   Moreover  revenues are expected to witness 27 5  growth in fiscal 2019 Abiomed forecasts fiscal 2018 revenues in the range of  565  575 million  This marks an increase of 27 29  from the fiscal 2016 level  Operating margin is projected in the band of 23 25  Positive Earnings Surprise HistoryAbiomed has an impressive earnings surprise history  The company outpaced the Zacks Consensus Estimate in the trailing four quarters  delivering a positive average earnings surprise of 10 8  ABIOMED  Inc  Price and Consensus   Impella Product LineAbiomed s expanding product portfolio will strengthen the company s foothold in the prophylactic high risk PCI and cardiogenic shock patient market  In this regard  the company s Impella line of products deserves a mention  Per management  Impella is the world s smallest heart pump  It is a support system of percutaneous  catheter based devices offering hemodynamic support to the heart Abiomed s Impella 2 5  Impella CP and Impella 5 0 are FDA approved pumps that treat cardiogenic shock  Furthermore  the Impella 2 5 and Impella CP are approved to treat urgent percutaneous coronary interventions  PCI  such as stenting or balloon angioplasty and cure blocked coronary arteries  The company s right side heart pump  the Impella RP device  cures right heart failure The company also has an Automated Impella Controller  which is the primary user control interface for the Impella platform featuring a highly exclusive10 inch high resolution display Per a research report by bcc Research  the global market for cardiac medical devices is projected to reach  67 5 billion by 2019 at a CAGR of 5 3  during 2014 2019  Considering the l prospects in the niche space  we expect Abiomed to gain solid market tractions in the years to come Other PicksOther top ranked stocks in the market at large are Integer Holdings Corporation   NYSE ITGR    Alibaba Group Holding Limited   NYSE BABA   and Intuitive Surgical  Inc    NASDAQ ISRG   Alibaba Group flaunts a Zacks Rank  1  The company has a long term expected earnings growth rate of 30 7  Integer Holdings has a long term expected earnings growth rate of 15   The stock carries a Zacks Rank  2 Intuitive Surgical has a long term expected earnings growth rate of 9 2   The stock carries a Zacks Rank  2 Zacks Editor in Chief Goes  All In  on This Stock Full disclosure  Kevin Matras now has more of his own money in one particular stock than in any other  He believes in its short term profit potential and also in its prospects to more than double by 2019  Today he reveals and explains his surprising move in a new Special Report ,2018-01-01,Zacks Investment Research,https://www.investing.com/analysis/5-reasons-why-you-should-buy-abiomed-abmd-stock-right-now-200277026,200277026
112661,334176,ISRG,Walgreens Boots  WBA  Tops Q1 Earnings  Margins Decline,opinion,"Walgreens Boots Alliance  Inc    NASDAQ WBA   reported adjusted earnings per share  EPS  of  1 28 in first quarter fiscal 2018  up 16 4  year over year and 15 5  at constant exchange rate  CER   Adjusted EPS surpassed the Zacks Consensus Estimate of  1 27 as well On a reported basis  net earnings came in at  821 million  reflecting a decrease of 22 1  from the prior year quarter  Reported earnings came in at 81 cents per share  showing a 16 5  decline on a year over year basis Total SalesWalgreens Boots recorded total sales of  30 74 billion in the fiscal first quarter  up 7 9  year over year and 7 2  at CER  The top line outpaced the Zacks Consensus Estimate of  30 33 billion Segments in DetailWalgreens Boots currently reports under three operating segments  Retail Pharmacy USA  Retail Pharmacy International and Pharmaceutical Wholesale The Retail Pharmacy USA division recorded sales of  22 5 billion in the first quarter  highlighting an increase of 8 9  on a year over year basis  Within this segment  total sales at comparable drugstores rose 4 7   while prescriptions filled in comparable stores grew 8 9  on account of Medicare Part D growth and volume growth from previously announced strategic pharmacy collaborations  Comparable retail sales dropped 0 9  due to lower sales at the consumables and general merchandise category and the personal care category  partially offset by increased sales in the health and wellness as well as beauty categories Pharmacy sales  which accounted for 72 4  of the Retail Pharmacy USA division s sales in the quarter  increased 14 1  from the year ago quarter  Pharmacy sales at comparable stores rose 7 4  on higher volumes Revenues at the Retail Pharmacy International division rose 4 1  on a year over year basis  down 0 8  at CER  to  3 1 billion owing to currency fluctuations  At CER  comparable store sales in the first quarter decreased 0 7  year over year along with a 0 1  decline in comparable pharmacy sales The Pharmaceutical Wholesale division recorded quarterly sales of  5 7 billion  up 5 6  year over year  up 4 5  at CER  Walgreens Boots Alliance  Inc  Price  Consensus and EPS Surprise 
    MarginsGross profit in the reported quarter increased 3 1  year over year to  7 34 billion  However  reported gross margin contracted 100 basis points  bps  to 23 9  Selling  general and administrative  SG A  expenses were up 3 9  year over year to  5 91 billion  However  adjusted operating income remained flat at  1 43 billion  Adjusted operating margin contracted 30 bps to 4 7  Financial ConditionWalgreens Boots exited the first quarter with cash and cash equivalents of  1 83 billion  compared with  3 30 billion at the end of fiscal 2017  Long term debt was  12 74 billion  compared with  12 68 billion at the end of the fiscal 2017 The company generated operating cash flow of  961 million in first quarter fiscal 2018  compared with  525 million a year ago  The resultant free cash flow was  583 million in the quarter under review GuidanceWalgreens Boots has raised the low end of its outlook for fiscal 2018 by 5 cents per share and anticipates adjusted EPS of  5 45 to  5 70 compared with the previously provided range of  5 40  5 70  The Zacks Consensus Estimate for fiscal 2018 earnings is pegged at  5 54  within the company s guided range However  per management  the adjusted EPS outlook for fiscal 2018 does not include any impact from the latest U S  tax legislation  which slashes corporate tax rates from 35  to 21   Moreover  the guidance assumes current exchange rates for the rest of the fiscal Our TakeWalgreens Boots reported an impressive first quarter of fiscal 2018  We are also encouraged by the increase in sales at the Retail Pharmacy International segment  Moreover  Walgreens Boots has been gaining on account of the company s strategic tie ups  which brought more patients to its U S  pharmacies We are also upbeat about the Rite Aid acquisition deal for which the company got regulatory approval in September 2017  Per Walgreens Boots  this modified merger contract is in line with its growth strategy and offers additional operational benefits  It will also help the company expand and optimize retail pharmacy network in key U S  markets  including the Northeast Also  we are upbeat about the company expanding global footprint with its decision to acquire a 40  stake in Sinopharm Holding Guoda Drugstores Co   Ltd   GuoDa   a subsidiary of China National Accord Medicines Corporation Ltd  On completion  this investment should provide a strong impetus to Walgreens Boots  worldwide retail pharmacy business  Notably  Shanghai based GuoDa is a large national pharmacy chain in China  It is the retail pharmacy platform of China National Pharmaceutical Group Corporation  CNPGC  Moreover  the company s acceptance of the proposal to sell part of its investment in its Chinese wholesale partner Guangzhou Pharmaceuticals Corporation for huge cash returns buoys optimism Zacks Rank   Key PicksWalgreens Boots carries a Zacks Rank  3  Hold   A few better ranked stocks in the broader medical sector are Bio Rad Laboratories  Inc    NYSE BIO    Integer Holdings Corporation   NYSE ITGR   and Intuitive Surgical  Inc    NASDAQ ISRG   
Bio Rad Laboratories flaunts a Zacks Rank  1  Strong Buy   The company has a long term expected earnings growth rate of 25  and has gained 34 8  over a year  You can see Intuitive Surgical has a long term expected earnings growth rate of 9 2   The stock carries a Zacks Rank  2  Buy  and has gained 82  in a year s time Integer Holdings has a long term expected earnings growth rate of 15   The stock carries a Zacks Rank  2 and has gained 54 7  in a year Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2018-01-03,Zacks Investment Research,https://www.investing.com/analysis/walgreens-boots-wba-tops-q1-earnings-margins-decline-200277650,200277650
112681,334196,ISRG,Bio Rad  BIO  Beats Earnings And Revenue Estimates In Q3,opinion,Bio Rad Laboratories  Inc    NYSE BIO   reported third quarter 2017 earnings of 91 cents per share  a 46 8  surge from the year ago figure  The bottom line also surpassed the Zacks Consensus Estimate of 33 cents by a wide margin  Notably  net income in the quarter was favorably impacted by higher sales and a significantly improved gross margin  Net sales came in at  535 million  up 5 2  year over year  up 3 4  at constant exchange rate or CER   The top line also beat the Zacks Consensus Estimate of  521 million by 2 7   The year over year improvement in sales was largely driven by a strong performance in the Europe and Asia Pacific  Also  Bio Rad registered solid growth across many key life science and diagnostics product areas Quarter in DetailOn a segmental basis  the Life Science s net sales came in at  193 6 million  up 8 7  year over year  up 7 6  at CER   At CER  sales rose on the back of a strong performance at Droplet Digital PCR  ddPCR   food safety and gene expression product lines as well as revenues generated from the recent acquisition of RainDance Technologies  This growth was however  offset by a decrease in process chromatography media sales Bio Rad Laboratories  Inc  Price  Consensus and EPS Surprise   Within Clinical Diagnostics  the company registered sales of  338 million  up 3 3  year over year  up 1 2  at CER   This upside resulted from an increase in blood typing  immunology and quality control product lines Gross margin of 56 9  during the reported quarter was up 199 basis points  bps  year over year on an 8 9  climb in gross profits  Adjusted operating margin in the same period expanded 315 basis points to 8 7  with 65 1  rise in operating profit The company exited the third quarter with cash and cash equivalents plus short term investments of  721 million compared with  717 million at the end of the second quarter  Year to date  net cash provided by operating activities was  34 5 million compared with  121 3 million in the year ago period 2017 Guidance For fourth quarter 2017  Bio Rad expects net sales in the range of  615  625 million  This includes sales from the recently acquired RainDance Technologies  The stock has seen the Zacks Consensus Estimate for current quarter s sales being pegged at  617 2 million within the projected band  Fourth quarter gross margin is anticipated to be within 54 5 55   in line with the year to date results  The operating margin for the fourth quarter of 2017 is anticipated to be within the band of 9 5 10 5  Bottom LineBio Rad posted a strong quarterly show with both earnings and sales beating the Zacks Consensus Estimate by significant margins  Sales growth was majorly driven bystrong sales of Droplet Digital PCR instruments and consumables  cell biology and food safety products in the life science group  Also  strong growth in product for blood typing  quality control and autoimmune testing in the diagnostic group contributed to the top line boost in the quarter under review Zacks Rank   Key PicksBio Rad has a Zacks Rank  3  Hold   A few better rankedmedical stocks are PetMed Express  Inc    NASDAQ PETS    Luminex Corporation   NASDAQ LMNX   and Intuitive Surgical  Inc    NASDAQ ISRG    While PetMed and Luminex sport a Zacks Rank  1  Strong Buy   Intuitive Surgical carries a Zacks Rank  2  Buy   You can see PetMed reported earnings per share of 43 cents in the second quarter of fiscal 2018  up 79 2  from the year ago quarter s 24 cents  Also  gross margin expanded 548 bps year over year to 35 2  in the reported quarter Luminex reported adjusted earnings per share of 19 cents in the third quarter of 2017  up 216 7  year over year  Revenues increased almost 4 1  year over year to  74 1 million Intuitive Surgical posted adjusted earnings of  2 77 per share in the third quarter of 2017  up 34 5  on a year over year basis  Also  revenues grew 18  year over year to  806 1 million Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2017-11-12,Zacks Investment Research,https://www.investing.com/analysis/biorad-bio-beats-earnings-and-revenue-estimates-in-q3-200264615,200264615
112682,334197,ISRG,Weight Watchers  WTW  To Issue  500M Senior Notes Due 2025 ,opinion,"Weight Watchers International Inc    NYSE WTW   recently announced an offering of  500 million senior notes  due in 2025  The notes will be unsecured and will be guaranteed by the company s subsidiaries  The company intends to enter into a new  150 million revolving credit facility to refinance its existing one Share Price MovementWeight Watchers  share price movement in the past six months has been impressive  The company s shares have returned almost 78  compared with the  s rally of just 7 4   The current level is also higher than the S P 500 s return of 7 6  Coming back to the news  the interest rate  conversion rate and certain other terms of the notes are yet to be determined  The company intends to use the net proceeds of the offering  expected borrowings from a proposed new term loan facility worth  1 390 million and cash on hand to repay all amounts outstanding under its existing credit facilities  Weight Watchers  plans to terminate such facilities and pay related fees and expenses We believe that the company s strong balance sheet will help aid in capitalizing investment opportunities and pursuing strategic acquisitions  which will improve prospects  Moreover  the senior notes offering will reduce the company s cost of capital  thus strengthening balance sheet and supporting growth Weight Watchers is the largest provider of weight control programs in the world  The core of their business is weekly meetings  wherein they demonstrate scientifically designed programs  incorporate group support and educate about healthy eating patterns  behavior modification and physical activity Zacks Rank   Key PicksCurrently  Weight Watchers carries a Zacks Rank  3  Hold  A few better ranked stocks in the broader medical sector are PetMed Express   NASDAQ PETS    Luminex Corporation   NASDAQ LMNX   and Intuitive Surgical   NASDAQ ISRG   Notably  PetMed Express sports a Zacks Rank  1  Strong Buy   The company has a long term expected earnings growth rate of 10   You can see  Luminex represented a stellar return of 6 4  over the last year  The stock flaunts a Zacks Rank  1 Intuitive Surgical has a long term expected earnings growth rate of 9 1   The stock has a Zacks Rank  2  Buy  
Today s Stocks from Zacks  Hottest Strategies
It s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively 
And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2017-11-14,Zacks Investment Research,https://www.investing.com/analysis/weight-watchers-wtw-to-issue-500m-senior-notes-due-2025-200265157,200265157
112683,334198,ISRG,The Zacks Analyst Blog Highlights  Activision  Marriott  Intuitive Surgical  Edison International And TELUS,opinion,For Immediate ReleaseChicago  IL   November 15  2017   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include Activision   NASDAQ ATVI    Marriott   NASDAQ MAR    Intuitive Surgical   NASDAQ ISRG    Edison International   NYSE EIX   and TELUS   NYSE TU   Today  Zacks is promoting its   Buy   stock recommendations   Here are highlights from Tuesday s Analyst Blog  Top Stock Reports for Activision  Marriott and SurgicalThe Zacks Research Daily presents the best research output of our analyst team  Today s Research Daily features new research reports on 16 major stocks  including Activision     Marriott    and Intuitive Surgical     These research reports have been hand picked from the roughly 70 reports published by our analyst team today You can see Buy ratedActivision s shares have been strong performers this year  with the stock up  76 2  in the year to date period vs  the Zacks Toys  Games and Hobbies industry s  48 7  gain in that same time period  Activision s third quarter 2017 results benefitted from increasing digital revenues  King Digital buyout and strength in franchises  Activision also raised guidance for the full year The Zacks analyst likes the company s attempts to become a broad based media company  Apart from launching a movie studio and consumer products division  the company is also strengthening its presence in the lucrative e sports market Activision had added twelve teams in the e sports league for its newest franchise  Overwatch  However  hit driven and competitive nature of the video game industry begets caution  You can Shares of Buy rated Marriott have outperformed the Zacks Hotels industry in the year to date period  the stock is up  45 6  vs   16 2  gain for the industry   Marriott s third quarter 2017 adjusted earnings exceeded expectations and rose 26 4  year over year Notably  with the acquisition of Starwood  Marriott became the world s largest hotel company  In fact  this buyout is likely to result in a bigger brand with increased scale and a robust development pipeline in the long run  The Zacks analyst likes Marriott s rising North American business  sizeable international exposure and attractive brand position These factors are likely to continue to drive growth  Yet  lingering political uncertainties in key international markets and currency headwinds might continue to limit revenue growth  Moreover  integration risks linked to Starwood purchase is an added concern  Even so  its investments in technology for hotel bookings are anticipated to improve guest experience  which in turn might boost occupancy  You can  Buy rated Intuitive Surgical s shares have outperformed the Zacks Medical Instruments industry over the last three months  gaining  19 4  vs  5 3   Its third quarter earnings and revenues both topped expectations The company s procedure performance in Asia showed continued strength with solid growth in China  Japan and Korea  Intuitive Surgical gained significantly on the CE Mark approval for da Vinci X in Europe  The stock received a further boost on the recent FDA approval for da Vinci X The Zacks analyst likes the company s solid outlook for the coming quarters  Further  incremental spending on product development and higher investments in international markets are prudent moves that are likely to drive long term growth  The company is also expected to enhance its organizational capabilities and gain prominence in the markets of Europe and Asia  You can  Other noteworthy reports we are featuring today Edison International    and TELUS    Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation Today  Zacks is promoting its   Buy   stock recommendations   About Zacks Equity ResearchZacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long term Continuous coverage is provided for a universe of 1 150 publicly traded stocks  Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance  Recommendations and target prices are six month time horizons Strong Stocks that Should Be in the NewsMany are little publicized and fly under the Wall Street radar  They re virtually unknown to the general public  Yet today s 220 Zacks Rank  1  Strong Buys  were generated by the stock picking system that has nearly tripled the market from 1988 through 2015  Its average gain has been a stellar  26  per year Follow us on Twitter  Join us on Facebook  NASDAQ FB   Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates Media ContactZacks Investment Research800 767 3771 ext  9339Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ,2017-11-14,Zacks Investment Research,https://www.investing.com/analysis/the-zacks-analyst-blog-highlights-activision-marriott-intuitive-surgical-edison-international-and-telus-200265452,200265452
112684,334199,ISRG,Intuitive Surgical  ISRG  To Gain From Procedural Business,opinion,"On Nov 15  we issued an updated research report on Intuitive Surgical Inc    NASDAQ ISRG     manufacturer of the da Vinci surgical system  an advanced robot assisted surgical system  and related instruments and accessories   Among major positives  the Sunnyvale based company has had an impressive run on the bourses  of late  A glimpse at the recent price performance reveals a favorable return of 81 7  in the past year compared  with the  s rally of 20 1   The company has a solid track record characterized by earnings beats in all of the trailing four quarters   Recently  Intuitive Surgical reported stellar performance on the back of higher adoption of the da Vinci system among physicians and overall growth in global procedures  The system enables minimally invasive surgery that helps avoid the trauma associated with open surgery  The company s performance was also driven by growing volumes  courtesy of general surgery  oncology  urology and gynecology procedures Intuitive Surgical consistently introduces technologies for surgical systems  The company plans to launch an upgrade   da Vinci X   to its flagship Vinci Xi technology  Management confirmed the submission of documents for CE Mark approval of Vinci X  Further  the company expects availability of this device in Europe by the end of 2017  In the long haul  extensive expenditure on product pipeline and expansion in international markets like Europe should drive growth for the company On the flipside  the company expects procedure growth rate to slow down outside the United States in the upcoming quarters  The lengthy sale and purchase order cycle of the da Vinci system has added to the company s woes  Also  expenses on research and development  R D  increased significantly in the first half of 2017  reflecting high spending on advanced imaging  advanced instrumentation and next generation robotics Zacks Rank   Key PicksIntuitive Surgical carries a Zacks Rank  3  Hold  A few better ranked medical stocks are PetMed Express  Inc    NASDAQ PETS    Align Technology  Inc    NASDAQ ALGN   and Myriad Genetics  Inc    NASDAQ MYGN    All these stocks sport a Zacks Rank  1  Strong Buy   You can see  PetMed has a long term expected earnings growth rate of 10   The stock has rallied roughly 71 8  in the last year Align Technology has a long term expected earnings growth rate of 28 9   The stock has gained 170 1  in the last year Myriad Genetics has a long term expected earnings growth rate of 15   The stock has gained 87 1  in the last year 
Zacks  Best Private Investment Ideas
While we are happy to share many articles like this on the website  our best recommendations and most in depth research are not available to the public 
Starting today  for the next month  you can follow all Zacks  private buys and sells in real time  Our experts cover all kinds of trades  from value to momentum       from stocks under  10 to ETF and option moves       from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises  You can even look inside exclusive portfolios that are normally closed to new investors ",2017-11-15,Zacks Investment Research,https://www.investing.com/analysis/intuitive-surgical-isrg-to-gain-from-procedural-business-200265752,200265752
112708,334223,ISRG,Penumbra  PEN  Posts Earnings  Revenues Top Estimates In Q3,opinion,Penumbra  Inc    NYSE PEN   reported third quarter 2017 earnings per share of a penny  comparing favorably with a loss of 4 cents in the year ago quarter  The figure is also better than the Zacks Consensus Estimate of a loss of 7 cents Revenues in the reported quarter rose 24 9  year over year  up 24 1  at constant exchange rate or CER  to  83 9 million  exceeding the Zacks Consensus Estimate of  79 million On a geographic basis  third quarter revenues in the United States  representing 66 3  of total sales  grossed  55 7 million  up 25 4  from the year ago quarter  same at CER   Meanwhile  international sales  33 7  of total sales  advanced 23 9  year over year  up 21 5  at CER  to  28 3 million Penumbra  Inc  Price  Consensus and EPS Surprise   Going by product category  revenues from neuro products grew 23 4   up 22 5  at CER  to  58 7 million in the quarter under review  Revenues from peripheral vascular product business rose to  25 2 million in the third quarter  reflecting an increase of 28 4   up 27 8  at CER  year over year Operational UpdatePenumbra s third quarter gross margin was 65 3   reflecting a 147 basis point  bps  expansion year over year  Gross profit rose 27 8  Research and development expenses totaled  8 1 million  up 25 2   while sales  general and administrative expenses amounted to  45 9 million  up 21 8  year over year  Operating profit in the reported quarter came in at  0 7 million  comparing favorably with the operating loss of  1 3 million in the prior year quarter Financial UpdatePenumbra exited the third quarter of 2017 with cash and cash equivalents of  65 6 million as compared with  76 6 million at the end of the second quarter Our TakePenumbra exited third quarter 2017 with better than expected results  The year over year comparison of earnings was favorable  Moreover  the company witnessed strong growth across all geographies and product lines  The company is focusing on product innovation through research and development Penumbra is an active player in the fast growing interventional therapies space  In fact  the company s products primarily cater to the unmet clinical needs in two major markets   neuro and peripheral vascular Zacks Rank   Key PicksPenumbra has a Zacks Rank  3  Hold  A few better ranked stocks in the broader medical sector are PetMed Express  Inc    NASDAQ PETS    Luminex Corporation   NASDAQ LMNX   and Intuitive Surgical  Inc    NASDAQ ISRG    Notably  PetMed and Luminex sport a Zacks Rank  1  Strong Buy   while Intuitive Surgical carries a Zacks Rank  2  Buy   You can see PetMed reported earnings per share of 43 cents in the second quarter of fiscal 2018  up 79 2  from the year ago quarter s 24 cents  Also  gross margin expanded 548 bps year over year to 35 2  in the reported quarter Luminex reported adjusted earnings per share of 19 cents in the third quarter of 2017  up 216 7  year over year  Revenues increased almost 4 1  year over year to  74 1 million Intuitive Surgical posted adjusted earnings of  2 77 per share in the third quarter of 2017  up 34 5  year over year  Revenues rose 18  year over year to  806 1 million Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2017-11-07,Zacks Investment Research,https://www.investing.com/analysis/penumbra-pen-posts-earnings-revenues-top-estimates-in-q3-200263510,200263510
112709,334224,ISRG,VWR Q3 Earnings Top  Sell Off To Avantor Approaching Closure,opinion,VWR Corporation   NASDAQ VWR   reported third quarter 2017 adjusted earnings per share  EPS  of 54 cents  reflecting a 22 7  rise from the year ago figure  The bottom line also surpassed the Zacks Consensus Estimate of 46 cents by 17 4  on strong top line performance Including one time items  the company reported third quarter net EPS of 37 cents  up 19 4  year over year Revenues in the reported quarter were up 5 2  year over year to  1 2 billion  The figure also surpassed the Zacks Consensus Estimate of  1 18 billion  On an organic basis  revenues increased 2 2  VWR Corporation Price  Consensus and EPS Surprise   Revenues in the Americas totaled  717 6 million  up 1 4  year over year  down 0 8  organically  in the quarter under review  The decline in Americas  organic growth was due to one less billing day in the third quarter  Organic revenue growth further reduced as a result of the adverse weather conditions in Puerto Rico  Texas and Florida EMEA APAC revenues in the quarter grossed  477 6 million  up 11 5  year over year and up 7 4  on an organic basis  Foreign exchange boosted sales by 4 4   while acquisition less dispositions dented revenues by  0 8 million VWR reported third quarter gross margin of 27 9   an expansion of 40 basis points year over year  Sales  general and administrative expenses rose 9 2  to  251 5 million  The company posted operating income of  83 1 million  flat year over year  Operating margin contracted 37 basis points to 6 9  Merger UpdatePost first quarter earnings release  VWR had inked a definitive agreement with Avantor  Inc  to get acquired by the latter for an enterprise value of  6 4 billion  In view of this  VWR no longer plans to provide or update any financial guidance  The acquisition is expected to complete in fourth quarter 2017 Our TakeVWR s third quarter report was quite impressive with both the top and the bottom line beating the Zacks Consensus Estimate  Geographically  the company recorded growth in the Americas and EMEA APAC during the same period On a brighter note  management looks forward to benefits from the proposed merger with Avantor  already in process  The combined entity s suite of products  services and solutions will help the company generate a higher degree of relevance with Biopharma and Industrial customers  Also  the buyout is expected to generate significant synergies over the next three years  In addition  the transaction is likely to create a robust product and service portfolio for production scale biopharma  Furthermore  this deal will help strengthen VWR s business in the Asia Pacific region Zacks Rank   Key PicksVWR currently has a Zacks Rank  3  Hold   A few better ranked stocks in the broader medical sector are PetMed Express  Inc    NASDAQ PETS    Luminex Corporation   NASDAQ LMNX   and Intuitive Surgical  Inc    NASDAQ ISRG    Notably  PetMed and Luminex sport a Zacks Rank  1  Strong Buy   while Intuitive Surgical carries a Zacks Rank  2  Buy   You can see PetMed reported earnings per share of 43 cents in the second quarter of fiscal 2018  up 79 2  from the year ago quarter s 24 cents  Also  gross margin expanded 548 bps year over year to 35 2  in the reported quarter Luminex reported adjusted earnings per share of 19 cents in the third quarter of 2017  up 216 7  year over year  Revenues increased almost 4 1  year over year to  74 1 million Intuitive Surgical posted adjusted earnings of  2 77 per share in the third quarter of 2017  up 34 5  year over year  Also  revenues rose 18  year over year to  806 1 million Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2017-11-07,Zacks Investment Research,https://www.investing.com/analysis/vwr-q3-earnings-top-selloff-to-avantor-approaching-closure-200263505,200263505
112710,334225,ISRG,Haemonetics  HAE  Q2 Earnings Beat Estimates  EPS View Up,opinion,Haemonetics Corporation   NYSE HAE   reported adjusted earnings per share  EPS  of 48 cents in the second quarter of fiscal 2018  up 4 3  year over year  The bottom line also beat the Zacks Consensus Estimate of 41 cents On a reported basis  Haemonetics posted earnings of 38 cents  flat year over year Total RevenuesRevenues were up 2 3  year over year  up 2 1  at constant exchange rate or CER  to  225 4 million in the reported quarter  The top line also exceeded the Zacks Consensus Estimate of  220 million Haemonetics Corporation Price  Consensus and EPS Surprise   Geographically  Haemonetics witnessed a 6 1  year over year  same at CER  rise in revenues in North America to  138 8 million  However  international revenues declined 3 1   down 3 7  at CER  to  86 6 million Revenues by Product CategoriesHaemonetics reports operating results under four business franchises  Plasma  Haemostasis Management  Cell Processing and Blood Center At Plasma  reported revenues of  109 8 million  48 7  of total revenues  were up 6  year over year  up 5 7  at CER  Revenues at BloodCenter  31 8  of total revenues  declined 3 4   down 3 8  at CER  to  71 7 million Hemostasis Management franchise revenues  8  of total revenues  rose 10 1   up 10 4  at CER  to  18 1 million  Revenues from Cell Processing dipped 0 7   down 0 8  at CER  to  25 8 million  11 4  of total revenues  MarginsHaemonetics  second quarter gross margin was 46 4   down 94 basis points  bps  year over year Operating income was  24 2 million in the second quarter of fiscal 2018  a 2 1  slip year over year  Operating margin contracted 49 bps year over year to 10 8  in the quarter Financial PositionHaemonetics exited the second quarter of fiscal 2018 with cash and cash equivalents of  203 6 million compared with  171 7 million at the end of the preceding year  The company s long term obligations  long term debt and other long term liabilities  were  214 8 million in the quarter under review  down from  237 2 million at the end of the first quarter of fiscal 2018  Haemonetics generated operating cash flow of  97 3 million compared with  69 9 million in the year ago period  Adjusted free cash flow  before transformation and restructuring costs  was  75 3 million this quarter compared with  41 3 million a year ago Fiscal 2018 GuidanceHaemonetics reaffirmed its fiscal 2018 revenue guidance  The company still expects full year revenues to be in line with fiscal 2017 revenues  The guidance for Plasma revenue growth remains unchanged in the 3 5  range  Hospital revenue growth is expected within 7 10   unchanged  band  Blood Center revenues are expected to decline in the range of 7 10   same as the previous guidance  The stock has seen the Zacks Consensus Estimate for 2018 sales being pegged at  889 5 million However  the company raised its 2018 adjusted EPS guidance to a new range of  1 65  1 75 from the earlier band of  1 55  1 65  The Zacks Consensus Estimate of  1 61 remains below the guided range Our TakeHaemonetics exited second quarter fiscal 2018 on a promising note with earnings and revenues both beating the Zacks Consensus Estimate  Continued momentum in new business generation and geographical expansions have helped the company deliver strong results in the recent past  However  we are disappointed with the fact that despite encouraging growth noticed in the Plasma and Hospitals  the company s sluggish Blood Center business moderated the overall growth in the reporting cycle The company s strong cash position boosts investors  confidence  It is also optimistic about the strong market adoption of its NexSys PCS plasmapheresis system  which recently received an FDA approval  The company s increased fiscal 2018 adjusted earnings guidance is also impressive Zacks Rank   Other Key PicksHaemonetics currently has a Zacks Rank  2  Buy   A few other top ranked stocks in the broader medical sector are PetMed Express  Inc    NASDAQ PETS    Luminex Corporation   NASDAQ LMNX   and Intuitive Surgical  Inc    NASDAQ ISRG    PetMed and Luminex sport a Zacks Rank  1  Strong Buy   while Intuitive Surgical carries a Zacks Rank of 2  You can see PetMed reported earnings per share of 43 cents in the second quarter of fiscal 2018  up 79 2  from the year ago quarter s 24 cents  Also  gross margin expanded 548 bps year over year to 35 2  in the reported quarter Luminex reported adjusted earnings per share of 19 cents in the third quarter of 2017  up 216 7  year over year  Revenues increased almost 4 1  year over year to  74 1 million Intuitive Surgical posted adjusted earnings of  2 77 per share in the third quarter of 2017  up 34 5  year over year  Also  revenues rose 18  year over year to  806 1 million Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2017-11-07,Zacks Investment Research,https://www.investing.com/analysis/haemonetics-hae-q2-earnings-beat-estimates-eps-view-up-200263495,200263495
112711,334226,ISRG,Inogen  INGN  Beats Earnings And Revenue Estimates In Q3,opinion,"Inogen Inc    NASDAQ INGN   reported third quarter 2017 earnings of 33 cents per share which comfortably beat the Zacks Consensus Estimate of 29 cents and improved from the year ago figure of 16 cents The upside was driven by roughly 26 8  growth in revenues  which totaled  69 million and surpassed the Zacks Consensus Estimate of  64 0 million Q3 DetailsSales revenues surged 33 8  to  63 1 million  while rental revenues declined 18 7  to  5 9 million Total gross margin was 48 1   up from  46 2  in the comparative period of 2016  Sales gross margin was 50 3  compared with 48 6  in the prior year quarter  The improvement was primarily attributable to increased mix toward direct to consumer sales and lower cost of goods sold per unit  This was partially offset by declining business to business average selling prices  Rental gross margin was 24 3  versus 30 7  in the year ago quarter  The downside resulted from reimbursement rate reductions  This was partially offset by reduced cost of rental revenues primarily associated with lower depreciation Inogen  Inc Price  Consensus and EPS Surprise
    General and administrative expenses were  10 4 million  up from  8 7 million in the comparative quarter of 2016  This was primarily due to  0 6 million of patent litigation settlement expenses  increased personnel related expenses and higher patent defense legal costs GuidanceConsidering the solid performance in the third quarter  Inogen raised its guidance for 2017 revenues to the range of  244  248 million  compared with the previous  239  243 million  This represents year over year growth of 20 3  to 22 3  Our TakeInogen reported stellar third quarter 2017 results  beating the Zacks Consensus Estimate for both the counts  The company witnessed solid growth in revenues and adjusted earnings on a year over year basis  In our view  solid domestic and international business to business sales have led to the impressive quarterly performance  In the upcoming quarters  the company expects direct to consumer sales to be its fastest growing channel followed by domestic business to business sales  In this context  the company recently signed a lease for its expansion site in Ohio to accelerate growth in domestic direct to consumer sales channel On the flip side  declining rental might mar the company s prospects  Since the company generates a significant portion of its revenues from the international market  volatile foreign exchange rate will always pose a concern Zacks Rank   Key PicksInogen currently carries a Zacks Rank  3  Hold  A few better ranked stocks in the broader medical sector are PetMed Express  Inc    NASDAQ PETS    Luminex Corporation   NASDAQ LMNX   and Intuitive Surgical  Inc    NASDAQ ISRG    PetMed and Luminex sport a Zacks Rank  1  Strong Buy   while Intuitive Surgical carries a Zacks Rank  2  Buy   You can see  PetMed reported earnings per share of 43 cents in the second quarter of fiscal 2018  up 79 2  from the year ago quarter s 24 cents  Also  gross margin expanded 548 basis points year over year to 35 2  in the reported quarter Luminex reported adjusted earnings per share of 19 cents in the third quarter of 2017  up 216 7  year over year  Revenues increased almost 4 1  year over year to  74 1 million Intuitive Surgical posted adjusted earnings of  2 77 per share in the third quarter of 2017  up 34 5  year over year  Also  revenues rose 18  year over year to  806 1 million 
Wall Street s Next Amazon  NASDAQ AMZN 
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2017-11-08,Zacks Investment Research,https://www.investing.com/analysis/inogen-ingn-beats-earnings-and-revenue-estimates-in-q3-200263477,200263477
112712,334227,ISRG,Align Technology At 52 Week High  What s Driving The Stock ,opinion,Share price of Align Technology  Inc    NASDAQ ALGN   scaled a new 52 week high of  246 84 on Nov 7  closing nominally lower at  246 46  The company has gained 78 4  over the last six months  much higher than the S P 500 s gain of 8 2   Align Technology has also beat the broader  s gain of 5 3  with respect to share price over the last six months  The stock has a market cap of  19 76 billion Further  Align Technology s estimate revision trend for the current year is favorable  In the past 60 days  nine estimates moved up while one shifted down  Consequently  estimates were up from  3 40 per share to  3 56 The company also has a trailing four quarter average positive earnings surprise of 16 6   Its positive long term growth of 28 9  holds promise as well  The company s five year historical growth rate is also favorable at 19 5  as compared with the broader industry s 8 4  and the S P 500 s 2 8  Align Technology sports a Zacks Rank  1  Strong Buy   The company has an impressive Growth  of B  Our Growth Style Score highlights all the vital metrics of a company s financials to obtain a clearer picture of the quality and sustainability of its growth  Our research shows that stocks with Style Scores of A or B when combined with a Zacks Rank  1  2  Buy  or 3  Hold  offer the best investment opportunities  Align Technology  Inc  Price and Consensus     Growth DriversThe market is upbeat about Align Technology s recently reported impressive third quarter performance  The year over year growth in earnings and revenues is encouraging  Additionally  the company has a strong cash balance that enables it to carry out share repurchases and in turn provide solid returns to investors  The expansion in gross and operating margin also buoys optimism  The company is also constantly investing in R D for product innovation Recently  the company opened its first office in Canada to support growth in the region  According to the company  Canada is its second largest market based on Invisalign case volumes Align Technology has also become part of the NASDAQ 100 Index and the NASDAQ 100 Equal Weighted Index recently All these factors are expected to boost the company s share price Other Key PicksOther top ranked stocks in the broader medical sector are PetMed Express  Inc    NASDAQ PETS    Luminex Corporation   NASDAQ LMNX   and Intuitive Surgical  Inc    NASDAQ ISRG    Notably  PetMed and Luminex sport a Zacks Rank  1  while Intuitive Surgical carries a Zacks Rank  2  You can see PetMed has a long term expected earnings growth rate of 10   The stock has rallied roughly 91 7  over the last year Luminexhas a long term expected earnings growth rate of 16 3   The stock has gained 8 6  in the last year Intuitive Surgical has a long term expected earnings growth rate of 9 1   The stock has gained 71 2  in the last year Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2017-11-08,Zacks Investment Research,https://www.investing.com/analysis/align-technology-at-52week-high-whats-driving-the-stock-200263473,200263473
112713,334228,ISRG,Myriad Genetics  MYGN  Beats On Q1 Earnings   Revenues ,opinion,"Myriad Genetics  Inc    NASDAQ MYGN   reported adjusted earnings per share  EPS  of 26 cents in the first quarter of fiscal 2018  up 13  year over year  Moreover  adjusted EPS beat the Zacks Consensus Estimate by 23 8  and surpassed the company s guided range of 19 21 cents Reported net income came in at  81 1 million or earnings of  1 15 per share in the quarter  against a net loss of  1 2 million or loss of 2 cents per share in the year ago quarter RevenuesTotal revenues rose 7 2  year over year to  190 2 million in the first quarter  The figure also outpaced the Zacks Consensus Estimate of  182 3 million and the company s guidance range of  181  183 million  The year over year rise in the top line was primarily on account of strong demand for Hereditary Cancer and GeneSight tests  
Myriad Genetics  Inc  Price  Consensus and EPS Surprise
     Quarter in DetailsSegment wise  Molecular diagnostic tests  94  of total revenue  recorded total revenues of  178 8 million  up 8 3  year over year  mainly on account of a 300  rise in GeneSight testing revenues to  28 8 million  EndoPredict testing revenues grew 11 8  year over year to  1 9 million in the reported quarter  Moreover  Vectra DA testing revenues came in at  16 million  up 37 9  year over year  while other testing revenues rose 4 2  to  2 5 million In the Prolaris testing space  volumes continued to grow double digits in the fiscal first quarter  However  Prolaris tests registered revenues of  2 9 million in the quarter  flat year over year  Also  Hereditary Cancer testing revenues dropped 9  year over year to  126 7 million  while volumes grew year over year for the third consecutive quarter with pricing at par with expectations Pharmaceutical and clinical service revenues  accounting for the rest  in the quarter totaled  11 4 million  reflecting a year over year decline of 8 1  Margin TrendsGross margin in the quarter under review contracted 10 basis points  bps  to 77 4   According to management  the gross margin performance was adversely affected by Hereditary Cancer test pricing issue but partially offset byimproved efficiencies in Hereditary Cancer production process  rising margin from GeneSight business and increasing new product reimbursement Operating expenses rose 1 3  to  133 million owing to a 2 9  rise in selling  general and administrative  SG A  expenses to  115 2 million  Research and development  R D  expenses  however  declined 8 2  to  17 8 million in the reported quarter  Overall  operating margin increased 400 bps to 7 5  Financial PositionMyriad Genetics exited the fiscal first quarter with cash  cash equivalents and marketable securities of  148 3 million  compared with  150 7 million at the end of fiscal 2017  Year to date  cash flow from operations totaled  23 5 million  as against net cash used for the same of  2 9 million in the year ago period  Also  during the quarter  the company registered free cash flow of  22 7 million  compared with  4 6 million in the year ago period GuidanceMyriad Genetics has reiterated the guidance for fiscal 2018  The company continues to expect revenues in the range of  750  770 million  The Zacks Consensus Estimate of  764 2 million lies within the guided range On the bottom line front  the company expects to generate adjusted EPS in the range of  1 00  1 05  The current Zacks Consensus Estimate of  1 04 is within but near to the higher end of the company s guidance range Management has provided the guidance for the second quarter of fiscal 2018  The company estimates adjusted earnings per share of 22 24 cents on total revenues of  187  189 million  The Zacks Consensus Estimate for adjusted EPS of 25 cents and revenues of  190 million exceeds the company s guided range  Our ViewMyriad Genetics kick started fiscal 2018 on a solid note with its first quarter numbers exceeding the Zacks Consensus Estimate  The company observed strong growth in both GeneSight and EndoPredict testing revenues along with continued year over year growth in Hereditary Cancer volumes with pricing at par with expectations On the flip side  unfavorable foreign currency translation continues to pose a threat  With a considerable portion of its revenues coming from outside the United States  the company faces the risk of exchange rate fluctuations  Additionally  macroeconomic uncertainty and higher expenses owing to extensive pipeline of some tests may impact the company s margins Zacks Rank   Other Key PicksMyriad Genetics has a Zacks Rank  2  Buy  Other top ranked stocks in the broader medical sector are PetMed Express  Inc    NASDAQ PETS    Luminex Corporation   NASDAQ LMNX   and Intuitive Surgical  Inc    NASDAQ ISRG    Notably  PetMed and Luminex sport a Zacks Rank  1  Strong Buy   while Intuitive Surgical carries a Zacks Rank  2  You can see PetMed reported earnings per share of 43 cents in the second quarter of fiscal 2018  up 79 2  from the year ago quarter s 24 cents  Also  gross margin expanded 548 bps year over year to 35 2  in the reported quarter Luminex reported adjusted earnings per share of 19 cents in the third quarter of 2017  up 216 7  year over year  The company s revenues in the quarter increased almost 4 1  year over year to  74 1 million Intuitive Surgical posted adjusted earnings of  2 77 per share in the third quarter of 2017  up 34 5  on a year over year basis  Also  revenues increased 18  year over year to  806 1 million Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2017-11-08,Zacks Investment Research,https://www.investing.com/analysis/myriad-genetics-mygn-beats-on-q1-earnings--revenues-200263472,200263472
112718,334233,ISRG,DaVita  DVA  Q3 Earnings Miss   Revenues Beat   17 View Dull,opinion,DaVita Inc    NYSE DVA   reported third quarter 2017 adjusted operating earnings of 81 cents per share that missed the Zacks Consensus Estimate of 94 cents  Further  earnings declined from 14 7  on a year over year basis Total revenues increased 5 1  year over year to  3 92 billion and beat the Zacks Consensus Estimate of  3 89 billion  The year over year improvement was mainly attributable to a 3 8  rise in patient service revenues to  2 62 billion and 16 5  increase in capitated revenues to  1 02 billion from the year ago quarter DaVita carries a Zacks Rank  4  Sell   DaVita HealthCare Partners Inc  Price and Consensus     Segment UpdateDavita Medical Group   DMG  DMG  the nation s largest operator of medical groups and physician networks  provides integrated care management as an operating division of DaVita  focusing on delivering healthcare through a broad range of services For the third quarter of 2017  DMG incurred adjusted operating loss of  5 million  which excludes  601 million non cash goodwill impairment and other adjusted items  In the third quarter  DaVita announced the restructuring of the DMG segment that eliminated 350 non clinical positions  Thus  management at DaVita expects annualized savings of around  40 million per year starting 2018 DaVita Kidney CareAs an operating division of DaVita  DaVita Kidney Care focuses on setting worldwide standards for clinical  social and operational practices in kidney care  DaVita saw solid results from the Kidney Care business Adjusted operating income in the third quarter at the segment was  404 million  up 1  year over year  primarily driven by an extra treatment day in the quarter  Notably  the company saw a negative financial impact of Hurricane Harvey and Irma  which is estimated to be approximately  7 million for higher costs and approximately  7 million of lost contribution from missed treatment and uncollected revenues owing to disruption of the company s billing process during the natural disasters U S Dialysis and Related Lab ServicesRevenue per treatment for U S  dialysis and lab business was essentially flat with the last quarter  In fact  management at DaVita expects revenue per treatment to essentially remain flat in the fourth quarter as well  The company s patient care costs were up approximately  1 76 per treatment compared with the last quarter Financial UpdateFor the twelve months ended Sep 30  2017  DaVita had an operating cash flow of  2 08 billion and free cash flow of  1 49 billion  Operating cash flow was  553 million in the third quarter and  1 56 billion year to date Share Repurchase UpdateDaVita bought back almost 2 million shares of the company s common stock for approximately  117 million at an average price of  59 09 per share  In October  DaVita s board of directors approved an additional share repurchase authorization worth approximately  1 253 billion As of Nov 7  2017  DaVita repurchased a total of 11 4 million shares of the company s common stock for a total of  702 million at an average price of  61 30 a share GuidanceDaVita expects adjusted consolidated operating income for 2017 in the range of  1 620 billion to  1 685 billion  lower than the previously issued range of  1 675 billion to  1 775 billion The company estimates adjusted operating income at the Kidney Care segment in the band of  1 570 billion to  1 600 billion  Notably  the previously issued range was  1 565 billion to  1 625 billion For the full year  DaVita expects adjusted consolidated operating income in the range of  50 million to  85 million  significantly lower than the previous guidance of  110 million to  150 million Our TakeDaVita ended third quarter fiscal 2017 on a mixed note  Strong growth in patient services is likely to boost the company s growth trajectory in the coming quarters  DaVita s continuous improvement in Kidney care is commendable as well  The company s efforts to control expenses hold promise  A compelling inorganic growth story supported by its strong financial position is another positive  However  DaVita is challenged by adverse effects of healthcare reforms  rise in Medicare costs  and an increase in Medicare Advantage  MA  beneficiaries  Also  MA rate cuts are likely to hurt the bottom line in the near future  Lackluster performance by the company s DMG segment and a slashed guidance for the full year indicate looming concerns ahead for the stock  Sluggishness in the dialysis and lab businesses adds to our concerns Q3 Earnings of MedTech Majors at a GlanceThe Q3 earnings season is drawing to a close  with most of the S P members having reported their numbers  Medical  one of the broader sectors among the 16 Zacks sectors  is expected to put up an impressive show this quarter PetMed Express   NASDAQ PETS   reported earnings per share of 43 cents in the second quarter of fiscal 2018  up 79 2  on a year over year basis  Also  gross margin expanded 548 bps year over year to 35 2  in the reported quarter  The stock sports a Zacks Rank  1  Strong Buy   You can see Luminex   NASDAQ LMNX   reported adjusted earnings per share of 19 cents in the third quarter of 2017  up 216 7  year over year  Revenues in the quarter increased almost 4 1  year over year to  74 1 million  The stock flaunts a Zacks Rank  1 Intuitive Surgical   NASDAQ ISRG   posted adjusted earnings of  2 77 per share in the third quarter of 2017  up 34 5  year over year  Revenues increased 18  year over year to  806 1 million  The stock carries a Zacks Rank 2  Buy  Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2017-11-08,Zacks Investment Research,https://www.investing.com/analysis/davita-dva-q3-earnings-miss--revenues-beat-17-view-dull-200263471,200263471
112719,334234,ISRG,Dull MFA   Mineral Nutrition Sales Hurt Phirbo  Rivalry Rife,opinion,"On Nov 9  we issued an updated research report on Phibro Animal Health Corporation   NASDAQ PAHC    The company has a Zacks Rank  4  Sell  
This is a New Jersey based leading globally diversified animal health and mineral nutrition company  Over the last three months  it has been trading above the broader   The stock has declined 8 7  compared with a 3 1  gain of the broader industry 
Notably  Phibro ended the second quarter of fiscal 2017 on a mixed note with the bottom line exceeding the Zacks Consensus Estimate and revenues declining marginally on a year over year basis  Segment wise  Medicated feed additives  MFA  business was weak in the United States   4 2 million of that business decline was due to reduced sales of medically important antimicrobials  primarily on the change in consumer preferences and the less use of certain antimicrobials in the market  This apart  an unfavorable timing of certain customer orders hampered the business Phibro Animal Health Corporation Price

   Also  a persistent decline in Mineral Nutrition segment sales is likely to be a drag on business  Customer consolidation can also affect Phibro s revenues  Plus  an unfavorable currency movement and a tough competitive scenario continue to pose as other headwinds 
On a positive note  Animal Health has continued to remain a key contributor  delivering growth over the last few quarters  Per Phibro  its animal health products are excellent in preventing  controlling and treating diseases in animals as well as increasing nutrition to improve health  We believe  a diverse product portfolio will allow the company to address the distinct growing conditions of livestock in different regions of the world 
Phibro has extended its reach beyond the United States to enter Brazil and other countries in South America  China  India and Asia Pacific  Russia and Africa  This we feel will help the company counter competition 
The company continues to invest in the Far East Asia where the poultry and dairy industries are expected to grow exponentially  The company currently expands its dairy business in the markets of Australia  Brazil and Mexico  We believe that despite the economic turmoil in Russia  Greece  Brazil and China  Phibro has performed quite well and has the potential to maintain the momentum 
Key Picks
A few better ranked stocks in the broader medical sector are PetMed Express  Inc    NASDAQ PETS    Luminex Corp    NASDAQ LMNX   and Intuitive Surgical  Inc    NASDAQ ISRG    While PetMed and Luminex sport a Zacks Rank  1  Strong Buy   Intuitive Surgical carries a Zacks Rank  2  Buy   You can see 
PetMed has a long term expected earnings growth rate of 10   The stock has surged roughly 78 6  over the last year 
Luminex has a long term expected earnings growth rate of 16 3   The stock has gained 1 9  in the last year 
Intuitive Surgical has a long term expected earnings growth rate of 9 1   The stock has surged 85 2  in the last year 
Today s Stocks from Zacks  Hottest Strategies
It s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2017-11-09,Zacks Investment Research,https://www.investing.com/analysis/dull-mfa--mineral-nutrition-sales-hurt-phirbo-rivalry-rife-200263828,200263828
112747,334262,ISRG,Cardinal Health  CAH  Beats On Q1 Earnings  FY18 View Intact,opinion,"Cardinal Health Inc    NYSE CAH   reported first quarter fiscal 2018 adjusted earnings of  1 09 per share  which beat the Zacks Consensus Estimate of  1 01  However  earnings declined 12 1  on a year over year basis Revenues increased 1 9  on a year over year basis to almost  32 64 billion but missed the Zacks Consensus Estimate of  33 43 billion  The stock has a Zacks Rank  4  Sell  Segmental AnalysisPharmaceutical Segment  Pharmaceutical revenues inched up 1  to  28 92 billion on a year over year basis  The segment witnessed strong growth in the Specialty business and also gained a huge number of Pharmaceutical Distribution customers The segment witnessed a 13  drop in profits  thanks to generic pharmaceutical pricing and the company s recent investments in its Pharmaceutical IT platform  However  solid performance by the Red Oak Sourcing platform has partially offset the negative effect Medical Segment  Revenues at the segment increased 14  to  3 72 billion primarily on higher contributions from new and existing customers Medical segment profits increased 1  to  129 million  courtesy of higher contributions from new and existing customers and acquisitions  However  lower contributions from the Veterans Affairs contract partially affected sales at the segment  
Cardinal Health  Inc  Price and Consensus
     Major HighlightsIn the reported quarter  Cardinal Health closed the acquisition of Medtronic s   NYSE MDT   Patient Recovery business for  6 1 billion in cash  Further  Cardinal Health launched ConnectSource  a new cloud based patient engagement platform in the first quarter Cardinal Health entered into an agreement in the first quarter to distribute self manufactured surgeon gloves directly in certain international markets The company also announced an agreement to make its Cordis subsidiary the exclusive distributor of Medinol coronary stents in the United States MarginsAs a percentage of revenues  gross margin expanded 220 basis points  bps  to 5 1  of net revenues Distribution  selling  general and administrative  SG A  expenses increased 15  on a year over year basis to  1062 million in the reported quarter GuidanceThe company reaffirmed its fiscal 2018 guidance for adjusted earnings per share from continuing operations at  4 85  5 10 Our TakeCardinal Health ended first quarter fiscal 2017 on a solid note  courtesy of a solid performance by the Medical segment  An encouraging fiscal 2018 guidance instills our confidence in the stock  Meanwhile  the company is banking on strategic buyouts  joint ventures and supply agreements to drive growth  The deal with MedTech bigwig Medtronic is likely to boost the company s growth trajectory  On the flipside  although the Pharmaceutical segment witnessed strong growth in the Specialty business and gained a huge number of Pharmaceutical Distribution customers  profits at the segment were hurt by generic pharmaceutical pricing  Increasing generic pricing pressure is a major headwind  Intensifying competition and customer concentration are other bottlenecks  A sluggish macroeconomic scenario and tough product pricing environment are likely to impede growth Peer ReleasesIntuitive Surgical Inc    NASDAQ ISRG   posted adjusted earnings of  2 77 per share in the third quarter of 2017  beating the Zacks Consensus Estimate of  1 97 on stellar revenue growth  The stock has a Zacks Rank  2  Buy  PetMed Express  Inc  s   NASDAQ PETS   adjusted earnings per share of 43 cents for the second quarter of fiscal 2018 were up 79 2  from the year ago quarter  Also  earnings surpassed the Zacks Consensus Estimate by 43 3   The stock sports a Zacks Rank  1  Strong Buy   You can see Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2017-11-05,Zacks Investment Research,https://www.investing.com/analysis/cardinal-health-cah-beats-on-q1-earnings-fy18-view-intact-200258446,200258446
112748,334263,ISRG,Henry Schein  HSIC  Misses Q3 Earnings  Margins Decline,opinion,"Henry Schein  Inc    NASDAQ HSIC   reported adjusted earnings per share  EPS  of 87 cents in the third quarter of 2017  up 3 6  year over year  However  adjusted EPS missed the Zacks Consensus Estimate of 90 cents by 3 33   The year over year upside in earnings was driven by strong revenue growth 
Revenues in Detail
Henry Schein reported revenues of  3 16 billion in the third quarter  up 10 3  year over year and also above the Zacks Consensus Estimate of  3 05 billion  The year over year improvement came on the back of 8 8  growth in local currencies and 1 5  increase owing to foreign currency exchange  At local currencies  internally generated sales increased 4 8  and acquisition growth was 4  
The company recorded sales of  2 12 billion in the North American market  up 6 2  year over year  Sales totaled  1 04 billion in the international market  up 19 9  year over year 
Segment Analysis    
Henry Schein derives revenues from four operating segments  Dental  Medical  Animal Health  and Technology and Value added services 
In the third quarter  the company derived  1 48 billion in revenues from global Dental sales  up 11 1  year over year  This includes 9 1  growth in local currencies and 2  contribution from foreign currency exchange  At local currencies  internally generated sales increased 1 6  and acquisition growth was 7 5   Internal growth at local currencies included 0 8  growth in North America and 3 2  rise internationally 
Henry Schein  Inc  Price  Consensus and EPS Surprise
   The company s global Animal Health segment witnessed 11 7  rise in revenues to  882 6 million  This includes 9 9  growth in local currencies and 1 8  increase from foreign currency exchange  At local currencies  internally generated sales increased 8  and acquisition growth was 1 9   The 8  internal growth in local currencies included 9  rise in North America and 6 9  improvement internationally 
Worldwide Medical revenues rose 8  year over year to  690 8 million  Growth in local currencies was 7 9   with a 0 1  increase owing to favorable foreign exchange 
Revenues from global Technology and Value added Services grew 4 1  to  109 million  This included 3 7  growth in local currencies and a 0 4  rise related to foreign currency exchange  Acquisitions contributed 0 7  in the quarter under review 
Margin Trend         
Gross profit increased 6 1  to  836 1 million in the reported quarter  However  gross margin declined 90 basis points  bps  from the year ago quarter to 26 5  due to a 12  rise in cost of sales  higher than the revenue growth rate   
Despite a 7  rise in selling  general   administrative expenses of  622 5 million  adjusted operating income improved 3 6  year over year to  213 6 million  However  adjusted operating margin contracted 40 bps year over year to 6 8  in the reported quarter 
Financial Position
Henry Schein exited third quarter 2017 with cash and cash equivalents of  79 9 million  compared with  74 7 million at the end of second quarter 2017  Year to date net cash provided by operating activities was  307 5 million  compared with  378 1 million in the year ago period 
During the quarter under review  the company bought back approximately 1 4 million shares for almost  125 million  At the close of the third quarter  the company had  425 million authorized for repurchase of common stock 
2017   2018 EPS Guidance
Henry Schein updated its 2017 adjusted EPS guidance  excluding litigation settlement expenses and a fourth quarter loss related with the company s divestiture of equity ownership in E4D Technologies   The company now expects adjusted EPS in the range of  3 59  3 61  reflecting 8 9  growth from the 2016 adjusted EPS figure of  3 31  The previous adjusted EPS 2017 guidance range was  3 59  3 65  The Zacks Consensus Estimate for 2017 adjusted EPS is  3 64  outside the guided range 
The company also provided the guidance for 2018 EPS  Henry Schein expects reported EPS for 2018 in the band of  3 85  3 96  reflecting an annualized growth rate of 7 10  compared with the midpoint of the company s 2017 adjusted EPS guidance range 
Our Take
Henry Schein exited third quarter 2017 on a mixed note  All four of the company s operating segments recorded strong year over year growth  Henry Schein s strong share gains in the North American and overseas markets along with solid revenues raise optimism 
Despite the better than expected revenue performance  we are disappointed with the year over year deterioration in Henry Schein s gross and operating margin due to higher cost of sales and expenses 
Zacks Rank   Key Picks
Henry Schein has a Zacks Rank  3  Hold  
A few better ranked stocks in the broader medical sector are PetMed Express  Inc    NASDAQ PETS    Luminex Corp    NASDAQ LMNX   and Intuitive Surgical  Inc    NASDAQ ISRG    Notably  PetMed and Luminex sport a Zacks Rank  1  Strong Buy   while Intuitive Surgical carries a Zacks Rank  2  Buy   You can see 
PetMed reported earnings per share of 43 cents in the second quarter of fiscal 2018  up 79 2  from the year ago quarter s 24 cents  Also  gross margin expanded 548 bps year over year to 35 2  in the reported quarter 
Luminex reported adjusted earnings per share of 19 cents in the third quarter of 2017  up 216 7  year over year  Revenues increased almost 4 1  year over year to  74 1 million 
Intuitive Surgical posted adjusted earnings of  2 77 per share in the third quarter of 2017  up 34 5  on a year over year basis  Also  revenues increased 18  year over year to  806 1 million 
Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2017-11-06,Zacks Investment Research,https://www.investing.com/analysis/henry-schein-hsic-misses-q3-earnings-margins-decline-200261290,200261290
112749,334264,ISRG,CVS Health  CVS  Beats Q3 Earnings Estimates  Updates View,opinion,"CVS Health Corporation s   NYSE CVS   third quarter 2017 adjusted earnings per share  EPS  of  1 50 declined from the year ago figure of  1 64  However  adjusted EPS beat the Zacks Consensus Estimate by a penny 
The year over year decline in earnings was due to disappointing Retail LTC numbers as well as lower margins 
Without one time adjustments  EPS from continuing operations in the third quarter came in at  1 26  down from  1 43 in the prior year quarter CVS Health Corporation Price  Consensus and EPS Surprise

   Net revenues in the quarter increased 3 5  year over year to  46 18 billion  almost in line with the Zacks Consensus Estimate  Strong revenue growth in the Pharmacy Services segment was partially offset by a decline in Retail LTC revenues in the quarter 
Quarter in Details
Pharmacy Services revenues increased 8 1  to  32 89 billion in the reported quarter  driven by growth in specialty pharmacy volumes  higher pharmacy network claim volumes as well as brand inflation  This was  however  partially offset by increased generic dispensing and price compression 
Pharmacy network claims processed during the quarter climbed 8 3  to 374 2 million on a 30 day equivalent basis  backed by net new business growth  Also  the Mail Choice processed claim count was 66 9 million  up 6 1  on a 30 day equivalent basis on continued adoption of Maintenance Choice offerings and a rise in specialty pharmacy claims 
Revenues from CVS Health s Retail LTC dropped 2 7  year over year to  19 59 billion  primarily due to a 3 2  decrease in same store sales  continued reimbursement pressure and an increase in the generic dispensing rate 
Front end same store sales were down 2 8  year over year  Front store sales were affected by soft customer traffic and efforts to rationalize promotional strategies  which were partially offset by an increase in basket size 
Pharmacy same store sales also declined 3 4  in the reported quarter  Sales were affected approximately 435 basis points  bps  due to recent generic drug introductions  Also  Pharmacy same store prescription volumes inched up 0 3  on a 30 day equivalent basis  This apart  marketplace changes that restricted CVS Pharmacy from participating in certain networks had a 420 bps negative impact on same store prescription volumes 
The generic dispensing rate  the proportion of all generic prescriptions to total number of prescriptions dispensed  increased approximately 100 bps to 87  at the Pharmacy Services segment and around bps to 87 2  at the Retail LTC segment 
Gross profit dropped 4 9  to  7 12 billion and gross margin contracted 140 bps to 15 4   Total operating margin in the quarter declined 93 bps to 5 4  
CVS Health exited the third quarter with cash and cash equivalents and short term investments of  2 56 billion compared with  2 16 billion at the end of second quarter 2017  Year to date  net cash provided by operating activities was  8 14 billion  up 1 5  from the year ago period 
During the third quarter  CVS Health opened 56 new retail stores and shut five retail locations  Further  the company relocated five retail stores  As of Sep 30  2017  CVS Health operated 9 751 retail stores  including pharmacies in Target stores across 49 U S  states as well as the District of Columbia  Puerto Rico and Brazil 
2017 Outlook
CVS Health has narrowed its 2017 adjusted EPS guidance to  5 87  5 91 from the earlier band of  5 83  5 93 The Zacks Consensus Estimate of  5 88 is within the guided range  However  full year operating cash flow guidance has been reiterated at the range of  7 7  8 6 billion and free cash flow at the band of  6 0  6 4 billion 
For the fourth quarter  the company expects adjusted EPS of  1 88  1 92  The Zacks Consensus Estimate for the fourth quarter is pegged at  1 91  within the company s projection 
Our Take
CVS Health exited the third quarter on a solid note  However  weak year over year Retail LTC comparisons along with margin decline resulted in a dull earnings performance 
Nonetheless  the year over year growth in the top line was driven by a strong Pharmacy Services segment  benefiting from the upside in the specialty services 
Zacks Rank   Key Picks
CVS Health has a Zacks Rank  3  Hold  
A few better ranked stocks in the broader medical sector are PetMed Express  Inc    NASDAQ PETS    Luminex Corp    NASDAQ LMNX   and Intuitive Surgical  Inc    NASDAQ ISRG    Notably  PetMed and Luminex sport a Zacks Rank  1  Strong Buy   while Intuitive Surgical carries a Zacks Rank  2  Buy   You can see 
PetMed reported earnings per share of 43 cents in the second quarter of fiscal 2018  up 79 2  from the year ago quarter s 24 cents  Also  gross margin expanded 548 bps year over year to 35 2  in the reported quarter 
Luminex reported adjusted earnings per share of 19 cents in the third quarter of 2017  up 216 7  year over year  The company s revenues in the quarter increased almost 4 1  year over year to  74 1 million 
Intuitive Surgical posted adjusted earnings of  2 77 per share in the third quarter of 2017  up 34 5  year over year  Also  revenues increased 18  year over year to  806 1 million 
Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2017-11-06,Zacks Investment Research,https://www.investing.com/analysis/cvs-health-cvs-beats-q3-earnings-estimates-updates-view-200261287,200261287
112750,334265,ISRG,Hill Rom  HRC  Q4 Earnings And Revenues Top  Margins Up,opinion,"Hill Rom Holdings  Inc    NYSE HRC   reported fourth quarter fiscal 2017 adjusted earnings per share  EPS  of  1 32  an 11 9  increase from the year ago quarter  Adjusted earnings surpassed the Zacks Consensus Estimate by 3 9  and remained above the company s projected range of  1 26  1 30 
This strong bottom line performance was on the back of strong revenue growth  continued margin expansion  strategic investments to drive future growth and a lower tax rate  all of which helped offset a modest impact from the recent hurricanes 
Including one time adjustments  Hill Rom reported earnings of  1 03 per share compared with 77 cents in the year ago quarter Hill Rom Holdings Inc Price  Consensus and EPS Surprise

    
Full year adjusted EPS was  3 86  up 14 2  from the year ago period 
Revenue Details
Revenues in the fourth quarter of fiscal 2017 increased 4 6  year over year to  738 million  up 4  at CER   The top line also exceeded the Zacks Consensus Estimate of  732 million  Fiscal 2017 revenues came in at  2 74 billion  up 3  on a reported basis and up 4  at CER 
This strong revenue growth in the reported quarter was driven by a momentum in core business  the acquisition of Mortara and value added from newly introduced products 
Geographically  U S  revenues grew 3  to  513 million while revenues outside the U S  increased 8   up 5  at CER  to  225 million  Core revenue growth was 3  at CER  in line with the company s expectation 
Segmental Performance
In the fiscal fourth quarter  Patient Support Systems revenues decreased 3  year over year  down 4  at CER  to  371 million  The segment s domestic revenues declined 2   However  after adjusting for divestitures  U S  core revenues increased 2   Product and service revenues increased 4   partially offset by a decline in rental revenues 
Revenues at the Front Line Care segment  which include both Welch Allyn  Respiratory Care and Mortara  increased 16  to  245 million  same at CER   Apart from contribution from Mortara  the performance was driven by contributions from new products  strong growth of thermometry and blood pressure monitoring devices plus double digit growth in respiratory care business 
The Surgical Solutions segment revenues increased 9   up 7  at CER  to  122 million  This upside was backed by strong U S  growth with a record placement of Integrated Table Motion and contribution from other products like the iLED7 and the new TS 3000 Mobile Operating Table 
Margins
Reported gross margin in the fiscal fourth quarter was 49 1   unchanged year over year on account of a 4 6  increase in total cost of revenues  Adjusted gross margin grew 10 bps to 49 3  on the back of the company s consistent initiative with portfolio diversification  benefits from cost and sourcing efficiencies  new product launches and the accretive gains from Mortara  Adjusted operating margin improved 70 bps to 19 3  
Outlook
Hill Rom has initiated its fiscal 2018 guidance and has also provided the fiscal first quarter view 
For the full year  the company expects revenue growth in the 3 4  range on a reported basis  Up 2  to 3  at CER   Excluding foreign currency  Mortara  divestitures and other non strategic assets  the company expects core revenues to increase 3   Hill Rom also expects adjusted EPS in the range of  4 22  4 30  The stock has seen the Zacks Consensus Estimate for fiscal 2018 earnings being pegged at  4 30 on revenues of  2 88 billion 
For the first quarter  Hill Rom expects revenue growth of around 3  on a reported basis  or approximately 2  at CER   The company s core revenues are expected to remain flat year over year   In addition  the company expects adjusted earnings per share of 77 79 cents  The stock has seen the Zacks Consensus Estimate for first quarter earnings being pegged at 92 cents on revenues of  695 9 million 
Our Take
Hill Rom exited fiscal 2017 on a strong note with the fourth quarter earnings and revenues exceeding the respective Zacks Consensus Estimate  The company saw a solid year over year increase in revenues on strong international growth  Hill Rom is currently aiming to gain traction in the untapped international market on successful execution  courtesy its efficient international team and organizational realignment  The company is putting efforts in product innovation through research and development  A slew of product launches in the fourth quarter is encouraging 
However  a decline in revenues at the Patient Support Systems segment is quite disappointing  Also  foreign exchange remains a headwind 
Zacks Rank   Other Key Picks
Hill Rom has a Zacks Rank  2  Buy   A few other top ranked stocks in the broader medical sector are PetMed Express  Inc    NASDAQ PETS    Luminex Corp    NASDAQ LMNX   and Intuitive Surgical  Inc    NASDAQ ISRG    While PetMed and Luminex sport a Zacks Rank  1  Strong Buy   Intuitive Surgical carries a Zacks Rank  2  You can see 
PetMed reported earnings per share of 43 cents in the second quarter of fiscal 2018  up 79 2  from the year ago quarter s 24 cents  Also  gross margin expanded 548 bps year over year to 35 2  in the reported quarter 
Luminex reported adjusted earnings per share of 19 cents in the third quarter of 2017  up 216 7  year over year  The company s revenues in the quarter increased almost 4 1  year over year to  74 1 million 
Intuitive Surgical posted adjusted earnings of  2 77 per share in the third quarter of 2017  up 34 5  year over year  Also  revenues increased 18  year over year to  806 1 million 
Wall Street s Next Amazon  NASDAQ AMZN 
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2017-11-06,Zacks Investment Research,https://www.investing.com/analysis/hillrom-hrc-q4-earnings-and-revenues-top-margins-up-200261286,200261286
112752,334267,ISRG,QIAGEN  QGEN  Meets Q3 Earnings  Lags Revenues  Keeps View,opinion,QIAGEN N V    NASDAQ QGEN   reported third quarter 2017 adjusted earnings per share of 32 cents  up 10 3  year over year  The reported figure is on par with the Zacks Consensus Estimate At constant exchange rate or CER  the company reported adjusted earnings per share  EPS  of 32 cents  which met the low end of the company s guidance of 32 33 cents at CER QIAGEN s reported EPS in the quarter was 21 cents  up 40  year over year Revenues in DetailNet sales at actual rates in the third quarter grew 7  on a year over year basis to  364 million  same at CER   However  the top line missed the Zacks Consensus Estimate of  365 1 million Meanwhile  considering the acquisition of OmicSoft in January  revenues increased 1   Currency translation did not have any material impact on net sales  Also  organic expansion contributed 6  of total CER growth Region wise  sales from the Americas  47  of revenues  grew 3  at CER  while revenues from Europe Middle East Africa  32   and Asia Pacific Japan  20   increased 15  and 7   respectively  at CER  Sales in the top seven emerging markets  17   exhibited growth of 19  year over year at CER in the quarter under review  Qiagen N V  Price  Consensus and EPS Surprise     Segments in DetailQIAGEN primarily generates revenues from Molecular Diagnostics  Applied Testing  Pharma and Academia  which represented 49   10   19  and 22  of net sales  respectively  during the reported quarter Molecular diagnostics sales were up 9  at CER  driven by substantial growth in QuantiFERON latent TB tests  QIAsymphony automation system consumables portfolio and solid performance of companion diagnostic pharma collaborations  Sales derived from Applied Testing rose 15  at CER  on increased uptake of new products in human ID and forensics Pharma sales rose 5  at CER in the third quarter and Academia sales improved 2  at CER backed by growing demand Operational UpdateAdjusted operating income in the third quarter increased 9  year over year to  96 1 million  Also  the adjusted operating margin expanded 40 basis points to 26 4   Financial UpdateQIAGEN exited the third quarter with cash and cash equivalents of  671 8 million  up from  542 8 million in the preceding quarter  Year to date net cash from operating activities was  210 7 million  down from  241 6 million a year ago  Moreover  the company reported year to date free cash flow of  146 1 million compared with  186 7 million in the year ago period In January 2017  QIAGEN completed a synthetic share repurchase that combined a direct capital repayment with a reverse stock split as part of a commitment to return  300 million to shareholders  The transaction was announced in August 2016 and involved an approach used by various large  multinational Dutch companies to boost shareholders  returns in a faster and more efficient manner than traditional open market purchases  QIAGEN intended to repay the balance of the commitment through open market share repurchases in 2017  However  QIAGEN has completed  300 million of its share repurchase goal ahead of the end of 2017 through the open market repurchase of 1 91 million shares on the Frankfurt Stock Exchange 2017 GuidanceQIAGEN has maintained its 2017 guidance for adjusted net sales growth at 7   CER   Moreover  the adjusted EPS guidance has been reiterated at the band of  1 25  1 27 at CER This is based on operating and financial leverage which includes benefits from the completion of the  300 million share repurchase plan and efficiency actions taken in 2016  This  however  excludes the expected 7 cents per share of restructuring costs planned for 2017  The Zacks Consensus Estimate for 2017 earnings of  1 26 is within the guided range  The Zacks Consensus Estimate for 2017 revenues is pegged at  1 42 billion The company also provided its financial guidance for the fourth quarter of 2017  Net sales are expected to grow 5 6  at CER  Adjusted EPS is expected at around 41 42 cents at CER on an underlying basis  The Zacks Consensus Estimate for fourth quarter revenues is pegged at  407 65 million  while the consensus estimate for earnings stands at 42 cents Our TakeQIAGEN ended the third quarter on a mixed note  We are impressed with balanced growth across all of the company segments  Furthermore  on the profitability front  QIAGEN delivered strong performance with respect to operating margin  We are also upbeat about the company s strategic focus to drive growth through Sample to Insight offerings  Meanwhile  its commitment to return more to shareholders through increased share repurchases reflects its solid cash position On the flip side  declining HPV sales in the United States continues to be a drag  Competitive landscape and strong reliance on collaborations also continue to be concerns Zacks Rank   Key PicksQIAGENhas a Zacks Rank  3  Hold  A few better ranked stocks in the broader medical sector are PetMed Express  Inc    NASDAQ PETS    Luminex Corporation   NASDAQ LMNX   and Intuitive Surgical  Inc    NASDAQ ISRG    Notably  PetMed and Luminex sport a Zacks Rank  1  Strong Buy   while Intuitive Surgical carries a Zacks Rank  2  Buy   You can see PetMed reported earnings per share of 43 cents in the second quarter of fiscal 2018  up 79 2  from the year ago quarter s 24 cents  Also  gross margin expanded 548 basis points year over year to 35 2  in the reported quarter Luminex reported adjusted earnings per share of 19 cents in the third quarter of 2017  up 216 7  year over year  The company s revenues in the quarter increased almost 4 1  year over year to  74 1 million Intuitive Surgical posted adjusted earnings of  2 77 per share in the third quarter of 2017  up 34 5  on a year over year basis  Also  revenues increased 18  year over year to  806 1 million Zacks  Hidden TradesWhile we share many recommendations and ideas with the public  certain moves are hidden from everyone but selected members of our portfolio services  Would you like to peek behind the curtain today and view them Starting now  for the next month  I invite you to follow all Zacks  private buys and sells in real time from value to momentum   from stocks under  10 to ETF to option movers   from insider trades to companies that are about to report positive earnings surprises  we ve called them with 80   accuracy   You can even look inside portfolios so exclusive that they are normally closed to new investors ,2017-11-06,Zacks Investment Research,https://www.investing.com/analysis/qiagen-qgen-meets-q3-earnings-lags-revenues-keeps-view-200263313,200263313
112753,334268,ISRG,Wright Medical  WMGI  Portfolio Solid  Lower Extremities Dull,opinion,"On Nov 6  we issued an updated research report on Wright Medical Group N V    NASDAQ WMGI    The company recently reported third quarter results  wherein adjusted earnings were in line with the Zacks Consensus Estimate  Exclusive platforms and technologies like PERFORM Reversed glenoid  ORTHOLOC 3Di and the SIMPLICITI shoulder system acted as key catalysts in the third quarter  Wright Medical currently carries a Zacks Rank  3  Hold  Wright Medical is focusing on product innovation through research and development  The company recently launched INVISION Total Ankle Revision System   the first system developed for total ankle revision arthroplasty  Of the other major platforms  the launch of PERFORM Reversed is expected to boost revenues Wright Medical s solid guidance boosts investor confidence  The company expects net sales for 2017 in the band of  740 million to  745 million  This includes negative impact from foreign currency exchange of approximately 1   The company forecasts full year 2017 adjusted EBITDA from continuing operations of  84 million to  88 million However  lackluster international performance of the Lower extremities segment is a matter of concern  Sales at the segment declined 0 6  on a year over year basis to  65 4 million in the third quarter  The U S  lower extremities business sales fell 0 3  in the third quarter  Internationally  lower extremities sales declined 1 7  on a year over year basis  
Wright Medical Group N V  Price
     
Of the other concerns  pricing pressure continues to trouble Wright Medical  Increased costs related to product launch and re building infrastructure are expected to exert pressure on margins  Problems associated with distributors are major headwinds In the past six months  Wright Medical has underperformed the broader industry with respect to price  The company has lost 11 8   comparing unfavorably with the broader  s gain of almost 6 5  Q3 Earnings of MedTech Majors at a GlanceMeanwhile  Q3 earnings season has taken center stage  with most of the S P members having reported their numbers  Medical  one of the broader sectors among the 16 Zacks sectors  is expected to put up an impressive show this quarter PetMed Express   NASDAQ PETS   reported earnings per share of 43 cents in the second quarter of fiscal 2018  up 79 2  on a year over year basis  Also  gross margin expanded 548 bps year over year to 35 2  in the reported quarter  The stock sports a Zacks Rank  1  Strong Buy      You can see Luminex   NASDAQ LMNX   reported adjusted earnings per share of 19 cents in the third quarter of 2017  up 216 7  year over year  Revenues in the quarter increased almost 4 1  year over year to  74 1 million  The stock flaunts a Zacks Rank  1 Intuitive Surgical   NASDAQ ISRG   posted adjusted earnings of  2 77 per share in the third quarter of 2017  up 34 5  year over year  Also  revenues increased 18  year over year to  806 1 million  The stock carries a Zacks Rank 2  Buy  Zacks  Hidden TradesWhile we share many recommendations and ideas with the public  certain moves are hidden from everyone but selected members of our portfolio services  Would you like to peek behind the curtain today and view them Starting now  for the next month  I invite you to follow all Zacks  private buys and sells in real time from value to momentum   from stocks under  10 to ETF to option movers   from insider trades to companies that are about to report positive earnings surprises  we ve called them with 80   accuracy   You can even look inside portfolios so exclusive that they are normally closed to new investors ",2017-11-06,Zacks Investment Research,https://www.investing.com/analysis/wright-medical-wmgi-portfolio-solid-lower-extremities-dull-200263309,200263309
112754,334269,ISRG,Phibro Animal  PAHC  Beats On Q1 Earnings  Reiterates View,opinion,Phibro Animal Health Corporation   NASDAQ PAHC   reported adjusted earnings per share  EPS  of 38 cents in the first quarter of fiscal 2018  up 5 6  year over year  Adjusted EPS also surpassed the Zacks Consensus Estimate by a penny  According to the company  the year over year improvement was primarily driven by a higher gross profit ratio  reduced interest expenses and a lower effective income tax rate         The company s reported EPS of 39 cents  up 25 8  from the year ago quarter Net SalesIn the reported quarter  Phibro s net sales were  193 4 million  up 2 9  year over year  The improvement was driven by sales growth in the Animal Health  Mineral Nutrition segment and Performance Products  Phibro Animal Health Corporation Price  Consensus and EPS Surprise     Sales by SegmentsNet sales at the Animal Health segment increased 3  to  128 8 million in the reported quarter on the back of volume increases in the nutritional specialty and vaccine product groups within the segment  While nutritional specialty products grew 17   sales from vaccines increased 25   principally on volume growth of products for poultry and swine industries However  sales at Medicated feed additives  MFAs  and Other fell 5  primarily due to volume decline Domestic net sales at MFAs and Other declined by  10 5 million due to reduced volumes of medically important antimicrobials and unfavorable timing of certain customer orders  International net sales increased by  6 7 million  driven by growth across most regions  including the benefit of improved economic conditions in Brazil Net sales at the Mineral Nutrition segment increased 1  to  52 1 million on higher average selling prices resulting from an increase in underlying raw material commodity price  However  the rise in average selling prices was partially offset by lower volumes of trace mineral products Net sales at the Performance Products segment increased 5  to  12 5 million on higher average selling prices and volumes of copper based products Operational UpdatePhibro s fiscal first quarter gross profit increased 3 4  year over year to  63 4 million  The gross margin expanded 33 basis points  bps  to 32 8  Selling  general and administrative expenses rose 4 6  to  41 million  Operating margin was marginally flat year over year at 11 6  in the quarter Financial Update                                                             Year to date  Phibro generated  4 8 million in cash flow from operations compared with  21 5 million in the year ago period  Capital expenditure amounted to  5 million in this period  reflecting a reduction from  5 9 million in the year ago quarter FY18 OutlookPhibro has reiterated its guidance for fiscal 2018  The company expects to generate net sales of  765  790 million  The current Zacks Consensus Estimate of  780 2 million falls within the guided range Phibro provided its adjusted EPS guidance in the range of  1 55  1 61  The current Zacks Consensus Estimate of  1 57 is also within the company s guided range Our TakePhibro ended the fiscal 2018 first quarter on a solid note with Earnings ahead of the Zacks Consensus Estimate  The company witnessed considerable improvement across all segments  We are also encouraged by the expansion in the gross margin in the reported quarter Zacks Rank   Key PicksPhibro has a Zacks Rank  3  Hold  A few better ranked stocks in the broader medical sector are PetMed Express  Inc    NASDAQ PETS    Luminex Corporation   NASDAQ LMNX   and Intuitive Surgical  Inc    NASDAQ ISRG    Notably  PetMed and Luminex sport a Zacks Rank  1  Strong Buy   while Intuitive Surgical carries a Zacks Rank  2  Buy   You can see PetMed reported earnings per share of 43 cents in the second quarter of fiscal 2018  up 79 2  from the year ago quarter s 24 cents  Also  gross margin expanded 548 bps year over year to 35 2  in the reported quarter Luminex reported adjusted earnings per share of 19 cents in the third quarter of 2017  up 216 7  year over year  Revenues increased almost 4 1  year over year to  74 1 million Intuitive Surgical posted adjusted earnings of  2 77 per share in the third quarter of 2017  up 34 5  year over year  Also  revenues rose 18  year over year to  806 1 million Zacks  Hidden TradesWhile we share many recommendations and ideas with the public  certain moves are hidden from everyone but selected members of our portfolio services  Would you like to peek behind the curtain today and view them Starting now  for the next month  I invite you to follow all Zacks  private buys and sells in real time from value to momentum   from stocks under  10 to ETF to option movers   from insider trades to companies that are about to report positive earnings surprises  we ve called them with 80   accuracy   You can even look inside portfolios so exclusive that they are normally closed to new investors ,2017-11-06,Zacks Investment Research,https://www.investing.com/analysis/phibro-animal-pahc-beats-on-q1-earnings-reiterates-view-200263273,200263273
112755,334270,ISRG,Intuitive Surgical Inc  Breakout Of The Day With S P 500 component,opinion,"Intuitive Surgical Inc  NASDAQ ISRG 
 Intuitive Surgical  Inc   Intuitive  designs  manufactures and markets da Vinci Surgical Systems  and related instruments and accessories  The Company s da Vinci Surgical System consists of a surgeon s console  a patient side cart and a vision system   source  Reuters 
TECHNICAL ANALYSIS     FUNDAMENTAL ANALYSIS     The score relative to the fundamental analysis is based on my own algorithm that calculates more than 100 indicators divided into different areas  In this analysis  about 40 of the 100 indicators will be shown  selected according to the importance and the sector in which the company operates  The analysis refers to the annual  and quarterly  Income statement and Balance sheet of the last 3 5 years     The indication  n  in the  Annual Growth  graph refers to the year of the last annual Income statement and Balance sheet available    The indication  n  in the chart  Quarterly   YoY   Growth  refers to the last quarterly Income statement available    The  Quarterly   YoY   Growth  chart shows the trend in revenue  operating income and net income in the last quarter  compared to the same quarter 12 months earlier    The numbers inside the charts are in millions of      The term  TTM  in the chart refers to the Trailing Twelve Months  sum of the last 4 quarters available     The two moving averages on the price chart are the Exponential moving average 50 and the Exponential moving average 100  while the moving average on the volume chart is the Simple moving average 20 
DISCLAIMER  The information in this blog post represents my own analysis opinions and does not contain a recommendation for any particular security or investment ",2017-11-07,Lorenzo Riccio,https://www.investing.com/analysis/-intuitive-surgical-inc--breakout-of-the-day--sp-500-component--200263340,200263340
112780,334295,ISRG,Becton  Dickinson  BDX  Beats On Q4 Earnings  Guidance Solid,opinion,"Becton  Dickinson and Company   NYSE BDX    popularly known as BD  reported fourth quarter fiscal 2017 earnings of  2 40 per share  which beat the Zacks Consensus Estimate of  2 38 and increased 13 2  on a year over year basis The company registered revenues of  3 166 billion  down from  3 231 billion in the year ago period  Revenues  however  beat the Zacks Consensus Estimate of  3 136 billion Quarterly DetailsThe BD Medical segment generated revenues of  2 115 billion  which declined 5 3  from the prior year period  The segment s results reflect an adverse impact from the change in the U S  dispensing business model The BD Life Sciences segment generated revenues of  1 051 billion  up 5 5  from the year ago quarter  The segment s performance reflects strong numbers across the Biosciences  Diagnostic Systems and Preanalytical Systems units U S  Revenues were roughly  1 644 billion  down 5 9  on a reported basis but up 2 1  on a comparable basis International revenues rose 2 6  to  1 522 billion  However  comparable  currency neutral basis revenues rose 6 9  on the back of solid growth across the company s businesses Becton  Dickinson and Company Price  Consensus and EPS Surprise   GuidanceThe company expects fiscal 2018 revenues to increase 5  to 6   The company expects adjusted earnings per share between  10 55 and  10 65 on a stand alone basis  which represents growth of approximately 12   Zacks Rank   Key PicksBecton  Dickinson currently carries a Zacks Rank  2  Buy  A few other top ranked stocks in the broader medical sector are PetMed Express  Inc    NASDAQ PETS    Luminex Corporation   NASDAQ LMNX   and Intuitive Surgical  Inc    NASDAQ ISRG    Notably  PetMed and Luminex sport a Zacks Rank  1  Strong Buy   while Intuitive Surgical carries a Zacks Rank  2  Buy   You can see PetMed reported earnings per share of 43 cents for the second quarter of fiscal 2018  up 79 2  from the year ago quarter s 24 cents  Also  gross margin expanded 548 bps year over year to 35 2  in the reported quarter Luminex reported third quarter adjusted earnings per share of 19 cents  up 216 7  year over year  The company s revenues in the quarter increased almost 4 1  year over year to  74 1 million Intuitive Surgical posted adjusted earnings of  2 77 per share  up 34 5  year over year  in the third quarter of 2017  Also  revenues increased 18  year over year to  806 1 million 
Zacks  Best Private Investment Ideas
While we are happy to share many articles like this on the website  our best recommendations and most in depth research are not available to the public 
Starting today  for the next month  you can follow all Zacks  private buys and sells in real time  Our experts cover all kinds of trades  from value to momentum       from stocks under  10 to ETF and option moves       from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises  You can even look inside exclusive portfolios that are normally closed to new investors ",2017-11-01,Zacks Investment Research,https://www.investing.com/analysis/becton-dickinson-bdx-beats-on-q4-earnings-guidance-solid-200257959,200257959
112781,334296,ISRG,Integra Gains On Global Growth  Hurricanes Hamper Business,opinion,On Oct 31  we issued an updated research report on Integra LifeSciences Holdings Corporation   NASDAQ IART    The stock currently has a Zacks Rank  3  Hold  Integra LifeSciences exited the third quarter of 2017 on a disappointing note  with both earnings and revenues missing the respective Zacks Consensus Estimate  Also  contraction in adjusted operating margin and adjusted gross margin adds to the woes On a positive note  over the last six months  shares of Integra Lifesciences have been trading slightly above the broader   The stock has gained 0 8  against the 0 8  loss of the broader industry over the same time frame  A consistently strong performance of its Orthopedics and Tissue Technologies  segment buoys optimism Integra LifeSciences Holdings Corporation Price   We believe the company s recent product diversification bolstered investors  confidence  thereby boosting the stock price further  Of late  within Orthopedics and Tissue Technologies segment  the company launched several new regenerative products for the surgical reconstruction market  In the third quarter of 2017  the company registered mid single digit growth in Regenerative Technologies franchise  primarily banking on the addition of Derma Sciences and strong growth in patient skin portfolio Within tissue ablation  the global launch of CUSA Clarity is getting good response in the United States and abroad  Integra LifeSciences expects all these products to drive growth in 2017 and beyond We are also optimistic about the fact that Integra LifeSciences has successfully witnessed certain key overseas developments  despite facing foreign exchange fluctuations across its international business  Also  the company has adopted several near term objectives under its three pillar strategy  Management also expects to gain market traction through strategic partnerships and acquisitions On the flip side  foreign exchange and stiff competition pose as potent headwinds  Also  many of Integra LifeSciences  manufacturing  development or research facilities are vulnerable to natural disasters or unprecedented events  which depending on their severities  might force the company to cease development and manufacturing of some or all of its products It is important to note that last quarter  the impact of back to back hurricanes has grossly affected wound care and orthopedic procedures  particularly in Florida  In addition  the company was unable to fulfill certain private label orders because of the disruption to operations in Puerto Rico  leading to a double digit decrease in private label sales in the third quarter Key PicksA few better ranked stocks in the broader medical sector are PetMed Express  Inc    NASDAQ PETS    Luminex Corporation   NASDAQ LMNX   and Intuitive Surgical  Inc    NASDAQ ISRG    Notably  PetMed and Luminex sport a Zacks Rank  1  Strong Buy   while Intuitive Surgical carries a Zacks Rank  2  Buy   You can see PetMed has a long term expected earnings growth rate of 10   The stock has soared roughly 54  over the last six months Luminex has a long term expected earnings growth rate of 16 3   The stock has gained 6 3  over the last three months Intuitive Surgical has a long term expected earnings growth rate of 9 1   The stock has surged 33 5  over the last six months Zacks  Best Private Investment IdeasWhile we are happy to share many articles like this on the website  our best recommendations and most in depth research are not available to the public Starting today  for the next month  you can follow all Zacks  private buys and sells in real time  Our experts cover all kinds of trades  from value to momentum       from stocks under  10 to ETF and option moves       from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises  You can even look inside exclusive portfolios that are normally closed to new investors ,2017-11-01,Zacks Investment Research,https://www.investing.com/analysis/integra-gains-on-global-growth-hurricanes-hamper-business-200257941,200257941
112782,334297,ISRG,STERIS  STE  Q2 Earnings Miss   Revenues Beat  Margins Up,opinion,STERIS plc   NYSE STE   reported second quarter fiscal 2018 adjusted earnings per share  EPS  of 94 cents  up 5 6  from the year ago quarter  However  earnings missed the Zacks Consensus Estimate of 95 cents On a reported basis  EPS came in at 75 cents  up 59 6  year over year Revenues in DetailSTERIS generated revenues of  634 2 million  down 1 9  year over year  Meanwhile  the top line beat the Zacks Consensus Estimate of  630 million  The year over year decline was a result of sales loss owing to divested businesses  Organic revenue growth at constant currency was 4  year over year  primarily driven by balanced growth in two of the four segments The company operates through four segments  Healthcare Products  Healthcare Specialty Services  Applied Sterilization Technologies and Life Sciences Revenues from the Healthcare Products segment declined 2  year over year to  302 1 million in the reported quarter  This was largely due to an 8  decline in capital equipment revenues and a 1  decrease in consumable revenues as a result of divestitures  which in turn were partially offset by an 8  increase in service revenues  STERIS PLC Price  Consensus and EPS Surprise     Revenues from the Healthcare Specialty Services segment declined 15 7  to  116 1 million on a reported basis due to linen divestitures  However  organic revenues grew 10   reflecting growth at IMS North America Revenues from Applied Sterilization Technologies rose 5  to  126 5 million while organic revenues grew 5  on the back of increased demand from the segment s core medical device customers Revenues from the Life Sciences segment grew 10  to  89 5 million in the quarter on 13  growth in Service revenues  8  increase in consumable revenues and 9  rise in capital equipment revenues  On an organic basis  revenues increased 9  year over year  MarginsAdjusted gross margin improved 360 basis points  bps  year over year to 42 2  in the reported quarter on account of synergies from divested low margin businesses  improvement in operational efficiencies  a favorable product mix and pricing STERIS witnessed a 6 3  year over year decline in selling  general and administrative expenses to  153 4 million  Research and development expenses fell 4 8  to  13 9 million  Accordingly  adjusted operating margin expanded 490 bps on a year over year basis to 15 7  in the reported quarter Financial DetailsSTERIS exited second quarter fiscal 2018 with cash and cash equivalents of  295 6 million compared with  294 8 million at the end of first quarter fiscal 2018  The company had a long term debt of  1 45 billion at the end of second quarter fiscal 2018 compared with  1 49 billion at the end of first quarter fiscal 2018 Year to date  the company generated  217 4 million in cash flow from operations  up 15 3  from the year ago period  Free cash flow in this period was  144 million compared with  119 4 million in the prior year period 2018 GuidanceSTERIS continues to expect 4 5  of organic revenue growth in fiscal 2018 on a constant currency basis from the prior fiscal  Adjusted EPS is projected in the range of  3 96  4 09 Our TakeSTERIS exited second quarter fiscal 2018 on a mixed note  The year over year decline in revenues is a disappointment  On the positive side  organic growth performance was strong across three of the segments  Further  growth in free cash flow reserve is indicative of the company s strong cash balance  The company has also made certain divestments and organizational changes  which are expected to better align with its operations Zacks Rank   Other Key PicksSTERIS has a Zacks Rank  2  Buy  Other top ranked stocks in the broader medical sector are PetMed Express  Inc    NASDAQ PETS    Luminex Corporation   NASDAQ LMNX   and Intuitive Surgical  Inc    NASDAQ ISRG    Notably  PetMed and Luminex sport a Zacks Rank  1  Strong Buy   while Intuitive Surgical carries a Zacks Rank  2  You can see PetMed reported earnings per share of 43 cents in the second quarter of fiscal 2018  up 79 2  from the year ago quarter s 24 cents  Also  gross margin expanded 548 bps year over year to 35 2  in the reported quarter Luminex reported adjusted earnings per share of 19 cents in the third quarter of 2017  up 216 7  year over year  The company s revenues in the quarter increased almost 4 1  year over year to  74 1 million Intuitive Surgical posted adjusted earnings of  2 77 per share in the third quarter of 2017  up 34 5  on a year over year basis  Also  revenues increased 18  year over year to  806 1 million Zacks  Best Private Investment IdeasWhile we are happy to share many articles like this on the website  our best recommendations and most in depth research are not available to the public Starting today  for the next month  you can follow all Zacks  private buys and sells in real time  Our experts cover all kinds of trades  from value to momentum       from stocks under  10 to ETF and option moves       from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises  You can even look inside exclusive portfolios that are normally closed to new investors ,2017-11-01,Zacks Investment Research,https://www.investing.com/analysis/steris-ste-q2-earnings-miss--revenues-beat-margins-up-200257940,200257940
112783,334298,ISRG,Omnicell s Higher Investments Drive Costs  Competition Rife,opinion,On Nov 2  we issued an updated research report on Mountain View  CA based Omnicell Inc    NASDAQ OMCL    The company develops and markets end to end automation solutions for the medication use process Omnicell exited third quarter 2017 on a mixed note with earnings beating the Zacks Consensus Estimate and revenues missing the same  Also  weak gross margin scenario is a matter of concern  We believe the company s strategies including portfolio expansion  acquisitions and penetration into the medication adherence market continue to drive expenses  Meanwhile  expenses related to the recently launched XT series have been exerting pressure on the bottom line Omnicell s lowering of the high end of the full year 2017 adjusted revenue guidance is reflective of the fact that the overall weakness will continue  A tough competitive landscape also acts as a dampener   Over the last three months  Omnicell s shares have been trading below the broader   As per the latest share price movement  the stock has lost 1   significantly underperforming the broader industry s addition of 2 9  On a positive note  the year over year increase in earnings and revenues was impressive  The company witnessed balanced growth across all business lines in the quarter  We are encouraged to note that the company is working on product innovation through R D  Over the recent past  Omnicell has been observed to gain consistently from series of product launches  the latest being XT Series Automated Supply Dispensing system  and strategic partnerships Zacks Rank   Key PicksOmnicell has a Zacks Rank  5  Strong Sell  A few better ranked stocks in the broader medical sector are PetMed Express  Inc    NASDAQ PETS    Luminex Corporation   NASDAQ LMNX   and Intuitive Surgical  Inc    NASDAQ ISRG    Notably  PetMed and Luminex sport a Zacks Rank  1  Strong Buy   while Intuitive Surgical carries a Zacks Rank  2  Buy   You can see PetMed has a long term expected earnings growth rate of 10   The stock has rallied roughly 87 6  over the last year Luminex has a long term expected earnings growth rate of 16 3   The stock has gained 18  in the last year Intuitive Surgical has a long term expected earnings growth rate of 9 1   The stock has gained 67 6  last year Zacks  Best Private Investment IdeasWhile we are happy to share many articles like this on the website  our best recommendations and most in depth research are not available to the public Starting today  for the next month  you can follow all Zacks  private buys and sells in real time  Our experts cover all kinds of trades  from value to momentum       from stocks under  10 to ETF and option moves       from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises  You can even look inside exclusive portfolios that are normally closed to new investors ,2017-11-01,Zacks Investment Research,https://www.investing.com/analysis/omnicells-higher-investments-drive-costs-competition-rife-200257936,200257936
112784,334299,ISRG,DexCom  DXCM  Q3 Loss Narrower Than Expected  Revenues Meet ,opinion,DexCom  Inc    NASDAQ DXCM   reported a loss of 3 cents per share in the third quarter of 2017  narrower than the Zacks Consensus Estimate of a loss of 15 cents  Also  the figure improved from a loss of 22 cents reported in the year ago quarter Total revenues grew 24 2  to  184 6 million from  148 6 million in the year ago quarter  Revenues met the Zacks Consensus Estimate Segmental detailsSensor revenues  71  of total revenues  grew 24  on a year over year basis to  131 1 million  Transmitter revenues  21   increased 20  from the prior year quarter to  38 2 million  Receiver revenues  8   grew 15  year over year to  14 4 million  Other revenues  including revenues from services  freight  accessories  etc    accounting for the rest  totaled  0 9 million DexCom  Inc  Price  Consensus and EPS Surprise     Operational DetailsDexCom generated gross margin  as a percentage of revenues  of 68 8   compared with 68  in the same quarter of the prior year  Notably  gross margin expanded 76 basis points  bps  year over year International business displayed continued to grow in the quarter  generating  33 3 million in revenues  up 83  on a year over year basis  Notably  international business represented 18  of total revenues in the third quarter Research and development  R D  expenses totaled  43 3 million in the quarter  contracting 1 4  from  43 9 million a year ago Selling  general and administrative expenses totaled  84 2 million in the reported quarter  increasing 11 2  from  75 7 million in the prior year quarter Financial UpdateAs of Sep 30  DexCom had  525 8 million in cash  cash equivalents and short term marketable securities versus  496 6 million at the end of the second quarter of 2017 GuidanceThe company expects global revenues to come in at the low end of its previously issued guidance of  710 million to  740 million  For the full year  DexCom reaffirmed the low end of the 67  to 70  gross margin guidance Zacks Rank   Key PicksDexCom has a Zacks Rank  3  Hold  A few better ranked stocks in the broader medical sector are PetMed Express  Inc    NASDAQ PETS    Luminex Corporation   NASDAQ LMNX   and Intuitive Surgical  Inc    NASDAQ ISRG    Notably  PetMed and Luminex sport a Zacks Rank  1  Strong Buy   while Intuitive Surgical carries a Zacks Rank  2  Buy   You can see PetMed reported earnings per share of 43 cents in the second quarter of fiscal 2018  up 79 2  from the year ago quarter s 24 cents  Also  gross margin expanded 548 bps year over year to 35 2  in the reported quarter Luminex reported adjusted earnings per share of 19 cents in the third quarter of 2017  up 216 7  year over year  The company s revenues in the quarter increased almost 4 1  year over year to  74 1 million Intuitive Surgical posted adjusted earnings of  2 77 per share in the third quarter of 2017  up 34 5  year over year  Also  revenues increased 18  year over year to  806 1 million Zacks  Best Private Investment IdeasWhile we are happy to share many articles like this on the website  our best recommendations and most in depth research are not available to the public Starting today  for the next month  you can follow all Zacks  private buys and sells in real time  Our experts cover all kinds of trades  from value to momentum       from stocks under  10 to ETF and option moves       from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises  You can even look inside exclusive portfolios that are normally closed to new investors ,2017-11-01,Zacks Investment Research,https://www.investing.com/analysis/dexcom-dxcm-q3-loss-narrower-than-expected-revenues-meet-200257934,200257934
112785,334300,ISRG,Align Technology  ALGN  Gains On InvisAlign  Competition Rife,opinion,On Oct 31  we issued an updated research report on Align Technology  Inc    NASDAQ ALGN    The stock currently sports a Zacks Rank  1  Strong Buy  Align Technology  which manufactures and markets a system of clear aligner therapy  intra oral scanners and CAD CAM  computer aided design and manufacturing  digital services used in dentistry  orthodontics and dental records storage  has been trading above its  over the past month  The stock has gained 26  in this period as compared to 0 9  growth of the industry  The company delivered an encouraging third quarter of 2017  posting better than expected earnings and revenues We are encouraged by the company s solid InvisAlign Technology prospects and growth in North America and internationally  The company s receipt of two U S  patents for SmartTrack Aligner material also buoys optimism Moreover  Align Technology has been seeing strong international sales  especially in the EMEA and APAC regions  The third quarter marked another milestone for the company where China became the second largest market globally with United States topping the numbers  Align Technology witnessed balanced sales growth across all its channels in the recent past  primarily driven by high InvisAlign Technology case volumes  Solid performance in the summer drove Invisalign growth in the global teen market In an encouraging development  the company recently signed a distribution agreement with Patterson Dental  Per the non exclusive agreement  effective September 2017  Align Technology s iTero Element intraoral scanning system will be available as part of Patterson Dental s CAD CAM portfolio in the United States and Canada  On the flipside  adverse foreign exchange translation continues to raise concerns for Align Technology s international operations  Also  escalating costs and expenses are weighing on margins  Moreover  a tough competitive landscape and other macroeconomic headwinds pose a threat Other Key PicksOther top ranked stocks in the broader medical sector are PetMed Express  Inc    NASDAQ PETS    Luminex Corporation   NASDAQ LMNX   and Intuitive Surgical  Inc    NASDAQ ISRG    Notably  PetMed and Luminex sport a Zacks Rank  1  while Intuitive Surgical carries a Zacks Rank  2  Buy   You can see PetMed has a long term expected earnings growth rate of 10   The stock has rallied roughly 87 6  over the last year Luminexhas a long term expected earnings growth rate of 16 3   The stock has gained 18  in the last year Intuitive Surgicalhas a long term expected earnings growth rate of 9 1   The stock has gained 67 6  last year Zacks  Best Private Investment IdeasWhile we are happy to share many articles like this on the website  our best recommendations and most in depth research are not available to the public Starting today  for the next month  you can follow all Zacks  private buys and sells in real time  Our experts cover all kinds of trades  from value to momentum       from stocks under  10 to ETF and option moves       from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises  You can even look inside exclusive portfolios that are normally closed to new investors ,2017-11-01,Zacks Investment Research,https://www.investing.com/analysis/align-technology-algn-gains-on-invisalign-competition-rife-200257901,200257901
112786,334301,ISRG,Pacific Biosciences  PACB  Q3 Loss Narrower Than Estimated,opinion,Pacific Biosciences of California Inc    NASDAQ PACB   reported a loss of 19 cents per share in the third quarter of 2017  a penny narrower than the Zacks Consensus Estimate  The loss is in line with the year ago quarter  Strength in China and Asia boosted the company s bottom line in the quarter  The company has a Zacks Rank  3  Hold  Revenues of  24 million missed the Zacks Consensus Estimate of  28 million and declined 4 2  on a year over year basis  Notably  the DNA sequencing market is highly competitive owing to the presence of several established players  Cutthroat competition in the niche space is the primary reason for the year over year decline in revenues Segment DetailsProduct revenues rose 12 7  to almost  20 3 million  Service revenues declined 7 8  from the year ago quarter to almost  3 2 million  Year to date  Pacific Biosciences generated  68 5 million in product and service revenues  up 26  from  54 2 million generated in the first three quarters of 2016 Consumable revenues in the reported quarter were  10 6 million  up 62  on a year over year basis  Consumable revenue growth was driven by higher installed base of instruments and growth in sequel instrument utilization Instrument revenues in the third quarter were  9 7 million  down from  11 5 million on a year over year basis  At the end of the quarter under review  Pacific Biosciences installed base of sequel instruments totaled around 200 instruments The company didn t record any contractual revenues in the quarter Pacific Biosciences of California  Inc  Price and Consensus   Margin DetailsIn the third quarter  Pacific Biosciences generated gross profit of  8 2 million  As a percentage of revenues  gross margin in the quarter was 35   down substantially from a year ago Operating expenses in the third quarter of 2017 totaled  29 8 million  compared with  29 4 million on a year over year basis  Year to date  operating expenses in 2017 were  94 4 million  R D expenses in the quarter totaled   15 8 million  down from  17 5 million a year ago  Sales  general and administrative expenses in the third quarter were  40 million  compared with  11 9 million in the third quarter of 2016 Financial UpdateCash and investments at the end of the third quarter was  84 million  compared with  102 6 million at the end of the second quarter OutlookManagement expects full year revenues of around  90 million and an improvement in gross margin performance  For the fourth quarter  Pacific Biosciences expects gross margin in the range of 37  to 40  of net revenues Our ViewpointSolid contribution from the Instrument and Consumable revenue platforms acted as a significant positive for Pacific Biosciences in the third quarter  The improvement in margin sales of the Sequel System is another encouraging factor  The company also witnessed significant strength in China  Notably  it placed numerous system orders in the region with both new and existing customers  Of the major concerns  the DNA sequencing market is highly competitive owing to the presence of several established players  Cutthroat competition in the niche space is a headwind  However  problems related to the limited availability of SMRT cells  Single Molecule  Real Time  for the Sequel system and higher non cash operating expenses are expected to mar prospects Companies Reporting Solid Earnings ResultsIntuitive Surgical Inc    NASDAQ ISRG   posted adjusted earnings of  2 77 per share in the third quarter of 2017  beating the Zacks Consensus Estimate of  1 97 on stellar revenue growth  The stock has a Zacks Rank  2  Buy  PetMed Express  Inc  s   NASDAQ PETS   adjusted earnings per share of 43 cents in the second quarter of fiscal 2018 were up 79 2  from the year ago quarter  Also  earnings surpassed the Zacks Consensus Estimate by 43 3   The stock has a Zacks Rank  1  Strong Buy   You can see Becton  Dickinson and Company   NYSE BDX    popularly known as BD  reported fourth quarter fiscal 2017 earnings of  2 40 per share  which beat the Zacks Consensus Estimate of  2 38 and increased 13 2  on a year over year basis  The stock has a Zacks Rank  2 Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana      Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2017-11-02,Zacks Investment Research,https://www.investing.com/analysis/pacific-biosciences-pacb-q3-loss-narrower-than-estimated-200258177,200258177
112791,334306,ISRG,PerkinElmer  PKI  Beats Q3 Earnings  Updates  17 Guidance,opinion,"PerkinElmer Inc    NYSE PKI   reported third quarter 2017 adjusted earnings of 73 cents per share  beating the Zacks Consensus Estimate of 72 cents The company  based in Waltham  MA  reported adjusted revenues of approximately  554 million  which beat the Zacks Consensus Estimate of  552 million  Revenues also surpassed the year ago figure of  548 million Segment DetailsRevenues from Discovery   Analytical Solutions  DAS  totaled  385 4 million in the third quarter  up 4  from  365 1 million in the year ago quarter Meanwhile  operating profit margin  as a percentage of revenues  was 16 1  compared with the prior year quarter s level of 16 2  In the Diagnostics segment  revenues were  168 9 million as compared with  149 4 million in the year ago quarter  This reflects a 5  increase organically Meanwhile  operating profit margin for the segment  as a percentage of revenues  was 33 5  compared with 33 8  in the year ago quarter  PerkinElmer  Inc  Price  Consensus and EPS Surprise     
Margin DetailsAdjusted gross margin  as a percentage of revenues  was 49 8  in the quarter  down 10 basis points  bps  year over year  The deterioration was a result of acquisitions and divestitures executed in 2016 Adjusted selling  general   administrative  SG A  expenses  as a percentage of revenues  were 24 2   down 80 bps from the year ago quarter Research and Development  R D  expenses  as a percentage of revenues  rose 40 bps in the third quarter to  34 9 million As a result  the company s overall adjusted operating margin from continuing operations was 19 3  of net revenues  up 30 bps on a year over year basis Financial DetailsIn the first nine months of 2017  PerkinElmer s operating cash flow from continuing operations was  165 million  The company concluded the quarter with approximately  1 1 billion in debt and  709 million in cash Guidance RaisedThe company revised its adjusted earnings guidance for full year 2017  PerkinElmer now expects adjusted earnings per share in the band of  2 87  2 89  compared with the previous range of  2 84  2 92 Zacks Rank   Key PicksPerkinElmer has a Zacks Rank  3  Hold  A few better ranked stocks in the broader medical sector are PetMed Express  Inc    NASDAQ PETS    Luminex Corporation   NASDAQ LMNX   and Intuitive Surgical  Inc    NASDAQ ISRG    Notably  PetMed and Luminex sport a Zacks Rank  1  Strong Buy   while Intuitive Surgical carries a Zacks Rank  2  Buy   You can see  PetMed reported second quarter fiscal 2018 earnings of 43 cents  up 79 2  from 24 cents in the year ago quarter  Gross margin expanded 548 bps year over year to 35 2  Luminex reported third quarter 2017 adjusted earnings of 19 cents  up 216 7  year over year  The company s revenues in the quarter increased almost 4 1  year over year to  74 1 million Intuitive Surgical posted third quarter 2017 adjusted earnings of  2 77  up 34 5  on a year over year basis  Revenues increased 18  year over year to  806 1 million Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2017-11-02,Zacks Investment Research,https://www.investing.com/analysis/perkinelmer-pki-beats-q3-earnings-updates-17-guidance-200258176,200258176
112797,334312,ISRG,Allscripts  MDRX  Q3 Earnings Meet  Revenues Beat Estimates,opinion,Allscripts Healthcare Solutions  Inc    NASDAQ MDRX   reported third quarter 2017 adjusted earnings of 16 cents per share  in line with the Zacks Consensus Estimate  The figure surpassed year ago earnings of 14 cents Adjusted revenues  which exclude acquisition related deferred revenues  Netsmart   grew 11 7  to  451 2 million and surpassed the Zacks Consensus Estimate of  430 million Further  the company completed the acquisition of McKesson Corporation  NYSE MCK  s hospital and health system IT business  known as the Enterprise Information Solutions  EIS  business  on Oct 2  Allscripts Healthcare Solutions  Inc  Price  Consensus and EPS Surprise     Quarter DetailsKey Highlights  Solid growth in U S  Core Solutions and Services  fueled by Sunrise electronic health record  EHR  platform and Allscripts Revenue Cycle Management Services  buoyed optimism in the third quarter  The company also inked a new partnership to develop and deploy preauthorization solutions for medical procedures at the point of care  Moreover  the company expanded its international client roster in the quarter Bookings  Bookings in the third quarter were  304 million  highest to date   up 4  on a year over year basis  Notably  50  of net bookings was generated by the software delivery unit  while the remaining came from client services Software Delivery  Support and Maintenance Revenues  This segment comprises all software  hardware  subscription  other transactions and support and maintenance revenues  Revenues at the segment increased 12  to  295 million in the quarter Client Services Revenues  This segment takes care of recurring managed services and other project based client services  Client service revenues were up 10  on a year over year basis to  156 million Recurring Revenues  This segment covers subscriptions  recurring transactions  support and maintenance and recurring managed services  Adjusted recurring revenues increased 11  on a year over year basis Non recurring Revenues  This segment comprises systems sales and other project based client services  Adjusted non recurring revenues at the segment increased 9  on a year over year basis Margin DetailsGross margin expanded 262 basis points  bps  to 44 9  in the third quarter  As a percentage of revenues  Allscripts registered adjusted gross margin of 48 4  in the third quarter  compared with 47 6  in the year ago quarter Software gross margin  as a percentage of revenues  increased 150 bps on a year over year basis  However  Client service margin in the third quarter came in at 15 6  of revenues  compared to 16 8  in the same period last year According to the company  adjusted operating expenses in the quarter totaled  148 million  reflecting an 11  year over year increase Selling  general   administrative expenses increased 18 8  to  117 4 million and research and development expenses rose 13 1  to  51 1 million from a year ago GuidanceFor 2017  the company expects revenues at the high end of the earlier provided range of  1 79 billion to  1 82 billion   The adjusted earnings per share growth guidance has been reaffirmed at the band of 10  to 15   Adjusted EBITDA is expected at the high end of the previously provided range of  345 million to  365 million Per management  Allscripts  2017 guidance includes three months of financial contribution from the EIS acquisition in the fourth quarter of 2017  Moreover  the company anticipates to incur nearly  50 million in severance and transaction costs related to the EIS transaction starting from the fourth quarter of 2017  which are expected to be recognized quarterly until no later than the fourth quarter of 2018 Our TakeAllscripts exited the third quarter on a favorable note  A solid guidance for 2017 and an encouraging long term outlook are the key highlights of the quarter  Also  expansion in margin is encouraging  We look forward to the takeover of the hospital and health system business of McKesson Corporation  Allscripts  continued reliance on mergers and acquisition activities poses substantial integration risks  Furthermore  intensifying competition is a major dampener  The company s products have a long sales cycle which involves intensive decision making at different managerial levels Zacks Rank   Key PicksAllscripts has a Zacks Rank  3  Hold  A few better ranked stocks in the broader medical sector are PetMed Express  Inc    NASDAQ PETS    Luminex Corporation   NASDAQ LMNX   and Intuitive Surgical  Inc    NASDAQ ISRG    Notably  PetMed and Luminex sport a Zacks Rank  1  Strong Buy   while Intuitive Surgical carries a Zacks Rank  2  Buy   You can see PetMed reported earnings per share of 43 cents in the second quarter of fiscal 2018  up 79 2  from the year ago quarter s 24 cents  Also  gross margin expanded 548 bps year over year to 35 2  in the reported quarter Luminex reported adjusted earnings per share of 19 cents in the third quarter of 2017  up 216 7  year over year  Revenues in the quarter increased almost 4 1  year over year to  74 1 million Intuitive Surgical posted adjusted earnings of  2 77 per share in the third quarter of 2017  up 34 5  year over year  Revenues increased 18  year over year to  806 1 million Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2017-11-02,Zacks Investment Research,https://www.investing.com/analysis/allscripts-mdrx-q3-earnings-meet-revenues-beat-estimates-200258140,200258140
112798,334313,ISRG,Bruker  BRKR  Q3 Earnings   Revenues Beat Estimates  View Up,opinion,Bruker Corporation   NASDAQ BRKR   reported adjusted earnings per share  EPS  of 29 cents in the third quarter of 2017  down 9 4  from the year ago figure  However  adjusted EPS beat the Zacks Consensus Estimate by a couple of cents Excluding one time items  Bruker reported net income of  37 million or 23 cents per share in the third quarter  compared with  46 5 million or 29 cents  respectively  in the year ago quarter Revenues in DetailBruker reported revenues of  435 6 million in the third quarter  up 10 6  year over year  The top line surpassed the Zacks Consensus Estimate of  414 million  Excluding a 4 8  positive effect from acquisitions and a 2 4  favorable impact from changes in foreign currency rates  Bruker reported year over year organic revenue growth of 3 4  in the quarter under reveiw  Geographically and currency adjusted  European revenues increased in mid teens year over year in the third quarter  North America revenues increased low  to mid single digits  In Asia Pacific  organic revenues declined marginally  While China revenues again rose double digits in the third quarter  it was offset by a steep decline in Japan and soft performance in other Asia Pacific regions Bruker Corporation Price  Consensus and EPS Surprise     Management expects continued organic revenue growth in 2018 on the back of the multi year margin expansion initiative Per management  the company registered organic revenue growth based on NANO and CALID Group Bruker s BioSpin Group reported low single digit revenue growth on year to date basis  Revenues were however flat year over year  Per management  the upside was led by strong contribution from aftermarket and service sales  which were up low double digits in both the quarter and the year to date periods The Bruker NANO reported high single digit revenue growth on a year over date basis on the back of strong organic growth and contributions from the January 2017 Hysitron acquisition of nanoindenting products  Also  year to date growth at AXS was driven by higher industrial growth and recovery in the European markets  On an organic basis  NANO group revenues rose low double digits CALID revenues increased mid single digits year to date on an organic basis in the third quarter  CALID gained from the InVivo consumables acquisition made in January 2017  Year to date  Daltonics mass spec revenues within the CALID Group increased and Optics products garnered solid revenue growth on strong execution and improved applied and industrial market demand BEST revenues rose 11  organically on a year to date basis backed by higher MRI OEM consumer demand and the Bruker OST acquisition made in November 2016 Margin TrendGross margin in the reported quarter contracted 156 basis points  bps  to 45 5   According to the company  adjusted gross margin declined 130 bps to 47 6  owing to a predicted gross margin headwind from acquisitions  negative currency effects as well as product  geographic and business mix Selling  general   administrative expenses increased 6 3  to  102 9 million and research and development expenses rose 7 9  to  40 9 million from the year ago period  The other charges contracted 6 5  year over year to  4 3 million  Overall  operating margin contracted 20 bps to 11 5  Financial PositionBruker exited third quarter 2017 with cash and cash equivalents and short term investments of  429 2 million  down from  440 3 million at the end of the second quarter  Year to date net cash provided by operating activities was  50 7 million  compared with  40 million in the year ago period 2017 GuidanceBruker provided an update to its guidance for 2017 Total revenue growth rate expectation for the year has been raised to a band of 8 8 5  from the earlier 4 5 6 0   Moreover  organic revenue growth guidance has been lifted to 2 5 3  from 1 5 2  on continued acquisition growth expectations of 4 5   previously 3 5 4   and a foreign currency tailwind of around 1   The current Zacks Consensus Estimate for 2017 revenues is pegged at  1 71 billion The company expects 2017 adjusted operating margin increase of approximately 70 100 bps year over year  up from the previous guidance of 40 70 bps  This includes an approximate 40 bps headwind in fiscal 2017 from the recent acquisitions   Bruker raised adjusted EPS projections to a range of  1 17  1 20 from  1 08  1 12  The current Zacks Consensus Estimate for 2017 EPS is pegged at  1 12 Our TakeBruker exited the third quarter on a solid note  The company also raised 2017 guidance  which is indicative of brighter prospects  The company s strategic acquisition activity has been encouraging  We are also upbeat about the company s current focus on product development through increased R D  On the flip side  competitive landscape and macroeconomic headwinds continue to pose challenges for the company  Also  the contraction in both gross and operating margin is disappointing Zacks Rank   Key PicksBruker currently carries a Zacks Rank  3  Hold  A few better ranked stocks in the broader medical sector are PetMed Express  Inc    NASDAQ PETS    Luminex Corporation   NASDAQ LMNX   and Intuitive Surgical  Inc    NASDAQ ISRG    Notably  PetMed and Luminex sport a Zacks Rank  1  Strong Buy   while Intuitive Surgical carries a Zacks Rank  2  Buy   You can see PetMed reported earnings per share of 43 cents in the second quarter of fiscal 2018  up 79 2  from the year ago quarter s 24 cents  Also  gross margin expanded 548 bps year over year to 35 2  in the reported quarter Luminex reported adjusted earnings per share of 19 cents in the third quarter of 2017  up 216 7  year over year  The company s revenues in the quarter increased almost 4 1  year over year to  74 1 million Intuitive Surgical posted adjusted earnings of  2 77 per share in the third quarter of 2017  up 34 5  year over year  Also  revenues increased 18  year over year to  806 1 million Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2017-11-02,Zacks Investment Research,https://www.investing.com/analysis/bruker-brkr-q3-earnings--revenues-beat-estimates-view-up-200258135,200258135
112819,334334,ISRG,Align Technology  ALGN  Q3 Earnings Top On Invisalign Sales,opinion,Align Technology  Inc    NASDAQ ALGN   reported earnings per share  EPS  of  1 01 in the third quarter of 2017  substantially up 60 3  year over year  Earnings were also higher than the company s guided range of 78 81 cents  The figure comfortably beat the Zacks Consensus Estimate of 82 cents RevenuesRevenues grew 38 3  year over year to  385 3 million in the quarter  surpassing the Zacks Consensus Estimate of  360 million  This also remained well ahead of the company s guided range of  355  360 million Per management  a strong top line was driven by robust Invisalign case shipments of 32 8  year over year to 236 1 thousand during the third quarter  This upside was backed by growth in North America and international regions  Also a 46 3  year over year surge in teenage cases across the board  reflecting a very strong summer teen season  contributed to the top line growth Segments in DetailRevenues at the Clear Aligner segment  88 7  of total revenue  soared 40 2  year over year to  341 6 million in the reported quarter  primarily driven by continued strong Invisalign case volume growth across all customer channels and geographical regions In the third quarter  Invisalign case shipments amounted to 236 065  up 32 8  year over year  aided by growth across all regions as well as the expansion of customer base  During the quarter  Align Technology Invisalign cases were shipped to 42 605 doctors worldwide  of which  24 845 were from North America while 17 760 were from international regions Revenues from Scanner and Service  11 3   improved significantly by 25  to  43 7 million MarginsGross margin in the third quarter was up 82 basis points  bps  year over year to 75 9  on a 33 7  rise in cost of net revenue During the quarter  Align Technology witnessed a 33 8  year over year increase in selling  general and administrative expenses to  169 5 million and an 18 5  rise in research and development  R D  expenses to  24 2 million  The operating margin  however  expanded 335 bps to 25 6  Financial DetailsAlign Technology exited the third quarter with cash and cash equivalents and short term marketable securities of  679 1 million  which marked a 12 8  rise from the preceding quarter In the reported quarter  Align Technology closed its earlier announced  50 million accelerated stock repurchase program  ASR  receiving a total of 0 4 million shares at a weighted average share price of  146 48  Management currently has  250 million available for repurchase under the existing stock repurchase authorization GuidanceFor the fourth quarter of 2017  the company projects EPS of 92 95 cents on revenues of  391  398 million  The company also expects Invisalign case shipments in the band of 245 000  250 000  up 29 32  over the same period a year ago Our TakeAlign Technology ended the third quarter on a solid note with both earnings and revenues beating the Zacks Consensus Estimate  We are upbeat about the continued strong Invisalign volumes  An extremely strong summer teen season drove the company s Invisalign growth within the global teen market Within Scanners and Service  the company witnessed a nice uptake of iTero scanners by GP dentists  With record contracts coming from the GP summit last September  the company expects this bullish trend to continue for the rest of 2017  Align is also looking forward to its recently inked distribution agreement with Patterson Dental for Align s iTero Element intraoral scanning system Additionally  the company has a strong cash balance that enables it to carry out share repurchase programs and in turn provide solid returns to its investors On the flip side  the company is exposed to foreign exchange fluctuations  seasonal demand fluctuations  higher operating expenses pertaining to an increased head count along with higher investments targeted toward growth acceleration in geographical expansion and portfolio extension Zacks Rank   Key PicksCurrently  Align Technology carries a Zacks Rank  3  Hold  Some better ranked stocks in the broader medical sector are PetMed Express  Inc    NASDAQ PETS    Abbott   NYSE ABT   and Intuitive Surgical  Inc    NASDAQ ISRG    Notably  PetMed sports a Zacks Rank  1  Strong Buy   while Abbott and Intuitive Surgical carry a Zacks Rank  2  Buy   You can see PetMed reported EPS of 43 cents for the second quarter of fiscal 2018  up 79 2  from the year ago quarter s 24 cents  Also  gross margin expanded 548 bps year over year to 35 2  in the reported quarter Abbott reported third quarter 2017 adjusted earnings from continuing operations of 66 cents per share  up 11 9  year over year  Also  third quarter worldwide sales came in at  6 83 billion  up 28 8  year over year  Intuitive Surgical posted adjusted earnings of  2 77 per share in the third quarter of 2017  up 34 5  on a year over year basis  Also  revenues rallied 18  year over year to  806 1 million Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2017-10-26,Zacks Investment Research,https://www.investing.com/analysis/align-technology-algn-q3-earnings-top-on-invisalign-sales-200221557,200221557
112820,334335,ISRG,Integra LifeSciences  IART  Misses On Q3 Earnings   Revenues,opinion,Integra LifeSciences Holdings Corporation   NASDAQ IART   reported adjusted earnings per share  EPS  of 45 cents in the third quarter of 2017  which declined 2 2  from the year ago figure Adjusted EPS also missed the Zacks Consensus Estimate of 47 cents  Including one time items  the company reported earnings of 4 cents per share  down 54  from the year ago quarter Revenue DiscussionTotal revenue in the reported quarter increased 11 4  year over year to  278 8 million  which lagged the Zacks Consensus Estimate of  286 million  Excluding revenues from acquisitions  discontinued products and the effect of currency exchange rates  organic revenues rose 1 5  year over year The solid revenue growth in the third quarter was primarily driven by strong contribution from the Orthopedics and Tissue Technologies segments Coming to product categories  revenues from the company s Specialty Surgical Solutions segment increased 3 4  to  164 8 million Orthopedics and Tissue Technologies revenues came in at  114 1 million in the third quarter  up 25 5  year over year Margin TrendGross margin contracted 81 basis points  bps  to 63 5  in the reported quarter  Per the company  adjusted gross margin contracted 60 bps to 68 7  Selling  general and administrative expenses increased 29 9  to  145 9 million in the reported quarter  while research and development expenses contracted 0 6  to  15 million  Adjusted operating margin saw a 763 bps contraction to 5 8  in the third quarter Financial PositionIntegra LifeSciences exited third quarter 2017 with cash and cash equivalents of  481 9 million  up from  154 6 million recorded at the end of second quarter 2017  As of Sep 30  2017  net cash flow from operating activities was  102 9 million  down from  109 9 million in the year ago quarter 2017 Outlook TweakedManagement has raised the full year 2017 revenue guidance from  1 125  1 140 billion to  1 165  1 175 billion  Meanwhile  full year 2017 organic revenue growth range was lowered to 4  from 6  to 7   The Zacks Consensus Estimate for full year 2017 revenues is  1 20 billion  below the guided range The company has revised its full year 2017 adjusted EPS guidance to 1 83  1 87 from the previous range of  1 88  1 94  The Zacks Consensus Estimate for 2017 adjusted earnings is pegged at  1 91  above the company s guided range Our TakeIntegra LifeSciences exited the third quarter of 2017 on a disappointing note  Also  contraction in adjusted operating margin and adjusted gross margin adds to the woes  Moreover  the drop in year over year investments in research and development is discouraging  In spite of the raised full year revenue guidance  the slashed full year adjusted earnings range adds to the woes However  the strong year over year increase in revenues on the back of its Orthopedics and Tissue Technologies segment buoys optimism  We are also encouraged to note that the company s segments saw year over year revenue growth in the quarter  Nonetheless  we believe the company is trying to execute its growth plan through an efficient management team Zacks Rank   Key PicksIntegra LifeSciences has a Zacks Rank  3  Hold  A few better ranked stocks in the broader medical sector are PetMed Express  Inc    NASDAQ PETS    Abbott   NYSE ABT   and Intuitive Surgical  Inc    NASDAQ ISRG    Notably  PetMed sports a Zacks Rank  1  Strong Buy   while Abbott and Intuitive Surgical carry a Zacks Rank  2  Buy   You can see PetMed reported EPS of 43 cents in the second quarter of fiscal 2018  up 79 2  from the year ago quarter s 24 cents  Also  gross margin expanded 548 bps year over year to 35 2  in the reported quarter Abbott reported third quarter 2017 adjusted earnings from continuing operations of 66 cents per share  up 11 9  year over year  Also  third quarter worldwide sales came in at  6 83 billion  up 28 8  year over year  Intuitive Surgical posted adjusted earnings of  2 77 per share in the third quarter of 2017  up 34 5  on a year over year basis  Also  revenues increased 18  year over year to  806 1 million Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2017-10-26,Zacks Investment Research,https://www.investing.com/analysis/integra-lifesciences-iart-misses-on-q3-earnings--revenues-200221507,200221507
112821,334336,ISRG,Quality Systems  QSII  Beats On Earnings   Revenues In Q2,opinion,"Quality Systems Inc    NASDAQ QSII   reported second quarter fiscal 2018 adjusted earnings of 22 cents per share  beating the Zacks Consensus Estimate by 6 cents  However  adjusted earnings deteriorated 4 3  on a year over year basis Revenues totaled  132 6 million  outpacing the Zacks Consensus Estimate of  131 million  Revenues also increased 4 7  on a year over year basis Quality Systems carries a Zacks Rank  4  Sell  Segment DetailsTotal software  hardware and related revenues increased 1 5  to  39 3 million  primarily driven by a 16 3  rise in software related subscription services  However  growth at this segment was partially offset by lower software license and hardware sales  which declined almost 17  in the quarter  The company expects software license and hardware revenues to remain under pressure for the remainder of the fiscal Support and maintenance revenues in the quarter totaled  41 7 million  up 7  on a year over year basis  Revenues at this segment were driven annual price increases Professional services revenues increased 9 9  to almost  7 7 million  The year over year increase was led by transfusion services  However  the rise was offset by a decline in sales of software products Coming to electronic data interchange  EDI  services  revenues increased 6 4  on a year over year basis to almost  23 million Meanwhile  the company s revenue cycle management  RCM  business revenues inched up 0 3  to  21 million in the quarter under review Quality System s recurring revenues were driven by contributions from subscription  support and maintenance  RCM and EDI  In the second quarter  recurring revenues reached a record level of 83  of total revenues  
Quality Systems  Inc  Price  Consensus and EPS Surprise
     
Quarter HighlightsEagleDream   Entrada Hold Promise  In August  Quality Systems completed the acquisition of EagleDream Health Inc  for roughly  26 million in cash  EagleDream Health is a cloud based analytics company that optimizes understanding across clinical  financial and administrative data to enhance practice performance Following the acquisition  NextGen Healthcare  a wholly owned subsidiary of Quality Systems  gained facilities to provide enriching care experience and accelerate patient engagement for ambulatory clinics and health systems  Management further expects to achieve per capita cost efficiency as well as enhanced work life balance for clinicians and staff in the quarter to come  read more    Entrada s pipeline has been offering new deals to Quality Systems for quite some time now  Earlier this year  NextGen Healthcare had acquired Entrada for  34 million  Per the second quarter fiscal 2018 results  Subscription revenues were significantly up on strength in Entrada  We believe the acquisition will prove accretive over the long haul Bookings Decline  Quality Systems registered bookings worth  26 million  down 24  on a year over year basis  Per management  subscription bookings continued to be a steady contributor to second quarter bookings  However  headwinds in the perpetual license bookings marred bookings growth in the quarter Margin DetailsQuality Systems  gross margin remained flat on a year over year basis at 56  of net revenues in the reported quarter Coming to operating expenses  the company recorded selling general   administrative  SG A  expenses of  41 million  down from  42 8 million a year ago  As a percentage of revenues  SG A expenses in the second quarter were 69   up 260 basis points  bps  on a year over year basis Meanwhile  research and development  R D  costs totaled  19 5 million  expanding 40 bps year over year  R D expenses rose in the second quarter on the back of incremental personnel costs  offset by increased software capitalization GuidanceFor fiscal 2018  the company projects revenues in the band of  522  530 million  up from the previously issued range of  512  530 million Adjusted earnings per share are projected in the range of 64 cents to 68 cents  compared with the previous 62 cents to 70 cents Our TakeQuality Systems posted a stellar second quarter of fiscal 2018  beating the Zacks Consensus Estimate on both the counts  We are particularly upbeat about the company s solid performance with regard to total software  hardware and related revenues  Quality Systems  solid recurring revenue base is a key catalyst for the quarters to come  Furthermore  the company s new Entrada and Eagle Dream solutions are likely to drive growth  On the flipside  ongoing sluggishness in the RCM customer base  intensifying competition and a strict regulatory environment are likely to mar the top line  Furthermore  management slashed the high end of the fiscal 2018 earnings guidance  signaling at looming concerns  The company expects software license and hardware revenues to remain under pressure for the remainder of the fiscal Companies With Solid Earnings ResultsIntuitive Surgical Inc    NASDAQ ISRG   posted adjusted earnings of  2 77 per share in the third quarter of 2017  beating the Zacks Consensus Estimate of  1 97 on stellar revenue growth  The stock has a Zacks Rank  2  Buy  PetMed Express  Inc  s   NASDAQ PETS   adjusted earnings per share of 43 cents for the second quarter of fiscal 2018 were up 79 2  from the year ago quarter  Also  earnings surpassed the Zacks Consensus Estimate by 43 3   The stock has a Zacks Rank  1  Strong Buy   You can see Cerner Corporation   NASDAQ CERN   promises a long term expected earnings growth of 13 8   In the just reported third quarter  Cerner registered revenues of  1 29 billion  up 7 7  on a year over year basis  The stock carries a Zacks Rank  2 Zacks  Best Private Investment IdeasWhile we are happy to share many articles like this on the website  our best recommendations and most in depth research are not available to the public Starting today  for the next month  you can follow all Zacks  private buys and sells in real time  Our experts cover all kinds of trades  from value to momentum       from stocks under  10 to ETF and option moves       from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises  You can even look inside exclusive portfolios that are normally closed to new investors ",2017-10-29,Zacks Investment Research,https://www.investing.com/analysis/quality-systems-qsii-beats-on-earnings--revenues-in-q2-200256969,200256969
112828,334343,ISRG,Omnicell  OMCL  Earnings Beat  Revenues Miss Estimates In Q3,opinion,Omnicell  Inc    NASDAQ OMCL   reported earnings per share of 42 cents in third quarter 2017  beating the Zacks Consensus Estimate by a penny  Earnings improved from the year ago figure of 40 cents as welll Revenues in DetailRevenues during the third quarter increased 5 7  year over year to  186 8 million  missing the Zacks Consensus Estimate of  192 million  The year over year upside was driven by the product sensation and related ramp up of the XT Series launch  Revenues also lagged the company s guided range of  188 million to  194 million owing to the impact of the Harvey and Irma hurricanes On a segmental basis  Omnicell s Automation and Analytics revenues inched up 1 5  year over year in the third quarter to  154 7 million However  revenues at the Medication Adherence segment rose 32 2  year over year to  32 1 million  Omnicell  Inc  Price  Consensus and EPS Surprise     Operational UpdateOmnicell s gross profit during the reported quarter increased 4 1  to  84 9 million  Gross margin contracted 70 basis points  bps  to 45 4   According to the company  adjusted gross margin in the third quarter was 47 6   reflecting a contraction of 310 bps year over year SG A expenses in the third quarter declined 4 2  year over year to  58 7 million  Research and development expenses rose 7 5  year over year to  16 4 million  Operating expenses were  75 1 million in the third quarter  down 1 9  year over year According to the company  adjusted operating expenses in the quarter totaled  67 2 million  down 1 9  from the year ago quarter Financial UpdateOmnicell exited third quarter 2017 with cash and cash equivalents of  7 5 million  compared with  26 9 million at the end of second quarter 2017 2017 GuidanceFor full year 2017  Omnicell expects product bookings in the range of  570  590 million  unchanged from the earlier forecast   The company has slashed the high end of the earlier guidance for adjusted revenues from the band of  720  740 million to  720  726 million  Moreover  the company now expects adjusted earnings in the band of  1 27 to  1 33 per shareas compared with  1 22 to  1 34 projected earlier  The Zacks Consensus Estimate for full year earnings per share is pegged at  1 29  The Zacks Consensus Estimate for full year revenues stands at  730 3 million The company also issued its fourth quarter 2017 guidance  Management expects adjusted revenues in the band of  201  207 million  Omnicell projects fourth quarter 2017 adjusted earnings between 49 cents and 55 cents  The Zacks Consensus Estimate for fourth quarter revenues is pegged at  207 1 million and earnings per share at 53 cents Our TakeOmnicell s third quarter 2017 performance was impressive with year over year increase in both earnings and revenues  Further  both of the company s segments witnessed year over year growth  We are encouraged to note that the company is working on product innovation through R D  Also  Omnicell is expected to gain from its recent launches and strategic partnerships During the third quarter  the company launched XT Series Automated Supply Dispensing system  which is another encouraging development  However  weak margin is a matter of concern Zacks Rank   Key PicksOmnicellhas a Zacks Rank  3  Hold  A few better ranked stocks in the broader medical sector are PetMed Express  Inc    NASDAQ PETS    Illumina  Inc    NASDAQ ILMN   and Intuitive Surgical  Inc    NASDAQ ISRG    Notably  PetMed sports a Zacks Rank  1  Strong Buy   while Illumina and Intuitive Surgical carry a Zacks Rank  2  Buy   You can see PetMed reported EPS of 43 cents for the second quarter of fiscal 2018  up 79 2  from the year ago quarter s 24 cents  Also  gross margin expanded 548 bps year over year to 35 2  in the reported quarter Illumina reported adjusted earnings per share of  1 11 in the third quarter of 2017  up 14 4  year over year  Also  Illumina s revenues grew 17 6  year over year to  714 million Intuitive Surgical posted adjusted earnings of  2 77 per share in the third quarter of 2017  up 34 5  on a year over year basis  Also  revenues increased 18  year over year to  806 1 million Zacks  Best Private Investment IdeasWhile we are happy to share many articles like this on the website  our best recommendations and most in depth research are not available to the public Starting today  for the next month  you can follow all Zacks  private buys and sells in real time  Our experts cover all kinds of trades  from value to momentum       from stocks under  10 to ETF and option moves       from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises  You can even look inside exclusive portfolios that are normally closed to new investors ,2017-10-29,Zacks Investment Research,https://www.investing.com/analysis/omnicell-omcl-earnings-beat-revenues-miss-estimates-in-q3-200257058,200257058
112829,334344,ISRG,Luminex  LMNX  Tops Q3 Earnings  Meets Revenue Estimates,opinion,"Headquartered in Austin  TX  Luminex Corporation   NASDAQ LMNX   reported earnings of 19 cents per share in the third quarter of 2017  surpassing the Zacks Consensus Estimate of 2 cents by a massive 850   Earnings also increased 216 7  year over year 
Revenues in the quarter increased almost 4 1  year over year to  74 1 million  almost in line with the Zacks Consensus Estimate of  74 million 
Segment Analysis
System Sales  Revenues declined 5 6  on a year over year basis to  9 9 million  Notably  the company shipped 266 multiplexing analyzers in the reported quarter  Here we note that the systems included MAGPIX  LX and FLEXMAP 3D 
Assay Revenues  Assay revenues grew 16 9  year over year 
Royalty Revenues  Coming to royalty revenues  sales at this segment declined 0 6  on a year over year basis to around  11 million  Royalty revenues in the reported quarter were affected by a reduction in audit findings and minimum royalty payments  offset by an increase in base royalties 
Consumables Sales  Revenues at the segment declined 13 7  to  10 6 million  This was owing to the effects of the timing of orders from the company s large partners Luminex Corporation Price  Consensus and EPS Surprise

   Quarter Highlights
Positive Tidings on the Regulatory Front  Luminex received FDA clearance for the ARIES C  difficile Assay in the reported quarter   Also  Luminex announced the receipt of CE IVD mark for the ARIES Norovirus Assay  
Luminex also announced that Japan s Central Social Insurance Medical Council has approved the recommendation by the Japanese Ministry of Health  Labor and Welfare  MHLW  to provide reimbursement for its proprietary VERIGENE assays  The approval was for two VERIGENE assays   the Gram Positive Blood Culture test and the Gram Negative Blood Culture test  Notably  Luminex is the only company in Japan with a clear automated sample to answer solution for blood culture identification 
Molecular Diagnostic Business Solid  Molecular Diagnostics Group placed more than 60 Sample to Answer systems in the reported quarter  The company now has more than 600 molecular Sample to Answer systems under contract with a total number of 400 active customers  Moreover  on average  VERIGENE customer now generates nearly  95 000 in assay revenues a year  while ARIES generates more than  40 000 a year as a reference 
Margins Details  Gross margin was 61 8  in the reported quarter  highlighting a contraction of 231 basis points  bps  year over year  The company has also made some standard cost adjustments related to improvements in labor utilization in the reported quarter to improve product margins  but the necessary adjustments to inventory in the current quarter affected the gross margin 
Operating expenses decreased 5 2  on a year over year basis  R D expenses in the quarter were down 16 4  on a year over year basis  Meanwhile  SG A costs inched up 0 2  year over year to  26 5 million  As a result  operating margin  as a percentage of revenues  was 11 7  and expanded 259 bps in the third quarter 
Financial Condition  The company exited the third quarter with approximately  110 9 million in cash and investments  up from  103 7 million in the second quarter 
Guidance
Luminex reiterated its 2017 annual revenue guidance at the band of  300 million to  310 million  This depicts 11  to 14  growth on a year over year basis  Luminex expects gross margins for the next few quarters in the mid 60s 
Meanwhile  the company projects fourth quarter 2017 revenues in the range of  76 million to  78 million 
Our Take
Luminex exited the third quarter on a solid note  The company s third quarter saw a strong top line  solid cash flow as well as profits  The company s Assay business will be its key growth driver over the long term  The company also witnessed favorable tidings at the regulatory front 
Further  the expansion in operating margin buoys optimism  On the flipside  low consumable revenues raise concern  Furthermore  the year over year drop in R D expenses is discouraging  Cutthroat competition in the niche space is another headwind 
Zacks Rank   Other Key Picks
Luminex sports a Zacks Rank  1  Strong Buy  
Other top ranked stocks in the broader medical sector are PetMed Express  Inc    NASDAQ PETS    Thermo Fisher Scientific Inc    NYSE TMO   and Intuitive Surgical  Inc    NASDAQ ISRG    Notably  PetMed sports a Zacks Rank  1  while Thermo Fisher Scientific and Intuitive Surgical carry a Zacks Rank  2  Buy   You can see 
PetMed reported EPS of 43 cents for the second quarter of fiscal 2018  up 79 2  from the year ago quarter s 24 cents  Also  gross margin expanded 548 bps year over year to 35 2  in the reported quarter 
Thermo Fisher Scientific reported adjusted earnings per share of  2 31 in the third quarter of 2017  up 13 8  year over year  The company s revenues grew 14  year over year to  5 12 billion 
Intuitive Surgical posted adjusted earnings of  2 77 per share in the third quarter of 2017  up 34 5  on a year over year basis  Also  revenues increased 18  year over year to  806 1 million 
Wall Street s Next Amazon  NASDAQ AMZN 
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2017-10-31,Zacks Investment Research,https://www.investing.com/analysis/luminex-lmnx-tops-q3-earnings-meets-revenue-estimates-200257396,200257396
112831,334346,ISRG,IDEXX Laboratories  IDXX  Q3 Earnings Beat  Revenues Miss ,opinion,"IDEXX Laboratories  Inc    NASDAQ IDXX   recorded third quarter 2017 earnings per share  EPS  of 79 cents  up 27   same at constant exchange rate  or CER  year over year on a reported basis  Further  the reported figure surpassed the Zacks Consensus Estimate of 75 cents 
Strong top line growth in the third quarter drove earnings 
Revenues in Detail
IDEXX s third quarter 2017 revenues rose 9 7  year over year  up 9  on organic basis  to  491 9 million  However  it missed the Zacks Consensus Estimate of  494 million 
The year over year increase was driven by strong global gains in Companion Animal Group  CAG  Diagnostics recurring revenues  including double digit organic revenue gains across consumable and reference lab as well as strong acceptance of rapid assays and veterinary software  services and diagnostic imaging systems 
IDEXX Laboratories  Inc  Price  Consensus and EPS Surprise
 
    
Segmental Analysis
IDEXX derives revenues from four operating segments  CAG  Water  Livestock  Poultry and Dairy  LPD   and Other 
In the third quarter  CAG revenues rose 10 7   up 9 6  organically  year over year to  426 7 million  The Water segment s revenues were up 11 1  from the prior year quarter  up 10 3  organically  to  31 million  LPD revenues  in the meanwhile  declined 4 7   down 6 5  organically  to  28 4 million  Revenues at the Other segment rose 9 3   up 9 1  organically  to  5 86 million 
Margins
Gross profit increased 11 1  to  274 million in the reported quarter  Gross margin expanded 70 basis points  bps  to 55 7  despite an 8 1  rise in cost of revenues to  217 9 million 
Sales and marketing expenses rose 11 1  to  88 8 million  while general and administrative expenses increased 8 7  to  57 2 million  Research and development expenses increased 7 4  to  27 6 million  Overall  operating margin in the quarter improved 70 bps to 20 4  
Financial Position
IDEXX exited the third quarter of 2017 with cash and cash equivalents of  169 million  up from  165 9 million at the end of the second quarter  Year to date net cash provided by operating activities was  252 2 million  compared with  238 2 million in the year ago period 
2017 Guidance
IDEXX narrowed its 2017 revenue outlook to  1 950  1 960 million from the previously provided range of  1 945  1 965 million  reflecting organic revenue growth expectations between 9 5  and 10   The Zacks Consensus Estimate for 2017 revenues is pegged at  1 95 billion  pegged at the lower end of  the guided range 
Management also raised its EPS guidance to  3 22  3 26 from the earlier  3 12  3 22  supported by continued operating margin expansion aligned with its long term goals  The updated outlook represents EPS growth of 32 34  on a reported basis  The Zacks Consensus Estimate for 2017 EPS is pegged at  3 17  below the guided range 
Our Take
IDEXX exited the third quarter on a mixed note  with earnings beating and revenues missing the Zacks Consensus Estimate  However  solid year over year growth in organic revenues buoys optimism  The company s raised EPS guidance for 2017 is also encouraging 
The stellar quarterly performance was driven by strong sales within the company s companion animal business  The companion animal market fundamentals remain solid with tremendous global runway for growth  Management s innovation based  multi modality global strategy  enabled by enhanced commercial capability  accelerated recurring CAG Diagnostics revenue growth  Moreover  the strong top line growth in this quarter was driven by considerable contributions from the rest of the business segments 
However  foreign currency fluctuations are expected to continue to hurt the company s operating results  although lower than the extent expected earlier 
Zacks Rank   Other Key Picks
IDEXX currently has a Zacks Rank  2  Buy  
Other top ranked stocks in the broader medical sector are PetMed Express  Inc    NASDAQ PETS    Thermo Fisher Scientific Inc    NYSE TMO   and Intuitive Surgical  Inc    NASDAQ ISRG    Notably  PetMed sports a Zacks Rank  1  Strong Buy   while Thermo Fisher Scientific and Intuitive Surgical carry a Zacks Rank  2  Buy   You can see 
PetMed reported EPS of 43 cents for the second quarter of fiscal 2018  up 79 2  from the year ago quarter s 24 cents  Also  gross margin expanded 548 bps year over year to 35 2  in the reported quarter 
Thermo Fisher Scientific reported adjusted earnings per share of  2 31 in the third quarter of 2017  up 13 8  year over year  Also  the company s revenues grew 14  year over year to  5 12 billion 
Intuitive Surgical posted adjusted earnings of  2 77 per share in the third quarter of 2017  up 34 5  on a year over year basis  Further  revenues increased 18  year over year to  806 1 million 
Wall Street s Next Amazon  NASDAQ AMZN 
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2017-10-31,Zacks Investment Research,https://www.investing.com/analysis/idexx-laboratories-idxx-q3-earnings-beat-revenues-miss-200257390,200257390
112837,334352,ISRG,Wright Medical Group  WMGI  Q3 Earnings In Line  Sales Miss,opinion,Wright Medical Group N V    NASDAQ WMGI   reported adjusted loss of 16 cents per share in the third quarter of 2017  in line with the Zacks Consensus Estimate  Also  the figure was narrower by 3 cents on a year over year basis Net sales in the third quarter totaled  171 million  which missed the Zacks Consensus Estimate of  174 million Quarter in DetailWright Medical reports revenues under the Total Extremities   Biologics segment Consolidated sales at the segment in the United States increased 7 5  from the year ago quarter to almost  126 9 million  Internationally  sales in the extremities and biologics business were up 11 1  year over year to  43 6 million  Becton  Dickinson and Company Price  Consensus and EPS Surprise    Total Extremities   Biologics includes four sub segments   Lower Extremities  Upper Extremities  Biologics and Sports Med   Other Lower Extremities  Sales at the segment declined 0 6  on a year over year basis to  65 4 million in the quarter  The U S  lower extremities business sales fell 0 3  in the third quarter  Internationally  lower extremities sales declined 1 7  on a year over year basis Upper Extremities  Sales at the segment increased 19 6  on a year over year basis to  76 million in the quarter under review  The U S  upper extremities business grew 18 6  on a year over year basis  Also  Upper extremities sales increased 22 3  on a year over year basis  internationally Biologics  Sales at the segment rose 3 7  on a year over year basis to  23 8 million in the quarter  The U S  biologics business grew 2 2  to  18 6 million in the quarter  Sales at the segment grew 9 6  internationally on a year over year basis Sports Med   Other  Sales at the segment rose 5 6  to  5 3 million from the year ago quarter  The U S  sports med   other segment sales declined 0 3  and increased 9 5  internationally in the third quarter GuidanceWright Medical expects net sales for full year 2017 in the band of  740 million to  745 million  This includes negative impact from foreign currency exchange of approximately 1   The company forecasts full year 2017 adjusted EBITDA from continuing operations in the range of  84 million to  88 million Our TakeWright Medical is striving toward product innovation through research and development  The company recently launched INVISION Total Ankle Revision System  This is the first system developed for total ankle revision arthroplasty  Per management  PERFORM Reversed launch will boost revenues after the company delivers additional instrument sets to the U S  market  However  decrease in Lower extremities and Upper extremities sales  internationally  is a matter of concern Zacks Rank   Key PicksWright Medical currently carries a Zacks Rank  3  Hold  A few better ranked stocks in the broader medical sector are PetMed Express  Inc    NASDAQ PETS    Luminex Corporation   NASDAQ LMNX   and Intuitive Surgical  Inc    NASDAQ ISRG    Notably  PetMed and Luminex sport a Zacks Rank  1  Strong Buy   while Intuitive Surgical carries a Zacks Rank  2  Buy   You can see  PetMed reported earnings per share of 43 cents for the second quarter of fiscal 2018  up 79 2  from the year ago quarter s 24 cents  Also  gross margin expanded 548 basis points year over year to 35 2  in the reported quarter Luminex reported adjusted earnings per share of 19 cents in the third quarter of 2017  up 216 7  year over year  The company s revenues in the quarter increased almost 4 1  year over year to  74 1 million Intuitive Surgical posted adjusted earnings of  2 77 per share in the third quarter of 2017  up 34 5  on a year over year basis  Also  revenues increased 18  year over year to  806 1 million Zacks  Best Private Investment Ideas While we are happy to share many articles like this on the website  our best recommendations and most in depth research are not available to the public Starting today  for the next month  you can follow all Zacks  private buys and sells in real time  Our experts cover all kinds of trades  from value to momentum       from stocks under  10 to ETF and option moves       from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises  You can even look inside exclusive portfolios that are normally closed to new investors ,2017-11-01,Zacks Investment Research,https://www.investing.com/analysis/wright-medical-group-wmgi-q3-earnings-in-line-sales-miss-200257859,200257859
112865,334380,ISRG,Thermo Fisher  TMO  Q3 Earnings   Sales Top  Guidance Up ,opinion,"Thermo Fisher Scientific Inc    NYSE TMO   reported better than expected performance in third quarter 2017  Adjusted EPS came in at  2 31  beating the Zacks Consensus Estimate by 3 1  and the year ago quarter figure by 13 8  
On a reported basis  second quarter EPS of  1 34 marked a 12 6  year over year rise 
Revenues in the quarter came in at  5 12 billion  up 14  year over year  Sales also exceeded the Zacks Consensus Estimate of  5 03 billion by 1 7  Thermo Fisher Scientific Inc Price  Consensus and EPS Surprise

    
Quarter in Detail
Organic revenues in the third quarter grew 5  year over year while acquisitions increased revenues by 8   Currency translation positively impacted total revenues by 1  
Thermo Fisher currently operates under four business segments  Life Sciences Solutions  Analytical Instruments  Specialty Diagnostics and Laboratory Products and Services 
Revenues at the Life Sciences Solutions segment  27  of total revenues  improved 5  year over year to  1 38 billion while Analytical Instruments Segment sales  23 3   rose 32  to  1 19 billion  reflecting the acquisition of FEI Company 
Revenues at the Laboratory Products and Services segment  37 8   rallied 15  to  1 93 billion  while the Specialty Diagnostics segment  16 5   recorded a 6  increase to  844 million 
Gross margin of 47 5  during the third quarter was down 67 basis points  bps  year over year  despite a 12 3  rise in gross profits  Adjusted operating margin expanded approximately 43 bps to 21 3   despite a 7 6  rise in selling  general and administrative expenses and 18 9  increase in research and development expenses 
The company exited the third quarter with cash and cash equivalents of  741 1 million compared with  611 million at the end of the previous quarter  Year to date net cash provided by operating activities was  2 13 billion compared with  2 05 billion in the year ago period 
Guidance Raised
Backed by a solid third quarter performance  a favorable foreign exchange environment forecast and also considering the recently closed acquisition of Patheon  Thermo Fisher has raised its full year 2017 financial guidance 
The revenue guidance has been raised to a range of  20 50  20 66 billion  growth of 12 13  from the previous year  from the earlier band of  19 71  19 89 billion  growth of 8 9    The current Zacks Consensus Estimate of  20 48 billion falls below this guided range 
The company has also raised its adjusted EPS guidance to a range of  9 29  9 38  reflecting growth of 12 13  from the previous year  The earlier prediction was in the  9 15  9 28 range  growth of 11 12    The Zacks Consensus Estimate of  9 33 per share remains within the guided band 
Bottom Line
Thermo Fisher ended the third quarter on a promising note with both adjusted earnings and revenues beating the Zacks Consensus Estimate 
We are encouraged by the company s series of product launches along with major progress in precision medicine initiatives  Thermo Fisher s acquisition of FEI Company has already started to boost its analytical instruments portfolio 
In the quarter  the company launched four new electron microscopy systems for structural biology and materials science research  Also  it has released a new iQ Series air quality monitoring platform and enabled the first FDA approved gene therapy  This apart  the company has opened Precision Medicine Customer Experience Center in Guangzhou  China 
We are currently looking forward to the recently completed  7 2 billion acquisition of Patheon  This is going to significantly enhance the company s value proposition for biopharma customers by adding leading contract development and manufacturing outsourcing services The raised guidance is all the more impressive and indicative of this overall bullish trend to continue through 2017 
Zacks Rank   Other Key Picks
Currently  Thermo Fisher has a Zacks Rank  2  Buy  
A few other stocks worth considering in the broader medical sector are PetMed Express  Inc    NASDAQ PETS    Abbott Labs   NYSE ABT   and Intuitive Surgical  Inc    NASDAQ ISRG    Notably  PetMed sports a Zacks Rank  1  Strong Buy   while both Abbott and Intuitive Surgical carry a Zacks Rank of 2 as well  You can see 
PetMed reported EPS of 43 cents for the second quarter of fiscal 2018  up 79 2  from 24 cents  reported in the year ago quarter  Also  gross margin expanded 548 bps year over year to 35 2  in the reported quarter 
Abbott reported third quarter 2017 adjusted earnings from continuing operations of 66 cents per share  up 11 9  year over year  Also  third quarter worldwide sales came in at  6 83 billion  up 28 8  year over year  
Intuitive Surgical posted adjusted earnings of  2 77 per share in the third quarter of 2017  up 34 5  on a year over year basis  Also  revenues increased 18  year over year to  806 1 million 
Zacks  Hidden TradesWhile we share many recommendations and ideas with the public  certain moves are hidden from everyone but selected members of our portfolio services  Would you like to peek behind the curtain today and view them Starting now  for the next month  I invite you to follow all Zacks  private buys and sells in real time from value to momentum   from stocks under  10 to ETF to option movers   from insider trades to companies that are about to report positive earnings surprises  we ve called them with 80   accuracy   You can even look inside portfolios so exclusive that they are normally closed to new investors ",2017-10-25,Zacks Investment Research,https://www.investing.com/analysis/thermo-fisher-tmo-q3-earnings--sales-top-guidance-up-200221015,200221015
112866,334381,ISRG,McKesson  MCK  Beats Earnings   Revenue Estimates In Q2 ,opinion,"McKesson Corporation   NYSE MCK   reported second quarter fiscal 2018  ended Sep 30  2017  earnings of  3 28 per share  beating the Zacks Consensus Estimate of  2 78  Earnings also surpassed the year ago figure of  2 96 McKesson posted sales of  52 1 billion  beating the Zacks Consensus Estimate of  51 6 billion  This was up from  50 0 billion last year Quarter in DetailMcKesson operates through two segments  Distribution Solutions and Technology Solutions  All growth rates given below are on a year over year basis Distribution Solutions revenues were  51 9 billion for the quarter  up 5  on a reported and constant currency basis However  revenues from the Technology Solutions business declined from  680 million in the year ago quarter to  120 million  This was due to the bifurcation of the Technology Solutions businesses to the Change Healthcare joint venture on Mar 1  The segment reflects only the numbers from the Enterprise Information Solutions business  
McKesson Corporation Price  Consensus and EPS Surprise
    Financial ConditionAs of Sep 30  McKesson had  2 6 billion in cash and cash equivalents against  2 8 billion as of Mar 31  During the reported quarter  ended Sep 30   the company generated cash worth  1 3 million from operations  During the first half of the year  McKesson repaid  545 million in long term debt  paid  1 9 billion for acquisitions  repurchased  650 million of its common stock  invested  255 million internally and paid  121 million in dividends Fiscal 2018 OutlookMcKesson expects GAAP earnings per diluted share in the range of  4 80 to  6 90 for the fiscal year ending Mar 31  2018  Adjusted Earnings for the same are expected in the range of  11 80 to  12 50 Zacks RankMcKesson currently carries a Zacks Rank  3  Hold  Companies Reporting Solid Earnings ResultsIntuitive Surgical Inc   NASDAQ ISRG   posted adjusted earnings of  2 77 per share in the third quarter of 2017  beating the Zacks Consensus Estimate of  1 97 on stellar revenue growth  The stock has a Zacks Rank  2  Buy  PetMed Express  Inc s   NASDAQ PETS   adjusted earnings per share of 43 cents for the second quarter of fiscal 2018 were up 79 2  from the year ago quarter  Also  earnings surpassed the Zacks Consensus Estimate by 43 3   The stock has a Zacks Rank  1  Strong Buy   You can see  Abbott   NYSE ABT   reported third quarter 2017 adjusted earnings from continuing operations of 66 cents per share  up 11 9  year over year  Third quarter worldwide sales came in at  6 83 billion  up 28 8  year over year  Abbott carries a Zacks Rank  2 Looking for Stocks with Skyrocketing Upside 
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana 
Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2017-10-25,Zacks Investment Research,https://www.investing.com/analysis/mckesson-mck-beats-earnings--revenue-estimates-in-q2-200221183,200221183
112867,334382,ISRG,Boston Scientific s  BSX  Q3 Earnings In Line  Guidance Up,opinion,"Boston Scientific Corporation   NYSE BSX   posted adjusted earnings per share  EPS  of 31 cents in the third quarter of 2017  up 14 8  from the year ago quarter  This figure remained in line with the Zacks Consensus Estimate  and fell exactly at the upper end of the company s adjusted EPS guidance range of 29 31 cents Without these adjustments  the company reported earnings of 20 cents per share  up 17 6  from the year ago period Revenues in DetailRevenues in the third quarter were up 5 6  year over year on reported basis and up 5 7  on operational basis  at constant exchange rate or CER  to  2 22 billion  The figure topped the company s guidance of  2 18  2 21 billion and also exceeded the Zacks Consensus Estimate of  2 20 billion Boston Scientific Corporation Price  Consensus and EPS Surprise
    Organic revenue growth in the third quarter  excluding the impact of changes in foreign currency exchange rates and sales from the acquisitions of EndoChoice Holdings and Symetis SA  was 4 3  year over year Geographically  in the third quarter  the company achieved operational growth of 4 2  in the U S   up 2 8  organically   up 8 8  in Europe  up 5 3    up 7 8  in the Asia  Middle East and Africa region  same  and up 18 3  in the emerging markets  up 18   Segment AnalysisBoston Scientific currently has three global reportable segments  Cardiovascular  Rhythm Management and MedSurg The company generates maximum revenues from Cardiovascular  Sales from its subsegments   Interventional Cardiology and Peripheral Interventions   were  589 million  up 4 2  year over year at CER  and  268 million  up 5 1    respectively  during the third quarter The second largest contributor to Boston Scientific s top line was Rhythm Management  which includes Cardiac Rhythm Management  CRM  and Electrophysiology  CRM reflected a 0 9  year over year increase in sales to  463 million at CER in the reported quarter Worldwide  sales from pacemakers  within CRM  declined 4 5  to  149 million while defibrillators were up 0 9  to  314 million Electrophysiology sales went up 17 6  year over year at CER to  71 million Other segments like Endoscopy  Urology and Pelvic Health and Neuromodulation  under the MedSurg broader group  recorded sales of  403 million  up 10  at CER    274 million  up 10 2   and  154 million  up 11    respectively MarginsGross margin contracted 45 basis points  bps  year over year to 71 3  on 7 2  rise in cost of products sold  Adjusted operating margin improved by a marginal 4 bps to 23 2  in the reported quarter  During the quarter  selling  general and administrative expenses went up 3 6  to  800 million  while research and development expenses increased 9 5  to  254 million  Royalty expenses reduced 20  to  16 million in the quarter Balance SheetBoston Scientific exited the third quarter with cash and cash equivalents of  210 million  up from  195 million at the end of the sequential last quarter  At the end of the third quarter  the company had a total long term debt of  5 68 billion  a marginal decline from  5 84 billion at the end of the second quarter GuidanceBoston Scientific has provided an update to its full year 2017 guidance Banking on a solid third quarter show and a gradually improving foreign exchange scenario  the company raised its 2017 revenue guidance to the range of  8 985  9 015 billion  annualized growth of 7 8  on reported basis and growth of 7  on operational basis including contribution of approximately 120 bps from EndoChoice and Symetis  from the earlier band of  8 89  8 99 billion  annualized growth of 6 7  on reported basis and growth of 6 8  on operational basis   The current Zacks Consensus Estimate for revenues is  8 95 billion  below the guided range Adjusted EPS guidance range for 2017  has been slightly narrowed to  1 24  1 27 from the earlier range of  1 23  1 27  The Zacks Consensus Estimate of  1 25 is within this guided range The company also provided its fourth quarter 2017 financial guidance  Adjusted earnings are expected in the band of 32 35 cents per share on revenues of  2 345  2 375 billion  The Zacks Consensus Estimate for EPS stands at 34 cents while for revenues  it is  2 32 billion Our TakeDespite back to back natural disasters  Boston Scientific managed to register solid third quarter performance with earnings in line with the Zacks Consensus Estimate and revenues  ahead of the mark  A gradually improving foreign exchange scenario has also started to contribute to the company s overall topline performance The raised guidance is all the more impressive and indicative of this overall bullish trend to continue through the rest of 2017 Boston Scientific is leaving no stone unturned to strengthen its core businesses and invest in new technologies and global markets  which accounted for higher sales across all its geographies in the third quarter  We are also encouraged with the company gaining a number of approvals for its products  both in the domestic and overseas markets Among the recent developments  worth mentioning is the company s recent acquisition of Apama Medical  the developer of the single shot Apama Radiofrequency  RF  Balloon Catheter System for the treatment of atrial fibrillation This apart  the company received an FDA approval forMRI labeling and announced the U S  launch of the Resonate family of implantable cardioverter defibrillator  ICD  and cardiac resynchronization therapy defibrillator  CRT D  systems  This combines the HeartLogic Heart Failure Diagnostic  EnduraLife battery technology and SmartCRT Technology This apart  the company received CE Mark for updated  Directions for Use  for the WATCHMAN LAAC Device in Europe  The company s ACURATE neo Transapical Aortic Valve System has also gained CE Mark  The company expects to begin a controlled launch throughout Europe during the fourth quarter of 2017 Zacks Rank   Other Key PicksCurrently  Boston Scientific carries a Zacks Rank  2  Buy  Some other top ranked stocks in the broader medical sector are PetMed Express  Inc    NASDAQ PETS    Abbott   NYSE ABT   and Intuitive Surgical  Inc    NASDAQ ISRG    Notably  PetMed sports a Zacks Rank  1  Strong Buy   while Abbott and Intuitive Surgical carry a Zacks Rank  2  You can see PetMed reported EPS of 43 cents in second quarter fiscal 2018  up 79 2  from the year ago quarter s 24 cents  Also  gross margin expanded 548 bps year over year to 35 2  in the reported quarter Abbott reported third quarter 2017 adjusted earnings from continuing operations of 66 cents per share  up 11 9  year over year  Also  third quarter worldwide sales came in at  6 83 billion  up 28 8  year over year  Intuitive Surgical posted adjusted earnings of  2 77 per share in third quarter 2017  up 34 5  on a year over year basis  Also  revenues increased 18  year over year to  806 1 million Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2017-10-25,Zacks Investment Research,https://www.investing.com/analysis/boston-scientifics-bsx-q3-earnings-in-line-guidance-up-200221266,200221266
112868,334383,ISRG,GNC Holdings  GNC  Lags Q3 Earnings   Revenues  Margins Down,opinion,GNC Holdings  Inc    NYSE GNC   reported third quarter 2017 adjusted earnings per share  EPS  of 32 cents  reflecting a massive 45 8  year over year deterioration  Adjusted EPS also missed the Zacks Consensus Estimate by a penny  Per management  the hurricanes Harvey  Irma and Maria have dented the adjusted EPS figure to the tune of 2 cents The year over year decline can be attributed to a dull revenue performance in the reported quarter  primarily because of underperformance by the U S    Canada and manufacturing wholesale segments Including one time items  the company reported earnings of 31 cents per share  down 34  year over year RevenuesRevenues during the reported quarter dropped 2 9  year over year to  609 5 million  The figure also missed the Zacks Consensus Estimate of  616 million The lower sales at the U S    Canada and manufacturing wholesale segments can be cited as the major reason for the disappointing numbers Same store sales increased 1 3  in domestic company owned stores  including GNC com sales  in the third quarter of 2017  In domestic franchise locations  same store sales declined 1 7   GNC Holdings  Inc  Price  Consensus and EPS Surprise     Segments in DetailsGNC Holdings reports operations under three segments  U S    Canada  including company owned stores in the United States  Puerto Rico and Canada  franchise stores in the United States and e commerce   International  including franchise locations in approximately 50 countries  The Health Store and China operations   and Manufacturing Wholesale  comprising manufactured products sold to other segments  third party contract manufacturing and sales to wholesale partners  During the reported quarter  GNC Holdings  revenues from the U S    Canada segment dropped 3 5  to  507 1 million  primarily owing to a  12 million decrease due to the discontinuation of the Gold Card program in the United States and the introduction of the company s new loyalty programs  In domestic franchise locations as well  revenues declined nearly  7 5 million  partially offset by a 1 3  increase in retail same store sales  However  GNC com sales were up 41 9  in the third quarter Revenues at the international segment increased 19 3  to  49 1 million  Revenues from international franchisees rose  2 8 million  Revenues from the China business increased  4 8 million in the reported quarter Revenues at the manufacturing wholesale segment  excluding intersegment revenues  decreased 13 1  to  53 3 million  Within this segment  third party contract manufacturing sales fell 14 9  to  31 2 million owing to lower demand related to reduced sales for some customers  Sales to wholesale partners decreased 10 5  year over year from  24 7 million to  22 1 million in the quarter  However  Intersegment sales increased to  58 million in the quarterfrom the year ago  53 million on the company s increased focus on proprietary products   MarginGross profit deteriorated 8 6  in the reported quarter to  196 8 million  Consequently  gross margin contracted 200 basis points  bps  to 32 3  Selling  general and administrative expenses rose 1 7  to  150 9 million  Accordingly  adjusted operating margin deteriorated 320 bps to 7 5  Financial PositionGNC Holdings exited the third quarter with cash and cash equivalents of  40 1 million  down from  51 9 million at the end of second quarter 2017  Long term debt was  1 38 billion at the end of the quarter  compared with  1 51 billion at the end of second quarter 2017  Year to date  the net cash flow from operating activities was  149 6 million  compared with  169 7 million a year ago Further  the company generated year to date free cash flow of  124 8 million as compared with  162 8 million in the year ago quarter  One New GNC  Plan UpdateEarlier  management had announced plans to revamp its existing business model  dubbed as the  One New GNC   The company has been seeing transformational changes during the third quarter of 2017 as well  Transaction growth was up 12 4  in the third quarter  As of Oct 25  9 6 million consumers had joined the company s loyalty programs  including approximately 585 000 customers enrolled in the PRO Access membership Our TakeGNC Holdings exited the third quarter of 2017 on a disappointing note with revenues and earnings missing the Zacks Consensus Estimate  The underperformance can be attributed to lower sales in the company s U S    Canada and manufacturing wholesale segments  Also  the decline in gross and adjusted operating margin is a matter of concern On a positive note  during the third quarter  management witnessed positive response for its New GNC Plan  New consumer enrollment under the myGNC Rewards Program  The company has also been witnessing improvement in transactions and e commerce business  which buoys optimism Zacks Rank   Key PicksCurrently  GNC Holdings has a Zacks Rank  3  Hold  A few better ranked stocks in the broader medical sector are PetMed Express  Inc    NASDAQ PETS    Abbott   NYSE ABT   and Intuitive Surgical  Inc    NASDAQ ISRG    Notably  PetMed sports a Zacks Rank  1  Strong Buy   while Abbott and Intuitive Surgical carry a Zacks Rank  2  Buy   You can see PetMed reported EPS of 43 cents in the second quarter of fiscal 2018  up 79 2  from the year ago quarter s 24 cents  Also  gross margin expanded 548 bps year over year to 35 2  in the reported quarter Abbott reported third quarter 2017 adjusted earnings from continuing operations of 66 cents per share  up 11 9  year over year  Also  third quarter worldwide sales came in at  6 83 billion  up 28 8  year over year  Intuitive Surgical posted adjusted earnings of  2 77 per share in the third quarter of 2017  up 34 5  on a year over year basis  Also  revenues increased 18  year over year to  806 1 million Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2017-10-25,Zacks Investment Research,https://www.investing.com/analysis/gnc-holdings-gnc-lags-q3-earnings--revenues-margins-down-200221255,200221255
112869,334384,ISRG,Stryker  SYK  Earnings And Revenues Beat Estimates In Q3,opinion,"Stryker Corp   NYSE SYK   reported adjusted earnings of  1 52 per share in the third quarter of 2017  which comfortably beat the Zacks Consensus Estimate by 2 cents  Earnings improved from  1 39 per share in the year ago quarter The company  based in Kalamazoo  MI  has maintained its streak of positive earnings surprise  Meanwhile  in the trailing four quarters  the company posted earnings beats  with an average of 1 86   Currently  Stryker carries a Zacks Rank  3  Hold  The upside in earnings was primarily driven by a rise in revenues to  3 01 billion  which beat the Zacks Consensus Estimate of  2 97 billion  At constant currency  cc   net sales improved 5 8  from the year ago quarter Segment DetailsOrthopaedics net sales of  1 1 billion increased 5 1  year over year in the reported quarter  Excluding the 0 3  impact of acquisitions  net sales in the quarter increased 4 5  in cc  including 6 5  from increased unit volume  This was partially offset due to lower prices MedSurg net sales of  1 3 billion increased 6 7  in the reported quarter  Excluding the 0 6  impact of acquisitions  net sales in the quarter increased 5 6  in cc  including 5 6  increased unit volume Neurotechnology and Spine net sales of  0 5 billion increased 6 9  in the reported quarter  Net sales in the quarter increased 8 1  from increased unit volume  This was partially offset due to lower prices GuidanceFor the fourth quarter of 2017  Stryker expects adjusted earnings in the range of  1 92  1 97 per share  For full year  the company expects adjusted earnings in the band of  6 45 to  6 50  Stryker expects organic sales growth of 6 5  to 7 0  for full year 2017 Our TakeWe believe Stryker s innovative product pipeline will be a key catalyst in the near term  Furthermore  growing adoption of MAKO will drive sales in the orthopedic and reconstructive surgery market On the flip side  China might prove to be a challenging market for the company  Coming to supply related headwinds  the company has been grappling with issues in the spine business for long  We believe that this may prove to be a major drawback in the quarters ahead  Nevertheless  Stryker s efforts in sales force management should bode well Companies Reporting Solid Earnings ResultsIntuitive Surgical Inc   NASDAQ ISRG   posted adjusted earnings of  2 77 per share in the third quarter of 2017  beating the Zacks Consensus Estimate of  1 97 on stellar revenue growth  The stock holds a Zacks Rank  2  Buy  
PetMed Express  Inc s   NASDAQ PETS   adjusted earnings per share of 43 cents for the second quarter of fiscal 2018 were up 79 2  from the year ago quarter  Also  earnings surpassed the Zacks Consensus Estimate by 43 3   The stock sports a Zacks Rank  1  Strong Buy   ou can see Abbott   NYSE ABT   reported third quarter 2017 adjusted earnings from continuing operations of 66 cents per share  up 11 9  year over year  Third quarter worldwide sales amounted  6 83 billion  up 28 8  year over year  Abbott carries a Zacks Rank  2 
Wall Street s Next Amazon  NASDAQ AMZN 
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2017-10-26,Zacks Investment Research,https://www.investing.com/analysis/stryker-syk-earnings-and-revenues-beat-estimates-in-q3-200221431,200221431
112870,334385,ISRG,Cerner  CERN  Misses On Q3 Earnings  Bookings Decline Y Y,opinion,Cerner Corp   NASDAQ CERN   reported adjusted third quarter 2017 earnings of 61 cents per share  missing the Zacks Consensus Estimate by a penny  The lackluster third quarter performance can be primarily attributed to the year over year decline in bookings  which had scaled an all time high in the last quarter  However  earnings rose 3 4  on a year over year basis The company reported net revenues of  1 28 billion  falling short of the Zacks Consensus Estimate of  1 29 billion  However  revenues rose 7 7  on a year over year basis  Cerner holds a Zacks Rank  2  Buy  Bookings DisappointIn the third quarter  Cerner registered bookings worth  1 111 billion  down 22 5  on a year over year basis  In fact  bookings were below the company s previously issued guidance owing to the postponement of several big contracts from this quarter to tentatively the fourth quarter of 2017 Notably  bookings in the last quarter totaled  1 64 billion  up 16  on a year over year basis Nonetheless  Cerner is well positioned for a strong full year performance based on solid bookings guidance for the fourth quarter  Next quarter bookings are expected in the band of  1 75 billion to  2 billion  with the midpoint reflecting 30  growth on a year over year basis  The midpoint of the fourth quarter booking guidance would increase full year 2017 bookings guidance by 8  on a year over year basis Segment DetailsSystems sales increased 8  to  324 million  Sales were buoyed by licensed software and subscriptions  partially offset by a decline in technology resale Total support  maintenance and services  including professional and managed services  rose 7 8  from the year ago quarter to  927 8 million  This reflects solid execution by the company s service organizations  Revenue Cycle has also been a strong contributor  courtesy of strong sales and contribution from RevWorks services  revenue management services   Population Health service businesses also drove revenues in the third quarter on solid growth in the flagship HealtheIntent solutions  The company has been targeting the broader shift from fee for service to value based care for long  Cerner also posted an impressive performance in the ambulatory and small hospital market Reimbursement Travel revenues increased 8 7  in the quarter  slightly below the company s full year expected growth rate Geographically  domestic revenues increased 7  from the year ago quarter to  1 13 billion  while non U S  revenues increased 10  to  142 million Margin   Balance Sheet DetailsGross margin in the third quarter was 82 7  of revenues  down 50 basis points  bps  from a year ago  The decline was due to the lower mix of sublicensed software and lackluster performance by the technology resale business  Adjusted operating margin in the third quarter was 23 1  of net sales  down 130 bps from a year ago Cerner ended the third quarter of 2017 with  964 million in total cash and investments  Total debt for Cerner  including capital lease obligations  was  535 million FY17 Guidance LoweredFor the fourth quarter  Cerner forecasts revenues between  1 3 billion and  1 35 billion  with the midpoint reflecting growth of 5  on a year over year basis  Adjusted earnings are expected in the band of 60 cents to 62 cents per share  midpoint of which is flat on a year over year basis For the full year  management expects revenues at around  5 15 billion  which is at the low end of the previously issued range of  5 15 billion to  5 25 billion  thanks to lower bookings in the third quarter  Cerner currently forecasts 2017 adjusted earnings at  2 42  lower than the previously issued range of  2 46 and  2 54 Companies Reporting Solid Earnings ResultsIntuitive Surgical Inc    NASDAQ ISRG   posted adjusted earnings of  2 77 per share in the third quarter of 2017  beating the Zacks Consensus Estimate of  1 97 on stellar revenue growth  The stock has a Zacks Rank  2 PetMed Express  Inc  s   NASDAQ PETS   adjusted earnings per share of 43 cents for the second quarter of fiscal 2018 were up 79 2  from the year ago quarter  Also  earnings surpassed the Zacks Consensus Estimate by 43 3   The stock has a Zacks Rank  1  Strong Buy   You can see Abbott   NYSE ABT   reported third quarter 2017 adjusted earnings from continuing operations of 66 cents per share  up 11 9  year over year  Third quarter worldwide sales came in at  6 83 billion  up 28 8  year over year  Abbott carries Zacks Rank  2 Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2017-10-26,Zacks Investment Research,https://www.investing.com/analysis/cerner-cern-misses-on-q3-earnings-bookings-decline-yy-200221430,200221430
112871,334386,ISRG,ResMed  RMD  Q1 Earnings Top On Growth In All Business Lines,opinion,ResMed Inc    NYSE RMD   announced first quarter fiscal 2018 adjusted earnings per share  EPS  of 66 cents  up 6 5  from the prior year quarter  Earnings also beat the Zacks Consensus Estimate by a penny Including one time items  ResMed reported EPS of 60 cents in the quarter  up 11 1  year over year Revenues in DetailsRevenues in the reported quarter increased 12 5  year over year  up 11  at constant exchange rate or CER  to  523 7 million  The figure also beat the Zacks Consensus Estimate of  501 million On a geographic basis  excluding Brightree  revenues in the Americas totaled  296 6 million  reflecting an 11  increase over the prior year quarter  Moreover  revenues from Brightree in the reported quarter totaled  38 1 million  up 15  year over year  Revenues in combined EMEA and APAC were  189 million  highlighting an 11  year over year rise at CER Adjusted gross margin contracted 56 basis points  bps  year over year to 58 4  in the reported quarter  Selling  general and administrative expenses were up 11 6  year over year to  143 8 million  while there was an 8 6  increase in Research and Development expenses to  37 4 million  This led to an 11  rise in adjusted operating expenses  which amounted to  181 2 million  Accordingly  adjusted operating margin in the quarter contracted 9 bps to 23 7  Financial UpdateResMed exited first quarter fiscal 2018 with cash and cash equivalents of  811 1 million  compared with  821 9 million at the end of fiscal 2017 Year to date  the company generated  93 9 million of cash flow from operations  up from the year ago figure of  86 2 million Concurrent to its first quarter earnings release  ResMed announced a regular quarterly dividend of 35 cents per share  The dividend will be paid on Dec 14  to shareholders of record as on Nov 9 As previously declared  ResMed temporarily suspended its share repurchase program due to the recent acquisitions  However  the company still expects to recommence the buy back program sometime in fiscal 2018 GuidanceManagement expects SG A expenses  as a percentage of revenues  at around 26  at the end of fiscal 2018  R D expenses  as a percentage of revenues  are projected at 7  for fiscal 2018  This reflects marketing expenses associated with product launches along with the ongoing legal expenses Our TakeResMed exited the first quarter on a promising note  On the brighter side  the company achieved solid double digit global revenue growth this quarter  led by sales from Software as a Service businesses as well as its new mask products and devices  The company also recently launched the AirFit N20 Classic nasal mask for positive airway pressure  PAP  treatment in Europe  All these factors boost investor faith in the stock However  challenges like competitive bidding and reimbursement issues continue to plague the stock  The company also remains exposed to foreign exchange fluctuations Zacks Rank   Key PicksResMed currently carries a Zacks Rank  4  Sell  A few better ranked stocks in the broader medical sector are PetMed Express  Inc    NASDAQ PETS    Abbott   NYSE ABT   and Intuitive Surgical  Inc    NASDAQ ISRG    Notably  PetMed sports a Zacks Rank  1  Strong Buy   while Abbott and Intuitive Surgical carry a Zacks Rank  2  Buy   You can see PetMed reported EPS of 43 cents in the second quarter of fiscal 2018  up 79 2  from the year ago quarter s 24 cents  Also  gross margin expanded 548 bps year over year to 35 2  in the reported quarter Abbott reported third quarter 2017 adjusted earnings from continuing operations of 66 cents per share  up 11 9  year over year  Also  third quarter worldwide sales came in at  6 83 billion  up 28 8  year over year  Intuitive Surgical posted adjusted earnings of  2 77 per share in the third quarter of 2017  up 34 5  on a year over year basis  Also  revenues increased 18  year over year to  806 1 million Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2017-10-26,Zacks Investment Research,https://www.investing.com/analysis/resmed-rmd-q1-earnings-top-on-growth-in-all-business-lines-200221428,200221428
112879,334394,ISRG,Intuitive Surgical  ISRG  Beats On Q3 Earnings   Revenues,opinion,"Intuitive Surgical Inc    NASDAQ ISRG   posted adjusted earnings of  2 77 per share in the third quarter of 2017  crushing the Zacks Consensus Estimate of  1 97 on stellar revenue growth  Also  the figure improved 34 5  on a year over year basis  Interestingly  over the past four quarters  the company beat estimates at an average of 7 8  Revenues increased 18  year over year to  806 1 million  driven by growth in instrument  accessory and service  and systems revenues  Revenues also beat the Zacks Consensus Estimate of  752 million It is important to note that the company s stockholders approved a three for one split of the issued and outstanding common stock  which began trading on a split adjusted basis on Oct 6  The stock currently has a Zacks Rank  3  Hold  
Intuitive Surgical  Inc  Price  Consensus and EPS Surprise
    Business HighlightsSolid Procedure Trends  Intuitive Surgical posted solid numbers in the quarter  courtesy of rising customer adoption of procedures and growth in system placements  The company outperformed in the Mature and Growth procedures  especially in general and thoracic surgery Precisely  third quarter procedures increased approximately 15  on a year over year basis  U S  procedures grew approximately 12  and outside of the United States  OUS  procedures grew approximately 23  year over year  Procedure performance in Asia showed continued strength on solid growth in China  Japan and Korea  Added to this  solid growth in prostatectomy procedure volumes lent Intuitive Surgical a competitive edge in the broader prostate surgery market in the third quarter Launches Bode Well  In the third quarter  Intuitive Surgical expanded the launch of two additional instruments and accessories for da Vinci X and Xi platforms in seven countries  In fact  the company initiated a limited launch of a refined vessel sealer in Europe in the reported quarter  Management announced plans to file the first 510 k  for FDA approval of da Vinci SP program by year end  and submissions for additional indications thereafter International Sales  Globally  Intuitive Surgical s system placements included 25 in Europe  14 in Japan  five in India  four in New Mexico and one in China  However  as the OUS markets are in early stages of adoption  sales might be lower than estimated in the region Revenue SegmentsInstruments and Accessories  Revenues at the segment grew 15  to  401 million in the quarter  driven by strong procedure growth and increased sales of stapling and vessel sealing products  Revenues realized per procedure were approximately  1 880 compared with  1 870 in the year ago quarter System Sales increased 15  to  237 million buoyed by higher system placements  partially offset by lower average selling prices  Notably  Intuitive Surgical generated approximately  7 million in revenues associated with operating leases in the reported quarter compared with  4 million in the third quarter of 2016  Coming to the company s flagship da Vinci surgical platform  the company shipped 169 surgical systems  up from 134 in the third quarter of 2016 Service The company registered revenues of  147 million  up 13  on a year over year basis on growth in the installed base of da Vinci systems MarginIntuitive Surgical s adjusted gross margin in the reported quarter contracted 130 basis points  bps  to 71 8  of net revenues  The decrease in margins was due to a  7 million medical device tax refund  which was received in 2016 Notably  management at Intuitive Surgical expects margins to fluctuate based on the company s mix of new products  mix of systems in instrument and accessory revenue  reduction of product costs and the reinstatement of the medical device tax in 2018 Financial UpdateIntuitive Surgical ended the third quarter of 2017 with  3 8 billion in cash  cash equivalents  and investments  up by  379 billion on a year over year basis  This was primarily driven by cash generated from operations and employee stock option exercises Bottom LineIntuitive Surgical exited the third quarter on a solid note  beating the Zacks Consensus Estimate on both the counts  Procedure performance in Asia showed continued strength with solid growth in China  Japan and Korea  The company gained significantly on the CE Mark approval for da Vinci X in Europe  The stock has got a further boost on the recent FDA approval of the same in the recent past  A positive outlook for the coming quarters also raises our confidence in the stock  Further  incremental spending on product development and higher investments in international markets are likely to drive long term growth  However  the da Vinci Surgical System has a long sale and purchase order cycle which might act against the company  In fact  the stock looks a tad expensive  adding to our concerns  Intuitive Surgical expects sales to be lower outside the United States Key PicksA few better ranked stocks in the broader medical sector are SONOVA HOLDING   OTC SONVY    EnteroMedics Inc    NASDAQ ETRM   and Luminex Corporation   NASDAQ LMNX    All the stocks sport a Zacks Rank  1  Strong Buy   You can see  SONOVA represented a solid return of 8 1  over the last three months  The company has a long term expected earnings growth rate of 7  EnteroMedics has an average earnings beat of 55 8  for the trailing four quarters  The company has a solid return of 7 1  for the past month Luminex came up with a positive earnings surprise of 188 9  last quarter  The stock has a long term expected earnings growth rate of 16 3  Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2017-10-19,Zacks Investment Research,https://www.investing.com/analysis/intuitive-surgical-isrg-beats-on-q3-earnings--revenues-200220138,200220138
112880,334395,ISRG,Abaxis  ABAX  Posts In Line Earnings In Q2  Lags Revenues,opinion,"Abaxis  Inc    NASDAQ ABAX   reported second quarter fiscal 2018 adjusted earnings per share of 29 cents  in line with the Zacks Consensus Estimate  However  the adjusted EPS figure declined 42  from the year ago figure of 50 cents Total RevenueIn the fiscal second quarter  Abaxis recorded revenues of  58 9 million  reflecting an increase of 0 5  from a year ago  The top line however missed the Zacks Consensus Estimate of  61 million  According to the company  foreign currency exchange rate fluctuations had a negligible or 0 4  impact on Abaxis  top line Segments in DetailOn a geographic basis  revenues from North America  accounting for 79 7  of total revenue  declined 0 2  to  46 9 million in the reported quarter  Revenues from the international markets  accounting for the rest  improved 3 5  to  11 9 million Abaxis operates through three main segments  namely  Veterinary  Medical and Other  In the reported quarter  Veterinary sales accounted for 82 5  of total sales  Medical contributed 15 8  while the remaining 1 8  was generated from Other  
ABAXIS  Inc  Price  Consensus and EPS Surprise
     Veterinary market revenues improved 0 5  year over year to  48 5 million  driven by a 3  uptick in veterinary consumable revenues to  39 3 million  Veterinary instrument revenues were down 10  year over year to  7 5 million Revenues from the medical market were down from  9 4 million in the same quarter last year to  9 3 million as strength in Piccolo instrument was offset by decline in medical rotors  Also  revenues at the North American medical division totaled  6 8 million  up 1 5  year over year  On a global basis  Abaxis sold 225 Piccolos in the quarter compared with 208 a year ago Abaxis exhibited strong consumable growth  up 2  year over year to  46 4 million in the quarter  Within the consumable product lines  total rotor revenues were  31 6 million  almost in line with  31 7 million in the year ago quarter  On a global basis  Abaxis sold 2 55 million rotor units in the quarter under review  down from 2 57 million units in the year ago quarter  Hematology reagents and rapid assays drove growth in consumable revenues in the reported quarter However  total instruments  sales decreased 7  to  9 2 million due to lower veterinary instrument sales Operational UpdatesFiscal second quarter s gross profit dropped 0 3  to  32 2 million  Gross margin contracted 50 basis points  bps  to 54 6  Research and development expenses increased 23 8  year over year to  6 1 million and sales and marketing expenses rose 10 9  to  12 5 million  General and administrative expenses however declined 4 3  to  4 2 million  However  the resultant operating income was down 19 7  to  9 4 million in the quarter  while operating margin declined 410 bps to 16  Financial UpdateAbaxis exited the fiscal second quarter with cash  cash equivalents and short term investments of  148 8 million  compared with  137 7 million in first quarter fiscal 2018 Our TakeAbaxis exited the second quarter of fiscal 2018 on a disappointing with revenues lagging the Zacks Consensus Estimate  Also  a decline in both gross and operating margin is a matter of concern  However  a year over year increase in revenues buoys optimism  We are looking forward to improved consumable revenues that boosted veterinary sales performance at Abaxis in the quarter Meanwhile  we are encouraged to note that the company is initiating new sales and marketing strategies  In this regard  the company recently started shipping VetScan UA  a hand held urine chemistry analyzer in September  Moreover  the latest launches of VetScan Phenobarbital Profile and VetScan Canine Pancreatic Lipase Rapid Test buoy optimism  Abaxis plans additional product launches in fiscal 2018  including the VetScan FUSE connectivity system  According to the company  addition of these products will drive growth over the long haul Zacks Rank   Key PicksCurrently  Abaxis has a Zacks Rank  3  Hold  A few better ranked stocks in the broader medical sector are PetMed Express  Inc    NASDAQ PETS    Abbott   NYSE ABT   and Intuitive Surgical  Inc    NASDAQ ISRG    Notably  PetMed sports a Zacks Rank  1  Strong Buy   while Abbott and Intuitive Surgical carry a Zacks Rank  2  Buy   You can see PetMed reported EPS of 43 cents in the second quarter of fiscal 2018  up 79 2  from the year ago quarter s 24 cents  Also  gross margin expanded 548 bps year over year to 35 2  in the reported quarter Abbott reported third quarter 2017 adjusted earnings from continuing operations of 66 cents per share  up 11 9  year over year  Also  third quarter worldwide sales came in at  6 83 billion  up 28 8  year over year on a reported basis  Intuitive Surgical posted adjusted earnings of  2 77 per share in the third quarter of 2017  up 34 5  on a year over year basis  Also  revenues increased 18  year over year to  806 1 million Zacks  Hidden TradesWhile we share many recommendations and ideas with the public  certain moves are hidden from everyone but selected members of our portfolio services  Would you like to peek behind the curtain today and view them Starting now  for the next month  I invite you to follow all Zacks  private buys and sells in real time from value to momentum   from stocks under  10 to ETF to option movers   from insider trades to companies that are about to report positive earnings surprises  we ve called them with 80   accuracy   You can even look inside portfolios so exclusive that they are normally closed to new investors ",2017-10-24,Zacks Investment Research,https://www.investing.com/analysis/abaxis-abax-posts-inline-earnings-in-q2-lags-revenues-200220927,200220927
112883,334398,ISRG,Edwards Lifesciences  EW  Q3 Earnings  Sales Lag  View Intact,opinion,"Edwards Lifesciences Corporation   NYSE EW   reported third quarter 2017 adjusted earnings per share  EPS  of 84 cents  which missed the Zacks Consensus Estimate of 86 cents by 2 3   However  adjusted earnings improved 23 5  year over year  primarily driven by strong sales growth at the company s transcatheter heart valves business Excluding one time items  net income in the third quarter came in at  170 1 million or 79 cents per share  up 20 3  or 21 5  year over year  respectively Sales DetailsEdwards Lifesciences  third quarter sales improved 11 1  to  821 5 million  However  the figure missed the Zacks Consensus Estimate of  834 million by 1 5   Underlying sales increased 12 9   including the impact of Germany stocking sales as customers in the nation chose to purchase additional inventory of the SAPIEN 3 valve in anticipation of a potential supply interruption resulting from recent intellectual property litigation  Revenues were primarily driven by considerable growth in transcatheter heart valve sales as well as strong performance by Surgical Heart Valve Therapy and Critical Care product lines too across all regions  
Edwards Lifesciences Corporation Price  Consensus and EPS Surprise
     Segments DetailsFor the third quarter  the company reported Transcatheter Heart Valve Therapy  THVT  sales of  481 2 million  reflecting 17 3  growth over the prior year quarter  In the United States  THVT sales in the quarter totaled  311 6 million  up 20 1  year over year  Growth was driven by excellent clinical performance by SAPIEN 3 as well continued strong therapy implementation across all regions Surgical Heart Valve Therapy sales in the quarter were  195 6 million  up 2 4  from the prior year quarter  This was led by strong demand for the EDWARDS INTUITY Elite valve system and strong uptake of core products outside the United States  partially offset by the continuing shift from surgical aortic valves to the SAPIEN 3 valves in the United States and Europe Critical Care sales were  144 7 million in the reported quarter  representing an increase of 4 5  from third quarter 2016   Solid growth across all product categories was driven by strong growth in the company s core products and the Enhanced Surgical Recovery Program  mainly in the United States and Asia Pacific MarginsIn the third quarter  gross margin expanded 120 basis points  bps  to 74  owing to a more profitable product mix  led by growing sales of transcatheter valves as well as a favorable comparison of supply chain expenditures  This was however partially offset by expenses incurred due to flooding from Hurricane Maria in Puerto Rico and the shutdown of the company s manufacturing plant in Switzerland SG A expenses rose 6 5  year over year to  244 6 million on account of sales and personnel related expenses  primarily in the Transcatheter Valve  THV  segment R D expenditures increased 26 5  year over year to  142 9 million owing to continued investments in the company s transcatheter aortic valve and mitral valve program  Adjusted operating margin in the quarter expanded 50 bps to 26 9  as the rise in revenues outweighed the increase in operating expenses Cash PositionEdwards Lifesciences exited the third quarter with cash and cash equivalents and short term investments of  1 4 billion  compared with  1 13 billion at the end of the second quarter  Long term debt in the quarter totaled  1 03 billion  compared with  1 02 billion reported in the previous quarter Cash flow from operating activities was  310 8 million in the third quarter  compared with  197 7 million in the previous quarter  Excluding capital spending of  42 3 million  free cash flow was  268 5 million  During the quarter  average diluted shares outstanding were 216 2 million  2017 Guidance StaysEdwards Lifesciences has reaffirmed its full year 2017 sales expectations at the high end of the previously projected range of  3 2  3 4 billion  The Zacks Consensus Estimate for full year revenue is  3 40 billion  coinciding with the high end of the guided range  Adjusted EPS expectations have also been reinstated at  3 65  3 85  The Zacks Consensus Estimate for full year adjusted EPS stands at  3 78  within the company s guided range For the fourth quarter of 2017  the company projects sales  after adjusting for the effect of Germany stocking sales  between  855 million and  895 million  The Zacks Consensus Estimate for revenues is  874 2 million  within the company s projected range  The company estimates adjusted EPS between 84 cents and 94 cents  Meanwhile  the Zacks Consensus Estimate for adjusted EPS is 92 cents  which is also within the company s forecasted range Our TakeEdwards Lifesciences exited the third quarter on a disappointing note with both earnings and revenues lagging the respective Zacks Consensus Estimate  The company s business was affected by the recent natural disasters in the Caribbean and the United States  Edwards Lifesciences has principal manufacturing locations for its Critical Care products in Puerto Rico and the Dominican Republic  In Puerto Rico  the company had to discontinue production due to floods which affected the top line to some extent  The company also had to postpone a number of procedures in Houston and Florida  Per management  natural disasters negatively impacted third quarter sales to the tune of  2 million Nevertheless  strong transcatheter valve sales in the domestic market as well as overseas is a major positive  The company also performed well on its gross margin front  which raises optimism Management expects to gain traction in the ever expanding TAVR market  based on increasing preference in favor of transcatheter aortic valve replacement as well as compelling clinical evidence  leading to strong adoption of THV therapy  However  tough competition in the cardiac devices market and reimbursement issues continue to pose challenges Zacks Rank   Key PicksCurrently  Edwards Lifesciences has a Zacks Rank  3  Hold  A few better ranked stocks in the broader medical sector are PetMed Express  Inc    NASDAQ PETS    Abbott   NYSE ABT   and Intuitive Surgical  Inc    NASDAQ ISRG    Notably  PetMed sports a Zacks Rank  1  Strong Buy   while Abbott and Intuitive Surgical carry a Zacks Rank  2  Buy   You can see PetMed reported EPS of 43 cents for the second quarter of fiscal 2018  up 79 2  from the year ago quarter s 24 cents  Also  gross margin expanded 548 bps year over year to 35 2  in the reported quarter Abbott reported third quarter 2017 adjusted earnings from continuing operations of 66 cents per share  up 11 9  year over year  Also  third quarter worldwide sales came in at  6 83 billion  up 28 8  year over year  Intuitive Surgical posted adjusted earnings of  2 77 per share in the third quarter of 2017  up 34 5  on a year over year basis  Also  revenues increased 18  year over year to  806 1 million Zacks  Hidden TradesWhile we share many recommendations and ideas with the public  certain moves are hidden from everyone but selected members of our portfolio services  Would you like to peek behind the curtain today and view them Starting now  for the next month  I invite you to follow all Zacks  private buys and sells in real time from value to momentum   from stocks under  10 to ETF to option movers   from insider trades to companies that are about to report positive earnings surprises  we ve called them with 80   accuracy   You can even look inside portfolios so exclusive that they are normally closed to new investors ",2017-10-24,Zacks Investment Research,https://www.investing.com/analysis/edwards-lifesciences-ew-q3-earnings-sales-lag-view-intact-200220926,200220926
112884,334399,ISRG,Illumina  ILMN  Tops Q3 Earnings   Revenues  Raises Guidance,opinion,Illumina  Inc    NASDAQ ILMN   reported adjusted earnings per share  EPS  of  1 11 in the third quarter of 2017  which beat the Zacks Consensus Estimate of 98 cents  Adjusted earnings also surpassed the year ago number by 14 4  Including one time items  the company reported EPS of  1 11  compared with 87 cents a year ago RevenuesIn the reported quarter  Illumina s revenues grew 17 6  year over year to  714 million  Moreover  the top line beat the Zacks Consensus Estimate by 2 9   Illumina  Inc  Price  Consensus and EPS Surprise     Per management  top line growth in the third quarter can be attributed to strong uptake of sequencing consumables and instruments as well as microarray portfolios  Moreover  the NovaSeq platform continued to drive growth with close to 200 NovaSeq systems currently at customers  hands since the launch in January 2017  Management is also hopeful that recent launches like S4 flow cell  Xp workflow and Nextera DNA Flex library preparation kit will drive NovaSeq demand Product revenues  83 5  of total revenue  increased 15 9  year over year to  596 million  Service and Other  15 5   revenues were up 26 9  year over year to  118 million Operational UpdateIllumina s adjusted gross margin came in at 67 5   reflecting a contraction of 267 basis points  bps  year over year owing to NovaSeq introduction  higher array services revenues and product mix within sequencing consumables  Excluding amortization of acquired intangible assets and including stock based compensation expenses  adjusted gross margin was 68 8   highlighting a contraction of 320 bps from a year ago Research and development expenses were up 20 1  year over year to  134 million and selling  general   administrative expenses rose 6 3  to  167 million  Consequently  the adjusted operating margin of 25 4  reflected a decline of 117 bps from the year ago period Financial UpdateIllumina exited the third quarter with cash and cash equivalents and short term investments of  2 04 billion  up from  1 89 billion in the third quarter  Year to date net cash provided by operating activities was  581 million  compared with  517 million in the year ago period 2017 GuidanceBanking on the solid third quarter performance  Illumina has raised its full year 2017 revenue growth expectations to 13  from the earlier provided range of 12   Meanwhile  the Zacks Consensus Estimate for full year 2017 revenues is pegged at  2 69 billion The company raised its adjusted EPS to the band of  3 73  3 78 from the earlier  3 60  3 70  The Zacks Consensus Estimate for Illumina s 2017 bottom line stands at  3 64  far below the low end of the guided range  Our TakeIllumina exited the third quarter on a solid note  We are also encouraged by the year over year increase in both the fronts  The company has also raised its full year 2017 revenue guidance and the adjusted EPS range  We are looking forward to the performance of NovaSeq S4 flow cell  reagent kit and NovaSeq Xp workflow for its NovaSeq 6000 System On the flip side  weak margins owing to the lower instrument margin associated with NovaSeq launch and higher array services mix will continue to act as deterrents  Also  a tough competitive landscape is a concern Zacks Rank   Key PicksCurrently  Illumina has a Zacks Rank  3  Hold  Some better ranked stocks in the broader medical sector are PetMed Express  Inc    NASDAQ PETS    Abbott   NYSE ABT   and Intuitive Surgical  Inc    NASDAQ ISRG    Notably  PetMed sports a Zacks Rank  1  Strong Buy   while Abbott and Intuitive Surgical carry a Zacks Rank  2  Buy   You can see PetMed reported EPS of 43 cents for the second quarter of fiscal 2018  up 79 2  from the year ago quarter s 24 cents  Also  gross margin expanded 548 bps year over year to 35 2  in the reported quarter Abbott reported third quarter 2017 adjusted earnings from continuing operations of 66 cents per share  up 11 9  year over year  Also  third quarter worldwide sales came in at  6 83 billion  up 28 8  year over year  Intuitive Surgical posted adjusted earnings of  2 77 per share in the third quarter of 2017  up 34 5  on a year over year basis  Also  revenues increased 18  year over year to  806 1 million Zacks  Hidden TradesWhile we share many recommendations and ideas with the public  certain moves are hidden from everyone but selected members of our portfolio services  Would you like to peek behind the curtain today and view them Starting now  for the next month  I invite you to follow all Zacks  private buys and sells in real time from value to momentum   from stocks under  10 to ETF to option movers   from insider trades to companies that are about to report positive earnings surprises  we ve called them with 80   accuracy   You can even look inside portfolios so exclusive that they are normally closed to new investors ,2017-10-24,Zacks Investment Research,https://www.investing.com/analysis/illumina-ilmn-tops-q3-earnings--revenues-raises-guidance-200220919,200220919
112886,334401,ISRG,Accuray s  ARAY  Q1 Loss In Line  Revenues Beat Estimates,opinion,Accuray Incorporated   NASDAQ ARAY   reported a loss of 7 cents per share in the first quarter of fiscal 2018  in line with the Zacks Consensus Estimate  The figure was narrower than the loss of 12 cents incurred in the year ago quarter Total revenue in the first quarter increased approximately 5 1  year over year to  90 9 million and beat our estimate of  89 million  The year over year upside was driven by product revenue growth of 9 3  Segment AnalysisProduct Revenues  Revenues at the segment increased 9 3  to  38 9 million on the back of solid performances by the CyberKnife  TomoTherapy Systems and Radixact platforms of the segment  The increase in product revenues was driven by backlog conversion of orders to revenues from the EIMEA and Japan regions  Accuray Incorporated Price  Consensus and EPS Surprise     Service Revenues  Revenues at the segment saw a modest year over year increase of 2 2  to  52 million  Per management  growth at the segment was primarily driven by continued install base expansion Gross Order Update  In the reported quarter  gross product orders totaled  55 6 million  up 10 6  year over year  The rise in gross orders was supported by the company s flagship Radixact System and TomoTherapy Other HighlightsRadixact Platform Drives Sales  The company s new TomoTherapy product platform  also known as Radixact  continued to contribute to the top line  Radixact represented the majority of Accuray s TomoTherapy order mix in the reported quarter Japan witnessed stellar performances at the Radixact and TomoTherapy platforms The Precision System  Accuray announced the launch of new precision treatment planning system recently  The system leverages on the company s flagship Radixact and CyberKnife system platforms  This will provide significantly improve treatment speed and overall throughput of the CyberKnife system IBMS Data Management System for TomoTherapy  Accuray also announced 510 k  clearance for the new IBMS data management system for TomoTherapy  It is a centralized database that shares and makes data accessible between multiple accurate systems  enhancing flexibility and improving workflow efficiency in the radiation therapy department Margin DetailsGross margin  as a percentage of net revenues  expanded 566 basis points  bps  in the first quarter to 41 9   This was primarily driven by a significant rise in both product and service gross margins  Product gross margin improved on the back of CyberKnife systems in first quarter 2018 as compared to prior year quarter Operating expenses in the first quarter totaled  40 2 million  compared with  37 9 million in the year ago period GuidanceAccuray reaffirmed the guidance for fiscal 2018 The company maintains full year revenue projection at the band of  390 million to  400 million  This represents growth of 2  to 4  on a year over year basis The company also expects a 5  increase in gross orders in fiscal 2018 Adjusted EBITDA for fiscal 2018 is anticipated in the range of  25 million to  30 million  up 23  to 47  year over year Our TakeAccuray reported loss in the first quarter of fiscal 2018  However  the loss was narrower than the year ago figure  The company exited the quarter on a solid note with earnings meeting the consensus estimate and revenues surpassing the same  The year over year increase in both Product and Service revenues is encouraging  The reaffirmed guidance also buoys optimism  However  fluctuations in currency exchange rates  particularly because of a strong dollar  will continue to affect the company s backlog and top line Zacks Rank   Key PicksCurrently  Accuray has a Zacks Rank  3  Hold  Some better ranked stocks in the broader medical sector are PetMed Express  Inc    NASDAQ PETS    Abbott   NYSE ABT   and Intuitive Surgical  Inc    NASDAQ ISRG    Notably  PetMed sports a Zacks Rank  1  Strong Buy   while Abbott and Intuitive Surgical carry a Zacks Rank  2  Buy   You can see PetMed reported EPS of 43 cents in the second quarter of fiscal 2018  up 79 2  from the year ago quarter s 24 cents  Also  gross margin expanded 548 bps year over year to 35 2  in the reported quarter Abbott reported third quarter 2017 adjusted earnings from continuing operations of 66 cents per share  up 11 9  year over year  Also  third quarter worldwide sales came in at  6 83 billion  up 28 8  year over year  Intuitive Surgical posted adjusted earnings of  2 77 per share in the third quarter of 2017  up 34 5  on a year over year basis  Also  revenues increased 18  year over year to  806 1 million Zacks  Hidden TradesWhile we share many recommendations and ideas with the public  certain moves are hidden from everyone but selected members of our portfolio services  Would you like to peek behind the curtain today and view them Starting now  for the next month  I invite you to follow all Zacks  private buys and sells in real time from value to momentum   from stocks under  10 to ETF to option movers   from insider trades to companies that are about to report positive earnings surprises  we ve called them with 80   accuracy   You can even look inside portfolios so exclusive that they are normally closed to new investors ,2017-10-24,Zacks Investment Research,https://www.investing.com/analysis/accurays-aray-q1-loss-in-line-revenues-beat-estimates-200220918,200220918
112892,334407,ISRG,NuVasive  NUVA  Q3 Earnings Top  Revenues Lag  Guidance Cut,opinion,NuVasive  Inc    NASDAQ NUVA   reported third quarter 2017 adjusted earnings per share  EPS  of 52 cents  reflecting a 30  rise from the year ago quarter  The figure also surpassed the Zacks Consensus Estimate of 48 cents Solid revenue growth primarily led to this year over year bottom line improvement Including one time items  the company reported third quarter 2017 net income per share of 64 cents  a significant improvement from the year ago figure of 7 cents per share Revenues in the reported quarter increased 3 2  year over year to  247 4 million  up 3 4  at constant exchange rate or CER   The figure however  missed the Zacks Consensus Estimate of  255 million The above upside in revenues was driven by a robust performance in the international market on strong growth across all geographical regions  In the United States  procedural volumes were sluggish  unable to meet the company s expectations NuVasive  Inc  Price  Consensus and EPS Surprise    However  putting together the impact of hurricanes Harvey and Irma on NuVasive s U S  results and Maria on the company s international results along with one less selling day  the revenue growth would have been approximately 6  year over year In the reported quarter  the company s U S  Spinal Hardware business registered more than 2  growth backed by introduction of new products  Adjusting the impact of the hurricanes and offsetting the effect of one less selling day  the U S  Spinal Hardware business approximately grew 5  year over year The U S  Surgical Support business declined 12 7  in the third quarter  primarily on continued softness in biologics business  With new competitive products entering the market  the company faces challenges in the field  Also  procedural issues are affecting revenue volumes However  the international business recorded 46  growth at CER on continued strong demand of the company s spine technology outside the United States  particularly in the key markets of Italy  Germany and Japan In the quarter under review  there was a 10 8  increase in cost of goods sold  Despite that  gross profits inched up 0 8  to  181 8 million  Yet the company reported a 180 basis point  bps  year over year contraction in gross margin to 73 5  in the third quarter that includes a 90 bps year over year impact from low margin businesses Sales  marketing and administrative expenses went down 4 6  to  125 8 million  while research and development expenses increased 1 6  to  12 7 million NuVasive posted adjusted operating income of  43 3 million in the reported quarter  reflecting a 20 1  rise from the year ago number  Adjusted operating margin expanded 247 bps to 17 5  in the quarter under review The company exited third quarter 2017 with cash  cash equivalents and short term investments of  62 2 million  down from  130 9 million at the end of the previously reported quarter OutlookIn view of the continued impact of Maria in Puerto Rico in the fourth quarter as well as the anticipated lower U S  procedural volumes  NuVasive has updated its full year 2017 guidance Currently  the company expects to report revenue growth of 7 2   lower than the earlier expected rate of 11 1  at CER to approximately  1 030 billion  earlier it was  1 065 billion  in 2017  The figure also remains lower than the current Zacks Consensus Estimate of  1 06 billion NuVasive also lowered its guidance for full year 2017 adjusted earnings per share to  1 91 as compared to the previous expectation of  2 per share  The current Zacks Consensus Estimate of  1 99 remains significantly above the company s guidance  Additionally  adjusted operating margin for the year is currently expected at 16 6  compared with the former projection of 17 1  Our TakeNuVasive exited the third quarter with better than expected earnings and revenue numbers  This quarter  the company s performance was significantly dependent on stellar international growth  The company noted that the reported quarter marked the fourth consecutive one  registering more than 20  growth in international business  However  overall sales in the quarter were grossly impacted by procedural volumes related challenges in the United States and the adverse impact of Harvey and Irma on NuVasive s U S  results and Maria on the international front With chances of the fourth quarter revenues being affected by Maria in Puerto Rico and due to the anticipated lower U S  procedural volumes continuing into the same period  NuVasive is pressed to reduce its full year guidance  which is disappointing Zacks Rank   Key PicksCurrently  NuVasive has a Zacks Rank  4  Sell  A few better ranked stocks in the broader medical sector are PetMed Express  Inc    NASDAQ PETS    Abbott   NYSE ABT   and Intuitive Surgical  Inc    NASDAQ ISRG    Notably  PetMed sports a Zacks Rank  1  Strong Buy   while both Abbott and Intuitive Surgical carry a Zacks Rank  2  Buy   You can see PetMed reported EPS of 43 cents for the second quarter of fiscal 2018  up 79 2  from 24 cents  reported in the year ago quarter  Also  gross margin expanded 548 bps year over year to 35 2  in the reported quarter Abbott reported third quarter 2017 adjusted earnings from continuing operations of 66 cents per share  up 11 9  year over year  Also  third quarter worldwide sales came in at  6 83 billion  up 28 8  year over year  Intuitive Surgical posted adjusted earnings of  2 77 per share in the third quarter of 2017  up 34 5  on a year over year basis  Also  revenues increased 18  year over year to  806 1 million Zacks  Hidden TradesWhile we share many recommendations and ideas with the public  certain moves are hidden from everyone but selected members of our portfolio services  Would you like to peek behind the curtain today and view them Starting now  for the next month  I invite you to follow all Zacks  private buys and sells in real time from value to momentum   from stocks under  10 to ETF to option movers   from insider trades to companies that are about to report positive earnings surprises  we ve called them with 80   accuracy   You can even look inside portfolios so exclusive that they are normally closed to new investors ,2017-10-24,Zacks Investment Research,https://www.investing.com/analysis/nuvasive-nuva-q3-earnings-top-revenues-lag-guidance-cut-200221043,200221043
112895,334410,ISRG,Baxter  BAX  Beats On Earnings   Sales In Q3  2017 View Up,opinion,Baxter International Inc    NYSE BAX   reported third quarter 2017 adjusted earnings per share of 64 cents  which beat the Zacks Consensus Estimate by 5 cents and improved from the year ago figure of 56 cents  Baxter currently has a Zacks Rank  2  Buy  The figure was also above the company s guided range of 58 cents to 60 cents  Interestingly  over the last four quarters  the company delivered positive earnings surprises  the average being 15 3  Baxter posted sales of  2 71 billion  beating the Zacks Consensus Estimate of  2 66 billion  At constant currency  cc   revenues increased 6  on a year over year basis  U S  sales were up 8  year over year to  1 6 billion  International sales increased 4  at cc to almost  1 5 billion  Baxter International Inc  Price  Consensus and EPS Surprise     Segmental DetailsSales at the hospital products segment climbed 7  at cc on a year over year basis to  1 7 billion  Hospital Products sales in the quarter were driven by solid sales in the U S  fluid systems and select anesthesia and critical care products  Hospital Sales were also driven by solid demand for injectable pharmaceuticals and hospital pharmacy compounding services Meanwhile  sales increased 3  at cc to  1 billion at the renal products segment  Renal products sales were supported by improved performance across all major product lines and therapies globally Quarterly HighlightsBaxter Acquires Claris  In the third quarter  Baxter completed the acquisition of India based Claris Injectables  a global generic injectables pharmaceutical company for almost  625 million  In December 2016  Baxter had initiated the agreement  Per management  the acquisition will bolster Baxter s foothold in the generic pharmaceuticals space New Patients Enrolled  In the third quarter  Baxter registered patients under two new clinical trials for a unique expanded hemodialysis therapy enabled by THERANOVA  a dialyzer for treatment of chronic and acute renal failure  In fact  Baxter is expected to launch hemodialysis enabled by THERANOVA in Australia  New Zealand  France  Germany  Switzerland and Belgium by the end of this year Hurricanes Deal a Blow  Management at Baxter announced a possibility of shortfall in supply of certain products in the next quarter  This is because the company is still grappling with limited production at all three manufacturing sites in Puerto Rico Hurricane Maria  However  the company has been granted regulatory approval by the FDA for special importation of products from facilities in Ireland  Australia  Canada and Mexico to maintain the product supply balance in the U S  market International Foothold Fortified  Baxter launched the oXIRIS set for continuous renal replacement therapy  CRRT  and sepsis management protocols in select markets of Europe  Middle East and Africa in the quarter  Notably  oXIRIS  which leverages on the company s flagship PRISMAFLEX system  is expected to lend Baxter a competitive edge in the global market Guidance LiftedFor full year 2017  Baxter estimates sales growth of approximately 4  at cc  Adjusted earnings for the full year are expected in the band of  2 40 to  2 43 per diluted share  up from the previous band of  2 34 to  2 40 Baxter expects fourth quarter revenues to face a negative impact of approximately  70 million  thanks to the operational disruption resulting from hurricane Maria  Adjusted earnings for the fourth quarter are expected in the band of 56 cents to 59 cents per diluted share  Net sales in the fourth quarter are expected to rise 2  at cc Other Companies With Solid Earnings ResultsIntuitive Surgical Inc    NASDAQ ISRG   posted adjusted earnings of  2 77 per share in the third quarter of 2017  beating the Zacks Consensus Estimate of  1 97 on stellar revenue growth  The stock has a Zacks Rank  2 PetMed Express  Inc    NASDAQ PETS   adjusted announced earnings per share of 43 cents for the second quarter of fiscal 2018  up 79 2  from the year ago quarter  Also  earnings surpassed the Zacks Consensus Estimate by 43 3   The stock has a Zacks Rank  1  Strong Buy   You can see Abbott   NYSE ABT   reported third quarter 2017 adjusted earnings from continuing operations of 66 cents per share  up 11 9  year over year  Third quarter worldwide sales came in at  6 83 billion  up 28 8  year over year  Abbott carries Zacks Rank  2 Zacks  Hidden TradesWhile we share many recommendations and ideas with the public  certain moves are hidden from everyone but selected members of our portfolio services  Would you like to peek behind the curtain today and view them Starting now  for the next month  I invite you to follow all Zacks  private buys and sells in real time from value to momentum   from stocks under  10 to ETF to option movers   from insider trades to companies that are about to report positive earnings surprises  we ve called them with 80   accuracy   You can even look inside portfolios so exclusive that they are normally closed to new investors ,2017-10-24,Zacks Investment Research,https://www.investing.com/analysis/baxter-bax-beats-on-earnings--sales-in-q3-2017-view-up-200221004,200221004
112896,334411,ISRG,Walgreens Boots  WBA  Tops Q4 Earnings  Issues 2018 View,opinion,"Walgreens Boots Alliance  Inc    NASDAQ WBA   reported adjusted earnings per share  EPS  of  1 31 in fourth quarter fiscal 2017  up 22 4  year over year  Adjusted EPS surpassed the Zacks Consensus Estimate of  1 22 On a reported basis  net earnings came in at  802 million  reflecting a decrease of 22 1  from the prior year quarter  Reported earnings came in at 76 cents per share  showing a 20  decline on a year over year basis For full year 2017  adjusted EPS came in at  5 10  up 11 1  from the year ago quarter  The figure also surpassed the Zacks Consensus Estimate of  5 01 Total SalesWalgreens Boots recorded total sales of  30 15 billion in the fiscal fourth quarter  up 5 3  year over year and up 6 4  at constant exchange rate  CER   The top line outpaced the Zacks Consensus Estimate of  30 05 billion Fiscal 2017 sales totaled  118 21 billion  up 0 7  from the year ago period   Moreover  the figure beat the Zacks Consensus Estimate of  118 16 billion by a slight margin 
Walgreens Boots Alliance  Inc  Price  Consensus and EPS Surprise
  
   Segments in DetailWalgreens Boots currently reports under three operating segments  Retail Pharmacy USA  Retail Pharmacy International and Pharmaceutical Wholesale The Retail Pharmacy USA division recorded sales of  22 3 billion in the fourth quarter  highlighting an increase of 7 5  on a year over year basis  Within this segment  total sales at comparable drugstores rose 3 1   while prescriptions filled in comparable stores grew 8 7  on account of Medicare Part D growth and volume growth from previously announced strategic pharmacy collaborations  Comparable retail sales dropped 2 1  due to lower sales at the consumables and general merchandise category and the personal care category  partially offset by increased sales in the health and wellness as well as beauty categories Pharmacy sales  which accounted for 72 1  of the Retail Pharmacy USA division s sales in the quarter  increased 12 6  from the year ago quarter  and pharmacy sales at comparable stores rose 5 6  on higher volumes Revenues at the Retail Pharmacy International division declined 3 2  on a year over year basis  down 0 4  at CER  to  2 9 billion owing to currency fluctuations  At CER  comparable store sales in the fourth quarter decreased 0 2  year over year  while comparable pharmacy sales increased 0 5  led by growth in the U K The Pharmaceutical Wholesale division recorded quarterly sales of  5 4 billion  up 0 8  year over year  up 5 4  at CER  MarginsGross profit in the reported quarter declined 2 6  year over year to  7 34 billion  Accordingly  reported gross margin contracted 70 basis points  bps  to 24 3  Selling  general and administrative  SG A  expenses were up 2 8  year over year to  6 22 billion  However  adjusted operating income increased 1 4  to  1 12 billion as the rise in revenues outweighed the increase in operating expenses  In contrast  adjusted operating margin contracted 20 bps to 3 7  Financial ConditionWalgreens Boots exited fiscal 2017 with cash and cash equivalents of  3 30 billion  compared with  9 81 billion at the end of fiscal 2016  Long term debt was  12 68 billion  compared with  18 71 billion at the end of the prior fiscal The company generated operating cash flow of  7 25 billion in fiscal 2017 compared with  7 85 billion a year ago  The resultant free cash flow was  5 9 billion in fiscal 2017 GuidanceWalgreens Boots has issued the fiscal 2018 guidance  The company expects adjusted EPS in the  5 40  5 70 range for the fiscal  The current Zacks Consensus Estimate for fiscal 2017 earnings is pegged at  5 48  within but near to the lower end of the company s guided range Our TakeWalgreens Boots reported an impressive fourth quarter of fiscal 2017 with both earnings and sales surpassing the Zacks Consensus Estimate  However  declining sales at the Retail Pharmacy International was a disappointment  Nevertheless  Walgreens Boots has been gaining on account of the company s strategic tie ups which brought more patients to its U S  pharmacies In September  Walgreens Boots announced the receipt of U S  Federal Trade Commission  FTC  approval for the purchase of 1 932 stores  three distribution centers and related inventory from Rite Aid for a total of  4 375 billion  Synergies of  300 million are expected to be realized within four years of initial closing of the transaction  achieved majorly from procurement  cost savings and other operational areas  Per Walgreens Boots  this modified merger contract is in line with its growth strategy and offers additional operational benefits  It will also help the company expand and optimize retail pharmacy network in key U S  markets  including the Northeast Zacks Rank   Key PicksCurrently  Walgreens Boots has a Zacks Rank  4  Sell  A few better ranked stocks in the broader medical sector are PetMed Express  Inc    NASDAQ PETS    Abbott   NYSE ABT   and Intuitive Surgical  Inc    NASDAQ ISRG    Notably  PetMed sports a Zacks Rank  1  Strong Buy   while Abbott and Intuitive Surgical carry a Zacks Rank  2  Buy   You can see PetMed reported EPS of 43 cents in the second quarter of fiscal 2018  up 79 2  from the year ago quarter s 24 cents  Also  gross margin expanded 548 bps year over year to 35 2  in the reported quarter Abbott reported third quarter 2017 adjusted earnings from continuing operations of 66 cents per share  up 11 9  year over year  Also  third quarter worldwide sales came in at  6 83 billion  up 28 8  year over year  Intuitive Surgical posted adjusted earnings of  2 77 per share in the third quarter of 2017  up 34 5  on a year over year basis  Also  revenues increased 18  year over year to  806 1 million Zacks  Hidden TradesWhile we share many recommendations and ideas with the public  certain moves are hidden from everyone but selected members of our portfolio services  Would you like to peek behind the curtain today and view them Starting now  for the next month  I invite you to follow all Zacks  private buys and sells in real time from value to momentum   from stocks under  10 to ETF to option movers   from insider trades to companies that are about to report positive earnings surprises  we ve called them with 80   accuracy   You can even look inside portfolios so exclusive that they are normally closed to new investors ",2017-10-24,Zacks Investment Research,https://www.investing.com/analysis/walgreens-boots-wba-tops-q4-earnings-issues-2018-view-200221002,200221002
112919,334434,ISRG,Intuitive Surgical  ISRG  Beats On Q2 Earnings   Revenues,opinion,"Intuitive Surgical Inc    NASDAQ ISRG   posted adjusted earnings of  5 05 per share in the second quarter of 2017  crushing the Zacks Consensus Estimate of  4 86 on stellar revenue growth  Also  the figure improved 3 9  on a year over year basis  Interestingly  in the last four quarters  the company beat estimates at an average of 11 4  Revenues increased 12 8  year over year to  756 2 million  driven by growth in recurring instrument  accessory and service and systems revenue  Revenues also beat the Zacks Consensus Estimate of  726 million Following the results  share price was up 0 5  to close at  971 73  Also  shares of Intuitive Surgical have returned 53 23  year to date  outperforming the  s gain of 20 84  Business HighlightsIntuitive Surgical posted solid numbers in the quarter under review  courtesy of rising customer adoption of procedures and growth in system placements Worldwide da Vinci procedure volumes grew approximately 16  year over year  The increase can be attributed to stellar performances in the U S  general surgery and worldwide urologic procedures  Notably  the company shipped 166 da Vinci surgical systems  up from 130 in the second quarter of 2016 Revenue DetailsInstruments and Accessories  Revenues at the segment grew 17 2  to  397 8 million in the quarter  driven by strong procedure growth and increased sales of stapling and vessel sealing products  Revenues realized per procedure were approximately  1 830 compared with  1 810 in the year ago quarter System  Sales increased 7  to  216 4 million buoyed by higher revenues from operating lease activities  Intuitive Surgical placed 166 system orders in the quarter  up from 130 in the year ago quarter  Management at Intuitive Surgical noted that 27 systems were placed under operating lease transactions  compared with 15 systems in the year ago quarter Service  The Company registered revenues of  142 million  up 11  on a year over year basis due to growth in the installed base of da Vinci systems International GrowthPer management  the company posted revenues of  205 million outside the U S   up 11  from the second quarter of 2016 The company placed 63 system orders  compared with 51 in the year ago quarter and 56 in the first quarter of 2017  These included 29 into Europe  14 into Japan  5 into India  5 into Australia and 3 into China Intuitive Surgical  Inc  Price  Consensus and EPS Surprise
    Financial Update
 Intuitive Surgical ended the reported quarter with  3 4 billion in cash  cash equivalents  and investments  down by  1 4 billion on a year over year basis Our TakeWe believe that the growing adoption of Intuitive Surgical s da Vinci system among physicians for general surgery  oncology  urology and gynecology procedures is a key growth catalyst  Moreover  increasing procedural volumes outside the U S  present significant growth opportunities for the company Zacks Rank   Key PicksThe company has a Zacks Rank  3  Hold  A few better ranked stocks in the broader medical sector are Edwards Lifesciences Corporation   NYSE EW    CryoLife  Inc    NYSE CRY   and EDAP TMS SA   NASDAQ EDAP    Notably  EDAP TMS sports a Zacks Rank  1  Strong Buy   while Edwards Lifesciences and CryoLife have a Zacks Rank  2  Buy   You can see  EDAP TMS represents an impressive return of 25 5  for the last three months  The company delivered a solid earnings surprise of 533 3  in the last reported quarter Edwards Lifesciences has a long term expected earnings growth rate of 15 2   Notably  the stock boasts an impressive one year return of 10  CryoLife yielded a strong return of 3 5  over the last one month  The stock delivered a positive earnings surprise of 80  in the last reported quarter Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ",2017-07-20,Zacks Investment Research,https://www.investing.com/analysis/intuitive-surgical-(isrg)-beats-on-q2-earnings---revenues-200202645,200202645
112920,334435,ISRG,Ashland  Interactive Brokers  IDEXX Labs And Intuitive Surgical In Focus,opinion,"Ashland  Ticker  ASH
Ashland Global  NYSE ASH  rose steadily from January through to a top in June  It consolidated and then pulled back violently over the last 4 weeks  Friday it touched the 200 day SMA and printed a Hammer  possible reversal   The RSI and MACD are both oversold and showing signs of reversing  Look for a higher close Monday to participate higher   
Interactive Brokers  Ticker  IBKR

Interactive Brokers  NASDAQ IBKR  consolidated over the winter and then dropped back in March  Since then it has moved steadily higher reaching the latest consolidation zone 2 weeks ago and settling  The RSI is overbought but pulling back while the MACD is near a cross down  Look for a push out of consolidation to participate higher or on the short side   
IDEXX Labs  Ticker  IDXX
IDEXX Laboratories  NASDAQ IDXX  rose from a November low to consolidate from December through February  It took off from there to a new consolidation over support from May through July  It broke that support to the downside to start August and has consolidated since  The RSI stalling in the bearish zone while the MACD is falling  Look for push lower to participate to the downside   
Intuitive Surgical ISRG  Ticker  ISRG
Intuitive Surgical  NASDAQ ISRG  moved higher with a gap up out of consolidation in April  It continued until a new plateau started to build in June over support  The consolidation has tightened and has price pinned between the 20 and 50 day SMA over the last 4 weeks  The RSI is holding in the bullish range with the MACD leveling  Look for a push higher to participate to the upside   
Toronto Dominion  Ticker  TD
Toronto Dominion  TO TD  is pulling back from a lower high and entering a prior support resistance range  The RSI is at the lower edge of the bullish zone with the MACD falling and near zero  Look for a bounce or break lower to participate further   
Up Next  Bonus Idea
After reviewing over 1 000 charts  I have found some good setups for the week  These were selected and should be viewed in the context of the broad  picture reviewed Friday which heading into August Options Expiration sees the equity markets showing some signs of tiring  especially the IWM 
Elsewhere look for gold to continue higher while crude oil consolidates at resistance  The US Dollar Index bounce may be over while US Treasuries are biased higher in the short run  The Shanghai Composite and Emerging Markets  NYSE EEM  are both looking better to the downside short term in their uptrends 
Volatility has crept up but may be stretched  but worth paying closer attention to it in the short run  This changes the bias to lower for the equity index ETF s SPY  NYSE SPY   IWM and QQQ  Their charts all show some signs of weakness in the short term  especially the IWM  but less weakness longer term especially the QQQ  Use this information as you prepare for the coming week and trad em well 
The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment  I or my affiliates may hold positions or other interests in securities mentioned in the Blog  please see my  page for my full disclaimer ",2017-08-14,Gregory W. Harmon,https://www.investing.com/analysis/ashland-interactive-brokers-idexx-labs-intuitive-surgical--toronto-200206953,200206953
112921,334436,ISRG,Intuitive Surgical At 52 Week High  What s Driving The Stock ,opinion,Share price of Sunnyvale  CA based Intuitive Surgical Inc   NASDAQ ISRG   scaled a new 52 week high of  990 14 on Aug 15  eventually closing a bit lower at  985 42  The company has gained 15 8  over the last three months  much better than the S P 500 s 4 6  rise and the broader industry s gain of 1 4   Taking the stable performance of the stock into consideration  we expect Intuitive Surgical to scale higher in the coming quarters  The company s positive long term growth of 9 1  also holds promise Average volume of shares traded over the last one year was remarkable at approximately 344 3K  The stock has a market cap of  36 60 billion  Over the last 30 days  two analysts have raised their earnings estimates for the current year  while one has slashed the estimate  The net effect has taken the Zacks Consensus Estimate for the current quarter from  20 16 per share to  20 58 CatalystsThe market is upbeat about Intuitive Surgical s licensing agreement with JustRight Surgical  The deal enables Intuitive Surgical with a global license to JustRight Surgical s intellectual property in energy based vessel sealing and tissue stapling technologies for use in the robotics field  Joint product development and an equity financing arrangement are also part of the agreement Intuitive Surgical  Inc  Price and Consensus    Also  the company posted an impressive second quarter  Both earnings and revenues registered a year over year increase in the quarter  The company also witnessed growth in all the segments  The international performance was also encouraging We believe that the growing adoption of Intuitive Surgical s da Vinci system among physicians for general surgery  oncology  urology and gynecology procedures is a key catalyst  Moreover  increasing procedural volumes outside the United States open up considerable opportunities for the company The company is further putting efforts in product innovation through research and developments  In this regard  the recent FDA approval for da Vinci X instils confidence in investors This apart  the company is expected to gain prominence in Europe and Asia by enhancing its organizational capabilities  which should further drive its stock price Zacks Rank   Key PicksIntuitive Surgicalcurrently carries a Zacks Rank  3  Hold   A few better ranked medical stocks are Edwards Lifesciences Corp    NYSE EW    Lantheus Holdings  Inc    NASDAQ LNTH   and Align Technology  Inc    NASDAQ ALGN    Edwards Lifesciences and Align Technology sport a Zacks Rank  1  Strong Buy   while Lantheus Holdings carries a Zacks Rank  2  Buy   You can see Edwards Lifesciences has a long term expected earnings growth rate of 15 2   The stock has gained around 2 7  over the last three months Align Technology has a long term expected earnings growth rate of 26 6   The stock has rallied roughly 30 8  over the last three months Lantheus Holdings has a long term expected earnings growth rate of 12 5   The stock has gained 6 7  over the last three months The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2017-08-15,Zacks Investment Research,https://www.investing.com/analysis/intuitive-surgical-at-52week-high-whats-driving-the-stock-200207659,200207659
112922,334437,ISRG,Will Intuitive Surgical  ISRG  Disappoint In Q3 Earnings ,opinion,"Intuitive Surgical s   NASDAQ ISRG   third quarter results  scheduled for release on Oct 19  are expected to show steady growth in instruments and accessories revenues   one of the major revenue components  While this could majorly drive its third quarter earnings  an expected improvement in revenues at all other segments should help the company generate solid results this season It is important to note that Intuitive Surgical delivered positive earnings surprises in the past four quarters  the average being 7 8   Similar to the prior quarter  strong procedure growth and increased sales of stapling and vessel sealing products are expected to be the main factors driving the surge in instrument and accessories revenues The Zacks Consensus Estimate for instrument and accessories revenues stands at  394 million for the third quarter  This reflects an increase of 13 2  from the year ago quarter  Continued development in European markets  solid access to the company s products in Asia and new platforms in imaging and advanced instruments are likely to drive revenues at the segment Intuitive Surgical  Inc  Price and Consensus
    Other Factors at PlayWe believe that the growing adoption of Intuitive Surgical s da Vinci system among physicians for general surgery  oncology  urology and gynecology procedures is a catalyst for the third quarter  Overall  Q3 revenues are expected at around  752 3 million  up 10 2  from the prior year quarter  Below are the other factors that might influence Intuitive Surgical s quarterly results this earnings season Solid Procedure Trends  Expectations of outperformance in the Mature and Growth procedures  especially in general and thoracic surgery  is likely to boost the company s top line  Added to this  solid growth in prostatectomy procedure volumes is likely to lend Intuitive Surgical a competitive edge in the broader prostate surgery market in the third quarter Geographically  procedure growth in the third quarter is expected to be led by China  Germany and Japan  In Germany  procedure growth is likely to be supported by solid installed base expansion Furthermore  procedure trends are expected to be solid globally  with growth led by general surgery and global urology segments Systems   Service Unit Hold Promise  Solid growth in the company s product and systems segment is expected to drive the company s third quarter earnings  In fact  the Zacks Consensus Estimate for revenues at this segment stands at  216 million  up 5 4  on a year over year basis  The increase reflects higher system placements and operating lease revenues   However  this might be partially offset by lower average selling prices and lease buyout revenues at the segment Coming to revenues at the services segment  the Zacks Consensus Estimate stands at  145 million  up 11 5  on a year over year basis Growth in System s Installed Base  Buoyed by higher system placements and operating lease revenues  we expect the company s total systems installed base to be 4231 units  up 82 units from the last quarter  It is important to note that Intuitive Surgical generated approximately  6 million in revenues from operating leases last quarter  compared with 4 million in the second quarter of 2016 Here is what our quantitative model predicts Intuitive Surgical does not have the right combination of two main ingredients   a positive  and Zacks Rank  3  Hold  or higher   for increasing the odds of an earnings beat Zacks ESP  The Earnings ESP for Intuitive Surgical is  0 49   as the Most Accurate estimate is  1 96 and the Zacks Consensus Estimates is pegged at  1 97  You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Intuitive Surgical carries a Zacks Rank  3  which increases the predictive power of ESP  However  we also need a positive ESP to be confident of an earnings beat  In fact  the Zacks Consensus Estimate for earnings reflects a decline of 4 2  on a year over year basis Stocks Worth a LookHere are a few medical stocks worth considering as they have the right combination of elements to post an earnings beat this quarter Abbott   NYSE ABT   has an Earnings ESP of  0 17  and a Zacks Rank  2  Buy   You can see  Align Technology  Inc    NASDAQ ALGN   has an Earnings ESP of  2 06  and a Zacks Rank  3 Henry Schein  Inc    NASDAQ HSIC   has an Earnings ESP of  0 33  and a Zacks Rank  3 Looking for Stocks with Skyrocketing Upside  Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2017-10-17,Zacks Investment Research,https://www.investing.com/analysis/will-intuitive-surgical-isrg-disappoint-in-q3-earnings-200219280,200219280
112948,334463,ISRG,Analyst Reports For GM  VMware And Southwest Airlines ,opinion,"Thursday June 8  2017
Today s Research Daily features new research reports on 16 major stocks  including General Motors  GM   VMware  VMW   and Southwest Airlines  LUV   These research reports have been hand picked from the roughly 70 reports published by our analyst team today 
You can see 
General Motors shares have been strong performers over the past year  the stock is up  17  vs   11 4  for the Zacks Auto sector    16 6  for Ford   though they have struggled lately  The Zacks analyst likes the company s capital allocation strategy  investments in plants in the U S  and emerging markets  product launches and focus on technology development  Moreover  the company s focus on capital deployment is expected to boost shareholder returns  However  the automaker is under pressure due to lower U S  vehicles sales in 2016  a recent settlement related to the 2014 ignition switch recall and a large fine by China for monopolistic pricing behavior  General Motors  quarterly earnings estimate has been going up lately 
 You can   
VMware shares have gained  17 9  year to date  underperforming the Zacks Software industry  up  21 5   but outperforming the S P 500  up  7 2    VMware s revenues continue to register strong growth driven by its innovative product offerings like NSX  AirWatch  vSphere and vSAN  The Zacks analyst likes its innovative product pipeline  strategic partnerships  frequent contract wins and robust international sales  The company continues to benefit from its strength in the virtualization and hybrid cloud market  VMware s impressive first quarter results and positive fiscal year guidance  up from the previous guidance  driven by expanding product portfolio  partnerships and continuing enterprise deal wins will help the stock maintain momentum in the rest of fiscal 2018  However lackluster IT spending and mounting competition are headwinds 
 You can   
Southwest Airlines shares have been standout performers this year  they are up  19 5  in the year to date period vs   11 5  gain for the Zacks Airline industry and  8  gain for the S P 500 index  The stock s positive momentum has been particularly notable since mid March  which got a boost from the company s quartelry report when it modestly came short of estimates but raised guidance and announced a dividend hike and raised the buyback authorization  
 You can   
Other noteworthy reports we are featuring today include Johnson Controls  NYSE JCI   Intuitive Surgical  NASDAQ ISRG  and ArcelorMittal  MT  
Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge 
With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research 
It s not the one you think 

Sheraz Mian
Director of Research
Note  Sheraz Mian heads the Zacks Equity Research department and is a well regarded expert of aggregate earnings  He is frequently quoted in the print and electronic media and publishes the weekly and reports  If you want an email notification each time Sheraz publishes a new article  please 
Today s Must Read









Featured Reports

The Zacks analyst believes new orders of  1 6B  boosted Orbital ATK s backlog to  14 8B  Its R D expenses are helping to churn new and high quality products assuring a steady flow of orders 


While Cabot s cost management and attractive Marcellus program bode well  the covering analyst would prefer to wait for further natural gas price recovery before recommending investors purchase shares 


The Zacks analyst believes that Hawaiian Holdings continues to gain from unit revenue growth  smoother labor relations and impressive punctuality record with fewer flight cancellations 


Per the Zacks analyst  a well balanced portfolio and focus on strategic investments should benefit MAA 


Despite competition and deflationary pressure  United Natural s buyout strategies  efforts to grow market share and margin improvement initiatives remain its strength  per Zacks analyst 


The covering analyst believes that the company will benefit from its ongoing expansions  However  business deconsolidation and currency headwinds are concerns for the company 


Per the Zacks analyst  strategy to internationalize the bank and focus on less risky products remained a key strength at Itau Unibanco  

New Upgrades

The Zacks analyst is bullish on Intuitive Surgical gaining the FDA nod for its prime product da Vinci X following its European CE Mark in April  High international investment is also encouraging 


Per the Zacks analyst  Pentair will gain from industry strength  dealer wins  product innovations and the sale of the Valves   Controls business  Focus on price increases will help mitigate inflation 


Endocyte s restructuring initiative  including reduction in workforce  and shift in pipeline focus to CAR  T bi specific adaptor program will boost its cash position  according to the Zacks analyst 

New Downgrades

The covering analyst thinks Donaldson s sales will continue to be hurt by prolonged weakness in the gas turbine market  Also  soft demand for industrial filtration solutions is making matters worse 


The Zacks analyst believes that the concentration of Maxim s mobility revenues  which are largely dependent on Samsung  KS 005930   is a concern and could only be mitigated through its diversification strategy 


While ArcelorMittal should gain from its efforts to cut debt   costs  it remains hamstrung by demand weakness in Europe and China and is still exposed to cheap steel imports  per the Zacks analyst ",2017-06-08,Zacks Investment Research,"https://www.investing.com/analysis/analyst-reports-for-gm,-vmware-and-southwest-airlines-200194125",200194125
112949,334464,ISRG,The Fed In The Main Circus Tent  Global Week Ahead,opinion,In the Global Week Ahead  stock markets and central bankers the world over brace for a rate hike from the USA After last Friday s sudden tech stock sell off  will momentum traders   in NY and London alike   keep selling pressure on the risk markets going into this meeting Or will bargain hunters overwhelm them  Buy the dip  right On Wednesday  a two day United States Federal Open Market Committee  FOMC  meeting produces a 2 pm ET statement  This will be accompanied by fresh forecasts Consensus expects a 25 basis point rate hike  Expect further FOMC detail surrounding its reinvestment plans    on a huge QE inflated balance sheet Chair Janet Yellen s presser should be the main trader event Regarding the FOMC summary outlook  expect a cautious tone  The  dot plots  of all the individual contributors will be watched for internal dynamics  Realize the Fed members are mostly trained economists  They will remain data dependent Recent U S  macro prints foretell dovish guidance 1  Consumer Inflation is feeling downward pressure of late  Ditto for wages 2  Job growth averaged just  121K the past three months 3  U S  GDP grew by  1 2  in Q1  GDPNow for Q2 is  2 8   Average quarterly first half growth sums to a  muddle through   1 5  rate After this mid June meeting  the FOMC should shift to the sidelines  Coming meetings can steadily evaluate second half U S  and global risks  growth rates  jobs and the dollar   and monitor the waning pressure underlying recent inflation data The September meeting should give up a third and final 25 bps rate hike this year On Thursday and Friday  traders get follow on money policy from abroad 1  United Kingdom  Don t expect policy changes from the Bank of England  BoE   The BoE should state it is looking at any upside risks to inflation as transitory   Watch for any statements that concern the recent parliamentary election 2  Japan  The Bank of Japan s  BoJ  policy and guidance should center on whether the central bank lessens bond purchases    in a mini taper of sorts 3  Indonesia  Expect the Bank Indonesia to leave its 7 day reverse repo rate unchanged at 4 75   That country s all important inflation rate is running at  4 3  y y  This is close to their  3  inflation target  Growth this year should be similar to last year  at  5 0  y y 4  Russia  Expect the Bank of Russia to deliver another rate cut of 25 to 50 basis points 5  Switzerland  Expect the Swiss National Bank to leave its policies intact  This small nation s monetary policy outlook relies heavily on the European Central Bank This sums up to a monetary policy pile up  It should make for a packed end to the Global Week Ahead Top Zacks  1 Rank  STRONG BUY  stocks Siemens   OTC SIEGY    This is the  122 billion market cap Germany electronics giant  The Zacks long term VGM score is a D  but that comes with a B in Value Applied Materials   NASDAQ AMAT    Yes  the long term Zacks VGM score is B  But do the tech stock short sellers care  Watch the price dynamics on stocks like this all week long Intuitive Surgical   NASDAQ ISRG    Much has been made of overpriced stocks  This one is priced at a cool  916 a share when I looked  That comes with an easily won Zacks VGM score of F  with a conclusive F in Value This Medical instruments stock has a terrific surgery room robot  but how many surgery rooms are left to implement it Key Global Macro The Fed meeting wraps up Wednesday  That is the event held in the main circus tent  Thursday and Friday have the usual pile up of quid pro quo monetary policy meetings Conservative central bankers want to get all of their ducks in a row  before holding any serious meeting On Monday  Turkey s GDP growth rate came in at  5 0  y y  The prior read was  3 5  The consumer inflation rate  CPI  in India looks to come in at  2 8  y y On Tuesday  the closely watched ZEW indexes hit from Germany  Current Conditions was at 83 9 while Economic Sentiment was at 20 60 The NFIB small business optimism index should get to 105 from 104 5 Broad retail sales in Brazil look to decline to  3 0  from  2 7  y y On Wednesday  the 2 day FOMC meeting in the USA concludes  The Fed Funds rate at 1 0  should go to 1 25  Retail sales in China looks set for another  10 7  y y climb  It sounds strong  but it looks canned The final HICP inflation reading in Germany comes out  The prior was  1 4  y y Argentina s unemployment rate is forecast to climb to 8 0  from 7 6  On Thursday  the Bank of Indonesia looks to hold the line on its repo rate  at 4 75  The Bank of England  BoE  meets and issues a rate decision The Swiss National Bank  SNB  holds a monetary policy assessment meeting U S  initial claims should be low again  The last reading was 243K On Friday  the Bank of Japan  BoJ  issues a policy statement and Governor Kuroda holds a press conference   The overnight rate is  0 1   Yes  that s a negative rate The Eurozone HICP inflation rate comes out  The core rate should be  0 90  y y U S  building permits and housing starts come out  Look for starts to go from 1 172M to 1 260M  Meanwhile  look for permits to go from 1 228M to 1 260M The summer building season heats up ,2017-06-11,Zacks Investment Research,https://www.investing.com/analysis/the-fed-in-the-main-circus-tent:-global-week-ahead-200194630,200194630
112950,334465,ISRG,Dave   Buster s  Ebix  Siemens  Applied Materials And Intuitive Surgical Highlighted As Zacks Bull And Bear Of The Day ,opinion,"For Immediate Release

	Chicago  IL   June 13  2017   Dave   Buster s  NASDAQ        as the Bull of the Day  Ebix  NASDAQ        as the Bear of the Day  In addition  Zacks Equity Research provides analysis on Siemens  OTCMKTS         Applied Materials  NASDAQ AMAT   NASDAQ        and Intuitive Surgical  NASDAQ ISRG   NASDAQ        

	Here is a synopsis of all five stocks 

  

	One of the best stories in the restaurant sector over the past few years has definitely been that of Dave   Buster s  NASDAQ         The company has seen its stock price surge  and it has largely fought through an environment that has taken down many of its top competitors 

	But after the most recent earnings report  shares have struggled  even though the company beat earnings yet again  Comps growth was slowing down  and investors focused in on this issue to sell shares of the company  So  now that we have seen a dip in the shares  many have to be asking  is this the end of the road for the dream run in Dave   Buster s stock 

Why PLAY Could Have Room to Run

	In the company s most recent earnings report  earnings easily beat the consensus estimate as the company posted EPS of 87 cents compared to 81 cents per share for the expectation  Revenues were also higher by double digit percentage levels when compared to the year ago period 

	The firm also increased the bottom end of its earnings guidance range  looks to grow comps in the range of 2  3   and is continuing with its expansion plans as they seek to develop another dozen locations  So  guidance for the company wasn t bad by any stretch  meaning that investors are selling off the partial slowdown in the company s growth trajectory 

	However  PLAY remains an incredible growth story  even if things are slowing down just a tad  This is especially true when you compare some of PLAY s key growth metrics to the industry at large 

	PLAY currently has cash flow growth that is roughly four times the industry average  projected EPS growth that is roughly three times the industry average  and an ROE in excess of 20   Add in industry crushing projected sales growth and a sales to asset ratio below 1 0  and you start to question why anyone is worried about this stock from a growth perspective at all  No wonder PLAY has an  A  growth score right now and is one of the best growth stories out there in the market today 

Earnings Estimates

	Strength is further confirmed when we look to recent earnings estimate revisions for PLAY stock  While estimates have slumped for the current quarter  the next quarter and then full year period remain pretty bright 

	In fact  we have seen six estimates go higher in the past sixty days for the current year compared to zero lower  and the same level for the next year time frame too  But it isn t just the number of increases  as the magnitude has been impressive as well  We have seen the consensus estimate increase by over 7  in the past sixty days for the full year  and a full four percent for the next year time frame 

	And while the current quarter estimate has declined by about 3 6  in the past two months  it is more than made up for by the 7 4  increase in the next quarter period  Overall  the stock has a great earnings estimate picture to go along with an incredible history in earnings season including a lack of misses since its debut on the market making PLAY a Zacks Rank  1  Strong Buy  stock  and one that is a good candidate to persevere through its recent malaise  and power back to new highs 

  

	Recent trading in the tech world is giving investors pause about more picks in the sector  forcing many to refocus on only the most promising names in the field  This strategy looks to leave many companies in the dust  and could put a premium on stocks that are actually growing revenues too 

	This is bad news for stocks like Ebix  NASDAQ         as this software supplier to the insurance industry has seen weakness leading into recent trading  and has some sluggish fundamentals too  Such underlying trends may prove to be a rough environment for EBIX investors no matter what is happening in the broad tech sector  Let s take a closer look at why we are so bearish on this struggling stock right now 

Weak Fundamentals

	Ebix currently has a VGM Score of  F   putting it in the very bottom from a fundamental look  The company actually doesn t receive a component grade value  growth  momentum above  C   so the poor fundamentals are pretty widespread for this name 

	From a value look  EBIX struggles with its P CF that is far higher than the industry average  and a PEG ratio that is quickly approaching two  In terms of growth  the company s EPS track record isn t exactly inspiring  as it has a historical EPS growth rate of under 2   and a projected EPS growth rate less than 0 5  for the future too  Add in a  D  Grade for momentum  and it is easy to see why the fundamental picture is so poor for this company right now 

Sluggish Estimate Trend

	Though Ebix has a solid history when it comes to beating earnings estimates  the company does not have a great trend when we look to the most recent analyst estimates  We haven t seen any analysts increase their estimates for Ebix stock in the past two months for either the current year or the current quarter time frames 

	The magnitude of these declines has also been troubling  as we see a double digit percentage decline in the consensus estimate for both the current quarter and the following quarter  over just the past two months  Add in a nearly six percent decline in the consensus estimate for the full year over the past two months  and it shouldn t be a surprise that EBIX has a Zacks Rank  5  Strong Sell  right now 

Additional content 

The Fed in the Main Circus Tent

	In the Global Week Ahead  stock markets and central bankers the world over brace for a rate hike from the USA 

	After last Friday s sudden tech stock sell off  will momentum traders   in NY and London alike   keep selling pressure on the risk markets going into this meeting 
	Or will bargain hunters overwhelm them  Buy the dip  right 
	On Wednesday  a two day United States Federal Open Market Committee  FOMC  meeting produces a 2 pm ET statement  This will be accompanied by fresh forecasts 
	Consensus expects a 25 basis point rate hike  Expect further FOMC detail surrounding its reinvestment plans    on a huge QE inflated balance sheet 
	Chair Janet Yellen s presser should be the main trader event 
	Regarding the FOMC summary outlook  expect a cautious tone  The  dot plots  of all the individual contributors will be watched for internal dynamics  Realize the Fed members are mostly trained economists  They will remain data dependent 
	Recent U S  macro prints foretell dovish guidance 
	1  Consumer Inflation is feeling downward pressure of late  Ditto for wages 
	2  Job growth averaged just  121K the past three months 
	3  U S  GDP grew by  1 2  in Q1  GDPNow for Q2 is  2 8   Average quarterly first half growth sums to a  muddle through   1 5  rate 
	After this mid June meeting  the FOMC should shift to the sidelines  Coming meetings can steadily evaluate second half U S  and global risks  growth rates  jobs and the dollar   and monitor the waning pressure underlying recent inflation data 
	The September meeting should give up a third and final 25 bps rate hike this year On Thursday and Friday  traders get follow on money policy from abroad  
	1  United Kingdom  Don t expect policy changes from the Bank of England  BoE   The BoE should state it is looking at any upside risks to inflation as transitory  Watch for any statements that concern the recent parliamentary election 
	2  Japan  The Bank of Japan s  BoJ  policy and guidance should center on whether the central bank lessens bond purchases    in a mini taper of sorts 
	3  Indonesia  Expect the Bank Indonesia to leave its 7 day reverse repo rate unchanged at 4 75   That country s all important inflation rate is running at  4 3  y y  This is close to their  3  inflation target  Growth this year should be similar to last year  at  5 0  y y 
	4  Russia  Expect the Bank of Russia to deliver another rate cut of 25 to 50 basis points 
	5  Switzerland  Expect the Swiss National Bank to leave its policies intact  This small nation s monetary policy outlook relies heavily on the European Central Bank 
	This sums up to a monetary policy pile up  It should make for a packed end to the Global Week Ahead Top Zacks  1 Rank  STRONG BUY  stocks Siemens  OTCMKTS        This is the  122 billion market cap Germany electronics giant  The Zacks long term VGM score is a D  but that comes with a B in Value Applied Materials  NASDAQ        Yes  the long term Zacks VGM score is B  But do the tech stock short sellers care  Watch the price dynamics on stocks like this all week long Intuitive Surgical   NASDAQ        Much has been made of overpriced stocks  This one is priced at a cool  916 a share when I looked  That comes with an easily won Zacks VGM score of F  with a conclusive F in Value 
	This Medical instruments stock has a terrific surgery room robot  but how many surgery rooms are left to implement it 



About the Bull and Bear of the Day

	Every day  the analysts at Zacks Equity Research select two stocks that are likely to outperform  Bull  or underperform  Bear  the markets over the next 3 6 months 

About Zacks Equity Research

	Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long term 

	Continuous analyst coverage is provided for a universe of 1 150 publicly traded stocks  Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance  Recommendations and target prices are six month time horizons 

Strong Stocks that Should Be in the News

	Many are little publicized and fly under the Wall Street radar  They re virtually unknown to the general public  Yet today s 220 Zacks Rank  1  Strong Buys  were generated by the stock picking system that has nearly tripled the market from 1988 through 2015  Its average gain has been a stellar  26  per year  











	Follow us on Twitter  

	Join us on Facebook  NASDAQ FB   

	Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates 

	Media Contact

	Zacks Investment Research

	800 767 3771 ext  9339





	Zacks com provides investment resources and informs you of these resources  which you may choose to use in making your own investment decisions  Zacks is providing information on this resource to you subject to the Zacks  Terms and Conditions of Service  disclaimer    

Past performance is no guarantee of future results  Inherent in any investment is the potential for loss   This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ",2017-06-12,Zacks Investment Research,"https://www.investing.com/analysis/dave---buster's,-ebix,-siemens,-applied-materials-and-intuitive-surgical-highlighted-as-zacks-bull-and-bear-of-the-day-200194838",200194838
112951,334466,ISRG,Why Does Intuitive Surgical Score As A Strong Buy Right Now,opinion,"Intuitive Surgical Inc    NASDAQ ISRG    the provider of the famous da Vinci surgical system is on a healthy growth trajectory of late  Over the last three months  the stock was trading consistently ahead of the S P 500 Index  It has rallied 20 9  in this period  compared with the market s mere 2 7  gain  The stock has a market cap of  33 1 billion 
Also over this period  the company s share price has outperformed the Zacks categorized  sub industry s gain of nearly 8  

With solid growth prospects  this Zacks Rank  1  Strong Buy  stock is an attractive pick at present  Let s find out whether the recent positive trend is a sustainable one 
A stellar first quarter 2017 result was a major market sentiment booster  thanks to the rising customer adoption of procedures and growth in system placements 
Also  the company gained significantly on the certifying CE Mark approval for da Vinci X in Europe  The stock has further received a boost on the recent U S  FDA approval of the same 
Notably  Intuitive Surgical has been riding high on solid prospects on its da Vinci platform  In this regard  da Vinci procedure volumes grew worldwide approximately 18  year over year in the first quarter of 2017  Reasons cited for this uptrend are stellar performances in the U S  general surgery and worldwide urologic procedures 
The company has shipped 133 da Vinci surgical systems  up from 110 in the first quarter of 2016 
Taking the stock s stable performance of into consideration  the Intuitive Surgical is expected to scale higher in the coming quarters  The company s positive long term growth of 9 4  also holds promise 
The company s estimate revision trend for the current year has been favorable  In the past 60 days  three analysts moved north  with one movement in the opposite direction  The magnitude of estimate revision increased around 2 3  to  20 16 per share  over the same time frame 
However  downsides may come from the fact that the da Vinci Surgical System has a long sale and purchase order cycle as it is a major capital investment for hospitals that requires approval of the senior management at purchasing institutions 
The above time lag may act against the company s interests  Also the stock s valuation looks stretched at this moment 
Key Picks
Other top ranked medical stocks are Align Technology  Inc    NASDAQ ALGN    Inogen  Inc    NASDAQ INGN   and Accelerate Diagnostics  Inc    NASDAQ AXDX    Notably  Align Technology and Inogen sport a Zacks Rank  1  Strong Buy   while Accelerate Diagnostics carries a Zacks Rank  2  Buy   You can see 
Align Technology has an expected long term adjusted earnings growth of almost 24 1   The stock has roughly added 30 6  over the last three months 
Inogen has a long term expected earnings growth rate of 17 5   The stock has a solid one year return of around 90 2  
Accelerate Diagnostics has an expected long term adjusted earnings growth of 30   The stock has supplemented roughly 14 2  over the last three months 
3 Top Picks to Ride the Hottest Tech Trend
Zacks just released a Special Report to guide you through a space that has already begun to transform our entire economy   
Last year  it was generating  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for those who make the right trades early ",2017-06-16,Zacks Investment Research,https://www.investing.com/analysis/why-does-intuitive-surgical-score-as-a-strong-buy-right-now-200195739,200195739
112952,334467,ISRG,The Big Picks  ISRG  NDAQ  PSX  TD And TIF,opinion,"Intuitive Surgical  Ticker  ISRG
Intuitive Surgical  NASDAQ ISRG   has plodded methodically higher since the beginning of the year  It made a high 2 weeks ago and pulled back  setting up for a chance to get in the stock if you have missed the run  The Bollinger Bands  are squeezing  often a precursor to a move  and the RSI is turning back higher after working off an overbought condition  The MACD is starting to level after pulling back  Look for a push over short term resistance to participate higher   
NASDAQ  Ticker  NDAQ
NASDAQ  started higher in December  It paused on the move higher for a month and then resumed to a top the first of March  Since then it pulled back in a 2 steps to a low in May and then reversed  Last week it made a high near the March top and pulled back  Friday saw a bullish engulfing candle  suggesting more upside  The RSI is in the bullish zone and rising while the MACD is also moving higher  Look for a push to new highs to participate   
Phillips 66  NYSE PSX   Ticker  PSX
Phillips 66  NYSE PSX   pulled back from a top in December finding support finally in April  The price action from February through to last week has been a consolidation of that drop  It ended when the price broke to the upside  It failed early and fell back but Friday pushed back higher  The RSI is bullish and rising while the MACD is also rising  Look for continuation to participate higher   
Toronto Dominion  Ticker  TD
Toronto Dominion Bank  TO TD   started higher out of consolidation in September  It ran higher to ta top in February before starting a 3 month decline  That bottomed out under the 200 day SMA in May and reversed higher  Now it is stalling near the April consolidation zone and the 10 day SMA  The RSI is bullish and rising while the MACD is rising  Look for a new push higher to participate   
Tiffany  Ticker  TIF
Tiffany  NYSE TIF   started a run higher in February  peaking in March just under 100  It made a small pullback from there  consolidated and then gapped down in May  Following the gap down it reversed above the consolidation before the recent pullback  Friday saw a bullish Marubozu candle  a foreboding for more upside  The RSI is also turning back higher in the bullish zone and the MACD is level and positive  avoiding a cross down  Look for continuation to participate higher   
Up Next  Bonus Idea
After reviewing over 1 000 charts  I have found some good setups for the week  These were selected and should be viewed in the context of the broad  picture reviewed Friday which saw with Options Expiration and the June FOMC meeting in the rear view mirror  equities looking to emerge on the other side mainly unscathed  There is consolidation in the SPY  NYSE SPY  and Russell 2000  NYSE IWM  but perhaps more damage in the QQQ 
Elsewhere look for gold to continue to pullback while crude oil trends lower  The US Dollar Index has moved to consolidation in its pullback while US Treasuries are biased to continue higher  The Shanghai Composite and Emerging Markets  NYSE EEM  are biased to the upside with the Chinese market drifting up  while Emerging Markets consolidate in their longer trend up 
Volatility looks to remain at abnormally low levels keeping a breeze at the backs of equities  Their charts show continued strength in all 3 Index ETF s on the longer timeframe but consolidation in the SPDR S P 500  NYSE SPY  and pullbacks in the IWM and QQQ  NASDAQ QQQ  on the shorter timeframe  Use this information as you prepare for the coming week and trad em well 
The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment  I or my affiliates may hold positions or other interests in securities mentioned in the Blog  please see my  page for my full disclaimer ",2017-06-19,Gregory W. Harmon,"https://www.investing.com/analysis/intuitive-surgical,-nasdaq,-phillips-66,-toronto-dominion-and-tiffany-200195862",200195862
112953,334468,ISRG,Will Intuitive Surgical  ISRG  Surprise In Q2 Earnings ,opinion,"Intuitive Surgical Inc    NASDAQ ISRG   is scheduled to report second quarter 2017 results after the closing bell on Jul 20  Last quarter  the company s earnings exceeded the Zacks Consensus Estimate by 17 63   Also  the company delivered an average beat of 14 44  in the trailing four quarters Let s see how things are shaping up for Intuitive Surgical prior to this announcement Factors at PlayWe believe that the growing adoption of Intuitive Surgical s da Vinci system among physicians for general surgery  oncology  urology and gynecology procedures is a key catalyst  Earlier  da Vinci procedures increased approximately 18  year over year in the first quarter of 2017  For the second quarter  the company expects procedure growth rate to slow down a bit outside the U S  The company anticipates full year 2017 procedure growth within 12  to 14   Full year 2017 gross profit margin is expected in the upper end of the range of 69  to 71  of net revenue Moreover  rising procedural volumes outside the U S   particularly in Europe  fortifies the company s market position  In fact  the integrated Table Motion product line has gained significant traction within a short span of time and is likely to boost the company s top line in the to be reported quarter  Meanwhile  increased spending on product development and higher investments in expanding the company s footprint in international markets are prudent moves to drive long term growth in our view We note that Intuitive Surgical outperformed the Zacks  sub industry in the last one year  While the stock has returned 41 11   the sub industry has gained only 10 08  Intuitive Surgical  Inc  Price  Consensus and EPS Surprise
    Earnings Whispers Our proven model does not conclusively show that Intuitive Surgical is likely to beat on earnings this quarter  This is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  That is not the case here  as you will see below Zacks ESP  Intuitive Surgical s Earnings ESP is 0 00  since both the Most Accurate estimate and the Zacks Consensus Estimate stand at  4 86  You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Intuitive Surgical has a Zacks Rank  3  Though a favorable Zacks Rank increases the predictive power of ESP  the company s ESP of 0 00  makes surprise prediction difficult Also  we caution against stocks with a Zacks Rank  4 or 5  Sell rated  going into the earnings announcement  especially when the company is seeing negative estimate revisions Stocks to ConsiderHere are a few companies you may want to consider as our proven model shows that they have the right combination of elements to post an earnings beat this quarter   Thermo Fisher Scientific Inc    NYSE TMO   has an Earnings ESP of 0 44  and a Zacks Rank  2  You can see  Dextera Surgical Inc    NASDAQ DXTR   has an Earnings ESP of  9 09  and holds a Zacks Rank  2 Telefex Incorporated   NYSE TFX   has an Earnings ESP of  1 06  and carries a Zacks Rank  2 5 Trades Could Profit  Big League  from Trump PoliciesIf the stocks above spark your interest  wait until you look into companies primed to make substantial gains from Washington s changing course Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals  tariffs  lower taxes  higher interest rates  and spending surges in defense and infrastructure ",2017-07-17,Zacks Investment Research,https://www.investing.com/analysis/will-intuitive-surgical-(isrg)-surprise-in-q2-earnings-200201878,200201878
112955,334470,ISRG,Medical Product Stocks  Earnings On Jul 20  ABT  ISRG   More,opinion,"The second quarter earnings season is in its nascent stage with 30 S P 500 participants having reported results as of Jul 14  According to the latest   the earnings cycle has witnessed an encouraging start  courtesy of stable bank results  Total earnings for these members have gone up 13 8  on 6 0  increase in revenues  The uptrend was the result of reduced regulatory burden  tax law changes and an improved outlook for the domestic economy Per the latest Earnings Preview report  the second quarter earnings for the S P 500 companies are expected to be up 6 6  from the year ago quarter on 4 5  higher revenues  With the majority of earnings yet to be released  the next fortnight will be crucial in deciding whether this quarter will turn out to be a game changer  Irrespective of the outcome  investors focusing on the Medical sector can expect good news The medical sector  one of the 16 broader Zacks sectors  is expected to witness 3 7  higher revenues in the quarter along with a decline of 1 0  in revenues  Investors are adopting a wait and watch about the space as the Zacks categorized Medical   Products industry has registered growth of 0 55  in the last one month  underperforming the S P 500 Index that gained around 0 86   The market remained jittery for a major part of the month due to uncertainties surrounding the future of the healthcare act Let s take a sneak peek into the performance of four major medical product companies that are expected to report earnings early next week Abbott Laboratories   NYSE ABT   is scheduled to report second quarter 2017 results before the opening bell on Jul 20  Abbott has been on a healthy growth trajectory in Established Pharmaceuticals Division  EPD  business  The company has delivered encouraging operational sales growth in the trailing few quarters  However  the absence of any substantial advancement in this division in the recent past has compelled the company to maintain low expectations at high single digit growth in the yet to be reported quarter  You can uncover the best stocks to buy or sell before they re reported with our  Our proven model does not conclusively show that Abbott is likely to beat earnings this quarter  This is because Abbott Laboratories has an  of 0 00  and a Zacks Rank  2  Buy   That is because both the Most Accurate estimate and the Zacks Consensus Estimate are at 60 cents  Abbott s Zacks Rank  2 increases the predictive power of ESP  However  the company s 0 00  ESP makes surprise prediction difficult   Read more   Abbott Laboratories Price and EPS Surprise
    Intuitive Surgical Inc    NASDAQ ISRG   is set to report second quarter results after the closing bell  We believe that growing adoption of Intuitive Surgical s da Vinci system among physicians for general surgery  oncology  urology and gynecology procedures is a key growth catalyst for the company  You can see  Our proven model does not conclusively show that Intuitive Surgical is likely to beat on earnings this quarter  This is because Intuitive Surgical currently has an Earnings ESP of 0 00  and a Zacks Rank  3  Hold   This is because both the Most Accurate estimate and the Zacks Consensus Estimate are pegged at  4 86   Read more    Intuitive Surgical  Inc  Price and EPS Surprise
    Headquartered in Watertown  MA  athenahealth Inc    NASDAQ ATHN    through its cloud based network provides services that manage the administrative duties of medical providers  The company s software platform handles billing management  quality measurement and reporting  clinical documentation and data exchange  patient communication and referrals and many other related tasks The company is scheduled to report second quarter earnings  We believe that the company s strong product portfolio  expanding physician base and unique business model will boost prospects for the company  However  our proven model does not conclusively show that the company is likely to beat on earnings  given the combination of a Zacks Rank  3 and Earnings ESP of 0 00    Read more    athenahealth  Inc  Price and EPS Surprise
    Abaxis  Inc    NASDAQ ABAX   is scheduled to report its second quarter 2017  It is a California based manufacturer of portable Medical  human  and Veterinary  animal  blood analysis systems that provide clinicians with rapid blood constituent measurements in medical and veterinarian markets worldwide Abaxis currently carries a Zacks Rank  3  Hold  and has an Earnings ESP of 0 00   That is because both the Most Accurate estimate and the Zacks Consensus Estimate stand at 32 cents ABAXIS  Inc  Price and EPS Surprise
    Irrespective of an earnings beat or miss  investors should focus on companies  fundamentals to make investment decisions  Therefore  don t forget to check our full write up on earnings releases of these stocks later 5 Trades Could Profit   Big League   from Trump PoliciesIf the stocks above spark your interest  wait until you look into companies primed to make substantial gains from Washington s changing course Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals  tariffs  lower taxes  higher interest rates  and spending surges in defense and infrastructure ",2017-07-18,Zacks Investment Research,"https://www.investing.com/analysis/medical-product-stocks'-earnings-on-jul-20:-abt,-isrg---more-200202126",200202126
112979,334494,ISRG,Intuitive Surgical  ISRG  Beats On Q1 Earnings   Revenues,opinion,"Intuitive Surgical Inc    NASDAQ ISRG   posted adjusted earnings of  4 67 per share in the first quarter of 2017  crushing the Zacks Consensus Estimate of  3 97 on stellar revenue growth  Also  the figure improved 27 2  on a year over year basis  Interestingly  over the past four trailing quarters  the company beat estimates at an average of 11 55  Revenues increased 13  year over year to  674 million  driven by growth in recurring instrument  accessory and service  and systems revenue  Revenues also beat the Zacks Consensus Estimate of  661 million The stock currently holds a Zacks Rank  2  Buy  Intuitive Surgical  Inc  Price  Consensus and EPS Surprise
    Business HighlightsIntuitive Surgical posted solid numbers in the quarter  courtesy of rising customer adoption of procedures and growth in system placements Worldwide da Vinci procedure volumes grew approximately 18  year over year  thanks to stellar performances in the U S  general surgery and worldwide urologic procedures  Notably  the company shipped 133 da Vinci surgical systems  up from 110 in the first quarter of 2016 Revenue DetailsInstruments and Accessories  Revenues at the segment grew 18 2  to  380 8 million in the quarter  driven by strong procedure growth and increased sales of stapling and vessel sealing products  Revenues realized per procedure were approximately  1 840 compared with  1 830 in the year ago quarter System  Sales increased 3 6  to  153 2 million buoyed by higher revenues from operating lease activities  Intuitive Surgical placed 133 system orders in the quarter  up from 110 in the year ago quarter  Management at Intuitive Surgical noted that 21 systems were placed under operating lease transactions  compared with 19 systems in the year ago quarter  At the end of the quarter  there were 95 systems in the field under operating leases Service The Company registered revenues of  140 2 million  up 12 6  on a year over year basis on growth in the installed base of da Vinci systems International GrowthPer management  the company posted revenues of  183 million outside the U S   up 12  from the first quarter of 2016 The company placed 56 system orders  compared with 36 in the year ago quarter and 63 in the fourth quarter  These included 21 orders in Europe  seven in Korea  six in India  six in Japan and two in China Financial UpdateIntuitive Surgical ended the first quarter of 2017 with  3 1 billion in cash  cash equivalents  and investments  down by  1 7 billion on a year over year basis OutlookIntuitive Surgical plans to launch an upgrade to the company s flagship Vinci Xi technology   da Vinci X  In this regard  management confirmed the submission of documents for the CE Mark approval for Vinci X  Furthermore  the company expects availability of this device in Europe by the second quarter For the second quarter  the company expects procedure growth rate to slow down a bit outside the U S Intuitive Surgical anticipates full year 2017 procedure growth within 12  to 14   up from the previously provided range of 9  to 12  Full year 2017 gross profit margin is expected in the upper end of the previously provided range of 69  to 71  of net revenue Our TakeWe believe that the growing adoption of Intuitive Surgical s da Vinci system among physicians for general surgery  oncology  urology and gynecology procedures is a key growth catalyst  Moreover  increasing procedural volumes outside the U S  present significant growth opportunities for the company Intuitive Surgical outperformed the Zacks categorized  sub industry over the last one year  driven by its earnings outperformance and higher procedural volumes  The company s shares gained 21 4  over this period compared with the industry s gain of around 1 2  Other Key PicksOther top ranked stocks in the broader medical sector include Inogen Inc    NASDAQ INGN    Hologic  Inc    NASDAQ HOLX   and Sunshine Heart Inc   NASDAQ SSH    Notably  all the stocks sport a Zacks Rank  1  Strong Buy   You can see  Inogen has a long term expected earnings growth rate of 17 50   The stock represents an impressive one year return of 55 8  Hologic has a long term expected earnings growth rate of 11 33   The stock has a stellar one year return of roughly 15 3  Sunshine Heart posted a positive earnings surprise of 58 24  in the last reported quarter  The stock has a stellar EPS growth record  last 3 5 years of actual earnings  of almost 22  Will You Make a Fortune on the Shift to Electric Cars  Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ",2017-04-19,Zacks Investment Research,https://www.investing.com/analysis/intuitive-surgical-(isrg)-beats-on-q1-earnings---revenues-200183760,200183760
112980,334495,ISRG,4 Healthcare Megatrends For Investors,opinion,"When you think about investing to powerfully grow your money into the future  what giant long term trends come to mind first 
Certainly anything on the cutting edge of technology does    from mobile  the cloud  and AI to robotics  alternative energy  and autonomous cars 
But do you know what sector is bigger than technology and has trounced it by 3 times since 1999 
Healthcare  And it offers just as much innovation  if not more    with more diversification  If you are investing for the future  you need exposure to the healthcare sector to grow truly life changing wealth 
Opportunity Disguised
But what about the impending  repeal and replace  of Obamacare and all the Washington saber rattling over drug prices  Don t these make the sector  un investable  
To the contrary  any policy moves offer only more opportunity in the 750 companies and 12 industries to choose from  And bigger picture  healthcare profits are still being driven by four big forces that won t stop for another decade at least 
The 4 Megatrend Drivers of Healthcare Profits
1  Boomer Power  An aging population living longer means more care is needed into the  active 90s  
The demographic trends are clear  US and global populations are aging  as the Millennial baby boom may not be rivaled any time soon 
Plus  people are living longer on average just because of improving economic standards  the quality of food  water  and medical care  and an awareness of health dangers like smoking 
More      
                                                                                                      

We are approaching what could be the investment opportunity of a lifetime  A new medical breakthrough has the potential to impact humanity on a scale that compares to the discovery of microbes and the introduction of vaccines 
Zacks has just launched an initiative to target maximum profits from it  Gains could rival Incyte s leap of  951  in 6 years and Intuitive Surgical  NASDAQ ISRG  s explosion of  4 237  in 13 years 
You re invited to be among the first to see our recommendations  Don t delay  access to this information closes Sunday  April 23 

                                                                                                      
This adds up to a big increase in the number of people living into their nineties  And that means more innovative care will be needed from several medical industries  including pharmaceuticals  cardiovascular technologies  neurological treatments  hospital equipment and instruments  biotechnology  and cancer research discoveries 
2  Science Power  The breakthroughs in genetics and technology are creating new life saving and life enhancing companies as I write 
The age of genetics has ushered in unprecedented advances in scientific and medical research  We have gone from understanding and battling disease with scalpels and poisonous chemotherapies to treating cancer with targeted genetic breakthroughs and vaccines created from one s own immune system 
This megatrend is nowhere near slowing down as companies  investors  and charities pour billions of dollars every year into new R D to cure everything from heart and digestive ailments to pediatric and neuro degenerative diseases 
3  Earnings Power  The follow on from all that R D are new products and solutions creating new channels of sales and profits 
In 2016  the healthcare sector was responsible for over 40  of the earnings in the S P 500  bigger than the financial  energy  and telecom sectors combined  And the strength of this profit engine is only enhanced by its diversity across hundreds of companies and a dozen space age industries 
The beauty of this wealth of investing opportunities is that when one area is out of favor due to political or regulatory headwinds  there are always three or four other industries creating dynamic sales and profit growth 
4  M A Power  The big Pharma companies need to keep their pipelines full and avoid the revenue drops created by  patent cliffs  
During this bull market  over  500 billion in deals have been done  mostly by big drug companies buying emerging biotech plays for 50 100  takeout premiums 
One of my favorite biotech investments of the past few years was a company called Medivation  which got snatched up by Pfizer  NYSE PFE  for  14 billion in 2016    but not before a bidding war was fought by some of the biggest names in pharma  forcing Pfizer to pay top dollar 
While the pace of M A may slow down from the frenzy we ve seen the past few years  it will always be a positive force driving values in the sector    especially if any tax reform policy unleashes a tidal wave of overseas corporate cash onto US shores 
The Power of Vision
These 4 megatrends don t look like they will stop in this decade  And probably not in the next one either  So make sure you have a long term investing plan to capitalize on them 
I know I ll be looking for the next Intuitive Surgical  which made new all time highs this week and handed early investors a 4 200  return since June of 2000 
If you d like to target big gains like this  I invite you to join me inside Zacks  newest investment portfolio  
The confluence of the megatrends above are setting up what may be the most exciting investment opportunity of our lifetimes  Healthcare Innovators is designed to capitalize on these powerful forces and hand investors some of the biggest gains they ve ever seen 
Now  picking the best stocks in this sector requires a considerable amount of research  But if you make the right calls  the reward can be phenomenal 
But you don t have to follow FDA filings or subscribe to medical journals  That s my job  Healthcare Innovators enables you to piggy back on my in depth research 
I ve kept a close eye on 3 companies at the forefront of the next wave of cancer treatment  what the National Cancer Institute has called  a class of living drugs   These companies could change the world  I reveal them and a number of other promising stocks positioned to capitalize on one or more of the megatrends we ve talked about 
You can be among the first to see these picks  by clicking the link below  Please note  We must limit the number of investors who share this information  Access closes Sunday  April 23 

Good Investing 
Kevin Cook
Kevin  Senior Stock Strategist at Zacks  is a leading expert in biotech and medical stocks  He now provides commentary and recommendations for Zacks  new investment portfolio   ",2017-04-21,Zacks Investment Research,https://www.investing.com/analysis/4-healthcare-megatrends-for-investors-200184389,200184389
112981,334496,ISRG,Outline Of T  Rowe Price Diversified Mid Cap Growth Fund  PRDMX ,opinion,"T  Rowe Price Diversified Mid Cap Growth Fund    seeks capital appreciation  PRDMX invests a bulk of its assets in a portfolio of common stocks of mid cap companies that are included in the S P MidCap 400 Index or the Russell Midcap Growth Index 

	This Mid Growth product has a history of positive total returns for over 10 years  Specifically  the fund s returns over the 3  5 year benchmarks  3 year 8 8  and 5 year 12 2   To see how this fund performed compared in its category  and other  1 and  2 Ranked Mutual Funds    

	PRDMX s performance  as of the last filing  when compared to funds in its category was in the top 48  over the past 1 year  and in the top 27  over the past 3 years and in the top 30  over the past 5 years 

	The T  Rowe Price Diversified Mid Cap Growth Fund  as of the last filing  allocates its fund in top three markets  Large Growth  Small Growth and Large Value  Further  as of the last filing  Fiserv Inc  NASDAQ FISV   Ross Stores Inc  NASDAQ ROST  and Intuitive Surgical Inc  NASDAQ ISRG  were the top holdings for PRDMX 

	This Zacks Rank  2  Buy  was incepted in January 2004 and is managed by   PRDMX carries an expense ratio of 0 87  and requires a minimal initial investment of  2 500 

Want key mutual fund info delivered straight to your inbox  

	Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing mutual funds  each week ",2017-05-01,Zacks Investment Research,https://www.investing.com/analysis/outline-of-t.-rowe-price-diversified-mid-cap-growth-fund-(prdmx)-200186589,200186589
112983,334498,ISRG,Investors Are Latching On To Robotics ETFs,opinion,"Technology is one of those sectors where consumers and investors are constantly looking for the next big thing  The truly innovative service or product that is going to have life changing impact and ultimately lead to extensive profits for shareholders  One of the emerging frontiers in this race is the application of robotics and artificial intelligence in our everyday lives 
Companies that research  develop  and bring to market ground breaking robot technology can make a significant contribution to both businesses and ordinary consumers  Not surprisingly  there are now several ways for investors to play this thriving industry through diversified and globally focused exchange traded funds  ETFs  
The largest and most established ETF in this class is the ROBO Global Robotics and Automation Index ETF  NASDAQ ROBO   This fund has  576 million dedicated to a group of 85 stocks around the world engaged in the hardware  software  and management of automated products or services  That may include autonomous vehicles  3D printers  navigational systems  medical devices  and more 
Because this fund is index based  it s portfolio construction and stock weighting criteria are determined by a strict rules based methodology  For stocks to be considered  they must meet minimum market capitalization and historical daily trading minimums  Under normal circumstances  the index allows for 40  of the portfolio to be dedicated to foreign stocks as well 
The top holding in ROBO isiRobot Corporation  NASDAQ IRBT   which accounts for just over 2  of the asset allocation  The smaller footprint of this stock within the diversified ETF helps minimize the single stock risk that is inherent with stock picking or more focused investment strategies 
ROBO debuted in 2013 to a smattering of attention and relatively modest growth  However  over the last twelve months  the ETF has soared  40 92  and recently hit a new all time high  That easily bests the sector specific benchmark TTechnology Select Sector SPDR  NYSE XLK  return of  32 82  and significantly outperforms the broader market as well 

ETF investors have clearly taken notice of this trend as evidenced by a steadier trading pattern and surging volume in the chart above  According to   this fund has gained  416 million in net new money over the last year  That makes up approximately 72  of ROBO s current assets under management  The combination of strong returns and an attractive growth story likely make this an appealing thematic fund for tech savvy investors to identify with 
There is also another relatively new competitor to ROBO that is off to a great start in its first year of existence as well  The Global X Robotics   Artificial Intelligence Thematic Index ETF NASDAQ BOTZ  is a more concentrated approach to the industry that holds just 28 stocks  The top holding  Intuitive Surgical Inc  NASDAQ ISRG  represents nearly 8  of the exposure within the index 
This top heavy distribution of capital may appeal to those who are seeking a differentiated approach in the robotics industry  According to the fund fact sheet  48  of the holdings are Japanese companies and just 21  reside in the United States  The smaller selection of stocks in BOTZ truly represents an enhanced international footprint than ROBO 
The performance of this fund has slightly trailed that of ROBO over its short eight month lifespan  It has still managed to accumulate nearly  100 million in assets under management  which is impressive for an upstart thematic ETF with little track record 
Those who are considering these types of ETFs should also be aware of their expenses as well  ROBO charges an annual expense ratio of 0 95   while BOTZ comes in at 0 68   These management fees are high when compared to ultra low cost sector ETFs  However  it s common practice that niche strategies or uncommon industries will entail a proportionately larger expense to run 
The Bottom Line
The recent success of the robotics ETFs has brought with it a concomitant rush to capitalize on an outperforming area of the market  The real test for these funds will be whether the assets stay put during a prolonged slump or enhanced volatility 
Thematic funds can be useful for investors that want to capitalize on an industry specific trend or simply overweight a portion of their sector exposure using a unique ETF  Before considering these funds for your portfolio  it s important to evaluate how they fit with other existing positions and if their risks are appropriate for your investment style 
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq  Inc ",2017-05-24,David Fabian,https://www.investing.com/analysis/investors-are-latching-on-to-robotics-etfs-200191021,200191021
112999,334514,ISRG,3 Things To Watch When Intuitive Surgical Reports After N Y  Close,opinion,"Intuitive Surgical  NASDAQ ISRG    Health Care  Health Care Equipment   Supplies   Reports January 24  After Market Closes 
Key Takeaways
The Estimize consensus is calling for earnings per share of  6 16 on  754 09 million in revenue  20 cents higher than Wall Street on the bottom line and  6 million on the top
da Vinci sales increased by 9  in the fourth quarter with full year procedures jumping 15  from a year earlier
New products and international expansion remain a key area of focus moving forward
Intuitive Surgical prepares to announce fourth quarter results after Tuesday s closing bell  Increasing adoption of its flagship da Vinci surgical system helped deliver 6 consecutive quarters of better than expected earnings and revenue  Analysts expect the ongoing success of the robotic arm along with international expansion  new partnerships and a robust pipeline of new products to aide financial performance 
For the fourth quarter  analysts at Estimize expect earnings to come in at  6 16 per share  about 4  higher than the same period last year  Estimate activity in the past 3 months hasn t changed  likely in response to the Trump administration  Revenue for the period is forecasted to increase by 11  to  754 09 million  marking a 5th consecutive quarter of double digit growth  The stock increased by 16  in the past 12 months but took a downturn following the election  Practically speaking  Trump s proposed policies don t appear to take aim at the robotic arm maker  In an early look at the upcoming report  management noted that it sold 163 systems during the period and total of 537 for all of 2016  That figure presents a 9  gain from a year earlier and also brings the total number of systems in production near 4000  Procedures for the year increased approximately 15  from 652 000 in 2015 to 753 000 in 2016  The growth in overall procedures validates the efficacy of the system and help drive sales moving forward  More importantly it increases the need for high margin disposable instruments that generates more than 70  of ISRG s total revenue 
In international markets  ISRG made similar progress with the volume of total system sales and procedures trending higher  The company did see some weakness in areas of Europe causing a 12  decline in system placement in the region  Dollar appreciation along with macroeconomic uncertainty could pose additional problems moving forward
Intuitive continues to look for new ways to bring robots to surgery  One of the exciting developments in the pipeline is a patient side cart that could be used in conjunction with the company s Xi platform  The device is still in development but could be well on its way to regulatory review in the near future 
Do you think ISRG can beat estimates ",2017-01-24,Estimize,https://www.investing.com/analysis/3-things-to-watch-when-intuitive-surgical-reports-after-n.y.-close-200173443,200173443
113000,334515,ISRG,Will Intuitive Surgical  ISRG  Surprise In Q1 Earnings ,opinion,"Intuitive Surgical Inc    NASDAQ ISRG   is scheduled to report first quarter 2017 results after the closing bell on Apr 18  Last quarter  the company s earnings exceeded the Zacks Consensus Estimate by 0 76   Also  the company delivered an average beat of 11 55  in the trailing four quarters  Let s see how things are shaping up prior to this announcement Factors at PlayWe believe that the growing adoption of Intuitive Surgical s da Vinci system among physicians for general surgery  oncology  urology and gynecology procedures is a key catalyst  In this regard  the venture with Dextera Surgical to initiate a joint development program on robotic staplers for da Vinci Surgical System is notable  da Vinci procedures increased approximately 15  year over year in the fourth quarter of 2016 Moreover  rising procedural volumes outside the U S   particularly in Europe  fortifies the company s market position  In 2016  approximately 753 000 surgical procedures were performed with the da Vinci Surgical System  This reflects an increase of approximately 15  from approximately 652 000 procedures performed in 2015  The growth in overall 2016 procedure volume was primarily driven by growth in U S  general surgery procedures and worldwide urologic procedures  In fact  the integrated Table Motion product line has gained significant traction within a short span of time and is likely to boost the top line in the to be reported quarter Meanwhile  increased spending on product development and higher investments in expanding the company s footprint in international markets are prudent moves to drive long term growth in our view  Intuitive Surgical  Inc  Price and EPS Surprise
    We note that Intuitive Surgical outperformed the Zacks  sub industry in the last one year  While the stock returned 22 73   the sub industry gained only 2 50  Earnings Whispers  Our proven model does not conclusively show that Intuitive Surgical is likely to beat on earnings this quarter  This is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  That is not the case here  as you will see below Zacks ESP  Intuitive Surgical s Earnings ESP is 0 00  since both the Most Accurate estimate and the Zacks Consensus Estimate stand at  3 97  You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Intuitive Surgical has a Zacks Rank  3  Though a favorable Zacks Rank increases the predictive power of ESP  the company s ESP of 0 00  makes surprise prediction difficult Also  we caution against stocks with a Zacks Rank  4 or 5  Sell rated  going into the earnings announcement  especially when the company is seeing negative estimate revisions Stocks to ConsiderHere are three companies you may want to consider as our proven model shows that they have the right combination of elements to post an earnings beat this quarter   Applied Materials  Inc    NASDAQ AMAT   has an Earnings ESP of  1 32  and a Zacks Rank  1  You can see  The Chemours Company   NYSE CC   has an Earnings ESP of  4 08  and a Zacks Rank  1 Hill Rom Holdings  Inc    NYSE HRC   has an Earnings ESP of  1 27  and a Zacks Rank  2 The Best   Worst of ZacksToday you are invited to download the full  up to the minute list of 220 Zacks Rank  1  Strong Buys  free of charge  From 1988 through 2015 this list has averaged a stellar gain of  25  per year  Plus  you may download 220 Zacks Rank  5  Strong Sells   Even though this list holds many stocks that seem to be solid  it has historically performed 6X worse than the market ",2017-04-12,Zacks Investment Research,https://www.investing.com/analysis/will-intuitive-surgical-(isrg)-surprise-in-q1-earnings-200182848,200182848
113001,334516,ISRG,Health Care And Technology  A Perfect Combo For Stock Investors Now ,opinion,"When you try to talk to investors about the health care sector these days  the discussion inevitably leads to the ongoing battle over Obamacare and the AHCA  The future is very uncertain for this sector  and investors have seen some volatile trading for ETFs tracking the broad market  such as XLV  or worries over pricing issues for funds in the biotech sector  like IBB 
And given the ongoing discussion for this sector  it is hard to say what the final outcome will be for Americans  or the stocks tracking this key market either 
How to Play This Situation
One thing that isn t going to change about the health care industry going forward  however  is its continued adoption of technology  The health care world has been a bit slow to adopt new technological practices  but the area is finally coming on strong as of late 
Honestly  it is about time  as the area is definitely long overdue for a technological shakeup  Still  it can be hard to separate the areas of this market with high potential  and those that are just a passing fad  After all  there are plenty of buzzwords when it comes to the intersection of technology and health care  and like many things in health care  the jargon can be confusing 
Some of the latest buzzwords that investors have been talking about in this market include informatics  telemedicine  and even  cyborgization   though some of these areas are definitely hitting the mainstream lately  But to get to the bottom of this story and to understand what is really going on with the adoption of technology in the health care world  I spoke with Andrew Chanin  the CEO of PureFunds  His company is probably best known for its cybersecurity ETF  HACK   but they also have a suite of other sector focused funds  including the PureFunds ETFx HealthTech ETF  IMED  
As such  he was able to shed some light on this interesting topic for the latest edition of the Dutram Report  and clue us in on why this market might be worth focusing in on now 
My Chat with Andrew
In the interview  Andrew and I discuss why it has taken so long for health care companies to adopt technology  and what they are doing about this lack of investment these days  Andrew and I also converse about the prospects of this corner of the market in today s market environment  and if an Obamacare replacement will be a concern for investors in this area 
We also talk about IMED in a bit greater detail  and we dive into some of the fund holdings  such as Teladoc  TDOC   Additionally  we take a long at the large cap vs  small cap breakdown  noting how this fund might differ from some out there that are just focused on medical devices and companies like MDT  and how PureFunds  IMED which includes both device stocks like ISRG but also more software oriented plays such as MDRX could be a bit different for investors 
Lastly  we discuss how this might be an area for investors to focus on for growth  and what some of those buzzwords I mentioned earlier mean for investors right now  In particular  this idea of cyborgization could have transformative effects for many people out there  but that is really only the tip of the iceberg in this quickly growing  but little discussed health tech market 
Bottom Line
Andrew and I also talk about why numerous companies are focusing in on this corner of the health care market now  and what investors need to know about how this sort of strategy might fit into a portfolio too  So  if you have been unsure of what to do with your health care investments in light of the legislative uncertainty  this podcast is definitely a must listen 
But do you think health tech is the next hot area for investors in this sector  Listen to this edition of the Dutram Report and be the judge yourself  And make sure to write us in at podcast   zacks com or find me on twitter  to let me know what you think of this interview  and health care investing as well 
But for more news and discussion regarding the world of ETFs  make sure to be on the lookout for   and check out the 
Want key ETF info delivered straight to your inbox 
Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ",2017-04-13,Zacks Investment Research,https://www.investing.com/analysis/health-care-and-technology:-a-perfect-combo-for-stock-investors-now-200182875,200182875
113002,334517,ISRG,Why Is Intuitive Surgical  ISRG  Up 4 6  Since The Last Earnings Report ,opinion,"It has been about a month since the last earnings report for Intuitive Surgical  Inc    NASDAQ ISRG    Shares have added about 4 6  in that time frame  outperforming the market 
Will the recent positive trend continue leading up to the stock s next earnings release  or is it due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important drivers Intuitive Surgical  ISRG  Beats on Q4 Earnings   RevenuesIntuitive Surgical Inc   ISRG  posted adjusted earnings of  5 30 per share in the fourth quarter of 2016  beating the Zacks Consensus Estimate by four cents  courtesy of stellar revenue growth  Also  the figure improved 2 3  on a year over year basis Revenues increased 11 9  year over year to  756 9 million  driven by higher procedural volume and growth across all business segments  Revenues were above the Zacks Consensus Estimate of  747 million as well  Recurring revenues totaled  521 million  representing almost 69  of the quarter s top line Quarter HighlightsIntuitive Surgical s performance in the quarter was solid with rising customer adoption of procedures and growth in system placements Worldwide da Vinci procedure volumes grew approximately 15  year over year  thanks to stellar performances in U S  general surgery and worldwide urologic procedures  Notably  the company shipped 163 da Vinci surgical systems  up from 158 in the fourth quarter of 2015 In the U S   increasing adoption of general surgery procedures  stupendous growth in urology procedures worldwide  and modest growth in the urology and gynecology drove procedural volumes in the quarter  Additionally  growth in the segments of ventral and inguinal hernia repair  colon resection and lung resection was also encouraging Revenue DetailsInstruments and Accessories revenues grew 18 6  to  386 3 million in the quarter driven by a higher number of procedures and increased sales in stapling and vessel sealing products  Revenues realized per procedure were approximately  1 900 compared with  1 840 in the year ago quarter System sales increased 2 3  to  235 9 million driven by higher revenues from operating lease activities  Intuitive Surgical placed 163 systems in the quarter  up from 158 in the year ago quarter  Management at Intuitive Surgical noted that 13 systems were placed under operating lease transactions compared with 16 systems in the year ago quarter  At the end of the quarter  there were 79 systems in the field under operating leases Coming to Service  the company registered revenues of  134 7 million  up 12 1  on a year over year basis on growth in the installed base of da Vinci systems Outside the U S   the company placed 63 systems compared with 75 in the year ago quarter and 49 in the sequential quarter  The company noted that 26 were installed in Europe  3 in China  15 in Japan and 19 in other international markets Balance SheetIntuitive Surgical had cash  cash equivalents and investments of  4 8 billion as of Dec 31  2016  The company aims to use this cash for capital allocation programs  The company also entered into an accelerated share repurchase program with The Goldman Sachs Group  Inc   NYSE GS   Per the agreement  Intuitive Surgical will repurchase  2 0 billion of its common stock from Goldman  Notably  Goldman is expected to make an initial delivery of approximately 2 4 million shares of Intuitive s common stock by approximately Jan 27  2017 
How Have Estimates Been Moving Since Then 
Analysts were quiet during the last two month period as none of them issued any earnings estimate revisions Intuitive Surgical  Inc  Price and Consensus
    VGM Scores
At this time  Intuitive Surgical s stock has a nice Growth Score of  B   though it is lagging a lot on the momentum front with an  D   Charting a similar path  the stock was allocated a grade of  D  on the value side  putting it in the bottom 40  for this investment strategy 
Overall  the stock has an aggregate VGM Score of  D   If you aren t focused on one strategy  this score is the one you should be interested in 
The company s stock is suitable solely for growth based on our styles scores 
Outlook
The stock has a Zacks Rank  3  Hold   We are expecting an inline return from the stock in the next few months ",2017-04-13,Zacks Investment Research,https://www.investing.com/analysis/why-is-intuitive-surgical-(isrg)-up-4.6-since-the-last-earnings-report-200182723,200182723
113003,334518,ISRG,Zacks Podcast Highlights  Should Investors Forget The Obamacare Battle And Focus On HealthTech Stocks Instead ,opinion,"For Immediate Release
Chicago  IL   While Washington continues to debate Obamacare and the AHCA  investors interested in the health care market are puzzled about what to focus on next in this important sector  Fortunately  in this week s Dutram Report  we focus in on a key area of the health care world which is likely to grow in importance no matter what happens with politics  Check it out for more information  To listen to the podcast  click here      

When you try to talk to investors about the health care sector these days  the discussion inevitably leads to the ongoing battle over Obamacare and the AHCA  The future is very uncertain for this sector  and investors have seen some volatile trading for ETFs tracking the broad market  such as   or worries over pricing issues for funds in the biotech sector  like  
And given the ongoing discussion for this sector  it is hard to say what the final outcome will be for Americans  or the stocks tracking this key market either 
How to Play This Situation
One thing that isn t going to change about the health care industry going forward  however  is its continued adoption of technology  The health care world has been a bit slow to adopt new technological practices  but the area is finally coming on strong as of late 
Honestly  it is about time  as the area is definitely long overdue for a technological shakeup  Still  it can be hard to separate the areas of this market with high potential  and those that are just a passing fad  After all  there are plenty of buzzwords when it comes to the intersection of technology and health care  and like many things in health care  the jargon can be confusing 
Some of the latest buzzwords that investors have been talking about in this market include informatics  telemedicine  and even  cyborgization   though some of these areas are definitely hitting the mainstream lately  But to get to the bottom of this story and to understand what is really going on with the adoption of technology in the health care world  I spoke with Andrew Chanin  the CEO of PureFunds  His company is probably best known for its cybersecurity ETF   but they also have a suite of other sector focused funds  including the PureFunds ETFx HealthTech ETF  
As such  he was able to shed some light on this interesting topic for the latest edition of the Dutram Report  and clue us in on why this market might be worth focusing in on now 
My Chat with Andrew
In the interview  Andrew and I discuss why it has taken so long for health care companies to adopt technology  and what they are doing about this lack of investment these days  Andrew and I also converse about the prospects of this corner of the market in today s market environment  and if an Obamacare replacement will be a concern for investors in this area 
We also talk about IMED in a bit greater detail  and we dive into some of the fund holdings  such as Teladoc   NYSE TDOC    Additionally  we take a long at the large cap vs  small cap breakdown  noting how this fund might differ from some out there that are just focused on medical devices and companies like   NYSE MDT    and how PureFunds  IMED which includes both device stocks like   NASDAQ ISRG   but also more software oriented plays such as   NASDAQ MDRX   could be a bit different for investors 
Lastly  we discuss how this might be an area for investors to focus on for growth  and what some of those buzzwords I mentioned earlier mean for investors right now  In particular  this idea of cyborgization could have transformative effects for many people out there  but that is really only the tip of the iceberg in this quickly growing  but little discussed health tech market 
Bottom Line
Andrew and I also talk about why numerous companies are focusing in on this corner of the health care market now  and what investors need to know about how this sort of strategy might fit into a portfolio too  So  if you have been unsure of what to do with your health care investments in light of the legislative uncertainty  this podcast is definitely a must listen 
But do you think health tech is the next hot area for investors in this sector  Listen to this edition of the Dutram Report and be the judge yourself  And make sure to write us in at podcast   zacks com or find me on twitter  to let me know what you think of this interview  and health care investing as well 
But for more news and discussion regarding the world of ETFs  make sure to be on the lookout for    and check out the 

Want key ETF info delivered straight to your inbox 
Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week  
 
About Zacks
Zacks com is a property of Zacks Investment Research  Inc   which was formed in 1978  The later formation of the Zacks Rank  a proprietary stock picking system  continues to outperform the market by nearly a 3 to 1 margin  The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter  Profit from the Pros  In short  it s your steady flow of Profitable ideas GUARANTEED to be worth your time    
Follow Eric on Twitter  
Join us on Facebook  
Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates 
Media ContactZacks Investment Research
800 767 3771 ext  9339


Past performance is no guarantee of future results  Inherent in any investment is the potential for loss   This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ",2017-04-17,Zacks Investment Research,https://www.investing.com/analysis/zacks-podcast-highlights:-should-investors-forget-the-obamacare-battle-and-focus-on-healthtech-stocks-instead-200183233,200183233
113006,334521,ISRG,Should You Make A Bet On The Healthcare Stocks ,opinion," 0     A Wide Focused Outlook On The Healthcare Market 3     Hidden Gems In the Healthcare Sector 6     Immunotherapy  Robotic Surgery and Investment Ideas 14     Where To Invest In The Healthcare Market 19     Neurocrine Biosciences  NBIX    How Do Stocks Get Picked For The Healthcare Innovators Service  26     Episode Round Up  Welcome to Episode  78 of the Zacks Market Edge Podcast 
Every week  host and Zacks stock strategist  Tracey Ryniec  will be joined by guests to discuss the hottest investing topics in stocks  bonds and ETFs and how it impacts your life 
In this episode  Tracey is joined by Kevin Cook  Zacks Senior Strategist and the editor of the newly launched newsletter service the  
Healthcare stocks have gotten a bad rap over the last few years as the biotech rally faltered and on worries about drug pricing and the repeal of Obamacare 
But healthcare covers many industries  Zacks includes 800 stocks in its medical sector including those involved in devices  eye care  dentistry  staffing  rehabilitation  information systems and nursing homes 
While there have been disruptive technologies in tech  social media and even in retail  few are paying any attention to the possibilities in healthcare  That means there is an opening for investors 
Uncovering the Hidden Gems in Healthcare
Some companies get a lot of publicity for their medical breakthroughs  and rightly so  But there are a group of smaller companies that are creating devices and therapies that are enhancing patient lives that you might never have even heard of 
Tracey recently stumbled across two of those 
1        While doing a Hidden Gem video  she ran across BioTelemetry  BEAT  which makes wireless cardiac monitoring devices  It s expected to see double digit earnings growth in 2017 and 2018 
2        She came across Insulet  PODD   the maker of insulin management systems  after insiders bought shares  Tracey held it in her Insider Trader portfolio for several months  It s not yet profitable  but it s also expected to see double digit earnings growth the next 2 years 
Immuno oncology Could Be Huge
An area that Kevin is watching closely  as is the rest of the world  is immune oncology  This is a technique of using the body s own immune system to fight cancer 
Several companies are involved in this hot area including Incyte  INCY   Merck  NYSE MRK  and Bristol Myers Squibb 
There are several Phase III trials ongoing which is the critical juncture for these treatments   Fingers crossed  
What Other Companies Are Pushing the Envelope 
1        Intuitive Surgical  NASDAQ ISRG  is looking to break out to new highs again  It makes robotic surgical systems  The stock isn t cheap  It trades with a forward P E of 38 but you re buying it for the growth story 
2        Edwards Lifesciences  EW  is a leading manufacturer of heart valves  Shares are trading at 28x but earnings are expected to grow in the double digits in 2017 and 2018 
3        Neurocrine Biosciences  NBIX  researches drugs for neurological and endocrine disorders  It s been in the news lately because the FDA approved its first drug for movement disorder tardive dyskinesia  or TD 
There are a lot of opportunities in the healthcare stocks 
How do you narrow down the choices 
Kevin discusses his methods for picking stocks  starting with the Zacks Rank  and how he will pick the 20 or so companies that will make up his Healthcare Innovators portfolio 
What other exciting breakthroughs could be on the way in healthcare and how can you invest in it 
Find out the answer to this and more on this week s podcast 
Interested in Healthcare Innovators 
Zacks new service  Healthcare Innovators  is launching this week 
Kevin Cook will be exploring the entire world of healthcare in this long term portfolio ",2017-04-18,Zacks Investment Research,https://www.investing.com/analysis/should-you-make-a-bet-on-the-healthcare-stocks-200183522,200183522
113008,334523,ISRG,Zacks Market Edge Highlights  Insulet  Incyte  Intuitive Surgical And Edwards Lifesciences,opinion,"For Immediate Release

	Chicago  IL   April 19  2017   Zacks Market Edge is a podcast hosted weekly by Zacks Stock Strategist Tracey Ryniec  Every week  Tracey will be joined by guests to discuss the hottest investing topics in stocks  bonds and ETFs and how it impacts your life  To listen to the podcast  click here      

Should You Make a Bet on Healthcare Stocks 

	Welcome to Episode  78 of the Zacks Market Edge Podcast 



	Every week  host and Zacks stock strategist  Tracey Ryniec  will be joined by guests to discuss the hottest investing topics in stocks  bonds and ETFs and how it impacts your life 

	In this episode  Tracey is joined by Kevin Cook  Zacks Senior Strategist and the editor of the newly launched newsletter service the   

	Healthcare stocks have gotten a bad rap over the last few years as the biotech rally faltered and on worries about drug pricing and the repeal of Obamacare 

	But healthcare covers many industries  Zacks includes 800 stocks in its medical sector including those involved in devices  eye care  dentistry  staffing  rehabilitation  information systems and nursing homes 

	While there have been disruptive technologies in tech  social media and even in retail  few are paying any attention to the possibilities in healthcare  That means there is an opening for investors 

Uncovering the Hidden Gems in Healthcare

	Some companies get a lot of publicity for their medical breakthroughs  and rightly so  But there are a group of smaller companies that are creating devices and therapies that are enhancing patient lives that you might never have even heard of 

	Tracey recently stumbled across two of those 

	1  While doing a Hidden Gem video  she ran across BioTelemetry  BEAT  which makes wireless cardiac monitoring devices  It s expected to see double digit earnings growth in 2017 and 2018 

	2  She came across Insulet  NASDAQ           the maker of insulin management systems  after insiders bought shares  Tracey held it in her Insider Trader portfolio for several months  It s not yet profitable  but it s also expected to see double digit earnings growth the next 2 years 

Immuno oncology Could Be Huge

	An area that Kevin is watching closely  as is the rest of the world  is immune oncology  This is a technique of using the body s own immune system to fight cancer 

	Several companies are involved in this hot area including Incyte  NASDAQ           Merck  NYSE MRK  and Bristol Myers Squibb 

	There are several Phase III trials ongoing which is the critical juncture for these treatments   Fingers crossed  

What Other Companies Are Pushing the Envelope 

	1  Intuitive Surgical  NASDAQ ISRG   NASDAQ          is looking to break out to new highs again  It makes robotic surgical systems  The stock isn t cheap  It trades with a forward P E of 38 but you re buying it for the growth story 

	2  Edwards Lifesciences  NYSE          is a leading manufacturer of heart valves  Shares are trading at 28x but earnings are expected to grow in the double digits in 2017 and 2018 

	3  Neurocrine Biosciences researches drugs for neurological and endocrine disorders  It s been in the news lately because the FDA approved its first drug for movement disorder tardive dyskinesia  or TD 

	There are a lot of opportunities in the healthcare stocks 

	How do you narrow down the choices 

	Kevin discusses his methods for picking stocks  starting with the Zacks Rank  and how he will pick the 20 or so companies that will make up his Healthcare Innovators portfolio 

	What other exciting breakthroughs could be on the way in healthcare and how can you invest in it 

	Find out the answer to this and more on this week s podcast 

Interested in Healthcare Innovators 

	Zacks new service  Healthcare Innovators  is launching this week 

	Kevin Cook will be exploring the entire world of healthcare in this long term portfolio 



	Tracey Ryniec manages the Insider Trader and Value Investor portfolios at Zacks com  She hosts 2 weekly podcasts   and the    You can also catch her on Twitter at   

About Zacks 

	Zacks com is a property of Zacks Investment Research  Inc   which was formed in 1978  The later formation of the Zacks Rank  a proprietary stock picking system  continues to outperform the market by nearly a 3 to 1 margin  The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter  Profit from the Pros  In short  it s your steady flow of Profitable ideas GUARANTEED to be worth your time    

 

 

 

 

	Follow us on Twitter  

	Join us on Facebook  

	Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates 

	Media Contact

	Zacks Investment Research

	800 767 3771 ext  9339





Past performance is no guarantee of future results  Inherent in any investment is the potential for loss   This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ",2017-04-18,Zacks Investment Research,"https://www.investing.com/analysis/zacks-market-edge-highlights:-insulet,-incyte,-intuitive-surgical-and-edwards-lifesciences-200183789",200183789
113010,334525,ISRG,After ISRG Q1 Earnings  3 Medical Instrument Stocks Looking Up,opinion,"The first quarter earnings season has commenced on an encouraging note for most sectors  Per the latest   the first quarter earnings for the S P 500 companies are expected to be up 7 6  from the year ago quarter on 6 3  growth in revenues 
Unfavorably  the Medical sector is likely to be among the worst performers of the 16 Zacks sectors  with earnings expected to decrease 0 6  versus growth of 4 5  in the preceding quarter  year over year basis   Margins are also expected to decline 0 7  from the year ago quarter 
On the brighter side  the new format of the  Trump care   AHCA  with the proposal of Patient and State Stability Fund  PSSF  amendment looks optimistic for the medical space at the moment  Per the postulates of the PSSF  the government would set aside  15 billion as a  risk sharing  program to provide payments to health insurers for individual claims of the prospective patients 
We believe the sharing of the cost burden by the government would result in lower premiums  Furthermore  this would pave way for the insurance companies to provide services to maximum people in need 
Undoubtedly  the promising approach of the new  Trump care  regime  if brought into being  would immediately result in broadening of customer base for the Medical Instrument companies as well  who could have otherwise suffered  owing to their exorbitant products and services  
On a dismal note  the medical instrument companies liked the old template of AHCA as well  as it promised to repeal the infamous 2 3  medical device tax  While the old proposal failed to gather support in the House  thanks to solid opposition from both conservative and moderate lawmakers  the fraternity is currently worried whether the final plan will still call for the repealing of the medical device tax 
Meanwhile  the Zacks classified  industry traded below the S P 500 over the last one year  The industry gained roughly 2   way lower than the S P 500 s return of 11 4   Furthermore  a weak industry rank  bottom 42  of more than 250 industries  raises investor concern 

Intuitive Surgical Broke the Ice
In the wake of such a volatile backdrop  Intuitive Surgical Inc    NASDAQ ISRG    a bigwig in the niche space  reported its earnings results on Tuesday  registering stellar year over year growth 
Notably  the company posted adjusted earnings of  4 67 per share  up 27 2  on the back of 13 3  growth in revenues  year over year   Adjusted earnings of this medical instrument stock crushed the Zacks Consensus Estimate of  3 97 
Intuitive Surgical s performance in the quarter was backed by solid international growth  Per management  the company posted revenues of  183 million outside the U S   up 12  from the first quarter of 2016  The company placed 56 system orders  compared with 36 in the year ago quarter and 63 in the fourth quarter  These included 21 orders in Europe  seven in Korea  six in India  six in Japan and two in China 
Intuitive Surgical shares gained 21 4  in the last year 

3 Medical Instruments Stocks in Focus
While the Medical Instrument industry has been oscillating between hope and despair  Intuitive Surgical s impressive earnings performance instills investor confidence  Meanwhile  let us take a look at three other stocks from the sector  which are expected to put up an impressive show this earnings season  Notably  we have zeroed in on companies with strong fundamentals  a favorable  and a significant share of overseas business 
Inogen Inc    NASDAQ INGN   develops  manufactures and markets portable oxygen concentrators  POC   POCs are used by patients who suffer from chronic respiratory conditions and need long term oxygen therapy 
Of the major positives  revenues at Inogen multiplied at a CAGR of 39 4  over the last four years  Notably  the stock sports a Zacks Rank  1  Strong Buy  
The company is expected to release its first quarter results on May 8  The Zacks Consensus Estimate for adjusted earnings is currently pegged at 12 cents per share  a penny higher than what the company had recorded in the year ago quarter 
Inogen generates a significant portion of its revenues from international markets  In fiscal 2016  the company s business to business international sales accounted for almost 25  of net revenues  increasing 41 8  on a year over year basis 
Over the last year  the stock added 55 8  

Masimo Corporation   NASDAQ MASI   develops  manufactures and markets a family of non invasive monitoring systems 
This Zacks Rank  2  Buy  stock has a compelling growth story with revenues and adjusted earnings multiplying at CAGR of 9  and 18   respectively  over the last four years  You can see  
The company is scheduled to report first quarter results on May 3  after the closing bell  The Zacks Consensus Estimate for first quarter earnings is 60 cents per share  up from 53 cents in the year ago quarter 
Masimo s top line has been leveraging on its international operations for long  In fact  the stock gained considerably in fiscal 2016  especially outside the U S  as total international sales jumped nearly 12   with Latin America and Asia showcasing solid growth 
The stock represented a stellar return of 119  over the last year 

Teleflex Incorporated   NYSE TFX   designs  develops  manufactures  and supplies single use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide 
The Zacks Rank  2 stock has strong fundamentals as well  Teleflex s revenues multiplied at a CAGR of 4 8   while adjusted earnings jumped 14 1  over the last five years 
The company is expected to report first quarter results on Apr 27  Meanwhile  the Zacks Consensus Estimate for adjusted earnings is pegged at  1 67  15 cents higher than what the company had posted in the year ago quarter 
Teleflex has strong overseas business  In the last reported quarter  revenues from Europe  Middle East and Africa expanded 3  on a constant currency basis to  135 7 million  The improvement in European revenue was largely driven by increased sales in the company s urology  interventional  vascular  and respiratory products  Notably  China continues to be an important area of growth for Teleflex 
Teleflex gained almost 26  in the last year 

Will You Make a Fortune on the Shift to Electric Cars 
Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge 
With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research 
It s not the one you think ",2017-04-19,Zacks Investment Research,"https://www.investing.com/analysis/after-isrg-q1-earnings,-3-medical-instrument-stocks-looking-up-200183806",200183806
113035,334550,ISRG,Intuitive Surgical  ISRG  Q3 Earnings  What s In Store ,opinion,"Intuitive Surgical Inc   NASDAQ ISRG   is set to report third quarter 2016 results on Oct 18  after the closing bell  Last quarter  the company reported earnings of  4 86 per share  which exceeded the Zacks Consensus Estimate by 65 cents We note that on an average  Intuitive Surgical posted a positive earnings surprise of 18 05  over the last four quarters Let s see how things are shaping up prior to this announcement Factors at PlayWe believe that growing adoption of Intuitive Surgical s da Vinci system among physicians for general surgery  oncology  urology and gynecology procedures is a key catalyst  In this regard  the venture with Dextera Surgical to initiate a joint development program on robotic staplers for da Vinci Surgical System is notable Moreover  rising procedural volumes outside the U S   particularly in Europe  fortifies the company s market position  In fact  the integrated Table Motion product line has gained significant traction within a short span of time and is likely to boost the top line INTUITIVE SURG Price and EPS Surprise
    Meanwhile  increased spending on product development and higher investment in expanding the company s footprint in international markets are prudent moves to drive long term growth in our view However  unfavorable currency fluctuations  increasing regulatory headwinds and low capital investment in hospitals are expected to be major dampeners Earnings WhispersOur proven model does not conclusively show that Intuitive Surgical is likely to beat earnings this quarter  That is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  That is not the case here as you will see below Zacks ESP  Intuitive Surgical currently has an Earnings ESP of 0 00   This is because both the Most Accurate estimate and the Zacks Consensus Estimate are pegged at  4 35 Zacks Rank  Intuitive Surgical carries a Zacks Rank  3 which increases the predictive power of ESP  However  the company s 0 00  ESP makes surprise prediction difficult Please note that we caution against stocks with a Zacks Rank  4 or 5  Sell rated  going into the earnings announcement  especially when the company is seeing negative estimate revision Stocks to ConsiderHere are some companies you may want to consider as our model shows they have the right combination of elements to post an earnings beat this quarter Ariad Pharmaceuticals Inc    NASDAQ ARIA    with an Earnings ESP of  10 00  and a Zacks Rank  1  You can see   Additionally  the stock represents a stellar one year return of 81 8  Exelixis Inc    NASDAQ EXEL    with an Earnings ESP of  15 39  and a Zacks Rank  2  Notably  the company has a stupendous one year return of 107 1  Glaukos Corporation   NYSE GKOS   has an Earnings ESP of  200 00  and carries a Zacks Rank  1  We note that the company represents an impressive one year return of 59 9  Confidential from Zacks Beyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-10-13,Zacks Investment Research,https://www.investing.com/analysis/intuitive-surgical-(isrg)-q3-earnings:-what's-in-store-200158878,200158878
113036,334551,ISRG,Medical Stocks Q3 Earnings On Oct 18  JNJ  UNH  CPHD  ISRG,opinion,The Q3 earnings season has just begun and we are yet to get a clear picture of the overall market condition  The season has seen an encouraging start courtesy of stable bank results  However  growth trends are still dreary particularly due to the weaknesses in the energy  transportation and auto sectors The energy sector remains a big drag on the aggregate growth picture  with total earnings for the sector expected to be down 68 3  from the same period last year  The transportation sector decline will primarily stem from the legacy air carriers  particularly American Airlines   NASDAQ AAL   and United Continental   NYSE UAL    which are experiencing higher costs  The auto sector s growth issue is primarily due to lackluster performance by Ford   NYSE F   As per the latest  report  the overall third quarter earnings for the S P 500 companies are expected to be down 2 9  from the year ago quarter on revenues that are estimated to improve 1 2  The medical sector which was among the best performing sectors in Q2  is yet to come up with its scorecard  Our report shows that this sector will continue its stellar performance in Q3  with earnings expected to grow 2 7  on revenue growth of 7 4  With four medical stocks including industry bellwether Johnson   Johnson   NYSE JNJ   scheduled to report results on Oct 18  let s see how these stocks are placed ahead of the earnings announcements Johnson   Johnson  which delivered an earnings beat in the last reported quarter  has a diversified business model with a presence in three segments  Consumer  Pharmaceutical and Medical Devices  JOHNSON   JOHNS Price and EPS Surprise   The New Brunswick  NJ based company s Pharma segment is once again expected to drive results this quarter on the back of strong sales of new products as well as core growth products  Robust market growth and increased share should boost sales of Simponi and Stelara  Imbruvica should benefit from increased patient uptake  New cancer treatment  Darzalex  is off to an encouraging start in the U S  It gained EU approval in May 2016  This should further add to the drug s sales Currency and devaluation in Venezuela will remain headwinds while the company s share buyback will boost the bottom line  J J has an  of  4 24  and a Zacks Rank  3  Hold   which makes it likely that the company will beat estimates in Q3 as well   Read more    Cepheid   NASDAQ CPHD   is scheduled to report third quarter earnings results after market close on the same date  The company has a Zacks Rank  1  Strong Buy  but an Earnings ESP of  8 33   You can see  CEPHEID INC Price and EPS Surprise   Last quarter  the company posted a positive earnings surprise of 35 71   It is worth noting that Cepheid outperformed the Zacks Consensus Estimate in the preceding four quarters  with an average positive earnings surprise of 38 53    Read more   Health insurer  UnitedHealth Group Inc    NYSE UNH   also has the right combination of a favorable Zacks Rank  2  Buy  and a positive Earnings ESP   1 44    which makes it likely that it will beat estimates in Q3 UNITEDHEALTH GP Price and EPS Surprise   UnitedHealth s health services segment  Optum  has been recording double digit earnings growth for the several quarters and the third quarter should be no exception  Within the segment  Optum Rx sales are expected to outpace the other two sub segments   OptumHealth and OptumInsight  This is because the Catamaran acquisition has been bringing in new business wins and strong renewal rates for Optum Rx  thereby fuelling growth at the segment   Read more   Intuitive Surgical Inc   NASDAQ ISRG   is set to report third quarter 2016 results on Oct 18  after the closing bell  Last quarter  the company reported earnings of  4 86 per share  which exceeded the Zacks Consensus Estimate by 65 cents  Intuitive Surgical currently has an Earnings ESP of 0 00  and a Zacks Rank  3 INTUITIVE SURG Price and EPS Surprise   We believe that the growing adoption of Intuitive Surgical s da Vinci system among physicians for general surgery  oncology  urology and gynecology procedures is a key catalyst  In this regard  the venture with Dextera Surgical to initiate a joint development program on robotic staplers for da Vinci Surgical System is notable  However  unfavorable currency fluctuations  increasing regulatory headwinds and low capital investment in hospitals are expected to be major dampeners   Read more   Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ,2016-10-16,Zacks Investment Research,"https://www.investing.com/analysis/medical-stocks-q3-earnings-on-oct-18:-jnj,-unh,-cphd,-isrg-200159144",200159144
113048,334563,ISRG,Intuitive Surgical And InTouch Health Form Partnership,opinion,Intuitive Surgical Inc    NASDAQ ISRG   recently inked a strategic partnership with telehealth network and managed services provider   InTouch Health  Under the terms of the agreement  the da Vinci maker will not only invest in InTouch but will also jointly develop patient informatics solutions for surgical systems The investment will definitely help InTouch enhance the functionality and scale of its telehealth cloud  Jointly  the companies will focus on developing products  which include solutions that will deliver data to surgeons in the form of 3D reconstructions of anatomical structures Such innovative solutions will improve the work flow of a surgeon  using the da Vinci surgical system  We also believe the availability of this surgeon friendly application along with da Vinci will drive faster adoption of the system  thereby boosting procedural growth Notably  worldwide da Vinci procedure volumes rose approximately 17  year over year to 176K in the first quarter of 2016  Procedures in the U S  grew approximately 15   while that outside the U S  increased about 22  Intuitive Surgical forecasts 2016 procedural volumes in the range of 12  to 14   up from the earlier guided range of 9  to 12  INTUITIVE SURG Price   Intuitive Surgical continues to focus on developing new products that enhance the capabilities of the da Vinci system  During the first quarter of 2016  the company launched intra operative Table Motion that received strong customer feedback on its utility  particularly in general surgery Intuitive Surgical also launched 30 millimeter Xi stapler designed to facilitate stapling in thoracic procedures and Xi Single Site instrument and accessory kit during the quarter We believe incremental spending on product development and higher investment on expanding the company s footprint in international markets  particularly in Europe  are prudent moves that will drive growth Zacks Rank   Key PicksCurrently  Intuitive Surgical carries a Zacks Rank  3  Hold  Better ranked medical instrument stocks include CryoLife   NYSE CRY    IRadimed   NASDAQ IRMD   and Masimo Corp   NASDAQ MASI    All the three stocks sport a Zacks Rank  1  Strong Buy  ,2016-06-13,Zacks Investment Research,https://www.investing.com/analysis/intuitive-surgical-and-intouch-health-form-partnership-200135888,200135888
113049,334564,ISRG,Intuitive Surgical  Forex   Regulatory Woes Continue To Hurt,opinion,On Jun 21  we issued an updated research report on Sunnyvale based Intuitive Surgical   NASDAQ ISRG     manufacturer of the da Vinci surgical system  an advanced robot assisted surgical system  and related instruments and accessories  The company currently carries a Zacks Rank  4  Sell  Over the last 60 days  the Zacks Consensus Estimate for full year 2016 earnings moved down by 11 cents to  17 56 per share  as most analysts revised their estimates downward In the past  the company faced several headwinds including delayed market acceptance of new products  risk of procedure adoption   Other than that  unfavorable currency fluctuation impacted the company s growth trajectory to a large extent  as the company is expanding its presence in international markets  Increasing regulatory headwinds and low capital investment in hospitals are the other dampeners On the positive side  Intuitive Surgical reported impressive first quarter 2016 results with both earnings and revenues steering past the Zacks Consensus Estimate  Expenses on research and development  R D  increased significantly in the first quarter  reflecting high spending on advanced imaging  advanced instrumentation and next generation robotics In the long haul  extensive expenditure on product pipeline and expansion in international markets like Europe should drive growth for the company Stocks to ConsiderBetter ranked stocks in the same space include Cryolife Inc   NYSE CRY    IRadimed Corp    NASDAQ IRMD   and Masimo Corporation   NASDAQ MASI    Each of these stocks sports a Zacks Rank  1  Strong Buy  ,2016-06-21,Zacks Investment Research,https://www.investing.com/analysis/intuitive-surgical:-forex---regulatory-woes-continue-to-hurt-200137544,200137544
113050,334565,ISRG,New Stock Research Reports For June 23  2016,opinion,"Tuesday  June 23  2016
Today s must read reports are for IBM  NYSE IBM   IBM   General Motors Company  NYSE GM   GM  and MetLife  NYSE MET   Inc   MET  
IBM shares performed strongly this year  lik s revenues are likely reflecting investors  confidence in its transition plan  But the analyst pionts out that the transition will remain a long and slow process  with the company facing tough competition in the cloud computing   data analytics spaces  However  IBM s forays into such higher growth and higher value segments continue to remain its major positives   You can   
General Motors shares have lagged Ford  F   reflecting a combination of headwinds like problems in its manufacturing operations  increased recalls related expenses and the  2 5  decline in global sales in the first quarter of 2016  Offsetting these negatives  the Zacks analyst points out the potential benefits from fresh domestic investments  focus on the emerging markets and new product launches   You can   
The Zacks Consensus estimates for MetLife for this year and next have been coming down lately  Driving this negative revisions trend is a combination of headwinds like low interest rates  an adverse foreign exchange situation  and potential regulatory changes unfavorable to the variable annuities business  The stock has been down lately  but the analyst points out some of the key positives as well  like the recent shedding of its SIFI status  separation of its U S  retail business  and a record of profitable acquisitions and strategic divestitures   You can   
Other noteworthy reports on today s line up include Sempra Energy  NYSE SRE   SRE   Intuitive Surgical  NASDAQ ISRG   Inc   ISRG  and Weyerhaeuser Co   WY  You can find all of today s stock research reports  
Sheraz Mian
Director of Research
Today s Must Read









Featured Reports

The analyst thinks the water and waste water service provider is well positioned to gain from strategic acquisitions and its regulated operations


Increasing procedural volumes in the U S  and international markets represent a significant growth opportunity for the company


With crude advancing 90  from 12 year lows and Apache s production being 65  oil weighted  it is well positioned to ride the recovery


Weyerhaeuser s decision to close its Montana based Lumber and Plywood Mill will allow it to better align the capacities of the remaining mills in the region 


The Zacks analyst thinks Sempra Energy faces headwinds in the form of stringent government regulations and operational risks


Annaly is focusing on further diversification of its array of investment and financing options  but competition with other players and adverse economic conditions remain a concern

New Upgrades

The Zacks analyst believes Statoil is gaining momentum with the start up of operations on several new oil and gas fields


The covering analyst stresses that Roper s strategic business model will likely drive growth in the long run despite weakness in its energy and industrial divisions


According to the Zacks analyst  AGL is a particularly good pick because it provides strong dividend yield as well as low risk earnings growth

New Downgrades

UDR has started to feel the impact of increased apartment supply in several markets  according to the covering analyst


The analyst thinks foreign exchange translation has been hurting Domino s results and this is likely to continue despite a weaker U S  dollar in 2016


The analyst believes extreme interest rate volatility  weakness in derivative markets and widening of spreads is likely to weigh on CME Group s  NASDAQ CME  performance",2016-06-23,Zacks Investment Research,"https://www.investing.com/analysis/new-stock-research-reports-for-june-23,-2016-200137903",200137903
113051,334566,ISRG,Intuitive Surgical At 52 Week High On High Procedural Volume,opinion,Share price of Intuitive Surgical   NASDAQ ISRG   rallied to a new 52 week high of  661 94 on Jun 23  eventually closing a tad bit lower at  661 32  This represents a strong one year return of about 33 64   much better than the S P 500 s return of 0 52  over the same time frame Currently  Intuitive Surgical carries a Zacks Rank  3  Hold   The stock has a market cap of 25 17 billion and a long term expected earnings growth rate of 11 26  Key CatalystsIntuitive Surgical reported an impressive first quarter of 2016 with exceptional global procedure growth  solid capital placement  strong product margin and new product launches  Notably  the company reported adjusted earnings of  3 67 per share  which beat the Zacks Consensus Estimate by 21 cents  INTUITIVE SURG Price and Consensus   Strong procedural volumes of da Vinci System  robot assisted surgery system  in U S  and international markets was a major growth catalyst  Intuitive Surgical shipped about 110 da Vinci Systems in the first quarter  99 in the year ago quarter   Worldwide  da Vinci procedures grew nearly 17  from the first quarter of 2015 Intuitive Surgical s expanding product line is also a significant positive for the long term  The recent FDA approval of the  Integrated Table Motion  for da Vinci Xi Surgical System  in collaboration with Hill Rom Holdings  is a noteworthy development for the company  This has also been accompanied by the launch of 30 millimeter Xi stapler  Xi Single Site Instrument and clinical usage of SP products  which are likely to propel growth for the company Estimate RevisionsThe Zacks Consensus Estimate for fiscal 2016 decreased by 11 cents to  17 56 over the last 60 days  Similarly  for fiscal 2017  estimates dropped by 7 cents to  20 51 over the same time frame Key PicksBetter ranked stocks in the sector include CryoLife Inc   NYSE CRY    IRadimed Corp   NASDAQ IRMD   and Masimo Corp    NASDAQ MASI    All the three stocks sport a Zacks Rank  1  Strong Buy  ,2016-06-23,Zacks Investment Research,https://www.investing.com/analysis/intuitive-surgical-at-52-week-high-on-high-procedural-volume-200138036,200138036
113052,334567,ISRG,MedTech Tailwinds At A Glance  Which Stocks To Buy ,opinion,"Over the past few years  the U S  medical device market has undergone a substantial transformation  While there are a lot of thorny regulatory and financial issues that hardly look resolved anytime soon  the powerful long term tailwinds  including mergers   acquisitions  emerging market expansion  positive demographic trends and new product innovation have been the vital force behind the continued uptrend of the sector s performance 
In addition  the recent change in consumer demand and market dynamics have led to a dramatic transformation in the healthcare system  This is evident from the growing prevalence of minimally invasive surgeries  rising demand for liquid biopsy tests  use of IT for ensuring quick and improved patient care and the shift of the payment system to a value based model  among others 
Adding to the advantage is the temporary two year suspension of the controversial and dreadful 2 3  medical device excise tax which took a toll on the entire MedTech industry since its enactment in 2013 Data published in a report in FierceMedical Device stated that in 2014  Johnson   Johnson  NYSE JNJ   JNJ  made a payment of  180 million in medical device tax payments  while Medtronic  NYSE MDT   MDT   legacy Covidien and Smith   Nephew  LON SN   SNN  paid  112 million   60 million and  25 million  respectively 
Let s go through some of the major long term tailwinds of the MedTech sector  These include M A  Divestment and Emerging Market 
M A Boom Continues 
Going by the last available EvaluateGroup data  the first half of 2015 saw 86 mergers and acquisitions  totaling  83 billion  a rise of 166  from the year ago period  Although the next report is not yet released  the unofficial talk is that the full year target of  100 billion of M A valuation was effortlessly reached with the legacy continuing into 2016 
Medtronic  MDT   after its path breaking  42 9 billion acquisition of Irish rival Covidien  in Jan 2015   has not taken a breather from strategic M As  Among many others  the company recently entered into an  for a total value of  1 1 billion  This acquisition is expected to significantly boost Medtronic s cardiac rhythm and heart failure business  alongside providing a strong foothold in the global niche 
Some other significant consolidation deals of recent times are discussed below 
Abbott Laboratories  NYSE ABT   ABT    St  Jude Medical  STJ   In April  Abbott announced its decision to consolidate with St  Jude Medical for a deal value of  25 billion  Post completion  this will create a leader in high growth cardiovascular markets  including atrial fibrillation  structural heart and heart failure as well as earn a leading position in the high growth neuromodulation market 
DENTSPLY International  NASDAQ XRAY   XRAY    Sirona  A  that closed in March  this consolidation is aimed at forming a leading global manufacturer of professional dental products and materials 
Thermo Fisher  TMO    Affimetrix Thermo Fisher  following the Life Technologies buyout  has undertaken several meaningful acquisitions as part of its strategy to effectively deploy capital  The latest in the league was the company s  for a value of  1 3 billion  The acquisition is expected to boost Thermo Fisher s biosciences and genetic analysis portfolio 
Thermo Fisher   FEI Company  FEIC    for  4 2 billion will enable it to access FEI s industry leading high performance electron microscopy platform used for protein study  which in turn facilitates life science research 
Medtronic  MDT    HeartWare  HTWR   This June  Medtronic entered into an   for a total value of  1 1 billion  This acquisition is expected to significantly boost Medtronic s cardiac rhythm and heart failure business  alongside providing a strong foothold in the global niche 
Zimmer Biomet   LDR Holding Corp   LDRH   Zimmer Biomet s spine portfolio is expected to get a major boost with the    LDRH   for a total deal value of  1 billion 
Divestments 
The medical device majors continue to offload their non core business segments  specifically to focus on the main segments and also to divest assets that are similar to the ones acquired through mergers  as required by the U S  Federal Trade Commission  FTC  and other international anti trust regulators  This restricts the chance of monopoly practice in the market 
Let s take a look at some of the significant divestments of recent times 
Bayer  DE BAYGN   who had sold off its diabetes devices unit to Japan based Panasonic Healthcare Holdings Co   for  1 13 billion in Jan 2016  is once again preparing to spin off its radiology supplies business valued at  3 billion  According to the company  while the sale of the loss making diabetes devices unit will enable it to focus more on its profitable life sciences operations  the radiology business divestment is a part of the company s initiative to acquire agrochemical giant Monsanto  NYSE MON  under a mega   62 billion deal 
In Mar 2016  Mindray Medical International Limited declared its sell off to Solid Union Limited  a wholly owned subsidiary of Excelsior Union Limited  for  28 per American Depositary Share  ADS  
In Jan 2016  VCA Inc   WOOF   a healthcare major  sold off a majority interest in its subsidiary Vetstreet  Inc     a software as a service  SaaS  provider of marketing solutions and health information analytics to veterinary practices and animal health product manufacturer   to Henry Schein  NASDAQ HSIC   a provider of health care products and services to office based dental  animal health and medical practitioners 
Huge Emerging Market Openings
As per recent data from Euromonitor International  the global medical device production value is likely to register strong growth of almost 6  in 2016  to reach  315 billion  While the traditional market continues to be plagued by difficulties  thanks to growing regulatory scrutiny and pricing pressure and the emerging markets of Latin America and Eastern Europe are showing no signs of turnaround  the healthcare industry s turnover in Brazil and Russia is estimated to decline by 3  and 2   respectively  over 2016   it s the Asia Pacific region on which all the bets are placed this year 
The MedTech market in Asia Pacific grew the fastest at a CAGR of 10  during 2008 2014 and is expected to continue to grow rapidly over 2016 as well  According to the report  China s and India s healthcare service revenues are expected to grow by 12  and 9   respectively  in 2016 alone  resulting in a large number of new hospital construction projects and soaring demand for medical and surgical equipment 
Abbott continues to lead the emerging market investment trend with about 50  of sales from this region  In the first quarter of 2016  sales in key emerging markets climbed 12  driven by growth in India and China 
At Medtronic  while growth in the rest of the world was low to declining  the emerging markets demonstrated strong growth in its fourth quarter of fiscal 2016  which contributed 185 basis points  bps  to the company s overall revenue growth  Post Covidien integration  the combined entity is likely to generate about  27 billion in total revenue  including  3 7 billion from emerging markets 
Boston Scientific Corporation  NYSE BSX   BSX  achieved 21  organic growth in emerging markets in the first quarter of 2016  ahead of the company s target of reaching 15  of sales by 2017 from 8  in 2013 
Strongest Links
Among the medical product stocks  companies like NuVasive  Inc   NUVA  and GW Pharmaceuticals plc  GWPH  look attractive  with both sporting a Zacks Rank  1  Strong Buy   Boston Scientific Corp   BSX   Zimmer Biomet Holdings  Inc  and St  Jude Medical Inc   STJ  are also well positioned with a Zacks Rank  2  Buy  
In the medical instrument space  we are positive on ABIOMED  Inc   ABMD   Masimo Corp   MASI  and Mesa Laboratories Inc   MLAB  among others  all carrying a Zacks Rank  1  Besides  Steris Plc  STE   Natus Medical Inc   BABY  and Hologic Inc   HOLX   all with a Zacks Rank  2  are also expected to do well 
Weaker Stocks
Coming to the weakest links in the MedTech sector  we advise investors to stay away from names that offer little growth opportunity in the near term  These include companies for which estimate revision trends reflect a bearish sentiment 
Stocks which do not look inspiring are DexCom  Inc   DXCM   ConforMIS  Inc   CFMS   Intuitive Surgical  NASDAQ ISRG   Inc   ISRG   ResMed Inc   RMD   Smith   Nephew plc  SNN  and Meridian Bioscience  Inc   VIVO  all carrying a bearish Zacks Rank  4  Sell   Phibro Animal Health Corporation  PAHC  and Community Health Systems  Inc   CYH  bear a Zacks Rank  5  Strong Sell  ",2016-07-13,Zacks Investment Research,https://www.investing.com/analysis/medtech-tailwinds-at-a-glance:-which-stocks-to-buy-200141804,200141804
113054,334569,ISRG,Will ISRG s Run Come To An End This Quarter ,opinion,"Intuitive Surgical  NASDAQ ISRG  Health Care   Health Care Equipment and Supplies   Reports July 19  After Market Closes
Key Takeaways
The Estimize consensus is looking for earnings per share of  5 02 on  648 51 million in revenue  7 cents higher than Wall Street on the bottom line and  5 million on the top
Intuitive Surgical s robust growth the past year comes from the success of its surgical systems  particularly the da Vinci
Q1 featured a 17  increase in procedures performed with the da Vinci and an 11  jump in systems sold
What are you expecting for   
The past year has been extremely volatile for the healthcare industry  but that hasn t held true for Intuitive Surgical  Over the same period  the stock is up 15 72  primarily due to the success of its flagship product  the da Vinci surgical system 
Earnings have followed suit and have topped expectations in each of the past 4 quarters  Early signs suggest that the company will continue its streak of strong earnings when it releases Q2 results this Tuesday 
The Estimize consensus is looking for earnings per share of  5 02 on  648 51 million in revenue  7 cents higher than Wall Street on the bottom line and  5 million on the top  Compared to a year earlier this represents an 8  increase in earnings with sales expected to jump 10  
Estimates have been trending upwards over the last 3 months which typically means a strong report is on the way 

Intuitive Surgical has been fortunate to have found success with its da Vinci surgical systems  In each of the past 5 quarters  the company has posted double digit gains on both the top and bottom line 
Q1 in particular saw worldwide da Vinci procedures grow by 17  compared to the first quarter of 2015  This was primarily driven by an increase in general surgery and urologic procedures in the U S  Shipments of its flagship product also rose to 110 systems compared to 99 in the first quarter of 2015 
Minimally invasive robotic surgeries are still in their early stages  leaving Intuitive Surgical with a lot room to run  The company makes its biggest margins from new accessories such as the Xi Vessel Sealer  Xi Firefly and Xi Stapler  If system wide sales continue to grow at their current pace and Intuitive Surgical can capitalize on global expansion  then sky s the limit for earnings potential 
Do you think ISRG can beat estimates ",2016-07-19,Estimize,https://www.investing.com/analysis/will-intuitive-surgicals-run-come-to-an-end-this-quarter-200142599,200142599
113055,334570,ISRG,Intuitive Surgical  ISRG  Tops Q2 Earnings   Sales  Stock Up,opinion,Shares of Intuitive Surgical Inc    NASDAQ ISRG   surged almost 7  in after hours trading following another impressive quarterly result  The da Vinci system maker posted adjusted earnings of  5 62 per share in the second quarter of 2016  up 23  on a year over year basis on significant revenue growth and margin expansion Including stock based compensation  adjusted earnings came in at  4 86 per share  which crushed the Zacks Consensus Estimate by 65 cents and surged 28 3  from the year ago quarter  Revenues increased 14 3  year over year to  670 1 million  driven by higher procedural volume and growth across all segments  Revenues were higher than the Zacks Consensus Estimate of  643 million as well  Recurring revenues totaled  447 million  representing almost 75  of the revenues in the quarter  Procedure DetailsWorldwide da Vinci procedure volumes grew approximately 16  year over year to 176K  Procedures in the U S  grew approximately 13   while that outside the U S  increased about 25  Increasing adoption in general surgery procedures in the U S   continued growth in urology procedures worldwide and modest growth in the U S  urology and gynecology drove the procedure growth in the quarter Management stated that under the general surgery  inguinal hernia repair and ventral hernia repair growth remains strong  while growth in colorectal surgery was solid Procedure growth was variable by country in Europe  with strong performance in Germany offsetting a slight sequential decline in the U K  Procedure growth improved modestly  both in the Nordic countries and France   In Asia  procedure growth in Japan was solid while growth in Korea was robust and accelerated sequentially  Growth in procedures in China was also strong in the reported quarter  INTUITIVE SURG Price  Consensus and EPS Surprise   Revenue DetailsInstruments and Accessories revenues grew 14 3  to  339 3 million in the quarter driven by a higher number of procedures  Revenues realized per procedure were approximately  1 810 which decreased slightly on a sequential basis System sales increased 15 2  to  202 7 million driven by higher revenues from operating lease activities as well as system average selling price  ASP   Intuitive Surgical placed 130 systems in the quarter  up from 118 in the year ago quarter Management at Intuitive Surgical noted that 15 systems were placed under operating lease transactions in the second quarter  compared with 19 in the first quarter  and 5 systems in the year ago quarter  At the end of the second quarter  there were 66 systems out in the field under operating leases Intuitive Surgical generated approximately  4 million of revenue associated with operating leases in the reported quarter  compared with  1 million in the year ago quarter  and  4 million in the first quarter 2016 The company also generated almost  13 million of revenues from lease buyouts compared with  6 million in the first quarter  and  4 million in the year ago quarter Of the total systems placed during the first quarter  77  were da Vinci Xi as compared to 72  in the preceding quarter Globally  system average selling price  ASP  increased to  1 56 million  almost  60 000 higher than the year ago quarter ASP  The year over year growth primarily reflects a higher mix of dual console systems and sales of Table Motion Hospital financed approximately 37  of the systems installed in the quarter under review  down from 17  in the last quarter  Intuitive Surgical directly financed 31 systems of which 19 were structured as operating leases Outside the U S   the company placed 51 systems compared with 46 systems in the year ago quarter and 36 systems in the first quarter  The company noted that 22 were placed in Europe  4 in China  and 13 in Japan Service revenues were up 13 1  to  128 1 million on growth in the installed base of da Vinci Surgical systems Margin DetailsAdjusted gross margin expanded 410 basis points  bps  to 70 6  in the reported quarter buoyed by lower product and product repair costs  improved manufacturing efficiencies and favorable revenue mix Adjusted operating margin expanded 610 bps to 38  owing to lower selling  general   administrative expenses  SG A   which as a percentage of revenues  decreased 240 bps on a year over year basis  Research   development  R D  expenses  as a percentage of revenues  also decreased 30 bps Balance SheetIntuitive Surgical had cash  cash equivalents and investments of  4 2 billion as of Jun 30  2016  as compared with  3 8 billion as of Mar 31  2016 GuidanceIntuitive Surgical now forecasts 2016 procedural volumes in the range of 14  to 15   up from the earlier guided range of 12  to 14   However  the company expects procedure growth to slow down in the second half of 2016 Intuitive Surgical noted that its da Vinci Sp  Single port  program is progressing as planned  Management expects first markets for the device to include head and neck surgery  urology and colorectal surgery The company now expects fewer lease buyouts and lower upgrade and other system revenue in the third and fourth quarter as compared to the second quarter  Second half 2016 system ASPs will likely be lower than the second quarter driven by product and channel mix Management expects 2016 gross margin in the range of 70  to 71   up from the previously guided range of 69  to 70   However  gross margin is expected to decline in the second half of 2016 Further  the company anticipates a 12  to 15  year over year increase in operating expenses in 2016  as the company continues to invest in robotic assisted surgery Our TakeWe believe that growing adoption of Intuitive Surgical s da Vinci system among physicians for general surgery  oncology  urology and gynecology procedures is a key growth catalyst  Moreover  increasing procedural volumes outside the U S  presents significant growth opportunity for the company Further  the integrated Table Motion has gained significant traction within a short span of time  which will boost top line growth Meanwhile  incremental spending on product development and higher investment on expanding the company s footprint in international markets  particularly in Europe  are prudent moves that will drive long term growth The company expects to invest in developing imaging products  new kinds of endoscopes and expanding its fluorescence imaging portfolio  However  higher spending can weigh on margins in the near term Moreover  we believe the positive trends are quarter specific and the company has a long way to go in order to sustain the momentum  These include continued growth in the U S  as well as international procedural volume  particularly in China  Japan and Europe  Notably  markets outside the U S  are still in the early stages of adoption  hence system placements are expected to remain inconsistent in the near term Zacks Rank   Key PicksCurrently  Intuitive Surgical carries a Zacks Rank  4  Sell  Better ranked medical instrument stocks include Abiomed   NASDAQ ABMD    Masimo Corp   NASDAQ MASI   and Mesa Laboratories   NASDAQ MLAB    All the three stocks sport a Zacks Rank  1  Strong Buy  ,2016-07-19,Zacks Investment Research,"https://www.investing.com/analysis/intuitive-surgical-(isrg)-tops-q2-earnings---sales,-stock-up-200142989",200142989
113069,334584,ISRG,A Euro Inspired Reversal Day,opinion,"T2108 Status  63 8 T2107 Status  31 7 VIX Status  14 5General  Short term  Trading Call  MILDLY bearishActive T2108 periods  Day  15 over 20   Day  14 over 30   Day  14 over 40   Day  12 over 50   underperiod   Day  1 over 60   ending 1 day under 60    overperiod   Day  329 under 70  
Commentary  the S P 500  SPY  staged a sharp reversal  Today s strong 1 7  gain places the index just below a major test of strength and within a shout of completely reversing all of August s sell off 

The S P 500 leaves the prior day s weakness in the dust  A major test of resistance now looms 
T2108 jumped as well but refused to break into overbought territory  My favorite technical indicator closed at 63 8  and even faded a bit off its highs  So the tease just below overbought conditions continues  In  I declared T2108 had gotten close enough because  after all  T2108 has now gone 329 trading days without breaking through official overbought territory  With this context   close enough  is sufficient 

More important is the meaning of overbought in this case  Until the S P 500 breaks through 200DMA resistance AND follows through  my trading call will stay some shade of bearish  right now  mild    If the index follows through on a breakout  I flip right back to bullish with the assumption that a major overbought rally is underway  Again  one step at a time 

The volatility index was hit hard by the sudden return of excited buyers  The VIX hit a fresh 2 month low on a 13 5  decline and is once again below the 15 35 pivot   I call it a pivot for a good reason 

The volatility index quickly resumes its descent even as the 15 35 pivot serves as a magnet
A major driver of the action was the European Central Bank  ECB   Whatever President Mario Draghi said  I hope to write a quick piece on it over the weekend   thumped the euro  FXE  and sent traders scrambling for  risk on  trades  I closed out my short on EUR USD  The dollar index was a major beneficiary   Super Mario  helped to save the dollar s current trading range  The U S  dollar even surged against the Japanese yen  FXY  

The euro plunges and faces its own critical 200DMA test against the U S  dollar  A total breakdown looms 


The dollar index confirms nice bounce from the lower depths of its on going trading range  Can it finally break out from the short term downtrend in place since March 
Once again  the currency markets are key to the stock market  This swift move is a game changer  If the euro proceeds to break down  the stock market could get a turbo boost  The next looming caveat would be yet another Fed meeting next week  The Fed may  decide  to counteract the U S  dollar s resurgent strength with an extra dose of deference to the uncertain economic conditions preventing it from starting its rate tightening cycle  Paradoxically  the market could like that kind of talk as well 

Although my trading bias is now set to mildly bearish  I found myself all day hunting down buying opportunities  especially in biotech  When I looked up and noticed my bullish posture  I hunted down Goldman Sachs  N GS  and faded its bounce  I am looking for the 50DMA to hold as resistance 


Goldman Sachs  GS  does not quite reverse the previous day s sudden selling  For now  the declining 50DMA rules trading 
Even if GS eventually wiggles its way above its 50DMA I like it now as a hedge on bullishness  The stock overall looks very weak  If the next calamity for the market is a financial incident  GS could be right at the center 

Speaking of hedges  Caterpillar  N CAT  was the big post earnings reversal of the day  It managed to stay green for the day even after its 50DMA resistance held strong  I was fortunate to rush in to call options near the open after I noticed buyers piling into the gap down  It turned into a quick double  I am still holding shares short 

Caterpillar attempts a contrary move to breakout above its 50DMA resistance after first doing a post earnings gap down 
Back to biotech 

Earlier this month    O GILD  as a good bio tech  catch up  play  Since then  it has steadily  albeit in choppy fashion  marched higher even as the iShares Nasdaq Biotechnology ETF  IBB  has barely followed support off its lows  Today was a big day as GILD soared 5 8  for a double 50 and 200DMA breakout 


Gilead Sciences  GILD  rallies to the edge of a major breakout and end of its downtrend from recent highs
Given I had already made several successful trades on IBB and Valeant Pharmaceuticals  N VRX   I was very content to sit on my GILD call options  they do not expire until next year   As I noted in   I was primed to lock in profits on my IBB call options  I also decided to lock in profits on my shares  That decision turned out well as it freed me to buy another intraday dip that I in turn flipped  VRX was in focus for me given its extreme sell off the previous day  I bought a call option soon after the open given the stock gapped down an additional 7   I was on the lookout for signs of strength  as soon as I noticed some  I added shares 

I later discovered that the short selling firm Citron that took down VRX confirmed that Andrew Left would appear on BloombergTV at 12 30pm Eastern  I locked in profits on the shares ahead of that interview  Sure enough  the stock began to wane after 12 30pm  I set a limit order to double down on my call option in case the selling got bad  I got filled in due time  I was not watching the interview  but I am guessing the strength returned after the interview ended  Going into the close  VRX was about 21  off its low of the day and I locked in substantial profits on my call options  VRX still ended the day down 7 4   roughly flat with its open  This kind of wide ranging volatility is a trader s dream 

Valeant Pharmaceuticals  VRX  is struggling to get back on its feet after Citron s squeeze


A roller coaster ride intraday equals a lot of trading opportunities 
One reversal I completely missed   by mere minutes   was in Build a bear Workshop  BBW    sent investors selling in a panic  I hesitated just a few minutes and quicker  more calm traders and investors  stepped right in and relieved BBW of most its losses  Clearly  the market is jittery  but these jitters are often turning into major buying opportunities  even if short term  

Build a bear Workshop craters momentarily as panic quicky gives way to cooler heads

Build a bear Workshop s buying opportunity lasted less than 10 minutes
A reversal I inexcusably missed was Intuitive Surgical  O ISRG   I was looking to follow up   I was watching the stock like a hawk 

 but after concluding that ISRG was on pace to completely fill its gap  I relaxed  Big mistake  ISRG eventually continued its sell off  but when signs of life appeared it took off like a rocket into the close  The stock recovered from its 50DMA and even closed above the upper Bollinger Band again 

Intuitive Surgical  ISRG  comes back from a 50DMA breakdown and barely misses a complete fill of its post earnings gap up 
Needless to say  after all this  I was not in a bearish mood  Now  Alphabet  GOOG  and Amazon com  O AMZN  got 10   after hours gains after reporting earnings  It will be difficult to get in a bearish mood tomorrow  Friday  October 23rd   Stay tuned 
Daily T2108 vs the S P 500
Black line  T2108  measured on the right   Green line  S P 500  for comparative purposes  Red line  T2108 Overbought  70    Blue line  T2108 Oversold  20  
Weekly T2108

Be careful out there 

Full disclosure  long IBB call options  short CAT and GS  long GILD call options  net long the U S  dollar",2015-10-23,Dr. Duru,https://www.investing.com/analysis/a-euro-inspired-reversal-day-269008,269008
113070,334585,ISRG,5 Stocks To Watch  ALL  DD  ICE  ISRG  ITW,opinion,"Here are the Rest of the Top 10 
Allstate  N ALL 
Allstate started moving lower in May  culminating in a bottom with the broad market in late August  Since then it has had a strong trend higher  That trend met initial resistance in early November and pulled back slightly to the 100 day SMA  Finding support there  it bounced and is back at resistance  The RSI is in the bullish zone and the MACD is crossing up after a mild pullback  Both support a further push higher 
DuPont  N DD 
DuPont broke through support heading lower in June and keep on going  It did not find a bottom until late September  But when it did  it moved higher quickly  Since early November  it has been consolidating in a tight range though  The RSI is bullish and has worked off an overbought condition while the MACD is falling  A mixed story  Look for the break of the channel in either direction to participate 
Intercontinental Exchange  N ICE 
Intercontinental Exchange moved higher off of a tight flat SMA combination in October  It met resistance in early November and has been consolidating under it since then  Friday saw the price push back to resistance with the RSI jumping higher off of the mid line  The MACD has not turned yet though  Look for a break of resistance to participate in the upside 
Intuitive Surgical  O ISRG 
Intuitive Surgical jumped to a high near 565 in July only to trickle lower to a low to start October  From that point it made a Double Bottom and pushed back higher  A quick spike to near the September resistance was pushed back and then after some consolidation  it moved back to that same resistance  Friday saw a strong candle push higher to that level again  The RSI is bullish and moving higher while the MACD is turning up towards a cross  Look to participate in upside on a break over that resistance 
Illinois Tool Works  N ITW 
Illinois Tool Works hit 100 in February  March and April  and then started a move lower  Who says a there is no such thing as a triple top  That move found support in a double bottom at 80 and started higher  Last week the price failed at prior resistance  printing a Shooting star reversal candle  After 2 days though it found support and moved higher in a strong Marubozu candle to end the week at resistance again  The RSI is bullish and the MACD is flat after a pullback  Look for a break of resistance to participate in the upside 
After reviewing over 1 000 charts  I have found some good setups for the week  These were selected and should be viewed in the context of the broad Market Macro picture reviewed Friday which  heading into next week sees the equity markets looking mixed in the short run and at resistance  while better in the intermediate term 
Elsewhere look for gold to continue the bounce in its downtrend while crude oil continues lower  The US dollar index is biased lower in the short term in its uptrend while US Treasuries look lower in the broad consolidation 
The Shanghai Composite looks better to the upside  but with resistance nearby while Emerging Markets are biased to the downside  Volatility looks to remain subdued  keeping the bias higher for the equity index ETFs N SPY  N IWM and O QQQ  Short term the QQQ looks best and ready to challenge the all time high  while the SPY and IWM lag  Longer term they are all at prior consolidation areas and need a catalyst 
After a week where the ECB disappointed  the FOMC is pushing hard with rhetoric it will tighten  that they equity indexes did not crater can also be viewed as strength  Use this information as you prepare for the coming week and trad em well 
Disclaimer  The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment  I or my affiliates may hold positions or other interests in securities mentioned in the Blog  Please see my Disclaimer page for my full disclaimer ",2015-12-06,Gregory W. Harmon,"https://www.investing.com/analysis/top-trade-ideas-for-the-week-of-december-7,-2015:-the-rest-374667",374667
113071,334586,ISRG,Will Intuitive Surgical Report Strong Q4 Earnings ,opinion,"Intuitive Surgical Inc   O ISRG  Health Care   Health Care Equipment   Supplies   Reports January 21  After Market Closes
Key Takeaways
The Estimize consensus calls for EPS of  5 09 and revenue of  650 17 million  about 7 cents higher than Wall Street s EPS estimates
The biggest catalyst to Intuitive Surgical s growth is the widespread adoption of its da Vinci surgical Systems
Intuitive Surgical is expanding internationally  opening up significant upside growth potential

ISRG data by YCharts
The darling of health care equipment  Intuitive Surgical is scheduled to report Q4 2015 earnings this Thursday  after the markets close  This past week  ISRG reported guidance of  677 million for Q4 revenue  which invoked Wall Street to revise their previous revenue estimate of  617 million  That said  the Estimize consensus calls for EPS of  5 09  eight cents higher than the Street  and revenue of  650 17million  Compared to Q4 2014  this represents a projected YoY increase in EPS and revenue of 3  and 7   respectively 

Intuitive Surgical specializes in developing and manufacturing robot assisted devices for use in simple medical procedures to general surgery  Over the past 15 years  the company has experienced uninterrupted growth due to the widespread adoption of their flagship machine  the da Vinci surgical systems  At its core  the da Vinci provides surgeons and patients with a device that reduces length of stay  readmission  complications and infections traditionally associated with minimally invasive surgery  Intuitive Surgical s systems were initially used by urologists and gynecologists and only recently have been gained mainstream adoption in general surgery  oncology and cancer treatment  Moreover  Intuitive Surgical is expanding internationally  opening up significant upside growth potential 

The biggest catalyst to Intuitive s growth has been the success of the da Vinci surgical systems  In just Q4 2015  the number of procedures performed with da Vinci systems increased by 15   The biggest slight against these systems have been their astronomical price tag  The retail value of a da Vinci robot can be as high as  2 5 million  That said  these machines are very costly to manufacture and produce very low margins  Intuitive generates most of its profits from servicing and accessories The upside potential for Intuitive Surgical is sky high  especially since they have only begun expanding into international markets  International procedures have grown by double digits each of the handful of years  even as a strong dollar hinders worldwide sales  If Intuitive Surgical is able to successfully capitalize on widespread adoption  cancer treatment procedures  and global expansion  then sky s the limit for earnings potential ",2016-01-21,Estimize,https://www.investing.com/analysis/will-intuitive-surgical-report-strong-q4-earnings-381122,381122
113076,334591,ISRG,Can Intuitive Surgical Top Expectations Yet Again  Here s What To Watch,opinion,"Intuitive Surgical  NASDAQ ISRG  Health Care   Health Care Equipment   Supplies   Reports April 19  After Market Closes
Key Takeaways
The Estimize community is calling for EPS of  4 41 on revenue expectations of 592 51  11 cents higher than Wall Street on the bottom line and  6 5 million higher on the top
Intuitive Surgical s robust growth the past year comes from the success of its surgical systems  particularly the da Vinci
The surgical robotics company makes its biggest margins on accessories for its systems
What are you expecting for  
The past year has been extremely volatile for healthcare and biotech companies  In fact  the Vanguard Health Care  NYSE VHT  ETF  which tracks many of these stocks  is down 7 49  in the past 12 months  This hasn t been the case for Intuitive Surgical  which has moved in the exact opposite direction  Over the same period  the stock is up 15 72  primarily due to the success of its flagship product  the da Vinci surgical system  Earnings have followed suit and have topped expectations in each of the past 3 quarters  
This quarter  the Estimize community is calling for EPS of  4 41 on revenue expectations of 592 51 million  11 cents higher than Wall Street on the bottom line and  6 5 million higher on the top  However our Select Consensus  a weighted average of our most accurate analysts and recent estimates  is calling for a larger beat of 13 cents and  7 5 million  This margin has expanded in past three months with EPS revisions increasing 4   If all goes as expected  profitability will grow 23  on a 12  increase in revenue  year over year 

Intuitive Surgical s robust growth the past year comes from the success of its surgical systems   particularly the da Vinci  In Q4 2015  the number of procedures performed with a da VInci system increased 15   Procedures volume should continue to see these gains with expectations of increasing by 10  this year  The biggest slight against these systems have been their astronomical price tag  which could hamper sales in the near future  However  Intuitive makes its biggest margins from new accessories such as the Xi Vessel Sealer  Xi Firefly and Xi Stapler  System wide sales are expected to be carried by new accessories and have been forecasted to rise 9 6   If Intuitive Surgical is able to successfully capitalize on widespread adoption  and global expansion  then sky s the limit for earnings potential 
Do you think ISRG can beat estimates ",2016-04-19,Estimize,https://www.investing.com/analysis/can-intuitive-surgical-top-expectations-yet-again-heres-what-to-watch-200125517,200125517
113092,334607,ISRG,Watch These Health Care ETFs,opinion,"The Health Care sector comprises many different types of companies  From biotechs to pharmaceuticals to equipment manufacturers  it can be difficult to know in which portion of the sector an investor should place their money 
While industries within the Health Care sector can be completely different  they each face volatility that investors can capitalize on  For instance  Intuitive Surgical Inc   NASDAQ ISRG   a company specializing in medical robotics  saw its share price soar 23  over a four day stretch in April 2014  only to fall 33  from the high by the end of the same month 
Price Fluctuations May Vary
While ETFs do not usually experience price fluctuations this rapidly  their holdings can  and these fluctuations will affect the overall value of the ETF  As I ve said before  a fund s performance is only as good as its holdings  iShares DJSU Medical Devices Index  NYSE IHI   which allocates over 3  of its assets to ISRG  serves as a great example  Coinciding with ISRG s move  the value of IHI rose nearly 4  to begin April  and ended the month by declining 7  from the high 
Knowing the quality of a fund s holdings is key when determining investment opportunities  The movement of a few bad stocks held by IHI dramatically impacted investors in the fund 
Dangerous Sector
The Health Care sector overall is particularly dangerous for investors  as it ranks 7th out of 10 in my   It receives my Dangerous rating  and as expected  investors must tread carefully  Bottoms up analysis of ETFs based on their holdings drives my  on ETFs  These ratings allow investors to know more about the relative merits of ETFs 
We cover 22 Health Care ETFs which hold anywhere from 20 to 309 different stocks  This difference in holdings means that each funds  performance can be drastically different from the next 
A good way to navigate a Dangerous rated sector such as Health Care is through the use of an ETF pair trade  i e  long short strategy   The following ETF pair trade can be used to capitalize upon the volatility of the Health Care sector for both upside or downside 
Long  SPDR   Health Care  ARCA XLV 
Short  PowerShares Dynamic Heathcare  NYSE PTH 
XLV  ranks second out of the 99 Heath Care ETFs and mutual funds I cover and earns my Very Attractive rating  This ETF allocates 30  of its value to Attractive or better rated stocks and also has very low Total Annual Costs of 0 20   XLV holds high quality stocks while not charging investors too much to do so 
On the other hand  PTH receives my Dangerous rating and is my second worst rated Health Care ETF  PTH allocates over 50  of its value to Dangerous or worse rated stocks while allocating 0  to Attractive or better stocks  Despite this poor allocation  PTH charges investors 0 66  in Total Annual Costs  Why should someone want to pay a manager three times more to invest his or her money in worse holdings 
This pair trade gives investors exposure to one of the best Health Care ETFs while minimizing risk of loss by shorting one of the worst Health Care ETFs 
Attractive Play
Johnson   Johnson  NYSE JNJ  is one of my favorite stocks in XLV and earns my Attractive rating  As I wrote back in   JNJ is a consistently growing company that remains undervalued  Over the past decade  JNJ has grown after tax profits  NOPAT  by 8  compounded annually  The company currently earns a top quintile return on invested capital  ROIC  of 15   The best part about JNJ is its valuation  If JNJ is able to grow NOPAT by only 7  compounded annually for the next 15 years  the stock is worth   156 share today  a 51  increase from its current price of  103 share  With consistent history of profit growth  a diversified product line  and multiple expansion markets throughout the world  JNJ is in a great position to exceed even these expectations  While JNJ s price has increased since April  it still remains a strong value play with very little downside that will greatly benefit long term investors 
The The Spectranetics Corporation  NASDAQ SPNC  is one of my least favorite stocks in PTH and earns my Dangerous rating  Since 2010  SPNC s NOPAT has declined by 21  compounded annually  The company has a bottom quintile ROIC of 1   SPNC has also generated negative economic earnings in every one of the last 15 years  The stock fell over 8  earlier in the year  but despite this decline still remains overvalued  To justify its current valuation of   23 share  Alkermes  NASDAQ ALKS  would have to grow NOPAT by 20  compounded annually for the next 46 years  This expectation is highly unlikely for any company  especially one that has seen its profit decline and one that operates in a highly specialized industry  Investors should avoid SPNC and PTH 
Going long XLV allows investors to take advantage of the upside in the Health Care sector and see consistent long term growth from companies like JNJ  Being short PTH allows investors to hedge against companies like SPNC and other high momentum stocks held by PTH  As I recently   momentum stocks will plunge from their highs at a moment s notice  and its best for investors to buy quality companies whose prices will appreciate long term  This pair trade allows you to do just that  short the momentum stocks and go long on those that will benefit over the long haul 
Kyle Guske II contributed to this report 
Disclosure  David Trainer owns JNJ  David Trainer and Kyle Guske II receive no compensation to write about any specific stock  sector  or theme ",2014-06-18,David Trainer,https://www.investing.com/analysis/watch-these-health-care-etfs-216576,216576
113093,334608,ISRG,Distractions Removed  S P 500 Now Fully Bullish,opinion,"T2108 Status  50 3 VIX Status  12 3 General  Short term  Trading Call  Can add to existing buys now that the S P 500 has broken out above its 50DMA  Stop on a close below the 50DMA  Cannot consider shorting until such a breakdown or T1208 overbought conditions Active T2108 periods  Day  289 over 20   includes day  280 at 20 01    Day  3 over 40   Day  1 over 50   overperiod   Day  28 under 60   Day  29 under 70 
Commentary Monday s surge for the S P 500  SPDR S P 500  ARCA SPY   above its 50 day moving average  DMA  provided great validation of  to avoid trading on headlines  The 0 85  gain also took the index above the previous bear bull line  With oversold conditions fading in the mirror and likely leaving behind overly aggressive bears who yet again failed to chase the market down  yesterday s move on the S P 500 is fully bullish 
The S P 500 breaks out  closes at its high of the day  and punctuates the bounce from oversold conditions

Of course  only new highs  all time and 52 week  will validate this bullish push  As I assess the odds I just remind myself what has happened after each bounce back from sell offs inspired by negative headlines 
Incredibly  the NASDAQ  PowerShares QQQ  NASDAQ QQQ   punched to fresh FOURTEEN year highs  I think this is a great occasion for showing a monthly chart 
The picture is enough said  the NASDAQ is an awesome recovery to behold 

I am truly embarrassed to have to look back on this chart with hindsight to report that buying a simple breakout above the highs of the last bull market could have been just one of two trades over the last three years  The other trade would have been either to buy the subsequent dip in 2011 for truly committed bulls or to buy again on the next breakout in 2012  This is classic  trend is your friend  kind of action  Heck  it is even  buy the dip  kind of action 
In the wake of the dot com crash in 2000  two friends and I placed bets on the number of years the NASDAQ would need to establish a full recovery  I was the most bearish at 25 years  My friends bet 10 and 15 years  At least that bet was made in 2001 dollars 
T2108 closed at 50 3   climbing another five percentage points  It continues to confirm the bullish bounce from oversold conditions earlier this month 
The volatility index  the VIX  has of course continued to plunge  Last week s surge toward the 15 35 pivot is almost ancient history as the VIX now tests the lower edge of the presumed upward channel 
Can the VIX s upward trending channel hold 

ProShares Ultra VIX Short Term Futures  ARCA UVXY  is of course getting freshly crushed and ground  Its breakout above the 50DMA is definitely ancient history now 
UVXY playing a familiar tune  a close at all time lows

Now for some interesting stock charts befitting the current trading setup 
Facebook  NASDAQ FB  and Intuitive Surgical  NASDAQ ISRG  are experiencing Bollinger  Band  BB  squeezes  In both cases  post earnings moves took the stocks well above their respective upper Bollinger Bands and essentially exhausted buyers  Both stocks are struggling to regain post earnings momentum 
A breakout  or breakdown  from here should be quite decisive  In particular  if FB manages to break out higher  it could should be part of a fresh rally in tech and the stock market in general  I cannot imagine a major sell off in the middle of a fresh FB run up 
Facebook is still struggling to regain its post earnings momentum so this BB squeeze should be decisive

Intuitive Surgical has yet to make a fresh post earnings high so its BB squeeze should be decisive

Another sign buyers are on the move  U S  Steel  NYSE X  continues its strong post earnings rally as it punches a fresh 3 year high  I am guessing buyers are hunting out relatively  cheap  stocks that can help them play catch up with the stock market 
At the beginning of this year  I said I would pay more attention to steel stocks again and start writing about them  I never got around to it  and I certainly regret it now   AK Steel  NYSE AKS  is still in my portfolio   I can only watch now 
A person on Twitter reminded me about Nucor  NYSE NUE   The stock is around post recession highs but is essentially flat on the year  Perhaps there is still good catch up potential there 

U S  Steel surges to fresh 3 year highs  buyers looking for  cheap  stocks for playing catch up with the stock market 
Daily T2108 vs the S P 500

Black line  T2108  measured on the right   Green line  S P 500  for comparative purposes Red line  T2108 Overbought  70    Blue line  T2108 Oversold  20  Weekly T2108

Be careful out there 
Disclosure  long UVXY shares and puts  long SSO call options  short FB and long call options  long ISRG call options",2014-08-19,Dr. Duru,"https://www.investing.com/analysis/distractions-removed,-s-p-500-now-fully-bullish-223131",223131
113094,334609,ISRG,Top Trade Ideas   Week Of September 15  2014  AKAM  BK  DPZ And More,opinion,"Here are the Rest of the Top 10 
Akamai Technologies  Ticker  AKAM
Akamai Technologies  NASDAQ AKAM  has moved between multi year support and resistance since February  as it rises along the 200 day SMA  It is now at trend resistance and the neckline of an Inverse Head and Shoulders pattern with support or more upside from a rising RSI and MACD 
The Bank of New York Mellon  Ticker  BK
The Bank of New York Mellon  NYSE BK  is at resistance at 40 as it may be completing a consolidation that began in July  The RSI is rising and bullish and the MACD about to cross up to support a push higher  to continue the trend that began in April 
Domino s Pizza  Ticker  DPZ
Domino s Pizza  NYSE DPZ  is at resistance that has been in place since April  The recent trend higher has support to continue from the bullish RSI and MACD 
Intuitive Surgical  Ticker  ISRG
Intuitive Surgical  NASDAQ ISRG  is bouncing along at a resistance zone between 480 and 490  The RSI held in the bullish zone on the recent pullback and is rising along with a MACD that has leveled 
Knight Transportation  Ticker  KNX
Knight Transportation  NYSE KNX  is making a third touch at the 26 30 area  this time after only a minor pullback  The RSI is strong and bullish near 70 with a MACD rising  both supporting a push through higher 
After reviewing over 1 000 charts  I have found some good setups for the week  These were selected and should be viewed in the context of the broad Market Macro picture reviewed Friday which  heading into September Options Expiration Week sees the equity markets looking tired and ready for a pullback  Elsewhere look for Gold to continue lower while Crude Oil does the same  The US Dollar Index is strong and looks to continue higher while US Treasuries are biased lower  The Shanghai Composite is also strong and biased higher with Emerging Markets looking to continue their pullback  Volatility looks to remain subdued keeping the bias higher for the equity index ETF s SPDR S P 500  ARCA SPY   iShares Russell 2000 Index  ARCA IWM  and PowerShares QQQ  NASDAQ QQQ   Their charts show more consolidation in the zone for the IWM and a possibility of consolidation or even a pullback for both the SPY and QQQ  Use this information as you prepare for the coming week and trad em well 
Disclaimer  The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment  I or my affiliates may hold positions or other interests in securities mentioned in the Blog  please see my  page for my full disclaimer ",2014-09-15,Gregory W. Harmon,"https://www.investing.com/analysis/top-trade-ideas---week-of-september-15,-2014:-akam,-bk,-dpz-and-more-225769",225769
113095,334610,ISRG,Calm Before The Fed,opinion,"T2108 Status  58 9 T2107 Status  55 9 VIX Status  13 1General  Short term  Trading Call  Neutral  Quick drop from all time highs keeps me assuming market remains in a chopfest Active T2108 periods  Day  130 over 20   Day  89 above 30   Day  33 above 40   Day  17 over 50   overperiod   Day  1 under 60   underperiod   Day  199 under 70  
Commentary On Friday  the S P 500  via SPDR S P 500  ARCA SPY   made a very marginal new all time high  T2108 failed to cooperate and instead pulled back marginally  Yesterday  Monday  April 27th  marked mild follow through on that bearish divergence  The S P 500 pulled back a mere  0 4  but T2108 tumbled all the way below 60   Once again  overbought conditions are proving elusive on this 199th day straight without T2108 trading into overbought territory   And now we are going for an extended period without oversold conditions too   The chopfest essentially continues even with the very subtle upward  tilt  to the index 

A chopfest that is managing an ever so subtle upward bias
The Federal Reserve is coming up on Wednesday  but I find myself unable to pull the trigger on my typical  fade volatility  pre Fed trade  Volatility in the form of the VIX is generally trending down into this meeting  The Fed has done such a great job in calming the markets and sending volatility lower that I am left wondering how in the world could it pull off the trick again at these levels  So this time around I took a bit of a flyer and doubled down on my  just in case  ProShares Ultra VIX Short Term Futures  ARCA UVXY  call options 

ProShares Ultra VIX Short Term Futures  UVXY  is back to familiar territory with a downtrend in place for most of 2015
The fascinating part of this return to low volatility is that central banks continue trying  mostly in vain  to warn financial markets of growing risks in the current complacency and on going reach for yield     But of course  markets can hardly take time to listen to the warnings because they follow what the central banks DO  And what they continue to do is reassure markets with their actions and policies 
Anyway  I mainly wrote this to call your attention to an uptrend that is in grave danger from some notable topping action and distribution  Distribution occurs when a stock ETF fails to make progress while at the same time selling volume greatly outpaces buying volume  This is exactly what is unfolding for iShares Nasdaq Biotechnology  NASDAQ IBB  
IBB has been a market darling  providing tremendous returns despite the tremendous risk embedded in many of its individual components  The monthly chart below shows the relentless nature of the uptrend  The daily chart shows the technical damage happening in the short term  All eyes should now be watching to see whether the uptrend support can hold yet again  If not  look out 

You simply cannot find a better trend than this one  since 2010 2011  almost every month has traded consistently with upward momentum

However  the party for IBB may finally come to a significant pause if not an end if this pattern of distribution widens and buyers do not soon step up yet again to defend the uptrend
Oh  and speaking of medical related stocks  Intuitive Surgical  NASDAQ ISRG  failed to maintain its pre earnings bullish posture  The selling has yet to end post earnings 

Intuitive Surgical disappoints
Daily T2108 vs the S P 500
Black line  T2108  measured on the right   Green line  S P 500  for comparative purposes  Red line  T2108 Overbought  70    Blue line  T2108 Oversold  20  
Weekly T2108
Be careful out there 
Full disclosure  long UVXY call options",2015-04-28,Dr. Duru,"https://www.investing.com/analysis/t2108-update-(april-27,-2015)--a-calm-before-the-fed-249837",249837
113096,334611,ISRG,5 Charts To Trade Now  HDP  ISRG  FTNT  BOX  WIX,opinion,"This is a quick post on five charts that caught my eye on Tuesday  May 19th  All charts annotated at and downloaded from  
Hortonworks  NASDAQ HDP  has struggled to make a good post IPO impression  The first earnings report underwhelmed and led to a fresh all time low  The last earnings report was initially well received and then faded to a slightly negative close  However  on Tuesday  May 19th  HDP made a tremendous 15  surge that not only resumes momentum for the stock but also represents a breakout  All it took was a Barclay s  upgrade to outperform and a price target of  30 

Hortonworks  Inc   HDP  makes a fresh breakout attempt after an ominous post earnings fade
Intuitive Surgical  Inc   NASDAQ ISRG  is the stock I want to love  The last earnings report was uninspiring and traders and investors bailed fast  The selling finally ended around 200 day moving average  DMA  support  Now  a Bollinger  Band  BB  squeeze is developing  I would love to anticipate a breakout here  However  given the poor post earnings performance  I will instead follow the break out of the BB squeeze in whatever direction it moves 

Intuitive Surgical  Inc   ISRG  is stabilizing post earnings with a critical retest of 200DMA support
Fortinet Inc   NASDAQ FTNT  is another BB squeeze candidate  Its technical profile is much better than ISRG here  The stock gapped up nicely post earnings and has consolidated ever since  This setup makes FTNT look like a coiled spring   ready to break out and resume the very strong upward trend in the stock 

Fortinet Inc   FTNT  looks ready to extend its run up further
Ever since Jim Cramer   NYSE BOX   I have been wary of betting this is eventually a single digit stock  I now have put options after the stock has slowly but surely sagged despite periodic hype fests from Cramer gushing over the stock  It is rarely a good sign when an IPO comes right out the box  so to speak  with a very poor earnings report  especially one that immediately retests post IPO lows  The chart below shows a pattern of lower highs  It seems only a matter of time before a lower low occurs 

Box  Inc   BOX  looks ready to breakdown as it hugs all time lows
Finally  Wix xom  NASDAQ WIX  is the stock that has really called me to return  I was hoping for a pullback from a strong response to the last earnings report  The current breakout makes such a pullback unlikely  So  instead  I will have to buy back into this one on momentum  Note the persistence of strong  high volume  buying since earnings 

Wix com  WIX  makes a fresh breakout
Full disclosure  long BOX put options",2015-05-20,Dr. Duru,"https://www.investing.com/analysis/charts-to-trade:-hdp,-isrg,-ftnt,-box,-wix-252402",252402
113097,334612,ISRG,Overbought Trading Conditions Remain Elusive,opinion,"T2108 Status  59 9 T2107 Status  27 8 VIX Status  17 7  small bounce off 200DMA General  Short term  Trading Call  Neutral  target of 1996 on the S P 500 occurred ahead of overbought conditions Active T2108 periods  Day  8 over 20   Day  7 over 30   Day  7 over 40   Day  5 over 50   overperiod   Day  1 under 60   ending 3 days over 60    Day  322 under 70 
Commentary 322 trading days and counting since T2108 last traded in overbought conditions  I thought THIS would be the week for finally bringing the streak to an end  but T2108 took a sharp detour yesterday 

Like a forcefield  overbought conditions once again defy a breakthrough by T2108
In parallel  the S P 500  SPDR S P 500  N SPY   lost a fraction of a percent as the index turned its back on the recent 50DMA breakout 

The S P 500  SPY  may have stalled out for now
The small loss on the day helped the volatility index  the VIX  finally end its 10 day losing streak  The VIX jumped 9 3  yesterday with a bounce off its 200DMA 

The angst of August has become a distant memory  The drama with Glencore  L GLEN  helped spark a very brief revival of angst 
The big rally in the Australian dollar came to a screeching halt  As I have indicated before  I am VERY skeptical about the sustainability of this rally 

The Australian dollar printed a higher low against the Japanese yen as Glencore collapsed on September 29  2015
Earnings season has begun so  as always during this time  I am staying away from overplaying my hand with the technical calls  However  I think it is very surprising that the volatility index declined so steadily going into earnings season  This decline sets up the potential for some very disruptive moves if any major company delivers particularly bad news  So with T2108 scraping at overbought levels  a volatility index hovering above the 15 35 pivot  and a market taking a suddenly calm outlook on earnings  I am definitely avoiding any major bullish bets   Trading call is still neutral  
On a related noted  I have pumped the brakes on the trade on iShares Nasdaq Biotechnology  O IBB   I have written  on this trade  ever since Presidential candidate Hillary Clinton bashed the sector  The rally off the bottom has definitely stalled and could even be poised to make at least one more lower low  I think at this point  it makes sense to wait to see whether IBB can generate another big swoosh of selling and or a retest of the big low last month on high selling volume  Note well that a breakout from the current consolidation might run IBB right into declining 50DMA resistance  My upside target remains a complete reversal of the post Clinton selling 

iShares Nasdaq Biotechnology  IBB  ran into effective resistance at its downtrending 20DMA even as a trading range extends from September s washout selling 
Speaking of the health care sector  Intuitive Surgical  O ISRG  has my attention again as the stock briefly cracked 52 week lows  The stock is on the edge of a major breakdown ahead of earnings next week on October 20th  I am always biased on ISRG to look for a buying opportunity  but the current trading action looks very bearish 

Intuitive Surgical  ISRG  flirts with a fresh breakdown as it trades well below flash crash levels and levels from the last three earnings reports
Daily T2108 vs the S P 500
Black line  T2108  measured on the right   Green line  S P 500  for comparative purposes  Red line  T2108 Overbought  70    Blue line  T2108 Oversold  20  
Weekly T2108
Full disclosure  long SVXY shares  short AUD JPY  net long U S  dollar  long GLD",2015-10-14,Dr. Duru,"https://www.investing.com/analysis/t2108-update-(october-13,-2015)--overbought-trading-conditions-remain-268074",268074
113126,334641,ISRG,Stocks Post Small Gains To Close Out Week,opinion,Stocks were up slightly on Friday as a series of economic reports gave investors a mixed picture of the state of the economy  Personal income for January fell  but spending was up slightly  Consumer sentiment data and manufacturing sentiment were also positive  but construction spending surprisingly fell in January  A higher U S  dollar and lower euro also limited market gains on the day  Nevertheless  all of the major averages closed in the green and the Dow Jones Industrial Average continues to hold above 14 000   Major Averages The Dow Jones Industrial Average rose 35 points  or 0 25 percent  to 14 090   The S P 500 added around 3 5 points  or 0 23 percent  to 1 518   The Nasdaq Composite was up almost 10 points  or 0 30 percent  to 3 170   Personal Income and Spending Personal income fell 3 6 percent in January after rising 2 6 percent in December  This compared to consensus estimates of a decline of 2 4 percent   While personal income was down  spending rose in January  For the month  personal spending was up 0 2 percent after a gain of 0 1 percent in December  The January spending figures were in line with consensus estimates   Consumer Sentiment The final reading for the February University of Michigan Consumer Sentiment Index was released on Friday  The data showed that the index rose to 77 6 versus a preliminary reading of 76 3  This was a gain versus the 73 8 reading from January  Consensus estimates called for a reading of 76 3   ISM Index Data from the ISM Manufacturing Index showed that manufacturing activity rose in February  The index climbed from 53 1 in January to 54 2 in the most recent month  The reading was the strongest since June 2011 and came in ahead of consensus expectations calling for a decline to 52 4   Construction Spending While other economic reports showed strength  construction spending fell 2 1 percent in January after rising 1 1 percent in December  This was significantly worse than consensus expectations calling for an increase of 0 5 percent Commodities Crude oil fell on Friday despite a higher equity market  Near the close of stock trading  NYMEX crude futures had lost around 1 30 percent to  90 85  Brent crude oil had lost a little less than 1 percent to  110 54  Natural gas futures also fell on the session and were last down 0 80 percent to  3 46   Precious metals were little changed on Friday  COMEX gold futures lost 0 17 percent to  1 575 30 in late trade  Silver was last trading up around 0 20 percent to  28 53   In the agricultural complex  both corn and wheat recorded modest gains  Late in the day  corn was up 0 71 percent and wheat had climbed 0 84 percent  Significant movers in soft commodities included cocoa  which was down 2 50 percent  sugar and orange juice concentrate futures  Sugar fell 2 60 percent and orange juice lost more than 5 percent   Bonds Near the close of equity trading  the iShares Barclays 20  Year Treasury Bond ETF  TLT  was up around 0 50 percent to  118 83   With the exception of the 2 Year Note  yields fell on the day  The 5 Year Note yield lost two basis points to 0 75 percent  Both the 10 Year Note and 30 Year Bond yields lost three basis points to 1 85 percent and 3 06 percent  respectively   Currencies A number of currency pairs made sharp moves on Friday and overall the greenback was higher  The PowerShares DB US Dollar Index Bullish ETF  UUP   which tracks the performance of the greenback versus a basket of foreign currencies  added around 0 36 percent to  22 45   The closely watched EUR USD pair was last trading down 0 30 percent to  1 3018 as the euro is approaching a key support level  The U S  dollar also continued its rise against the Japanese yen with the USD JPY climbing more than 1 percent  The British Pound also fell sharply against the greenback with the GBP USD losing nearly 1 percent on Friday   Volatility and Volume The VIX was close to unchanged on Friday  falling less than 0 40 percent to 15 45   Volume was slightly heavier than usual on the session  Around 137 million SPDR S P 500 ETF  SPY  shares traded hands compared to a 3 month daily average of 134 million   Stock Movers Intuitive Surgical  ISRG  recouped some of Thursday s losses after analysts backed the company in the wake of an FDA examination of its safety data  The stock fell 11 percent on Thursday  but bounced back more than 8 percent on Friday   Foster Wheeler  FWLT  shares lost more than 16 percent after the company s fiscal Q4 earnings report   McDermott International  MDR  plunged 16 percent after a disappointing fourth quarter earnings report   OmniVision Technologies  OVTI  plunged 12 percent after disappointing Q3 earnings results and an analyst downgrade   Salesforce com  CRM  surged almost 8 percent on Friday after the company delivered fourth quarter results which were ahead of expectations   Shares of small cap medical supplies company Nanosphere  NSPH  rose almost 14 percent on the session after Cannacord Genuity launched coverage on the stock with a Buy rating and  5 price target   Sinclair Broadcast Group  SBGI  jumped nearly 13 percent after the company agreed to buy the broadcast assets of 18 television stations owned by Barrington Broadcasting Group LLC for  370 million  Sinclair also agreed to operate or provide sales services for six other stations   Mentor Graphics  MENT  fell 5 percent after releasing its fiscal fourth quarter earnings results  BY Scott Rubin,2013-03-03,Benzinga ,https://www.investing.com/analysis/stocks-post-small-gains-to-close-out-week-157381,157381
113127,334642,ISRG,Dow Snaps Winning Streak  Stocks Record Minor Losses,opinion,The Dow Jones Industrial Average snapped an impressive 10 day winning streak on Friday as stocks posted small losses   The euro climbed back above the closely watched  1 30 mark on the day  but risk appetite was tepid throughout the session  Economic reports showed a surprise drop in consumer sentiment in March and rising consumer prices  Although losses were small across the board  all three major averages closed lower   Major Averages The Dow Jones Industrial Average lost 26 points  or 0 18 percent  to 14 513   The S P 500 fell a little less than 3 points  or 0 16 percent  to 1 561   The Nasdaq declined around 10 points  or 0 30 percent  to 3 249   CPI Consumer prices increased in February  largely on a surge in energy costs  The CPI rose 0 7 percent for the month after being flat in January  The consensus expected CPI to increase by 0 5 percent   Core CPI was up 0 2 percent in February  compared to a gain of 0 3 percent in January  Core CPI excludes volatile food and energy costs  The February figure was in line with consensus estimates   Michigan Consumer Sentiment The preliminary reading of the University of Michigan Consumer Confidence Index recorded a surprise decline in March  The index fell from 77 6 in February to 71 8 for March  This compared to consensus estimates which called for the reading to hold steady at 77 6   Commodities Crude oil recorded gains to end the week on Friday  Late in the day  NYMEX crude futures were up 0 49 percent to  93 48  Brent futures were last trading a little less than 1 percent higher to  109 99  Natural gas recorded a better than 1 percent gain on the day and was last trading at  3 86   At last check  COMEX gold futures were unchanged at  1 590 90  Silver was down around 0 18 percent to  28 76  Copper futures lost 0 54 percent on the session   Bonds Near the close of equity trading on Friday  the iShares Barclays 20  Year Treasury Bond ETF  TLT  was up around 0 35 percent to  115 62  Yields moved lower on the session   The 2 Year Note yield lost one basis point to 0 25 percent while the 5 Year saw its yield drop four basis points to 0 83 percent   The 10 Year Note yield also lost four basis points to 1 99 percent while the 30 Year Bond yield fell two basis points to 3 22 percent   Currencies The U S  dollar fell on Friday with the PowerShares DB US Dollar Index Bullish ETF  UUP   which tracks the performance of the greenback versus a basket of foreign currencies  losing 0 40 percent to  22 41   The closely watched EUR USD pair was last up 0 35 percent to  1 3055  The only other significant mover on the day was the USD JPY which fell 0 67 percent   Volatility and Volume The VIX rose slightly to end the week on Friday but remains near 52 week low levels  The VIX added 1 50 percent to 11 47 on the session   Volume was lighter than normal to close out the trading week  Around 101 million SPDR S P 500 ETF  SPY  shares traded hands compared to a 3 month daily average of 131 million   Stock Movers Ulta Salon  Cosmetics   Fragrance  ULTA  was trading down more than 17 percent near the close after disappointing Q1 guidance   Shares of small cap biotech name Progenics Pharmaceuticals  PGNX  were up better than 28 percent after the company s quarterly earnings results came in better than expected   CenterPoint Energy  CNP  jumped around 7 percent on Friday after the company announced it was combining its pipeline and other assets with OGE Energy and ArcLight Capital Partners   OGE Energy  OGE   a nearly  7 billion Oklahoma City based company  rose around 10 percent on the news   DirecTV  DTV  had climbed almost 5 percent heading into the close after the company dropped out of the bidding for Vivendi GVT  a Brazilian phone and Internet company   Stec  Inc   STEC  lost more than 8 percent after the company released a disappointing quarterly earnings report   Intuitive Surgical  ISRG  shed more than 6 percent after a doctors  group questioned the usefulness of its da Vinci robotic surgery device   VirnetX Holding  AMEX VHC  fell around 15 percent the day after the company lost a patent case brought against Cisco  CSCO    Aeropostale  ARO  lost 5 percent after its Q4 earnings results and a disappointing Q1 outlook   Comstock Resources  CRK  climbed around 13 percent on Friday after the company announced it has agreed to sell oil and gas properties in Reeves and Gaines counties in West Texas to Rosetta Resources  ROSE    Retailer Zumiez  ZUMZ  jumped better than 5 percent on the day after its Q4 earnings results BY Scott Rubin,2013-03-15,Benzinga ,https://www.investing.com/analysis/dow-snaps-winning-streak;-stocks-record-minor-losses-159201,159201
113128,334643,ISRG,Key Levels On Intuitive Surgical  Inc  ,opinion,Intuitive Surgical  Inc   ISRG  took a beating yesterday  Many investors are wondering where the support levels can be found  Below on the chart you will find them ,2013-07-10,Nicholas Santiago,"https://www.investing.com/analysis/key-levels-on-intuitive-surgical,-inc.-174705",174705
113129,334644,ISRG,Intuitive Surgical Gets Crushed   Opportunity Looms ,opinion,In the  it is better to be born lucky than smart  category  we sold all of our Intuitive Surgical  ISRG   with the last position being purged from client accounts  at  510 per share  about 60 days ago The double top in the chart  from mid 2012  and then early 2013  meant the stock was on our radar screen  and its failure to move materially higher after decent earnings reports also left me puzzled As a growth stock  we were always leery given ISRG s lofty valuation  at 22 x  price to cash flow and 8 x  price to 4 quarter trailing revenues  not to mention the 27 x  P E ratio  for the 17  expecetd growth in 2013  Some investors are absolutely opposed to owning such a stock to begin with  but our philosophy is to own a blend of growth and value  and to keep the growth stocks with the higher valuations on a very short leash  That being said  yesterday s 17  price drop to the  410 area has us interested again in getting long ISRG  albeit with some qualifications  Morningstar   prior to the pre announcement   had an intrinsic value on ISRG of  420 per share  We would really like the stock under  400  with the caveat that we will look at the change in forward revenue and earnings estimates over the next few days to see how bad the damage is One of my favorite technicians and a guy whose work I have very high regard for   Gray Morrow of Yosemite Asset Management in San Luis Obispo  California   wrote the following technical summary for ISRG given yesterday s action  Gary is a far better technician than I  although he does very little fundamental analysis From Gary S  Morrow Intuitive Surgical has taken a crushing blow this morning  The earnings inspired flush began with a huge gap lower open that dropped shares over 15   This breakdown move has pushed ISRG below not only its 2013 lows but its 2012 bottom as well  Its no surprise that volume is running extremely heavy in the early going  By the close of trade today will be the heaviest downside day since the first quarter of 2009 Despite this powerful breakdown a low risk entry opportunity may soon develop  The longer term charts show considerable support near the  400 00 area  ISRG s 40 week moving average  which has not be tested since mid  09  rest at  405 00  Slightly below is a major retracement level  With the exception of a steep pullback in the second half of 2010  ISRG traced out a huge bull run from its 2009 lows  This mega bull move carried the stock from  100 00 all the way up to the 2012 peak of  600 00  At the  400 00 area ISRG will have retraced 1 3 of this rally  Slightly below this important level is the 2010 high just above  390 00  This was a key turning point during the stock s 2009 2012 rally  A spike high was left behind here before ISRG began working through a nine month pullback  The second  and more powerful  leg of the bull run began when this pullback ended in January of 2011 I expect the  400 00 area to provide significant support as this week s breakdown plays out  A base built in this support zone would be ideal rather than a quick upside reversal  A laddered entry would be the optimum strategy with initial purchases made as shares dip below  405 00  Additions would be made below  400 00 and again under  395 00  As this basing process plays out an oversold reading matching that of the 2010 bottom could be reached  Once this bottoming action is complete I believe patient ISRG bulls will be rewarded with a healthy recovery move  Initial target would be the previous 2013 lows set back in March at  455 00 Finally  on a personal note  as someone who was diagnosed with a malignant  cancerous  prostate tumor that required surgical removal in December  2007  the DaVinci and the quality of life that it offers I m sure has left many males with a high regard for the company  the machine and the urological surgeons that spent the time to get trained on the machine  However  the company may have tried to push the procedure into too many other areas  too quickly This decline will re set expectations We think opportunity looms for ISRG  We ll try and keep readers updated as we move along  although we can t promise such ,2013-07-10,Brian Gilmartin,https://www.investing.com/analysis/intuitive-surgical-gets-crushed--opportunity-looms-174750,174750
113149,334664,ISRG,Market Primer  Futures Down After China PMI  US Sequester ,opinion,Futures Down after China PMI  Sequester U S  equity futures were down in the pre market after Chinese PMI came in at 50 10 Thursday night  worse than the 50 2 that was expected  The fiscal sequestration is also set to go into effect today   Top News In other news around the markets  Italian PMI came in below expectations at 45 8  expectations were for 47 60 French PMI was reported better than expected at 43 9  expectations were for 43 6 German PMI beat expectations at 50 3  more than the 50 1 that economists were anticipating S P 500 futures down about 8 50 points at 1504 75  The EUR USD was lower at 1 3002 Asian Markets Asian shares were generally lower following the disappointing Chinese PMI report  The Hong Kong Hang Seng slipped 0 61   while the Shanghai Composite was down 0 17   The exception was Japan s Nikkei 225  which rallied 0 41    European Markets European shares were broadly lower  The FTSE shed about 0 73   while the DAX fell 1 07    Commodities Commodities largely down  Gold fell 0 59  to trade at  1568 80  while silver shed a more dramatic 1 25  to trade at  28 03 Crude oil dropped 1 68  to  90 50 and natural gas slummped 0 40  to trade at  3 4720  Copper and palladium were most severely hit  Copper fell 2 03  while palladium shed 2 17    Currencies The U S  dollar showed relative strength on Friday  with the dollar index rallying 0 44  to 82 36  The GBP USD and EUR USD were both big losers  falling 0 82  and 0 44   respectively  At the same time  the USD CHF rose 0 56  and EUR GBP added 0 35    Pre Market Movers Stocks moving in the pre market included  Groupon  GRPN  shares were up nearly 5  after CEO Andrew Mason was fired Thursday night Intuitive Surgical  ISRG  shares rallied over 7  in the pre market after falling over 11  Thursday  Analysts at Cantor Fitzgerald upgraded the stock to a Buy rating Best Buy  BBY  shares rallied over 2  after reporting better than expected earnings Salesforce  CRM  shares were up over 4  after posting earnings Thursday night Economics On the economics calendar Friday  investors will get Personal Income and Personal Spending at 8 30am  At 9am  the U S  manufacturing PMI will be released  At 9 55am  the University of Michigan Consumer Sentiment indicator will be reported  Then  at 10am  ISM Manufacturing is set to be released  BY Sam Mattera,2013-03-01,Benzinga ,"https://www.investing.com/analysis/market-primer:-futures-down-after-china-pmi,-us-sequester-157380",157380
